<SEC-DOCUMENT>0001144204-11-046091.txt : 20110812
<SEC-HEADER>0001144204-11-046091.hdr.sgml : 20110812
<ACCEPTANCE-DATETIME>20110812161158
ACCESSION NUMBER:		0001144204-11-046091
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		9
CONFORMED PERIOD OF REPORT:	20110630
FILED AS OF DATE:		20110812
DATE AS OF CHANGE:		20110812

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LIXTE BIOTECHNOLOGY HOLDINGS, INC.
		CENTRAL INDEX KEY:			0001335105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				202903526
		STATE OF INCORPORATION:			DE

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51476
		FILM NUMBER:		111031528

	BUSINESS ADDRESS:	
		STREET 1:		248 ROUTE 25A
		STREET 2:		NO. 2
		CITY:			EAST SETAUKET
		STATE:			NY
		ZIP:			11733
		BUSINESS PHONE:		310 203 2902

	MAIL ADDRESS:	
		STREET 1:		248 ROUTE 25A
		STREET 2:		NO. 2
		CITY:			EAST SETAUKET
		STATE:			NY
		ZIP:			11733

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SRKP 7 INC
		DATE OF NAME CHANGE:	20050803
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>v229457_10q.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<html>
<head>
    <title>Unassociated Document</title>
    <!--Licensed to: Vintage Filings-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">UNITED STATES</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Washington, D.C. 20549</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FORM 10-Q</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; ">
<tr>
<td align="left" valign="top" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings">x</font></div>
</td>
<td align="left" valign="top" width="84%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the quarterly period ended June 30, 2011</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; ">
<tr>
<td align="left" valign="top" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings">&#168;</font></div>
</td>
<td align="left" valign="top" width="84%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission file number:&#160;&#160;000-51476</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">LIXTE BIOTECHNOLOGY HOLDINGS, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Exact name of registrant as specified in its charter)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; ">
<tr>
<td valign="top" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Delaware</font></div>
</td>
<td valign="top" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">20-2903526</font></div>
</td>
</tr><tr>
<td valign="top" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(State or other jurisdiction of</font></div>
</td>
<td valign="top" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(I.R.S. Employer</font></div>
</td>
</tr><tr>
<td valign="top" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">incorporation or organization)</font></div>
</td>
<td valign="top" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Identification Number)</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">248 Route 25A, No. 2</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">East Setauket, New York 11733</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address of principal executive offices)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(631) 942-7959</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Registrant&#8217;s telephone number, including area code)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Not applicable</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Former name, former address and former fiscal year, if changed since last report)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160; Yes <font style="DISPLAY: inline;" face="Wingdings">x</font> No <font style="DISPLAY: inline;" face="Wingdings">&#168;</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160; Yes <font style="DISPLAY: inline;" face="Wingdings">&#168;</font> No <font style="DISPLAY: inline;" face="Wingdings">&#168;</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer (as defined in Rule 12b-2 of the Exchange Act).</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; ">
<tr>
<td align="left" valign="top" width="44%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Large accelerated filer <font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#168;</font></font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="44%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accelerated filer <font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#168;</font></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="44%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Non-accelerated filer <font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#168;</font></font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="44%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Smaller reporting company <font style="DISPLAY: inline; FONT-FAMILY: wingdings">x</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160; Yes <font style="DISPLAY: inline;" face="Wingdings">&#168;</font> No <font style="DISPLAY: inline;" face="Wingdings">x</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As of August 11, 2011, the Company had 35,259,142 shares of common stock, $0.0001 par value, issued and outstanding.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Documents incorporated by reference:&#160;&#160;None</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="Page2"><!--EFPlaceholder--></a>LIXTE BIOTECHNOLOGY HOLDINGS, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">AND SUBSIDIARY</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a development stage company)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">TABLE OF CONTENTS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; ">
<tr>
<td valign="top" width="90%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Page</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Number</font></font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">PART I - FINANCIAL INFORMATION</font></div>
</td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="90%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 1. Condensed Consolidated Financial Statements</font></div>
</td>
<td valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="90%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Condensed Consolidated Balance Sheets -</font></div>
</td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">June 30, 2011 (Unaudited) and December 31, 2010</font></div>
</td>
<td valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="90%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Condensed Consolidated Statements of Operations (Unaudited) -</font></div>
</td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Three Months Ended June 30, 2011 and 2010, Six Months Ended June 30, 2011 and 2010, and Period from August 9, 2005 (Inception) to June 30, 2011 (Cumulative)</font></div>
</td>
<td valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="90%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Condensed Consolidated Statement of Stockholders&#8217; Equity (Deficiency) -</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">August 9, 2005 (Inception) to June 30, 2011 (Unaudited)</font></div>
</td>
<td valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="90%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Condensed Consolidated Statements of Cash Flows (Unaudited) -</font></div>
</td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Six Months Ended June 30, 2011 and 2010 and Period from August 9, 2005 (Inception) to June 30, 2011 (Cumulative)</font></div>
</td>
<td valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="90%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Notes to Condensed Consolidated Financial Statements (Unaudited) -</font></div>
</td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Three Months Ended June 30, 2011 and 2010, Six Months Ended June 30, 2011 and 2010, and Period from August 9, 2005 (Inception) to June 30, 2011 (Cumulative)</font></div>
</td>
<td valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="90%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></div>
</td>
<td valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">23</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="90%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 3. Quantitative and Qualitative Disclosures About Market Risk</font></div>
</td>
<td valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">30</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="90%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 4. Controls and Procedures</font></div>
</td>
<td valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">30</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="90%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">PART II - OTHER INFORMATION</font></div>
</td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="90%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 1. Legal Proceedings</font></div>
</td>
<td valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">31</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="90%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 1A. Risk Factors</font></div>
</td>
<td valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">31</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="90%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</font></div>
</td>
<td valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">31</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="90%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 3. Defaults Upon Senior Securities</font></div>
</td>
<td valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">31</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="90%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 4. Reserved</font></div>
</td>
<td valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">31</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="90%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 5. Other Information</font></div>
</td>
<td valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">31</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="90%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 6. Exhibits</font></div>
</td>
<td valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">31</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="90%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SIGNATURES</font></div>
</td>
<td valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">32</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="Page3"><!--EFPlaceholder--></a>Forward-Looking Statements</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This Quarterly Report on Form 10-Q contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company&#8217;s financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as &#8220;intend,&#8221; anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;potential(ly),&#8221; &#8220;continue,&#8221; &#8220;forecast,&#8221; &#8220;predict,&#8221; &#8220;plan,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect&#8221; or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research and development results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto included in Item 1 of this Quarterly Report on Form 10-Q.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PART I - FINANCIAL INFORMATION</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; ">
<tr valign="top">
<td align="right" style="WIDTH: 63pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 1.</font></div>
</td>
<td align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">LIXTE BIOTECHNOLOGY HOLDINGS, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">AND SUBSIDIARY</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a development stage company)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; ">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">June 30,</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">December 31,</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Unaudited)</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">ASSETS</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Current assets:</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">34,234</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">119,091</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Money market funds</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,301,089</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,601,006</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Funds on deposit with law firm</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">50,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Grant receivable</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">116,485</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Advances on research and development contract services</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">63,356</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10,100</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Prepaid expenses and other current assets</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">22,395</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">34,646</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total current assets</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,421,074</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,931,328</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total assets</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,421,074</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,931,328</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Current liabilities:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accounts payable and accrued expenses</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">80,799</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">28,345</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Research and development contract liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">89,550</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Liquidated damages payable under registration rights agreement</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">74,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">74,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Due to stockholder</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">92,717</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">92,717</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total current liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">337,066</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">195,062</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Commitments and contingencies</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stockholders&#8217; equity:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Preferred stock, $0.0001 par value; authorized &#8211; 10,000,000 shares; issued &#8211; None</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Common stock, $0.0001 par value; authorized - 100,000,000 shares; issued and outstanding &#8211; 35,259,142 shares and 35,077,178 shares at June 30, 2011 and December 31, 2010, respectively</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,526</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,508</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Additional paid-in capital</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,709,0561</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,662,559</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Deficit accumulated during the development stage</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(6,628,569</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(5,929,801</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total stockholders&#8217; equity</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,084,008</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,736,266</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total liabilities and stockholders&#8217; equity</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,421,074</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,931,328</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">See accompanying notes to condensed consolidated financial statements.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">LIXTE BIOTECHNOLOGY HOLDINGS, INC. AND SUBSIDIARY</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a development stage company)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; ">
<tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="6" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="6" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Period from</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">August 9,</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2005</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Inception) to</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="6" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Three Months Ended</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">June 30,</font></font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="6" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Six Months Ended</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">June 30,</font></font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">June 30,</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(Cumulative)</font></font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Revenues</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Costs and expenses:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">General and administrative costs, including $40,528 and $20,534 of stock-based compensation costs for the three months ended June 30, 2011 and 2010, respectively, $40,528 and $93,274 of stock-based compensation costs for the six months ended June 30, 2011 and 2010, respectively, and $2,293,051 of stock-based compensation costs for the period from August 9, 2005 (inception) to June 30, 2011 (cumulative)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">123,581</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">76,892</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">213,197</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">265,470</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,819,075</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Depreciation</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,909</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Research and development costs, including $-0- and ($1,762) of stock-based costs (credit) for the three months ended June 30, 2011 and 2010, respectively, $982 and $18,127 of stock-based costs for the six months ended June 30, 2011 and 2010, respectively, and $465,034 of stock-based costs for the period from August 9, 2005 (inception) to June 30, 2011 (cumulative), respectively. Research and development costs include $6,250 and $5,208 to a related party for the three months ended June 30, 2011 and 2010, respectively, $12,500 and $5,208 for the six months ended June 30, 2011 and 2010, respectively, and $30,208 for the period from August 9, 2005 (inception) to June 30, 2011 (cumulative). Research and development costs for&#160;the period from August 9, 2005 (inception) to June 30, 2011 (cumulative) have been reduced by $244,479, representing the proceeds of a government grant related to such costs.</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">224,208</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">233,104</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">485,654</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">394,977</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,708,501</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Reverse merger costs</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">50,000</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total costs and expenses</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">347,789</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">309,996</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">698,851</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">660,447</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">6,579,485</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Loss from operations</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(347,789</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(309,996</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(698,851</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(660,447</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(6,579,485</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Interest income</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">37</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">333</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">83</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">548</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">27,385</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Interest expense</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,469</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Liquidated damages under registration rights agreement</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(74,000</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net loss</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(347,752</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(309,663</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(698,768</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(659,899</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(6,628,569</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net loss per common share - basic and diluted</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(0.01</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(0.01</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(0.02</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(0.02</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted average common shares outstanding - basic and diluted</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">35,079,178</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">35,077,178</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">35,078,183</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">34,389,333</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">See accompanying notes to condensed consolidated financial statements.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">LIXTE BIOTECHNOLOGY HOLDINGS, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">AND SUBSIDIARY</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a development stage company)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS&#8217; EQUITY (DEFICIENCY)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Period from August 9, 2005 (Inception) to June 30, 2011</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; ">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="6" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Common&#160;Stock</font></font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Advances</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Under</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Equity</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Additional</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Paid-in</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Deficit</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accumulated</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">During&#160;the</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Development</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stockholders&#8217;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Equity</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Shares</font></font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Amount</font></font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Financing</font></font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Capital</font></font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Stage</font></font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(Deficiency)</font></font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="28%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance, August 9, 2005 (inception)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Shares issued to founding stockholder</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">19,021,786</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,902</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(402</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,500</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="28%" style="PADDING-BOTTOM: 2px; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net loss</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(16,124</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(16,124</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance, December 31, 2005</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">19,021,786</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,902</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(402</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(16,124</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(14,624</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="28%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Shares issued in connection with reverse merger transaction</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,005,177</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">401</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">62,099</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">62,500</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Shares issued in private placement, net of offering costs</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,555,220</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">355</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">969,017</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">969,372</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="28%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock-based compensation costs</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">97,400</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">97,400</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%" style="PADDING-BOTTOM: 2px; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net loss</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(562,084</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(562,084</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="28%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance, December 31, 2006</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">26,582,183</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,658</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,128,114</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(578,208</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">552,564</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Shares issued in private placement, net of offering costs</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">999,995</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">100</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">531,220</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">531,320</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="28%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock-based compensation costs</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">250,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">25</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">890,669</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">890,694</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock-based research and development costs</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">50,836</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">50,836</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="28%" style="PADDING-BOTTOM: 2px; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net loss</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(1,648,488</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(1,648,488</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance, December 31, 2007</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">27,832,178</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,783</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,600,839</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,226,696</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">376,926</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="28%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock-based compensation costs</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">357,987</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">357,987</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock-based research and development costs</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">100,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">213,051</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">213,061</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="28%" style="PADDING-BOTTOM: 2px; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net loss</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(1,271,522</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(1,271,522</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance, December 31, 2008</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">27,932,178</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,793</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,171,877</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(3,498,218</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(323,548</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="28%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Shares issued in private placements, net of offering costs</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,420,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">242</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,096,808</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,097,050</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Advances under equity financing</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,200,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,200,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="28%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock-based compensation costs</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">150,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">15</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">745,965</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">745,980</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock-based research and development costs</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">132,933</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">132,933</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="28%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net loss</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(1,551,333</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(1,551,333</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance, December 31, 2009</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">30,502,178</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,050</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,200,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,147,583</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(5,049,551</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,301,082</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="28%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Shares issued in private placements, net of offering costs</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,575,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">458</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,200,000</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,287,042</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,087,500</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock-based compensation costs</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">160,712</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">160,712</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="28%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock-based research and development costs</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">67,222</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">67,222</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="28%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net loss</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(880,250</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(880,250</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="28%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance, December 31, 2010</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">35,077,178</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,508</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,662,559</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(5,929,801</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,736,266</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercise of stock options</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">181,964</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">18</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,982</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,000</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="28%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock-based compensation costs</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">40,528</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">40,528</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock-based research and development costs</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">982</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">982</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="28%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net loss</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(698,768</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(698,768</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%" style="PADDING-BOTTOM: 4px; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance, June 30, 2011 (Unaudited)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">35,259,142</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,526</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,709,051</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(6,628,569</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,084,008</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">See accompanying notes to condensed consolidated financial statements.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">LIXTE BIOTECHNOLOGY HOLDINGS, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;AND SUBSIDIARY</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a development stage company)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; ">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="6" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Six&#160;Months&#160;Ended</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">June&#160;30,</font></font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Period&#160;from</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">August&#160;9,</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2005</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Inception)&#160;to</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">June&#160;30,</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(Cumulative)</font></font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash flows from operating activities:</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net loss</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(698,768</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(659,899</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(6,628,569</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Adjustments to reconcile net loss to net cash used in operating activities:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Depreciation</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,909</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock-based compensation costs</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">40,528</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">93,274</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,293,051</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock-based research and development costs</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">982</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">18,127</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">465,034</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Changes in operating assets and liabilities:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Increase) decrease in -</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Funds on deposit with law firm</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">50,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Grant receivable</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">116,485</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Advances on research and development contract services</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(53,256</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(8,310</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(63,356</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Prepaid expenses and other current assets</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12,251</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,958</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(22,395</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Increase (decrease) in -</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accounts payable and accrued expenses</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">52,454</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(6,430</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">80,799</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Liquidated damages payable under registration rights agreement</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">74,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Research and development contract liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">89,550</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">29,007</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">89,550</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net cash used in operating activities</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(389,774</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(529,273</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(3,709,977</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash flows from investing activities:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Decrease (increase) in money market funds</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">299,917</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,050,150</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,301,089</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Purchase of office equipment</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(1,909</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net cash provided by (used in) investing activities</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">299,917</font></font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(2,050,150</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(1,302,998</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash flows from financing activities:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Proceeds from exercise of stock options</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,000</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,000</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Proceeds from sale of common stock to consulting firm</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">250</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Proceeds from sale of common stock to founder</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,500</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Proceeds from issuance of notes payable to consultant</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">200,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Repayment of notes payable to consultant</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(200,000</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash acquired in reverse merger transaction</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">62,500</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Gross proceeds from sale of securities</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,087,500</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,331,389</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Payment of private placement offering costs</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(446,147</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Advances received from stockholder</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">92,717</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net cash provided by financing activities</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">5,000</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,087,500</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">5,047,209</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net increase (decrease)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(84,857</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,491,923</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">34,234</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance at beginning of period</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">119,091</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,543,991</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance at end of period</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">34,234</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">52,068</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">34,234</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Supplemental disclosures of cash flow information:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash paid for -</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Interest</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2,469</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Income taxes</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Non-cash financing activities:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Decrease in advances under equity financing</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,200,000</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,200,000</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Aggregate exercise price of warrants and options exercised on a cashless basis</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">84,207</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">84,207</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">See accompanying notes to condensed consolidated financial statements.<a name="Page8"><!--EFPlaceholder--></a></font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">LIXTE BIOTECHNOLOGY HOLDINGS, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;AND SUBSIDIARY</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a development stage company)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Three Months and Six Months Ended June 30, 2011 and 2010, and</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Period from August 9, 2005 (Inception) to June 30, 2011 (Cumulative)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1. Basis of Presentation</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The condensed consolidated financial statements of Lixte Biotechnology Holdings, Inc. and its wholly-owned subsidiary, Lixte Biotechnology, Inc. (the &#8220;Company&#8221;) at June 30, 2011, for the three months and six months ended June 30, 2011 and 2010, and for the period from August 9, 2005 (inception) to June 30, 2011 (cumulative), are unaudited. In the opinion of management, all adjustments (including normal recurring adjustments) have been made that are necessary to present fairly the financial position of the Company as of June 30, 2011, the results of its operations for the three months and six months ended June 30, 2011 and 2010, and for the period from August 9, 2005 (inception) to June 30, 2011 (cumulative), and its cash flows for the six months ended June 30, 2011 and 2010, and for the period from August 9, 2005 (inception) to June 30, 2011 (cumulative). Operating results for the interim periods presented are not necessarily indicative of the results to be expected for a full fiscal year. The condensed balance sheet at December 31, 2010 has been derived from the Company&#8217;s audited financial statements.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The statements and related notes have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been omitted pursuant to such rules and regulations. These financial statements should be read in conjunction with the financial statements and other information included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2010, as filed with the SEC.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.&#160; Organization and Business Operations</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Organization</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On June 30, 2006, Lixte Biotechnology, Inc., a privately-held Delaware corporation (&#8220;Lixte&#8221;) incorporated on August 9, 2005, completed a reverse merger transaction with SRKP 7, Inc. (&#8220;SRKP&#8221;), a non-trading public shell company, whereby Lixte became a wholly-owned subsidiary of SRKP. On December 7, 2006, SRKP amended its Certificate of Incorporation to change its name to Lixte Biotechnology Holdings, Inc. (&#8220;Holdings&#8221;). Unless the context indicates otherwise, Lixte and Holdings are hereinafter referred to as the &#8220;Company&#8221;.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For financial reporting purposes, Lixte was considered the accounting acquirer in the merger and the merger was accounted for as a reverse merger. Accordingly, the historical financial statements presented herein are those of Lixte. The stockholders&#8217; equity section of SRKP has been retroactively restated for all periods presented to reflect the accounting effect of the reverse merger transaction. All costs associated with the reverse merger transaction were expensed as incurred.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company is considered a &#8220;development stage company&#8221; under current accounting standards, as it has not yet commenced any revenue-generating operations, does not have any cash flows from operations, and is dependent on debt and equity funding to finance its operations.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company&#8217;s common stock was listed for trading on the OTC Bulletin Board commencing September 24, 2007 under the symbol &#8220;LIXT&#8221;. It is presently traded on the OTC Market (also referred to as the &#8220;Pink Sheets&#8221;) under the symbol &#8220;LIXT.PK&#8221;.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Operating Plans</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company is developing new treatments for human cancers for which better therapies are urgently needed. The Company&#8217;s drug discovery process is based on discerning clues to potential new targets for cancer treatments reported in the increasingly large body of literature characterizing the molecular variants, which characterize human cancers. In the past decade, there has been an unprecedented expansion in knowledge of biochemical defects in the cancer cell. The Company selects drugs for which there are existing data suggesting that they may affect the altered pathways of the cancer cell and may be given safely to humans. The Company seeks to rapidly arrive at patentable structures through analysis of the literature rather than screening of thousands of structures for activity against a particular biochemical pathway.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This approach has led to the development of two classes of drugs, phosphatase inhibitors (PTase-i), designated by the Company as the LB-100 series of compounds, and histone deacetylase inhibitors (HDACi), designated by the Company as the LB-200 series of compounds. The LB-100 series consists of novel structures, which have the potential to be first in their class and the latter group contains compounds, which have the potential to be the most effective of this class. The Company has demonstrated that lead compounds of both series of drugs are active against a broad spectrum of human cancers in cell culture and against several types of human cancers in animal models. The research on new drug treatment was initiated in 2006 with the National Institute of Neurologic Disorders and Stroke (NINDS), National Institutes of Health (NIH) under a continuing Cooperative Research and Development Agreement (CRADA). The research at NINDS is led by Dr. Zhengping Zhuang, an internationally recognized investigator in the molecular pathology of cancer. The initial focus of the CRADA was on the most common and uniformly fatal brain tumor of adults, glioblastoma multiforme (GBM). The work at NIH has now extended to the most common brain tumor of children, medulloblastoma, and to the most common cancer of children, neuroblastoma. Because of the propensity of malignant melanoma to metastasize to the brain, recent studies have encompassed studying the effectiveness of drugs developed for the treatment of primary brain tumors to the treatment of melanoma.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The second class of drugs (LB-200) under development by the Company is the histone deacetylase inhibitors. Many pharmaceutical companies are also developing drugs of this type, and at least two companies have an HDACi approved for clinical use, in both cases for the treatment of a type of lymphoma. Despite this significant competition, the Company has demonstrated that its HDACi have broad activity against many cancer types, have neuroprotective activity, and have anti-fungal activity. In addition, these compounds have low toxicity, making them attractive candidates for development. It appears that one type of molecule has diverse effects, affecting biochemical processes that are fundamental to the life of the cell, whether they are cancer cells, nerve cells, or even fungal cells. The neuroprotective activity of the Company&#8217;s HDACi has been demonstrated in the test tube in model systems that mimic injury to brain cells such as occurs in stroke and Alzheimer&#8217;s disease. Potentially, this type of protective activity may have application to a broad spectrum of other chronic neurodegenerative diseases, including Parkinson&#8217;s Disease and Amytrophic Lateral Sclerosis (ALS, or Lou Gehrig&#8217;s Disease).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company&#8217;s primary objective is to bring one lead compound of the LB-100 series to clinical trial. In late 2009 and early 2010, the Company raised sufficient financial resources to carry out the preclinical studies needed for an application to the FDA to carry out a Phase I clinical trial. The Company has engaged a leading pharmaceutical manufacturing company, a clinical research organization, and a drug development company specializing in pharmacologic and toxocologic characterization of new anticancer drugs to oversee and carry out the studies necessary to obtain FDA approval to commence a Phase I clinical trial.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On September 17, 2010, the National Cancer Institute Experimental Therapeutics (NExT) Program Senior Advisory Committee (SAC) approved a collaboration by NCI with the Company for clinical evaluation of LB-100, one of the Company&#8217;s drug compounds. This collaboration is a milestone-based approach in which NCI will first confirm studies of the LB-100 compound in an animal model of glioblastoma multiforme, the most common brain tumor of adults, and conduct an initial exploratory toxicology study in an animal model. At milestone intervals, the SAC will re-evaluate project progress before considering assignment of additional support and resources to this project.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company believes that it has adequate funds on hand to support operations at current levels, including commencing, but not completing, a Phase I clinical trial of the Company&#8217;s LB-100 compound, and to continue to grow its patent portfolio and maintain its applications for international protection of lead compounds of both the LB-100 and LB-200 series, without having to raise additional funds, until early 2012.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Going Concern</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company&#8217;s condensed consolidated financial statements have been presented on the basis that it is a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company is in the development stage and has not generated any revenues from operations to date, and does not expect to do so in the foreseeable future. The Company has experienced recurring operating losses and negative operating cash flows since inception, and has financed its working capital requirements through the recurring sale of its equity securities. As a result, the Company&#8217;s independent registered public accounting firm, in its report on the Company&#8217;s 2010 consolidated financial statements, has raised substantial doubt about the Company&#8217;s ability to continue as a going concern.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company&#8217;s ability to continue as a going concern is dependent upon its ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations. The Company&#8217;s condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At June 30, 2011, the Company had not yet commenced any revenue-generating operations. All activity through June 30, 2011 has been related to the Company&#8217;s formation, capital raising efforts and research and development activities. As such, the Company has yet to generate any cash flows from operations, and is dependent on debt and equity funding from both related and unrelated parties to finance its operations. Prior to June 30, 2006, the Company&#8217;s cash requirements were funded by advances from the Company&#8217;s founder aggregating $92,717.<a name="Page10"><!--EFPlaceholder--></a></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Because the Company is currently engaged in research at an early stage, it will likely take a significant amount of time to develop any product or intellectual property capable of generating revenues. As such, the Company&#8217;s business is unlikely to generate any sustainable revenues in the next several years, and may never do so. Even if the Company is able to generate revenues in the future through licensing its technologies or through product sales, there can be no assurance that the Company will be able to generate a profit.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company&#8217;s activities for the remainder of 2011 will consist of continuing drug discovery and development efforts. The Company&#8217;s primary objective is to&#160;gain FDA approval of&#160;the Company's LB-100 compound for entry into a&#160;Phase I clinical trial by the end of 2011. The Company was not able to expedite this process so as to obtain such approval by its June 30, 2011 target date.&#160;Although the Company has not identified any specific obstacles to the submission of the FDA application, the overall process of large animal testing and formal documentation of the long-term stability of the LB-100 compound has been slower than originally anticipated.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company raised $500,000 in November 2009, $1,787,500 in January 2010, and $500,000 in February 2010, all through the sale of its securities to fund its business activities. The Company also received $244,479 from the Internal Revenue Service under its Qualifying Therapeutic Discovery Grant program, consisting of $127,994 on November 9, 2010 and $116,485 on February&#160;1, 2011. As a result, the Company believes that its existing resources are adequate to fund operations until early 2012 at a level that will allow the continuation of the Company&#8217;s two drug development programs currently in process and commencement, but not completion, of a Phase I clinical trial of LB-100.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The amount and timing of future cash requirements will depend on the pace of these programs, particularly the completion of the Phase I trial of LB-100. After completion of the Phase I trial, the next step will be to determine the anti-cancer activity against a particular type of human cancer in Phase II trials. To complete the Phase I trial and carry out Phase II trials, the Company anticipates that it will be necessary to raise additional funds beginning in early 2012 from a combination of debt or equity financings, and/or the sale, licensing or joint venturing of its intellectual properties. Market conditions present uncertainty as to the Company&#8217;s ability to secure additional funds, as well as its ability to reach profitability. There can be no assurances that the Company will be able to secure additional financing, or obtain favorable terms on such financing if it is available, or as to the Company&#8217;s ability to achieve positive earnings and cash flows from operations. Continued negative cash flows and lack of liquidity create significant uncertainty about the Company&#8217;s ability to fully implement its operating plan beyond early 2012, as a result of which the Company may have to reduce the scope of its planned operations. If cash resources are insufficient to satisfy the Company&#8217;s liquidity requirements, the Company would be required to scale back or discontinue its technology and product development programs, or obtain funds, if available, through strategic alliances that may require the Company to relinquish rights to certain of its technologies products, or to discontinue its operations entirely.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3. Summary of Significant Accounting Policies</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Principles of Consolidation</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The accompanying condensed consolidated financial statements include the financial statements of Holdings and its wholly-owned subsidiary, Lixte. All intercompany balances and transactions have been eliminated in consolidation.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Cash Concentrations</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company&#8217;s cash balances may periodically exceed federally insured limits. The Company has not experienced a loss in such accounts to date. The Company maintains its accounts with financial institutions with high credit ratings.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Research and Development</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Research and development costs are expensed as incurred. Research and development expenses consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company's treatments and product candidates.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Amounts that become due, pursuant to contractual commitments, on research and development contracts with third parties are recorded as a liability, with the related amount of such contracts recorded as advances on research and development contract services on the Company&#8217;s balance sheet. Such advances on research and development contract services are expensed over their life on the straight-line basis, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different expensing schedule is more appropriate. The Company reviews the status of its research and development contracts on a quarterly basis.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="Page11"><!--EFPlaceholder--></a>The funds paid to NINDS of the NIH, pursuant to the CRADA effective March 22, 2006, as amended, represented an advance on research and development costs and therefore had future economic benefit. Accordingly, such costs have been charged to expense when they are actually expended by the provider, which is, effectively, as they perform the research activities that they were contractually committed to provide. Absent information that would indicate that a different expensing schedule was more appropriate (such as, for example, from the achievement of performance milestones or the completion of contract work), such advances have been expensed over the contractual service term on a straight-line basis, which, in management&#8217;s opinion, reflects a reasonable estimate of when the underlying research and development costs were being incurred.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Patent Costs</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company's research efforts and any related patent applications, all patent costs, including patent-related legal and filing fees, are expensed as incurred. Patent costs were $95,126 and $82,091 for the three months ended June 30, 2011 and 2010, respectively, $234,271 and $170,780 for the six months ended June 30, 2011 and 2010, respectively, and $1,005,605 for the period from August 9, 2005 (inception) to June 30, 2011 (cumulative). Patent costs are included in research and development costs in the Company's condensed consolidated statements of operations.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Income Taxes</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company has elected to deduct research and development costs on a current basis for federal income tax purposes. Start-up and organization costs were deferred until January 1, 2008. Accordingly, the Company then began to amortize such costs over a 180-month period.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For federal income tax purposes, net operating losses can be carried forward for a period of 20 years until they are either utilized or until they expire.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On January 1, 2007, the Company adopted new accounting rules which address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. The new accounting rules also provide guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. The adoption of the new accounting rules did not have a material effect on the Company&#8217;s financial statements. As of June 30, 2011, no liability for unrecognized tax benefits was required to be recorded.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company files income tax returns in the U.S. federal jurisdiction and is subject to income tax examinations by federal tax authorities for the year 2008 and thereafter. The Company&#8217;s policy is to record interest and penalties on uncertain tax provisions as income tax expense. As of June 30, 2011, the Company has no accrued interest or penalties related to uncertain tax positions.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Government Grant Under Qualifying Therapeutic Discovery Project</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under the Patient Protection and Affordable Care Act signed into law on March 23, 2010 (the &#8220;Act&#8221;), the Internal Revenue Service and the Department of Health and Human Services established the qualifying therapeutic discovery project to consider and award certifications for qualified investments by project sponsors. On July 20, 2010, the Company applied for a grant pursuant to the Act based upon qualified investments made in 2009 and 2010. On October 29, 2010, the Company was notified that qualified investments totaling $488,958 had been certified and that a grant in the amount of $244,479 had been awarded to the Company.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The proceeds of the grant were received by the Company in installments, consisting of $127,994 on November 9, 2010, and $116,485 on February 1, 2011, which was reflected as a receivable at December 31, 2010. For financial statement purposes, the grant of $244,479 was offset against research and development costs in the statement of operations for the year ended December 31, 2010.<a name="Page12"><!--EFPlaceholder--></a></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Stock-Based Compensation</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company periodically issues stock options and warrants to officers, directors and consultants for services rendered. Options vest and expire according to terms established at the grant date.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company accounts for share-based payments to officers and directors by measuring the cost of services received in exchange for equity awards based on the grant date fair value of the awards, with the cost recognized as compensation expense in the Company&#8217;s financial statements over the vesting period of the awards.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company accounts for share-based payments to consultants by determining the value of the stock compensation based upon the measurement date at either (a) the date at which a performance commitment is reached or (b) at the date at which the necessary performance to earn the equity instruments is complete.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Options granted to Scientific Advisory Board committee members and outside consultants are revalued each reporting period to determine the amount to be recorded as an expense in the respective period. As the options vest, they are valued on each vesting date and an adjustment is recorded for the difference between the value already recorded and the then current value on the date of vesting.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">11</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Earnings Per Share</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company&#8217;s computation of earnings per share (&#8220;EPS&#8221;) includes basic and diluted EPS. Basic EPS is measured as the income (loss) available to common shareholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., warrants and options) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted loss per common share is the same for all periods presented because all warrants and stock options outstanding are anti-dilutive.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At June 30, 2011 and 2010, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; ">
<tr>
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;&#160;</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="6" nowrap valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">June 30,</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrants</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">13,454,552</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">13,607,426</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock options</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">3,350,000</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">3,540,000</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16,804,552</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">17,147,426</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Fair Value of Financial Instruments</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The carrying amounts of cash, money market funds, advances on research and development contract services, prepaid expenses and other current assets, accounts payable and accrued expenses, research and development contract liabilities, liquidated damages payable under registration rights agreement and due to stockholder approximate their respective fair values due to the short-term nature of these items.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Use of Estimates</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Recent Accounting Pronouncements</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In May&#160;2011, the Financial Accounting Standards Board (the &#8220;FASB&#8221;)&#160;issued Accounting Standards Update (the &#8220;ASU&#8221;)&#160;No.&#160;2011-4, which amends the Fair Value Measurements Topic of the Accounting Standards Codification (the &#8220;ASC&#8221;)&#160;to help achieve common fair value measurement and disclosure requirements in U.S. GAAP and IFRS.&#160;&#160;ASU No.&#160;2011-4 does not require additional fair value measurements and is not intended to establish valuation standards or affect valuation practices outside of financial reporting.&#160;&#160;The ASU is effective for interim and annual periods beginning after December&#160;15, 2011. The Company will adopt the ASU as required.&#160;&#160;The ASU will affect the Company&#8217;s fair value disclosures, but is not expected to have any impact on the Company&#8217;s financial position or results of operations.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In June&#160;2011, the FASB issued ASU No.&#160;2011-5, which amends the Comprehensive Income Topic of the ASC.&#160;&#160;The ASU eliminates the option to present the components of other comprehensive income as part of the statement of changes in shareholders&#8217; equity, and instead requires consecutive presentation of the statement of net income and other comprehensive income either in a continuous statement of comprehensive income or in two separate but consecutive statements.&#160;&#160;ASU No.&#160;2011-5 is effective for interim and annual periods beginning after December&#160;15, 2011.&#160;&#160;The Company will adopt the ASU as required.&#160;&#160;The ASU is not expected to have any impact on the Company&#8217;s financial position or results of operations.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company&#8217;s financial statement presentation or disclosures.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4. Share Exchange Agreement and Private Placement</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Share Exchange Agreement</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On June 30, 2006, pursuant to a Share Exchange Agreement dated as of June 8, 2006 (the &#8220;Share Exchange Agreement&#8221;) by and among Holdings, Dr. John S. Kovach (&#8220;Seller&#8221;) and Lixte, Holdings issued 19,021,786 shares of its common stock in exchange for all of the issued and outstanding shares of Lixte (the &#8220;Exchange&#8221;). Previously, on October 3, 2005, Lixte had issued 1,500 shares of its no par value common stock to its founder for $1,500, which constituted all of the issued and outstanding shares of Lixte prior to the Exchange. As a result of the Exchange, Lixte became a wholly-owned subsidiary of Holdings.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to the Exchange, Holdings issued to the Seller 19,021,786 shares of its common stock. Holdings had a total of 25,000,832 shares of common stock issued and outstanding after giving effect to the Exchange and the 1,973,869 shares of common stock issued in the initial closing of the private placement.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As a result of the Exchange and the shares of common stock issued in the initial closing of the private placement, on June 30, 2006, the stockholders of the Company immediately prior to the Exchange owned 4,005,177 shares of common stock, equivalent to approximately 16% of the issued and outstanding shares of the Company&#8217;s common stock, and the former stockholder of Lixte acquired control of the Company.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Share Exchange Agreement was determined through arms-length negotiations between Holdings, the Seller and Lixte. In connection with the Exchange, the Company paid WestPark Capital, Inc. an aggregate cash fee of $50,000.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Private Placements</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On June 30, 2006, concurrently with the closing of the Exchange, the Company sold an aggregate of 1,973,869 shares of its common stock to accredited investors in an initial closing of a private placement at a per share price of $0.333, resulting in aggregate gross proceeds to the Company of $657,299. The Company paid to WestPark Capital, Inc., as placement agent, a commission of 10% and a non-accountable fee of 4% of the gross proceeds of the private placement and issued five-year warrants to purchase common stock equal to (a) 10% of the number of shares sold in the private placement exercisable at $0.333 per share and (b) an additional 2% of the number of shares sold in the private placement also exercisable at $0.333 per share. A total of 236,864 warrants were issued. Net cash proceeds to the Company, after the deduction of all private placement offering costs and expenses, were $522,939.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On July 27, 2006, the Company sold an aggregate of 1,581,351 shares of its common stock to accredited investors in a second closing of the private placement at a per share price of $0.333 resulting in aggregate gross proceeds to the Company of $526,590. The Company paid to WestPark Capital, Inc., as placement agent, a commission of 10% and a non-accountable fee of 4% of the gross proceeds of the private placement and issued five-year warrants to purchase common stock equal to (a) 10% of the number of shares sold in the private placement exercisable at $0.333 per share and (b) an additional 2% of the number of shares sold in the private placement also exercisable at $0.333 per share. A total of 189,762 warrants were issued. Net cash proceeds to the Company were $446,433.<a name="Page14"><!--EFPlaceholder--></a>&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In conjunction with the private placement of common stock, the Company issued a total of 426,626 five-year warrants to WestPark Capital, Inc. exercisable at the per share price of the common stock sold in the private placement ($0.333 per share). The warrants issued to WestPark Capital, Inc. do not contain any price anti-dilution provisions. However, such warrants contain cashless exercise provisions and demand registration rights, but the warrant holder has agreed to waive any claims to monetary damages or financial penalties for any failure by the Company to comply with such registration requirements. Based on the foregoing, the warrants were accounted for as equity and were not accounted for separately from the common stock and additional paid-in capital accounts. The warrants had no accounting impact on the Company&#8217;s consolidated financial statements.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On June 30, 2011, WestPark Capital, Inc. exercised warrants to acquire a portion of the above described warrants, consisting of 152,874 shares of common stock, on a cashless basis. Such cashless exercise resulted in WestPark Capital, Inc. receiving a net of 100,929 shares.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On July 27, 2011, the Company agreed to extend warrants to acquire the remaining portion of the above described warrants, consisting of 273,752 shares of common stock, to July 27, 2012.&#160;&#160;In conjunction with the extension of the warrants, the cashless exercise feature was deleted.&#160;&#160;On July 27, 2011, the fair value of the warrant extension, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $199,839 ($0.73 per share), and will be charged to operations during the three months ending September 30, 2011.&#160;&#160;The fair value of the warrant extension was calculated using the following input variables: stock price - $0.79; exercise price - $0.333; expected life - 1 year; expected volatility &#8211; 308.8%; expected dividend yield - 0%; risk-free interest rate &#8211; 0.14%.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As part of the Company&#8217;s private placement of its securities completed on July 27, 2006, the Company entered into a registration rights agreement with the purchasers, whereby the Company agreed to register the shares of common stock sold in the private placement, and to maintain the effectiveness of such registration statement, subject to certain conditions. The agreement required the Company to file a registration statement within 45 days of the closing of the private placement and to have the registration statement declared effective within 120 days of the closing of the private placement. On September 8, 2006, the Company filed a registration statement on Form SB-2 to register 3,555,220 shares of the common stock sold in the private placement. Since the registration statement was not declared effective by the Securities and Exchange Commission within 120 days of the closing of the private placement, the Company was required to pay each investor prorated liquidated damages equal to 1.0% of the amount raised per month, payable monthly in cash.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">13</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On the date of the closing of the private placement, the Company believed it would meet the deadlines under the registration rights agreement with respect to filing a registration statement and having it declared effective by the Securities and Exchange Commission. As a result, the Company did not record any liabilities associated with the registration rights agreement at June 30, 2006. At December 31, 2006, the Company determined that the registration statement covering the shares sold in the private placement would not be declared effective within the requisite time frame and therefore accrued six months liquidated damages under the registration rights agreement aggregating approximately $74,000, which has been presented as a current liability for all periods presented. The Company&#8217;s registration statement on Form SB-2 was declared effective by the Securities and Exchange Commission on May 14, 2007. At March 31, 2011, the registration penalty to the investors had not been paid.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On December 12, 2007, the Company sold an aggregate of 999,995 shares of its common stock to accredited investors in a second private placement at a per share price of $0.65, resulting in aggregate gross proceeds to the Company of $650,000. The Company paid to WestPark Capital, Inc., as placement agent, a commission of 10% and a non-accountable fee of 4% of the gross proceeds of the private placement and issued five-year warrants to purchase common stock equal to (a) 10% of the number of shares sold in the private placement exercisable at $0.65 per share and (b) an additional 2% of the number of shares sold in the private placement also exercisable at $0.65 per share. Net cash proceeds to the Company were $531,320.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In conjunction with the second private placement of common stock, the Company issued a total of 120,000 five-year warrants to WestPark Capital, Inc. exercisable at the per share price of the common stock sold in the private placement ($0.65 per share). The warrants issued to WestPark Capital, Inc. do not contain any price anti-dilution provisions. However, such warrants contain cashless exercise provisions and demand registration rights, but the warrant holder has agreed to waive any claims to monetary damages or financial penalties for any failure by the Company to comply with such registration requirements. Based on the foregoing, the warrants were accounted for as equity and were not accounted for separately from the common stock and additional paid-in capital accounts. The warrants had no accounting impact on the Company&#8217;s consolidated financial statements.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As part of the Company&#8217;s second private placement of its securities completed on December 12, 2007, the Company entered into a registration rights agreement with the purchasers, whereby the Company agreed to register the shares of common stock sold in the second private placement at its sole cost and expense. The registration rights agreement terminates at such time as the common shares may be sold in market transactions without regard to any volume limitations. The registration rights agreement requires the Company to file a registration statement within 75 days of receipt of written demand from holders who represent at least 50% of the common shares issued pursuant to the second private placement, provided that no demand shall be made for less than 500,000 shares, and to use its best efforts to cause such registration statement to become and remain effective for the requisite period. The registration rights agreement also provides for unlimited piggyback registration rights. The registration rights agreement does not provide for any penalties in the event that the Company is unable to comply with its terms.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During the year ended December 31, 2009, the Company completed three closings of the third private placement of common stock units, consisting of a total of 1,420,000 shares of common stock and 1,420,000 warrants to acquire common stock, as follows:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On February 10, 2009, the Company sold an aggregate of 658,000 common stock units to accredited investors in a first closing of a third private placement at a per unit price of $0.50, resulting in aggregate gross proceeds to the Company of $329,000. Net cash proceeds to the Company were $269,790.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On March 2, 2009, the Company sold an aggregate of 262,000 common stock units to accredited investors in a second closing of the third private placement at a per unit price of $0.50, resulting in aggregate gross proceeds to the Company of $131,000. Net cash proceeds to the Company were $112,460.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On April 6, 2009, the Company sold an aggregate of 500,000 common stock units to accredited investors in a third closing of the third private placement at a per unit price of $0.50, resulting in aggregate gross proceeds to the Company of $250,000. Net cash proceeds to the Company were $214,800.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Each unit sold in the third private placement consisted of one share of the Company&#8217;s common stock and a five-year warrant to purchase an additional share of the Company&#8217;s common stock on a cashless exercise basis at an exercise price of $0.50 per common share. The Company paid to WestPark Capital, Inc., as placement agent, a commission of 10% and a non-accountable fee of 4% of the gross proceeds of the third private placement and issued five-year warrants to purchase common stock equal to (a) 10% of the number of shares sold in the third private placement exercisable at $0.50 per share and 10% of the number of shares issuable upon exercise of warrants issued in the third private placement exercisable at $0.50 per share; and (b) an additional 2% of the number of shares sold in the third private placement also exercisable at $0.50 per share and 2% of the number of shares issuable upon exercise of the warrants issued in the third private placement exercisable at $0.50 per share.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In conjunction with the closings of the third private placement of common stock units during the year ended December 31, 2009, the Company issued a total of 340,800 five-year warrants to WestPark Capital, Inc., which are exercisable at the per unit price of the common stock units sold in the third private placement ($0.50 per unit). Included in the 340,800 warrants issued to WestPark Capital, Inc. are 170,400 warrants which are only exercisable with respect to common shares that are acquired by investors upon their exercise of the warrants acquired as part of the units sold in the third private placement. The warrants issued to WestPark Capital, Inc. do not contain any price anti-dilution provisions. However, such warrants contain cashless exercise provisions and demand registration rights, but the warrant holder has agreed to waive any claims to monetary damages or financial penalties for any failure by the Company to comply with such registration requirements. Based on the foregoing, the warrants were accounted for as equity and were not accounted for separately from the common stock and additional paid-in capital accounts. The warrants had no accounting impact on the Company&#8217;s consolidated financial statements.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">14</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At the request of the holders, the Company has agreed to include any shares sold in the third private placement and any shares issuable upon exercise of the related warrants to be included in any registration statement filed with the Securities and Exchange Commission permitting the resale of such shares, subject to customary cutbacks, at the Company&#8217;s sole cost and expense.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Effective November 6, 2009, the Company sold 1,000,000 common stock units to an accredited investor in a fourth private placement at a per unit price of $0.50, resulting in proceeds to the Company of $500,000. There were no commissions paid with respect to the fourth private placement. The closing price of the Company&#8217;s common stock on November 6, 2009 was $0.50 per share.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Each unit sold in the fourth private placement consisted of one share of the Company&#8217;s common stock, one three-year warrant to purchase an additional share of the Company&#8217;s common stock at an exercise price of $0.50 per share, and one three-year warrant to purchase an additional share of the Company&#8217;s common stock at an exercise price of $0.75 per share.&#160;The warrants do not have any reset provisions.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At the request of the holder, the Company has agreed to include the shares sold in the fourth private placement and any shares issuable upon exercise of the related warrants in any registration statement filed by the Company with the Securities and Exchange Commission permitting the resale of such securities, subject to customary cutbacks. The units sold were not registered under the Securities Act of 1933, as amended (the &#8220;Act&#8221;), in reliance upon the exemption from registration contained in Section 4(2) of the Act and Regulation D promulgated thereunder. Based on the foregoing, the warrants were accounted for as equity and were not accounted for separately from the common stock and additional paid-in capital accounts. The warrants had no accounting impact on the Company&#8217;s consolidated financial statements.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="Page16"><!--EFPlaceholder--></a>Effective January 20, 2010, the Company raised $1,787,500 in a fifth private placement of units sold to certain of its existing stockholders or their designees, all of whom were accredited investors, consisting of an aggregate of 3,575,000 units at a purchase price of $0.50 per unit. Each unit consisted of one share of common stock, one three-year warrant to purchase a share of common stock at an exercise price of $0.50 per share, and one three-year warrant to purchase a share of common stock at an exercise price of $0.75 per share. The warrants do not have any reset provisions. The closing price of the Company&#8217;s common stock on January 20, 2010 was $0.49 per share. There were no commissions paid with respect to the private placement. Upon request by the holder, the Company has agreed to include the shares issued and those shares issuable upon exercise of the warrants in any registration statement filed by the Company with the Securities and Exchange Commission permitting the resale of such securities, subject to customary cutbacks. The units sold were not registered under the Act, in reliance upon the exemption from registration contained in Section 4(2) of the Act and Regulation D promulgated thereunder. The Company accounted for the issuance of the units as a capital transaction. As of December 31, 2009, $1,200,000 had been advanced to the Company under this private placement, with the balance of $587,500 being received by the Company in January 2010.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Effective February 22, 2010, the Company raised $500,000 through the sale to an accredited investor of 1,000,000 units at a purchase price of $0.50 per unit. Each unit consisted of one share of common stock, one three-year warrant to purchase a share of common stock at an exercise price of $0.50 per share, and one three year-year warrant to purchase a share of common stock at an exercise price of $0.75 per share. The warrants do not have any reset provisions. The closing price of the Company&#8217;s common stock on February 22, 2010 was $0.50 per share. There were no commissions paid with respect to the private placement. Upon request by the holder, the Company has agreed to include the shares issued and those shares issuable upon exercise of the warrants in any registration statement filed by the Company with the Securities and Exchange Commission permitting the resale of such securities, subject to customary cutbacks. The units sold were not registered under the Act, in reliance upon the exemption from registration contained in Section 4(2) of the Act and Regulation D promulgated thereunder. The Company accounted for the issuance of the units as a capital transaction.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5. Money Market Funds &#8212; Fair Value</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Money market funds at June 30, 2011 and December 31, 2010 consisted of an investment in the Class A Shares of Western Asset New York Municipal Money Market Fund with a market value of $1,301,089 and $1,601,006, respectively. The stated purpose of this money market fund is to provide income exempt from both regular federal income tax and New York State and New York City personal income tax from a portfolio of high quality short-term municipal obligations selected for liquidity and stability of principal.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level 1: quoted prices (unadjusted) in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">15</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level 2: inputs other than quoted prices included within Level 1 that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level 3: unobservable inputs for the asset or liability are only used when there is little, if any, market activity for the asset or liability at the measurement date. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Money market funds are the only financial instrument that is measured and recorded at fair value on the Company&#8217;s balance sheet on a recurring basis. The following table presents money market funds at their level within the fair value hierarchy at June 30, 2011 and December&#160;31, 2010.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; ">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Total</font></font></div>
</td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Level&#160;1</font></font></div>
</td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Level&#160;2</font></font></div>
</td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Level&#160;3</font></font></div>
</td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">June 30, 2011:</font></div>
</td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Money market funds</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,301,089</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,301,089</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December 31, 2010:</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Money market funds</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,601,006</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,601,006</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6. Related Party Transactions</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Prior to June 30, 2006, the Company&#8217;s founding stockholder and Chief Executive Officer, Dr. John Kovach, had periodically made advances to the Company to meet operating expenses. Such advances are non-interest-bearing and are due on demand. At June 30, 2011 and December 31, 2010, stockholder advances totaled $92,717.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company&#8217;s office facilities have been provided without charge by Dr. Kovach. Such costs were not material to the financial statements and, accordingly, have not been reflected therein.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In view of the Company&#8217;s development stage status and limited resources, Dr. Kovach did not receive any compensation from the Company during 2010 or in prior years. However, on February 18, 2011, the Company&#8217;s Board of Directors approved a salary to Dr. Kovach of $5,000 per month beginning March 15, 2011.&#160;&#160;In connection therewith, Dr. Kovach reduced his academic commitment from 80% to 60% in order to devote more time to the Company&#8217;s activities. Accordingly, during the three months ended June 30, 2011, the six months ended June 30, 2011, and the period from August 9, 2005 (inception) through June 30, 2011 (cumulative), Dr. Kovach was paid a salary of $15,000, $17,500 and $17,500, respectively.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dr. Kovach is not involved in other business activities but could, in the future, become involved in other business opportunities that become available. Accordingly, he may face a conflict in selecting between the Company and his other business interests. The Company has not yet formulated a policy for the resolution of such potential conflicts.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7. Stock Options and Warrants</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On June 30, 2006, effective with the closing of the Exchange, the Company granted to Dr.&#160;Philip Palmedo, an outside director of the Company, stock options to purchase an aggregate of 200,000 shares of common stock, exercisable for a period of five years at $0.333 per share, with one-third of the options (66,666 shares) vesting immediately upon joining the Board and one-third vesting annually on each of June 30, 2007 and 2008. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $62,000 ($0.31 per share), of which $20,666 was charged to operations on June 30, 2006, and the remaining $41,334 was charged to operations ratably from July 1, 2006 through June 30, 2008.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On June 30, 2006, effective with the closing of the Exchange, the Company also granted to Dr.&#160;Palmedo additional stock options to purchase 190,000 shares of common stock exercisable for a period of five years at $0.333 per share for services rendered in developing the business plan for Lixte, all of which were fully vested upon issuance. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $58,900 ($0.31 per share), and was charged to operations at June 30, 2006.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On June 30, 2011, Dr. Palmedo exercised options to acquire 100,000 shares of common stock, which were part of the above described grants, on a cashless basis. Such cashless exercise resulted in Dr. Palmedo receiving a net of 66,020 shares. The remaining above described options to acquire 290,000 shares of common stock subsequently expired unexercised.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On June 30, 2011, the Company granted to Dr.&#160;Palmedo stock options to purchase 200,000 shares of common stock exercisable for a period of five years from date of grant at $0.98 per share, which was the fair market value of the Company&#8217;s common stock on such date. The options vest ratably in equal quarterly installments of 25,000 each beginning July 1, 2011. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was initially determined to be $196,000 ($0.98 per share).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">16</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On June 30, 2006, effective with the closing of the Exchange, the Company granted to Dr. Stefan Madajewicz and Dr. Iwao Ojima, two members of its Scientific Advisory Committee, stock options to purchase an aggregate of 100,000 shares of common stock (50,000 each) exercisable for a period of five years at $0.333 per share, with one-half of the options vesting annually on each of June 30, 2007 and June 30, 2008. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was charged to operations ratably from July 1, 2006 through June 30, 2008.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In August 2008, Dr. Madajewicz resigned from his position and waived his right to his vested stock option to purchase 50,000 shares of common stock.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On June 30, 2011, Dr. Ojima exercised options to acquire 15,015 shares of common stock for a cash payment of $5,000. Dr. Ojima&#8217;s remaining options to acquire 34,985 shares of common stock subsequently expired unexercised.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On June 30, 2011, the Company granted to Dr.&#160;Ojima stock options to purchase 50,000 shares of common stock exercisable for a period of five years from the date of grant at $0.98 per share, which was the fair market value of the Company&#8217;s common stock on such date. The options vest ratably in equal quarterly installments of 6,250 shares each beginning July 1, 2011. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was initially determined to be $49,000 ($0.98 per share).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On June 30, 2006, the fair value of the aforementioned stock options was initially calculated using the following Black-Scholes input variables: stock price - $0.333; exercise price - $0.333; expected life - 5 to 7 years; expected volatility - 150%; expected dividend yield - 0%; risk-free interest rate - 5%. On June 30, 2007, the Black-Scholes input variables utilized to determine the fair value of the aforementioned stock options were stock price - $0.333; exercise price - $0.333; expected life - 4 to 6 years; expected volatility - 150%; expected dividend yield - 0%; risk-free interest rate - 4.5%. On June 30, 2008, the fair value of the aforementioned stock options was calculated using the following Black-Scholes input variables: stock price - $0.30; exercise price - $0.333; expected life - 3 to 5 years; expected volatility - 154.5%; expected dividend yield - 0%; risk-free interest rate - 3.28%. On June 30, 2011, the fair value of the aforementioned stock options was calculated using the following Black-Scholes input variables: stock price - $0.98; exercise price - $0.98; expected life - 5 years; expected volatility - 308.8%; expected dividend yield - 0%; risk-free interest rate - 1.58%.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On February 5, 2007, the Company entered into an agreement (the &#8220;Chem-Master Agreement&#8221;) with Chem-Master International, Inc. (&#8220;Chem-Master&#8221;), a company co-owned by Francis Johnson, a consultant to the Company, pursuant to which the Company granted a five-year option to purchase 100,000 shares of the Company&#8217;s common stock at an exercise price of $0.333 per share. The fair value of this option, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $31,000 ($0.31 per share) using the following Black-Scholes input variables: stock price on date of grant - $0.333; exercise price - $0.333; expected life - 5 years; expected volatility - 150%; expected dividend yield - 0%; risk-free interest rate - 4.5%. The $31,000 fair value was charged to operations as research and development costs on February 5, 2007 as the option was fully vested and non-forfeitable on the date of issuance. The Company has the right to terminate the Chem-Master Agreement at any time during its term upon sixty days prior written notice. On February 5, 2009, provided that the Chem-Master Agreement had not been terminated prior to such date, the Company agreed to grant Chem-Master a second five-year option to purchase an additional 100,000 shares of the Company&#8217;s common stock at an exercise price of $0.333 per share. As of September 30, 2008, the Company determined that it was likely that this option would be issued. Accordingly, the fair value of the option has been reflected as a charge to operations for the period from October 1, 2008 through February 5, 2009. The Company granted the second five-year option on February 5, 2009.<a name="Page18"><!--EFPlaceholder--></a>&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On September 30, 2008, the fair value of the aforementioned stock option was initially calculated using the following Black-Scholes input variables: stock price - $0.50; exercise price - $0.333; expected life &#8211; 5.35 years; expected volatility &#8211; 275.7%; expected dividend yield - 0%; risk-free interest rate &#8211; 2.48%. On February 5, 2009, the fair value of the aforementioned stock option was calculated for the stock option revaluation purposes using the following Black-Scholes input variables: stock price - $0.60; exercise price - $0.333; expected life &#8211; 5 years; expected volatility &#8211; 414.1%; expected dividend yield - 0%; risk-free interest rate &#8211; 1.89%.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On January 29, 2008, the Chem-Master Agreement was amended to extend its term to February 15, 2014. Pursuant to the amendment, the Company issued 100,000 shares of its restricted common stock, valued at $75,000, and granted an option to purchase 200,000 shares of common stock. The option is exercisable for a period of two years from the vesting date at $1.65 per share, with one-half (100,000 shares) vesting on August 1, 2009, and one-half (100,000 shares) vesting on February 1, 2011. The fair value of this option, as calculated pursuant to the Black-Scholes option-pricing model, was initially determined to be $96,000 ($0.48 per share) using the following Black-Scholes input variables: stock price on date of grant - $0.75; exercise price - $1.65; expected life - 5 years; expected volatility - 120.1%; expected dividend yield - 0%; risk-free interest rate - 3.09%.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">17</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The fair value of the restricted common stock issued was charged to operations as research and development costs on January 29, 2008. On February 1, 2011, the fair value of the aforementioned stock options was determined to be $66,000 ($0.33 per share) calculated using the following Black-Scholes input variables: stock price - $0.35; exercise price - $1.65; expected life - 2 years; expected volatility &#8211; 325.6%; expected dividend yield - 0%; risk-free interest rate -2.07%, which resulted in a charge to operations of $982 during the six months ended June 30, 2011. On June 30, 2010, the fair value of the aforementioned stock options was determined to be $62,000 ($0.31 per share) calculated using the following Black-Scholes input variables: stock price - $0.35; exercise price - $1.65; expected life - 2.59 years; expected volatility &#8211; 233.2%; expected dividend yield - 0%; risk-free interest rate - 0.93%, which resulted in a credit to operations of $1,472 during the three months ended June 30, 2010 and a charge to operations of $5,786 during the six months ended June 30, 2010.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On June 20, 2007, the Board of Directors of the Company approved the 2007 Stock Compensation Plan (the &#8220;2007 Plan&#8221;), which provides for the granting of awards, consisting of common stock options, stock appreciation rights, performance shares, or restricted shares of common stock, to employees and independent contractors, for up to 2,500,000 shares of the Company&#8217;s common stock, under terms and condition, as determined by the Company&#8217;s Board of Directors.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On September 12, 2007, in conjunction with his appointment as a director of the Company, the Company granted to Dr. Stephen Carter stock options to purchase an aggregate of 200,000 shares of common stock under the 2007 Plan, exercisable for a period of five years from vesting date at $0.333 per share, with one-half (100,000 shares) vesting annually on each of September 12, 2008 and 2009. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $204,000 ($1.02 per share), and was charged to operations ratably from September 12, 2007 through September 12, 2009. Effective April 20, 2010, Dr. Carter resigned as a director for personal reasons. Consequently, pursuant to the stock option agreement, Dr. Carter had twelve months from April 20, 2010 to exercise his stock options to acquire 200,000 shares of the Company&#8217;s common stock. On April 20, 2011 Dr. Carter&#8217;s stock options expired unexercised.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On September 12, 2007, the Company entered into a consulting agreement with Gil Schwartzberg, pursuant to which the Company granted to Mr. Schwartzberg stock options to purchase an aggregate of 1,000,000 shares of common stock, exercisable for a period of four years from the vesting date at $1.00 per share, with one-half of the options (500,000 shares) vesting immediately and one-half (500,000 shares) vesting on September 12, 2008. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was initially determined to be $945,000 ($0.945 per share), of which $465,000 was attributed to the fully-vested options and was thus charged to operations on September 12, 2007. The remaining unvested portion of the fair value of the options was charged to operations ratably from September 12, 2007 through September 12, 2008.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On October 15, 2009, the Company amended the above described consulting agreement with Gil Schwartzberg to extend it for an additional four years and granted to Mr. Schwartzberg stock options to purchase an additional aggregate of 1,000,000 shares of common stock, exercisable for a period of four years from the vesting date at $1.00 per share, with one-half of the options (500,000 shares) vesting immediately and one-half (500,000 shares) vesting on October 15, 2010. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $750,000 ($0.75 per share) on October 15, 2009, of which $375,000 was attributed to the fully-vested options and was thus charged to operations on October 15, 2009. The remaining unvested portion of the fair value of the options was charged to operations ratably from October 15, 2009 through October 15, 2010. On June 30, 2010, the fair value of the aforementioned stock options was determined to be $170,000 ($0.34 per share) calculated using the following Black-Scholes input variables: stock price - $0.35; exercise price - $1.00; expected life - 4.29 years; expected volatility &#8211; 233.2%; expected dividend yield - 0%; risk-free interest rate - 0.93%, which resulted in a charge to operations of $8,068 during the three months ended June 30, 2010 and a charge to operations of $68,479 during the six months ended June 30, 2010.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On September 12, 2007, the Company entered into a consulting agreement with Francis Johnson, a co-owner of Chem-Master International, Inc., and granted to Professor Johnson stock options to purchase an aggregate of 300,000 shares of common stock, exercisable for a period of four years from the vesting date at $0.333 per share, with one-third (100,000 shares) vesting annually on each of September 12, 2008, 2009 and 2010. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was initially determined to be $300,000 ($1.00 per share). The unvested portion of the fair value of the options was charged to operations ratably from September 12, 2007 through September 12, 2010. On June 30, 2010, the fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $102,000 ($0.34 per share) which resulted a credit to operations of $290 during the three months ended June 30, 2010 and a charge to operations of $12,340 during the six months ended June 30, 2010.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On September 12, 2007, the fair value of the aforementioned stock options was initially calculated using the following Black-Scholes input variables: stock price - $1.05; exercise price - $0.333 to $1.00; expected life - 4 to 6 years; expected volatility - 150%; expected dividend yield - 0%; risk-free interest rate - 5%. On October 15, 2009, the fair value of the aforementioned stock options was initially calculated using the following Black-Scholes input variables: stock price - $0.75; exercise price - $1.00; expected life - 5 years; expected volatility &#8211; 259.1%; expected dividend yield - 0%; risk-free interest rate &#8211; 1.91%. On June 30, 2010, the fair value of the aforementioned stock options was calculated for the stock option revaluation purposes using the following Black-Scholes input variables: stock price - $0.35; exercise price - $0.333; expected life - 4.23; expected volatility &#8211; 233.2%; expected dividend yield - 0%; risk-free interest rate &#8211; 0.93%.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As the Company&#8217;s common stock commenced trading on September 24, 2007, the Company was able to utilize such trading data to generate revised volatility factors as of the various subsequent measurement dates.</font><br>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">18</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On September 20, 2007, the Company entered into a one-year consulting agreement (the &#8220;Mirador Agreement&#8221;) with Mirador Consulting, Inc. (&#8220;Mirador&#8221;), pursuant to which Mirador was to provide the Company with various financial services. Pursuant to the Mirador Agreement, the Company agreed to pay Mirador $5,000 per month and also agreed to sell Mirador 250,000 shares of the Company&#8217;s restricted common stock for $250 ($0.001 per share). The fair value of this transaction was determined to be in excess of the purchase price by $262,250 ($1.049 per share), reflecting the difference between the $0.001 purchase price and the $1.05 price per share as quoted on the OTC Bulletin Board on the transaction date, and was charged to operations as stock-based compensation on September 20, 2007, being that the shares were fully vested and non-forfeitable on the date of issuance.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On October 7, 2008, the Company appointed Dr. Mel Sorensen to its Board of Directors. Dr. Sorensen is a medical oncologist with extensive experience in cancer drug development, first at the National Cancer Institute, then at Bayer and GlaxoSmithKline, before becoming President and Chief Executive Officer of a new cancer therapeutics company, Ascenta Therapeutics, in 2004. Dr. Sorensen was paid an annual consulting fee of $40,000, payable in quarterly installments over a one year period commencing October 7, 2008, to assist the Company in identifying a strategic partner. Dr. Sorensen was also granted a stock option to purchase 200,000 shares of the Company&#8217;s common stock, exercisable at $0.50 per share for a period of five years from each tranche&#8217;s vesting date. The option vests as to 25,000 shares on January 1, 2009, and a further 25,000 shares on the first day of each subsequent calendar quarter until all of the shares are vested. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $100,000 ($0.50 per share), and was charged to operations ratably from October 7, 2008 through October 7, 2010. During the three and six months ended June 30, 2010, the Company recorded charges to operations of $12,466 and $24,795, respectively, with respect to these options.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On October 7, 2008, the fair value of the aforementioned stock options was calculated using the following Black-Scholes input variables: stock price - $0.50; exercise price - $0.50; expected life - 5 years; expected volatility &#8211; 275.7%; expected dividend yield - 0%; risk-free interest rate &#8211; 2.48%.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On July 27, 2009, the Company entered into an agreement with Pro-Active Capital Group, LLC (&#8220;Pro-Active&#8221;) to retain Pro-Active on a non-exclusive basis for a period of twelve months to provide consulting advice to the Company to assist the Company in obtaining research coverage, gaining web-site exposure and coverage on financial blogs and web-sites, enhancing the Company&#8217;s visibility to the institutional, retail brokerage and on-line trading communities, and organizing, or assisting in organizing, investor road-shows and presentations. In exchange for such consulting advice, at the initiation of the agreement, the Company agreed to issue to Pro-Active 150,000 shares of restricted common stock and three-year warrants to purchase an aggregate of 150,000 shares of common stock, exercisable 50,000 at $0.75 per share, 50,000 at $1.00 per share, and 50,000 at $1.25 per share. The fair value of the 150,000 shares issued was determined to be $100,500 ($0.67 per share), reflecting the price per share of the Company&#8217;s common stock, as quoted on the OTC Bulletin Board, on the transaction date. The fair value of the three-year warrants, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $97,500 ($0.65 per share) using the following Black-Scholes input variables: stock price on date of grant - $0.67; exercise price - $0.75 to $1.25; expected life - 3 years; expected volatility &#8211; 259.1%; expected dividend yield - 0%; risk-free interest rate - 1.91%. The $198,000 aggregate fair value of the shares and warrants issued was charged to operations as stock-based compensation on July 27, 2009, as the shares and warrants were fully vested and non-forfeitable on the date of issuance.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Effective May 2, 2011, the Company elected Dr. Robert B. Royds to its Board of Directors. Dr. Royds<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>is Chairman of the Board and Medical Director of Theradex Systems, Inc., a leading clinical research organization, with research bases in Europe, Australia and Japan. Dr. Royds is responsible for the scientific affairs of Theradex Systems, Inc. Dr. Royds was trained in internal medicine and pharmacology, and he has extensive experience in all stages of the clinical drug development process. Before founding Theradex Systems, Inc., Dr. Royds was Senior Research Physician at Hoffmann-La Roche, Inc., and Associate Director for Clinical Pharmacology International at Merck, Sharp, and Dohme Research Laboratories. Dr. Royds has been a consultant/advisor to the National Institute of Child Health and Development and the National Cancer Institute on issues of clinical trial design and international standardization of data sets of clinical trials of new investigational anti-cancer agents. Dr. Royds has served as the physician-monitor for the Clinical Trials Monitoring Service of the National Cancer Institute since 1979, and has been the Principal Investigator for this contract since 1982.</font><br>
&#160; </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Effective May 1, 2011, Dr. Royds was granted stock options to purchase 200,000 shares of the Company&#8217;s common stock, exercisable for a period of five years from each tranche&#8217;s vesting date, at $0.98 per share, which was the fair market value of the Company&#8217;s common stock on such date. The options vested as to 25,000 shares on May 1, 2011, and a further 25,000 shares vest on the first day of each subsequent quarter until all of the shares are vested. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $196,000 ($0.98 per share), and is being charged to operations ratably from May 2, 2011 through February 1, 2013. During the three months and six months ended June 30, 2011, the Company recorded a charge to operations of $40,528 with respect to these options.</font></div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On May 2, 2011, the fair value of the aforementioned stock options was calculated using the following Black-Scholes input variables: stock price - $0.98; exercise price - $0.98; expected life &#8211; 6.76 years; expected volatility &#8211; 308.8%; expected dividend yield - 0%; risk-free interest rate &#8211; 1.58%.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Additional information with respect to common stock warrants and stock options issued is provided at Notes 4 and 8.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If and when the aforementioned stock options and warrants are exercised, the Company expects to satisfy such stock obligations through the issuance of authorized but unissued shares of common stock.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">19</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="Page20"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A summary of stock option and warrant activity, including warrants to purchase common stock that were issued in conjunction with the Company&#8217;s private placements, is presented in the tables below.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; ">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;</font></div>
</td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Number</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">of</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Shares</font></font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;</font></div>
</td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Weighted</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Average</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Exercise</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Price</font></font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;</font></div>
</td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Weighted</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Average</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Remaining</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Contractual</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Life</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(in&#160;Years)</font></font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Options and warrants outstanding at December 31, 2009</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,997,426</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.664</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Granted</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,150,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.625</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercised</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cancelled</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Options and warrants outstanding at December 31, 2010</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">17,147,426</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.643</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Granted</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">450,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.980</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercised</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(267,889</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.333</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cancelled</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(524,985</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">0.333</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Options and warrants outstanding at June 30, 2011</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">16,804,552</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">0.667</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1.78</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Options and warrants exercisable at December 31, 2010</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">16,877,026</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">0.639</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="9%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Options and warrants exercisable at June 30, 2011</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16,209,152</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.660</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.68</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total deferred compensation expense for the outstanding value of unvested stock options was approximately $400,500 at June 30, 2011, which is being recognized subsequent to June 30, 2011 over a weighted-average period of forty-four months.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Information regarding stock options and warrants outstanding and exercisable is summarized as follows at June 30, 2011:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; ">
<tr>
<td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" nowrap valign="bottom" width="31%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="32%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrants</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="31%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrants</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" nowrap valign="bottom" width="31%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="32%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">And</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="31%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">And</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" nowrap valign="bottom" width="31%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="32%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Options</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="31%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Options</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="31%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercise</font></div>
</td>
<td nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="32%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Outstanding</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="31%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercisable</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px double"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="31%" style="BORDER-BOTTOM: black 2px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Prices</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="32%" style="BORDER-BOTTOM: black 2px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(Shares)</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="31%" style="BORDER-BOTTOM: black 2px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(Shares)</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="31%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.333</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="31%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">773,752</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="30%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">773,752</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="31%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.500</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="31%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,535,800</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="30%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,365,400</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="31%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.650</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="31%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">120,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="30%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">120,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="31%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.750</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="31%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,625,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="30%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,625,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="31%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.980</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="31%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">450,000</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="30%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">25,000</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="31%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.000 </font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="31%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,050,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="30%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,050,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="31%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.250 </font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="31%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">50,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="30%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">50,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="31%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.650 </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="31%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">200,000</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="30%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">200,000</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="31%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="31%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16,804,552</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="30%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16,209,152</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The intrinsic value of exercisable but unexercised in-the-money stock options and warrants at June 30, 2011 was approximately $5,369,360, based on a fair market value of $0.98 per share on June 30, 2011. The intrinsic value of exercisable but unexercised in-the-money stock options and warrants at December 31, 2010 was approximately $26,600, based on a fair market value of $0.35 per share on December 31, 2010.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Outstanding options and warrants to acquire 425,000 shares of the Company&#8217;s common stock had not vested at June 30, 2011. At June 30, 2011, warrants and options exercisable do not include warrants to acquire 170,400 shares of common stock that are contingent upon the exercise of warrants contained in units sold as part of the third private placement (see Note 4).</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">8.</font> <font style="DISPLAY: inline; FONT-WEIGHT: bold">Commitments and Contingencies</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">CRADA</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="Page21"><!--EFPlaceholder--></a>Effective March 22, 2006, the Company entered into a CRADA, as amended, with the NINDS of the NIH. The CRADA is for a term of 66 months from the effective date and can be unilaterally terminated by either party by providing written notice within sixty days. The CRADA provides for the collaboration between the parties in the identification and evaluation of agents that target the Nuclear Receptor CoRepressor (N-CoR) pathway for glioma cell differentiation. The CRADA also provides that NINDS and the Company will conduct research to determine if expression of N-CoR correlates with prognosis in glioma patients. Pursuant to the CRADA, the Company initially agreed to provide funds under the CRADA in the amount of $200,000 per year to fund two technical assistants for the technical, statistical and administrative support for the research activities, as well as to pay for supplies and travel expenses. The first $200,000 was due within 180 days of the effective date and was paid in full on July 6, 2006. The second $200,000 was paid in full on June 29, 2007. In June 2008, the CRADA was extended to September 30, 2009, with no additional funding required for the period between July 1, 2008 and September 30, 2008. For the period from October 1, 2008 through September 30, 2009, the Company agreed to provide additional funding under the CRADA of $200,000, to be paid in four quarterly installments of $50,000, each commencing on October 1, 2008. The first and second quarterly installments of $50,000 were paid on September 29, 2008 and March 5, 2009, respectively.&#160;During August&#160;2009, the Company entered into an amendment to the CRADA to extend its term from September 30, 2009 through September 30, 2011.&#160;Pursuant to such amendment, the Company has agreed to aggregate payments of $100,000 in two installments of $50,000, payable on October 1, 2010 and January 5, 2011, inclusive of any prior unpaid commitments. The October 1, 2010 installment was paid on September 29, 2010 and the January 5, 2011 installment was paid on December 27, 2010.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">20</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Effective as of September 19, 2008, the Company entered into an agreement with the NIH providing the Company with an exclusive license for all patents submitted jointly with the NIH under the CRADA. The agreement provided for an initial payment of $25,000 to NIH within 60 days of September 19, 2008, and for a minimum annual royalty of $30,000 on January 1 of each calendar year following the year in which the CRADA is terminated. The agreement also provides for the Company to pay specified royalties based on (i) net sales by the Company and its sub-licensees, (ii) the achievement of certain clinical benchmarks, and (iii) the granting of sublicenses. The Company paid the initial $25,000 obligation on November 10, 2008 and charged the amount to general and administrative costs during the year ended December 31, 2008. As of June 30, 2011, no additional amounts were due pursuant to this agreement.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Research and Development Contracts</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On February 5, 2007, the Company entered into a two-year agreement pursuant to which the Company engaged Chem-Master to synthesize a compound designated as LB-100, and any other compound synthesized by Chem-Master pursuant to the Company&#8217;s request, which have potential use in treating a disease, including, without limitation, cancers such as glioblastomas. Pursuant to the Chem-Master Agreement, the Company agreed to reimburse Chem-Master for the cost of materials, labor, and expenses for other items used in the synthesis process, and also agreed to grant Chem-Master a five-year option to purchase shares of the Company&#8217;s common stock. The Company has the right to terminate the Chem-Master Agreement at any time during its term upon sixty days prior written notice.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On January 29, 2008, the Chem-Master Agreement was amended to extend its term to February 15, 2014, and to expressly provide for the design and synthesis of a new series of compounds designated as LB-300. Pursuant to the Chem-Master Agreement, as amended, the Company reimbursed Chem-Master for the costs of materials, labor and expenses aggregating $1,500 and $20,000 during the three months ending June 30, 2011 and 2010, respectively. During the six months ending June 30, 2011 and 2010, reimbursements to Chem-Master amounted to $6,325 and $33,000, respectively.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On March 17, 2010, the Company engaged Theradex Systems, Inc. to assist the Company in bringing LB-100 through the FDA approval process at a total estimated cost of $105,064, of which $15,205 had been incurred through June 30, 2011. As of June 30, 2011, work was proceeding under this contract. Dr. Robert B. Royds, the founder, Chairman of the Board and Medical Director of Theradex Systems, Inc., was appointed to the Company&#8217;s Board of Directors on May 2, 2011.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On March 17, 2011, the Company entered into an agreement with Ascentage Pharma Group to conduct a series of studies at a total estimated cost of $20,000, of which $15,000 had been paid through June 30, 2011. Ascentage Pharma Group is an offshoot of Ascenta Therapeutics, of which Dr. Mel Sorensen, a director of the Company, is the President and Chief Executive Officer and a director. Ascentage Pharma Group and Ascenta Therapeutics have a continuing business relationship and certain common shareholders. However, Dr. Sorensen does not have any direct business relationship with or ownership in Ascentage Pharma Group.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On January 7, 2011, the Company entered into a Master Laboratory Services Agreement with WIL Research Laboratories, LLC for a series of studies. As of June 30, 2011, work orders for studies having a total estimated cost of $108,240 were in process under this agreement. As of June 30, 2011, the Company had paid $54,120 towards these work orders.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On January 18, 2011, the Company entered into an agreement with Ash Stevens for a series of studies with a total estimated cost of $90,000. As of June 30, 2011, the Company had paid $29,700 towards these studies.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Consulting Arrangements</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On April 7, 2010, the Company entered into an agreement with Dr. Mel Sorensen providing for consultation and advice over the ensuing twelve month period regarding the preparation and strategy for obtaining FDA approval for the clinical trial of the lead compound of the LB-100 series. The agreement called for an annual fee of $25,000, payable in two installments of $12,500 on April 15, 2010 and October 15, 2010. On February 18, 2011, the Company&#8217;s Board of Directors approved a one-year extension of the agreement for an additional annual fee of $25,000, payable in two installments of $12,500 on April 15, 2011 and October 15, 2011. All installments have been paid as due.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">21</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="Page22"><!--EFPlaceholder--></a>The following table sets forth the Company&#8217;s principal cash obligations and commitments for the next five fiscal years as of June 30, 2011 aggregating $470,236, of which $256,267 is included in current liabilities in the condensed consolidated balance sheet at June 30, 2011.&#160; Amounts included in the 2011 column represent amounts due at June 30, 2011 for the remainder of the 2011 fiscal year ending December 31, 2011.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; ">
<tr>
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;</font></div>
</td>
<td align="left" colspan="2" nowrap valign="bottom" width="10%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;</font></div>
</td>
<td colspan="6" nowrap valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Payments&#160;Due&#160;By&#160;Year</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;</font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Total</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2012</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Research and development contracts</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">291,019</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">291,019</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Consulting agreement</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12,500</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12,500</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Liquidated damages payable under registration rights agreement</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">74,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">74,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Due to stockholder</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">92,717</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">92,717</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">470,236</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">470,236</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">9.</font> <font style="DISPLAY: inline; FONT-WEIGHT: bold">Subsequent Events</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On July 27, 2011, the Company agreed to extend warrants to acquire 273,752 shares of common stock that were previously issued in connection with the Company&#8217;s first private placement in 2006 to July 27, 2012.&#160;&#160;In conjunction with the extension of the warrants, the cashless exercise feature was deleted.&#160;&#160;On July 27, 2011, the fair value of the warrant extension, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $199,839 ($0.73 per share), and will be charged to operations during the three months ending September 30, 2011.&#160;&#160;The fair value of the warrant extension was calculated using the following input variables: stock price - $0.79; exercise price - $0.333; expected life - 1 year; expected volatility &#8211; 308.8%; expected dividend yield - 0%; risk-free interest rate &#8211; 0.14%.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">22</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="Page23"><!--EFPlaceholder--></a><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; ">
<tr valign="top">
<td style="WIDTH: 63pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 2.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Overview</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On June 30, 2006, Lixte Biotechnology, Inc., a privately-held Delaware corporation (&#8220;Lixte&#8221;) incorporated on August 9, 2005, completed a reverse merger transaction with SRKP 7, Inc. (&#8220;SRKP&#8221;), a non-trading public shell company, whereby Lixte became a wholly-owned subsidiary of SRKP. On December 7, 2006, SRKP amended its Certificate of Incorporation to change its name to Lixte Biotechnology Holdings, Inc. (&#8220;Holdings&#8221;). Unless the context indicates otherwise, Lixte and Holdings are hereinafter referred to as the &#8220;Company&#8221;.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For financial reporting purposes, Lixte was considered the accounting acquirer in the merger and the merger was accounted for as a reverse merger. Accordingly, the historical financial statements presented herein are those of Lixte. The stockholders&#8217; equity section of SRKP has been retroactively restated for all periods presented to reflect the accounting effect of the reverse merger transaction. All costs associated with the reverse merger transaction were expensed as incurred.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company is considered a &#8220;development stage company&#8221; under current accounting standards, as it has not yet commenced any revenue-generating operations, does not have any cash flows from operations, and is dependent on debt and equity funding to finance its operations.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company&#8217;s common stock was listed for trading on the OTC Bulletin Board commencing September 24, 2007 under the symbol &#8220;LIXT&#8221;. It is presently traded on the OTC Market (also referred to as the &#8220;Pink Sheets&#8221;) under the symbol &#8220;LIXT.PK&#8221;.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Going Concern</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company&#8217;s condensed consolidated financial statements have been presented on the basis that it is a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company is in the development stage and has not generated any revenues from operations to date, and does not expect to do so in the foreseeable future.&#160;&#160;The Company has experienced recurring operating losses and negative operating cash flows since inception, and has financed its working capital requirements through the recurring sale of its equity securities.&#160;&#160;As a result, the Company&#8217;s independent registered public accounting firm, in its report on the Company&#8217;s 2010 consolidated financial statements, has raised substantial doubt about the Company&#8217;s ability to continue as a going concern.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company&#8217;s ability to continue as a going concern is dependent upon its ability to develop additional sources of capital and to ultimately achieve sustainable revenues and profitable operations. The Company&#8217;s condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At June 30, 2011, the Company had not yet commenced any revenue-generating operations. All activity through June 30, 2011 has been related to the Company&#8217;s formation, capital raising efforts and research and development activities. As such, the Company has yet to generate any cash flows from operations, and is dependent on debt and equity funding from both related and unrelated parties to finance its operations. Prior to June 30, 2006, the Company&#8217;s cash requirements were funded by advances from the Company&#8217;s founder.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Because the Company is currently engaged in research at an early stage, it will likely take a significant amount of time to develop any product or intellectual property capable of generating revenues. As such, the Company&#8217;s business is unlikely to generate any sustainable revenues in the next several years, and may never do so. Even if the Company is able to generate revenues in the future through licensing its technologies or through product sales, there can be no assurance that the Company will be able to generate a profit.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company&#8217;s activities for the remainder of 2011 will consist of continuing drug discovery and development efforts. The Company&#8217;s primary objective is to&#160;gain FDA approval of&#160;the Company's LB-100 compound for entry into a&#160;Phase I clinical trial by the end of 2011. The Company was not able to expedite this process so as to obtain such approval by its June 30, 2011 target date.&#160; The Company has not identified any specific obstacles to the submission of the FDA application, but the overall process of large animal testing and formal documentation of the long-term stability of the LB-100 compound has been slower than originally anticipated.&#160;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company raised $500,000 in November 2009, $1,787,500 in January 2010, and $500,000 in February 2010, all through the sale of its securities to fund its business activities. The Company also received $244,479 from the Internal Revenue Service under its Qualifying Therapeutic Discovery Grant program, consisting of $127,994 on November 9, 2010 and $116,485 on February&#160;1, 2011.&#160;&#160;As a result, the Company believes that its existing resources are adequate to fund operations until early 2012&#160;at a level that will allow the continuation of the Company&#8217;s two drug development programs currently in process and commencement, but not completion, of a Phase I clinical trial of LB-100.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">23</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="Page24"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The amount and timing of future cash requirements will depend on the pace of these programs, in particular, completion of the Phase I trial of LB-100.&#160;&#160;After completion of the Phase I trial, the next step will be to determine the anti-cancer activity against a particular type of human cancer in Phase II trials. To complete the Phase I trial and carry out Phase II trials, the Company anticipates that it will be necessary to raise additional funds beginning in early 2012 from a combination of additional debt or equity financings, and/or the sale, licensing or joint venturing of its intellectual properties.&#160;&#160;Market conditions present uncertainty as to the Company&#8217;s ability to secure additional funds, as well as its ability to reach profitability. There can be no assurances that the Company will be able to secure additional financing, or obtain favorable terms on such financing if it is available, or as to the Company&#8217;s ability to achieve positive earnings and cash flows from operations. Continued negative cash flows and lack of liquidity create significant uncertainty about the Company&#8217;s ability to fully implement its operating plan beyond early 2012, as a result of which the Company may have to reduce the scope of its planned operations. If cash resources are insufficient to satisfy the Company&#8217;s liquidity requirements, the Company would be required to scale back or discontinue its technology and product development programs, or obtain funds, if available, through strategic alliances that may require the Company to relinquish rights to certain of its technologies products, or to discontinue its operations entirely.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Recent Accounting Pronouncements</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In May&#160;2011, the Financial Accounting Standards Board (the &#8220;FASB&#8221;)&#160;issued Accounting Standards Update (the &#8220;ASU&#8221;)&#160;No.&#160;2011-4, which amends the Fair Value Measurements Topic of the Accounting Standards Codification (the &#8220;ASC&#8221;)&#160;to help achieve common fair value measurement and disclosure requirements in U.S. GAAP and IFRS.&#160;&#160;ASU No.&#160;2011-4 does not require additional fair value measurements and is not intended to establish valuation standards or affect valuation practices outside of financial reporting.&#160;&#160;The ASU is effective for interim and annual periods beginning after December&#160;15, 2011. The Company will adopt the ASU as required.&#160;&#160;The ASU will affect the Company&#8217;s fair value disclosures, but is not expected to have any impact on the Company&#8217;s financial position or results of operations.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In June&#160;2011, the FASB issued ASU No.&#160;2011-5, which amends the Comprehensive Income Topic of the ASC.&#160;&#160;The ASU eliminates the option to present the components of other comprehensive income as part of the statement of changes in shareholders&#8217; equity, and instead requires consecutive presentation of the statement of net income and other comprehensive income either in a continuous statement of comprehensive income or in two separate but consecutive statements.&#160;&#160;ASU No.&#160;2011-5 is effective for interim and annual periods beginning after December&#160;15, 2011.&#160;&#160;The Company will adopt the ASU as required.&#160;&#160;The ASU is not expected to have any impact on the Company&#8217;s financial position or results of operations.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company&#8217;s financial statement presentation or disclosures.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Critical Accounting Policies and Estimates</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company prepared its condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Management periodically evaluates the estimates and judgments made. Management bases its estimates and judgments on historical experience and on various factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates as a result of different assumptions or conditions.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following critical accounting policies affect the more significant judgments and estimates used in the preparation of the Company&#8217;s condensed consolidated financial statements.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Research and Development</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Research and development costs are expensed as incurred. Research and development expenses consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company's treatments and product candidates.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Amounts that become due, pursuant to contractual commitments, on research and development contracts with third parties are recorded as a liability, with the related amount of such contracts recorded as advances on research and development contract services on the Company&#8217;s balance sheet. Such advances on research and development contract services are expensed over their life on the straight-line basis, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different expensing schedule is more appropriate. The Company reviews the status of its research and development contracts on a quarterly basis.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The funds paid to NINDS of the NIH, pursuant to the CRADA effective March 22, 2006, as amended, represented an advance on research and development costs and therefore had future economic benefit. Accordingly, such costs have been charged to expense when they are actually expended by the provider, which is, effectively, as they perform the research activities that they were contractually committed to provide. Absent information that would indicate that a different expensing schedule was more appropriate (such as, for example, from the achievement of performance milestones or the completion of contract work), such advances have been expensed over the contractual service term on a straight-line basis, which, in management&#8217;s opinion, reflects a reasonable estimate of when the underlying research and development costs were being incurred.<a name="Page25"><!--EFPlaceholder--></a></font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">24</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Patent Costs</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company's research efforts and any related patent applications, all patent costs, including patent-related legal and filing fees, are expensed as incurred.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Stock-Based Compensation</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company periodically issues stock options and warrants to officers, directors and consultants for services rendered. Options vest and expire according to terms established at the grant date.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company accounts for share-based payments to officers and directors by measuring the cost of services received in exchange for equity awards based on the grant date fair value of the awards, with the cost recognized as compensation expense in the Company&#8217;s financial statements over the vesting period of the awards.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company accounts for share-based payments to consultants by determining the value of the stock compensation based upon the measurement date at either (a) the date at which a performance commitment is reached or (b) at the date at which the necessary performance to earn the equity instruments is complete.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Options granted to Scientific Advisory Board committee members and outside consultants are revalued each reporting period to determine the amount to be recorded as an expense in the respective period. As the options vest, they are valued on each vesting date and an adjustment is recorded for the difference between the value already recorded and the then current value on the date of vesting.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The fair value of stock-based compensation is affected by several variables, the most significant of which are the life of the equity award, the exercise price of the security as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock over the term of the equity award.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Income Taxes</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Plan of Operation</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">General Overview of Plans</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company&#8217;s original focus was the development of new treatments for the most common and most aggressive type of brain cancer of adults, glioblastoma multiforme (&#8220;GBM&#8221;), and the most common cancer of children, neuroblastoma. The Company has expanded the scope of its anti-cancer investigational activities to include the most common brain tumor of children, medulloblastoma, and also to several other types of more common cancers. This expansion of activity is based on documentation that each of two distinct types of drugs being developed by the Company has activity against cell lines of breast, colon, lung, prostate, pancreas, ovary, stomach and liver cancer, as well as against the major types of leukemias. LB-100 has now been shown to have activity in animal models of brain tumors of adults and children, and also against melanomas and sarcomas.&#160;&#160;Studies in animal models of human melanoma, lymphoma, sarcoma, brain tumors, and the rare neuroendocrine cancer, pheochromocytoma, have demonstrated marked potentiation by LB-100 of the anti-tumor activity of the widely used standard chemotherapeutic drugs. These studies confirm that the LB-100 compounds, combined with any of several &#8220;standard anti-cancer drugs&#8221;, have broad activity, affecting many different cell types of cancer. This is unusual and important because these compounds may be useful for treatment of cancer in general.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The research on brain tumors is proceeding in collaboration with the National Institute of Neurological Disorders and Stroke (&#8220;NINDS&#8221;) of the National Institutes of Health (&#8220;NIH&#8221;) under a Cooperative Research and Development Agreement (&#8220;CRADA&#8221;) entered into on March 22, 2006, as amended. The research at NINDS continues to be led by Dr. Zhengping Zhuang, an internationally recognized investigator in the molecular pathology of cancer. Dr. Zhuang is aided by two senior research technicians supported by the Company as part of the CRADA. The goal of the CRADA is to develop more effective drugs for the treatment of GBM through the processes required to gain Food and Drug Administration (&#8220;FDA&#8221;) approval for clinical trials. The Company has entered into an amendment to the CRADA to extend its term from September 30, 2009 through September 30, 2011.<a name="Page26"><!--EFPlaceholder--></a></font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">25</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During 2009, the Company signed material transfer agreements with academic investigators at major cancer centers in the United States, as well as with one investigator in China with a unique animal model of a sarcoma, to expand molecular and applied studies of the anti-cancer activity of the Company&#8217;s compounds.&#160;&#160;The Company retained the right to all discoveries made in these studies.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company&#8217;s longer-term objective is to secure one or more strategic partnerships with pharmaceutical companies with major programs in cancer, anti-fungal treatments, and/or neuroprotective measures. The Company&#8217;s immediate focus is to obtain approval from the FDA to carry a lead compound of the LB-100 series into a Phase I clinical trial. The Company believes the potent activity of these drugs in combination with standard non-specific chemotherapeutic drugs against a diverse array of common and uncommon cancers of adults and children merits bringing this treatment to patients as rapidly as possible. In addition, the demonstration of clinical benefit would be very important to potential investors and to large pharmaceutical companies looking to add an entirely new approach to their anti-cancer drug portfolios.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The significant diversity of the potential therapeutic value of the Company&#8217;s compounds stems from the fact that these agents modify critical pathways in cancer cells and in microorganisms such as fungi and appear to ameliorate pathologic processes that lead to brain injury caused by trauma or toxins or through as yet unknown mechanisms that underlie the major chronic neurologic diseases, including Alzheimer&#8217;s Disease, Parkinson&#8217;s Disease, and Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig&#8217;s Disease).&#160;&#160;Studies of the potential neuroprotective effects of homologs of each class of the Company&#8217;s compounds are continuing under a contract with Southern Research Institute, Birmingham, Alabama.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Plans for 2011 and Beyond</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company&#8217;s primary short-term objective is to&#160;gain FDA approval of&#160;the Company's LB-100 compound for entry into a&#160;Phase I clinical trial by the end of 2011. The Company was not able to expedite this process so as to obtain such approval by its June 30, 2011 target date.&#160; The Company has not identified any specific obstacles to the submission of the FDA application, but the overall process of large animal testing and formal documentation of the long-term stability of the LB-100 compound has been slower than originally anticipated.&#160;The cost for drug synthesis formulation and pharmacokinetic and toxicologic studies needed for an IND application is currently estimated to be approximately $1,200,000.&#160;&#160;The Company believes that it currently has sufficient resources to fund its operations through early 2012, including the commencement, but not the completion, of a Phase I clinical trial of LB-100 and the continued development of the LB-200 series.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The&#160;next step in the clinical development of LB-100 after the completion of a Phase I clinical trial is to obtain IND approval from the FDA to administer the drug to patients. In order to do this, the Company must demonstrate that LB-100 can be administered safely to human beings at a dose and at a frequency that achieves the desired pharmacologic effect, in this case inhibition of a specific enzyme, without being associated with toxicities considered unacceptable. A compound that has a mechanism of action similar to that of LB-100 has been given with safety and benefit to cancer patients outside the United States in the past. This similar compound has a chemical feature which appears to be responsible for most of its toxicity. This feature has been removed from LB-100, making it likely that the Company&#8217;s compound will be less toxic and, therefore, safer for human use.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Subject to the availability of resources, the Company expects to continue to fund additional studies to characterize the anti-cancer and anti-fungal activity of certain homologs of drugs of the LB-200 series in collaboration with academic partners and&#160;commercial research organizations.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Beginning March&#160;15, 2011, Dr. Kovach reduced his academic commitment to 60% from 80% in order to devote more time to managing the development of the Company&#8217;s compounds. He began receiving compensation of $5,000 per month from the Company at that time.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Results of Operations</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company is a development stage company and had not commenced revenue-generating operations at June 30, 2011.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Three Months Ended June 30, 2011 and 2010</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">General and Administrative Costs</font>.&#160;&#160;For the three months ended June 30, 2011, general and administrative costs were $123,581, which consisted of the fair value of stock options issued to directors and consultants of $40,528, consulting and professional fees of $38,188, insurance expense of $6,125, officer&#8217;s salary and related costs of $17,063, stock transfer fees of $3,504, travel and entertainment costs of $11,639, and other operating costs of $6,534.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the three months ended June 30, 2010, general and administrative costs were $76,892, which consisted of the fair value of stock options issued to directors and consultants of $20,534, consulting and professional fees of $32,185, insurance expense of $6,125, officer&#8217;s salary and related costs of $-0-, stock transfer fees of $2,433, travel and entertainment costs of $8,651, and other operating costs of $6,964.<a name="Page27"><!--EFPlaceholder--></a></font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">26</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Research and Development Costs</font>.&#160;&#160;For the three months ended June 30, 2011, research and development costs were $224,208, which consisted of the vested portion of the fair value of stock options issued to a vendor of $-0-, patent costs of $95,126, third-party contractor costs of $122,832, and consulting fees to a related party of $6,250.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the three months ended June 30, 2010, research and development costs were $233,104, which consisted of a credit for the vested portion of the fair value of stock options issued to a consultant and a vendor of $1,762, patent costs of $82,091, third-party contractor costs of $147,567 and consulting fees to a related party of $5,208.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Interest Income</font>.&#160;&#160;For the three months ended June 30, 2011 and 2010, interest income was $37 and $333, respectively.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Net loss</font>.&#160;&#160;For the three months ended June 30, 2011, the Company incurred a net loss of $347,752, as compared to a net loss of $309,663 for the three months ended June 30, 2010.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Six Months Ended June 30, 2011 and 2010</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">General and Administrative Costs</font>.&#160;&#160;For the six months ended June 30, 2011, general and administrative costs were $213,197, which consisted of the fair value of stock options issued to directors and consultants of $40,528, consulting and professional fees of $110,495, insurance expense of $12,250, officer&#8217;s salary and related costs of $20,035, stock transfer fees of $5,173, travel and entertainment costs of $13,527, and other operating costs of $11,189.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the six months ended June 30, 2010, general and administrative costs were $265,470, which consisted of the fair value of stock options issued to directors and consultants of $93,274, consulting and professional fees of $135,836, insurance expense of $12,250, officer&#8217;s salary and related costs of $-0-, stock transfer fees of $4,711, travel and entertainment costs of $9,261, and other operating costs of $10,138.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Research and Development Costs</font>.&#160;&#160;For the six months ended June 30, 2011, research and development costs were $485,654, which consisted of the vested portion of the fair value of stock options issued to a vendor of $981, patent costs of $234,271, third-party contractor costs of $237,902, and consulting fees to a related party of $12,500.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the six months ended June 30, 2010, research and development costs were $394,977, which consisted of&#160;&#160;the vested portion of the fair value of stock options issued to a consultant and a vendor of $18,126, patent costs of $170,780, third-party contractor costs of $200,863 and consulting fees to a related party of $5,208.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Interest Income</font>.&#160;&#160;For the six months ended June 30, 2011 and 2010, interest income was $83 and $548, respectively.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Net loss</font>.&#160;&#160;For the six months ended June 30, 2011, the Company incurred a net loss of $698,768, as compared to a net loss of $659,899 for the six months ended June 30, 2010.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Liquidity and Capital Resources &#8211; June 30, 2011</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company&#8217;s condensed consolidated financial statements have been presented on the basis that it is a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company is in the development stage and has not generated any revenues from operations to date, and does not expect to do so in the foreseeable future.&#160;&#160;The Company has experienced recurring operating losses and negative operating cash flows since inception, and has financed its working capital requirements through the recurring sale of its equity securities.&#160;&#160;As a result, the Company&#8217;s independent registered public accounting firm, in its report on the Company&#8217;s 2010 consolidated financial statements, has raised substantial doubt about the Company&#8217;s ability to continue as a going concern (see &#8220;Going Concern&#8221; above&#8221;).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company raised $500,000 in November 2009, $1,787,500 in January 2010 (of which $1,200,000 had been advanced to the Company at December 31, 2009), and $500,000 in February 2010, all through the sale of its securities to fund its business activities. The Company also received an aggregate of $244,479 (of which $127,994 was received in 2010 and $116,485 was received in 2011), from a federal grant program to support promising biotechnology initiatives.&#160;&#160;As a result, the Company believes that its existing resources are adequate to fund operations at current levels through early 2012 at a level that will allow the continuation of the Company&#8217;s two drug development programs currently in process and commencement, but not completion, of a Phase I clinical trial of LB-100.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Operating Activities</font>.&#160;&#160;For the six months ended June 30, 2011, operating activities utilized cash of $389,774, as compared to utilizing cash of $529,273 for the six months ended June 30, 2010, to support the Company&#8217;s ongoing research and development activities.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At June 30, 2011, the Company had a working capital surplus of $1,084,008, as compared to $1,736,266 at December 31, 2010, a decrease of $652,258 for the six months ended June 30, 2011.&#160;&#160;The decrease in working capital during the six months ended June 30, 2011 reflects a decrease in current assets and an increase in current liabilities as a result of the Company&#8217;s ongoing research and development activities.&#160;&#160;At June 30, 2011, the Company had cash and money market funds aggregating $1,335,323, as compared to $1,720,097 at December 31, 2010, a decrease of $384,774 for the six months ended June 30, 2011.&#160;&#160;The decrease in cash and money market funds during the six months ended June 30, 2011 reflects the Company&#8217;s ongoing research and development activities.<a name="Page28"><!--EFPlaceholder--></a></font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">27</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Investing Activities</font>.&#160;&#160;For the six months ended June 30, 2011, investing activities consisted of $299,917 being withdrawn from a money market fund. For the six months ended June 30, 2010, investing activities consisted of $2,050,150 being placed into a money market fund.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Financing Activities</font>.&#160;&#160;For the six months ended June 30, 2011, financing activities consisted of $5,000 of proceeds from the exercise of stock options. For the six months ended June 30, 2010, financing activities provided net cash of $1,087,500, consisting of the gross proceeds from the sale of securities of $2,287,500, less $1,200,000 of advances received through December 31, 2009.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Principal Commitments</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Effective March 22, 2006, the Company entered into a CRADA, as amended, with the NINDS of the NIH. The CRADA is for a term of 66 months from the effective date and can be unilaterally terminated by either party by providing written notice within sixty days. The CRADA provides for the collaboration between the parties in the identification and evaluation of agents that target the Nuclear Receptor CoRepressor (N-CoR) pathway for glioma cell differentiation. The CRADA also provides that NINDS and the Company will conduct research to determine if expression of N-CoR correlates with prognosis in glioma patients. Pursuant to the CRADA, the Company initially agreed to provide funds under the CRADA in the amount of $200,000 per year to fund two technical assistants for the technical, statistical and administrative support for the research activities, as well as to pay for supplies and travel expenses. The first $200,000 was due within 180 days of the effective date and was paid in full on July 6, 2006. The second $200,000 was paid in full on June 29, 2007. In June 2008, the CRADA was extended to September 30, 2009, with no additional funding required for the period between July 1, 2008 and September 30, 2008. For the period from October 1, 2008 through September 30, 2009, the Company agreed to provide additional funding under the CRADA of $200,000, to be paid in four quarterly installments of $50,000, each commencing on October 1, 2008. The first and second quarterly installments of $50,000 were paid on September 29, 2008 and March 5, 2009, respectively.&#160;During August&#160;2009, the Company entered into an amendment to the CRADA to extend its term from September 30, 2009 through September 30, 2011.&#160;Pursuant to such amendment, the Company has agreed to aggregate payments of $100,000 in two installments of $50,000, payable on October 1, 2010 and January 5, 2011, inclusive of any prior unpaid commitments. The October 1, 2010 installment was paid on September 29, 2010 and the January 5, 2011 installment was paid on December 27, 2010.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Effective as of September 19, 2008, the Company entered into an agreement with the NIH providing the Company with an exclusive license for all patents submitted jointly with the NIH under the CRADA. The agreement provided for an initial payment of $25,000 to NIH within 60 days of September 19, 2008, and for a minimum annual royalty of $30,000 on January 1 of each calendar year following the year in which the CRADA is terminated. The agreement also provides for the Company to pay specified royalties based on (i) net sales by the Company and its sub-licensees, (ii) the achievement of certain clinical benchmarks, and (iii) the granting of sublicenses. The Company paid the initial $25,000 obligation on November 10, 2008 and charged the amount to general and administrative costs during the year ended December 31, 2008. As of June 30, 2011, no additional amounts were due pursuant to this agreement.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On February 5, 2007, the Company entered into a two-year agreement pursuant to which the Company engaged Chem-Master to synthesize a compound designated as LB-100, and any other compound synthesized by Chem-Master pursuant to the Company&#8217;s request, which have potential use in treating a disease, including, without limitation, cancers such as glioblastomas. Pursuant to the Chem-Master Agreement, the Company agreed to reimburse Chem-Master for the cost of materials, labor, and expenses for other items used in the synthesis process, and also agreed to grant Chem-Master a five-year option to purchase shares of the Company&#8217;s common stock. The Company has the right to terminate the Chem-Master Agreement at any time during its term upon sixty days prior written notice.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On January 29, 2008, the Chem-Master Agreement was amended to extend its term to February 15, 2014, and to expressly provide for the design and synthesis of a new series of compounds designated as LB-300. Pursuant to the Chem-Master Agreement, as amended, the Company reimbursed Chem-Master for the costs of materials, labor and expenses aggregating $1,500 and $20,000 during the three months ending June 30, 2011 and 2010, respectively. During the six months ending June 30, 2011 and 2010, reimbursements to Chem-Master amounted to $6,325 and $33,000, respectively.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;On March 17, 2010, the Company engaged Theradex Systems, Inc. to assist the Company in bringing LB-100 through the FDA approval process at a total estimated cost of $105,064, of which $15,205 had been incurred through June 30, 2011. As of June 30, 2011, work was proceeding under this contract. Dr. Robert B. Royds, the founder, Chairman of the Board and Medical Director of Theradex Systems, Inc., was appointed to the Company&#8217;s Board of Directors on May 2, 2011.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On March 17, 2011, the Company entered into an agreement with Ascentage Pharma Group to conduct a series of studies at a total estimated cost of $20,000, of which $15,000 had been paid through June 30, 2011. Ascentage Pharma Group is an offshoot of Ascenta Therapeutics, of which Dr. Mel Sorensen, a director of the Company, is the President and Chief Executive Officer and a director. Ascentage Pharma Group and Ascenta Therapeutics have a continuing business relationship and certain common shareholders. However, Dr. Sorensen does not have any direct business relationship with or ownership in Ascentage Pharma Group.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On January 7, 2011, the Company entered into a Master Laboratory Services Agreement with WIL Research Laboratories, LLC for a series of studies. As of June 30, 2011, work orders for studies having a total estimated cost of $108,240 were in process under this agreement. As of June 30, 2011, the Company had paid $54,120 towards these work orders.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On January 18, 2011, the Company entered into an agreement with Ash Stevens for a series of studies with a total estimated cost of $90,000. As of June 30, 2011, the Company had paid $29,700 towards these studies.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On April 7, 2010, the Company entered into an agreement with Dr. Mel Sorensen providing for consultation and advice over the ensuing twelve month period regarding the preparation and strategy for obtaining FDA approval for the clinical trial of the lead compound of the LB-100 series. The agreement called for an annual fee of $25,000, payable in two installments of $12,500 on April 15, 2010 and October 15, 2010. On February 18, 2011, the Company&#8217;s Board of Directors approved a one-year extension of the agreement for an additional annual fee of $25,000, payable in two installments of $12,500 on April 15, 2011 and October 15, 2011. All installments have been paid as due.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table sets forth the Company&#8217;s principal cash obligations and commitments for the next five fiscal years as of June 30, 2011 aggregating $470,236, of which $256,267 is included in current liabilities in the condensed consolidated balance sheet at June 30, 2011.&#160; Amounts included in the 2011 column represent amounts due at June 30, 2011 for the remainder of the 2011 fiscal year ending December 31, 2011.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; ">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;</font></div>
</td>
<td align="left" colspan="2" nowrap valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;</font></div>
</td>
<td colspan="6" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Payments&#160;Due&#160;By&#160;Year</font></font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;</font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Total</font></font></div>
</td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2012</font></font></div>
</td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Research and development contracts</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">291,019</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">291,019</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Consulting agreement</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12,500</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12,500</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Liquidated damages payable under registration rights agreement</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">74,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">74,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Due to stockholder</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">92,717</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">92,717</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">470,236</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">470,236</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Off-Balance Sheet Arrangements</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At June 30, 2011, the Company did not have any transactions, obligations or relationships that could be considered off-balance sheet arrangements.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">29</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="Page30"><!--EFPlaceholder--></a><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; ">
<tr valign="top">
<td style="WIDTH: 63pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM&#160;3.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Not applicable.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; ">
<tr valign="top">
<td style="WIDTH: 63pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM&#160;4.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CONTROLS AND PROCEDURES</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a) Evaluation of Disclosure Controls and Procedures</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company carried out an evaluation, under the supervision and with the participation of its management, consisting of its principal executive officer and principal financial officer (who is the same person), of the effectiveness of the Company&#8217;s disclosure controls and procedures (as defined&#160;&#160;in&#160;&#160;Rules&#160;&#160;13a-15(e) and 15d-15(e) of the&#160;&#160;Exchange&#160;&#160;Act (defined&#160;&#160;below)). Based upon that evaluation, the Company&#8217;s principal executive officer and principal financial officer concluded that, as of the end of the period covered in this report, the Company&#8217;s disclosure controls and procedures were effective to ensure that information required to be disclosed in reports filed under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), is recorded, processed, summarized and reported within the required time periods and is accumulated and communicated to the Company&#8217;s management, consisting of the Company&#8217;s principal executive officer and principal financial officer,&#160;&#160;to allow timely decisions regarding required disclosure.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company&#8217;s management, consisting of its principal executive officer and principal financial officer, does not expect that its disclosure controls and procedures or its internal controls will prevent all error or fraud.&#160; A control system, no matter how well conceived and&#160;operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Furthermore, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs.&#160; Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.&#160;&#160;In addition, as conditions change over time, so too may the effectiveness of internal controls. However, management believes that the financial statements included in this report fairly present, in all material respects, the Company&#8217;s financial condition, results of operations and cash flows for the periods presented.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b) Changes in Internal Controls Over Financial Reporting</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company&#8217;s management, consisting of its principal executive officer and principal financial officer, has determined that no change in the Company&#8217;s internal control over financial reporting (as that term is defined in Rules 13(a)-15(f) and 15(d)-15(f) of the Securities Exchange Act of 1934) occurred during or subsequent to the end of the period covered in this report that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">30</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="Page31"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PART II - OTHER INFORMATION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; ">
<tr valign="top">
<td style="WIDTH: 63pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 1.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">LEGAL PROCEEDINGS</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company is currently not a party to any pending or threatened legal proceedings.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; ">
<tr valign="top">
<td style="WIDTH: 63pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 1A.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">RISK FACTORS</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Not applicable.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; ">
<tr valign="top">
<td style="WIDTH: 63pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 2.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Effective May 1, 2011, in conjunction with his appointment to the Company&#8217;s Board of Directors, Dr. Robert B. Royds was granted stock options to purchase 200,000 shares of the Company&#8217;s common stock, exercisable for a period of five years from each tranche&#8217;s vesting date, at $0.98 per share, which was the fair market value of the Company&#8217;s common stock on such date. The options vested as to 25,000 shares on May 1, 2011, and a further 25,000 shares vest on the first day of each subsequent quarter until all of the shares are vested. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $196,000 ($0.98 per share), and is being charged to operations ratably from May 2, 2011 through February 1, 2013. During the three months and six months ended June 30, 2011, the Company recorded a charge to operations of $40,528 with respect to these options.</font></div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On June 30, 2011, Dr. Philip Palmedo exercised options to acquire 100,000 shares of common stock on a cashless basis. Such cashless exercise resulted in Dr. Palmedo receiving a net of 66,020 shares.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On June 30, 2011, the Company granted to Dr.&#160;Palmedo stock options to purchase 200,000 shares of common stock exercisable for a period of five years from date of grant at $0.98 per share, which was the fair market value of the Company&#8217;s common stock on such date. The options vest ratably in equal quarterly installments of 25,000 each beginning July 1, 2011. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was initially determined to be $196,000 ($0.98 per share).</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On June 30, 2011, Dr. Iwao Ojima exercised options to acquire 15,015 shares of common stock for a cash payment of $5,000.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On June 30, 2011, the Company granted to Dr.&#160;Ojima stock options to purchase 50,000 shares of common stock exercisable for a period of five years from the date of grant at $0.98 per share, which was the fair market value of the Company&#8217;s common stock on such date. The options vest ratably in equal quarterly installments of 6,250 shares each beginning July 1, 2011. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was initially determined to be $49,000 ($0.98 per share).</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On June 30, 2011, WestPark Capital, Inc. exercised warrants to acquire 152,874 shares of common stock, on a cashless basis. Such cashless exercise resulted in WestPark Capital, Inc. receiving a net of 100,929 shares.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; ">
<tr valign="top">
<td style="WIDTH: 63pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 3.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">DEFAULTS UPON SENIOR SECURITIES</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Not applicable.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; ">
<tr valign="top">
<td style="WIDTH: 63pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 4.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">RESERVED</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Not applicable.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; ">
<tr valign="top">
<td style="WIDTH: 63pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 5.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">OTHER INFORMATION</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Not applicable.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; ">
<tr valign="top">
<td style="WIDTH: 63pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 6.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXHIBITS</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A list of exhibits required to be filed as part of this report is set forth in the Index to Exhibits, which is presented elsewhere in this document, and is incorporated herein by reference.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">31</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="Page32"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SIGNATURES</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In accordance with the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; ">
<tr>
<td align="left" valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="50%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">LIXTE BIOTECHNOLOGY HOLDINGS, INC.</font></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Registrant)</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="47%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="50%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date:&#160; August 11, 2011</font></div>
</td>
<td align="left" valign="top" width="3%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:&#160;</font></div>
</td>
<td align="left" valign="top" width="47%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">/s/&#160;JOHN S. KOVACH</font></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="47%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">John S. Kovach</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="47%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief Executive Officer and</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief Financial Officer</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="47%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Principal financial and accounting officer)</font></div>
</td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">32</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><a name="Page33"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">INDEX TO EXHIBITS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; ">
<tr>
<td align="left" valign="top" width="8%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exhibit</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Number</font></div>
</td>
<td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="90%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Description&#160;of&#160;Document</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="90%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">31.1</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Officer&#8217;s Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. (1)</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="90%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">32.1</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Officer&#8217;s Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (1)</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; ">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(1)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Filed herewith.</font></div>
</td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">33</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>v229457_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>
<head>
    <title>Unassociated Document</title>
    <!--Licensed to: Vintage Filings-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CERTIFICATIONS OF THE CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I, John S. Kovach, Chief Executive Officer and Chief Financial Officer of Lixte Biotechnology Holdings, Inc., certify that:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; ">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2011 of Lixte Biotechnology Holdings, Inc.;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; ">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; ">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; ">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and I have:</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; ">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; ">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; ">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; ">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; ">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; ">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; ">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; ">
<tr>
<td align="left" valign="top" width="50%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date:&#160;&#160;August 11, 2011</font></div>
</td>
<td align="left" valign="top" width="4%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:&#160;</font></div>
</td>
<td align="left" valign="top" width="46%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/ JOHN S. KOVACH</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="46%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">John S. Kovach</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="46%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief Executive Officer and</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="46%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief Financial Officer</font></div>
</td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>3
<FILENAME>v229457_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>
<head>
    <title>Unassociated Document</title>
    <!--Licensed to: Vintage Filings-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CERTIFICATIONS OF THE CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">UNDER SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In connection with the filing by Lixte Biotechnology Holdings, Inc. (the &#8220;Registrant&#8221;) of its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2011 (the &#8220;Quarterly Report&#8221;) with the Securities and Exchange Commission, I, John S. Kovach, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(i) The Quarterly Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(ii) The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A signed original of this written statement required by Section 906 has been provided to the Registrant and will be retained by the Registrant and furnished to the Securities and Exchange Commission or its staff upon request.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; ">
<tr>
<td valign="top" width="45%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date:&#160;&#160;August 11, 2011</font></div>
</td>
<td align="left" valign="top" width="4%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
</td>
<td align="left" valign="top" width="41%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/ JOHN S. KOVACH</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="45%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="41%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">John S. Kovach</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="45%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="41%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief Executive Officer and</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="45%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="41%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief Financial Officer</font></div>
</td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>4
<FILENAME>lixt-20110630.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- XBRL document created with Ez-XBRL version 3.0.1.2  -->
<!-- Based on XBRL 2.1  -->
<xbrli:xbrl xmlns:lixt="http://www.lixte.com/2011-06-30" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:country="http://xbrl.sec.gov/country/2011-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2011-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2011-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:invest="http://xbrl.sec.gov/invest/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2011-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:href="lixt-20110630.xsd" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
  <xbrli:context id="Context_6ME_31-Dec-2005">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2005-08-10</xbrli:startDate>
      <xbrli:endDate>2005-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_6ME_31-Dec-2005_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2005-08-10</xbrli:startDate>
      <xbrli:endDate>2005-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_6ME_31-Dec-2005_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lixt:AdvancesUnderEquityFinancingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2005-08-10</xbrli:startDate>
      <xbrli:endDate>2005-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_6ME_31-Dec-2005_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2005-08-10</xbrli:startDate>
      <xbrli:endDate>2005-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_6ME_31-Dec-2005_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2005-08-10</xbrli:startDate>
      <xbrli:endDate>2005-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_Custom_31-Dec-2006">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2006-01-01</xbrli:startDate>
      <xbrli:endDate>2006-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_Custom_31-Dec-2006_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2006-01-01</xbrli:startDate>
      <xbrli:endDate>2006-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_Custom_31-Dec-2006_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lixt:AdvancesUnderEquityFinancingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2006-01-01</xbrli:startDate>
      <xbrli:endDate>2006-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_Custom_31-Dec-2006_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2006-01-01</xbrli:startDate>
      <xbrli:endDate>2006-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_Custom_31-Dec-2006_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2006-01-01</xbrli:startDate>
      <xbrli:endDate>2006-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_Custom_31-Dec-2007">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2007-01-01</xbrli:startDate>
      <xbrli:endDate>2007-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_Custom_31-Dec-2007_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2007-01-01</xbrli:startDate>
      <xbrli:endDate>2007-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_Custom_31-Dec-2007_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lixt:AdvancesUnderEquityFinancingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2007-01-01</xbrli:startDate>
      <xbrli:endDate>2007-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_Custom_31-Dec-2007_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2007-01-01</xbrli:startDate>
      <xbrli:endDate>2007-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_Custom_31-Dec-2007_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2007-01-01</xbrli:startDate>
      <xbrli:endDate>2007-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_Custom_31-Dec-2008">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2008-01-01</xbrli:startDate>
      <xbrli:endDate>2008-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_Custom_31-Dec-2008_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2008-01-01</xbrli:startDate>
      <xbrli:endDate>2008-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_Custom_31-Dec-2008_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lixt:AdvancesUnderEquityFinancingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2008-01-01</xbrli:startDate>
      <xbrli:endDate>2008-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_Custom_31-Dec-2008_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2008-01-01</xbrli:startDate>
      <xbrli:endDate>2008-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_Custom_31-Dec-2008_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2008-01-01</xbrli:startDate>
      <xbrli:endDate>2008-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_Custom_31-Dec-2009">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-01-01</xbrli:startDate>
      <xbrli:endDate>2009-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_Custom_31-Dec-2009_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-01-01</xbrli:startDate>
      <xbrli:endDate>2009-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_Custom_31-Dec-2009_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lixt:AdvancesUnderEquityFinancingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-01-01</xbrli:startDate>
      <xbrli:endDate>2009-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_Custom_31-Dec-2009_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-01-01</xbrli:startDate>
      <xbrli:endDate>2009-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_Custom_31-Dec-2009_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-01-01</xbrli:startDate>
      <xbrli:endDate>2009-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_3ME_30-Jun-2010">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-04-01</xbrli:startDate>
      <xbrli:endDate>2010-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_6ME_30-Jun-2010">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_31-Dec-2010">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_31-Dec-2010_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lixt:AdvancesUnderEquityFinancingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_31-Dec-2010_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_31-Dec-2010_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_Custom_31-Dec-2010">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_Custom_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_Custom_31-Dec-2010_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lixt:AdvancesUnderEquityFinancingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_Custom_31-Dec-2010_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_Custom_31-Dec-2010_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_3ME_30-Jun-2011">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-04-01</xbrli:startDate>
      <xbrli:endDate>2011-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_6ME_30-Jun-2011">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_6ME_30-Jun-2011_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_6ME_30-Jun-2011_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lixt:AdvancesUnderEquityFinancingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_6ME_30-Jun-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_6ME_30-Jun-2011_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_30-Jun-2011">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_30-Jun-2011_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_30-Jun-2011_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lixt:AdvancesUnderEquityFinancingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_30-Jun-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_30-Jun-2011_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_Custom_30-Jun-2011">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2005-08-10</xbrli:startDate>
      <xbrli:endDate>2011-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_12-Aug-2011">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-08-11</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_09-Aug-2005">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2005-08-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_31-Dec-2005">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2005-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_09-Aug-2005_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2005-08-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_31-Dec-2005_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2005-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_09-Aug-2005_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lixt:AdvancesUnderEquityFinancingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2005-08-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_31-Dec-2005_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lixt:AdvancesUnderEquityFinancingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2005-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_09-Aug-2005_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2005-08-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_31-Dec-2005_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2005-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_09-Aug-2005_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2005-08-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_31-Dec-2005_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2005-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_31-Dec-2006">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2006-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_31-Dec-2006_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2006-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_31-Dec-2006_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lixt:AdvancesUnderEquityFinancingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2006-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_31-Dec-2006_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2006-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_31-Dec-2006_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2006-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_31-Dec-2007">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2007-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_31-Dec-2007_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2007-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_31-Dec-2007_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lixt:AdvancesUnderEquityFinancingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2007-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_31-Dec-2007_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2007-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_31-Dec-2007_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2007-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_31-Dec-2008">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2008-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_31-Dec-2008_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2008-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_31-Dec-2008_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lixt:AdvancesUnderEquityFinancingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2008-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_31-Dec-2008_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2008-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_31-Dec-2008_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2008-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_31-Dec-2009">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2009-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_31-Dec-2009_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2009-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_31-Dec-2009_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lixt:AdvancesUnderEquityFinancingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2009-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_31-Dec-2009_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2009-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_31-Dec-2009_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2009-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_30-Jun-2010">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Context_As_Of_08-Aug-2005">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2005-08-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="Shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USDPerShare">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <dei:EntityRegistrantName contextRef="Context_6ME_30-Jun-2011">LIXTE BIOTECHNOLOGY HOLDINGS, INC.</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey contextRef="Context_6ME_30-Jun-2011">0001335105</dei:EntityCentralIndexKey>
  <dei:CurrentFiscalYearEndDate contextRef="Context_6ME_30-Jun-2011">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityFilerCategory contextRef="Context_6ME_30-Jun-2011">Smaller Reporting Company</dei:EntityFilerCategory>
  <dei:TradingSymbol contextRef="Context_6ME_30-Jun-2011">lixt</dei:TradingSymbol>
  <dei:EntityCommonStockSharesOutstanding decimals="0" contextRef="Context_As_Of_12-Aug-2011" unitRef="Shares">35259142</dei:EntityCommonStockSharesOutstanding>
  <dei:DocumentType contextRef="Context_6ME_30-Jun-2011">10-Q</dei:DocumentType>
  <dei:AmendmentFlag contextRef="Context_6ME_30-Jun-2011">false</dei:AmendmentFlag>
  <dei:DocumentPeriodEndDate contextRef="Context_6ME_30-Jun-2011">2011-06-30</dei:DocumentPeriodEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="Context_6ME_30-Jun-2011">Q2</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="Context_6ME_30-Jun-2011">2011</dei:DocumentFiscalYearFocus>
  <us-gaap:Cash decimals="0" contextRef="Context_As_Of_31-Dec-2010" unitRef="USD">119091</us-gaap:Cash>
  <us-gaap:Cash decimals="0" contextRef="Context_As_Of_30-Jun-2011" unitRef="USD">34234</us-gaap:Cash>
  <us-gaap:Cash decimals="0" contextRef="Context_As_Of_31-Dec-2009" unitRef="USD">1543991</us-gaap:Cash>
  <us-gaap:Cash decimals="0" contextRef="Context_As_Of_30-Jun-2010" unitRef="USD">52068</us-gaap:Cash>
  <us-gaap:Cash decimals="0" contextRef="Context_As_Of_08-Aug-2005" unitRef="USD">0</us-gaap:Cash>
  <us-gaap:MoneyMarketFundsAtCarryingValue decimals="0" contextRef="Context_As_Of_31-Dec-2010" unitRef="USD">1601006</us-gaap:MoneyMarketFundsAtCarryingValue>
  <us-gaap:MoneyMarketFundsAtCarryingValue decimals="0" contextRef="Context_As_Of_30-Jun-2011" unitRef="USD">1301089</us-gaap:MoneyMarketFundsAtCarryingValue>
  <us-gaap:DepositsAssetsCurrent decimals="0" contextRef="Context_As_Of_31-Dec-2010" unitRef="USD">50000</us-gaap:DepositsAssetsCurrent>
  <us-gaap:DepositsAssetsCurrent decimals="0" contextRef="Context_As_Of_30-Jun-2011" unitRef="USD">0</us-gaap:DepositsAssetsCurrent>
  <us-gaap:GrantsReceivableCurrent decimals="0" contextRef="Context_As_Of_31-Dec-2010" unitRef="USD">116485</us-gaap:GrantsReceivableCurrent>
  <us-gaap:GrantsReceivableCurrent decimals="0" contextRef="Context_As_Of_30-Jun-2011" unitRef="USD">0</us-gaap:GrantsReceivableCurrent>
  <lixt:AdvancesOnResearchAndDevelopmentContractServices decimals="0" contextRef="Context_As_Of_31-Dec-2010" unitRef="USD">10100</lixt:AdvancesOnResearchAndDevelopmentContractServices>
  <lixt:AdvancesOnResearchAndDevelopmentContractServices decimals="0" contextRef="Context_As_Of_30-Jun-2011" unitRef="USD">63356</lixt:AdvancesOnResearchAndDevelopmentContractServices>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent decimals="0" contextRef="Context_As_Of_31-Dec-2010" unitRef="USD">34646</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent decimals="0" contextRef="Context_As_Of_30-Jun-2011" unitRef="USD">22395</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent decimals="0" contextRef="Context_As_Of_31-Dec-2010" unitRef="USD">1931328</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent decimals="0" contextRef="Context_As_Of_30-Jun-2011" unitRef="USD">1421074</us-gaap:AssetsCurrent>
  <us-gaap:Assets decimals="0" contextRef="Context_As_Of_31-Dec-2010" unitRef="USD">1931328</us-gaap:Assets>
  <us-gaap:Assets decimals="0" contextRef="Context_As_Of_30-Jun-2011" unitRef="USD">1421074</us-gaap:Assets>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent decimals="0" contextRef="Context_As_Of_31-Dec-2010" unitRef="USD">28345</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent decimals="0" contextRef="Context_As_Of_30-Jun-2011" unitRef="USD">80799</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <lixt:ResearchAndDevelopmentContractLiabilities decimals="0" contextRef="Context_As_Of_31-Dec-2010" unitRef="USD">0</lixt:ResearchAndDevelopmentContractLiabilities>
  <lixt:ResearchAndDevelopmentContractLiabilities decimals="0" contextRef="Context_As_Of_30-Jun-2011" unitRef="USD">89550</lixt:ResearchAndDevelopmentContractLiabilities>
  <lixt:LiquidatedDamagesPayableUnderRegistrationRightsAgreement decimals="0" contextRef="Context_As_Of_31-Dec-2010" unitRef="USD">74000</lixt:LiquidatedDamagesPayableUnderRegistrationRightsAgreement>
  <lixt:LiquidatedDamagesPayableUnderRegistrationRightsAgreement decimals="0" contextRef="Context_As_Of_30-Jun-2011" unitRef="USD">74000</lixt:LiquidatedDamagesPayableUnderRegistrationRightsAgreement>
  <us-gaap:DueToOfficersOrStockholdersCurrent decimals="0" contextRef="Context_As_Of_31-Dec-2010" unitRef="USD">92717</us-gaap:DueToOfficersOrStockholdersCurrent>
  <us-gaap:DueToOfficersOrStockholdersCurrent decimals="0" contextRef="Context_As_Of_30-Jun-2011" unitRef="USD">92717</us-gaap:DueToOfficersOrStockholdersCurrent>
  <us-gaap:LiabilitiesCurrent decimals="0" contextRef="Context_As_Of_31-Dec-2010" unitRef="USD">195062</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent decimals="0" contextRef="Context_As_Of_30-Jun-2011" unitRef="USD">337066</us-gaap:LiabilitiesCurrent>
  <us-gaap:PreferredStockValue decimals="0" contextRef="Context_As_Of_31-Dec-2010" unitRef="USD">0</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockValue decimals="0" contextRef="Context_As_Of_30-Jun-2011" unitRef="USD">0</us-gaap:PreferredStockValue>
  <us-gaap:CommonStockValue decimals="0" contextRef="Context_As_Of_31-Dec-2010" unitRef="USD">3508</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue decimals="0" contextRef="Context_As_Of_30-Jun-2011" unitRef="USD">3526</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock decimals="0" contextRef="Context_As_Of_31-Dec-2010" unitRef="USD">7662559</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock decimals="0" contextRef="Context_As_Of_30-Jun-2011" unitRef="USD">77090561</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage decimals="0" contextRef="Context_As_Of_31-Dec-2010" unitRef="USD">5929801</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>
  <us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage decimals="0" contextRef="Context_As_Of_30-Jun-2011" unitRef="USD">6628569</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_31-Dec-2010" unitRef="USD">1736266</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD">3508</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_31-Dec-2010_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember" unitRef="USD">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_31-Dec-2010_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD">7662559</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_31-Dec-2010_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD">-5929801</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_30-Jun-2011" unitRef="USD">1084008</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_30-Jun-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD">3526</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_30-Jun-2011_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember" unitRef="USD">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_30-Jun-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD">7709051</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_30-Jun-2011_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD">-6628569</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_09-Aug-2005" unitRef="USD">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_31-Dec-2005" unitRef="USD">-14624</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_09-Aug-2005_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_31-Dec-2005_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD">1902</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_09-Aug-2005_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember" unitRef="USD">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_31-Dec-2005_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember" unitRef="USD">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_09-Aug-2005_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_31-Dec-2005_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD">-402</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_09-Aug-2005_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_31-Dec-2005_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD">-16124</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_31-Dec-2006" unitRef="USD">552564</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_31-Dec-2006_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD">2658</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_31-Dec-2006_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember" unitRef="USD">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_31-Dec-2006_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD">1128114</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_31-Dec-2006_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD">-578208</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_31-Dec-2007" unitRef="USD">376926</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_31-Dec-2007_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD">2783</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_31-Dec-2007_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember" unitRef="USD">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_31-Dec-2007_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD">2600839</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_31-Dec-2007_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD">-2226696</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_31-Dec-2008" unitRef="USD">-323548</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_31-Dec-2008_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD">2793</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_31-Dec-2008_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember" unitRef="USD">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_31-Dec-2008_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD">3171877</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_31-Dec-2008_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD">-3498218</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_31-Dec-2009" unitRef="USD">1301082</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_31-Dec-2009_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD">3050</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_31-Dec-2009_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember" unitRef="USD">1200000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_31-Dec-2009_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD">5147583</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity decimals="0" contextRef="Context_As_Of_31-Dec-2009_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD">-5049551</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity decimals="0" contextRef="Context_As_Of_31-Dec-2010" unitRef="USD">1931328</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity decimals="0" contextRef="Context_As_Of_30-Jun-2011" unitRef="USD">1421074</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:PreferredStockParOrStatedValuePerShare decimals="4" contextRef="Context_As_Of_31-Dec-2010" unitRef="USDPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare decimals="4" contextRef="Context_As_Of_30-Jun-2011" unitRef="USDPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized decimals="0" contextRef="Context_As_Of_31-Dec-2010" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized decimals="0" contextRef="Context_As_Of_30-Jun-2011" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued decimals="0" contextRef="Context_As_Of_31-Dec-2010" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued decimals="0" contextRef="Context_As_Of_30-Jun-2011" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:CommonStockParOrStatedValuePerShare decimals="4" contextRef="Context_As_Of_31-Dec-2010" unitRef="USDPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare decimals="4" contextRef="Context_As_Of_30-Jun-2011" unitRef="USDPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized decimals="0" contextRef="Context_As_Of_31-Dec-2010" unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized decimals="0" contextRef="Context_As_Of_30-Jun-2011" unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued decimals="0" contextRef="Context_As_Of_31-Dec-2010" unitRef="Shares">35077178</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued decimals="0" contextRef="Context_As_Of_30-Jun-2011" unitRef="Shares">35259142</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding decimals="0" contextRef="Context_As_Of_31-Dec-2010" unitRef="Shares">35077178</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding decimals="0" contextRef="Context_As_Of_30-Jun-2011" unitRef="Shares">35259142</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:Revenues decimals="0" contextRef="Context_3ME_30-Jun-2010" unitRef="USD">0</us-gaap:Revenues>
  <us-gaap:Revenues decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">0</us-gaap:Revenues>
  <us-gaap:Revenues decimals="0" contextRef="Context_3ME_30-Jun-2011" unitRef="USD">0</us-gaap:Revenues>
  <us-gaap:Revenues decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">0</us-gaap:Revenues>
  <us-gaap:Revenues decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">0</us-gaap:Revenues>
  <us-gaap:GeneralAndAdministrativeExpense decimals="0" contextRef="Context_3ME_30-Jun-2010" unitRef="USD">76892</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">265470</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense decimals="0" contextRef="Context_3ME_30-Jun-2011" unitRef="USD">123581</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">213197</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">3819075</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:DepreciationNonproduction decimals="0" contextRef="Context_3ME_30-Jun-2010" unitRef="USD">0</us-gaap:DepreciationNonproduction>
  <us-gaap:DepreciationNonproduction decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">0</us-gaap:DepreciationNonproduction>
  <us-gaap:DepreciationNonproduction decimals="0" contextRef="Context_3ME_30-Jun-2011" unitRef="USD">0</us-gaap:DepreciationNonproduction>
  <us-gaap:DepreciationNonproduction decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">0</us-gaap:DepreciationNonproduction>
  <us-gaap:DepreciationNonproduction decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">1909</us-gaap:DepreciationNonproduction>
  <us-gaap:ResearchAndDevelopmentExpense decimals="0" contextRef="Context_3ME_30-Jun-2010" unitRef="USD">233104</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">394977</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense decimals="0" contextRef="Context_3ME_30-Jun-2011" unitRef="USD">224208</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">485654</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">2708501</us-gaap:ResearchAndDevelopmentExpense>
  <lixt:ReverseMergerCosts decimals="0" contextRef="Context_3ME_30-Jun-2010" unitRef="USD">0</lixt:ReverseMergerCosts>
  <lixt:ReverseMergerCosts decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">0</lixt:ReverseMergerCosts>
  <lixt:ReverseMergerCosts decimals="0" contextRef="Context_3ME_30-Jun-2011" unitRef="USD">0</lixt:ReverseMergerCosts>
  <lixt:ReverseMergerCosts decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">0</lixt:ReverseMergerCosts>
  <lixt:ReverseMergerCosts decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">50000</lixt:ReverseMergerCosts>
  <us-gaap:OperatingExpenses decimals="0" contextRef="Context_3ME_30-Jun-2010" unitRef="USD">309996</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">660447</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses decimals="0" contextRef="Context_3ME_30-Jun-2011" unitRef="USD">347789</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">698851</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">6579485</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss decimals="0" contextRef="Context_3ME_30-Jun-2010" unitRef="USD">-309996</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">-660447</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss decimals="0" contextRef="Context_3ME_30-Jun-2011" unitRef="USD">-347789</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">-698851</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">-6579485</us-gaap:OperatingIncomeLoss>
  <us-gaap:InvestmentIncomeNonoperating decimals="0" contextRef="Context_3ME_30-Jun-2010" unitRef="USD">333</us-gaap:InvestmentIncomeNonoperating>
  <us-gaap:InvestmentIncomeNonoperating decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">548</us-gaap:InvestmentIncomeNonoperating>
  <us-gaap:InvestmentIncomeNonoperating decimals="0" contextRef="Context_3ME_30-Jun-2011" unitRef="USD">37</us-gaap:InvestmentIncomeNonoperating>
  <us-gaap:InvestmentIncomeNonoperating decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">83</us-gaap:InvestmentIncomeNonoperating>
  <us-gaap:InvestmentIncomeNonoperating decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">27385</us-gaap:InvestmentIncomeNonoperating>
  <us-gaap:InterestExpense decimals="0" contextRef="Context_3ME_30-Jun-2010" unitRef="USD">0</us-gaap:InterestExpense>
  <us-gaap:InterestExpense decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">0</us-gaap:InterestExpense>
  <us-gaap:InterestExpense decimals="0" contextRef="Context_3ME_30-Jun-2011" unitRef="USD">0</us-gaap:InterestExpense>
  <us-gaap:InterestExpense decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">0</us-gaap:InterestExpense>
  <us-gaap:InterestExpense decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">2469</us-gaap:InterestExpense>
  <lixt:LiquidatedDamagesUnderRegistrationRightsAgreement decimals="0" contextRef="Context_3ME_30-Jun-2010" unitRef="USD">0</lixt:LiquidatedDamagesUnderRegistrationRightsAgreement>
  <lixt:LiquidatedDamagesUnderRegistrationRightsAgreement decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">0</lixt:LiquidatedDamagesUnderRegistrationRightsAgreement>
  <lixt:LiquidatedDamagesUnderRegistrationRightsAgreement decimals="0" contextRef="Context_3ME_30-Jun-2011" unitRef="USD">0</lixt:LiquidatedDamagesUnderRegistrationRightsAgreement>
  <lixt:LiquidatedDamagesUnderRegistrationRightsAgreement decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">0</lixt:LiquidatedDamagesUnderRegistrationRightsAgreement>
  <lixt:LiquidatedDamagesUnderRegistrationRightsAgreement decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">74000</lixt:LiquidatedDamagesUnderRegistrationRightsAgreement>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_6ME_31-Dec-2005" unitRef="USD">-16124</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_6ME_31-Dec-2005_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_6ME_31-Dec-2005_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember" unitRef="USD">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_6ME_31-Dec-2005_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_6ME_31-Dec-2005_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD">-16124</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_Custom_31-Dec-2006" unitRef="USD">-562084</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_Custom_31-Dec-2006_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_Custom_31-Dec-2006_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember" unitRef="USD">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_Custom_31-Dec-2006_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_Custom_31-Dec-2006_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD">-562084</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_Custom_31-Dec-2007" unitRef="USD">-1648488</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_Custom_31-Dec-2007_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_Custom_31-Dec-2007_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember" unitRef="USD">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_Custom_31-Dec-2007_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_Custom_31-Dec-2007_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD">-1648488</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_Custom_31-Dec-2008" unitRef="USD">-1271522</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_Custom_31-Dec-2008_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_Custom_31-Dec-2008_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember" unitRef="USD">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_Custom_31-Dec-2008_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_Custom_31-Dec-2008_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD">-1271522</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_Custom_31-Dec-2009" unitRef="USD">-1551333</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_Custom_31-Dec-2009_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_Custom_31-Dec-2009_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember" unitRef="USD">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_Custom_31-Dec-2009_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_Custom_31-Dec-2009_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD">-1551333</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_3ME_30-Jun-2010" unitRef="USD">-309663</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">-659899</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_Custom_31-Dec-2010" unitRef="USD">-880250</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_Custom_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_Custom_31-Dec-2010_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember" unitRef="USD">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_Custom_31-Dec-2010_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_Custom_31-Dec-2010_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD">-880250</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_3ME_30-Jun-2011" unitRef="USD">-347752</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">-698768</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_6ME_30-Jun-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_6ME_30-Jun-2011_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember" unitRef="USD">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_6ME_30-Jun-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_6ME_30-Jun-2011_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD">-698768</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">-6628569</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasicAndDiluted decimals="2" contextRef="Context_3ME_30-Jun-2010" unitRef="USDPerShare">-0.01</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted decimals="2" contextRef="Context_6ME_30-Jun-2010" unitRef="USDPerShare">-0.02</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted decimals="2" contextRef="Context_3ME_30-Jun-2011" unitRef="USDPerShare">-0.01</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted decimals="2" contextRef="Context_6ME_30-Jun-2011" unitRef="USDPerShare">-0.02</us-gaap:EarningsPerShareBasicAndDiluted>
  <lixt:WeightedAvgNumberOfOutstandingSharesBasicAndDiluted decimals="0" contextRef="Context_3ME_30-Jun-2010" unitRef="Shares">35077178</lixt:WeightedAvgNumberOfOutstandingSharesBasicAndDiluted>
  <lixt:WeightedAvgNumberOfOutstandingSharesBasicAndDiluted decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="Shares">34389333</lixt:WeightedAvgNumberOfOutstandingSharesBasicAndDiluted>
  <lixt:WeightedAvgNumberOfOutstandingSharesBasicAndDiluted decimals="0" contextRef="Context_3ME_30-Jun-2011" unitRef="Shares">35079178</lixt:WeightedAvgNumberOfOutstandingSharesBasicAndDiluted>
  <lixt:WeightedAvgNumberOfOutstandingSharesBasicAndDiluted decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="Shares">35078183</lixt:WeightedAvgNumberOfOutstandingSharesBasicAndDiluted>
  <lixt:ShareBasedCompensationCost decimals="0" contextRef="Context_3ME_30-Jun-2010" unitRef="USD">20534</lixt:ShareBasedCompensationCost>
  <lixt:ShareBasedCompensationCost decimals="0" contextRef="Context_3ME_30-Jun-2011" unitRef="USD">40528</lixt:ShareBasedCompensationCost>
  <lixt:ResearchAndDevelopmentStockBasedCost decimals="0" contextRef="Context_3ME_30-Jun-2010" unitRef="USD">-1762</lixt:ResearchAndDevelopmentStockBasedCost>
  <lixt:ResearchAndDevelopmentStockBasedCost decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">18127</lixt:ResearchAndDevelopmentStockBasedCost>
  <lixt:ResearchAndDevelopmentStockBasedCost decimals="0" contextRef="Context_3ME_30-Jun-2011" unitRef="USD">0</lixt:ResearchAndDevelopmentStockBasedCost>
  <lixt:ResearchAndDevelopmentStockBasedCost decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">982</lixt:ResearchAndDevelopmentStockBasedCost>
  <lixt:ResearchAndDevelopmentStockBasedCost decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">465034</lixt:ResearchAndDevelopmentStockBasedCost>
  <lixt:ResearchAndDevelopmentStockBasedCostRelatedParty decimals="0" contextRef="Context_3ME_30-Jun-2010" unitRef="USD">5208</lixt:ResearchAndDevelopmentStockBasedCostRelatedParty>
  <lixt:ResearchAndDevelopmentStockBasedCostRelatedParty decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">5208</lixt:ResearchAndDevelopmentStockBasedCostRelatedParty>
  <lixt:ResearchAndDevelopmentStockBasedCostRelatedParty decimals="0" contextRef="Context_3ME_30-Jun-2011" unitRef="USD">6250</lixt:ResearchAndDevelopmentStockBasedCostRelatedParty>
  <lixt:ResearchAndDevelopmentStockBasedCostRelatedParty decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">12500</lixt:ResearchAndDevelopmentStockBasedCostRelatedParty>
  <lixt:ResearchAndDevelopmentStockBasedCostRelatedParty decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">30208</lixt:ResearchAndDevelopmentStockBasedCostRelatedParty>
  <lixt:ResearchAndDevelopmentRepresentingProceedsOfGovernmentGrant decimals="0" contextRef="Context_3ME_30-Jun-2010" unitRef="USD">0</lixt:ResearchAndDevelopmentRepresentingProceedsOfGovernmentGrant>
  <lixt:ResearchAndDevelopmentRepresentingProceedsOfGovernmentGrant decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">0</lixt:ResearchAndDevelopmentRepresentingProceedsOfGovernmentGrant>
  <lixt:ResearchAndDevelopmentRepresentingProceedsOfGovernmentGrant decimals="0" contextRef="Context_3ME_30-Jun-2011" unitRef="USD">0</lixt:ResearchAndDevelopmentRepresentingProceedsOfGovernmentGrant>
  <lixt:ResearchAndDevelopmentRepresentingProceedsOfGovernmentGrant decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">0</lixt:ResearchAndDevelopmentRepresentingProceedsOfGovernmentGrant>
  <lixt:ResearchAndDevelopmentRepresentingProceedsOfGovernmentGrant decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">244479</lixt:ResearchAndDevelopmentRepresentingProceedsOfGovernmentGrant>
  <us-gaap:SharesOutstanding decimals="0" contextRef="Context_As_Of_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares">35077178</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding decimals="0" contextRef="Context_As_Of_30-Jun-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares">35259142</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding decimals="0" contextRef="Context_As_Of_09-Aug-2005_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares">0</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding decimals="0" contextRef="Context_As_Of_31-Dec-2005_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares">19021786</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding decimals="0" contextRef="Context_As_Of_31-Dec-2006_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares">26582183</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding decimals="0" contextRef="Context_As_Of_31-Dec-2007_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares">27832178</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding decimals="0" contextRef="Context_As_Of_31-Dec-2008_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares">27932178</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding decimals="0" contextRef="Context_As_Of_31-Dec-2009_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares">30502178</us-gaap:SharesOutstanding>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues decimals="0" contextRef="Context_6ME_31-Dec-2005" unitRef="USD">1500</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues decimals="0" contextRef="Context_6ME_31-Dec-2005_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD">1902</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues decimals="0" contextRef="Context_6ME_31-Dec-2005_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember" unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues decimals="0" contextRef="Context_6ME_31-Dec-2005_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD">-402</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues decimals="0" contextRef="Context_6ME_31-Dec-2005_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues decimals="0" contextRef="Context_6ME_31-Dec-2005_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares">19021786</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions decimals="0" contextRef="Context_Custom_31-Dec-2006" unitRef="USD">62500</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions decimals="0" contextRef="Context_Custom_31-Dec-2006_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD">401</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions decimals="0" contextRef="Context_Custom_31-Dec-2006_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember" unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions decimals="0" contextRef="Context_Custom_31-Dec-2006_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD">62099</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions decimals="0" contextRef="Context_Custom_31-Dec-2006_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions decimals="0" contextRef="Context_Custom_31-Dec-2006_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares">4005177</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts decimals="0" contextRef="Context_Custom_31-Dec-2006" unitRef="USD">969372</lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts>
  <lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts decimals="0" contextRef="Context_Custom_31-Dec-2006_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD">355</lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts>
  <lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts decimals="0" contextRef="Context_Custom_31-Dec-2006_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember" unitRef="USD">0</lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts>
  <lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts decimals="0" contextRef="Context_Custom_31-Dec-2006_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD">969017</lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts>
  <lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts decimals="0" contextRef="Context_Custom_31-Dec-2006_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD">0</lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts>
  <lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts decimals="0" contextRef="Context_Custom_31-Dec-2007" unitRef="USD">531320</lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts>
  <lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts decimals="0" contextRef="Context_Custom_31-Dec-2007_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD">100</lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts>
  <lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts decimals="0" contextRef="Context_Custom_31-Dec-2007_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember" unitRef="USD">0</lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts>
  <lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts decimals="0" contextRef="Context_Custom_31-Dec-2007_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD">531220</lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts>
  <lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts decimals="0" contextRef="Context_Custom_31-Dec-2007_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD">0</lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts>
  <lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts decimals="0" contextRef="Context_Custom_31-Dec-2009" unitRef="USD">1097050</lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts>
  <lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts decimals="0" contextRef="Context_Custom_31-Dec-2009_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD">242</lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts>
  <lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts decimals="0" contextRef="Context_Custom_31-Dec-2009_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember" unitRef="USD">0</lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts>
  <lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts decimals="0" contextRef="Context_Custom_31-Dec-2009_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD">1096808</lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts>
  <lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts decimals="0" contextRef="Context_Custom_31-Dec-2009_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD">0</lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts>
  <lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts decimals="0" contextRef="Context_Custom_31-Dec-2010" unitRef="USD">1087500</lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts>
  <lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts decimals="0" contextRef="Context_Custom_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD">458</lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts>
  <lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts decimals="0" contextRef="Context_Custom_31-Dec-2010_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember" unitRef="USD">-1200000</lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts>
  <lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts decimals="0" contextRef="Context_Custom_31-Dec-2010_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD">2287042</lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts>
  <lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts decimals="0" contextRef="Context_Custom_31-Dec-2010_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD">0</lixt:SharesIssuedInPrivatePlacementNetOfOfferingCosts>
  <lixt:SharesIssuedInPrivatePlacement decimals="0" contextRef="Context_Custom_31-Dec-2006_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares">3555220</lixt:SharesIssuedInPrivatePlacement>
  <lixt:SharesIssuedInPrivatePlacement decimals="0" contextRef="Context_Custom_31-Dec-2007_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares">999995</lixt:SharesIssuedInPrivatePlacement>
  <lixt:SharesIssuedInPrivatePlacement decimals="0" contextRef="Context_Custom_31-Dec-2009_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares">2420000</lixt:SharesIssuedInPrivatePlacement>
  <lixt:SharesIssuedInPrivatePlacement decimals="0" contextRef="Context_Custom_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares">4575000</lixt:SharesIssuedInPrivatePlacement>
  <lixt:AdvancesUnderEquityFinancingDuringPeriod decimals="0" contextRef="Context_Custom_31-Dec-2009" unitRef="USD">1200000</lixt:AdvancesUnderEquityFinancingDuringPeriod>
  <lixt:AdvancesUnderEquityFinancingDuringPeriod decimals="0" contextRef="Context_Custom_31-Dec-2009_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD">0</lixt:AdvancesUnderEquityFinancingDuringPeriod>
  <lixt:AdvancesUnderEquityFinancingDuringPeriod decimals="0" contextRef="Context_Custom_31-Dec-2009_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember" unitRef="USD">1200000</lixt:AdvancesUnderEquityFinancingDuringPeriod>
  <lixt:AdvancesUnderEquityFinancingDuringPeriod decimals="0" contextRef="Context_Custom_31-Dec-2009_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD">0</lixt:AdvancesUnderEquityFinancingDuringPeriod>
  <lixt:AdvancesUnderEquityFinancingDuringPeriod decimals="0" contextRef="Context_Custom_31-Dec-2009_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD">0</lixt:AdvancesUnderEquityFinancingDuringPeriod>
  <lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts decimals="0" contextRef="Context_Custom_31-Dec-2006" unitRef="USD">97400</lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts>
  <lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts decimals="0" contextRef="Context_Custom_31-Dec-2006_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD">0</lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts>
  <lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts decimals="0" contextRef="Context_Custom_31-Dec-2006_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember" unitRef="USD">0</lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts>
  <lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts decimals="0" contextRef="Context_Custom_31-Dec-2006_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD">97400</lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts>
  <lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts decimals="0" contextRef="Context_Custom_31-Dec-2006_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD">0</lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts>
  <lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts decimals="0" contextRef="Context_Custom_31-Dec-2007" unitRef="USD">890694</lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts>
  <lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts decimals="0" contextRef="Context_Custom_31-Dec-2007_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD">25</lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts>
  <lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts decimals="0" contextRef="Context_Custom_31-Dec-2007_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember" unitRef="USD">0</lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts>
  <lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts decimals="0" contextRef="Context_Custom_31-Dec-2007_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD">890669</lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts>
  <lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts decimals="0" contextRef="Context_Custom_31-Dec-2007_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD">0</lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts>
  <lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts decimals="0" contextRef="Context_Custom_31-Dec-2008" unitRef="USD">357987</lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts>
  <lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts decimals="0" contextRef="Context_Custom_31-Dec-2008_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD">0</lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts>
  <lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts decimals="0" contextRef="Context_Custom_31-Dec-2008_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember" unitRef="USD">0</lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts>
  <lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts decimals="0" contextRef="Context_Custom_31-Dec-2008_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD">357987</lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts>
  <lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts decimals="0" contextRef="Context_Custom_31-Dec-2008_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD">0</lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts>
  <lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts decimals="0" contextRef="Context_Custom_31-Dec-2009" unitRef="USD">745980</lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts>
  <lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts decimals="0" contextRef="Context_Custom_31-Dec-2009_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD">15</lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts>
  <lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts decimals="0" contextRef="Context_Custom_31-Dec-2009_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember" unitRef="USD">0</lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts>
  <lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts decimals="0" contextRef="Context_Custom_31-Dec-2009_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD">745965</lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts>
  <lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts decimals="0" contextRef="Context_Custom_31-Dec-2009_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD">0</lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts>
  <lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts decimals="0" contextRef="Context_Custom_31-Dec-2010" unitRef="USD">160712</lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts>
  <lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts decimals="0" contextRef="Context_Custom_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD">0</lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts>
  <lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts decimals="0" contextRef="Context_Custom_31-Dec-2010_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember" unitRef="USD">0</lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts>
  <lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts decimals="0" contextRef="Context_Custom_31-Dec-2010_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD">160712</lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts>
  <lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts decimals="0" contextRef="Context_Custom_31-Dec-2010_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD">0</lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts>
  <lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">40528</lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts>
  <lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts decimals="0" contextRef="Context_6ME_30-Jun-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD">0</lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts>
  <lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts decimals="0" contextRef="Context_6ME_30-Jun-2011_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember" unitRef="USD">0</lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts>
  <lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts decimals="0" contextRef="Context_6ME_30-Jun-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD">40528</lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts>
  <lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts decimals="0" contextRef="Context_6ME_30-Jun-2011_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD">0</lixt:StockIssuedDuringPeriodValueShareBasedCompensationCosts>
  <lixt:StockIssuedDuringPeriodSharesShareBasedCompensationCosts decimals="0" contextRef="Context_Custom_31-Dec-2007_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares">250000</lixt:StockIssuedDuringPeriodSharesShareBasedCompensationCosts>
  <lixt:StockIssuedDuringPeriodSharesShareBasedCompensationCosts decimals="0" contextRef="Context_Custom_31-Dec-2009_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares">150000</lixt:StockIssuedDuringPeriodSharesShareBasedCompensationCosts>
  <lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts decimals="0" contextRef="Context_Custom_31-Dec-2007" unitRef="USD">50836</lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts>
  <lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts decimals="0" contextRef="Context_Custom_31-Dec-2007_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD">0</lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts>
  <lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts decimals="0" contextRef="Context_Custom_31-Dec-2007_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember" unitRef="USD">0</lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts>
  <lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts decimals="0" contextRef="Context_Custom_31-Dec-2007_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD">50836</lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts>
  <lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts decimals="0" contextRef="Context_Custom_31-Dec-2007_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD">0</lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts>
  <lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts decimals="0" contextRef="Context_Custom_31-Dec-2008" unitRef="USD">213061</lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts>
  <lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts decimals="0" contextRef="Context_Custom_31-Dec-2008_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD">10</lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts>
  <lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts decimals="0" contextRef="Context_Custom_31-Dec-2008_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember" unitRef="USD">0</lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts>
  <lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts decimals="0" contextRef="Context_Custom_31-Dec-2008_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD">213051</lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts>
  <lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts decimals="0" contextRef="Context_Custom_31-Dec-2008_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD">0</lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts>
  <lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts decimals="0" contextRef="Context_Custom_31-Dec-2009" unitRef="USD">132933</lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts>
  <lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts decimals="0" contextRef="Context_Custom_31-Dec-2009_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD">0</lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts>
  <lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts decimals="0" contextRef="Context_Custom_31-Dec-2009_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember" unitRef="USD">0</lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts>
  <lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts decimals="0" contextRef="Context_Custom_31-Dec-2009_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD">132933</lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts>
  <lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts decimals="0" contextRef="Context_Custom_31-Dec-2009_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD">0</lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts>
  <lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts decimals="0" contextRef="Context_Custom_31-Dec-2010" unitRef="USD">67222</lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts>
  <lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts decimals="0" contextRef="Context_Custom_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD">0</lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts>
  <lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts decimals="0" contextRef="Context_Custom_31-Dec-2010_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember" unitRef="USD">0</lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts>
  <lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts decimals="0" contextRef="Context_Custom_31-Dec-2010_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD">67222</lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts>
  <lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts decimals="0" contextRef="Context_Custom_31-Dec-2010_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD">0</lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts>
  <lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">982</lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts>
  <lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts decimals="0" contextRef="Context_6ME_30-Jun-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD">0</lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts>
  <lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts decimals="0" contextRef="Context_6ME_30-Jun-2011_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember" unitRef="USD">0</lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts>
  <lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts decimals="0" contextRef="Context_6ME_30-Jun-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD">982</lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts>
  <lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts decimals="0" contextRef="Context_6ME_30-Jun-2011_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD">0</lixt:SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts>
  <lixt:SharesIssuedDuringPeriodSharesStockBasedResearchAndDevelopmentCosts decimals="0" contextRef="Context_Custom_31-Dec-2008_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares">100000</lixt:SharesIssuedDuringPeriodSharesStockBasedResearchAndDevelopmentCosts>
  <us-gaap:Depreciation decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">0</us-gaap:Depreciation>
  <us-gaap:Depreciation decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">0</us-gaap:Depreciation>
  <us-gaap:Depreciation decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">1909</us-gaap:Depreciation>
  <us-gaap:IncreaseDecreaseInDepositOtherAssets decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">0</us-gaap:IncreaseDecreaseInDepositOtherAssets>
  <us-gaap:IncreaseDecreaseInDepositOtherAssets decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">-50000</us-gaap:IncreaseDecreaseInDepositOtherAssets>
  <us-gaap:IncreaseDecreaseInDepositOtherAssets decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">0</us-gaap:IncreaseDecreaseInDepositOtherAssets>
  <lixt:IncreaseDecreaseInGrantReceivable decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">0</lixt:IncreaseDecreaseInGrantReceivable>
  <lixt:IncreaseDecreaseInGrantReceivable decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">-116485</lixt:IncreaseDecreaseInGrantReceivable>
  <lixt:IncreaseDecreaseInGrantReceivable decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">0</lixt:IncreaseDecreaseInGrantReceivable>
  <lixt:IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">8310</lixt:IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices>
  <lixt:IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">53256</lixt:IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices>
  <lixt:IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">63356</lixt:IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">-4958</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">-12251</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">22395</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">-6430</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">52454</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">80799</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <lixt:IncreaseDecreaseInLiquidatedDamagesPayableUnderRegistrationRightsAgreement decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">0</lixt:IncreaseDecreaseInLiquidatedDamagesPayableUnderRegistrationRightsAgreement>
  <lixt:IncreaseDecreaseInLiquidatedDamagesPayableUnderRegistrationRightsAgreement decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">0</lixt:IncreaseDecreaseInLiquidatedDamagesPayableUnderRegistrationRightsAgreement>
  <lixt:IncreaseDecreaseInLiquidatedDamagesPayableUnderRegistrationRightsAgreement decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">74000</lixt:IncreaseDecreaseInLiquidatedDamagesPayableUnderRegistrationRightsAgreement>
  <lixt:IncreaseDecreaseInResearchAndDevelopmentContractLiabilities decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">29007</lixt:IncreaseDecreaseInResearchAndDevelopmentContractLiabilities>
  <lixt:IncreaseDecreaseInResearchAndDevelopmentContractLiabilities decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">89550</lixt:IncreaseDecreaseInResearchAndDevelopmentContractLiabilities>
  <lixt:IncreaseDecreaseInResearchAndDevelopmentContractLiabilities decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">89550</lixt:IncreaseDecreaseInResearchAndDevelopmentContractLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">-529273</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">-389774</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">-3709977</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <lixt:PaymentsToAcquireMoneyMarketFunds decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">2050150</lixt:PaymentsToAcquireMoneyMarketFunds>
  <lixt:PaymentsToAcquireMoneyMarketFunds decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">-299917</lixt:PaymentsToAcquireMoneyMarketFunds>
  <lixt:PaymentsToAcquireMoneyMarketFunds decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">1301089</lixt:PaymentsToAcquireMoneyMarketFunds>
  <us-gaap:PaymentsToAcquireMachineryAndEquipment decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">0</us-gaap:PaymentsToAcquireMachineryAndEquipment>
  <us-gaap:PaymentsToAcquireMachineryAndEquipment decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">0</us-gaap:PaymentsToAcquireMachineryAndEquipment>
  <us-gaap:PaymentsToAcquireMachineryAndEquipment decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">1909</us-gaap:PaymentsToAcquireMachineryAndEquipment>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">-2050150</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">299917</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">-1302998</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <lixt:ProceedsFromSaleOfCommonStockToConsultingFirm decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">0</lixt:ProceedsFromSaleOfCommonStockToConsultingFirm>
  <lixt:ProceedsFromSaleOfCommonStockToConsultingFirm decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">0</lixt:ProceedsFromSaleOfCommonStockToConsultingFirm>
  <lixt:ProceedsFromSaleOfCommonStockToConsultingFirm decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">250</lixt:ProceedsFromSaleOfCommonStockToConsultingFirm>
  <lixt:ProceedsFromSaleOfCommonStockToFounder decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">0</lixt:ProceedsFromSaleOfCommonStockToFounder>
  <lixt:ProceedsFromSaleOfCommonStockToFounder decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">0</lixt:ProceedsFromSaleOfCommonStockToFounder>
  <lixt:ProceedsFromSaleOfCommonStockToFounder decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">1500</lixt:ProceedsFromSaleOfCommonStockToFounder>
  <us-gaap:CashAcquiredFromAcquisition decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">0</us-gaap:CashAcquiredFromAcquisition>
  <us-gaap:CashAcquiredFromAcquisition decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">0</us-gaap:CashAcquiredFromAcquisition>
  <us-gaap:CashAcquiredFromAcquisition decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">62500</us-gaap:CashAcquiredFromAcquisition>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">1087500</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">5331389</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:PaymentsOfStockIssuanceCosts decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">0</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">0</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">446147</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:ProceedsFromContributedCapital decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">0</us-gaap:ProceedsFromContributedCapital>
  <us-gaap:ProceedsFromContributedCapital decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">0</us-gaap:ProceedsFromContributedCapital>
  <us-gaap:ProceedsFromContributedCapital decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">92717</us-gaap:ProceedsFromContributedCapital>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">1087500</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">5000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">5047209</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">-1491923</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">-84857</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">34234</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:InterestPaid decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">0</us-gaap:InterestPaid>
  <us-gaap:InterestPaid decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">0</us-gaap:InterestPaid>
  <us-gaap:InterestPaid decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">2469</us-gaap:InterestPaid>
  <us-gaap:IncomeTaxesPaid decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">0</us-gaap:IncomeTaxesPaid>
  <us-gaap:IncomeTaxesPaid decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">0</us-gaap:IncomeTaxesPaid>
  <us-gaap:IncomeTaxesPaid decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">0</us-gaap:IncomeTaxesPaid>
  <lixt:DecreaseInAdvancesUnderEquityFinancing decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">1200000</lixt:DecreaseInAdvancesUnderEquityFinancing>
  <lixt:DecreaseInAdvancesUnderEquityFinancing decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">0</lixt:DecreaseInAdvancesUnderEquityFinancing>
  <lixt:DecreaseInAdvancesUnderEquityFinancing decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">1200000</lixt:DecreaseInAdvancesUnderEquityFinancing>
  <us-gaap:BasisOfAccounting contextRef="Context_6ME_30-Jun-2011">&lt;div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;1. Basis of Presentation
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The condensed consolidated financial statements of Lixte Biotechnology Holdings, Inc. and its wholly-owned subsidiary, Lixte Biotechnology, Inc. (the &amp;#8220;Company&amp;#8221;) at June 30, 2011, for the three months and six months ended June 30, 2011 and 2010, and for the period from August 9, 2005 (inception) to June 30, 2011 (cumulative), are unaudited. In the opinion of management, all adjustments (including normal recurring adjustments) have been made that are necessary to present fairly the financial position of the Company as of June 30, 2011, the results of its operations for the three months and six months ended June 30, 2011 and 2010, and for the period from August 9, 2005 (inception) to June 30, 2011 (cumulative), and its cash flows for the six months ended June 30, 2011 and 2010, and for the period from August 9, 2005 (inception) to June 30, 2011 (cumulative). Operating results for the interim periods presented are not necessarily indicative of the results to be expected for a full fiscal year. The condensed balance sheet at December 31, 2010 has been derived from the company's audited financial statements.
&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The statements and related notes have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been omitted pursuant to such rules and regulations. These financial statements should be read in conjunction with the financial statements and other information included in the Company&amp;#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2010, as filed with the SEC.
&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:BasisOfAccounting>
  <lixt:OrganizationAndBusinessOperationsTextBlock contextRef="Context_6ME_30-Jun-2011">&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;2.&amp;#160; Organization and Business Operations
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Organization&lt;br /&gt;
&lt;br /&gt;

&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;On June 30, 2006, Lixte Biotechnology, Inc., a privately-held Delaware corporation (&amp;#8220;Lixte&amp;#8221;) incorporated on August 9, 2005, completed a reverse merger transaction with SRKP 7, Inc. (&amp;#8220;SRKP&amp;#8221;), a non-trading public shell company, whereby Lixte became a wholly-owned subsidiary of SRKP. On December 7, 2006, SRKP amended its Certificate of Incorporation to change its name to Lixte Biotechnology Holdings, Inc. (&amp;#8220;Holdings&amp;#8221;). Unless the context indicates otherwise, Lixte and Holdings are hereinafter referred to as the &amp;#8220;Company&amp;#8221;.&lt;br /&gt;
&lt;br /&gt;

&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;For financial reporting purposes, Lixte was considered the accounting acquirer in the merger and the merger was accounted for as a reverse merger. Accordingly, the historical financial statements presented herein are those of Lixte. The stockholders&amp;#8217; equity section of SRKP has been retroactively restated for all periods presented to reflect the accounting effect of the reverse merger transaction. All costs associated with the reverse merger transaction were expensed as incurred.&lt;br /&gt;
&lt;br /&gt;

&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company is considered a &amp;#8220;development stage company&amp;#8221; under current accounting standards, as it has not yet commenced any revenue-generating operations, does not have any cash flows from operations, and is dependent on debt and equity funding to finance its operations.&lt;br /&gt;
&lt;br /&gt;

&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company&amp;#8217;s common stock was listed for trading on the OTC Bulletin Board commencing September 24, 2007 under the symbol &amp;#8220;LIXT&amp;#8221;. It is presently traded on the OTC Market (also referred to as the &amp;#8220;Pink Sheets&amp;#8221;) under the symbol &amp;#8220;LIXT.PK&amp;#8221;.&lt;br /&gt;
&lt;br /&gt;

&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Operating Plans&lt;br /&gt;
&lt;br /&gt;

&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company is developing new treatments for human cancers for which better therapies are urgently needed. The Company&amp;#8217;s drug discovery process is based on discerning clues to potential new targets for cancer treatments reported in the increasingly large body of literature characterizing the molecular variants, which characterize human cancers. In the past decade, there has been an unprecedented expansion in knowledge of biochemical defects in the cancer cell. The Company selects drugs for which there are existing data suggesting that they may affect the altered pathways of the cancer cell and may be given safely to humans. The Company seeks to rapidly arrive at patentable structures through analysis of the literature rather than screening of thousands of structures for activity against a particular biochemical pathway.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;This approach has led to the development of two classes of drugs, phosphatase inhibitors (PTase-i), designated by the Company as the LB-100 series of compounds, and histone deacetylase inhibitors (HDACi), designated by the Company as the LB-200 series of compounds. The LB-100 series consists of novel structures, which have the potential to be first in their class and the latter group contains compounds, which have the potential to be the most effective of this class. The Company has demonstrated that lead compounds of both series of drugs are active against a broad spectrum of human cancers in cell culture and against several types of human cancers in animal models. The research on new drug treatment was initiated in 2006 with the National Institute of Neurologic Disorders and Stroke (NINDS), National Institutes of Health (NIH) under a continuing Cooperative Research and Development Agreement (CRADA). The research at NINDS is led by Dr. Zhengping Zhuang, an internationally recognized investigator in the molecular pathology of cancer. The initial focus of the CRADA was on the most common and uniformly fatal brain tumor of adults, glioblastoma multiforme (GBM). The work at NIH has now extended to the most common brain tumor of children, medulloblastoma, and to the most common cancer of children, neuroblastoma. Because of the propensity of malignant melanoma to metastasize to the brain, recent studies have encompassed studying the effectiveness of drugs developed for the treatment of primary brain tumors to the treatment of melanoma.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;" &gt;&lt;div&gt;
&lt;/div&gt;&lt;div&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;br /&gt;
&lt;div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The second class of drugs (LB-200) under development by the Company is the histone deacetylase inhibitors. Many pharmaceutical companies are also developing drugs of this type, and at least two companies have an HDACi approved for clinical use, in both cases for the treatment of a type of lymphoma. Despite this significant competition, the Company has demonstrated that its HDACi have broad activity against many cancer types, have neuroprotective activity, and have anti-fungal activity. In addition, these compounds have low toxicity, making them attractive candidates for development. It appears that one type of molecule has diverse effects, affecting biochemical processes that are fundamental to the life of the cell, whether they are cancer cells, nerve cells, or even fungal cells. The neuroprotective activity of the Company&amp;#8217;s HDACi has been demonstrated in the test tube in model systems that mimic injury to brain cells such as occurs in stroke and Alzheimer&amp;#8217;s disease. Potentially, this type of protective activity may have application to a broad spectrum of other chronic neurodegenerative diseases, including Parkinson&amp;#8217;s Disease and Amytrophic Lateral Sclerosis (ALS, or Lou Gehrig&amp;#8217;s Disease).&lt;br /&gt;
&lt;br /&gt;

&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company&amp;#8217;s primary objective is to bring one lead compound of the LB-100 series to clinical trial. In late 2009 and early 2010, the Company raised sufficient financial resources to carry out the preclinical studies needed for an application to the FDA to carry out a Phase I clinical trial. The Company has engaged a leading pharmaceutical manufacturing company, a clinical research organization, and a drug development company specializing in pharmacologic and toxocologic characterization of new anticancer drugs to oversee and carry out the studies necessary to obtain FDA approval to commence a Phase I clinical trial.&lt;br /&gt;
&lt;br /&gt;

&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;On September 17, 2010, the National Cancer Institute Experimental Therapeutics (NExT) Program Senior Advisory Committee (SAC) approved a collaboration by NCI with the Company for clinical evaluation of LB-100, one of the Company&amp;#8217;s drug compounds. This collaboration is a milestone-based approach in which NCI will first confirm studies of the LB-100 compound in an animal model of glioblastoma multiforme, the most common brain tumor of adults, and conduct an initial exploratory toxicology study in an animal model. At milestone intervals, the SAC will re-evaluate project progress before considering assignment of additional support and resources to this project.&lt;br /&gt;
&lt;br /&gt;

&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company believes that it has adequate funds on hand to support operations at current levels, including commencing, but not completing, a Phase I clinical trial of the Company&amp;#8217;s LB-100 compound, and to continue to grow its patent portfolio and maintain its applications for international protection of lead compounds of both the LB-100 and LB-200 series, without having to raise additional funds, until early 2012.&lt;br /&gt;
&lt;br /&gt;

&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Going Concern&lt;br /&gt;
&lt;br /&gt;

&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company&amp;#8217;s condensed consolidated financial statements have been presented on the basis that it is a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company is in the development stage and has not generated any revenues from operations to date, and does not expect to do so in the foreseeable future. The Company has experienced recurring operating losses and negative operating cash flows since inception, and has financed its working capital requirements through the recurring sale of its equity securities. As a result, the Company&amp;#8217;s independent registered public accounting firm, in its report on the Company&amp;#8217;s 2010 consolidated financial statements, has raised substantial doubt about the Company&amp;#8217;s ability to continue as a going concern.&lt;br /&gt;
&lt;br /&gt;

&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company&amp;#8217;s ability to continue as a going concern is dependent upon its ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations. The Company&amp;#8217;s condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.&lt;br /&gt;
&lt;br /&gt;

&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;At June 30, 2011, the Company had not yet commenced any revenue-generating operations. All activity through June 30, 2011 has been related to the Company&amp;#8217;s formation, capital raising efforts and research and development activities. As such, the Company has yet to generate any cash flows from operations, and is dependent on debt and equity funding from both related and unrelated parties to finance its operations. Prior to June 30, 2006, the Company&amp;#8217;s cash requirements were funded by advances from the Company&amp;#8217;s founder aggregating $92,717.&lt;br /&gt;
&lt;br /&gt;

&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Because the Company is currently engaged in research at an early stage, it will likely take a significant amount of time to develop any product or intellectual property capable of generating revenues. As such, the Company&amp;#8217;s business is unlikely to generate any sustainable revenues in the next several years, and may never do so. Even if the Company is able to generate revenues in the future through licensing its technologies or through product sales, there can be no assurance that the Company will be able to generate a profit.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;" &gt;&lt;div&gt;
&lt;/div&gt;&lt;div&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;br /&gt;
&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company&amp;#8217;s activities for the remainder of 2011 will consist of continuing drug discovery and development efforts. The Company&amp;#8217;s primary objective is to&amp;#160;gain FDA approval of&amp;#160;the Company's LB-100 compound for entry into a&amp;#160;Phase I clinical trial by the end of 2011. The Company was not able to expedite this process so as to obtain such approval by its June 30, 2011 target date.&amp;#160;Although the Company has not identified any specific obstacles to the submission of the FDA application, the overall process of large animal testing and formal documentation of the long-term stability of the LB-100 compound has been slower than originally anticipated.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company raised $500,000 in November 2009, $1,787,500 in January 2010, and $500,000 in February 2010, all through the sale of its securities to fund its business activities. The Company also received $244,479 from the Internal Revenue Service under its Qualifying Therapeutic Discovery Grant program, consisting of $127,994 on November 9, 2010 and $116,485 on February&amp;#160;1, 2011. As a result, the Company believes that its existing resources are adequate to fund operations until early 2012 at a level that will allow the continuation of the Company&amp;#8217;s two drug development programs currently in process and commencement, but not completion, of a Phase I clinical trial of LB-100. &lt;br /&gt;
&lt;br /&gt;

&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The amount and timing of future cash requirements will depend on the pace of these programs, particularly the completion of the Phase I trial of LB-100. After completion of the Phase I trial, the next step will be to determine the anti-cancer activity against a particular type of human cancer in Phase II trials. To complete the Phase I trial and carry out Phase II trials, the Company anticipates that it will be necessary to raise additional funds beginning in early 2012 from a combination of debt or equity financings, and/or the sale, licensing or joint venturing of its intellectual properties. Market conditions present uncertainty as to the Company&amp;#8217;s ability to secure additional funds, as well as its ability to reach profitability. There can be no assurances that the Company will be able to secure additional financing, or obtain favorable terms on such financing if it is available, or as to the Company&amp;#8217;s ability to achieve positive earnings and cash flows from operations. Continued negative cash flows and lack of liquidity create significant uncertainty about the Company&amp;#8217;s ability to fully implement its operating plan beyond early 2012, as a result of which the Company may have to reduce the scope of its planned operations. If cash resources are insufficient to satisfy the Company&amp;#8217;s liquidity requirements, the Company would be required to scale back or discontinue its technology and product development programs, or obtain funds, if available, through strategic alliances that may require the Company to relinquish rights to certain of its technologies products, or to discontinue its operations entirely.
&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</lixt:OrganizationAndBusinessOperationsTextBlock>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="Context_6ME_30-Jun-2011">&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;3. Summary of Significant Accounting Policies
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Principles of Consolidation
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The accompanying condensed consolidated financial statements include the financial statements of Holdings and its wholly-owned subsidiary, Lixte. All intercompany balances and transactions have been eliminated in consolidation.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Cash Concentrations
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company&amp;#8217;s cash balances may periodically exceed federally insured limits. The Company has not experienced a loss in such accounts to date. The Company maintains its accounts with financial institutions with high credit ratings.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Research and Development
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Research and development costs are expensed as incurred. Research and development expenses consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company's treatments and product candidates.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Amounts that become due, pursuant to contractual commitments, on research and development contracts with third parties are recorded as a liability, with the related amount of such contracts recorded as advances on research and development contract services on the Company&amp;#8217;s balance sheet. Such advances on research and development contract services are expensed over their life on the straight-line basis, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different expensing schedule is more appropriate. The Company reviews the status of its research and development contracts on a quarterly basis.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The funds paid to NINDS of the NIH, pursuant to the CRADA effective March 22, 2006, as amended, represented an advance on research and development costs and therefore had future economic benefit. Accordingly, such costs have been charged to expense when they are actually expended by the provider, which is, effectively, as they perform the research activities that they were contractually committed to provide. Absent information that would indicate that a different expensing schedule was more appropriate (such as, for example, from the achievement of performance milestones or the completion of contract work), such advances have been expensed over the contractual service term on a straight-line basis, which, in management&amp;#8217;s opinion, reflects a reasonable estimate of when the underlying research and development costs were being incurred.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;" &gt;&lt;div&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Patent Costs
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company's research efforts and any related patent applications, all patent costs, including patent-related legal and filing fees, are expensed as incurred. Patent costs were $95,126 and $82,091 for the three months ended June 30, 2011 and 2010, respectively, $234,271 and $170,780 for the six months ended June 30, 2011 and 2010, respectively, and $1,005,605 for the period from August 9, 2005 (inception) to June 30, 2011 (cumulative). Patent costs are included in research and development costs in the Company's condensed consolidated statements of operations.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Income Taxes
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company has elected to deduct research and development costs on a current basis for federal income tax purposes. Start-up and organization costs were deferred until January 1, 2008. Accordingly, the Company then began to amortize such costs over a 180-month period.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;For federal income tax purposes, net operating losses can be carried forward for a period of 20 years until they are either utilized or until they expire.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;On January 1, 2007, the Company adopted new accounting rules which address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. The new accounting rules also provide guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. The adoption of the new accounting rules did not have a material effect on the Company&amp;#8217;s financial statements. As of June 30, 2011, no liability for unrecognized tax benefits was required to be recorded.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company files income tax returns in the U.S. federal jurisdiction and is subject to income tax examinations by federal tax authorities for the year 2008 and thereafter. The Company&amp;#8217;s policy is to record interest and penalties on uncertain tax provisions as income tax expense. As of June 30, 2011, the Company has no accrued interest or penalties related to uncertain tax positions.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Government Grant Under Qualifying Therapeutic Discovery Project
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Under the Patient Protection and Affordable Care Act signed into law on March 23, 2010 (the &amp;#8220;Act&amp;#8221;), the Internal Revenue Service and the Department of Health and Human Services established the qualifying therapeutic discovery project to consider and award certifications for qualified investments by project sponsors. On July 20, 2010, the Company applied for a grant pursuant to the Act based upon qualified investments made in 2009 and 2010. On October 29, 2010, the Company was notified that qualified investments totaling $488,958 had been certified and that a grant in the amount of $244,479 had been awarded to the Company.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new
 roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The proceeds of the grant were received by the Company in installments, consisting of $127,994 on November 9, 2010, and $116,485 on February 1, 2011, which was reflected as a receivable at December 31, 2010. For financial statement purposes, the grant of $244,479 was offset against research and development costs in the statement of operations for the year ended December 31, 2010.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Stock-Based Compensation
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company periodically issues stock options and warrants to officers, directors and consultants for services rendered. Options vest and expire according to terms established at the grant date.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company accounts for share-based payments to officers and directors by measuring the cost of services received in exchange for equity awards based on the grant date fair value of the awards, with the cost recognized as compensation expense in the Company&amp;#8217;s financial statements over the vesting period of the awards.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company accounts for share-based payments to consultants by determining the value of the stock compensation based upon the measurement date at either (a) the date at which a performance commitment is reached or (b) at the date at which the necessary performance to earn the equity instruments is complete.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Options granted to Scientific Advisory Board committee members and outside consultants are revalued each reporting period to determine the amount to be recorded as an expense in the respective period. As the options vest, they are valued on each vesting date and an adjustment is recorded for the difference between the value already recorded and the then current value on the date of vesting.
&lt;/font&gt;
&lt;/div&gt;&lt;div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Earnings Per Share&lt;br /&gt;
&lt;br /&gt;

&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company&amp;#8217;s computation of earnings per share (&amp;#8220;EPS&amp;#8221;) includes basic and diluted EPS. Basic EPS is measured as the income (loss) available to common shareholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., warrants and options) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.&lt;br /&gt;
&lt;br /&gt;

&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted loss per common share is the same for all periods presented because all warrants and stock options outstanding are anti-dilutive.&lt;br /&gt;
&lt;br /&gt;

&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;At June 30, 2011 and 2010, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.&lt;br /&gt;
&lt;br /&gt;

&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:center;" &gt;&lt;table cellspacing="0" cellpadding="0" width="80%"  style="font-family:times new roman;font-size:10pt;" &gt;&lt;tr&gt;&lt;td valign="bottom" width="76%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;&amp;#160;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="22%" colspan="6" nowrap="nowrap"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;June 30,
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="76%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;2011
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;2010
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="76%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="76%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Warrants
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;13,454,552
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;13,607,426
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="76%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Stock options
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;3,350,000
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;3,540,000
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="76%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Total
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;16,804,552
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;17,147,426
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Fair Value of Financial Instruments&lt;br /&gt;
&lt;br /&gt;

&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The carrying amounts of cash, money market funds, advances on research and development contract services, prepaid expenses and other current assets, accounts payable and accrued expenses, research and development contract liabilities, liquidated damages payable under registration rights agreement and due to stockholder approximate their respective fair values due to the short-term nature of these items.&lt;br /&gt;
&lt;br /&gt;

&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Use of Estimates&lt;br /&gt;
&lt;br /&gt;

&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;br /&gt;
&lt;br /&gt;

&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Recent Accounting Pronouncements&lt;br /&gt;
&lt;br /&gt;

&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;In May&amp;#160;2011, the Financial Accounting Standards Board (the &amp;#8220;FASB&amp;#8221;)&amp;#160;issued Accounting Standards Update (the &amp;#8220;ASU&amp;#8221;)&amp;#160;No.&amp;#160;2011-4, which amends the Fair Value Measurements Topic of the Accounting Standards Codification (the &amp;#8220;ASC&amp;#8221;)&amp;#160;to help achieve common fair value measurement and disclosure requirements in U.S. GAAP and IFRS.&amp;#160;&amp;#160;ASU No.&amp;#160;2011-4 does not require additional fair value measurements and is not intended to establish valuation standards or affect valuation practices outside of financial reporting.&amp;#160;&amp;#160;The ASU is effective for interim and annual periods beginning after December&amp;#160;15, 2011. The Company will adopt the ASU as required.&amp;#160;&amp;#160;The ASU will affect the Company&amp;#8217;s fair value disclosures, but is not expected to have any impact on the Company&amp;#8217;s financial position or results of operations.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;In June&amp;#160;2011, the FASB issued ASU No.&amp;#160;2011-5, which amends the Comprehensive Income Topic of the ASC.&amp;#160;&amp;#160;The ASU eliminates the option to present the components of other comprehensive income as part of the statement of changes in shareholders&amp;#8217; equity, and instead requires consecutive presentation of the statement of net income and other comprehensive income either in a continuous statement of comprehensive income or in two separate but consecutive statements.&amp;#160;&amp;#160;ASU No.&amp;#160;2011-5 is effective for interim and annual periods beginning after December&amp;#160;15, 2011.&amp;#160;&amp;#160;The Company will adopt the ASU as required.&amp;#160;&amp;#160;The ASU is not expected to have any impact on the Company&amp;#8217;s financial position or results of operations.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company&amp;#8217;s financial statement presentation or disclosures.
&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>

  <lixt:ShareExchangeAgreementAndPrivatePlacementTextBlock contextRef="Context_6ME_30-Jun-2011">
  &lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;4. Share Exchange Agreement and Private Placement
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Share Exchange Agreement
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;On June 30, 2006, pursuant to a Share Exchange Agreement dated as of June 8, 2006 (the &amp;#8220;Share Exchange Agreement&amp;#8221;) by and among Holdings, Dr. John S. Kovach (&amp;#8220;Seller&amp;#8221;) and Lixte, Holdings issued 19,021,786 shares of its common stock in exchange for all of the issued and outstanding shares of Lixte (the &amp;#8220;Exchange&amp;#8221;). Previously, on October 3, 2005, Lixte had issued 1,500 shares of its no par value common stock to its founder for $1,500, which constituted all of the issued and outstanding shares of Lixte prior to the Exchange. As a result of the Exchange, Lixte became a wholly-owned subsidiary of Holdings.
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Pursuant to the Exchange, Holdings issued to the Seller 19,021,786 shares of its common stock. Holdings had a total of 25,000,832 shares of common stock issued and outstanding after giving effect to the Exchange and the 1,973,869 shares of common stock issued in the initial closing of the private placement.&lt;br /&gt;
  &lt;br /&gt;

  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;
  &lt;/font&gt;
  &lt;/div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;As a result of the Exchange and the shares of common stock issued in the initial closing of the private placement, on June 30, 2006, the stockholders of the Company immediately prior to the Exchange owned 4,005,177 shares of common stock, equivalent to approximately 16% of the issued and outstanding shares of the Company&amp;#8217;s common stock, and the former stockholder of Lixte acquired control of the Company.&lt;br /&gt;
  &lt;br /&gt;

  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;
  &lt;/font&gt;
  &lt;/div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Share Exchange Agreement was determined through arms-length negotiations between Holdings, the Seller and Lixte. In connection with the Exchange, the Company paid WestPark Capital, Inc. an aggregate cash fee of $50,000.&lt;br /&gt;
  &lt;br /&gt;

  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;
  &lt;/font&gt;
  &lt;/div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Private Placements&lt;br /&gt;
  &lt;br /&gt;

  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;
  &lt;/font&gt;
  &lt;/div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;On June 30, 2006, concurrently with the closing of the Exchange, the Company sold an aggregate of 1,973,869 shares of its common stock to accredited investors in an initial closing of a private placement at a per share price of $0.333, resulting in aggregate gross proceeds to the Company of $657,299. The Company paid to WestPark Capital, Inc., as placement agent, a commission of 10% and a non-accountable fee of 4% of the gross proceeds of the private placement and issued five-year warrants to purchase common stock equal to (a) 10% of the number of shares sold in the private placement exercisable at $0.333 per share and (b) an additional 2% of the number of shares sold in the private placement also exercisable at $0.333 per share. A total of 236,864 warrants were issued. Net cash proceeds to the Company, after the deduction of all private placement offering costs and expenses, were $522,939.&lt;br /&gt;
  &lt;br /&gt;

  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;
  &lt;/font&gt;
  &lt;/div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;On July 27, 2006, the Company sold an aggregate of 1,581,351 shares of its common stock to accredited investors in a second closing of the private placement at a per share price of $0.333 resulting in aggregate gross proceeds to the Company of $526,590. The Company paid to WestPark Capital, Inc., as placement agent, a commission of 10% and a non-accountable fee of 4% of the gross proceeds of the private placement and issued five-year warrants to purchase common stock equal to (a) 10% of the number of shares sold in the private placement exercisable at $0.333 per share and (b) an additional 2% of the number of shares sold in the private placement also exercisable at $0.333 per share. A total of 189,762 warrants were issued. Net cash proceeds to the Company were $446,433.&amp;#160;&lt;br /&gt;
  &lt;br /&gt;

  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;In conjunction with the private placement of common stock, the Company issued a total of 426,626 five-year warrants to WestPark Capital, Inc. exercisable at the per share price of the common stock sold in the private placement ($0.333 per share). The warrants issued to WestPark Capital, Inc. do not contain any price anti-dilution provisions. However, such warrants contain cashless exercise provisions and demand registration rights, but the warrant holder has agreed to waive any claims to monetary damages or financial penalties for any failure by the Company to comply with such registration requirements. Based on the foregoing, the warrants were accounted for as equity and were not accounted for separately from the common stock and additional paid-in capital accounts. The warrants had no accounting impact on the Company&amp;#8217;s consolidated financial statements.
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

  &lt;/div&gt;&lt;div style="text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;On June 30, 2011, WestPark Capital, Inc. exercised warrants to acquire a portion of the above described warrants, consisting of 152,874 shares of common stock, on a cashless basis. Such cashless exercise resulted in WestPark Capital, Inc. receiving a net of 100,929 shares.
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

  &lt;/div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;On July 27, 2011, the Company agreed to extend warrants to acquire the remaining portion of the above described warrants, consisting of 273,752 shares of common stock, to July 27, 2012.&amp;#160;&amp;#160;In conjunction with the extension of the warrants, the cashless exercise feature was deleted.&amp;#160;&amp;#160;On July 27, 2011, the fair value of the warrant extension, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $199,839 ($0.73 per share), and will be charged to operations during the three months ending September 30, 2011.&amp;#160;&amp;#160;The fair value of the warrant extension was calculated using the following input variables: stock price - $0.79; exercise price - $0.333; expected life - 1 year; expected volatility &amp;#8211; 308.8%; expected dividend yield - 0%; risk-free interest rate &amp;#8211; 0.14%.&lt;br /&gt;
  &lt;br /&gt;

  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;As part of the Company&amp;#8217;s private placement of its securities completed on July 27, 2006, the Company entered into a registration rights agreement with the purchasers, whereby the Company agreed to register the shares of common stock sold in the private placement, and to maintain the effectiveness of such registration statement, subject to certain conditions. The agreement required the Company to file a registration statement within 45 days of the closing of the private placement and to have the registration statement declared effective within 120 days of the closing of the private placement. On September 8, 2006, the Company filed a registration statement on Form SB-2 to register 3,555,220 shares of the common stock sold in the private placement. Since the registration statement was not declared effective by the Securities and Exchange Commission within 120 days of the closing of the private placement, the Company was required to pay each investor prorated liquidated damages equal to 1.0% of the amount raised per month, payable monthly in cash.
  &lt;/font&gt;
  &lt;/div&gt;

  &lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;On the date of the closing of the private placement, the Company believed it would meet the deadlines under the registration rights agreement with respect to filing a registration statement and having it declared effective by the Securities and Exchange Commission. As a result, the Company did not record any liabilities associated with the registration rights agreement at June 30, 2006. At December 31, 2006, the Company determined that the registration statement covering the shares sold in the private placement would not be declared effective within the requisite time frame and therefore accrued six months liquidated damages under the registration rights agreement aggregating approximately $74,000, which has been presented as a current liability for all periods presented. The Company&amp;#8217;s registration statement on Form SB-2 was declared effective by the Securities and Exchange Commission on May 14, 2007. At March 31, 2011, the registration penalty to the investors had not been paid.
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;" &gt;&lt;div&gt;
  &lt;/div&gt;
  &lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

  &lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;On December 12, 2007, the Company sold an aggregate of 999,995 shares of its common stock to accredited investors in a second private placement at a per share price of $0.65, resulting in aggregate gross proceeds to the Company of $650,000. The Company paid to WestPark Capital, Inc., as placement agent, a commission of 10% and a non-accountable fee of 4% of the gross proceeds of the private placement and issued five-year warrants to purchase common stock equal to (a) 10% of the number of shares sold in the private placement exercisable at $0.65 per share and (b) an additional 2% of the number of shares sold in the private placement also exercisable at $0.65 per share. Net cash proceeds to the Company were $531,320.
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;In conjunction with the second private placement of common stock, the Company issued a total of 120,000 five-year warrants to WestPark Capital, Inc. exercisable at the per share price of the common stock sold in the private placement ($0.65 per share). The warrants issued to WestPark Capital, Inc. do not contain any price anti-dilution provisions. However, such warrants contain cashless exercise provisions and demand registration rights, but the warrant holder has agreed to waive any claims to monetary damages or financial penalties for any failure by the Company to comply with such registration requirements. Based on the foregoing, the warrants were accounted for as equity and were not accounted for separately from the common stock and additional paid-in capital accounts. The warrants had no accounting impact on the Company&amp;#8217;s consolidated financial statements.
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;As part of the Company&amp;#8217;s second private placement of its securities completed on December 12, 2007, the Company entered into a registration rights agreement with the purchasers, whereby the Company agreed to register the shares of common stock sold in the second private placement at its sole cost and expense. The registration rights agreement terminates at such time as the common shares may be sold in market transactions without regard to any volume limitations. The registration rights agreement requires the Company to file a registration statement within 75 days of receipt of written demand from holders who represent at least 50% of the common shares issued pursuant to the second private placement, provided that no demand shall be made for less than 500,000 shares, and to use its best efforts to cause such registration statement to become and remain effective for the requisite period. The registration rights agreement also provides for unlimited piggyback registration rights. The registration rights agreement does not provide for any penalties in the event that the Company is unable to comply with its terms.
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;During the year ended December 31, 2009, the Company completed three closings of the third private placement of common stock units, consisting of a total of 1,420,000 shares of common stock and 1,420,000 warrants to acquire common stock, as follows:
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

  &lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;On February 10, 2009, the Company sold an aggregate of 658,000 common stock units to accredited investors in a first closing of a third private placement at a per unit price of $0.50, resulting in aggregate gross proceeds to the Company of $329,000. Net cash proceeds to the Company were $269,790.
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;On March 2, 2009, the Company sold an aggregate of 262,000 common stock units to accredited investors in a second closing of the third private placement at a per unit price of $0.50, resulting in aggregate gross proceeds to the Company of $131,000. Net cash proceeds to the Company were $112,460.
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;On April 6, 2009, the Company sold an aggregate of 500,000 common stock units to accredited investors in a third closing of the third private placement at a per unit price of $0.50, resulting in aggregate gross proceeds to the Company of $250,000. Net cash proceeds to the Company were $214,800.
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Each unit sold in the third private placement consisted of one share of the Company&amp;#8217;s common stock and a five-year warrant to purchase an additional share of the Company&amp;#8217;s common stock on a cashless exercise basis at an exercise price of $0.50 per common share. The Company paid to WestPark Capital, Inc., as placement agent, a commission of 10% and a non-accountable fee of 4% of the gross proceeds of the third private placement and issued five-year warrants to purchase common stock equal to (a) 10% of the number of shares sold in the third private placement exercisable at $0.50 per share and 10% of the number of shares issuable upon exercise of warrants issued in the third private placement exercisable at $0.50 per share; and (b) an additional 2% of the number of shares sold in the third private placement also exercisable at $0.50 per share and 2% of the number of shares issuable upon exercise of the warrants issued in the third private placement exercisable at $0.50 per share.
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;In conjunction with the closings of the third private placement of common stock units during the year ended December 31, 2009, the Company issued a total of 340,800 five-year warrants to WestPark Capital, Inc., which are exercisable at the per unit price of the common stock units sold in the third private placement ($0.50 per unit). Included in the 340,800 warrants issued to WestPark Capital, Inc. are 170,400 warrants which are only exercisable with respect to common shares that are acquired by investors upon their exercise of the warrants acquired as part of the units sold in the third private placement. The warrants issued to WestPark Capital, Inc. do not contain any price anti-dilution provisions. However, such warrants contain cashless exercise provisions and demand registration rights, but the warrant holder has agreed to waive any claims to monetary damages or financial penalties for any failure by the Company to comply with such registration requirements. Based on the foregoing, the warrants were accounted for as equity and were not accounted for separately from the common stock and additional paid-in capital accounts. The warrants had no accounting impact on the Company&amp;#8217;s consolidated financial statements.
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;" &gt;&lt;div&gt;
  &lt;/div&gt;
  &lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

  &lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;At the request of the holders, the Company has agreed to include any shares sold in the third private placement and any shares issuable upon exercise of the related warrants to be included in any registration statement filed with the Securities and Exchange Commission permitting the resale of such shares, subject to customary cutbacks, at the Company&amp;#8217;s sole cost and expense.
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Effective November 6, 2009, the Company sold 1,000,000 common stock units to an accredited investor in a fourth private placement at a per unit price of $0.50, resulting in proceeds to the Company of $500,000. There were no commissions paid with respect to the fourth private placement. The closing price of the Company&amp;#8217;s common stock on November 6, 2009 was $0.50 per share.
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Each unit sold in the fourth private placement consisted of one share of the Company&amp;#8217;s common stock, one three-year warrant to purchase an additional share of the Company&amp;#8217;s common stock at an exercise price of $0.50 per share, and one three-year warrant to purchase an additional share of the Company&amp;#8217;s common stock at an exercise price of $0.75 per share.&amp;#160;The warrants do not have any reset provisions.
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

  &lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;At the request of the holder, the Company has agreed to include the shares sold in the fourth private placement and any shares issuable upon exercise of the related warrants in any registration statement filed by the Company with the Securities and Exchange Commission permitting the resale of such securities, subject to customary cutbacks. The units sold were not registered under the Securities Act of 1933, as amended (the &amp;#8220;Act&amp;#8221;), in reliance upon the exemption from registration contained in Section 4(2) of the Act and Regulation D promulgated thereunder. Based on the foregoing, the warrants were accounted for as equity and were not accounted for separately from the common stock and additional paid-in capital accounts. The warrants had no accounting impact on the Company&amp;#8217;s consolidated financial statements.
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

  &lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Effective January 20, 2010, the Company raised $1,787,500 in a fifth private placement of units sold to certain of its existing stockholders or their designees, all of whom were accredited investors, consisting of an aggregate of 3,575,000 units at a purchase price of $0.50 per unit. Each unit consisted of one share of common stock, one three-year warrant to purchase a share of common stock at an exercise price of $0.50 per share, and one three-year warrant to purchase a share of common stock at an exercise price of $0.75 per share. The warrants do not have any reset provisions. The closing price of the Company&amp;#8217;s common stock on January 20, 2010 was $0.49 per share. There were no commissions paid with respect to the private placement. Upon request by the holder, the Company has agreed to include the shares issued and those shares issuable upon exercise of the warrants in any registration statement filed by the Company with the Securities and Exchange Commission permitting the resale of such securities, subject to customary cutbacks. The units sold were not registered under the Act, in reliance upon the exemption from registration contained in Section 4(2) of the Act and Regulation D promulgated thereunder. The Company accounted for the issuance of the units as a capital transaction. As of December 31, 2009, $1,200,000 had been advanced to the Company under this private placement, with the balance of $587,500 being received by the Company in January 2010.
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Effective February 22, 2010, the Company raised $500,000 through the sale to an accredited investor of 1,000,000 units at a purchase price of $0.50 per unit. Each unit consisted of one share of common stock, one three-year warrant to purchase a share of common stock at an exercise price of $0.50 per share, and one three year-year warrant to purchase a share of common stock at an exercise price of $0.75 per share. The warrants do not have any reset provisions. The closing price of the Company&amp;#8217;s common stock on February 22, 2010 was $0.50 per share. There were no commissions paid with respect to the private placement. Upon request by the holder, the Company has agreed to include the shares issued and those shares issuable upon exercise of the warrants in any registration statement filed by the Company with the Securities and Exchange Commission permitting the resale of such securities, subject to customary cutbacks. The units sold were not registered under the Act, in reliance upon the exemption from registration contained in Section 4(2) of the Act and Regulation D promulgated thereunder. The Company accounted for the issuance of the units as a capital transaction.
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/div&gt;
  &lt;/div&gt;
&lt;/div&gt;
  </lixt:ShareExchangeAgreementAndPrivatePlacementTextBlock>

  <us-gaap:CashAndCashEquivalentsDisclosureTextBlock contextRef="Context_6ME_30-Jun-2011">&lt;div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;5. Money Market Funds &amp;#8212; Fair Value
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Money market funds at June 30, 2011 and December 31, 2010 consisted of an investment in the Class A Shares of Western Asset New York Municipal Money Market Fund with a market value of $1,301,089 and $1,601,006, respectively. The stated purpose of this money market fund is to provide income exempt from both regular federal income tax and New York State and New York City personal income tax from a portfolio of high quality short-term municipal obligations selected for liquidity and stability of principal.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Level 1: quoted prices (unadjusted) in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;" &gt;&lt;div&gt;&amp;#160;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Level 2: inputs other than quoted prices included within Level 1 that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Level 3: unobservable inputs for the asset or liability are only used when there is little, if any, market activity for the asset or liability at the measurement date. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Money market funds are the only financial instrument that is measured and recorded at fair value on the Company&amp;#8217;s balance sheet on a recurring basis. The following table presents money market funds at their level within the fair value hierarchy at June 30, 2011 and December&amp;#160;31, 2010.
&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;" &gt;&lt;table cellspacing="0" cellpadding="0" width="100%"  style="font-family:times new roman;font-size:10pt;" &gt;&lt;tr&gt;&lt;td valign="bottom"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" colspan="2" nowrap="nowrap"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Total
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" colspan="2" nowrap="nowrap"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new
 roman;font-size:10pt;font-weight:bold;" &gt;Level&amp;#160;1
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" colspan="2" nowrap="nowrap"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Level&amp;#160;2
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" colspan="2" nowrap="nowrap"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Level&amp;#160;3
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" colspan="2" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" colspan="2" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" colspan="2" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" colspan="2" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;June 30, 2011:
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" colspan="2" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" colspan="2" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" colspan="2" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" colspan="2" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="52%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Money market funds
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;1,301,089
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;1,301,089
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#8212;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#8212;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="52%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="52%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;December 31, 2010:
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="52%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Money market funds
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;1,601,006
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;1,601,006
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#8212;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#8212;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>

  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="Context_6ME_30-Jun-2011">
  &lt;div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;6. Related Party Transactions
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Prior to June 30, 2006, the Company&amp;#8217;s founding stockholder and Chief Executive Officer, Dr. John Kovach, had periodically made advances to the Company to meet operating expenses. Such advances are non-interest-bearing and are due on demand. At June 30, 2011 and December 31, 2010, stockholder advances totaled $92,717.
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company&amp;#8217;s office facilities have been provided without charge by Dr. Kovach. Such costs were not material to the financial statements and, accordingly, have not been reflected therein.
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;div style="text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;In view of the Company&amp;#8217;s development stage status and limited resources, Dr. Kovach did not receive any compensation from the Company during 2010 or in prior years. However, on February 18, 2011, the Company&amp;#8217;s Board of Directors approved a salary to Dr. Kovach of $5,000 per month beginning March 15, 2011.&amp;#160;&amp;#160;In connection therewith, Dr. Kovach reduced his academic commitment from 80% to 60% in order to devote more time to the Company&amp;#8217;s activities. Accordingly, during the three months ended June 30, 2011, the six months ended June 30, 2011, and the period from August 9, 2005 (inception) through June 30, 2011 (cumulative), Dr. Kovach was paid a salary of $15,000, $17,500 and $17,500, respectively.
  &lt;/font&gt;
  &lt;/div&gt;

  &lt;/div&gt;
  &lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Dr. Kovach is not involved in other business activities but could, in the future, become involved in other business opportunities that become available. Accordingly, he may face a conflict in selecting between the Company and his other business interests. The Company has not yet formulated a policy for the resolution of such potential conflicts.
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/div&gt;
&lt;/div&gt;
  </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>

  <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="Context_6ME_30-Jun-2011">
  &lt;div&gt;
  &lt;div&gt;
  &lt;div&gt;
  &lt;div&gt;
  &lt;div&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;"&gt;7. Stock Options and Warrants
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;On June 30, 2006, effective with the closing of the Exchange, the Company granted to Dr.&amp;#160;Philip Palmedo, an outside director of the Company, stock options to purchase an aggregate of 200,000 shares of common stock, exercisable for a period of five years at $0.333 per share, with one-third of the options (66,666 shares) vesting immediately upon joining the Board and one-third vesting annually on each of June 30, 2007 and 2008. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $62,000 ($0.31 per share), of which $20,666 was charged to operations on June 30, 2006, and the remaining $41,334 was charged to operations ratably from July 1, 2006 through June 30, 2008.
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;On June 30, 2006, effective with the closing of the Exchange, the Company also granted to Dr.&amp;#160;Palmedo additional stock options to purchase 190,000 shares of common stock exercisable for a period of five years at $0.333 per share for services rendered in developing the business plan for Lixte, all of which were fully vested upon issuance. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $58,900 ($0.31 per share), and was charged to operations at June 30, 2006.
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;On June 30, 2011, Dr. Palmedo exercised options to acquire 100,000 shares of common stock, which were part of the above described grants, on a cashless basis. Such cashless exercise resulted in Dr. Palmedo receiving a net of 66,020 shares. The remaining above described options to acquire 290,000 shares of common stock subsequently expired unexercised.
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-indent:0pt;display:block;"&gt;
  &lt;br/&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;On June 30, 2011, the Company granted to Dr.&amp;#160;Palmedo stock options to purchase 200,000 shares of common stock exercisable for a period of five years from date of grant at $0.98 per share, which was the fair market value of the Company&amp;#8217;s common stock on such date. The options vest ratably in equal quarterly installments of 25,000 each beginning July 1, 2011. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was initially determined to be $196,000 ($0.98 per share).
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;/div&gt;
  &lt;br/&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;On June 30, 2006, effective with the closing of the Exchange, the Company granted to Dr. Stefan Madajewicz and Dr. Iwao Ojima, two members of its Scientific Advisory Committee, stock options to purchase an aggregate of 100,000 shares of common stock (50,000 each) exercisable for a period of five years at $0.333 per share, with one-half of the options vesting annually on each of June 30, 2007 and June 30, 2008. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was charged to operations ratably from July 1, 2006 through June 30, 2008.
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-indent:0pt;display:block;"&gt;
  &lt;br/&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;In August 2008, Dr. Madajewicz resigned from his position and waived his right to his vested stock option to purchase 50,000 shares of common stock.
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-indent:0pt;display:block;"&gt;
  &lt;br/&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;On June 30, 2011, Dr. Ojima exercised options to acquire 15,015 shares of common stock for a cash payment of $5,000. Dr. Ojima&amp;#8217;s remaining options to acquire 34,985 shares of common stock subsequently expired unexercised.
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-indent:0pt;display:block;"&gt;
  &lt;br/&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;On June 30, 2011, the Company granted to Dr.&amp;#160;Ojima stock options to purchase 50,000 shares of common stock exercisable for a period of five years from the date of grant at $0.98 per share, which was the fair market value of the Company&amp;#8217;s common stock on such date. The options vest ratably in equal quarterly installments of 6,250 shares each beginning July 1, 2011. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was initially determined to be $49,000 ($0.98 per share).
  &lt;/font&gt;
  &lt;/div&gt;

  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;On June 30, 2006, the fair value of the aforementioned stock options was initially calculated using the following Black-Scholes input variables: stock price - $0.333; exercise price - $0.333; expected life - 5 to 7 years; expected volatility - 150%; expected dividend yield - 0%; risk-free interest rate - 5%. On June 30, 2007, the Black-Scholes input variables utilized to determine the fair value of the aforementioned stock options were stock price - $0.333; exercise price - $0.333; expected life - 4 to 6 years; expected volatility - 150%; expected dividend yield - 0%; risk-free interest rate - 4.5%. On June 30, 2008, the fair value of the aforementioned stock options was calculated using the following Black-Scholes input variables: stock price - $0.30; exercise price - $0.333; expected life - 3 to 5 years; expected volatility - 154.5%; expected dividend yield - 0%; risk-free interest rate - 3.28%. On June 30, 2011, the fair value of the aforementioned stock options was calculated using the following Black-Scholes input variables: stock price - $0.98; exercise price - $0.98; expected life - 5 years; expected volatility - 308.8%; expected dividend yield - 0%; risk-free interest rate - 1.58%.
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-indent:0pt;display:block;"&gt;
  &lt;br/&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;On February 5, 2007, the Company entered into an agreement (the &amp;#8220;Chem-Master Agreement&amp;#8221;) with Chem-Master International, Inc. (&amp;#8220;Chem-Master&amp;#8221;), a company co-owned by Francis Johnson, a consultant to the Company, pursuant to which the Company granted a five-year option to purchase 100,000 shares of the Company&amp;#8217;s common stock at an exercise price of $0.333 per share. The fair value of this option, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $31,000 ($0.31 per share) using the following Black-Scholes input variables: stock price on date of grant - $0.333; exercise price - $0.333; expected life - 5 years; expected volatility - 150%; expected dividend yield - 0%; risk-free interest rate - 4.5%. The $31,000 fair value was charged to operations as research and development costs on February 5, 2007 as the option was fully vested and non-forfeitable on the date of issuance. The Company has the right to terminate the Chem-Master Agreement at any time during its term upon sixty days prior written notice. On February 5, 2009, provided that the Chem-Master Agreement had not been terminated prior to such date, the Company agreed to grant Chem-Master a second five-year option to purchase an additional 100,000 shares of the Company&amp;#8217;s common stock at an exercise price of $0.333 per share. As of September 30, 2008, the Company determined that it was likely that this option would be issued. Accordingly, the fair value of the option has been reflected as a charge to operations for the period from October 1, 2008 through February 5, 2009. The Company granted the second five-year option on February 5, 2009.&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;On September 30, 2008, the fair value of the aforementioned stock option was initially calculated using the following Black-Scholes input variables: stock price - $0.50; exercise price - $0.333; expected life &amp;#8211; 5.35 years; expected volatility &amp;#8211; 275.7%; expected dividend yield - 0%; risk-free interest rate &amp;#8211; 2.48%. On February 5, 2009, the fair value of the aforementioned stock option was calculated for the stock option revaluation purposes using the following Black-Scholes input variables: stock price - $0.60; exercise price - $0.333; expected life &amp;#8211; 5 years; expected volatility &amp;#8211; 414.1%; expected dividend yield - 0%; risk-free interest rate &amp;#8211; 1.89%.
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;On January 29, 2008, the Chem-Master Agreement was amended to extend its term to February 15, 2014. Pursuant to the amendment, the Company issued 100,000 shares of its restricted common stock, valued at $75,000, and granted an option to purchase 200,000 shares of common stock. The option is exercisable for a period of two years from the vesting date at $1.65 per share, with one-half (100,000 shares) vesting on August 1, 2009, and one-half (100,000 shares) vesting on February 1, 2011. The fair value of this option, as calculated pursuant to the Black-Scholes option-pricing model, was initially determined to be $96,000 ($0.48 per share) using the following Black-Scholes input variables: stock price on date of grant - $0.75; exercise price - $1.65; expected life - 5 years; expected volatility - 120.1%; expected dividend yield - 0%; risk-free interest rate - 3.09%.
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;div&gt;
  &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="text-indent:0pt;display:block;"&gt;
  &lt;br/&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;The fair value of the restricted common stock issued was charged to operations as research and development costs on January 29, 2008. On February 1, 2011, the fair value of the aforementioned stock options was determined to be $66,000 ($0.33 per share) calculated using the following Black-Scholes input variables: stock price - $0.35; exercise price - $1.65; expected life - 2 years; expected volatility &amp;#8211; 325.6%; expected dividend yield - 0%; risk-free interest rate -2.07%, which resulted in a charge to operations of $982 during the six months ended June 30, 2011. On June 30, 2010, the fair value of the aforementioned stock options was determined to be $62,000 ($0.31 per share) calculated using the following Black-Scholes input variables: stock price - $0.35; exercise price - $1.65; expected life - 2.59 years; expected volatility &amp;#8211; 233.2%; expected dividend yield - 0%; risk-free interest rate - 0.93%, which resulted in a credit to operations of $1,472 during the three months ended June 30, 2010 and a charge to operations of $5,786 during the six months ended June 30, 2010.
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;On June 20, 2007, the Board of Directors of the Company approved the 2007 Stock Compensation Plan (the &amp;#8220;2007 Plan&amp;#8221;), which provides for the granting of awards, consisting of common stock options, stock appreciation rights, performance shares, or restricted shares of common stock, to employees and independent contractors, for up to 2,500,000 shares of the Company&amp;#8217;s common stock, under terms and condition, as determined by the Company&amp;#8217;s Board of Directors.
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;On September 12, 2007, in conjunction with his appointment as a director of the Company, the Company granted to Dr. Stephen Carter stock options to purchase an aggregate of 200,000 shares of common stock under the 2007 Plan, exercisable for a period of five years from vesting date at $0.333 per share, with one-half (100,000 shares) vesting annually on each of September 12, 2008 and 2009. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $204,000 ($1.02 per share), and was charged to operations ratably from September 12, 2007 through September 12, 2009. Effective April 20, 2010, Dr. Carter resigned as a director for personal reasons. Consequently, pursuant to the stock option agreement, Dr. Carter had twelve months from April 20, 2010 to exercise his stock options to acquire 200,000 shares of the Company&amp;#8217;s common stock. On April 20, 2011 Dr. Carter&amp;#8217;s stock options expired unexercised.
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;On September 12, 2007, the Company entered into a consulting agreement with Gil Schwartzberg, pursuant to which the Company granted to Mr. Schwartzberg stock options to purchase an aggregate of 1,000,000 shares of common stock, exercisable for a period of four years from the vesting date at $1.00 per share, with one-half of the options (500,000 shares) vesting immediately and one-half (500,000 shares) vesting on September 12, 2008. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was initially determined to be $945,000 ($0.945 per share), of which $465,000 was attributed to the fully-vested options and was thus charged to operations on September 12, 2007. The remaining unvested portion of the fair value of the options was charged to operations ratably from September 12, 2007 through September 12, 2008.
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;On October 15, 2009, the Company amended the above described consulting agreement with Gil Schwartzberg to extend it for an additional four years and granted to Mr. Schwartzberg stock options to purchase an additional aggregate of 1,000,000 shares of common stock, exercisable for a period of four years from the vesting date at $1.00 per share, with one-half of the options (500,000 shares) vesting immediately and one-half (500,000 shares) vesting on October 15, 2010. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $750,000 ($0.75 per share) on October 15, 2009, of which $375,000 was attributed to the fully-vested options and was thus charged to operations on October 15, 2009. The remaining unvested portion of the fair value of the options was charged to operations ratably from October 15, 2009 through October 15, 2010. On June 30, 2010, the fair value of the aforementioned stock options was determined to be $170,000 ($0.34 per share) calculated using the following Black-Scholes input variables: stock price - $0.35; exercise price - $1.00; expected life - 4.29 years; expected volatility &amp;#8211; 233.2%; expected dividend yield - 0%; risk-free interest rate - 0.93%, which resulted in a charge to operations of $8,068 during the three months ended June 30, 2010 and a charge to operations of $68,479 during the six months ended June 30, 2010.
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-indent:0pt;display:block;"&gt;
  &lt;br/&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;On September 12, 2007, the Company entered into a consulting agreement with Francis Johnson, a co-owner of Chem-Master International, Inc., and granted to Professor Johnson stock options to purchase an aggregate of 300,000 shares of common stock, exercisable for a period of four years from the vesting date at $0.333 per share, with one-third (100,000 shares) vesting annually on each of September 12, 2008, 2009 and 2010. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was initially determined to be $300,000 ($1.00 per share). The unvested portion of the fair value of the options was charged to operations ratably from September 12, 2007 through September 12, 2010. On June 30, 2010, the fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $102,000 ($0.34 per share) which resulted a credit to operations of $290 during the three months ended June 30, 2010 and a charge to operations of $12,340 during the six months ended June 30, 2010.
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-indent:0pt;display:block;"&gt;
  &lt;br/&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;On September 12, 2007, the fair value of the aforementioned stock options was initially calculated using the following Black-Scholes input variables: stock price - $1.05; exercise price - $0.333 to $1.00; expected life - 4 to 6 years; expected volatility - 150%; expected dividend yield - 0%; risk-free interest rate - 5%. On October 15, 2009, the fair value of the aforementioned stock options was initially calculated using the following Black-Scholes input variables: stock price - $0.75; exercise price - $1.00; expected life - 5 years; expected volatility &amp;#8211; 259.1%; expected dividend yield - 0%; risk-free interest rate &amp;#8211; 1.91%. On June 30, 2010, the fair value of the aforementioned stock options was calculated for the stock option revaluation purposes using the following Black-Scholes input variables: stock price - $0.35; exercise price - $0.333; expected life - 4.23; expected volatility &amp;#8211; 233.2%; expected dividend yield - 0%; risk-free interest rate &amp;#8211; 0.93%.
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-indent:0pt;display:block;"&gt;
  &lt;br/&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;As the Company&amp;#8217;s common stock commenced trading on September 24, 2007, the Company was able to utilize such trading data to generate revised volatility factors as of the various subsequent measurement dates.
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;div&gt;
  &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="text-indent:0pt;display:block;"&gt;
  &lt;br/&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;On September 20, 2007, the Company entered into a one-year consulting agreement (the &amp;#8220;Mirador Agreement&amp;#8221;) with Mirador Consulting, Inc. (&amp;#8220;Mirador&amp;#8221;), pursuant to which Mirador was to provide the Company with various financial services. Pursuant to the Mirador Agreement, the Company agreed to pay Mirador $5,000 per month and also agreed to sell Mirador 250,000 shares of the Company&amp;#8217;s restricted common stock for $250 ($0.001 per share). The fair value of this transaction was determined to be in excess of the purchase price by $262,250 ($1.049 per share), reflecting the difference between the $0.001 purchase price and the $1.05 price per share as quoted on the OTC Bulletin Board on the transaction date, and was charged to operations as stock-based compensation on September 20, 2007, being that the shares were fully vested and non-forfeitable on the date of issuance.
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;On October 7, 2008, the Company appointed Dr. Mel Sorensen to its Board of Directors. Dr. Sorensen is a medical oncologist with extensive experience in cancer drug development, first at the National Cancer Institute, then at Bayer and GlaxoSmithKline, before becoming President and Chief Executive Officer of a new cancer therapeutics company, Ascenta Therapeutics, in 2004. Dr. Sorensen was paid an annual consulting fee of $40,000, payable in quarterly installments over a one year period commencing October 7, 2008, to assist the Company in identifying a strategic partner. Dr. Sorensen was also granted a stock option to purchase 200,000 shares of the Company&amp;#8217;s common stock, exercisable at $0.50 per share for a period of five years from each tranche&amp;#8217;s vesting date. The option vests as to 25,000 shares on January 1, 2009, and a further 25,000 shares on the first day of each subsequent calendar quarter until all of the shares are vested. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $100,000 ($0.50 per share), and was charged to operations ratably from October 7, 2008 through October 7, 2010. During the three and six months ended June 30, 2010, the Company recorded charges to operations of $12,466 and $24,795, respectively, with respect to these options.
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;On October 7, 2008, the fair value of the aforementioned stock options was calculated using the following Black-Scholes input variables: stock price - $0.50; exercise price - $0.50; expected life - 5 years; expected volatility &amp;#8211; 275.7%; expected dividend yield - 0%; risk-free interest rate &amp;#8211; 2.48%.
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;On July 27, 2009, the Company entered into an agreement with Pro-Active Capital Group, LLC (&amp;#8220;Pro-Active&amp;#8221;) to retain Pro-Active on a non-exclusive basis for a period of twelve months to provide consulting advice to the Company to assist the Company in obtaining research coverage, gaining web-site exposure and coverage on financial blogs and web-sites, enhancing the Company&amp;#8217;s visibility to the institutional, retail brokerage and on-line trading communities, and organizing, or assisting in organizing, investor road-shows and presentations. In exchange for such consulting advice, at the initiation of the agreement, the Company agreed to issue to Pro-Active 150,000 shares of restricted common stock and three-year warrants to purchase an aggregate of 150,000 shares of common stock, exercisable 50,000 at $0.75 per share, 50,000 at $1.00 per share, and 50,000 at $1.25 per share. The fair value of the 150,000 shares issued was determined to be $100,500 ($0.67 per share), reflecting the price per share of the Company&amp;#8217;s common stock, as quoted on the OTC Bulletin Board, on the transaction date. The fair value of the three-year warrants, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $97,500 ($0.65 per share) using the following Black-Scholes input variables: stock price on date of grant - $0.67; exercise price - $0.75 to $1.25; expected life - 3 years; expected volatility &amp;#8211; 259.1%; expected dividend yield - 0%; risk-free interest rate - 1.91%. The $198,000 aggregate fair value of the shares and warrants issued was charged to operations as stock-based compensation on July 27, 2009, as the shares and warrants were fully vested and non-forfeitable on the date of issuance.
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-indent:0pt;display:block;"&gt;
  &lt;br/&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div&gt;

  &lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;Effective May 2, 2011, the Company elected Dr. Robert B. Royds to its Board of Directors. Dr. Royds&lt;font style="display:inline;font-weight:bold;"&gt;&amp;#160;
  &lt;/font&gt;is Chairman of the Board and Medical Director of Theradex Systems, Inc., a leading clinical research organization, with research bases in Europe, Australia and Japan. Dr. Royds is responsible for the scientific affairs of Theradex Systems, Inc. Dr. Royds was trained in internal medicine and pharmacology, and he has extensive experience in all stages of the clinical drug development process. Before founding Theradex Systems, Inc., Dr. Royds was Senior Research Physician at Hoffmann-La Roche, Inc., and Associate Director for Clinical Pharmacology International at Merck, Sharp, and Dohme Research Laboratories. Dr. Royds has been a consultant/advisor to the National Institute of Child Health and Development and the National Cancer Institute on issues of clinical trial design and international standardization of data sets of clinical trials of new investigational anti-cancer agents. Dr. Royds has served as the physician-monitor for the Clinical Trials Monitoring Service of the National Cancer Institute since 1979, and has been the Principal Investigator for this contract since 1982.
  &lt;/font&gt;
  &lt;br/&gt;
  &amp;#160;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;Effective May 1, 2011, Dr. Royds was granted stock options to purchase 200,000 shares of the Company&amp;#8217;s common stock, exercisable for a period of five years from each tranche&amp;#8217;s vesting date, at $0.98 per share, which was the fair market value of the Company&amp;#8217;s common stock on such date. The options vested as to 25,000 shares on May 1, 2011, and a further 25,000 shares vest on the first day of each subsequent quarter until all of the shares are vested. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $196,000 ($0.98 per share), and is being charged to operations ratably from May 2, 2011 through February 1, 2013. During the three months and six months ended June 30, 2011, the Company recorded a charge to operations of $40,528 with respect to these options.
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="text-indent:0pt;display:block;"&gt;
  &lt;br/&gt;
  &lt;/div&gt;
  &lt;div&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;On May 2, 2011, the fair value of the aforementioned stock options was calculated using the following Black-Scholes input variables: stock price - $0.98; exercise price - $0.98; expected life &amp;#8211; 6.76 years; expected volatility &amp;#8211; 308.8%; expected dividend yield - 0%; risk-free interest rate &amp;#8211; 1.58%.&lt;br/&gt;
  &lt;br/&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;Additional information with respect to common stock warrants and stock options issued is provided at Notes 4 and 8.&lt;br/&gt;
  &lt;br/&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;If and when the aforementioned stock options and warrants are exercised, the Company expects to satisfy such stock obligations through the issuance of authorized but unissued shares of common stock.
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;br/&gt;
  &lt;div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;div&gt;
  &lt;/div&gt;
  &lt;div&gt;
  &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;A summary of stock option and warrant activity, including warrants to purchase common stock that were issued in conjunction with the Company&amp;#8217;s private placements, is presented in the tables below.&lt;br/&gt;
  &lt;br/&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;"&gt;
  &lt;div&gt;
  &lt;table cellspacing="0" cellpadding="0" width="100%" style="font-family:times new roman;font-size:10pt;"&gt;
  &lt;tr&gt;
  &lt;td valign="bottom" style="text-align:left;padding-bottom:2px;"&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" style="text-align:left;padding-bottom:2px;"&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;"&gt;
  &lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;"&gt;
  &lt;font style="display:inline;"&gt;Number
  &lt;/font&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;"&gt;
  &lt;font style="display:inline;"&gt;of
  &lt;/font&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;"&gt;
  &lt;font style="display:inline;"&gt;Shares
  &lt;/font&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" style="text-align:left;padding-bottom:2px;"&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" style="text-align:left;padding-bottom:2px;"&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;"&gt;
  &lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;"&gt;
  &lt;font style="display:inline;"&gt;Weighted
  &lt;/font&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;"&gt;
  &lt;font style="display:inline;"&gt;Average
  &lt;/font&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;"&gt;
  &lt;font style="display:inline;"&gt;Exercise
  &lt;/font&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;"&gt;
  &lt;font style="display:inline;"&gt;Price
  &lt;/font&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" style="text-align:left;padding-bottom:2px;"&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" style="text-align:left;padding-bottom:2px;"&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;"&gt;
  &lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;"&gt;
  &lt;font style="display:inline;"&gt;Weighted
  &lt;/font&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;"&gt;
  &lt;font style="display:inline;"&gt;Average
  &lt;/font&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;"&gt;
  &lt;font style="display:inline;"&gt;Remaining
  &lt;/font&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;"&gt;
  &lt;font style="display:inline;"&gt;Contractual
  &lt;/font&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;"&gt;
  &lt;font style="display:inline;"&gt;Life
  &lt;/font&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;"&gt;
  &lt;font style="display:inline;"&gt;(in&amp;#160;Years)
  &lt;/font&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" style="text-align:left;padding-bottom:2px;"&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr style="background-color:#ccffcc;"&gt;
  &lt;td valign="bottom" width="64%" style="text-align:left;"&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;Options and warrants outstanding at December 31, 2009
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="9%" style="text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;7,997,426
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;$
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="9%" style="text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;0.664
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="9%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr style="background-color:#ffffff;"&gt;
  &lt;td valign="bottom" width="64%" style="text-align:left;"&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;Granted
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="9%" style="text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;9,150,000
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="9%" style="text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;0.625
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="9%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr style="background-color:#ccffcc;"&gt;
  &lt;td valign="bottom" width="64%" style="text-align:left;"&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;Exercised
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="9%" style="text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#8212;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="9%" style="text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#8212;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="9%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr style="background-color:#ffffff;"&gt;
  &lt;td valign="bottom" width="64%" style="text-align:left;padding-bottom:2px;"&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;Cancelled
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;
  &lt;font style="display:inline;"&gt;&amp;#8212;
  &lt;/font&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;
  &lt;font style="display:inline;"&gt;&amp;#8212;
  &lt;/font&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="9%" style="text-align:left;padding-bottom:2px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr style="background-color:#ccffcc;"&gt;
  &lt;td valign="bottom" width="64%" style="text-align:left;"&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;Options and warrants outstanding at December 31, 2010
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="9%" style="text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;17,147,426
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;$
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="9%" style="text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;0.643
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="9%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr style="background-color:#ffffff;"&gt;
  &lt;td valign="bottom" width="64%" style="text-align:left;"&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;Granted
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="9%" style="text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;450,000
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="9%" style="text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;0.980
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="9%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr style="background-color:#ccffcc;"&gt;
  &lt;td valign="bottom" width="64%" style="text-align:left;"&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;Exercised
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="9%" style="text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;(267,889
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;)&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="9%" style="text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;0.333
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="9%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr style="background-color:#ffffff;"&gt;
  &lt;td valign="bottom" width="64%" style="text-align:left;padding-bottom:2px;"&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;Cancelled
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;
  &lt;font style="display:inline;"&gt;(524,985
  &lt;/font&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;"&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;)&amp;#160;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;
  &lt;font style="display:inline;"&gt;0.333
  &lt;/font&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="9%" style="text-align:left;padding-bottom:2px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr style="background-color:#ccffcc;"&gt;
  &lt;td valign="bottom" width="64%" style="text-align:left;padding-bottom:4px;"&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;Options and warrants outstanding at June 30, 2011
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="9%" style="border-bottom:black 4px double;text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;
  &lt;font style="display:inline;"&gt;16,804,552
  &lt;/font&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;"&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;
  &lt;font style="display:inline;"&gt;$
  &lt;/font&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="9%" style="border-bottom:black 4px double;text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;
  &lt;font style="display:inline;"&gt;0.667
  &lt;/font&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="9%" style="border-bottom:black 4px double;text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;
  &lt;font style="display:inline;"&gt;1.78
  &lt;/font&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr style="background-color:#ffffff;"&gt;
  &lt;td valign="bottom" width="64%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="9%" style="text-align:right;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="9%" style="text-align:right;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="9%" style="text-align:right;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr style="background-color:#ccffcc;"&gt;
  &lt;td valign="bottom" width="64%" style="text-align:left;padding-bottom:4px;"&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;Options and warrants exercisable at December 31, 2010
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="9%" style="border-bottom:black 4px double;text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;
  &lt;font style="display:inline;"&gt;16,877,026
  &lt;/font&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;"&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;
  &lt;font style="display:inline;"&gt;$
  &lt;/font&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="9%" style="border-bottom:black 4px double;text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;
  &lt;font style="display:inline;"&gt;0.639
  &lt;/font&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="9%" style="text-align:left;padding-bottom:4px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr style="background-color:#ffffff;"&gt;
  &lt;td valign="bottom" width="64%" style="text-align:left;padding-bottom:4px;"&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;Options and warrants exercisable at June 30, 2011
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="9%" style="border-bottom:black 4px double;text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;16,209,152
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;"&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;$
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="9%" style="border-bottom:black 4px double;text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;0.660
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="9%" style="border-bottom:black 4px double;text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;1.68
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="top" width="1%" style="text-align:left;padding-bottom:4px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;/table&gt;
  &lt;br/&gt;
  &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;Total deferred compensation expense for the outstanding value of unvested stock options was approximately $400,500 at June 30, 2011, which is being recognized subsequent to June 30, 2011 over a weighted-average period of forty-four months.&lt;br/&gt;
  &lt;br/&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;Information regarding stock options and warrants outstanding and exercisable is summarized as follows at June 30, 2011:&lt;br/&gt;
  &lt;br/&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:center;"&gt;
  &lt;table cellspacing="0" cellpadding="0" width="80%" style="font-family:times new roman;font-size:10pt;"&gt;
  &lt;tr&gt;
  &lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="31%" nowrap="nowrap" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="32%" colspan="2" nowrap="nowrap"&gt;
  &lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;"&gt;Warrants
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="31%" colspan="2" nowrap="nowrap"&gt;
  &lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;"&gt;Warrants
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
  &lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="31%" nowrap="nowrap" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="32%" colspan="2" nowrap="nowrap"&gt;
  &lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;"&gt;And
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="31%" colspan="2" nowrap="nowrap"&gt;
  &lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;"&gt;And
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
  &lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="31%" nowrap="nowrap" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="32%" colspan="2" nowrap="nowrap"&gt;
  &lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;"&gt;Options
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="31%" colspan="2" nowrap="nowrap"&gt;
  &lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;"&gt;Options
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
  &lt;td valign="bottom" width="1%" nowrap="nowrap"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="31%" nowrap="nowrap"&gt;
  &lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;"&gt;Exercise
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" nowrap="nowrap"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="32%" colspan="2" nowrap="nowrap"&gt;
  &lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;"&gt;Outstanding
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="31%" colspan="2" nowrap="nowrap"&gt;
  &lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;"&gt;Exercisable
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
  &lt;td valign="bottom" width="1%" nowrap="nowrap" style="border-bottom:black 2px double;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="31%" nowrap="nowrap" style="border-bottom:black 2px double;"&gt;
  &lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;"&gt;
  &lt;font style="display:inline;"&gt;Prices
  &lt;/font&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" nowrap="nowrap" style="padding-bottom:2px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="32%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px double;"&gt;
  &lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;"&gt;
  &lt;font style="display:inline;"&gt;(Shares)
  &lt;/font&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="31%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px double;"&gt;
  &lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;"&gt;
  &lt;font style="display:inline;"&gt;(Shares)
  &lt;/font&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr style="background-color:#ccffcc;"&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;$
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="31%" style="text-align:right;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;0.333
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:right;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="31%" style="text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;773,752
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:right;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="30%" style="text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;773,752
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr style="background-color:#ffffff;"&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;$
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="31%" style="text-align:right;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;0.500
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:right;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:right;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="31%" style="text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;7,535,800
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:right;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="30%" style="text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;7,365,400
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr style="background-color:#ccffcc;"&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;$
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="31%" style="text-align:right;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;0.650
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:right;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="31%" style="text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;120,000
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:right;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="30%" style="text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;120,000
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr style="background-color:#ffffff;"&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;$
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="31%" style="text-align:right;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;0.750
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:right;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="31%" style="text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;5,625,000
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:right;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="30%" style="text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;5,625,000
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr style="background-color:#ccffcc;"&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;$
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="31%" style="text-align:right;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;0.980
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="31%" style="text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;450,000
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="30%" style="text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;25,000
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr style="background-color:#ffffff;"&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;$
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="31%" style="text-align:right;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;1.000
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:right;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="31%" style="text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;2,050,000
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:right;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="30%" style="text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;2,050,000
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr style="background-color:#ccffcc;"&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;$
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="31%" style="text-align:right;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;1.250
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:right;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="31%" style="text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;50,000
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:right;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="30%" style="text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;50,000
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr style="background-color:#ffffff;"&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;$
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="31%" style="text-align:right;padding-bottom:2px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;1.650
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:right;padding-bottom:2px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:right;padding-bottom:2px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="31%" style="border-bottom:black 2px solid;text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;
  &lt;font style="display:inline;"&gt;200,000
  &lt;/font&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:right;padding-bottom:2px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="30%" style="border-bottom:black 2px solid;text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;
  &lt;font style="display:inline;"&gt;200,000
  &lt;/font&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr style="background-color:#ccffcc;"&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="31%" style="text-align:left;padding-bottom:4px;"&gt;&amp;#160;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:right;padding-bottom:4px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="31%" style="border-bottom:black 4px double;text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;16,804,552
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:right;padding-bottom:4px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="30%" style="border-bottom:black 4px double;text-align:right;"&gt;
  &lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;16,209,152
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;&amp;#160;
  &lt;/font&gt;
  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;/table&gt;
  &lt;br/&gt;
  &lt;br/&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;The intrinsic value of exercisable but unexercised in-the-money stock options and warrants at June 30, 2011 was approximately $5,369,360, based on a fair market value of $0.98 per share on June 30, 2011. The intrinsic value of exercisable but unexercised in-the-money stock options and warrants at December 31, 2010 was approximately $26,600, based on a fair market value of $0.35 per share on December 31, 2010.&lt;br/&gt;
  &lt;br/&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/div&gt;

  &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;font style="display:inline;font-family:times new roman;font-size:10pt;"&gt;Outstanding options and warrants to acquire 425,000 shares of the Company&amp;#8217;s common stock had not vested at June 30, 2011. At June 30, 2011, warrants and options exercisable do not include warrants to acquire 170,400 shares of common stock that are contingent upon the exercise of warrants contained in units sold as part of the third private placement (see Note 4).
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;"&gt;
  &lt;br/&gt;
  &lt;/div&gt;
  &lt;/div&gt;
  &lt;/div&gt;
  &lt;/div&gt;
  &lt;/div&gt;
&lt;/div&gt;
  </us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>

  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Context_6ME_30-Jun-2011">&lt;div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-weight:bold;" &gt;8.
&lt;/font&gt;&lt;font style="display:inline;font-weight:bold;" &gt;Commitments and Contingencies
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;CRADA
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Effective March 22, 2006, the Company entered into a CRADA, as amended, with the NINDS of the NIH. The CRADA is for a term of 66 months from the effective date and can be unilaterally terminated by either party by providing written notice within sixty days. The CRADA provides for the collaboration between the parties in the identification and evaluation of agents that target the Nuclear Receptor CoRepressor (N-CoR) pathway for glioma cell differentiation. The CRADA also provides that NINDS and the Company will conduct research to determine if expression of N-CoR correlates with prognosis in glioma patients. Pursuant to the CRADA, the Company initially agreed to provide funds under the CRADA in the amount of $200,000 per year to fund two technical assistants for the technical, statistical and administrative support for the research activities, as well as to pay for supplies and travel expenses. The first $200,000 was due within 180 days of the effective date and was paid in full on July 6, 2006. The second $200,000 was paid in full on June 29, 2007. In June 2008, the CRADA was extended to September 30, 2009, with no additional funding required for the period between July 1, 2008 and September 30, 2008. For the period from October 1, 2008 through September 30, 2009, the Company agreed to provide additional funding under the CRADA of $200,000, to be paid in four quarterly installments of $50,000, each commencing on October 1, 2008. The first and second quarterly installments of $50,000 were paid on September 29, 2008 and March 5, 2009, respectively.&amp;#160;During August&amp;#160;2009, the Company entered into an amendment to the CRADA to extend its term from September 30, 2009 through September 30, 2011.&amp;#160;Pursuant to such amendment, the Company has agreed to aggregate payments of $100,000 in two installments of $50,000, payable on October 1, 2010 and January 5, 2011, inclusive of any prior unpaid commitments. The October 1, 2010 installment was paid on September 29, 2010 and the January 5, 2011 installment was paid on December 27, 2010.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;" &gt;&lt;div&gt;&amp;#160;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Effective as of September 19, 2008, the Company entered into an agreement with the NIH providing the Company with an exclusive license for all patents submitted jointly with the NIH under the CRADA. The agreement provided for an initial payment of $25,000 to NIH within 60 days of September 19, 2008, and for a minimum annual royalty of $30,000 on January 1 of each calendar year following the year in which the CRADA is terminated. The agreement also provides for the Company to pay specified royalties based on (i) net sales by the Company and its sub-licensees, (ii) the achievement of certain clinical benchmarks, and (iii) the granting of sublicenses. The Company paid the initial $25,000 obligation on November 10, 2008 and charged the amount to general and administrative costs during the year ended December 31, 2008. As of June 30, 2011, no additional amounts were due pursuant to this agreement.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Research and Development Contracts
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;On February 5, 2007, the Company entered into a two-year agreement pursuant to which the Company engaged Chem-Master to synthesize a compound designated as LB-100, and any other compound synthesized by Chem-Master pursuant to the Company&amp;#8217;s request, which have potential use in treating a disease, including, without limitation, cancers such as glioblastomas. Pursuant to the Chem-Master Agreement, the Company agreed to reimburse Chem-Master for the cost of materials, labor, and expenses for other items used in the synthesis process, and also agreed to grant Chem-Master a five-year option to purchase shares of the Company&amp;#8217;s common stock. The Company has the right to terminate the Chem-Master Agreement at any time during its term upon sixty days prior written notice.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;On January 29, 2008, the Chem-Master Agreement was amended to extend its term to February 15, 2014, and to expressly provide for the design and synthesis of a new series of compounds designated as LB-300. Pursuant to the Chem-Master Agreement, as amended, the Company reimbursed Chem-Master for the costs of materials, labor and expenses aggregating $1,500 and $20,000 during the three months ending June 30, 2011 and 2010, respectively. During the six months ending June 30, 2011 and 2010, reimbursements to Chem-Master amounted to $6,325 and $33,000, respectively.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;On March 17, 2010, the Company engaged Theradex Systems, Inc. to assist the Company in bringing LB-100 through the FDA approval process at a total estimated cost of $105,064, of which $15,205 had been incurred through June 30, 2011. As of June 30, 2011, work was proceeding under this contract. Dr. Robert B. Royds, the founder, Chairman of the Board and Medical Director of Theradex Systems, Inc., was appointed to the Company&amp;#8217;s Board of Directors on May 2, 2011.
&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;On March 17, 2011, the Company entered into an agreement with Ascentage Pharma Group to conduct a series of studies at a total estimated cost of $20,000, of which $15,000 had been paid through June 30, 2011. Ascentage Pharma Group is an offshoot of Ascenta Therapeutics, of which Dr. Mel Sorensen, a director of the Company, is the President and Chief Executive Officer and a director. Ascentage Pharma Group and Ascenta Therapeutics have a continuing business relationship and certain common shareholders. However, Dr. Sorensen does not have any direct business relationship with or ownership in Ascentage Pharma Group.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;On January 7, 2011, the Company entered into a Master Laboratory Services Agreement with WIL Research Laboratories, LLC for a series of studies. As of June 30, 2011, work orders for studies having a total estimated cost of $108,240 were in process under this agreement. As of June 30, 2011, the Company had paid $54,120 towards these work orders.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;On January 18, 2011, the Company entered into an agreement with Ash Stevens for a series of studies with a total estimated cost of $90,000. As of June 30, 2011, the Company had paid $29,700 towards these studies.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Consulting Arrangements
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;On April 7, 2010, the Company entered into an agreement with Dr. Mel Sorensen providing for consultation and advice over the ensuing twelve month period regarding the preparation and strategy for obtaining FDA approval for the clinical trial of the lead compound of the LB-100 series. The agreement called for an annual fee of $25,000, payable in two installments of $12,500 on April 15, 2010 and October 15, 2010. On February 18, 2011, the Company&amp;#8217;s Board of Directors approved a one-year extension of the agreement for an additional annual fee of $25,000, payable in two installments of $12,500 on April 15, 2011 and October 15, 2011. All installments have been paid as due.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The following table sets forth the Company&amp;#8217;s principal cash obligations and commitments for the next five fiscal years as of June 30, 2011 aggregating $470,236, of which $256,267 is included in current liabilities in the condensed consolidated balance sheet at June 30, 2011.&amp;#160; Amounts included in the 2011 column represent amounts due at June 30, 2011 for the remainder of the 2011 fiscal year ending December 31, 2011.
&lt;/font&gt;
&lt;/div&gt;&lt;br /&gt;
&lt;div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;" &gt;&lt;div&gt;&lt;div style="text-align:left;width:100%;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:8pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="page-break-after:always;width:100%;" &gt;&lt;div style="text-align:center;width:100%;" &gt;&amp;#160;
&lt;/div&gt;&lt;div style="text-align:center;width:100%;" &gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div&gt;&lt;div style="text-align:right;width:100%;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:8pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:left;" &gt;&lt;table cellspacing="0" cellpadding="0" width="100%"  style="font-family:times new roman;font-size:10pt;" &gt;&lt;tr&gt;&lt;td valign="bottom"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" colspan="2" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" colspan="6" nowrap="nowrap"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Payments&amp;#160;Due&amp;#160;By&amp;#160;Year
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" colspan="2" nowrap="nowrap"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Total
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" colspan="2" nowrap="nowrap"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;2011
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" colspan="2" nowrap="nowrap"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;2012
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="64%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Research and development contracts
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;291,019
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;291,019
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#8212;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="64%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Consulting agreement
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;12,500
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;12,500
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#8212;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="64%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Liquidated damages payable under registration rights agreement
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;74,000
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;74,000
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#8212;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="64%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Due to stockholder
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;92,717
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;92,717
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#8212;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="64%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Total
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;470,236
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;470,236
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#8212;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>

  <us-gaap:SubsequentEventsTextBlock contextRef="Context_6ME_30-Jun-2011">
  &lt;div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;div&gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-weight:bold;" &gt;9.
  &lt;/font&gt;&lt;font style="display:inline;font-weight:bold;" &gt;Subsequent Events
  &lt;/font&gt;
  &lt;/font&gt;
  &lt;/div&gt;
  &lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

  &lt;/div&gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;div&gt;&lt;div style="text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;background-color:#ffffff;" &gt;On July 27, 2011, the Company agreed to extend warrants to acquire 273,752 shares of common stock that were previously issued in connection with the Company&amp;#8217;s first private placement in 2006 to July 27, 2012.&amp;#160;&amp;#160;In conjunction with the extension of the warrants, the cashless exercise feature was deleted.&amp;#160;&amp;#160;On July 27, 2011, the fair value of the warrant extension, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $199,839 ($0.73 per share), and will be charged to operations during the three months ending September 30, 2011.&amp;#160;&amp;#160;The fair value of the warrant extension was calculated using the following input variables: stock price - $0.79; exercise price - $0.333; expected life - 1 year; expected volatility &amp;#8211; 308.8%; expected dividend yield - 0%; risk-free interest rate &amp;#8211; 0.14%.
  &lt;/font&gt;
  &lt;/div&gt;

  &lt;/div&gt;
  &lt;/div&gt;
  &lt;/div&gt;
&lt;/div&gt;
  </us-gaap:SubsequentEventsTextBlock>

  <us-gaap:ProceedsFromStockOptionsExercised decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">0</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">5000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">5000</us-gaap:ProceedsFromStockOptionsExercised>
  <lixt:ProceedsFromIssuanceOfNotesPayableToConsultants decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">0</lixt:ProceedsFromIssuanceOfNotesPayableToConsultants>
  <lixt:ProceedsFromIssuanceOfNotesPayableToConsultants decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">0</lixt:ProceedsFromIssuanceOfNotesPayableToConsultants>
  <lixt:ProceedsFromIssuanceOfNotesPayableToConsultants decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">200000</lixt:ProceedsFromIssuanceOfNotesPayableToConsultants>
  <lixt:RepaymentsOfNotesPayableToConsultant decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">0</lixt:RepaymentsOfNotesPayableToConsultant>
  <lixt:RepaymentsOfNotesPayableToConsultant decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">0</lixt:RepaymentsOfNotesPayableToConsultant>
  <lixt:RepaymentsOfNotesPayableToConsultant decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">200000</lixt:RepaymentsOfNotesPayableToConsultant>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">5000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised decimals="0" contextRef="Context_6ME_30-Jun-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD">18</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised decimals="0" contextRef="Context_6ME_30-Jun-2011_StatementEquityComponentsAxis_AdvancesUnderEquityFinancingMember" unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised decimals="0" contextRef="Context_6ME_30-Jun-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD">4982</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised decimals="0" contextRef="Context_6ME_30-Jun-2011_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised decimals="0" contextRef="Context_6ME_30-Jun-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares">181964</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <lixt:ShareBasedCompensationCost decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">2293051</lixt:ShareBasedCompensationCost>
  <lixt:ShareBasedCompensationCost decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">93274</lixt:ShareBasedCompensationCost>
  <lixt:ShareBasedCompensationCost decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">2293051</lixt:ShareBasedCompensationCost>
  <lixt:CashlessExerciseOfWarrantsAndOptionsAggregateExercisePrice decimals="0" contextRef="Context_6ME_30-Jun-2011" unitRef="USD">84207</lixt:CashlessExerciseOfWarrantsAndOptionsAggregateExercisePrice>
  <lixt:CashlessExerciseOfWarrantsAndOptionsAggregateExercisePrice decimals="0" contextRef="Context_Custom_30-Jun-2011" unitRef="USD">84207</lixt:CashlessExerciseOfWarrantsAndOptionsAggregateExercisePrice>
  <lixt:CashlessExerciseOfWarrantsAndOptionsAggregateExercisePrice decimals="0" contextRef="Context_6ME_30-Jun-2010" unitRef="USD">0</lixt:CashlessExerciseOfWarrantsAndOptionsAggregateExercisePrice>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>lixt-20110630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<schema targetNamespace="http://www.lixte.com/2011-06-30" elementFormDefault="qualified" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:lixt="http://www.lixte.com/2011-06-30" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:country="http://xbrl.sec.gov/country/2011-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2011-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2011-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:invest="http://xbrl.sec.gov/invest/2011-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2011-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <annotation>
    <appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="lixt-20110630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="lixt-20110630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="lixt-20110630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="lixt-20110630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:roleType roleURI="http://www.lixte.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>01 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lixte.com/role/StatementOfFinancialPositionClassified" id="StatementOfFinancialPositionClassified">
        <link:definition>02 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lixte.com/role/CondensedConsolidatedBalanceSheetsParenthetical" id="CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>03 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical]</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lixte.com/role/StatementOfIncomeAlternative" id="StatementOfIncomeAlternative">
        <link:definition>04 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lixte.com/role/Condensedconsolidatedstatementsofoperations" id="Condensedconsolidatedstatementsofoperations">
        <link:definition>05 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Parenthetical]</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lixte.com/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome" id="StatementOfShareholdersEquityAndOtherComprehensiveIncome">
        <link:definition>06 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIENCY)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lixte.com/role/StatementOfCashFlowsIndirect" id="StatementOfCashFlowsIndirect">
        <link:definition>07 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lixte.com/role/BasisOfPresentation" id="BasisOfPresentation">
        <link:definition>08 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lixte.com/role/OrganizationAndBusinessOperations" id="OrganizationAndBusinessOperations">
        <link:definition>09 - Disclosure - Organization and Business Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lixte.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>10 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lixte.com/role/Shareexchangeagreementandprivateplacement" id="Shareexchangeagreementandprivateplacement">
        <link:definition>11 - Disclosure - Share Exchange Agreement and Private Placement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lixte.com/role/Moneymarketfundsfairvalue" id="Moneymarketfundsfairvalue">
        <link:definition>12 - Disclosure - Money Market Funds Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lixte.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>13 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lixte.com/role/StockOptionsAndWarrants" id="StockOptionsAndWarrants">
        <link:definition>14 - Disclosure - Stock Options and Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lixte.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>15 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lixte.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>16 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/invest/2011-01-31" schemaLocation="http://xbrl.sec.gov/invest/2011/invest-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2011-01-31" schemaLocation="http://xbrl.sec.gov/country/2011/country-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2011-01-31" schemaLocation="http://xbrl.sec.gov/currency/2011/currency-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2011-01-31" schemaLocation="http://xbrl.sec.gov/exch/2011/exch-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2011-01-31" schemaLocation="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <element name="DocumentAndEntityInformationAbstract" id="lixt_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <element name="AdvancesOnResearchAndDevelopmentContractServices" id="lixt_AdvancesOnResearchAndDevelopmentContractServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant"/>
  <element name="ResearchAndDevelopmentContractLiabilities" id="lixt_ResearchAndDevelopmentContractLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant"/>
  <element name="LiquidatedDamagesPayableUnderRegistrationRightsAgreement" id="lixt_LiquidatedDamagesPayableUnderRegistrationRightsAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant"/>
  <element name="CondensedConsolidatedBalanceSheetsParentheticalAbstract" id="lixt_CondensedConsolidatedBalanceSheetsParentheticalAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <element name="ReverseMergerCosts" id="lixt_ReverseMergerCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration"/>
  <element name="LiquidatedDamagesUnderRegistrationRightsAgreement" id="lixt_LiquidatedDamagesUnderRegistrationRightsAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration"/>
  <element name="CondensedconsolidatedstatementsofoperationsAbstract" id="lixt_CondensedconsolidatedstatementsofoperationsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <element name="ResearchAndDevelopmentStockBasedCost" id="lixt_ResearchAndDevelopmentStockBasedCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration"/>
  <element name="ResearchAndDevelopmentStockBasedCostRelatedParty" id="lixt_ResearchAndDevelopmentStockBasedCostRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration"/>
  <element name="AdvancesUnderEquityFinancingMember" id="lixt_AdvancesUnderEquityFinancingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="SharesIssuedInPrivatePlacementNetOfOfferingCosts" id="lixt_SharesIssuedInPrivatePlacementNetOfOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration"/>
  <element name="SharesIssuedInPrivatePlacement" id="lixt_SharesIssuedInPrivatePlacement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="AdvancesUnderEquityFinancingDuringPeriod" id="lixt_AdvancesUnderEquityFinancingDuringPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration"/>
  <element name="SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts" id="lixt_SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration"/>
  <element name="SharesIssuedDuringPeriodSharesStockBasedResearchAndDevelopmentCosts" id="lixt_SharesIssuedDuringPeriodSharesStockBasedResearchAndDevelopmentCosts" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="ShareBasedCompensationCost" id="lixt_ShareBasedCompensationCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration"/>
  <element name="IncreaseDecreaseInGrantReceivable" id="lixt_IncreaseDecreaseInGrantReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration"/>
  <element name="IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" id="lixt_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration"/>
  <element name="IncreaseDecreaseInLiquidatedDamagesPayableUnderRegistrationRightsAgreement" id="lixt_IncreaseDecreaseInLiquidatedDamagesPayableUnderRegistrationRightsAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration"/>
  <element name="IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" id="lixt_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration"/>
  <element name="PaymentsToAcquireMoneyMarketFunds" id="lixt_PaymentsToAcquireMoneyMarketFunds" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration"/>
  <element name="ProceedsFromSaleOfCommonStockToConsultingFirm" id="lixt_ProceedsFromSaleOfCommonStockToConsultingFirm" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration"/>
  <element name="ProceedsFromSaleOfCommonStockToFounder" id="lixt_ProceedsFromSaleOfCommonStockToFounder" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration"/>
  <element name="ProceedsFromIssuanceOfNotesPayableToConsultants" id="lixt_ProceedsFromIssuanceOfNotesPayableToConsultants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration"/>
  <element name="RepaymentsOfNotesPayableToConsultant" id="lixt_RepaymentsOfNotesPayableToConsultant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration"/>
  <element name="DecreaseInAdvancesUnderEquityFinancing" id="lixt_DecreaseInAdvancesUnderEquityFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration"/>
  <element name="BasisOfPresentationAbstract" id="lixt_BasisOfPresentationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <element name="OrganizationAndBusinessOperationsAbstract" id="lixt_OrganizationAndBusinessOperationsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <element name="OrganizationAndBusinessOperationsTextBlock" id="lixt_OrganizationAndBusinessOperationsTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="ShareExchangeAgreementAndPrivatePlacementAbstract" id="lixt_ShareExchangeAgreementAndPrivatePlacementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <element name="ShareExchangeAgreementAndPrivatePlacementTextBlock" id="lixt_ShareExchangeAgreementAndPrivatePlacementTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="CashAndCashEquivalentsDisclosureAbstract" id="lixt_CashAndCashEquivalentsDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <element name="StockIssuedDuringPeriodValueShareBasedCompensationCosts" id="lixt_StockIssuedDuringPeriodValueShareBasedCompensationCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration"/>
  <element name="StockIssuedDuringPeriodSharesShareBasedCompensationCosts" id="lixt_StockIssuedDuringPeriodSharesShareBasedCompensationCosts" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="ResearchAndDevelopmentRepresentingProceedsOfGovernmentGrant" id="lixt_ResearchAndDevelopmentRepresentingProceedsOfGovernmentGrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration"/>
  <element name="CashlessExerciseOfWarrantsAndOptionsAggregateExercisePrice" id="lixt_CashlessExerciseOfWarrantsAndOptionsAggregateExercisePrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration"/>
  <element name="WeightedAvgNumberOfOutstandingSharesBasicAndDiluted" id="lixt_WeightedAvgNumberOfOutstandingSharesBasicAndDiluted" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>lixt-20110630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef roleURI="http://www.lixte.com/role/StatementOfFinancialPositionClassified" xlink:type="simple" xlink:href="lixt-20110630.xsd#StatementOfFinancialPositionClassified"/>
  <roleRef roleURI="http://www.lixte.com/role/StatementOfIncomeAlternative" xlink:type="simple" xlink:href="lixt-20110630.xsd#StatementOfIncomeAlternative"/>
  <roleRef roleURI="http://www.lixte.com/role/StatementOfCashFlowsIndirect" xlink:type="simple" xlink:href="lixt-20110630.xsd#StatementOfCashFlowsIndirect"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.lixte.com/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_Cash" use="optional" order="20.0" weight="1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue" use="optional" order="40.0" weight="1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaap_DepositsAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_DepositsAssetsCurrent" use="optional" order="60.0" weight="1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="loc_us-gaap_GrantsReceivableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_GrantsReceivableCurrent" use="optional" order="80.0" weight="1"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_AdvancesOnResearchAndDevelopmentContractServices" xlink:label="loc_lixt_AdvancesOnResearchAndDevelopmentContractServices"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_lixt_AdvancesOnResearchAndDevelopmentContractServices" use="optional" order="100.0" weight="1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="120.0" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.lixte.com/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="20.0" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.lixte.com/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" use="optional" order="20.0" weight="1"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ResearchAndDevelopmentContractLiabilities" xlink:label="loc_lixt_ResearchAndDevelopmentContractLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_lixt_ResearchAndDevelopmentContractLiabilities" use="optional" order="40.0" weight="1"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_LiquidatedDamagesPayableUnderRegistrationRightsAgreement" xlink:label="loc_lixt_LiquidatedDamagesPayableUnderRegistrationRightsAgreement"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_lixt_LiquidatedDamagesPayableUnderRegistrationRightsAgreement" use="optional" order="60.0" weight="1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="loc_us-gaap_DueToOfficersOrStockholdersCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DueToOfficersOrStockholdersCurrent" use="optional" order="80.0" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.lixte.com/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" use="optional" order="20.0" weight="1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="40.0" weight="1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" use="optional" order="60.0" weight="1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" use="optional" order="80.0" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.lixte.com/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="20.0" weight="1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="40.0" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.lixte.com/role/StatementOfIncomeAlternative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="20.0" weight="1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationNonproduction" xlink:label="loc_us-gaap_DepreciationNonproduction"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_DepreciationNonproduction" use="optional" order="40.0" weight="1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="60.0" weight="1"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ReverseMergerCosts" xlink:label="loc_lixt_ReverseMergerCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_lixt_ReverseMergerCosts" use="optional" order="80.0" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.lixte.com/role/StatementOfIncomeAlternative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="20.0" weight="1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating" use="optional" order="40.0" weight="1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_InterestExpense" use="optional" order="60.0" weight="-1"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_LiquidatedDamagesUnderRegistrationRightsAgreement" xlink:label="loc_lixt_LiquidatedDamagesUnderRegistrationRightsAgreement"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_lixt_LiquidatedDamagesUnderRegistrationRightsAgreement" use="optional" order="80.0" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.lixte.com/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="20.0" weight="1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_Depreciation" use="optional" order="40.0" weight="1"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ShareBasedCompensationCost" xlink:label="loc_lixt_ShareBasedCompensationCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_lixt_ShareBasedCompensationCost" use="optional" order="60.0" weight="1"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ResearchAndDevelopmentStockBasedCost" xlink:label="loc_lixt_ResearchAndDevelopmentStockBasedCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_lixt_ResearchAndDevelopmentStockBasedCost" use="optional" order="80.0" weight="1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInDepositOtherAssets" use="optional" order="100.0" weight="-1"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_IncreaseDecreaseInGrantReceivable" xlink:label="loc_lixt_IncreaseDecreaseInGrantReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_lixt_IncreaseDecreaseInGrantReceivable" use="optional" order="120.0" weight="-1"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:label="loc_lixt_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_lixt_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" use="optional" order="140.0" weight="-1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="160.0" weight="-1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="180.0" weight="1"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_IncreaseDecreaseInLiquidatedDamagesPayableUnderRegistrationRightsAgreement" xlink:label="loc_lixt_IncreaseDecreaseInLiquidatedDamagesPayableUnderRegistrationRightsAgreement"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_lixt_IncreaseDecreaseInLiquidatedDamagesPayableUnderRegistrationRightsAgreement" use="optional" order="200.0" weight="1"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:label="loc_lixt_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_lixt_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" use="optional" order="220.0" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.lixte.com/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_PaymentsToAcquireMoneyMarketFunds" xlink:label="loc_lixt_PaymentsToAcquireMoneyMarketFunds"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_lixt_PaymentsToAcquireMoneyMarketFunds" use="optional" order="20.0" weight="-1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment" use="optional" order="40.0" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.lixte.com/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised" use="optional" order="20.0" weight="1"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ProceedsFromSaleOfCommonStockToConsultingFirm" xlink:label="loc_lixt_ProceedsFromSaleOfCommonStockToConsultingFirm"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_lixt_ProceedsFromSaleOfCommonStockToConsultingFirm" use="optional" order="40.0" weight="1"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ProceedsFromSaleOfCommonStockToFounder" xlink:label="loc_lixt_ProceedsFromSaleOfCommonStockToFounder"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_lixt_ProceedsFromSaleOfCommonStockToFounder" use="optional" order="60.0" weight="1"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ProceedsFromIssuanceOfNotesPayableToConsultants" xlink:label="loc_lixt_ProceedsFromIssuanceOfNotesPayableToConsultants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_lixt_ProceedsFromIssuanceOfNotesPayableToConsultants" use="optional" order="80.0" weight="1"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_RepaymentsOfNotesPayableToConsultant" xlink:label="loc_lixt_RepaymentsOfNotesPayableToConsultant"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_lixt_RepaymentsOfNotesPayableToConsultant" use="optional" order="100.0" weight="-1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition" use="optional" order="120.0" weight="1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" use="optional" order="140.0" weight="1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts" use="optional" order="160.0" weight="-1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="loc_us-gaap_ProceedsFromContributedCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromContributedCapital" use="optional" order="180.0" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.lixte.com/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="20.0" weight="1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="40.0" weight="1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="60.0" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>lixt-20110630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef roleURI="http://www.lixte.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="lixt-20110630.xsd#DocumentAndEntityInformation"/>
  <roleRef roleURI="http://www.lixte.com/role/StatementOfFinancialPositionClassified" xlink:type="simple" xlink:href="lixt-20110630.xsd#StatementOfFinancialPositionClassified"/>
  <roleRef roleURI="http://www.lixte.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="lixt-20110630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <roleRef roleURI="http://www.lixte.com/role/StatementOfIncomeAlternative" xlink:type="simple" xlink:href="lixt-20110630.xsd#StatementOfIncomeAlternative"/>
  <roleRef roleURI="http://www.lixte.com/role/Condensedconsolidatedstatementsofoperations" xlink:type="simple" xlink:href="lixt-20110630.xsd#Condensedconsolidatedstatementsofoperations"/>
  <roleRef roleURI="http://www.lixte.com/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome" xlink:type="simple" xlink:href="lixt-20110630.xsd#StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef roleURI="http://www.lixte.com/role/StatementOfCashFlowsIndirect" xlink:type="simple" xlink:href="lixt-20110630.xsd#StatementOfCashFlowsIndirect"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.lixte.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" use="optional" order="0.0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityRegistrantName_2" use="optional" order="10.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_3"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityCentralIndexKey_3" use="optional" order="20.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_4"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_4" use="optional" order="30.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_5"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityFilerCategory_5" use="optional" order="40.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_6"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_TradingSymbol_6" use="optional" order="50.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_7"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_7" use="optional" order="60.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_8"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentType_8" use="optional" order="70.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_9"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_AmendmentFlag_9" use="optional" order="80.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_10"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentPeriodEndDate_10" use="optional" order="90.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_11"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_11" use="optional" order="100.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_12"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentFiscalYearFocus_12" use="optional" order="110.0"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.lixte.com/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" use="optional" order="0.0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AssetsAbstract_2" use="optional" order="10.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_3"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_Cash_3" use="optional" order="0.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_4"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_4" use="optional" order="10.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaap_DepositsAssetsCurrent_5"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_DepositsAssetsCurrent_5" use="optional" order="20.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="loc_us-gaap_GrantsReceivableCurrent_6"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_GrantsReceivableCurrent_6" use="optional" order="30.0"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_AdvancesOnResearchAndDevelopmentContractServices" xlink:label="loc_lixt_AdvancesOnResearchAndDevelopmentContractServices_7"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_lixt_AdvancesOnResearchAndDevelopmentContractServices_7" use="optional" order="40.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8" use="optional" order="50.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_9"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_AssetsCurrent_9" use="optional" order="60.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_10"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_Assets_10" use="optional" order="70.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_11"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_11" use="optional" order="20.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_12"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_11" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_12" use="optional" order="0.0"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ResearchAndDevelopmentContractLiabilities" xlink:label="loc_lixt_ResearchAndDevelopmentContractLiabilities_13"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_11" xlink:to="loc_lixt_ResearchAndDevelopmentContractLiabilities_13" use="optional" order="10.0"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_LiquidatedDamagesPayableUnderRegistrationRightsAgreement" xlink:label="loc_lixt_LiquidatedDamagesPayableUnderRegistrationRightsAgreement_14"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_11" xlink:to="loc_lixt_LiquidatedDamagesPayableUnderRegistrationRightsAgreement_14" use="optional" order="20.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="loc_us-gaap_DueToOfficersOrStockholdersCurrent_15"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_11" xlink:to="loc_us-gaap_DueToOfficersOrStockholdersCurrent_15" use="optional" order="30.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_16"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_11" xlink:to="loc_us-gaap_LiabilitiesCurrent_16" use="optional" order="40.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_17"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_11" xlink:to="loc_us-gaap_CommitmentsAndContingencies_17" use="optional" order="50.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_18"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_11" xlink:to="loc_us-gaap_StockholdersEquityAbstract_18" use="optional" order="60.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_19"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_18" xlink:to="loc_us-gaap_PreferredStockValue_19" use="optional" order="0.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_20"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_18" xlink:to="loc_us-gaap_CommonStockValue_20" use="optional" order="10.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_21"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_18" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_21" use="optional" order="20.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_22"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_18" xlink:to="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_22" use="optional" order="30.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_23"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_18" xlink:to="loc_us-gaap_StockholdersEquity_23" use="optional" order="40.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_24"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_11" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_24" use="optional" order="70.0"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.lixte.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" use="optional" order="0.0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2" use="optional" order="10.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3" use="optional" order="20.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_4"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_4" use="optional" order="30.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5" use="optional" order="40.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6" use="optional" order="50.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_7"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_7" use="optional" order="60.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8" use="optional" order="70.0"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.lixte.com/role/StatementOfIncomeAlternative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" use="optional" order="0.0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_Revenues_2" use="optional" order="10.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_3"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_3" use="optional" order="20.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_4"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_4" use="optional" order="0.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationNonproduction" xlink:label="loc_us-gaap_DepreciationNonproduction_5"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3" xlink:to="loc_us-gaap_DepreciationNonproduction_5" use="optional" order="10.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6" use="optional" order="20.0"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ReverseMergerCosts" xlink:label="loc_lixt_ReverseMergerCosts_7"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3" xlink:to="loc_lixt_ReverseMergerCosts_7" use="optional" order="30.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_8"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3" xlink:to="loc_us-gaap_OperatingExpenses_8" use="optional" order="40.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_9"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_9" use="optional" order="30.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_10"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_10" use="optional" order="40.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_11"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_InterestExpense_11" use="optional" order="50.0"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_LiquidatedDamagesUnderRegistrationRightsAgreement" xlink:label="loc_lixt_LiquidatedDamagesUnderRegistrationRightsAgreement_12"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_lixt_LiquidatedDamagesUnderRegistrationRightsAgreement_12" use="optional" order="60.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_13"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_13" use="optional" order="70.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_14"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_14" use="optional" order="80.0"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_WeightedAvgNumberOfOutstandingSharesBasicAndDiluted" xlink:label="loc_lixt_WeightedAvgNumberOfOutstandingSharesBasicAndDiluted_15"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_lixt_WeightedAvgNumberOfOutstandingSharesBasicAndDiluted_15" use="optional" order="90.0"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.lixte.com/role/Condensedconsolidatedstatementsofoperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" use="optional" order="0.0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ShareBasedCompensationCost" xlink:label="loc_lixt_ShareBasedCompensationCost_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_lixt_ShareBasedCompensationCost_2" use="optional" order="10.0"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ResearchAndDevelopmentStockBasedCost" xlink:label="loc_lixt_ResearchAndDevelopmentStockBasedCost_3"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_lixt_ResearchAndDevelopmentStockBasedCost_3" use="optional" order="20.0"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ResearchAndDevelopmentStockBasedCostRelatedParty" xlink:label="loc_lixt_ResearchAndDevelopmentStockBasedCostRelatedParty_4"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_lixt_ResearchAndDevelopmentStockBasedCostRelatedParty_4" use="optional" order="30.0"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ResearchAndDevelopmentRepresentingProceedsOfGovernmentGrant" xlink:label="loc_lixt_ResearchAndDevelopmentRepresentingProceedsOfGovernmentGrant_5"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_lixt_ResearchAndDevelopmentRepresentingProceedsOfGovernmentGrant_5" use="optional" order="40.0"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.lixte.com/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" use="optional" order="0.0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" use="optional" order="0.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" use="optional" order="0.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3_Default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3_Default" use="optional" order="0.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_4" use="optional" order="0.0"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_AdvancesUnderEquityFinancingMember" xlink:label="loc_lixt_AdvancesUnderEquityFinancingMember_5"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_lixt_AdvancesUnderEquityFinancingMember_5" use="optional" order="10.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6" use="optional" order="20.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_7"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_RetainedEarningsMember_7" use="optional" order="30.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_23"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_23" use="optional" order="130.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_8"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockholdersEquity_8" use="optional" order="10.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_9"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SharesOutstanding_9" use="optional" order="20.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_10"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_10" use="optional" order="30.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_11"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_11" use="optional" order="0.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_12"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_12" use="optional" order="40.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_13"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_12" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_13" use="optional" order="0.0"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_SharesIssuedInPrivatePlacementNetOfOfferingCosts" xlink:label="loc_lixt_SharesIssuedInPrivatePlacementNetOfOfferingCosts_14"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_lixt_SharesIssuedInPrivatePlacementNetOfOfferingCosts_14" use="optional" order="50.0"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_SharesIssuedInPrivatePlacement" xlink:label="loc_lixt_SharesIssuedInPrivatePlacement_15"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_lixt_SharesIssuedInPrivatePlacement_15" use="optional" order="60.0"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_AdvancesUnderEquityFinancingDuringPeriod" xlink:label="loc_lixt_AdvancesUnderEquityFinancingDuringPeriod_16"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_lixt_AdvancesUnderEquityFinancingDuringPeriod_16" use="optional" order="70.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_17"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_17" use="optional" order="80.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_18"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_18" use="optional" order="90.0"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_StockIssuedDuringPeriodValueShareBasedCompensationCosts" xlink:label="loc_lixt_StockIssuedDuringPeriodValueShareBasedCompensationCosts_19"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_lixt_StockIssuedDuringPeriodValueShareBasedCompensationCosts_19" use="optional" order="100.0"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_StockIssuedDuringPeriodSharesShareBasedCompensationCosts" xlink:label="loc_lixt_StockIssuedDuringPeriodSharesShareBasedCompensationCosts_20"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lixt_StockIssuedDuringPeriodValueShareBasedCompensationCosts_19" xlink:to="loc_lixt_StockIssuedDuringPeriodSharesShareBasedCompensationCosts_20" use="optional" order="0.0"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts" xlink:label="loc_lixt_SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts_21"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_lixt_SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts_21" use="optional" order="110.0"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_SharesIssuedDuringPeriodSharesStockBasedResearchAndDevelopmentCosts" xlink:label="loc_lixt_SharesIssuedDuringPeriodSharesStockBasedResearchAndDevelopmentCosts_22"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_lixt_SharesIssuedDuringPeriodSharesStockBasedResearchAndDevelopmentCosts_22" use="optional" order="120.0"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.lixte.com/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" use="optional" order="0.0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_2" use="optional" order="10.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" use="optional" order="0.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_4"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_NetIncomeLoss_4" use="optional" order="0.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" use="optional" order="10.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_6"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_Depreciation_6" use="optional" order="0.0"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ShareBasedCompensationCost" xlink:label="loc_lixt_ShareBasedCompensationCost_7"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_lixt_ShareBasedCompensationCost_7" use="optional" order="10.0"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ResearchAndDevelopmentStockBasedCost" xlink:label="loc_lixt_ResearchAndDevelopmentStockBasedCost_8"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_lixt_ResearchAndDevelopmentStockBasedCost_8" use="optional" order="20.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9" use="optional" order="30.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_10"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_10" use="optional" order="0.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInDepositOtherAssets_11"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_10" xlink:to="loc_us-gaap_IncreaseDecreaseInDepositOtherAssets_11" use="optional" order="0.0"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_IncreaseDecreaseInGrantReceivable" xlink:label="loc_lixt_IncreaseDecreaseInGrantReceivable_12"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_10" xlink:to="loc_lixt_IncreaseDecreaseInGrantReceivable_12" use="optional" order="10.0"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:label="loc_lixt_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_13"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9" xlink:to="loc_lixt_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_13" use="optional" order="10.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_14"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_14" use="optional" order="20.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_15"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_15" use="optional" order="30.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_16"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_15" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_16" use="optional" order="0.0"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_IncreaseDecreaseInLiquidatedDamagesPayableUnderRegistrationRightsAgreement" xlink:label="loc_lixt_IncreaseDecreaseInLiquidatedDamagesPayableUnderRegistrationRightsAgreement_17"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9" xlink:to="loc_lixt_IncreaseDecreaseInLiquidatedDamagesPayableUnderRegistrationRightsAgreement_17" use="optional" order="40.0"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:label="loc_lixt_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_18"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9" xlink:to="loc_lixt_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_18" use="optional" order="50.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19" use="optional" order="20.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" use="optional" order="10.0"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_PaymentsToAcquireMoneyMarketFunds" xlink:label="loc_lixt_PaymentsToAcquireMoneyMarketFunds_21"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" xlink:to="loc_lixt_PaymentsToAcquireMoneyMarketFunds_21" use="optional" order="0.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_22"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" xlink:to="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_22" use="optional" order="10.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_23"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_23" use="optional" order="20.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" use="optional" order="20.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_25"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_25" use="optional" order="0.0"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ProceedsFromSaleOfCommonStockToConsultingFirm" xlink:label="loc_lixt_ProceedsFromSaleOfCommonStockToConsultingFirm_26"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_lixt_ProceedsFromSaleOfCommonStockToConsultingFirm_26" use="optional" order="10.0"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ProceedsFromSaleOfCommonStockToFounder" xlink:label="loc_lixt_ProceedsFromSaleOfCommonStockToFounder_27"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_lixt_ProceedsFromSaleOfCommonStockToFounder_27" use="optional" order="20.0"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ProceedsFromIssuanceOfNotesPayableToConsultants" xlink:label="loc_lixt_ProceedsFromIssuanceOfNotesPayableToConsultants_28"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_lixt_ProceedsFromIssuanceOfNotesPayableToConsultants_28" use="optional" order="30.0"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_RepaymentsOfNotesPayableToConsultant" xlink:label="loc_lixt_RepaymentsOfNotesPayableToConsultant_29"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_lixt_RepaymentsOfNotesPayableToConsultant_29" use="optional" order="40.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_30"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_30" use="optional" order="50.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_31"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_31" use="optional" order="60.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_32"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_32" use="optional" order="70.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="loc_us-gaap_ProceedsFromContributedCapital_33"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_ProceedsFromContributedCapital_33" use="optional" order="80.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_34"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_34" use="optional" order="90.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_35"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_2" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_35" use="optional" order="30.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_36"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_2" xlink:to="loc_us-gaap_Cash_36" use="optional" order="40.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_37"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_37" use="optional" order="20.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_38"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_37" xlink:to="loc_us-gaap_InterestPaid_38" use="optional" order="0.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_39"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_37" xlink:to="loc_us-gaap_IncomeTaxesPaid_39" use="optional" order="10.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_40"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_40" use="optional" order="30.0"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_DecreaseInAdvancesUnderEquityFinancing" xlink:label="loc_lixt_DecreaseInAdvancesUnderEquityFinancing_41"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_40" xlink:to="loc_lixt_DecreaseInAdvancesUnderEquityFinancing_41" use="optional" order="0.0"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>lixt-20110630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef roleURI="http://xbrl.us/us-gaap/role/label/negated" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2008-03-31.xsd#negated"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_DocumentAndEntityInformationAbstract" xlink:label="loc_lixt_DocumentAndEntityInformationAbstract"/>
    <label xlink:type="resource" xlink:label="lab_lixt_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Document and Entity Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_DocumentAndEntityInformationAbstract" xlink:to="lab_lixt_DocumentAndEntityInformationAbstract"/>
    <label xlink:type="resource" xlink:label="lab_lixt_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Document and Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:label="lab_lixt_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">Document And Entity Information.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType"/>
    <label xlink:type="resource" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType"/>
    <label xlink:type="resource" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">ASSETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Cash</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xml:lang="en-US">Cash: Balance at beginning of period</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xml:lang="en-US">Cash: Balance at end of period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Money Market Funds, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="lab_us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Money market funds</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaap_DepositsAssetsCurrent"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_DepositsAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Funds On Deposit With Law Firm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsCurrent" xlink:to="lab_us-gaap_DepositsAssetsCurrent"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_DepositsAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Funds on deposit with law firm</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="loc_us-gaap_GrantsReceivableCurrent"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_GrantsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Grants Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantsReceivableCurrent" xlink:to="lab_us-gaap_GrantsReceivableCurrent"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_GrantsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Grant receivable</label>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_AdvancesOnResearchAndDevelopmentContractServices" xlink:label="loc_lixt_AdvancesOnResearchAndDevelopmentContractServices"/>
    <label xlink:type="resource" xlink:label="lab_lixt_AdvancesOnResearchAndDevelopmentContractServices" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Advances On Research and Development Contract Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_AdvancesOnResearchAndDevelopmentContractServices" xlink:to="lab_lixt_AdvancesOnResearchAndDevelopmentContractServices"/>
    <label xlink:type="resource" xlink:label="lab_lixt_AdvancesOnResearchAndDevelopmentContractServices" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Advances on research and development contract services</label>
    <label xlink:type="resource" xlink:label="lab_lixt_AdvancesOnResearchAndDevelopmentContractServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">The unamortized portion of the amounts paid in advance for contracted research and development services that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year, as of the balance sheet date.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Total assets</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Liabilities and Stockholders' Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current, Total</label>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ResearchAndDevelopmentContractLiabilities" xlink:label="loc_lixt_ResearchAndDevelopmentContractLiabilities"/>
    <label xlink:type="resource" xlink:label="lab_lixt_ResearchAndDevelopmentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Research and Development Contract Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_ResearchAndDevelopmentContractLiabilities" xlink:to="lab_lixt_ResearchAndDevelopmentContractLiabilities"/>
    <label xlink:type="resource" xlink:label="lab_lixt_ResearchAndDevelopmentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Research and development contract liabilities</label>
    <label xlink:type="resource" xlink:label="lab_lixt_ResearchAndDevelopmentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for contracted research and development activities.</label>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_LiquidatedDamagesPayableUnderRegistrationRightsAgreement" xlink:label="loc_lixt_LiquidatedDamagesPayableUnderRegistrationRightsAgreement"/>
    <label xlink:type="resource" xlink:label="lab_lixt_LiquidatedDamagesPayableUnderRegistrationRightsAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Liquidated Damages Payable Under Registration Rights Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_LiquidatedDamagesPayableUnderRegistrationRightsAgreement" xlink:to="lab_lixt_LiquidatedDamagesPayableUnderRegistrationRightsAgreement"/>
    <label xlink:type="resource" xlink:label="lab_lixt_LiquidatedDamagesPayableUnderRegistrationRightsAgreement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Liquidated damages payable under registration rights agreement</label>
    <label xlink:type="resource" xlink:label="lab_lixt_LiquidatedDamagesPayableUnderRegistrationRightsAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">Carrying value as of the balance sheet date of liability incurred for liquidated damages payable under registration rights agreement. Used to reflect the current portion of the liability that is due upon demand.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="loc_us-gaap_DueToOfficersOrStockholdersCurrent"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_DueToOfficersOrStockholdersCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Due to Officers or Stockholders, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToOfficersOrStockholdersCurrent" xlink:to="lab_us-gaap_DueToOfficersOrStockholdersCurrent"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_DueToOfficersOrStockholdersCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Due to stockholder</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_DueToOfficersOrStockholdersCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Due to stockholder</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Total current liabilities</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Preferred stock, $0.0001 par value; authorized - 10,000,000 shares; issued - None</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Preferred Stock, Value, Issued, Total</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xml:lang="en-US">Preferred Stock, Value, Issued, Beginning Balance</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xml:lang="en-US">Preferred Stock, Value, Issued, Ending Balance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Common stock, $0.0001 par value; authorized - 100,000,000 shares; issued and outstanding ; 35,259,142 shares and 35,077,178 shares at June 30, 2011 and December 31, 2010, respectively</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Common Stock, Value, Issued, Total</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xml:lang="en-US">Common Stock, Value, Issued, Beginning Balance</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xml:lang="en-US">Common Stock, Value, Issued, Ending Balance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Additional paid-in capital</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xml:lang="en-US">Additional Paid in Capital, Common Stock, Beginning Balance</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xml:lang="en-US">Additional Paid in Capital, Common Stock, Ending Balance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Development Stage Enterprise, Deficit Accumulated During Development Stage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:to="lab_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Deficit accumulated during the development stage</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US">Deficit accumulated during the development stage</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xml:lang="en-US">Deficit accumulated during the development stage</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Total stockholders' equity</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Total stockholders' equity</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xml:lang="en-US">Balance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Liabilities and Stockholders' Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Total liabilities and stockholders' equity</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_CondensedConsolidatedBalanceSheetsParentheticalAbstract" xlink:label="loc_lixt_CondensedConsolidatedBalanceSheetsParentheticalAbstract"/>
    <label xlink:type="resource" xlink:label="lab_lixt_CondensedConsolidatedBalanceSheetsParentheticalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">lixt_CondensedConsolidatedBalanceSheetsParentheticalAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_CondensedConsolidatedBalanceSheetsParentheticalAbstract" xlink:to="lab_lixt_CondensedConsolidatedBalanceSheetsParentheticalAbstract"/>
    <label xlink:type="resource" xlink:label="lab_lixt_CondensedConsolidatedBalanceSheetsParentheticalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">lixt_CondensedConsolidatedBalanceSheetsParentheticalAbstract</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Preferred stock, shares issued</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Preferred Stock, Shares Issued, Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Common stock, shares issued</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Common Stock, Shares, Issued, Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Common stock, shares outstanding</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xml:lang="en-US">Common Stock, Shares, Outstanding, Beginning Balance</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xml:lang="en-US">Common Stock, Shares, Outstanding, Ending Balance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Income Statement [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Revenues</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Revenues</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Costs and expenses:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">General and administrative costs, including $40,528 and $20,534 of stock-based compensation costs for the three months ended June 30, 2011 and 2010, respectively, $40,528 and $93,274 of stock-based compensation costs for the six months ended June 30, 2011 and 2010, respectively, and $2,293,051 of stock-based compensation costs for the period from August 9, 2005 (inception) to June 30, 2011 (cumulative)</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">General and Administrative Expense, Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationNonproduction" xlink:label="loc_us-gaap_DepreciationNonproduction"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_DepreciationNonproduction" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Depreciation, Nonproduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationNonproduction" xlink:to="lab_us-gaap_DepreciationNonproduction"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_DepreciationNonproduction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Depreciation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Research and development costs</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Research and Development Expense, Total</label>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ReverseMergerCosts" xlink:label="loc_lixt_ReverseMergerCosts"/>
    <label xlink:type="resource" xlink:label="lab_lixt_ReverseMergerCosts" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Reverse Merger Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_ReverseMergerCosts" xlink:to="lab_lixt_ReverseMergerCosts"/>
    <label xlink:type="resource" xlink:label="lab_lixt_ReverseMergerCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Reverse merger costs</label>
    <label xlink:type="resource" xlink:label="lab_lixt_ReverseMergerCosts" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Reverse merger costs</label>
    <label xlink:type="resource" xlink:label="lab_lixt_ReverseMergerCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">Cash fee incurred during the reporting period in connection with the Company's Share Exchange Agreement.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Total costs and expenses</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Total costs and expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Loss from operations</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Operating Income (Loss), Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Investment Income, Nonoperating</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNonoperating" xlink:to="lab_us-gaap_InvestmentIncomeNonoperating"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Interest income</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Investment Income, Nonoperating, Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Interest expense</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Interest Expense, Total</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US">Interest expense</label>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_LiquidatedDamagesUnderRegistrationRightsAgreement" xlink:label="loc_lixt_LiquidatedDamagesUnderRegistrationRightsAgreement"/>
    <label xlink:type="resource" xlink:label="lab_lixt_LiquidatedDamagesUnderRegistrationRightsAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Liquidated Damages Under Registration Rights Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_LiquidatedDamagesUnderRegistrationRightsAgreement" xlink:to="lab_lixt_LiquidatedDamagesUnderRegistrationRightsAgreement"/>
    <label xlink:type="resource" xlink:label="lab_lixt_LiquidatedDamagesUnderRegistrationRightsAgreement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Liquidated damages under registration rights agreement</label>
    <label xlink:type="resource" xlink:label="lab_lixt_LiquidatedDamagesUnderRegistrationRightsAgreement" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Liquidated damages under registration rights agreement</label>
    <label xlink:type="resource" xlink:label="lab_lixt_LiquidatedDamagesUnderRegistrationRightsAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">Costs incurred during the reporting period towards liquidated damages under registration rights agreement.</label>
    <label xlink:type="resource" xlink:label="lab_lixt_LiquidatedDamagesUnderRegistrationRightsAgreement" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US">Liquidated damages under registration rights agreement</label>
    <label xlink:type="resource" xlink:label="lab_lixt_LiquidatedDamagesUnderRegistrationRightsAgreement" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xml:lang="en-US">Liquidated damages under registration rights agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Net Income (Loss) Attributable To Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Net loss per common share - Basic and diluted (in dollars per share)</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Net loss per common share - Basic and diluted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_WeightedAvgNumberOfOutstandingSharesBasicAndDiluted" xlink:label="loc_lixt_WeightedAvgNumberOfOutstandingSharesBasicAndDiluted"/>
    <label xlink:type="resource" xlink:label="lab_lixt_WeightedAvgNumberOfOutstandingSharesBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Weighted Average Number Of Shares Outstanding, Basic and Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_WeightedAvgNumberOfOutstandingSharesBasicAndDiluted" xlink:to="lab_lixt_WeightedAvgNumberOfOutstandingSharesBasicAndDiluted"/>
    <label xlink:type="resource" xlink:label="lab_lixt_WeightedAvgNumberOfOutstandingSharesBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Weighted average common shares outstanding - Basic and diluted (in shares)</label>
    <label xlink:type="resource" xlink:label="lab_lixt_WeightedAvgNumberOfOutstandingSharesBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Weighted average common shares outstanding - Basic and diluted (in shares)</label>
    <label xlink:type="resource" xlink:label="lab_lixt_WeightedAvgNumberOfOutstandingSharesBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">The average number of shares issued and outstanding that are used in calculating common stock basic and diluted EPS, determined based on the timing of issuance of shares in the period.</label>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_CondensedconsolidatedstatementsofoperationsAbstract" xlink:label="loc_lixt_CondensedconsolidatedstatementsofoperationsAbstract"/>
    <label xlink:type="resource" xlink:label="lab_lixt_CondensedconsolidatedstatementsofoperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Condensedconsolidatedstatementsofoperations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_CondensedconsolidatedstatementsofoperationsAbstract" xlink:to="lab_lixt_CondensedconsolidatedstatementsofoperationsAbstract"/>
    <label xlink:type="resource" xlink:label="lab_lixt_CondensedconsolidatedstatementsofoperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Condensedconsolidatedstatementsofoperations [Abstract]</label>
    <label xlink:type="resource" xlink:label="lab_lixt_CondensedconsolidatedstatementsofoperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">CondensedConsolidatedStatementsOfOperations.</label>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ShareBasedCompensationCost" xlink:label="loc_lixt_ShareBasedCompensationCost"/>
    <label xlink:type="resource" xlink:label="lab_lixt_ShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Share-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_ShareBasedCompensationCost" xlink:to="lab_lixt_ShareBasedCompensationCost"/>
    <label xlink:type="resource" xlink:label="lab_lixt_ShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Share-based Compensation, Total</label>
    <label xlink:type="resource" xlink:label="lab_lixt_ShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US">Stock-based compensation costs</label>
    <label xlink:type="resource" xlink:label="lab_lixt_ShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Stock-based compensation costs</label>
    <label xlink:type="resource" xlink:label="lab_lixt_ShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">The aggregate amount of noncash, equity-based remuneration to employees and vendors, included in total general and administrative costs, related to general and administrative activities. This may include the value of stock or unit options and amortization of restricted stock or units. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</label>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ResearchAndDevelopmentStockBasedCost" xlink:label="loc_lixt_ResearchAndDevelopmentStockBasedCost"/>
    <label xlink:type="resource" xlink:label="lab_lixt_ResearchAndDevelopmentStockBasedCost" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Research and Development, Stock Based Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_ResearchAndDevelopmentStockBasedCost" xlink:to="lab_lixt_ResearchAndDevelopmentStockBasedCost"/>
    <label xlink:type="resource" xlink:label="lab_lixt_ResearchAndDevelopmentStockBasedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US">Stock-based research and development costs</label>
    <label xlink:type="resource" xlink:label="lab_lixt_ResearchAndDevelopmentStockBasedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Research and development stock based costs</label>
    <label xlink:type="resource" xlink:label="lab_lixt_ResearchAndDevelopmentStockBasedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">The aggregate amount of noncash, equity-based remuneration to employees and vendors, included in total research and development costs, related to research and development activities. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</label>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ResearchAndDevelopmentStockBasedCostRelatedParty" xlink:label="loc_lixt_ResearchAndDevelopmentStockBasedCostRelatedParty"/>
    <label xlink:type="resource" xlink:label="lab_lixt_ResearchAndDevelopmentStockBasedCostRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Research and Development, Stock Based Cost, Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_ResearchAndDevelopmentStockBasedCostRelatedParty" xlink:to="lab_lixt_ResearchAndDevelopmentStockBasedCostRelatedParty"/>
    <label xlink:type="resource" xlink:label="lab_lixt_ResearchAndDevelopmentStockBasedCostRelatedParty" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Research and development stock based costs,related party</label>
    <label xlink:type="resource" xlink:label="lab_lixt_ResearchAndDevelopmentStockBasedCostRelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">The aggregate amount of noncash, equity-based remuneration to related party, included in the total amount of research and development stock based costs, related to research and development activities. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</label>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ResearchAndDevelopmentRepresentingProceedsOfGovernmentGrant" xlink:label="loc_lixt_ResearchAndDevelopmentRepresentingProceedsOfGovernmentGrant"/>
    <label xlink:type="resource" xlink:label="lab_lixt_ResearchAndDevelopmentRepresentingProceedsOfGovernmentGrant" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Research and Development Costs, Representing Proceeds Of Government Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_ResearchAndDevelopmentRepresentingProceedsOfGovernmentGrant" xlink:to="lab_lixt_ResearchAndDevelopmentRepresentingProceedsOfGovernmentGrant"/>
    <label xlink:type="resource" xlink:label="lab_lixt_ResearchAndDevelopmentRepresentingProceedsOfGovernmentGrant" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Research and development, representing the proceeds of a government grant</label>
    <label xlink:type="resource" xlink:label="lab_lixt_ResearchAndDevelopmentRepresentingProceedsOfGovernmentGrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">The amount of grant applied for and received under the Patient Protection and Affordable Care Act signed into law on March 23, 2010 and is based upon qualified investments made in 2009 and 2010. The amount is recorded as an offset to the qualified investments made.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Statement, Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Statement, Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_AdvancesUnderEquityFinancingMember" xlink:label="loc_lixt_AdvancesUnderEquityFinancingMember"/>
    <label xlink:type="resource" xlink:label="lab_lixt_AdvancesUnderEquityFinancingMember" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Advance Under Equity Financing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_AdvancesUnderEquityFinancingMember" xlink:to="lab_lixt_AdvancesUnderEquityFinancingMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Additional Paid-in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Deficit Accumulated During the Development Stage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Balance (Shares)</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xml:lang="en-US">Balance (in shares)</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xml:lang="en-US">Balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Shares issued to founding stockholder</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Shares issued to founding stockholder (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Shares issued in connection with reverse merger transaction</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Shares issued in connection with reverse merger transaction (in shares)</label>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_SharesIssuedInPrivatePlacementNetOfOfferingCosts" xlink:label="loc_lixt_SharesIssuedInPrivatePlacementNetOfOfferingCosts"/>
    <label xlink:type="resource" xlink:label="lab_lixt_SharesIssuedInPrivatePlacementNetOfOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Shares Issued In Private Placement, Net Of Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_SharesIssuedInPrivatePlacementNetOfOfferingCosts" xlink:to="lab_lixt_SharesIssuedInPrivatePlacementNetOfOfferingCosts"/>
    <label xlink:type="resource" xlink:label="lab_lixt_SharesIssuedInPrivatePlacementNetOfOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Shares issued in private placements, net of offering costs</label>
    <label xlink:type="resource" xlink:label="lab_lixt_SharesIssuedInPrivatePlacementNetOfOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">Value of shares issued to private placements pursuant to a share exchange agreement net of offering costs.</label>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_SharesIssuedInPrivatePlacement" xlink:label="loc_lixt_SharesIssuedInPrivatePlacement"/>
    <label xlink:type="resource" xlink:label="lab_lixt_SharesIssuedInPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Shares Issued In Private Placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_SharesIssuedInPrivatePlacement" xlink:to="lab_lixt_SharesIssuedInPrivatePlacement"/>
    <label xlink:type="resource" xlink:label="lab_lixt_SharesIssuedInPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Shares issued in private placements, net of offering costs (in shares)</label>
    <label xlink:type="resource" xlink:label="lab_lixt_SharesIssuedInPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">Number of shares issued to private placements pursuant to a share exchange agreement net of offering costs.</label>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_AdvancesUnderEquityFinancingDuringPeriod" xlink:label="loc_lixt_AdvancesUnderEquityFinancingDuringPeriod"/>
    <label xlink:type="resource" xlink:label="lab_lixt_AdvancesUnderEquityFinancingDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Advances Under Equity Financing During Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_AdvancesUnderEquityFinancingDuringPeriod" xlink:to="lab_lixt_AdvancesUnderEquityFinancingDuringPeriod"/>
    <label xlink:type="resource" xlink:label="lab_lixt_AdvancesUnderEquityFinancingDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Advance under equity financing</label>
    <label xlink:type="resource" xlink:label="lab_lixt_AdvancesUnderEquityFinancingDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">Advance received by the company during the period through equity financing arrangement (selling common stock to individual or institutional investors).</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_StockIssuedDuringPeriodValueShareBasedCompensationCosts" xlink:label="loc_lixt_StockIssuedDuringPeriodValueShareBasedCompensationCosts"/>
    <label xlink:type="resource" xlink:label="lab_lixt_StockIssuedDuringPeriodValueShareBasedCompensationCosts" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_StockIssuedDuringPeriodValueShareBasedCompensationCosts" xlink:to="lab_lixt_StockIssuedDuringPeriodValueShareBasedCompensationCosts"/>
    <label xlink:type="resource" xlink:label="lab_lixt_StockIssuedDuringPeriodValueShareBasedCompensationCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Stock-based compensation costs</label>
    <label xlink:type="resource" xlink:label="lab_lixt_StockIssuedDuringPeriodValueShareBasedCompensationCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">The aggregate amount of noncash, equity-based remuneration to employees and vendors during the period for general and administrative activities. This may include the value of stock or unit options and amortization of restricted stock or units.</label>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_StockIssuedDuringPeriodSharesShareBasedCompensationCosts" xlink:label="loc_lixt_StockIssuedDuringPeriodSharesShareBasedCompensationCosts"/>
    <label xlink:type="resource" xlink:label="lab_lixt_StockIssuedDuringPeriodSharesShareBasedCompensationCosts" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_StockIssuedDuringPeriodSharesShareBasedCompensationCosts" xlink:to="lab_lixt_StockIssuedDuringPeriodSharesShareBasedCompensationCosts"/>
    <label xlink:type="resource" xlink:label="lab_lixt_StockIssuedDuringPeriodSharesShareBasedCompensationCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Stock-based compensation costs (in shares)</label>
    <label xlink:type="resource" xlink:label="lab_lixt_StockIssuedDuringPeriodSharesShareBasedCompensationCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">The aggregate number of shares issued in connection with noncash, equity-based remuneration to employees and vendors during the period related to general and administrative activities.</label>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts" xlink:label="loc_lixt_SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts"/>
    <label xlink:type="resource" xlink:label="lab_lixt_SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Shares Issued During Period, Value, Stock Based Research and Development Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts" xlink:to="lab_lixt_SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts"/>
    <label xlink:type="resource" xlink:label="lab_lixt_SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Stock-based research and development costs</label>
    <label xlink:type="resource" xlink:label="lab_lixt_SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">The aggregate amount of noncash, equity-based remuneration to employees and vendors during the period related to research and development activities. This may include the value of stock or unit options and amortization of restricted stock or units.</label>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_SharesIssuedDuringPeriodSharesStockBasedResearchAndDevelopmentCosts" xlink:label="loc_lixt_SharesIssuedDuringPeriodSharesStockBasedResearchAndDevelopmentCosts"/>
    <label xlink:type="resource" xlink:label="lab_lixt_SharesIssuedDuringPeriodSharesStockBasedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Shares Issued During Period, Shares, Stock Based Research and Development Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_SharesIssuedDuringPeriodSharesStockBasedResearchAndDevelopmentCosts" xlink:to="lab_lixt_SharesIssuedDuringPeriodSharesStockBasedResearchAndDevelopmentCosts"/>
    <label xlink:type="resource" xlink:label="lab_lixt_SharesIssuedDuringPeriodSharesStockBasedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Stock-based research and development costs (in shares)</label>
    <label xlink:type="resource" xlink:label="lab_lixt_SharesIssuedDuringPeriodSharesStockBasedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">Number of shares issued during the period as a result of any share-based compensation plan other than an employee stock ownership plan (ESOP).</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease) [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Depreciation, Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Increase (Decrease) In Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Increase (Decrease) in Operating Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">(Increase) decrease in -</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Increase (Decrease) In Funds On Deposit With Law Firm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Funds on deposit with law firm</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US">Funds on deposit with law firm</label>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_IncreaseDecreaseInGrantReceivable" xlink:label="loc_lixt_IncreaseDecreaseInGrantReceivable"/>
    <label xlink:type="resource" xlink:label="lab_lixt_IncreaseDecreaseInGrantReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Increase (Decrease) In Grant Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_IncreaseDecreaseInGrantReceivable" xlink:to="lab_lixt_IncreaseDecreaseInGrantReceivable"/>
    <label xlink:type="resource" xlink:label="lab_lixt_IncreaseDecreaseInGrantReceivable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Grant receivable</label>
    <label xlink:type="resource" xlink:label="lab_lixt_IncreaseDecreaseInGrantReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">The increase or decrease In grant receivable during the reporting period.</label>
    <label xlink:type="resource" xlink:label="lab_lixt_IncreaseDecreaseInGrantReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US">Grant receivable</label>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:label="loc_lixt_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices"/>
    <label xlink:type="resource" xlink:label="lab_lixt_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Increase (Decrease) In Advances On Research and Development Contract Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:to="lab_lixt_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices"/>
    <label xlink:type="resource" xlink:label="lab_lixt_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Advances on research and development contract services</label>
    <label xlink:type="resource" xlink:label="lab_lixt_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">The net change during the reporting period in advances on research and development services.</label>
    <label xlink:type="resource" xlink:label="lab_lixt_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US">Advances on research and development contract services</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Increase (Decrease) in Operating Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Increase (decrease) in -</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Increase (Decrease) In Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</label>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_IncreaseDecreaseInLiquidatedDamagesPayableUnderRegistrationRightsAgreement" xlink:label="loc_lixt_IncreaseDecreaseInLiquidatedDamagesPayableUnderRegistrationRightsAgreement"/>
    <label xlink:type="resource" xlink:label="lab_lixt_IncreaseDecreaseInLiquidatedDamagesPayableUnderRegistrationRightsAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Increase (Decrease) In Liquidated Damages Payable Under Registration Rights Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_IncreaseDecreaseInLiquidatedDamagesPayableUnderRegistrationRightsAgreement" xlink:to="lab_lixt_IncreaseDecreaseInLiquidatedDamagesPayableUnderRegistrationRightsAgreement"/>
    <label xlink:type="resource" xlink:label="lab_lixt_IncreaseDecreaseInLiquidatedDamagesPayableUnderRegistrationRightsAgreement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Liquidated damages payable under registration rights agreement</label>
    <label xlink:type="resource" xlink:label="lab_lixt_IncreaseDecreaseInLiquidatedDamagesPayableUnderRegistrationRightsAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">The net change during the reporting period in the amount of liquidated damages payable.</label>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:label="loc_lixt_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities"/>
    <label xlink:type="resource" xlink:label="lab_lixt_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Increase )Decrease) In Research and Development Contract Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:to="lab_lixt_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities"/>
    <label xlink:type="resource" xlink:label="lab_lixt_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Research and development contract liabilities</label>
    <label xlink:type="resource" xlink:label="lab_lixt_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Research and development contract liabilities</label>
    <label xlink:type="resource" xlink:label="lab_lixt_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">The net change during the reporting period in the amount of research and development contract liabilities.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_PaymentsToAcquireMoneyMarketFunds" xlink:label="loc_lixt_PaymentsToAcquireMoneyMarketFunds"/>
    <label xlink:type="resource" xlink:label="lab_lixt_PaymentsToAcquireMoneyMarketFunds" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Payments To Acquire Money Market Funds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_PaymentsToAcquireMoneyMarketFunds" xlink:to="lab_lixt_PaymentsToAcquireMoneyMarketFunds"/>
    <label xlink:type="resource" xlink:label="lab_lixt_PaymentsToAcquireMoneyMarketFunds" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Decrease (increase) in money market funds</label>
    <label xlink:type="resource" xlink:label="lab_lixt_PaymentsToAcquireMoneyMarketFunds" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">The cash outflow associated with the purchase of money market funds during the period.</label>
    <label xlink:type="resource" xlink:label="lab_lixt_PaymentsToAcquireMoneyMarketFunds" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US">Decrease (increase) in money market funds</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Payments to Acquire Machinery and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Purchase of office equipment</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US">Purchase of office equipment</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xml:lang="en-US">Purchase of office equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Proceeds from exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ProceedsFromSaleOfCommonStockToConsultingFirm" xlink:label="loc_lixt_ProceedsFromSaleOfCommonStockToConsultingFirm"/>
    <label xlink:type="resource" xlink:label="lab_lixt_ProceedsFromSaleOfCommonStockToConsultingFirm" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Proceeds From Sale Of Common Stock To Consulting Firm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_ProceedsFromSaleOfCommonStockToConsultingFirm" xlink:to="lab_lixt_ProceedsFromSaleOfCommonStockToConsultingFirm"/>
    <label xlink:type="resource" xlink:label="lab_lixt_ProceedsFromSaleOfCommonStockToConsultingFirm" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Proceeds from sale of common stock to consulting firm</label>
    <label xlink:type="resource" xlink:label="lab_lixt_ProceedsFromSaleOfCommonStockToConsultingFirm" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">The cash inflow from sale of common stock to consulting firm.</label>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ProceedsFromSaleOfCommonStockToFounder" xlink:label="loc_lixt_ProceedsFromSaleOfCommonStockToFounder"/>
    <label xlink:type="resource" xlink:label="lab_lixt_ProceedsFromSaleOfCommonStockToFounder" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Proceeds From Sale Of Common Stock To Founder</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_ProceedsFromSaleOfCommonStockToFounder" xlink:to="lab_lixt_ProceedsFromSaleOfCommonStockToFounder"/>
    <label xlink:type="resource" xlink:label="lab_lixt_ProceedsFromSaleOfCommonStockToFounder" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Proceeds from sale of common stock to founder</label>
    <label xlink:type="resource" xlink:label="lab_lixt_ProceedsFromSaleOfCommonStockToFounder" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">The cash inflow from sale of common stock to founder.</label>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ProceedsFromIssuanceOfNotesPayableToConsultants" xlink:label="loc_lixt_ProceedsFromIssuanceOfNotesPayableToConsultants"/>
    <label xlink:type="resource" xlink:label="lab_lixt_ProceedsFromIssuanceOfNotesPayableToConsultants" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Proceeds From Issuance Of Notes Payable To Consultants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_ProceedsFromIssuanceOfNotesPayableToConsultants" xlink:to="lab_lixt_ProceedsFromIssuanceOfNotesPayableToConsultants"/>
    <label xlink:type="resource" xlink:label="lab_lixt_ProceedsFromIssuanceOfNotesPayableToConsultants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Proceeds from issuance of notes payable to consultant</label>
    <label xlink:type="resource" xlink:label="lab_lixt_ProceedsFromIssuanceOfNotesPayableToConsultants" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">The cash inflow from a borrowing from a consultant supported by a written promise to pay an obligation.</label>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_RepaymentsOfNotesPayableToConsultant" xlink:label="loc_lixt_RepaymentsOfNotesPayableToConsultant"/>
    <label xlink:type="resource" xlink:label="lab_lixt_RepaymentsOfNotesPayableToConsultant" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Repayments Of Notes Payable To Consultant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_RepaymentsOfNotesPayableToConsultant" xlink:to="lab_lixt_RepaymentsOfNotesPayableToConsultant"/>
    <label xlink:type="resource" xlink:label="lab_lixt_RepaymentsOfNotesPayableToConsultant" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Repayment of notes payable to consultant</label>
    <label xlink:type="resource" xlink:label="lab_lixt_RepaymentsOfNotesPayableToConsultant" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">The cash outflow for a borrowing from a consultant supported by a written promise to pay an obligation.</label>
    <label xlink:type="resource" xlink:label="lab_lixt_RepaymentsOfNotesPayableToConsultant" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US">Repayment of notes payable to consultant</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Cash Acquired from Acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Cash acquired in reverse merger transaction</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Proceeds From Sale and Maturity Of Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Gross proceeds from sale of securities</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities, Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Payment of private placement offering costs</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US">Payment of private placement offering costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="loc_us-gaap_ProceedsFromContributedCapital"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_ProceedsFromContributedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Proceeds from Contributed Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromContributedCapital" xlink:to="lab_us-gaap_ProceedsFromContributedCapital"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_ProceedsFromContributedCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Advances received from stockholder</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_ProceedsFromContributedCapital" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Advances received from stockholder</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Net cash provided by financing activities</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Cash: Net increase (decrease)</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Net increase (decrease)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Supplemental disclosures of cash flow information:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Interest Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid" xlink:to="lab_us-gaap_InterestPaid"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Interest</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Income Taxes Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Income taxes</label>
    <label xlink:type="resource" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Income taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Non-cash financing activities:</label>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_DecreaseInAdvancesUnderEquityFinancing" xlink:label="loc_lixt_DecreaseInAdvancesUnderEquityFinancing"/>
    <label xlink:type="resource" xlink:label="lab_lixt_DecreaseInAdvancesUnderEquityFinancing" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Decrease In Advances Under Equity Financing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_DecreaseInAdvancesUnderEquityFinancing" xlink:to="lab_lixt_DecreaseInAdvancesUnderEquityFinancing"/>
    <label xlink:type="resource" xlink:label="lab_lixt_DecreaseInAdvancesUnderEquityFinancing" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Decrease in advances under equity financing</label>
    <label xlink:type="resource" xlink:label="lab_lixt_DecreaseInAdvancesUnderEquityFinancing" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Decrease in advances under equity financing</label>
    <label xlink:type="resource" xlink:label="lab_lixt_DecreaseInAdvancesUnderEquityFinancing" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">Value of decrease in advances under equity financing as part of noncash transaction.</label>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_BasisOfPresentationAbstract" xlink:label="loc_lixt_BasisOfPresentationAbstract"/>
    <label xlink:type="resource" xlink:label="lab_lixt_BasisOfPresentationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Basis Of Presentation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_BasisOfPresentationAbstract" xlink:to="lab_lixt_BasisOfPresentationAbstract"/>
    <label xlink:type="resource" xlink:label="lab_lixt_BasisOfPresentationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Basis Of Presentation [Abstract]</label>
    <label xlink:type="resource" xlink:label="lab_lixt_BasisOfPresentationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">Description containing the entire organization, consolidation and basis of presentation of financial statements disclosure.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="loc_us-gaap_BasisOfAccounting"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_BasisOfAccounting" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Basis Of Presentation [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccounting" xlink:to="lab_us-gaap_BasisOfAccounting"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_BasisOfAccounting" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Basis Of Accounting [Text Block]</label>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_OrganizationAndBusinessOperationsAbstract" xlink:label="loc_lixt_OrganizationAndBusinessOperationsAbstract"/>
    <label xlink:type="resource" xlink:label="lab_lixt_OrganizationAndBusinessOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Organization and Business Operations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_OrganizationAndBusinessOperationsAbstract" xlink:to="lab_lixt_OrganizationAndBusinessOperationsAbstract"/>
    <label xlink:type="resource" xlink:label="lab_lixt_OrganizationAndBusinessOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Organization and Business Operations [Abstract]</label>
    <label xlink:type="resource" xlink:label="lab_lixt_OrganizationAndBusinessOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_OrganizationAndBusinessOperationsTextBlock" xlink:label="loc_lixt_OrganizationAndBusinessOperationsTextBlock"/>
    <label xlink:type="resource" xlink:label="lab_lixt_OrganizationAndBusinessOperationsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Organization and Business Operations [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_OrganizationAndBusinessOperationsTextBlock" xlink:to="lab_lixt_OrganizationAndBusinessOperationsTextBlock"/>
    <label xlink:type="resource" xlink:label="lab_lixt_OrganizationAndBusinessOperationsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Organization and Business Operations [Text Block]</label>
    <label xlink:type="resource" xlink:label="lab_lixt_OrganizationAndBusinessOperationsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">The entire disclosure relating to the nature, operating plans,and the entity's ability to continue as a going concern for a reasonable period of time.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Significant Accounting Policies [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ShareExchangeAgreementAndPrivatePlacementAbstract" xlink:label="loc_lixt_ShareExchangeAgreementAndPrivatePlacementAbstract"/>
    <label xlink:type="resource" xlink:label="lab_lixt_ShareExchangeAgreementAndPrivatePlacementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Share Exchange Agreement and Private Placement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_ShareExchangeAgreementAndPrivatePlacementAbstract" xlink:to="lab_lixt_ShareExchangeAgreementAndPrivatePlacementAbstract"/>
    <label xlink:type="resource" xlink:label="lab_lixt_ShareExchangeAgreementAndPrivatePlacementAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Share Exchange Agreement and Private Placement [Abstract]</label>
    <label xlink:type="resource" xlink:label="lab_lixt_ShareExchangeAgreementAndPrivatePlacementAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ShareExchangeAgreementAndPrivatePlacementTextBlock" xlink:label="loc_lixt_ShareExchangeAgreementAndPrivatePlacementTextBlock"/>
    <label xlink:type="resource" xlink:label="lab_lixt_ShareExchangeAgreementAndPrivatePlacementTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Share Exchange Agreement and Private Placement [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_ShareExchangeAgreementAndPrivatePlacementTextBlock" xlink:to="lab_lixt_ShareExchangeAgreementAndPrivatePlacementTextBlock"/>
    <label xlink:type="resource" xlink:label="lab_lixt_ShareExchangeAgreementAndPrivatePlacementTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Share Exchange Agreement and Private Placement [Text Block]</label>
    <label xlink:type="resource" xlink:label="lab_lixt_ShareExchangeAgreementAndPrivatePlacementTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">The entire disclosure relating to the Share Exchange Agreement and Private Placement.</label>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_CashAndCashEquivalentsDisclosureAbstract" xlink:label="loc_lixt_CashAndCashEquivalentsDisclosureAbstract"/>
    <label xlink:type="resource" xlink:label="lab_lixt_CashAndCashEquivalentsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_CashAndCashEquivalentsDisclosureAbstract" xlink:to="lab_lixt_CashAndCashEquivalentsDisclosureAbstract"/>
    <label xlink:type="resource" xlink:label="lab_lixt_CashAndCashEquivalentsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:label="lab_lixt_CashAndCashEquivalentsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Share-based Arrangements to Obtain Goods and Services [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="lab_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Share-based Arrangements to Obtain Goods and Services [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Commitments and contingencies</label>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_CashlessExerciseOfWarrantsAndOptionsAggregateExercisePrice" xlink:label="loc_lixt_CashlessExerciseOfWarrantsAndOptionsAggregateExercisePrice"/>
    <label xlink:type="resource" xlink:label="lab_lixt_CashlessExerciseOfWarrantsAndOptionsAggregateExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Cashless Exercise of Warrants and Options Aggregate Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lixt_CashlessExerciseOfWarrantsAndOptionsAggregateExercisePrice" xlink:to="lab_lixt_CashlessExerciseOfWarrantsAndOptionsAggregateExercisePrice"/>
    <label xlink:type="resource" xlink:label="lab_lixt_CashlessExerciseOfWarrantsAndOptionsAggregateExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">The aggregate exercise price of warrants and options exercised on a cashless basis.</label>
    <label xlink:type="resource" xlink:label="lab_lixt_CashlessExerciseOfWarrantsAndOptionsAggregateExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Aggregate exercise price of warrants and options exercised on a cashless basis</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>lixt-20110630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef roleURI="http://www.lixte.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="lixt-20110630.xsd#DocumentAndEntityInformation"/>
  <roleRef roleURI="http://www.lixte.com/role/StatementOfFinancialPositionClassified" xlink:type="simple" xlink:href="lixt-20110630.xsd#StatementOfFinancialPositionClassified"/>
  <roleRef roleURI="http://www.lixte.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="lixt-20110630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <roleRef roleURI="http://www.lixte.com/role/StatementOfIncomeAlternative" xlink:type="simple" xlink:href="lixt-20110630.xsd#StatementOfIncomeAlternative"/>
  <roleRef roleURI="http://www.lixte.com/role/Condensedconsolidatedstatementsofoperations" xlink:type="simple" xlink:href="lixt-20110630.xsd#Condensedconsolidatedstatementsofoperations"/>
  <roleRef roleURI="http://www.lixte.com/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome" xlink:type="simple" xlink:href="lixt-20110630.xsd#StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef roleURI="http://www.lixte.com/role/StatementOfCashFlowsIndirect" xlink:type="simple" xlink:href="lixt-20110630.xsd#StatementOfCashFlowsIndirect"/>
  <roleRef roleURI="http://www.lixte.com/role/BasisOfPresentation" xlink:type="simple" xlink:href="lixt-20110630.xsd#BasisOfPresentation"/>
  <roleRef roleURI="http://www.lixte.com/role/OrganizationAndBusinessOperations" xlink:type="simple" xlink:href="lixt-20110630.xsd#OrganizationAndBusinessOperations"/>
  <roleRef roleURI="http://www.lixte.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="lixt-20110630.xsd#SummaryOfSignificantAccountingPolicies"/>
  <roleRef roleURI="http://www.lixte.com/role/Shareexchangeagreementandprivateplacement" xlink:type="simple" xlink:href="lixt-20110630.xsd#Shareexchangeagreementandprivateplacement"/>
  <roleRef roleURI="http://www.lixte.com/role/Moneymarketfundsfairvalue" xlink:type="simple" xlink:href="lixt-20110630.xsd#Moneymarketfundsfairvalue"/>
  <roleRef roleURI="http://www.lixte.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="lixt-20110630.xsd#RelatedPartyTransactions"/>
  <roleRef roleURI="http://www.lixte.com/role/StockOptionsAndWarrants" xlink:type="simple" xlink:href="lixt-20110630.xsd#StockOptionsAndWarrants"/>
  <roleRef roleURI="http://www.lixte.com/role/CommitmentsAndContingencies" xlink:type="simple" xlink:href="lixt-20110630.xsd#CommitmentsAndContingencies"/>
  <roleRef roleURI="http://www.lixte.com/role/SubsequentEvents" xlink:type="simple" xlink:href="lixt-20110630.xsd#SubsequentEvents"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.lixte.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_DocumentAndEntityInformationAbstract" xlink:label="loc_lixt_DocumentAndEntityInformationAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lixt_DocumentAndEntityInformationAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityRegistrantName_3" use="optional" order="0.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityCentralIndexKey_4" use="optional" order="10.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_CurrentFiscalYearEndDate_5" use="optional" order="20.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityFilerCategory_6" use="optional" order="30.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_TradingSymbol_7" use="optional" order="40.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_8" use="optional" order="50.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_9"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_DocumentType_9" use="optional" order="60.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_10"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_AmendmentFlag_10" use="optional" order="70.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_11"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_DocumentPeriodEndDate_11" use="optional" order="80.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_12"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_DocumentFiscalPeriodFocus_12" use="optional" order="90.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_13"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_DocumentFiscalYearFocus_13" use="optional" order="100.0"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.lixte.com/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_AssetsAbstract_3" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_Cash_4" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_5" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaap_DepositsAssetsCurrent_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_DepositsAssetsCurrent_6" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="loc_us-gaap_GrantsReceivableCurrent_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_GrantsReceivableCurrent_7" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_AdvancesOnResearchAndDevelopmentContractServices" xlink:label="loc_lixt_AdvancesOnResearchAndDevelopmentContractServices_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_lixt_AdvancesOnResearchAndDevelopmentContractServices_8" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_10"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_AssetsCurrent_10" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_11"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_Assets_11" use="optional" order="70.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_13"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_13" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ResearchAndDevelopmentContractLiabilities" xlink:label="loc_lixt_ResearchAndDevelopmentContractLiabilities_14"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_lixt_ResearchAndDevelopmentContractLiabilities_14" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_LiquidatedDamagesPayableUnderRegistrationRightsAgreement" xlink:label="loc_lixt_LiquidatedDamagesPayableUnderRegistrationRightsAgreement_15"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_lixt_LiquidatedDamagesPayableUnderRegistrationRightsAgreement_15" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="loc_us-gaap_DueToOfficersOrStockholdersCurrent_16"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_DueToOfficersOrStockholdersCurrent_16" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_17"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_LiabilitiesCurrent_17" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_18"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_CommitmentsAndContingencies_18" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_19"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_StockholdersEquityAbstract_19" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_20"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_19" xlink:to="loc_us-gaap_PreferredStockValue_20" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_21"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_19" xlink:to="loc_us-gaap_CommonStockValue_21" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_22"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_19" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_22" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_23"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_19" xlink:to="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_23" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_24"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_19" xlink:to="loc_us-gaap_StockholdersEquity_24" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_25"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_25" use="optional" order="70.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.lixte.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_4" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_PreferredStockSharesIssued_5" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_6" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CommonStockSharesIssued_8" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_CondensedConsolidatedBalanceSheetsParentheticalAbstract" xlink:label="loc_lixt_CondensedConsolidatedBalanceSheetsParentheticalAbstract_0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lixt_CondensedConsolidatedBalanceSheetsParentheticalAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.lixte.com/role/StatementOfIncomeAlternative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_Revenues_3" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_OperatingExpensesAbstract_4" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_5" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationNonproduction" xlink:label="loc_us-gaap_DepreciationNonproduction_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_DepreciationNonproduction_6" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ReverseMergerCosts" xlink:label="loc_lixt_ReverseMergerCosts_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_lixt_ReverseMergerCosts_8" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_9"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_OperatingExpenses_9" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_10"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_OperatingIncomeLoss_10" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_11"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_11" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_12"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_InterestExpense_12" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_LiquidatedDamagesUnderRegistrationRightsAgreement" xlink:label="loc_lixt_LiquidatedDamagesUnderRegistrationRightsAgreement_13"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_lixt_LiquidatedDamagesUnderRegistrationRightsAgreement_13" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_14"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetIncomeLoss_14" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_15"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_15" use="optional" order="70.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_WeightedAvgNumberOfOutstandingSharesBasicAndDiluted" xlink:label="loc_lixt_WeightedAvgNumberOfOutstandingSharesBasicAndDiluted_16"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_lixt_WeightedAvgNumberOfOutstandingSharesBasicAndDiluted_16" use="optional" order="80.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.lixte.com/role/Condensedconsolidatedstatementsofoperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ShareBasedCompensationCost" xlink:label="loc_lixt_ShareBasedCompensationCost_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_lixt_ShareBasedCompensationCost_3" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ResearchAndDevelopmentStockBasedCost" xlink:label="loc_lixt_ResearchAndDevelopmentStockBasedCost_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_lixt_ResearchAndDevelopmentStockBasedCost_4" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ResearchAndDevelopmentStockBasedCostRelatedParty" xlink:label="loc_lixt_ResearchAndDevelopmentStockBasedCostRelatedParty_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_lixt_ResearchAndDevelopmentStockBasedCostRelatedParty_5" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ResearchAndDevelopmentRepresentingProceedsOfGovernmentGrant" xlink:label="loc_lixt_ResearchAndDevelopmentRepresentingProceedsOfGovernmentGrant_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_lixt_ResearchAndDevelopmentRepresentingProceedsOfGovernmentGrant_6" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_CondensedconsolidatedstatementsofoperationsAbstract" xlink:label="loc_lixt_CondensedconsolidatedstatementsofoperationsAbstract_0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lixt_CondensedconsolidatedstatementsofoperationsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.lixte.com/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_8" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_24"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_NetIncomeLoss_24" use="optional" order="120.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_9"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_StockholdersEquity_9" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_26"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_StockholdersEquity_26" use="optional" order="140.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_10"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_SharesOutstanding_10" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_25"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_SharesOutstanding_25" use="optional" order="130.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_11"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_11" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_12"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_11" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_12" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_13"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_11" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_13" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_14"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_14" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_SharesIssuedInPrivatePlacementNetOfOfferingCosts" xlink:label="loc_lixt_SharesIssuedInPrivatePlacementNetOfOfferingCosts_15"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_lixt_SharesIssuedInPrivatePlacementNetOfOfferingCosts_15" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_SharesIssuedInPrivatePlacement" xlink:label="loc_lixt_SharesIssuedInPrivatePlacement_16"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_lixt_SharesIssuedInPrivatePlacement_16" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_AdvancesUnderEquityFinancingDuringPeriod" xlink:label="loc_lixt_AdvancesUnderEquityFinancingDuringPeriod_17"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_lixt_AdvancesUnderEquityFinancingDuringPeriod_17" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_18"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_18" use="optional" order="70.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_19"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_19" use="optional" order="80.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_StockIssuedDuringPeriodValueShareBasedCompensationCosts" xlink:label="loc_lixt_StockIssuedDuringPeriodValueShareBasedCompensationCosts_20"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_lixt_StockIssuedDuringPeriodValueShareBasedCompensationCosts_20" use="optional" order="90.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_StockIssuedDuringPeriodSharesShareBasedCompensationCosts" xlink:label="loc_lixt_StockIssuedDuringPeriodSharesShareBasedCompensationCosts_21"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lixt_StockIssuedDuringPeriodValueShareBasedCompensationCosts_20" xlink:to="loc_lixt_StockIssuedDuringPeriodSharesShareBasedCompensationCosts_21" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts" xlink:label="loc_lixt_SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts_22"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_lixt_SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts_22" use="optional" order="100.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_SharesIssuedDuringPeriodSharesStockBasedResearchAndDevelopmentCosts" xlink:label="loc_lixt_SharesIssuedDuringPeriodSharesStockBasedResearchAndDevelopmentCosts_23"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_lixt_SharesIssuedDuringPeriodSharesStockBasedResearchAndDevelopmentCosts_23" use="optional" order="110.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_CommonStockMember_4" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_AdvancesUnderEquityFinancingMember" xlink:label="loc_lixt_AdvancesUnderEquityFinancingMember_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_lixt_AdvancesUnderEquityFinancingMember_5" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_RetainedEarningsMember_7" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.lixte.com/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_3" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_NetIncomeLoss_5" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_us-gaap_Depreciation_7" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ShareBasedCompensationCost" xlink:label="loc_lixt_ShareBasedCompensationCost_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_lixt_ShareBasedCompensationCost_8" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ResearchAndDevelopmentStockBasedCost" xlink:label="loc_lixt_ResearchAndDevelopmentStockBasedCost_9"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_lixt_ResearchAndDevelopmentStockBasedCost_9" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_10"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_10" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_11"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_10" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_11" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInDepositOtherAssets_12"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_11" xlink:to="loc_us-gaap_IncreaseDecreaseInDepositOtherAssets_12" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_IncreaseDecreaseInGrantReceivable" xlink:label="loc_lixt_IncreaseDecreaseInGrantReceivable_13"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_11" xlink:to="loc_lixt_IncreaseDecreaseInGrantReceivable_13" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:label="loc_lixt_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_14"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_10" xlink:to="loc_lixt_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_14" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_15"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_10" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_15" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_16"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_10" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_16" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_17"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_16" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_17" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_IncreaseDecreaseInLiquidatedDamagesPayableUnderRegistrationRightsAgreement" xlink:label="loc_lixt_IncreaseDecreaseInLiquidatedDamagesPayableUnderRegistrationRightsAgreement_18"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_10" xlink:to="loc_lixt_IncreaseDecreaseInLiquidatedDamagesPayableUnderRegistrationRightsAgreement_18" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:label="loc_lixt_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_19"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_10" xlink:to="loc_lixt_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_19" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_21"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_21" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_PaymentsToAcquireMoneyMarketFunds" xlink:label="loc_lixt_PaymentsToAcquireMoneyMarketFunds_22"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_21" xlink:to="loc_lixt_PaymentsToAcquireMoneyMarketFunds_22" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_23"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_21" xlink:to="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_23" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_24"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_21" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_24" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_26"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_26" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ProceedsFromSaleOfCommonStockToConsultingFirm" xlink:label="loc_lixt_ProceedsFromSaleOfCommonStockToConsultingFirm_27"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25" xlink:to="loc_lixt_ProceedsFromSaleOfCommonStockToConsultingFirm_27" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ProceedsFromSaleOfCommonStockToFounder" xlink:label="loc_lixt_ProceedsFromSaleOfCommonStockToFounder_28"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25" xlink:to="loc_lixt_ProceedsFromSaleOfCommonStockToFounder_28" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ProceedsFromIssuanceOfNotesPayableToConsultants" xlink:label="loc_lixt_ProceedsFromIssuanceOfNotesPayableToConsultants_29"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25" xlink:to="loc_lixt_ProceedsFromIssuanceOfNotesPayableToConsultants_29" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_RepaymentsOfNotesPayableToConsultant" xlink:label="loc_lixt_RepaymentsOfNotesPayableToConsultant_30"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25" xlink:to="loc_lixt_RepaymentsOfNotesPayableToConsultant_30" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_31"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_31" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_32"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_32" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_33"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_33" use="optional" order="70.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="loc_us-gaap_ProceedsFromContributedCapital_34"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25" xlink:to="loc_us-gaap_ProceedsFromContributedCapital_34" use="optional" order="80.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_35"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_35" use="optional" order="90.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_36"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_3" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_36" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_37"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_3" xlink:to="loc_us-gaap_Cash_37" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_38"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_3" xlink:to="loc_us-gaap_Cash_38" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_39"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_39" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_40"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_39" xlink:to="loc_us-gaap_InterestPaid_40" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_41"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_39" xlink:to="loc_us-gaap_IncomeTaxesPaid_41" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_42"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_42" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_DecreaseInAdvancesUnderEquityFinancing" xlink:label="loc_lixt_DecreaseInAdvancesUnderEquityFinancing_43"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_42" xlink:to="loc_lixt_DecreaseInAdvancesUnderEquityFinancing_43" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_CashlessExerciseOfWarrantsAndOptionsAggregateExercisePrice" xlink:label="loc_lixt_CashlessExerciseOfWarrantsAndOptionsAggregateExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_42" xlink:to="loc_lixt_CashlessExerciseOfWarrantsAndOptionsAggregateExercisePrice" order="20.0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.lixte.com/role/BasisOfPresentation">
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_BasisOfPresentationAbstract" xlink:label="loc_lixt_BasisOfPresentationAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="loc_us-gaap_BasisOfAccounting_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lixt_BasisOfPresentationAbstract_0" xlink:to="loc_us-gaap_BasisOfAccounting_1" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.lixte.com/role/OrganizationAndBusinessOperations">
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_OrganizationAndBusinessOperationsAbstract" xlink:label="loc_lixt_OrganizationAndBusinessOperationsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_OrganizationAndBusinessOperationsTextBlock" xlink:label="loc_lixt_OrganizationAndBusinessOperationsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lixt_OrganizationAndBusinessOperationsAbstract_0" xlink:to="loc_lixt_OrganizationAndBusinessOperationsTextBlock_1" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.lixte.com/role/SummaryOfSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.lixte.com/role/Shareexchangeagreementandprivateplacement">
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ShareExchangeAgreementAndPrivatePlacementAbstract" xlink:label="loc_lixt_ShareExchangeAgreementAndPrivatePlacementAbstract_0"/>
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_ShareExchangeAgreementAndPrivatePlacementTextBlock" xlink:label="loc_lixt_ShareExchangeAgreementAndPrivatePlacementTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lixt_ShareExchangeAgreementAndPrivatePlacementAbstract_0" xlink:to="loc_lixt_ShareExchangeAgreementAndPrivatePlacementTextBlock_1" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.lixte.com/role/Moneymarketfundsfairvalue">
    <loc xlink:type="locator" xlink:href="lixt-20110630.xsd#lixt_CashAndCashEquivalentsDisclosureAbstract" xlink:label="loc_lixt_CashAndCashEquivalentsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lixt_CashAndCashEquivalentsDisclosureAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_1" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.lixte.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.lixte.com/role/StockOptionsAndWarrants">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_0" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_1" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.lixte.com/role/CommitmentsAndContingencies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.lixte.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" use="optional" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>10
<FILENAME>0001144204-11-046091-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-11-046091-xbrl.zip
M4$L#!!0````(`(J!##_4-ER[,X8``'8:!@`1`!P`;&EX="TR,#$Q,#8S,"YX
M;6Q55`D``R2)14XDB45.=7@+``$$)0X```0Y`0``[%U;<]LXEGZ?JOD/7&_5
M5'=59/-^<9*><NRDVSM)[+'3NSU/730)R9BF2`U(*5;_^@4H4:+$NPB2(,UY
MZ(E%`N<[AQ\.#BX'>/?WE[G#K0#RH>>^/Q/.^3,.N)9G0W?V_NS7Q\G5X_7M
M[=G??_KK7][]UV3"_?;AX3-G>]9R#MR`LQ`P`V!SWV'PS'W\<Q(^W5;&2>?\
MN7`N<MQD$I7^8/KX;?PL?%$\%Z*'+T_(@9?DOQS&X_J7#GP)WI\]!\'B\N+B
M^_?OY^0'<&YY\PN1%X0)KTXD#'7S\M*?S$QSL7M_:OI/YQZ:76P?;(L($TF(
MBB`P/:B>B`Z+B#RO7N"GT8LV6"!@$2TSWS<N3&0ASP%8L!5,P,O",5TS\-#Z
M$_X[JHB4L/<ZQ2M0+C8/HU==SW67\W1Y=H`N@O4"7."7)O@M@*"U$^%D8I0N
M?OL,W3^.+#8Q@R#;:O@A@D_+`/A1,<M;N@%:'RKA`^M\YJTNM@]3C&TM$<*D
MRBJW?9I2T,&0<U0BCY\PI?;?"J:+P`]2:@<OUG/Z^^1)2@$7!#DD"!F`7XG>
MANX*^$&Z@,VS-!$FM/ST,N&CM"+%5#FFR;%9OTMA`<$PC(OPZ4X'WY-%0<OY
M!MLWH@(^M-+1XP<IV#'5"$(_E83ADY1"86.!J2U)W;0DN(,3+%`&'OPDK6X?
MIED&5RU<_/;E\Z/U#.;F!+I^8+H6B".">4:*WL>^CN/>$0M?^F%5#V#*A1:_
M)-J^/_/A?.&0>L/?GD,W15S?A$#E58D_?_'MZ/'6[>1_RHL%\A8`!1#;<M=@
M+C9`-F[7\MP`O`0<Q"[N>O/OW]4O'W^7A,D-L";$06V`[TI@WP^#]?:WW:_0
M)K]/(4!<J-PAL,CPU[?_./N)Q_:4)$7@E7<7QX4C41<ILK:2L#[0LX_E8QNC
MX`:[ZI\(Y`FO3P0^JF7_[*@0<.U]$4'$5-@+MF,%HE]CHJ.?MO:K:-+?'P-<
M.^E&/_YGB36\]N8+S\5_^E<OT/\=_SGWW,?`L_[X`N9/`'7P"?:6!3,"=/?S
M]H&-8>#.#EHPV&#D;(C?VX02VU[D,E?-LY^BUQ+ZOKM(%;&'=I&&[96SYLI>
M$3_C_^K:`&W>^`1=_!,.YP9-(^(C+XNU'TEU$JEL&."/83KW)K1OW6MS`0/3
M&32?HM=R=1_9=`*;'D!@0A?8'TWDXG;IOPH:I2L]\B?DS_72#[QYC$)J_\)-
ME0PC>*&*5=6VK3I&G`Q&G`,@SAAT,AAT#H)78]S)3MPY`$*-H6>WH6</**3U
M+_34JEM5:]NJ8^C)8.@Y`.*,H2>#H><@>#6&GNR$G@,@U!AZ=AMZ]H!">O]"
M3[VZ5?6VK3J&G@R&G@,@SAAZ,AAZ#H)78^C)3N@Y`$*-H6>WH6</*&3T+_0T
MJEO5:-NJ8^C)8.@Y`.*,H2>#H><@>#6&GNR$G@,@U!AZ=AMZLD<AB>P5YB?_
MLW1)1A/?N[A3X">\7,VDI`C)5FW*I.H`3%J1I4V;],K__6ZZ]W,],>HFRS#8
MV.>@%4=/&K//.-)A8Z3#+@7&,0L;8Q:6&3*./CH=?;!+C7$<T?HXHCTR'(\J
M>Q)MU0]A6QVKCS$:*S':T(@S1G9L1';#X]48#S(S&ST$0HU19*>ST0Q2Z'`V
M6NA?W"E4GXT6VIR-[J=)J[*T79..<3R#<7S?63,&\0P&\?TGU1C!LQ/!]YU-
M8_C>;?C.'G^VRP@]BS9C,^M']FEHF64,'5D+'=FEP!@'LA$'LLR0,:AC99F>
M,6J,$5J7R_0-DR&:;N]9M'6P'[KZV;?MA+"".+E:SOICU$/689,VO%.(-[;V
MZ<E-%'O[;"C'&PV[Z)[=U'%@GQ9VFL7X,PZ!6!L"M=Y$1@HP2`&FO,`X"F9M
M%,R:DQ@9PB!#&/,AXSP)(_,D[#F/D1KL4(,IKS%.H74XA<::GQC)T"T9VLR!
MZ\FE5S'[J"W;9QRV,S=L9XP"XZ",N4$9<PP9(V]6(F_&J#$&6UT&6RV3H1_7
M/,7LH[5LGS'88B[88HP"8[#%7+#%'$/&8(N58(LQ:HS!5I?!5LMDZ,?%1C'[
MZ"W;9PRVF`NV&*/`&&PQ%VPQQY`QV&(EV&*,&F.PU66PU3(9^G&53\P^1LOV
M&8,MYH(MQB@P!EO,!5O,,60,ME@)MABCQAAL=1ELM4.&GEVV<G"4=PL)XSCD
M[7>VID[#/DL7;HSS^&PBX!]98@Y,?XG`3]L6$+X2518]BPL@M:76_NOC34;5
MT/=D4=`N\1NGUGP/4(C^2((-5]CLQV8D!;\NYP"9@8>.O4UI6'%#I]<8$W<#
M7&^.@Y-<@44F/I:8K#1Z&M,[:3T;P,N/(><>P`SZ`<+$^6K.`;?EQ@.8YIR2
M^?GVMV\?N0^W=]\^7O_R]>[SW<__XGZY^WQS^_7GQS?<[=?K\W<761*.Y5]C
MZB/3N<4!W,L_P+H<@'C+RJQJ+^EZB1!^]@GZENG\"YCHXR8QOIRP2>2F\ZHZ
M5NL3=`"ZQ@]F'BJIU./<='`A[@$L/!3@GHDC/9CIKN,Z'M2[%_H-F38N\;B>
M/WE..7$D?M[4?%`X\7WV0ZZ-;[A;!L3/D!*<#2R(4?OOS_BS5*G)$P,X0L+P
MG<C52(JH&((L'GS*'*E[A#>>M22=\;?UHN2WQ'W*/S=RXF7W-5[AGVSR\R?'
MG)6K<HKU!YLZ#THG8=Z'KK@2]^)G.F16E92TH>?FI4_X-[^<M'^*AU(2U61)
M(@VA@ASRWS1)NVHV<G:C?M-_+DNU^,4<>ZJ%_8X@&+R!Y<:KK2$HIM"1($D6
M)9F:G-ADV;%"BBP936B4,)TB\JI.2TX\XCJ2P^?)^(*#^?47$_T!@D]+U_:O
M@FL3H37V"/]K.DM`@R$J_I%7]R`*1#:#+YM8@H3QZ<:)^&YPO^)#/!KR?1#X
MVXZ,@M44W!O'/ERJ&)I(LNU3#<7/)"3Q'X`%X,I\<@`]BPB"*NO*'DR&)+IP
M2IDE%\G!C-J=^P!\[(^MYRO<RX`5<+P%\=1$*C*MX!&@%<3OT3`7:77O+DX2
MWP;R;,NJ.`A5:R&//LP]`@L3VA]?%L#U`2YY%SP#1+NI2K(JQ]Q;":'-H<RV
MJBA*AE(#)6VK"88D2&*L_Z,N.\?EX^$GK\D59#>G<"UIE54\DF99WA*[KGMS
M3?P69@'^!2V!_1F:3]"!`004O[BH2W*,@16$-X\ZVY`ZKQE&#=2A&\MW7K&B
M%,P<.?W2,AO%F6-80U'J8/T,_[.$-AZIX>':W)R!Z).$JU;1]`A9IGB`LV<<
ML\P0".>Q*9A8D_E=WWHJC#8UR?X(]#39Q8A+\,V[FTYQ;XS\.Q3.-CQ[#JZ"
MHBLQ1$W08G%IH<S&,&:;MB;&1ERP8"B\*NY!%;G:1CRJ)&F\JI8'@4.5*<"_
MVZ'-:`U+^8-8Z%@`/02E1A"%"&)3=[0,("E\?/;A2``E\3DL4$2UK/B,!>=8
M(1I.755%18EW]852&T.9X[`UWN`553@=9JR#?0RPF_^():,%@CZX`5.R1HL#
MFN5\Z80=P1)!=W9<@L;TAB$:.B_$IQ;JHNI,RYR1K"KJBFHTIV6\%]FLS]/H
M)#1)%>,..BFE`125-^7ENC,6()?81);=(["A0-X>IR+WR8(&&5MQCJ!/$MZH
M0>PY0W9>Q]%X.R2N<2%,;C_.`F16VQVE^S52`X*VN4NGW27ZQ^:PQ\^/[]3K
M)N5/!%D5Y9:-4+?9MVVTNG@%@Q?9,C&K;HKF`<A=*$#K?%[6C5\!^T1FC?SE
M.@C&;%ZR5Q-4H1UW'C\Y\GA\K8B*VC:(NCY:5)5VAW`TCA/LEK+U3KM+[+`0
M=4%@C#5EAW":+K8\`<!KB;&0IAHMC89JG--UW.HT76(+,O.MKMZQ1PFOAP?]
M4KL3)Z>>SG/<ZD115%6C9<;K"1B2*"ERRXV_^I$MB79GM-SN*!PQTFV[JW<"
MQK&S%C1!US2V-"C9[B39T$6A9<8GMTJ'.V=;&5G4R=X__NZ\TC)M*62;'UM>
MY`_W![.A1H76IPBRIK0=>)R8N9N(-7G94*I,N<9V.%RY=C.+=L>["XMD-H2P
MPH[$:@@/MTC<FXCLH2'KI.%^@2A-,893/LF2^WQ'_IPDQ&7MT<@"T"CH+.,V
M"7J3*7:U#)X]!/\$=CVN1NEI`L\?>;!\J8T@3#5G<PAO?7])RWX%L#:BJ$/*
M-=@)D&)]=0<-NH3TYN!6;\IUX#;;B/E4D/D-A`:X4NV7"CB:35=2>$T3M/2]
M=Z7:"OVVN\\6KH?IA#3FVL9*)#%315?7;)GH'L`*N,LR.^FE@TS?O(VL49VG
M2E);DR0=92^WI5.3DJZ7?N#-:PG[&;@`F0[)*K'GT-WNN%^!;9I6;:YHJF[$
MV%H@CC*V`G:)JB)K?%?@"@@IB)*B"VQ8+IG:)TB"H74%KICVDBX8O*:<"/`&
M+!#&$&:>?/7<!?+LI47^H.DY,X50PU+>MS:/I;SW;=LNW6(IIC(Y[:(RHO3L
M-EH^790D@9?C/4N.-*K`"B@M&;(1GU]O#U@!OT51/E@K[LIB"6"RKN!.L`M@
MQ<P7-5Y7XN/1$N"VN9TK@'SP!:`90->>7R:]N=AQ9U1=4VZQDVY&;K%#;D/?
M]N06TVU[_DFN^(B)=PMR/AP>86W)5Y]@$F\8\67MA(3:``J8IJJ\+&M-`BB@
MG"1K6OQ0G*8MD,R=,G0]OL9"'T`Q"55%,P[.G"D+XM:UO#GX[/GUJ3C)Y.)>
M"`44!7R<9!*2*HH"4DXR6=F@+9(H,JE)%44Q/2?9_,Q"<NNN@!^0CGKS!HY:
MO:A,?:\IQ=9S\R31Q%1`W(-]06UA*O*M6M=F2A[&T<&7*Q-S2G%V5P$6`(3?
MI37&XN,@#JJN*;?\K`!=N>5G`)K4MSVY);@FQQ/14J6GGY)2_Y26DJ.=RI*;
M15URK,08ZI(C+<90EQRG,8:ZN-'E'C]4[=RAKR"H'./EY60>)O$<U$Y3,,4\
MS*XPUMHVW!WHTW+_NL)[6NX9/;116\Y..9LHJLCK+0EGLME4ALE(RSD!=]>-
MIS+DLEM[V^-P(GML0@XXEG6]'>G]:$&-IHIUBINY%D0I):Q-$B<SP011$Q11
M;$=Z/YI0HUE?G>)FK@E1RNYJD\2)I*Z)H"C"P4QND]+[T83H)W"Q@INY)D0I
M1:M!$I=8KU/51B07KM$IAAX_J[RYSY0B7-=Y46F%(_7/BF0#)J->@^ZQD&Q`
M+NDUFN-PF85MI9$>O\1BMJ8V$JX?26:RT5;#R$B+K0JZZ^9:#6_9LR,;XVV9
MC1?'!U?F2(_TB)+T/I@^M,BF2>@L@X,$+O&$@&.?+SCAS^/;,PO$4L:8&YH<
M8A2[PICK@YFT8R[&JG8,%]G^#Y`U-&!?K69?EZ1=W4UC&6J;E+5LT)4CXF0:
MWZDHFM8AF\`['61)-\(Q!:LZ9!,\_AV,'GV'+!UT0:?S':+F`FS2"P'7#Q>:
MR1[C^GD9O$(N+"T0TPB69&(!KXAZ%2SIF_O#Z&Q;E(*%)H)&+J,I+9`ZOH(!
MM:`+HM8EOM)I`9W;+GG[D=[IERV.X615X7?MLP&,#R"\Q>/>1&5.SREH*4J8
MKW22[$9A%VV^911V0;M2Q8*+Z9BP=DJ.LL(SB;M$AC#?(%,>2):FC_^!XX%[
MY%D`V/[=]&=O!9!+GH?7]U+,23L90UN:E,YR8UZ36ATD4YJ4SL1C7I,R6ZUE
M63-H:10-@FF<0%-CCC+[Q)J"@V!HG$U#!??Q639-X:9S"TG*L6.-&9K*=MW=
MP50&+V)^J&WBKK-?,L)-3N<7A8,C.QO'76>7V@ZWIDMB.PV2RM:@/6ZC==QU
M]F/L'`FO\-5PD^HVQXMM[CR\!PAZFY/MOH+OX9/Z._H%)7%>;I',-F`V<*]1
M#]2J?])X+Y2L=T5/#U0\[1H?*HIMG$HG#2^G)R^%M?R'N[(P-C]D$94<#54L
M[07CHML#7-<=RHE;//ND7F-ND5%M*_A'5>2-XSM2^J0L54]96</M<;?=-<[(
M9<K8\PJ)2S?*`#Y>*-L>2'OKWB.XPK#N'=,*L7T%P=WT;CH%I+:*YQ%E>TY#
M-21-C"^A50#0,O;Z5_HJ@U#T)'<Z"+TK.%9,;%[0!J%W:1_;`UT3V8$*N=^C
M)]AK#VKY82@Z5`=$-;L1$UL<"+&'Y("2MWWQAL8K/0%?^W(^N1^Q7B.9:8/0
MN\J]M[RAZKP^",4'Y()2-N3QNJ;T(S:HGZ0F*[U@9`-I;I/=]8:#4+_*7<"B
MKO']Z'HHY=PU_I$[FNB2%$4I&]8VJ0N-%72#_*_<E%"3JM!8G"8G_Y?U+`WJ
M0F6GD:R0SK"R+GG^.#X%2V7,<.#(RTIN"2R%A-0>JE7CLN%>:ELM^;6'*E;K
M9T_0+6\E*CN9B,ZJ"SD@-')PI\'H1A%:OF5(2M>8BQB4%:HLS@R4_Q7'!CW2
M/+%NHQN\:LA]U*3V'*HR0*U?AQ.CNL!#6H!J#-`*P_5BB8,U)44S=*V/FKS&
M2*R1(S\':(4*3FRP#6"X3BPQ&Z7)BJ'W4I/:&VKZ&(HUN+8]*"M4\&*D!:A#
MY,)@O5C*(KC*:X+81TU>82C6S"&P`[1"E>TZ0VT`@W%B1=><QT\CZXT6K\![
MM7`:[M!,4,%O#9+VC/BLS>X'=B;`=_M-XO?8GXJ]&_5I;+<1:*L?V^22)-#N
MB+#T,X7HI>+PNJ2F;+LY#5'GZE'KV`9O"CJ[Z8=JFRHY/Z^J!9V^$[:?]DBL
M'HF"Q*O"</2KG]_X:FSQFETFU04HTH:4U].&7IO/3&Z=ED1C=]G``/0;H\QV
M<S:':ILJ$\6OJPF],I>97!E3-5%,RYWKJ7JCQVQA$>T5V*;**6NOJ@4-W&&6
MOJ&E[YJ]6D?9VGK=T`U3)27GM30;!KWC=JF(P6F]W8)7UL$5)ZIQ>+KG#;D5
MPX+ATAB-:U[2ZJ4G,>T2$]H2BR\;$0S>*"/WUK40P%\#DR'\_UL7O^OY,+@+
MG@&Z\GU0O8GEV;R,O.81)J^VW:[8=@VS^,.>!#)LE\G7P^MD'H`%X,I\<@"U
M*Y0*)36)*OEM!4&5=:4;;*4^*`5@491SYV:Y53=`IA4\`K2"5NF#X[._M2X)
MV<BKHNE4M<0742114?NJ6S'A5$FBKEZV2[I'8('#RQLP!0CAL.J%['(!N$Z:
M'<Q$-A0]SS&60=&%)BG.2A05H1^JE+CR3)3("4K-*G-E6=X21ZOWYIJX25P8
M_X)P\/D9FD_0P6,<"NYNHLI2;M=;!D47FB2]FR@K<C\T*2:8SFOQ^Q'J*)/A
M#S]#/"BR\0#)OC'GY@Q$-873"0]@!GWL#DE<_4`NY/:O9@B4/!WKY&#J5$A,
MZ%DA_NF9GL5L)<>:M*QN?B=.TT.*!L]KF<J5QM&--DG'8BA*]J=B3IL2GI*F
M0I&__0J":]-_OD?>"MK`_K#^U2?'\-TM`&&J.[NR`KBBU`$KHB%JL6L8R\MN
M"W,RF)-T0]-DMC`74V4B:;QAQ*^KJ8H[9!EV7X1$_C<OO-`&@2^>"]9?3/0'
M"#XM79N"R^$57MBQNE!>D]B21A0-P]C=,-(RMA+S@Q*VIVY4@Q?1(?FZ:3U#
M%Z`U]A]D$GE!*P*J)K$-E'D3<EVBK#HE?`K6##=PZZZ`3]O=[]IV=>%M@4X.
M=[=-GB7()=P]]@48N7XZ[HT/V=Y7_@EY\T?3`7?3V,K1-P_C\9<.*?T)HCFU
MT5$EJ6VAS1SC,(*VQ,2-TC#D3WA4CH<U;?%@*ZYQ?*=^^>;PE>@7]G=+5$$9
M.0OB*;9=B$W*Q6XOI!D!Y(AI#$]>7]\.GA*S^8=WVY:&=?RI<:__Q0R6"`;K
MN^DF\B.3#X_`(K_1Z-)WUYB<#*%E#7)#/>:P%U-%D21!T@UZ2FQ#R+OI+L>9
M+!V=M"VG3/"?)J<Y1&4"_:81%7]3658%63L)6>SCAQ,]\&D9`'N["XSJ]\N5
MU"2JLBVX:53%W]$0M?C(H0JXC&A]M\F1XJ@LX<++RVX+<]+K\:P!+N&I>5D3
MXZ/U4V&'X8!KD_\C8_H5=O)D,2S<CW<\"UQ_S"[(AF"(TE$T4E)\>\"3(V!=
MUA6-/=C%1)%D49)I`+_%$A$>W9.MP'3W^^WKI2<Q?U<<'8DE!LFR:I23:WES
M\,U\(4MZM,U[4#55N05;#RG*K;KK,2DZ'+TF-S&E[?FOWPD>7`Q43FCC*#,G
M'CK#5V+BX61#1ESX8/H0A[K;31X$5AE+_?0W)WAKP]7?9L';Y#\Y/U@[X/T9
M*3HQ'3AS+QTP#=Z&?T,,R0TN^05YU5\XYOKRR<%Q]MNYB6;0G9`WPZ?;OQ%9
MJ@]_..,B&5,,*Q(250)=![H@?#29FG/HK"\#.,?!A`N^<S@&--W-,Q_^"2X%
M4E_XYW<0UO_D.?96@'#.A4;AO"EWC]T11KO94_[7OQ#9%Z08>6_[9X[JF:KN
M-7E"W,6FLM3J*AI54KNWZJ:^;\^`$,DF>]%L\B_?<S8[,[CIAH@XZ/>CK(G0
MUI\QA0'W`7H!L)Y=S_%F:^X7_%E("LD;#ONL<\YT;0[BM[\_>XZSGGC?75R?
MOWSRH0U-M'Z35L>VZ`\!1O0W<[YX^]^Z*/)O28J&Z:YWOPAO?^3,@,,,!YS$
MO^$(S=]P4P]QI&#PC`#@YEC39S]$X<.7Z$^`M;0/"X:O$,?W)OQ75,LBC"*X
M*;8;=[6<X=;-&:0`KW`_0-Q<%X1F/W*!=U3;#]9ROG0P"5?@1UPC`M@+F$L;
M8FN>8^W"NKT%=`E)L2'Q1S%GH5WQRX[#F?:_L:B-G8D<9TELRKD>PMZ'0V1J
M@J28Q-_[D7LV5X![`L#%U=G$`-@X1+(+L%OQL;$)S,6F>7!3$R)G'>+8?]W_
M;^]+F]M&KD6_WZK['U"^GKIV%<3A3M&3294LVS-.QK;>R+EY]WU)@4"3Q!@$
M.%@D,[_^G:6[T0`!BM1*4D@EL4@"O9P^>Y^%XNCEDO`7"7'+H=,N`1H?@,&R
M@'$!#SGBJW%`G?T\!HF++FB*UC2(KO-E/MFJ6I:.)]#05./[J%SY"SE/HLX.
M5D?'&J7Z:('(X6G/=VE0=7QJ/%C`1%CB^U*X1,TPO&--,\"SJ9^X<.XKX<0M
MJ\@`)DZ`\LA*YD*D2&<@JB@3RNIU:!]M0+B$\0TD%DPK(9'2,(0X_PU'SDA?
MR4):F_GS8W#KPV/1!@=&7(Q%0"P:L`'>SUG`$F.,8_AAF<7H#4L1"P@ILD"H
M5V>$A4BN$F,,URL^\?Z[.W?"&3&"A9\DR!K*7/GR_;G)D5L6ZB4QLJL`&+DK
M8LPL!.2<(N\BYL(D%*6X9`M`X@91DL6X>V)OA,K(\6#Q\&:E[-&[@P<<FH]P
M]=I/Y]9,A$!0.`S\`C2(Y)*K2DO@FZZ_#`K`BA9^FI9@E63NO!I81"F)J%Y9
M,H^RP$-Z`[V.U@<D]4<6NK1U6F"1YY;.,\(0\`*X3&`83%D!O3/Z*;'.PC"#
ML7X7RRA.+7CI`[QN==HG?]?,Q"!UR>+6"-I&1C_U`_A-+Q2.=R<R+7[*#9@U
MI=50OK_$,R?T_TW;!4/^;98`=23)%RU-O@(UOD7"NP=-]Y9_'K:"W&TQNG2&
M[9\L$]R$<PK@5@[Q`]"<[PW:#$+\^PWZF7WWIWN'OPGR(B0JX7);>;B_>,GC
M;8-4!RN<OX2FFM<>;C!M@-&B(,*NW6`3S46`S#APKE&M`V$&3)R)\Y4A9VFP
M@NT#@D$^"PP;GBZJH#8I88$@^0?"Z$K$(+,6(IX!QT]C)TP<0R9=_O[W"VND
M#"]3O,,/YJRX]#`*3V`$,DF6V00H!K5$4">EVF>#M2=B,5E)"$R$ZRP$O%AC
M!*+V@?.`+ASF4FFDP$AK@P%(:*'^?@Y*A3]%99=4W8^A"3,0W5)IP4=#G!B^
MVL)2-7>M?BIJ-O\(`^22K."2[%%*-V`'">YK/Q'JW)&SJG%(84>8@-B?@E(/
MY\&Y7[@VAX?<:.FV&JYQG%P#%#5#&8Q)@6.Z`I1.1**PZ1JP!'TR/MA:B#:`
M,(96ZW#P2ZQT1$GFB(+&1QQ#OJ3,P&2--Y04>'Q][B=I%/NH/M9IX](N910G
M;$_GL'SM)&+K,L';>>`!L(?$T%\M0>Y.*Q&N\CX0S6O[,A9I'"&[N@)^B69M
MZN@=`-M9MX^!JH#"`ABO#"DQG>*WVD*N8XL`!F)H&+'@)$F$=21,O7@30P4@
MD+5-=C3L`1AUAL3>$/&1$O%7PU?F%^C4,=FZER<9(?G,M)_$8/061S@2PL!C
M!N;"&Z'GQ%Y"9IJ?$GF@$V@E4AP(AG5QQG!%R!EFXH1-87H[=\W9EA<)?I,L
M8'S!](BA#\=\FKQF>,&_%`1WBT+X)BG]("EW"JO&68#NF$.(DC^P0?WC1_V"
M1\*E$%KF^"1X`A`BDF<KW3%B8?7EZSF8H`&HJB`ZWD:`X@J=\:%+=.&00MCM
MDT8XDB1";MO5`JPLD\9^^_A_OYIZD_4Q1>R5H@$]WC`YZ\MJ;H[YLUXY01+=
MH)A=^.$WZQ(]H@75\,85M2[^WBAS#T4,!^4(T,[^BP`TA@81MG<P'1(K9(%)
MTI[N[>#%-!:.O-%#'CC/8!R0NR`J8_[F>NZ[<]!WTY192>PLR0^/=X>@8Q+S
M"H7P\`:QCNMZ<38CEWH$VND*N%Z$]T.XF@D6GR/1#;\*JO)GN4$FZ'9H"68Q
M*!F@U=-*`5Q"+I,7:"Z>393<'>USA!69"U:`KUJ3R".;/O!3Q/8,O1IS!W.J
M05'_-^D):)1$H)]G\(9UY<2^`V/;$@;&PZ((*'UWNG022@\$7DXV"IK7REJ`
MQ[,02[\)CZT!T,6!UMB7;GT+H^M`>#.R329^Y,[%@DP;3Z!ED*A]R9V[(@@*
M\`8K):#G$-;FR?$J'-+]?<H8LSPG=:PDF\TX@XRO9.&YE;5P5I;#I@@9*$%*
MZN+22>?7SDK?QQB+('4+7YL(:P:&$,A69XKF$)P?P2@I+U-\H\-%//+P-B3&
M2SJ\R8-9,$("2WDE:9RY*=V^I/,XRF9SF,<)5C*8`M=@G"+\,R?D!!`G<.R"
MT(B>B[+$P2Q=^&",218:1VG"`F:.'\*Q.;``,'+Y[,T3D+N_X;[A$)E=[GTW
M_/#'R`$!;9SE$HWU.1%DP)H4XI%I_2#*7$?`@,"T%H0T1$VVM9Q'R1*H!"-%
M_7#N3_PT`O[XZN(K?'/BOP;C120`!3+&)ZMRE`)^_.WM2:?=!OR/?1X:C2S,
MX9*V#'DS0ER/XPK8=WFJ7]^=G6\[4;=Z(J;$XD+(*$PX5B($]AP8=*(8']EC
MQ-XT0^:[^ZD?)ZGD3'[,<-/>G<`AD3$#\EV28Q+)S-SU#8,S,X;QV3>B`PC0
MDL6)BGP%3]43H-M3819R10%+"?"R4T])K#5*YP9LF%LB=V0_CL$-)H`NGI5@
M=$*<+?#AHG#$.U3R+F<!<2'<MWH[03<,[F2UY'G67G5"C-B##7HBD%N)9=T/
M%(>(T20UM8@C:\4/_90]/C`$NJ%SS\]GA^L'@R@"KIYF[(3^++(8W<J^:[WS
MDRA&%Q>M]#*-HV_">O7YX^=WEX!6ZZ_3NG\5(`/F^-BORIQPZ##],$,F>QY)
M8QI`I^J6T/A&Y1(KK]OSZOSWLW=GKTO[A8.B9:!"$#!>OXM;UO^;BW!&BLK_
MFV=..$,ZX>"34"Z6O&YN-`N!X!$DE!(]<X!@M,=12W/DXNQ@1Y*@@^!E,$P#
M$`INIJ4+K9-`'H4Y)DKK$?>7A3[>A<,*I@ZFG4QBC"=(LP7,#6,X'H:XV-8L
M\*,)8&L*W,E:8'(NO@5P_^7M)PF&ZRC^QB#X5?I.KD%4IWRO()F4.7MI)G?N
M!UXL0MM:")@TT-,Q6ZD80$KOPKLAXHEZLV6]!14F2W3$#G!.=!NBM*2H,&3X
M&(^P$&`MX,Y@EH4`[@C_1>5(3DHKM?&(V+64>;Z*;Q`A^9@2U/[PAY52OS2Q
MT\VOIE#)I44>Y903!CRTC(&:0+,T8).H510>5"O>`V&^T]WU#I)SDRFVC<56
M-/P.6^X+=-Y'0`8LFC0ZO6(AJ5B:J0.4A*J?Y'<-M=*Y97W"9T%#B!?P>Y:2
MWLA>5&4LD1O',+YX(4JBH:!@@F6I!=1*FH@>0OI$+5(#6)FYDM3@`G1HP@QO
M^0#_2<:Y3B*2:FIQ:#HRA58+4&V0'-Z)9`D:-:\&-0RZR0R):2Q%2O&7=@$R
MU1(7_:N\1HYC(B&ZIFLOV+O+1AS*2)L?)S8$6TNEP%<O2A6)89#Z)],LG,&&
MU<]D?SFRA#ZM,A&&V*?W`F"K:?3==VFXA?--<IP%0)P*:^%\L"2/@HL9<@9>
MD,<.P`X2*^&=(CHH.$HQP]8>T`G=P3`K0_6.>1K,5S`KV`H621X2B_YJO%%.
M60EB,V>JV3"J&W2)+<T=L:*W#&LL04X>7PGU`?:`/G=+PHN^9:E3!^E2C&W!
MC%?GJL,KC<.7\A8@!YB;39`Z6+FQDE62BH7<Y<*'S<-O?V0<]\L,F];%H6TH
M<5TW8R4I824%S_XL^#?HF`L1%QT+?H)I"BWK0BF/?#DH*8I%P_H>T5YE9%HN
M`XI.Y1OZ*J6/(]]<L$*!R!ALGE`W&%="+2&QK3P@^L*)`;V2*"PL]AT_R=M9
MK&!O2]"`K=^<E'3%2S<0<806[JNSWR[I['Z+,NL7,0<^6370Z\9A^\QN+Y2:
M$TW^D"CM<QAUS/<6HFCP*%HN6GP8B:(D1AH#R1#WQ'!=M"C&?'_F8!0^!U^:
M/!^HE32V;`K2P:>`?2-(((FRV)4S.#&N,TNE_BCTE$H-9)\ANV+",B'B2Q]`
M`2^,Y%@7<Z2?CVOK+QN"8#<X,[KF1'A0W$)1-`/DLZF#5B[G*<GX("<?.3?&
MC!@Y*:&E/]-0&ESEW5IB9X>`O8G`P.2TT@)C??Q[I#X;#D5'11@@9J"(DTR=
MM00`0T0RA9E'$;@Y0(U\BFA"\<T(0]856**H^]AZ6#8LY3A9RI?0N++LC&R#
MN+7I?\XXESL0L`0XL!Q62+Z2[Y\H"$34Y_??O[ZV+N)H%CL+&#KT@9#/O"MT
M,JPX,#]-`5]?79Z=O\[U570>!($S46%QH&U_/O^8>S$4%1?T6@'8FVD*86YF
M$[O;H*P0C19<7Q0"84Z.7D'02`)!NOT)WT5H/R&0#WNH>(&4EA*3%1U.L;*7
MHKLBD]6\EWP\!3<//EGC#[!OLO*5/X'('PR:S$W9&\*^"_%]&>"N(J)^4'+9
MTT&6=<5*6M99FF^<?2H`XX27`2?&^XW%B00]N0!0YN"_LQA-\XF`E0L=5$+A
M7@D:#MK*T"VM0%XL*0.`,Q8,,4&:FARZ83U'RGI,Z3P1@0]R,U'&(HEKQQ-_
M$I)-V4L;PK?LNE*(8V3PP6LJ"BE`"5Q0O/,`#=N:@'S$:"(9;TS?U8F]38RD
M1-C:K2:]H.3MFL5@7:+IRW=8%BYZ&@&MR^LQ/^1THS0Q-1TV,@L>36VN,*^K
M\5\;_`;'+WC\;6*FJ!R`A2.#GTAM,PERRAYX#.$*<F6OVY#@LXT`^25B=SYJ
M`$TNR/%SXE)4W/;Y]85<3AG7+.]()E3L0'%VTJYFD2P$@6BE`RDP2P&8,OG9
M.&H9;2:MX3G<\X;2LN'+9.KD#-$HQ"]=3C+[W`6M@F\L)C)OK&@7^OJ%]7A7
M=BYR\*ET[11#5M?B3Y&K(I!8&NC(54YFIA]!>$5J1M24P'BCT(9IAK>%%38K
MZ=H<+)MGTD<Z,"N(R%>(TX5B)A.J]:]&I&SB4YRK2O2V]>YD"*PL?!#%W_A%
M+IL6"PK5YS-6,1=\-FHMB1,(E5*?A\;+Q%Q0*3EH'W.[[5IABB2A`G9C:J/!
M`2:<KF.$%:.*3<YL7P?W*#2K&I<2OV]$7IO@H)T8$XQ=)OW9BS*,')XHF[IJ
M"D:\54'T.VLXWHC09\8[MT.+8JAZMHRD,IB_O*:C*<J4ZB;:B@O*S+.P.#SP
M)<#@!-5*8BN:4>'CH$1.?8ZD,F+=:\/S=F'_P->0T<GL;^*19E40Z>2'HY"L
M("^^`+2%Q:*DJIU@Z1&9AD_\HZ&;XZ2;L[52.,5+1.\VR2*<!J7O<Y2\*M8S
M,?*TN!B%="Q7D8"N:V#G$A$(4J9F@?!1Y1:,$!=3CW!TS4<2A'B5M7Y;BIM$
M8U%J&/>:XD(ODW&H=LM1*NH3Q3:RTZ4F%<:ZB-&'5RP+@XFN=3"CI1?T!DHQ
MPQ5Q$(\C:X?E/*`:]#*N:#:+2;&!W;P<=^U19]0PA6,*PU1!1:7P"NG-`;FF
MKFW\L!`;YH3214'*NHVV!;DG`_\;!1H[>$5<B%EP%JA&DJ3Q.=%:TBJ1'$A'
M\I]*WTN`<=,9NUZ`&E*DR27+SJEE<!\E8:L)O(#2R@+![66A6F>)\BNEM[)I
M,(E;!1%B;13)#?#B.L2OV;YH6>_Q=M^?EF%*@YH3EB=@*T0S3E"^,;X++ZU0
MB*MD=')OQ_HI!3@T!!(5WPX`QVC-$/.2DBPFSJ("RO62Z+S@J;5U.5)7:>*Q
MMH_'.BRJK]6;\R+-*D@)Q(CCDRP`RB,13G@C0Y0YE%E'GI9R2LH"64KM>J6W
MYBX]#X2?K5V@1M/\5P.[_WO-1TP[@E7$>/F"<27Y>S7^9QEU)OC2'O=>]!!<
M2^^$(B#T%G@Z7DLEU"2<'*BO?SFB1BT?YD#J+BI)G%5#O@RC&,]9@"[DV7Q-
MA2'='S$,6*U4U.C.&Q@O3`H,S0V$CKP$"UN5YY+^=0E.Y0!G#AH1F],!4>3F
MH80=>665RC056>-N0?:ZFRUT.4V5$1*%LY-4T-6<,JQJ+N>T:IB`YJ521R(@
M!9^CBND&WD=GOG<+SO3,JW66@D5>#MIMNPW0!X3\#&?-2;/M]MBV7G;LT>G(
M'O"/?W/"#"DRKVAHOOI!3&+S9T`8TTUE.J=RKQ2INYFLKZBELJFLFPN6F;:N
MH*J!+[O]OMT?C7/M]2/?U&!!,Y*FENR[+J-(<8[_`XJ$/Z5H9N.^'".V))_Z
M)48%9<GWYK;B;3)?Z66G.[+'XSXJ^AI48UG6D`#2Z0SM_NF`:JE)@.14R_72
M.O6NN+7KMR1/"LOO92E:55W)*0`:KL_RK1'I:'P9Q^,2UX8#PHA+690&F':!
M5JLX,@:\KD762$B9:B+&U4A6P=?A;#9RF=+RK1\R&0IYK;_X8^;0LAICXXB,
M#:1K:0:0`\U?2!J3FF^%\8I8R[:V\C0O'=?P5RE4M(U$05FK-L<VA>`*W=:P
M[(P*+=WP@FU8`:E8:OV9+!D4<7[(=A1%0\M8L<T9C2H>ULQ$0E*2\\J)D2-&
MND17Q4Z*\6>EEXO,)A>B^:60VD@A6*WZ>AH>`T0)922=P6Z('V,@T6+BAYJK
MD&,$U2[I%U%%RMER^E$5U`4Q81OF#GS]1P0ZF@4,748#2B%291J2Q)!U&=!I
MZC-#5,6+<X?F2NIA6]PED+"JNIQWT)^"C#19<Q4+C$]23E[ZF@19M366W&R.
M5:Q!@8_BD*4Z.76NHIC?`12D0`W2,/7#:(G*F[\KQP_P47I_:V`HSS97?,8\
M(8=RPB6GK_65M?#FFGSOQNV8\3B^'3CN-[Y"Q-;N."%FB*>BX#DH'.&VUT%8
MLQC$$M(,R2S#L8:AIP&=R2HRXVJ[MBIR14YR6);.UM:GI*/4Z<C!\F9Z!$UB
MJ54='!RKUIF@^#A5W,V4Z,`1\JA=/'.Z65W5[B\'D\DEBQ1^G1>5Y2YW-+"+
MJMB$H!VSA2:O10J^A96ZJ2"70I7(+Z`>TP3@EX%92O_C'`2*L`T"W\!YA*!<
M6F'=!%"0*]B.#^"$HHBCEF598`G<@A]$KI17A7RXM#%#04+S",:_*6/\X3_)
M;@[;%[(M=G2XS`DC+Y![$06(1(];_/9`E*F:V)I>R[K,%@M54M)@-T:S#`77
MIW>$W;<J]@"U!0XILNHB+^T-IW^N;UAOU0CD&9[UGMD4KLSUD)?[6U^<JQMS
M\K[7-"[)Z[)NU9Z$;T$I?E0EH,CV"+(*0U[]T8S;`LFW\$.5M>>:"+D';O@#
MP,A#XC[8?H[#.L/TUD74G^$9[Q?7J;U^U_2.JBX7G$7G%EZF?L>FI=94>++M
M!!H`J*(C]:<5U5-4_*(*0G0HY-#2UPBLJNC(Q^(`*L1=VJKJ6<KKR;F=+S.+
M"`OIMSD`#^TP,#0LMI=N:K_R,`[W8R/[VEHL#>T?$NW_7A=O)"M`UU5TMFI?
ME(_KPD_R'A0[-:%S5*"EBWTB.9P1G1..[@&3I9CJA7DF=.NQY`:X,3E$*>V%
M7F>??**RU3A_7D]+\4@R+84<F%@B/)&%&[BVE5V,K$)%1N@KDN*]JU$`T/0F
MY&4<&H7FL!#^;"&%#+IO)H("1KU,V(4>2.APP,3IC(NL@#B3OJDHK(_04R\E
M*MG4C_.H."0DK"05>TQ(CDXT6-EF<7496:?#BT@RYB,7AE#!;]LL2M%4LBG&
MO=#Z#%T*..#M9BDP#KR8E!7<N-I(*//*8P=/^P1/DG,[,&-,]YJ0OEI=64FE
MDTH?8?&&0RT!:]5'\3=V[:7K/:54VPHNB6)Y_G0JXIQO41J".\="5Q2OL<`4
M5`IP`#:VII3$XLH7UXG<C9-FNB/@%EB"=;ZL/S-`$($^6]K_WJHF^T/`7^<J
MC5.)$2[M)EGWYX^_VFN]W[C86E[F[Q,=3;>K`E"1FKC/"A83,]H-A@K_;T#_
M)-5E"6-.6\:X8WD3B`6B(JQ*,Q&AH%"T0J<)2>))(?4)*S?,V-TMR0C+\H1Y
M31[F3J2&+X6*AY6EU$AHJEPH)"J]<YR/JSB2,H^$(1F/VEH>-)47;:6H6X,G
MPJRNS+_WN+<F30G[FM`UE4EQ?%]/;GQ%?%O1'L8CE8G/>B4K^'"W4_'=00Y@
MY_$3)8XA=TCGEW,/2][45?,/XAZOY:EHYF?X-LI,K2`LE.9"04)$X)5,CDZ&
MDH_R!J@%3BQ;I-JJFP??Y#A)Q-&<J*TL9!<@A18<(Q*L9*C%)DRE\YP(OOA4
M"MU=&,]=@Q7WA<L=D@%VP1KQ.9UH(S5ND!KO,ETTLO8VMJ+;#7`!#".89D&Y
MC"\5!XF915&`4.Q2<3#KRB<25;=Y>0'RHF&A2=3,_F"=0N53T/F:V?P<E"9_
MD!907IJ`OS]1[P=B)J,IIJ!F8@*'0,VIWJ*[,,9E%O%R/+`[W2$'AIUV[?:X
M4]W?>'/K8-CJ,A<_+[N]OMT==62XV:AMCT[;N_<C+@[*8]G8_FW8'MQSH^("
M8/BF.^],>@.K]<OG7N/1+[KIS<OVQKP\+KZ-7?O`YOSJ?&^N8@],B!1">94'
MFBNLT)FF=*8RV2SD*@,<&:1L_;SXT[30_\YL:4=9@*H=7GGTBBYUN3$J"U4G
MU-*!F_DXW\UB!V9Q`\4C=7MT'X;A#G%*,4?-=R+2:R$US-KFS2008"JNSU`L
ML&#,V3"SP\5WJB`1,*90D"CY06^0?F0!J6)*C!R$]WQE9""V;OO8LBY3)TY/
MLB7[=LV6S89FHA&<0\558#_%I[=/-Q!)BM;2!%0C+L>Z0#+[MS!M<++K'*MS
MVCXA140J$0WN'B[NLM<4;>B\SA]E#W`NH0Y^1,==%>M4-PGLE>5(8^F=4*F7
MF-Z#]YO<68++S:!2+=OV8#I'*4*60U;-8&L9P*Q"'E7LK!RL=G7%A$N,9/ZN
MLIS\@LN8EF^S4TL55,B;E*P/K%?"UZ=,^$84HIQ8*ME$0FH[#&/RX3CH&/H-
MP,0]@I,YC6J"H@X&",\*.*`-%,7D65=[O!$LM]IU[H*[W:8;AG%(#./#9L&$
M=<_3]6I),AP>$Q9\+C9\C7T<J>BP0A+*M^0D:RFOM!=7^'1%D<&7U&$$7C.>
M`-7,CQM$.C!$^A*6])%1*6O%BY8II1%<FWI_G&$`)_OL'<^+U2U8D;NPPY>0
MAA1NOE&@AD6P-D(@K="S+-*_H"Z&[\0".&*H&/'$N)?TZ]7\<C".86[DVC\O
M1J;/A+ESC0DIXDMX6`C&"JD\CFHIJO))"B^JI!)9UX#WA)<`"CCR!@1>(D,J
M2^<19VG:12\<A=USF6Z@T%17V%4S\68+\"UT`:HWAFCK?'60KQL)?2$<#HXJ
M+(2RD)-40X[V/>?B3I0Z(A.'I_XTI0L;ZG-#T/+G$;,6]N,KC8,K/ZE23A9(
MM)1S1E13A@J<HZQ4>8=CS3+?4Q=>GCB1^Y:%:[#'";E.^3,%AN+Z*31"A$Y`
MEB7=L^8FJVW.Z,L&2_Y"=R]G@Y=R*!+551$V@ND/P&2Q31BOG>C&R&>KW(OG
M>T:'9PN!0%EEJOUY_>5W-=:?$7*4Z@N%D6'13XEG&_A1P!O4!LS<%8/<&KY^
M6'S=9(!3O$TTU01FJEH]_$?KLJ6UB3^RV$\\GTM,RI)+2495(1`EC%$,9I8@
M-U,CD'J:LS/MNT&=@BS>_/+9P>S/#44I,`ED);LZ,"9N(.,2!T<6D7"-Y*2X
M;+I/J*&6]0H/2+9Q)HR949_7$QO5M*I%2.-(.CJO^"_H=N'*[ES`X!_D1;VQ
MVL&%K!J_=S#;0WS8'U;Z#]TV_@*8'1[Z15Z5G+H7X:6H1Y;_.:I/9QA;!IMB
MG@'BU[E&_B3C>'JR@,4K'-'H0`]OF=WJ[<TU-I0C^YU`UX*ZYY7]*?''7RFQ
M_5*%N`DL`A/XR5SP>W_FN)H:N.J97:D5SU=-#?C6ETQ&9'1:MV(6SR/ZNO,D
MZYB3?*1DB7>(V!X.C8Z,,G_-QAO:Y,!+9-4+!U1+JA!2BI%"$+-R2BID]=SH
MV)"=0<?Z,I9F_^*F$=5=&5<M0%87X@%)RZT>/XV0OV!]OO[IJ3T>G%(<%4=$
M,7QDW4$90L1;D4(WCYK4E57TVP3CM0J-!RI'_O,_GBWG^,H1;IAYHLTV1@*Z
M%]"U=<I-%D-*#7&"0`;R;E\61P47K-?%L3I*Q6&KG77]J;PDD=GWN![B8X"O
M[^`3#=WC-X%R/A2N`;7E8;B=\AV:B$V-8Z=3NF"4Q3BVBT3(IRC$&1152@Z]
MJ%CNGL89'9*F<YG"^D[>$J=%]`3-N4G5/4Q&I+A+(2W.3Q(L@YG@,5OLL6`?
M!TB@V)'Y;1$6RJ#$%L\''D$-V&7G)9T1@Q2IX^EC)$D*T_HBA[Q2%AM[B<D5
M0E>>)..H?(JIH4B'&G,23J]K$.Y0$:X0?)+,04.6O<66SDHI4AK'6!YH-`/)
MR,Y(U1`;Q0.EFN2X)H4HWR7.G7`F..":*Q^1+E4*;,SQRIHZ?DP7K;I[&K]@
MY+G0E(;+S$FX"[!BA2KDW=_-79?'9%_)?*[\!B9?1X/X1X[X)A.=Y-?+"M\+
MJ,ELNH!\AA&$3TC//:E,A-_`2>6UW2OG-5_1R*_EY4TA[R!/'T.G&Q76XFN:
M5Y/7BBD7WV??MJI>9HZ%R2!.+",*F!91\XLS60`BT775]E93VQ^T4G*4.!=;
MAI=4NXI*S>I&DV\C,LYUN\D%J<3%?-5"'BM9(81C6(W+G1O!?)(;K=?8DX$E
MA>L!,B#66&$>]JSCDL[XGC`R]`([OV&6*T&FBHM1C)%1+O1*<1&^$2^B+((\
M&K`0#,ADY`2`TM[*6+4*!\1`*Q7Z)4DNS+$=R$\N93M4O1>LO6&L(S`NWJMJ
M=A?`GBZ1/ZY#H*DYN@5>[3W[JBW:`=]E>=EJ7=X0N`4+3.N5X2%]?W%I>DA5
M9@,I=[*?M.<'&?)'>+1EO:6OX4^ZNE=WVIQ1J&Z$7F%HS.N\C)YJ"XW%''$!
M<T!7Y*``<M_(6V1DQM&P6O=,%-Y)B->FCFQ%4DCO:%GO\B72W9H/8'2HAMY$
MKQ?+]LK$3AE7@2]1!4A]->P84-*AS,L(LS]\F0F>+^B5:,U:=F[5D4!@'OR:
M[L>FS(1S!V84PL[2W!;+RX^J^`-Y(ZX34"F+&0U*$O_<#LZ?4BOUN&5=U*Q,
M1A'@!7C(]5O+>WWEMT0+A424J*`[>>^N#C$'!)98%/)'JM>B?WHMDXED,HS.
MP@0[V*7L&5DWU4"@AAL=D6+^F\(&$_V4%DI'CMHW4CGB.(;/$?[4T7N8D;,1
M+5%)\E,],CM3#!;@Y?;KFDJ4*#YELJ^@;K%D!3@+MG`IOZY,A5@F@OK*X*\%
M>B\Z><SU48JV27JW1_T&V?=A1^4N8T8JHGG1H+DAJ>0&0A@M`Q(JU4F.CXD(
MHFMU?X#,/`W8)%!"DF(Z4#Q$7,@F%C74(;/@*1:PR'_750!5`\"/E4#@H.<\
MR[U!W5TWA)%Y(C;6Q-T171$$R=+!VM4_OVB_H,]++(,M/U_[7CK_^<5I^X<7
M5L%.V,G]@]/%^B\/[2U8T\\O)E&:1@L]RVAHS%(^#+FJ$W[G37?YO9BU?U"'
MF#O$JO[:1M-(O0IXIM%2`[-S6U@^JN.O<ALEM.AV82MNA'@*/PY?6&%T'3O+
MGU_PO_DV)VCBQVI7$ZIW#GNS*(WY1FR1%+)G^%)C2-\P`3^D!$(UZ)\/>JD/
M\>,PHZ<GH$,]J,TGTFF;?*#;\(%M^0#J@\^=!QSG-AH*N3<*:3]W"KE_*;E/
ME++MJ>S3FF]+W8^]IR,_AD-<<X,Z>\-$M<P%(3N+L?OJ"9Q$%+_Y+]>=3EW7
M=)+<E<\>FA_DG]);_>#"=I]H\]#7/*Y>,^'*C;C(3^TE,G9Z=G_0MP>#;H..
MS9H;$KH="0W;([O?'1XW">TDYJ?TG[N+^:.Z`;DTKZ:?G:V]Y38VNVGVBB*V
M9'9;[^C@6>%6?J>>W1NT[7;[V3N?GM<V&KH^>KH>]!NZ?BI_2`D(_8-6E+YB
MR8''QIO^4^/-'1@IK-WRHFP2B*/AI-5;.GA6VAG:I^W'<;@<*'X?R38:,CUH
M,AW9G?[C.'7V#;\+ZHOZ@(&S:DW[5!QD#_/1#BDW\0/6!?@?E7S]0>?O?\Q3
MF(LG7GG^&VGCR)'CL#(FOLZY+C951'-DVU7,6G"2N8U-G@06$HZ_B93[.=JW
M[#5J8Z8.]8+4/8#SML`J`YF+N]MY`8&EL^*R3)@#+<M1JO?M+68WVIK8\.'/
M3#9R\IR%,Q/Y^-P-)A8S'SL!4DX&`1X6.8N%T!V(/6Y01KD<G/S!O6*^<R%?
MSM8P4IWR*AN)>I<RF>91G)Y0^\'0H88`G%N(F7VI6"1-+L<SXKC_2.CXW\MN
MD0U[/3;V2HPOUIE>E35Q?,H\QAHB6"^$2O`85;.7L0]O++&:\4R$6&PXH"HK
M@DK4JVK&(77_N$RI<S),=(9UTUTG+]N=MS%%1K1PON4]2F5GPR3)%C)/DFLW
M<N(9)W!B@0S=H61#`ZE"P129-+VQ*575T%I*%')(BS4ZL(,0-72%S64!YM11
M@AR7PE"9SI@\K7?Y$(QUCVV6O1,5C\!.?Q=4?O\LIYZ+.`HCK%%]-^WU&3%4
MK#3C3U=[RE,_8DGA56Z[Y@7,<W/%./Y+3.ZE6FA<):A<?_C#V>5;L[Q&/C`5
M"?2JQ_K'DMC;6C'CRW]4C_4Y:A57?-)7&<74U)Q3W`WKZU->T2JQOD9+WU6\
MM'(]YY&GZQ)7K.J\>E4@!N8B6*J6W"I7V2@.9Q;6XDQ]U?!!R14MP*B<_B]G
M9Q?TX,</OU\:6\[_`A!9%="PO$A0^6$U+O97H4+R<)S5"TI4G7Y\"ZO4A[)X
ML"ZI:+022S2HL((`R[7\UR6:"U173Y6+*DAJ+7DJ=X1"'G<%*\F[UW-/2&ZB
MP26<0A15JFY!7E:$>@'H,J[YJ)T!Y[`7F[I0>Q5JLL&X`-,:S2LV+H]?S25Z
M9<&^'-#Y26-GEBQ5@#8[U\CZ)2O=EG*;4H!YCYE82^YB.]V=V=:#E$7;>RZ(
MF:V5;!`XFJ685R6U#2IX#QY:+.:@=2'ZJ@:X!<9S>;X1P43@4V,,8=8Z0S21
M13ID5<G%,@IU#V6V_PM3R^(V3J*[QZV51.9RE\1US&I%!L+)TGM<%QKK[PG'
M:&"#M>"$R]5VY.(<LVM-83*LB:+6E+LLJI8L*P[ZU%`S0A:=15E26GK5B\0K
MK/0ZLA*V%011G+E,H]_-]EQU\%`\J0X-[H%--6QFG]C,I]QFU`)Z`H2.V@*;
MB'`L3!(Q:=ZJN++'0@.?7P$!:22T=8\<ZMRN6UE1S2SI"`QT_S7;+'IB=(K:
M!1&,>NT%4H\+W:MV<*T\Q*>__)@E)S/'6;ZY!*0@52Y,<TWO`CL"@6W]%9#D
M+>+#7__S/RP+__>7P/^>OJ$J@N]E&>`SY;,\"[V+V+^"[5\$#ML_>@!B4/#A
M=S']^<4Y__VOX:?W_^JU3T"PG""9OZ!9UEUP>^"8NW>[L=_B4HR6@J)U5G#]
M2D!:&I(*-`;*R"\.$BSK.6E[N+U'\!_4(<%>PF,_CWM_I->7T*P'UA[:A88Z
M3CW%\S61DW=*.^4!UDSKNA%,>QN+Z9&Z!;;US/H5<`TK?=G6N[AE_2V:AQ;8
MS7^/KK#RKUGV\U($@5*^Y$`XRF_`[T%:JF&4HM\9V^UNQQZ=#HW:8U1HS*S.
M5RX63VV:6>>5XZB2R;HDFAZ,)EX#@-JZN<X6<$MQY8/NBYW=H[SO$/6`:H,2
MR6-AU4VU?'O0;I=6'D9H`4ASM+`-;,A']<7YX@YW\I)&4'8-:LZIGU)1P=WW
MN`1].%:7=6J#5,/9D:JD&E#]J':$10C13H!E1$&P.HFNL1M6DDT2W_.Q4C@V
MJY(GUVI8RB.QE$-F81>E#F`YQI4Y@'R`V<9V_*"5#X*TZ'!K+^J%/<#`;?NT
MUZTK]%E#2VPZSOPK_"`+%Y:6KB]^.O9XU+-/A^,;YI`W7#ZVN,5"NJ"SFP5Y
MI6:V5)I9Z9:'D<[\?"-F;H.IMR>\QXGTVY;\#I8R-K!CC6'WBE<DRDKZA&Y/
MH6J!RI=U3[/%0@#G3[%S=J58L5A$]&V4BYW1J+9R*/I.0!3*VULC[`1&[@Q_
MV%K$U1G,Q=D4`/%*&BN2&A$O6DS*6J<>Q]M$06GTA@R?!1FBWZY6C\8.>+J-
M!F)4'&6SN>7$BP06&L[2.0P_BX#\9#MEV;LB5Y(-D::UWY;UD>(E0MF,5+<L
MRH6C28,4=O9/D:073OS-.G>6:#O:Z.)N4?'U&2QWAI2.06_65-#ESTM.26R0
M^`&1^)#\`FO^GZ3!C.?`WM9=",!X<C]UWBVMJ#Q4<Z($\*G(<N#Q*BUXS7!/
MN1\[Z!*I[L:+C>+PKBFLTF"<=?W%HFZ\>=,(>,!E7M=N]7H]6RI3.(!OKG$6
M4UE^U="UV)V7WA\.1G9W/"Y>51/;A8>K.2^5-S>6-B,%R^$F3DDB+^,Z[1_8
M=6*%47@B0^(H9%>RZ;Y6?$JKK%/B9,P`*4E3_TJ<4"]5L^WC,HOA[)*2RT%@
M+V3\&?N)X;+D!&L-$>B,I6:Y/KOX+F+73U2S68:\<2:X.FHZ%IKQ#]W;3N<$
M2733G"WKS+#[>D-`Q7X.$.K8R_!J69]%RD*R!AEL:?Y1^)_P,E==JE++AK75
M11BHA^C&S6]EGTP9W4T3OQQTN_:X-V[$\/-AMM@@?63:5S=PS\%IQ^X-.K?E
MGMCT(<*NKC=8?S=PS]LSST%W:`_&[89Y'CSS[)R.[=&P>TOF*3E>OS^T^[V>
M&2/1\+[M>5_5IF[#X!YG5VS'_I&%)4.V2E:6/#0%+Y-T^N2HV`>F,NP.:ZBT
MQA@NX;KL=E;F=S***Z?NS53TJDPRKYG3Z?7D[NN:97D1A9&@E\DA?7<E%V,T
MP*$8SNC*3RBRQ_HUNA97(K:M)'/G^51J""3#0`#'DSL6QLLRFVR!_U1DA'%8
M2YIO0'8!LN:.S!:CK5P[OHQ9<@/'7Q#4,9LNQ4L@E7X6Q6:\D@!F1?D3=#$'
M;TX=V!IVN5L5#IL[]2V5\4$[+"[4",RE+EMY!V@86LPB$%*VN07)J*2$D%U%
M83NJE33V1<<'\!2*#ZEP-5A,WEG.Q`V2/SDO1K%V0@=`!ZPS_4HH@9<1862F
MP-P<\(-7?EAGAVYNJ_)-;G??ME/,E\&+#YDK%6U>#"O=S#``X"9W43VP0%O"
MJ.D\K-*91%=H&"1N[$^,E\BF3GQN>HMR=-"U3T?]6E<X=8'4-$Q-(%O6)=+!
M.F&S6L;._II=<"MUNKRB8$]2G=KVN*LL\J?$G"/1Y55LLNX1KCDE+%Z$U0C$
M25\+A]N"WQ*9NJ.>/1K476/:.)^YSFYE<&J=G*;%)\:J\E5PD\TR.DX%)_RR
M8QR[@%='PU9#SPC/+\Z7+X1,`]5<#GNNE^Z/WV*1CI-+%Z060H-BM$]0G"*X
M%A&LR5[SVE/+ZY>=\=@^[8U)H(],><ZW113R"\^!^A_/^*T\UM9,XTOG,;;H
M!IR9`V#X>NH24QE).5<\IS9&>`L8T`8,&&2)FGL:!4%TS4;:,L,,D-A'=2=Y
M(^45*Q8GJ.>/QC^9^H'^'I29G_+PY,"?XO<="Y4LX_NK")O[!2@_M9CJ_`3;
M.VV=_F`\YU&#78#?RA>@1IU8;?@U]I-O)U,$$X5K`]NR*"C<'*G=ZO1_:/PB
MQVL;G!43(*ITGDHS`;T?1B-+TA61S_#M=:UWA=K9D)RDT+C-Q1!R0T7:^S%Z
M[+`-9DE9S?D\#RB=@S7W\ALM"7DIC9G+/JOQQ(%58'F(?!9-^S5]6*N`:`Y,
M_I`1*:Z(V1:(0E9/I1*:;U*E*Y2U[ZF/]E'-'`0:&+8_`#5_I5TI-WN7PCS5
M@>5>Y>B>`'L"UY1G=<@).]WV3C.V+)`Q.=\]K<()W*E7OU7X\"&*%];EVY-N
MX8A[]F`PL+O==BGN8/O#!GW.QW;:&T"!3!XMD@J02"2\S*D`P:OOI\]S-]DM
M@5<$T[61VT).,`?("<,YE:<1S<O887&Q5H1$.\<ZK=PSQJGPP/5)NT992P+3
MUB5+Z",F6[`U>[.*NJUUT@08/KG>3-<G1O6$W;!1IN<`;:F6P0LA9$D&X7BX
MJD16O%FCKFI&+RO:2-['AE(-42*=`0\C#>MNI%F(MRWNT/,]F2GL1K%'OI)"
M_8DDB5R?:$S+J1MJ^Z3%2UZ8.]7I;U:O4\4;"V$M3KJ)4[E@J6CU=RO7,Y\;
M)UMMX/D\)W"4Q,?R0SXV2(^=A8Y_BP4Z?'3II,3_KO3N"CZT+4JHNPW"@T(8
MVLM1GZ)&91`V>L2H477>I!U]9+K<DSJS57U7]\*E2$'UV48DL1US!^D04:D!
MJ],G!!@16GRBDE.,$\HN*RR&'7DK97#EMTWLU4HE3!S?N[-?8?<8Z'M5_V_O
M`CL$+JSIO]/EX]_B-G(,-O)X/+CK7>1.EX_#P9TB-SC,K;E\W/WR<3AX]+M'
M<\JM;Q0'P*QZW7:3;W*(C*C.\UC+*7:\*`3+!QG`GEP4FOC=W!,V]X2'<T_8
M\,DGSP:ZR5NZB65N<IK>H`CNF^-TDPY)VXP"01&79L`E$];FM;.]R]4B4^8G
M9'(Z28&>>84+!ST1>F&RAC",'2:.RW=""(LH0S-^AH79$'JP\:LHR&!0K"64
M.H9?=O/:=&F?V_AJ1[FOENZ"EX02UX`+*5AJDL<3WU)97M=S/!=5UPB@$0@'
M`#K(M<LB-*3L*E_&U1V5S7+&4[X%X'%R%3`>7[,M'(]3N$D^P5.AA?G/;9U%
MK=WE&9451E,\H3HL4<RRW77PEPWN<K[XTX6/^":V5$ZHZ(%0=3EO/B_2;^4F
M69)E(1TY0LF?S5;8&*=JC&T&UY5JY`1:4N:R4]T>7'%=*B<MJ4FP'-)N2D(4
MX8ADT`B)@Q02[_);:%)UN6)@V=$W+O+W7!;PS;7TQFI#%5A(O(4B#ACEKT<G
MF)JXW>^:!+PV`!)A_E!5P$0IAS.1]]W)FWT)?=I[#/D26A_$),Y0_>ZTJ]"A
MTN\S')S2H:P?^&9_S]2/@2D7TG;JT$E[@'#8@@-HT+Z#`ZC7';,#:$MG0G<X
MMD?CQIEPJ-C-[NONUIC='79OA=G5616/C-P=X.B[('<'-/S^L$'N0T7N,\"<
MP!INC=Q*8]X5N1F-GQ:WN\ISORWC[O3MTW:#VP>)V^\QFH3PQ[3TZS!.JICH
MO9A:42B]!ML6_Y#7-FL.X<(-2_&:8[?QB^';VK5*<=Q$+6$Y[E*1"Y&1:5GO
MX;U5+1MXQ-NKNC6L7RA)F.9W6)NFP.5SOZ1E9)P1^DI*3OH[K>.GNUVFU1Y`
M]97:&@0V3%,/@(*7_#Z`T/#I0^33=;=U=_(9F,'SV[LMUJ_Z>OTV:@`[7?7I
M0O&QJ+OU*ZHU:S<[O(5M"/153@+XTFLL\^,&F9>3DMK!]G>"N.[.J&WWS;?R
M+45AL"KLJQSO5G3C<L7KV"A]-5D9NB%QA92:P-7R!OUFJ;[]UF!J;D6;6]&#
MN15M8M4>X^I3!9_^F>$5CV0H\JJJ*!2*9.8S>R5RV461"CWSE<U*42PX!\L4
M-1.AIO8LR9)J;J`X`4&+T2U"-I=X29FF><^XQ`F$S@M15V-F'D@&M+9`QN)F
M*=XZX<U9?8><ZMO31ED[0+IYKV\R/T=7K$K5NX[(D;C)6116^8NDES_*XG1^
M-]?0Q@HR[3R($W-+6=H8AFW"IG%9N6&95KTVEBG*Q550[[8Q\,L0I5CLQL0Y
M!JJI=$75HOC=?%$VO4+WK@_CB[K9W43C<3#%TZUE9,;]%O.AM6"5BKYNEH3!
M*:FIUS>7P/>@4&VC3]6D^=2+@3LI5-MH4"4CZ!X5*CW`#4H5RQ/#RM4VD8IO
MPT1]G8)D+.S,Y9(<8RQ1B?!>L/]CK<NE6^BZ82-@`%@^=I?2ICF"DUL<L\E5
M@)HT<%DKO93%A?NONJ\5['$I"*??Q0Q+"^#/[Y#"%EDP<SA"!/9!NVA,Q_TK
MO+/WC"?72/_FA!2#TN5R&.TBVY%IP2^QO\.(.J?(:))I)7\![#4(S\A]EX&O
MXKL,2"I6LH^E+\L3"<!-4$@A]U*YG@/**=1=NR-=BW$JW;KV[,&(VDO(5;$6
MK"1HA0C&QUI6KGC4ZQ2[ZP[5[]Z_7K#[/`69;^TFZN^FO)>13RGO_7%I1;L:
M&Q56QC^6TN>&DE:*J5M)6J/Q`7=]W_'.YABE*,BK)Q>#Y@5M48;A4'0Z88Z>
MDB-0FK`454;,..6$PY,55Q_`"[O20$<A1CFVCG>%8WMEFUD!R*^HH&+GQSIQ
M`K6TEP/)9R<"CY`KAJUCA&_23J>)M3AP(:PC0;O=35)811&I[A;$E!P.'J]Q
M"U&XKW(H'9L4I$O*(Q&%:RA0Z<AJ9&$C"Q]=%CYWX7+SY_*O?_GQELV2\V[+
MJDOSN9/,X0W\Y[UNS)6\TPVE=^RS;-QZKO]Y(`=(']<;YPQ:UB<0#2N,/,<4
MP`]`"TE>R;#[D_4!*SK^#U5TW+DE^_Z"HXS/][:W_=&4^%QE:N>4SK582:G3
M(=Y84M<[[:+N0@UL4#$B\2*=I>>!DR36&;<6(Z4?XUM$'(()@!+^,RSM?Z/X
MF_4)V*3K+X$YKJ$92R5'K5`7#05;H=<&_>MT3,N#CT/\B!6>I)`&[2]8,;\F
MP4>IF\M(R4HP'!;EO6/28*IS&E$J8^(DRQ86+).(M`"4$[$U%2`1L),]/Y<Z
MWVDM>EN7.&WQJW/T"8+P3,BC9[Q(HW.UY6D4^!$N<@YG;V'L*+Z4S.&G$TQ<
MM!8:7-$$\$N69TU$P.5(*:.4:D,I!R3L7U9I@E%!:0GI[59#J@=%JHC)3@;*
M8$Q9U:`LS[#^%VH;:R7>\@*[`@\_\),Y!1(:/\Q]0%[0YU<<$D>=+4%G^[=,
MP*;BND0.^#AK1:EPYZ&/NBUF)',A3^&@K#0'IB1ZMB("`40HTYB-]&XT$Y`#
ML'YIUGUS07_U<:6I.2*6)$9>XD]]J1)[+*59IT.KA6B:4CN!YF:P$W)U&F7(
ML*9>=-VR<OE.2>\1ZV-3H1IQ4<]-'.XW6KO%[*_+>T"U[0KI"!ZEWZV>N4X)
M#/*8V\A,*%Y9E95LZ.VPZ(T/N/,&6'!$X@,-S\1ZE86.]T>&DN\UH0P[&EB,
MJ-A%"PM"I[Z+US0DZX@G*RZ\EJP^E_47]`-T?X/QF8Z.-S:0BRI+MJP/^J*F
MAIHRK%[];S32Y%X45>NH,5K[B>XG#[2`UW))T0!4/Y],Z#H,A![JV/!B<@N4
MOE,XX3J^51H*=[Z+.AKL[;Y11QZA$6M1D8DB/NLP/EE)0Z&*#I3V@'FYV"@Q
MFB0BON)$&FGO5B`W14Q5O:-\:VX4Q]$DDM8YB2[C*:F.`88[M\#P;AG#I_YW
M$A*D:)E^"4P-TGB_AM@V*%DI9NV02LS,'QG]B92=PIO="OL;AO[D)-%[8V6A
M@7`2839@M,XR(*7G>BY"]@BAA(<'TD"`L$<;:&4K]-6*PJ9AT_OBZ[TRUOOA
ME'R0V-_T1#)U$^'7.3G-04[/<!9H-S<["W,20$C(]:J6#*J`#A-&H0M%0R`'
M1B"F;U/71F;-A#1Y'055945(\<&).50ZO5HSAJ^#@)1MBEL`+2D6*5#.Q(RU
M`54='>AJUF4F*_P`Q6$@`Q@"KE&#J6:BTA34<EQM2WFNJ?HQ8"U:ZLI:,34S
ML-6!A!<)W0*!S;["!%=5X+V:.F&9M/U84+L;I!&JJ80Y7PU%'"QQ5'G*9(,C
M$@YYV)0?)FF<+719*G0U*:;)EC#6/%^S<C?$9ZEK;+#B1<K)US'J,I13*)MG
M?9V;O7$XWUDRYPI75R+%CQ]+(C/*D5>2]T:O8(X#RCUX`Z(_.[2OVUN^.#XQ
M5P!S7#HH1']^T7Y!GY<8!"@_7_M>.O_Y1:?=_N&%I0;=??$X7ZS_\O"T84D_
MOYA$:1HM\I'+RY5+.>'GWG27WY\*O*E7L?PT6A[LVA7HW0@1`+[HO@"=[3IV
MEC^_X'_SK4V0?\1J)Q/L!V;!?BP*XBR:S170<*G<Y;Z15<W=TU=*?=Z&F1P=
M1ASRVI\/-O_G?^R$SV2QY3#M-*A]:&M_/JA]%\3N-HA]:&MO$'L;Q.X]$\16
M'W(SX38&PS[A]T;P[]-"=R'$?=['P0#\8!;:8$:ST`8SFH4VF+%/"ZU0E;2>
M#(KQ+(ZRT#L!^$?QF_]RW>G4=4U'[&VTJ<-QE]=HU87+A#</I%/O$_HV9-@L
MM,&,9J$-9C0+;3!C_P&^DU(WI?]L5NKDU?V@^\,MG8"'H_/51LS<3<U3P0_5
M`*3M[)T;=<M];/:G'X,=P..]O!\4&-\&=(P@-\&.G]I+X.4YCP])1WMY&]&P
M@X8=-.R@80<-.VC80<,.-J`<U^-H&$+#$!J&T#"$Y\L0[OU.;AOWS2&PC@T8
M?A"+WFM`CQM`-QA]5(!N,+K!Z.,"=(/1#48?%Z`;C#[XB]]#--'IXWIDWUJI
MT+M&]S7LI&$G1PGH!J,;C#XN0#<8W6#T<0&ZP>@&HP\0T$]R_5&Z`^HWT:MW
MNT3K/_4EVI;;J+I2A;5;7I1-`M%<1^]Z'5T-NX._C]8].AI".NYM-/R@X0<-
M/VCX0<,/&GYP(/%JAT)*1[*-AB,T'*'A"#NX<-0'+!)>N_W*3W_Y<>>&I^N]
M4G\7`;90O'#B=/4U;V![^VZIJM/KD79,';8L"3*+8&:90'ON77]WV-[^M'^X
MP/Z(V'#$*%R$W4;K6C9,T<&*G1BH#SFW`*>>">=S7TRM]]^%FU'CN"_3J>]B
M>_!W<<OZ6S0/K;]'5XX[MZVYX\G6(=A(+D!G)/9L\ZZP%T2BFI^H3B74C!&[
M0\`K#K4=$=^7(DRP3]4E=N76+SK48SL$&&.#[20]F0B'.DFH%C\>=Z/P!$##
M:UEG6S6$M8L[S5>9.MA0Z.6X:X\ZHV??\OH@D?]K#9)'A+O6U'%5\YNY<X7]
M.D6HNNAR7SGLJ>G.8;$"N\XCIC.22]1THR1-\N;O"V"<,7924?U]=&L5W<*>
MVN[8U($]1C(+5C;/C>_3_+&8RH:XU*S+;[JMWT[(W@T+:]HPWF;0Q[E?^QA:
M5SX\(GL\56&]AP6AHR4U^`&$G'&#Z4QU@EKXB'3`6*,L=K&58([NEN=[A*$Q
M<$]D_LBX79@"^#2W0Z0^T"9;]S)BS=1RFUHK<J=>:P4\&SC[K]$UK`:D![S[
M04SBS(E75N>4&76]='H;.3$U[GY'C1JC..%.6%?4)3AQ`AP&J,]8.C;='MCM
M=AME$C842N=`:'!$U$OK$W8)LCH#GKB58V7^%T`65,-0N-Q+&(D264,!/K'P
M,A?6@.VY'1?$W<)WN2V=[$6'X#EM_X!K&\(_V/T7K2'\#,<2I0)6AEV9?.RK
M'=7N7_;G\U$XGID\1((;W^-^PK11;"*&K*P@!AFZB?]]XS.($_B<[`%&&SC+
M9EF26F/2(0;6*Q\DY1*A\EHWR2P*W%=NML@"ZM3WN@"O:VQQ[/C&H5%O=#HG
M&_X8V0,X,.Z03G^7VJ/?R#.4)5#^[OFQS<.2V`:.`"DAR_'#JRBXDAVSJ1GL
M!#LX4I-A30WP'0CJ*`M`MJIN8%D*YIT-M$X]5#<,$RVQX5T6\DC4^DR^Y%PY
M?H"F:XG:L/VELT+]`9Y![C`-?)<:]W$W>VIO)M)K(0J]T0BAD464%J`46MD-
MS>RNC!!8X45^%!,E$9];1C!=WJ,367:0$7<"*DI0,5D"1PE3U#S4XI+M:&:3
M=0YV]8^W,*S7K?+\H2_32]"NQ%OLH7ANR).S.,9^GZ0QO5WESUPX*_SN[!K$
MP-TL]WOZ^%#,PYSFH2Q^G&,$FBR:/]878N2L"_S30?"G-QO\!PF(%SORT1TW
M>2M>^D"[_!*6S7XQG;(0Y0;6R#Z0%)%A2<WQO>RU6^PG.D.$0)N$=*L<>A=S
ML*"6UH43+(07H=I@@<V4@`$E^V\#CRJJI-+>!J[+"`<C+D'A!&8GJ%GI;!:+
M&;8UA==@S:2Y)<@`J'\IZE3`YV@(V,UW$;M^HEM[.TI=@2>GN$G2-K$'Y,MV
MJ]?KD0I(@]FR@7<H3M*YSSHEM<24JWHU'-K#X5#._-K"KL(()'\!^\2NJ]A6
M>0DK^2/*F[*R=HH4E(^K7G3","-G"+PCI%YJGLV(WH,_3F5+3*/!)BTMT8L#
M*">6ZP2N%`@`OB0SVLJ^1=?ZR:4[CP($&KUT4NAP;),"IEOETK%.A/5RV"5P
MOT)H=7)@@>X&:^`.N2^[;0(,#L"6,;TMO3<(NF@-Z90N&8N%P]!ZV>_8O5Y_
MPRCP+QSKBA7/OV7P5X>'JU(U`6@-KVIXE=*R@B2J9UC,J2R\-$%,(^=,'3_J
MC#?QGSNP'WH<6[G[Z&N,T0*+63>51KIB*5I'!-"&]-9O_O<4-@R\)"=*\D!-
M,V0OR&^PR3GR)C]!ON"*)^0H@U-[7,U1D"G4DW^Q;6][>._T?6?4/W@20RL?
MS2U%$1*;L9EY3@J.^V<&<MSJW"")#3Q<@DV@6XU/(B`#3R1N[$]@9*+*Q.96
MT*Z3S`/$;=D)FEVJZDNU'#1OLB!EZC#7R[XHDJVP;YH2A':[JQ;)6)_+G/):
M*G;9W4SO239)Q)\9'"L0FOB^])%F`:`*<+='TEJA4T"%2?SC/F#^@V+D5DJG
MQ(!ZQKU9<=R6<9/NX4E=E!8C>?GXM*!),NX[2=Z%7(;?F]RVTI]76!7^@22`
M,S+RJJTA4]<:$9`!("'(+?B_&/@M?96D(!#X@@'U9G9XDIZ9^SIS+:K3>321
MX*-;A13?=>'0&0^UOFF"]/7>:7/E:4N4>/"4=W^FH769BBFH*I\<S_E#7/ON
MO_G:%7[Y>.U$UI<__(4#`USCM2]>Q!+"^H"WEZZ//JNI[UIGWI6?1/$*YUCX
M:2K$+E;C9EEEO1JT-76\OA\3<NX$T[(%N9OA5S1F'HLXG]CT>JY2[V.HKE(0
M?JR%&?0"2`M;$/+2!?W%2R!#\N^RTNQ?R:LF6BJ>'GZ0FK]))P4R&6RBBN80
M[T>9)O9V@RH-PKDSJ.-.S(-0"P9%FIS=^0UF*Y^BH$7D.F[%=+V^/3ZMG:Y1
M:?=#I66\J9=Q&XEW)WT65W.(.NW0[@XT`/9=L^V/[Z+8-J[+0R9Y%5VYAH*6
M`[1)=YJ`425)G910RL#/+%'.P&D4!-$U?BKBJ!\N,R3,V$<.D+R1(R/."NM$
M*JX_Y1Z5]1^6''$6^%/\?H!H/&*F8?QZ%6$H1^"G*WBF,VC_8/P&I^;#N7C6
MRA>!![_CK[&??#N98C2*NN%&@J<9?@`Y5H3:R*Z@OM+.K`SG_S?3F::Z6T$;
M/55W!%.?HGD>$DS]5@6@3F^-7O>-5.T=@-5#8`UN`A9N^/;@ZK6ZIVOP4A+X
MZ>$U/JV&%W]?)L&-D.J!V75Z!TAU6@.`5*/;[<[H=;#BP.1:2KT3!&=T5:,&
MCGX)@#XI\:_P,:4G==L_G<_%XN23`R9;;)VII_3OG9]>LW?!?.PC#AXZ?&ME
MPT>W9;VJ'M(<R*80)5Z?&YU$UXCLDY7U(<;@Y(1B]Y,HY,="]+4;RI"^M#>U
M)%8.J]1:A]3-$\3=*A-TW3.SE1()"BK`LD0Z:!65/#+5JI^OE+B'N^7J=:KO
MS>_*-C"9H:"JWTJ8/[B`0J@K&!C0WW"[AS9K(BCV%ET:9F0RQ]1'ZY1F26-$
MXA6.7KCRQ($P/02X^E3XE'%F<<"N!F+Q0M2,LZ/P!.5-X>/%=P@]JRB5<7+%
M`;LR^!:=F/@J7[XF_G<`L.>L$AGY?!VC)S/$D#X?E[#.3,9VGGU`88CUTV..
MC4X9T.OUY%2P!VUUE>[&<00Z#D8H<W2P/P5P`&\S#2-7R^_.'YRBSVC02[%,
M9=I.00G2T>8&22+@_)3P(_"_8:".A*5F!-8U1HHBY2)""*\4W5FM+<A7$5E*
M>1KPC:.R1(IXKB(TS2#J+VX:X4;8IWJJ?:IE7"CBJ/8;8.AVS2FMT\RX]7`&
M6&-E/K[R44<&.^FV#VMI#K8W"C1[Z/QD#5J]C8+*?+8[&K1&MQ9:A9%:?6DP
MK'/BV\'5@*8B_L(SL<#A.&<&6.HR2M"JO0>X#V\)]VV!WN_T6YU[`7JG=3J^
M@^W1L*/]V"5:V4Y(--,=%V1RI<*"Q.$L.-4HQ6"C%'%'JTSP59X&QME8_99U
M4=+0:0`<KBC]68I7Z"(X/"(AD`.B;#%DB>C:(^_W2"8>H0JI39FP2OO9'%AB
M>K@Q?V637QYOP$MN>75E3.HJKJO3&@[J+YQ?%3><!RE'^GZQH[B9"DJ^\<7\
M%#:YT^_=IMKD3#>B1/JG#VY=C095C!1/8G?;JMN^`\]$?U;[+IS2X(P[AS9N
MEQ_4>(=,CEAY[U3'?Q33NJ.17&;!166F<T<':$6&0$Z+IIWV^MY]RSM087=;
M':;7';2&MZ?';JL]^D%=C9I1J376']JSX].NF9N[.>MVS77=OL^3J\GM>-*3
M:PW&6VO]O5ZK>P=FVFZ->W6G%PO/3RM.KV/W1]T=<JLY97D#.@SLT>EP:X1H
M-UKRH<L$1=#=XB7G>AF#HN<LKVJ`7Y+WD],TS219ZP)S0LH7"_0P_E*\`V"\
ME^[%W#-%BH\,\70PJS:QZ1;`3]2WQ7`.%4(AW7BP2N'ZO!H")OP$&(_9RNAG
ME0JFC14@##E8ET2`=L%B&40K(3@1%0]T*>A4*<DW=@A8-BT_6^(+7:H.L+L+
MTK:RD`HP`)ODR="IYFN=UF"@D]4.]2@:DCT"DLW];)VNHEN?RH#\D85<!X1,
M,2KWL5Q&(&OX4@`]P;5YKYN#II=S$5KG%/UT;QFR"L<5#T&VL'76+)FE:R;I
M#4'0M:9E51CT&IA/51+L^`E3UKKMOM24.JUV=X><M4+<]#H*:4__VD^PV_<Z
M^/X,%AE(>8$*(**'1`L=&%S$,SQ#6$5"%S*Q<."/!-Z!_U>1G?8:>`I.27U+
M79@-KYC2:Q%<:86'B\`4UL>^'*GM(3FLH:[.K;H5FR:5N#!EQUACX;7BS/<:
MR]JPYOW890UKKH_`4!$-Q(%R7R2RK%\`I8`]@,Z3_AN&FVT;X@`_?D*.;;RZ
M2VX*.1IO7=,@RN(MG(:RUM4V62JO!C7\VBQT4'0>UKT151S.XZ6R;'0@]@=Y
M.&Y_4%/8H#_DI\A3G8*N.LGD>9-!C*$&)S+40$%/R8-TGFVHAK".LN74U"R4
M`V,A(EG'9],M=/(04NC^:RCL$^MX-@Q2QQ<4;C*U7:FN8"J2L[?GE84;'.92
MA:@0@T^95RJ[L\Y\R&?$18LGV&D_H2X\DGDGK^ABQ/0:KJT3,2UGIKW1`S'3
M\J2/QDK+$VM&NGY<#^C%[8SR`^GUG\"-VVY7!,*WNGOAQJWSNI[:[>'I?;IQ
MAZ=V?S1^##_N<[U+NT]-OS+0F>*@R4=S0XBU719A%W$T%4D"0D4.N(/ZWWMH
ML753F;,[^F<DZV,OS2-*IDW:O8+IJY+,?LVKVP?=>@>A\!A2O=/NU@B1$EO=
M<#76';?ODZ,"G'K]=L-1GX2C[D^F(E!PI=[!;`W0IDX#>?!4/)F(5VU=[0\`
MZ^.7JL"V?<CM8'QOT9_CSGJ.WNU5Y"<+N*U6D.M215O=WD/KQN9(I"4W/')7
M'GF6;)>^@A]$B`7_T]CQUIR?W7Z5ODJF,"IVP*ID'C-GZ:@Q0(ES*#-'A().
M%'"7BH@8Z#)U9-<#?8.".!J!Q9Q7\K`6PL'BVJ0!HV9XATOI)H;P":5T,6BD
MQNY!W9ZR@"H-H')TR"<?D"W:F'*J'CG7XU7DFLJ'BC$FZQ<H:BSRZT0J_*1(
M%CBG0F*C8XXLCKH>!+ZVA;H,MZ6ST@^OM0`A?10+Q>;/)R((]`O=M8HK=9RA
M+L`3Q=%+K%F":G:[W5FS3"J"JM.\E'ZU[HZ%4KZ[U+6`5Z1-319!DQ7,.>S:
M/"](_?ZX<-TAL]:4^//\Z120"4-US'X%:L'%L5499]+2Y'=Y15M8[9]91`X]
M'N3+UW/K;18$`F93@3+\B[E+3E&\H1BLO-P]F6`/@&+CF:B:8":"MRB3*.4I
MKM?)W25IM+D^/GSFJO3W4546J0SE$5RN\),(K$O0/L-$4`X()I-4Q'MQ_(YZ
M#@."+/3Y@UX*B.1&033S$^F(HBN3!(,\4,.+?:([C"M"](HM+\YF9I2W#>PP
M3BC5&%?Y6;JEK'-^_&.8I'Z:R0S?$!][ZZQDM[Y?`N=[=+F`6?^.H$*"0$V:
M&YL@:5Q@,`D%UFUH[D=1@014N428*':6`AYR$U54P+;.$A<&<I"IZ5\I8`I`
MW"\!*._\$TJ?DRFXIH+3@/MM3L@!%DXD"6/558:ZHLQED()DRRA_F=30<,SU
M(P>FGV"$8S&)"`[/HP*4*ZXI#%P=.,#,=ZFB,:AD%3LIE!HOUN^Z(6UHNQA%
MTQ_([KV!X>&Z,7J+''G(;=VY*,QB^@T+24OX`S%<#*T<%-:<)QL4LHH<8*@Q
MXL7Z\V1@$0I[#G5XHO48BJJ+K5P].#5YN%8&\`]4;7.#<>-FF6,_X658IYW?
MO9C'L%M@6`D=UZZ11LIA^*[L7<-)-GO%BNP,.!0V&?/DJI)JMUM_..1&6V"U
MC,:#8J,MZ3^67TD0YK!N1.*QBL2GKY94ET@^N),?ZYY3QQO\/WS\I^*1W5%5
MM$Q].2=BBQ=Q='+&4;OGSA*LA\#Z!9CYTK9^^^V\8"[G3Q;L[12[&*0.J![&
M4-0;`6T2,/2"C-1%:I!0D4%L!N<:YK7I"?#0BJ[HN5RM`4635,91Z-1#%S4L
M!XM^S^1/UV("8$Q)BZ4N;C)]@I_#]>=F/!SO3(9VR+=`0(MP[K!N5J<%7?F)
M/V'RE4OWI;8K;V8);#!\''WC63FZYB2@>H#2H8:ZE&SK)S.@XYD3^O\FEP8"
M,U%Y+M2/,__-ISM#3%J)'.\DF4?7O(<E0@4T719^H(&C,4XET;FA"_<$+@'?
M5@H\N_S-.TCG)A<&)8G*2V>%'YTUST2=!X(-=AB+'437LJW;Y@#5C95FBQJI
M?)05TU$A4]WXJ1Q)A:LJ_-PUWJQ1[\K+,I)GJ_6T@=33AJ--[H^R#V-KO7P+
M9X==Y^VHVV+%23V<+CL>Y2`JQ'4]2$[]<%0MRT<#>:?7K4@.[3W.Y=2)NI+Z
M2JZM\2ECIJ:)]8-2-@GI_)*DMLGFWN3#*@DA69&L:J8G\F$=E$/^`!6170Y&
M?=SYK(X>BGD:U2<'Z*FJ`KN05=O0E_,[&CZI]1;_6GG)35X^>FB;%:^U6=V@
M3(-B=SX''K-PM%J0]Y'\)#V)[XR<0O*R>>*[=;D"\E\D.DS-"H34>V`E])I6
MXJ1RXW!ZJ[+I^3=D2,C5K?=9#`S+MLXR='T%OL.=21P`F[%_='&B/P"3A%68
M&O&JO'V+,T6FF=0OUAB-;H9BAV03NN`X`"]@'RHJ<Z1W`1]<..1,7;$"`1-B
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M."3V5WC^"[#=Y/6GKA[;N/X/P^-?UZ".@>`G\IYY"[>_H8]8:R5?&;2]"I^_
M=.[<Z/KOU+C^-X3<]L%*[I[>EX/_L>R'`V=77\)US?3I?>W;=R8P[>YA:[0Q
MY+90>NM.#0N*`:38NJ`"6<JX<U>,W7\7_6ULQ@.EF[,\$]0/J;Q07H7%8%X%
M8:==)L0]"S0DW3786D\57`>Q^SE*82%]>OZT0;%=4>S0<.KCE#UK<ZEW;^2Z
M!1\<*B>ZK$C)O4`,CK0H].XETQ5K7'*T22!-DD1K`70U(/US%'"3I7,P)[#+
MT03X=A9*9+UKX\8;>M8^5*3O'0.!#P"/SN"$%PO4X^!LBH5U<J2Q\`;@"L0B
MWBZY048>ALH;F0(/HPA&<ODJEE51AJI.]0=)?H7B$S;G$F)C5%:B;K%X,%(U
MN;G6!$SYZ_M@>P=XAO>QMTU4P5YY5P1!LG30\/CY1?L%?5YBD0/Y^=KWTOG/
M+SKM]@\OU"RWW4D:%SYYJ&'"4G]^,8G2-%J\J-N%7,\)/_:FN_Q^*Z_P'LFP
MW.]QBYB&'U.O@>.CP-&-D#;@B^X+*XRN8V?Y\PO^5\-X@D9MK$`Z02O'`L!:
M213XWC;@=2FB8P\!7'UML,4<]-SG#,/?Z\_B=DSM2($531M`;06H2U(X;P^L
MAG4V(NBPX-B(H%LSBW_2B\)K>.M6X#KC8,D&6EM!Z[WTM33@V@I<%^C!;^3V
M_LN;!HZ-W&[D]B&!JY';NT#K=U66LX'75O`ZCSBR*W."!F);0>PW?]H0XW:@
M>N6'N?#]7PS;>-WHB'NFV_Q8NK6)M?H"^LHLQLCD$PP(CM_\E^M.IZY;NO-9
M/P9YI33L_U![)`<._R]5-_11EE+@,*7AI=8[X<J^V;)VP3TBNKJTVQ+`#X)Y
M]=MY)LL?5RZ?D&\;_.8']Q3!1_9X/++[W6&#M,]S^8?'DU_>/ZH>,X6W6\-A
MOZ'N9OE[M/QJ>CN8Y1\$]'=0]Z?TGT;=_^D7SN5JN.5Q+?^8Q?O8EN5+&J1M
MEK]'RS]FF@.5NCMHZ*U9_AXMOU&I]TJE;CSHJH:"2F5K^.5Q+?^8!;S.=.MN
M`%2#MLWR&ZIKJ*Y!VZ-??J-<[Y5R?7_^ZN.+&*)R<$'PR/KV37#<?\+8',.]
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M:[C035SH!H.G(9QF1P>\HR;;8%]V]"27)26(]`]?N=DF`>%O62BL7IN2#SI/
MR<G7X+W_-%6E)<`V+"_*)H$X1AVH>G?/2PGJ#.W3=M\>#+I[I0D=(/T<WX[N
MPA$.3[YL2S$;<B[NC5`:QK6%]38<CAJ>U>RHT6(:9M!IC4X;7K!?5WS[L_T#
MOZ`]VN5O'4VSI^L_</`WRV^0_]F"OUE^@_Q'#O[FWN'A[AT$)W,X8'4]?>&C
MO;8]&JN]L=HWW#V,1G9[4\6EAGZ>YXZ:NX?F[F%OCZ'=&O8VI,0U/*O9T0&J
M*<=_('N]HWW(PWDFYEH3)M:8:HW&(TVP;AL[66\(_VK(X%GLZ'E97`];.?>Y
ML1$,QFI\GL]]1XUJ<$PTW6D--\14;4W2:;0\>.POF68_IFA(F-],XA\W0J?T
M^?#$Y=:(<+N=]H;[L]6O4>H$EB>F(HZ%9[G18BG"Q$&K$NQ(_%M8TRBVTKDH
MI!\!PF?PS=3*PBN1I/!JDL)&K$@:I-<.&*7+91Q]]Q=.*H*5];+?;MN#=GO-
M)+6MZ[GOSBT_L28"QXZ%&\U"6"<,FDT2\6<&4+/2J/B:%5V)V'*L:X%`$MZ)
M`Y^=F;"6(O8C#]<&"T]7)],HBZT%['V>M"K0MXS--Q)_@]Z'@]X?0\"!!:-S
M+&9.3,A;1-7Z%#OXP?2E`((FV0+63J@)"#Z-@B"Z3M8P^DV#9CNB6<767-B.
MB$MN/SH'K#R3+!T7SNCG%^T7]%E*5/HLY>]I.Q?`MUU[R4NY42\,H^O86?[\
M@O\]:#]Y[\CV<X3;.>#E][JP?C="&H8?NVM'LS5OV#_&1Q]9(WDSB0*/Y_BG
ME"Z/ZC,X!$PX\.43FVP0^=D@\MJEY;.4/HURL/?;.>#E/SOEX"QL:N0?V?*?
MG5[P?'&X40D:E>`@MG/`RW]V*H&,ZGNF+/5HE__LU(+GC<?WIQH\UGD]M$IP
M=`BNNIP]#(8?`18<!*$VFD?.L?/K[V?*M8]V^<].^WB?AVX\4UR^?^=$77,%
M&19ZD#)JD_-BE_T>!=%L,0<]=Q'[KMB@V3^D(J36]3AU\)]42=KK4O^WUYL:
M\KJ!O%Y=SIU8)*\?B<"."_N.;T<WZ6X-/37TM+<%U)Y`5=Z0[[@3R=4E,3W4
MNF]HTG54QLFNRV_J)3ZFL-D*_@>8YS<:]>S1(^?_'\*A-S3WM#37;FCN2`_]
MP2H=-7K5#GK5H+VA8L/S9I*'OOX]H_?GJEC9@][`/MU$9D?-YANJV]/E'[=J
M9?>&`[O_;*FN<5KM@W(U'#R8<K5G^-9P^3U=_E'K5IUNVVX_6Q[?T-R>+O^H
M-:OG37.-TVH?]*I1HU<U/+[1JQX,4`-[V!T\8R[?4-V>+O^H-:OG3G6-SVH?
M=*OQ::-;P?*;53:*TLV`Z@\>SA@^@+-M5MFH-EL!Z@'UFKTYVL8U]/3J2Z>U
M$<V>C_K2&*F-QO,PG-QN/Z#.<\C'WE!=HS\U5/?DNE7C&GHPW:K;7+LU7+[1
MK1[N`N`YL_B&Y/9T^4>M6#UKDGL*C]4CEGIX:$7K$;?2><A0\D??S6,)A\/?
M4EW=FB0*?.\@6RGW;K.[XY`U6PS)QG[[!J'T&%+J\&FG80<'L#E3N6S80<,.
M#L8[N->=ZG=6:#=NJ6+^^\>H0P'@#@+F`+=4Q8+[>9W$@Y0PM]K><8B8SM`^
M;??MP2/7&#I\.FA(^Q!V=Y/R>.2DW6V/[4Y#VK5ZX(\IMC@POYG$/V[X6(97
M-580&/84*;9&A=OMM#?<GZU^G0O+#]/8#Q/?143.A!5-+9'WMK`F66IEH?Q&
M>/#X23H7)XLH%"M8!2S?BK@1E^6$GG4M>WA;3FK]#=ZS>FW;ZK8['?@%OEPN
MX^B[OW!2$:RLEP.[-QS#_^"1B8.#1Z'E6%/'CRT`P3>1YDMZB3D5UE*`58*U
MEO')PO`MZV'W\DZX8C&!Z7L=FK!=M9_NT!ZVM]M,;U#<S-KXK2U([49>97S>
MYID#Q6*CK5#U^:61Y;A_9CZ`NL]!U`SX!`\#,,`ZCQ9+)UPQLSSM=D8_)98;
M+0`Q)%K,'<\*(SA"D:1PM&7D;EEGI6]L`WM@*6I9)C9Z$0WIAVZ0>:)RM9U1
M&\LO&:LMK"J=PT(0@5R`"NP>#L;*EO`S[DFA.;ZEQ\8''8`QXCZ0@@]?)5$`
M&TJLI1.G"A[IW(\]:QG[5X#9%IP-("<._BH1POH<P7?]UZU=^.1CB(`;!-'M
M/Y=__<N/67(R<YSEFW=^X@91DL7BRY1JP+]%RD=L$F'BX)&?(>!G!+WD[2I_
MYL)9X7=G<#+>5P#"6]SP7Q6A_D5-`$,M_)3>/@MA8'G,KB^2?&[]/ATO?/A=
M3']^<<Y__VOXZ?V_>NT3P,X31,P7?S5$U_J?#W50EIKCGNA^Z_$*1?WIK=.6
M)<]4(>[MQC'.AFB\<#KE*:H_'C+LM6)9L]4GW!LO&/]^XZ<PF?O3[7=;=_B_
MG[T[V[^=[^&IWDI3>)#-O9].A9OZ5\+ZY,3NW.IV45:WA[:I`UC4HH0$)`IB
MBP[:1@'I`*E[P@/)[J=S>N7SQ\_O+I7,_/SQ5U9"&37\Q)I&,0P`HRWPF>'0
M`LF=SN%[6".+:+T@#^4L,A'7":V)0-$<P%>Q$X!>B2/XH8.*QP36![.#GHCB
M>H6?00.]\DGWN8[]-!4A:A6^*VB9(.43_SL\Z#FKQ%P>OR5XD;@6-PH"!^Q_
MDEJPA/1:"%8D<";D:#Y_]/%4_:GO\I.X:(&:+7^$C3HS8HFDG*1PLJ#Y$GPR
M-Q!.;/T.FNXRA5G/H]_%$M2:!/Y^]?D$/KZ&N=+YM;.B5<T"'\[2<D406)X/
MH(IQ8IK&W(D3)%&^'9J5SP579A[LM0\#@83T,C>U8%Y!2`"'[`F&,.P-[05:
MD]P++0M>BF.!YY'PV<-LLS!*?(*)7":LW,=]MZR++$XRT+9PZ%0MLXAC/FA>
M/IVM,XL%G&NJMV!-L]!+``$\$>>O*^`[BR@+24U[*6^TR(Q8(6!A#'S72J]A
M7N'.0SBB`!`7UIF2\J>.6O]H`V7!LI.4GX1W'0_@`%\@&@!:)MER&8%:J-[4
M4',0;7U$"R*-:SPCAU37I3P]?#5`M*%CB)TK$2!L02\2$A&G?IRD^3[0GO(R
MC;:=TS8AK2*O"EJY)JW5)UUVFL$*R"@$H`Z9KGF:1."9%^=9?PL.OSNFUT8M
MZZ/ZIMT^M8U#P%>!LQ$;P+U>`B)+JXW4_O98,H<0.(?G^8BJ`%@\%:3/6)!6
M[VEPPM'YD:>)C=9.YE_[E#:X-CZH+A^*[Q(O^>*F$3ZEWDWG<93-YI7K,]%P
M'?DJ5EW&1`/W;'QU(G)P1EEL_9D!OQ!Q@%@.Z!4$K"'A:P/YEG``A="205T)
MC;:PO`430Q`2\A!O'!LP,9;K@4'S_<NS9;`R]Q\HB`!2+QFU@E4K%X#OLAC7
M=I;-LB3-OUZ'8E%@A"PGR%PR&0!^8-RQT.HBJ4"'MWY(M><'AF:^$)/-)!G2
MI)JWN+PYBBY]T,X,_IR15<<6"$.O(XD#V0RPC]J3@Y?(=BV?6*=-D/V;$\()
MK1BV:`23<9L@U:)@"%%:^8#`64A'Y.8:-!]X>4QC'3G=5ARLG!ZW75I"[1#:
MX=(=28?+[AJ/H;WMH-*H`==4K4J#\X9YBXI5/LDDMJ0U?%2*FT/HF!]_1]+U
M#12)Z,\8D*MNOQJ:4U%-@$?@)?%=H2X8$"BV6)\#@0&BG@@CR28+U+@\ZX\(
MI@I6Q>%+C),Q/%^*9+DL#6`^J1,HNF0^R\XJV`4.*"7C,!>,58!`0F#-$T7Y
M(EO`-T`2`0!XY02@"N+`/29W%'V27CKD+"7&[`3`2!RI54Q!+XRN%9#H*UC#
M]=QWYZ9ZDAA::GFG10U-"3\%;ZDS(`\&K1+@P>M$U4'[45_YKP%'`)]@:0DJ
MO04I)EDJ',>)/"I42U[Y\!+I3.[<%U="`=45,;K`+!=PD?2>"4BA.;IH$P8>
MO"C?G*'3C`34%$>7@RL]6DY/#(448WF`ZM0B>&$FM>+0^AQ=R9-J&Z+(G:."
M[)FZ'<`#%&A4_:LT,C=*4M23XL*)L$92\B&C%#TC-"EY)HO:"4^;L.1$!6Q9
MT%_])#_)6[#(9VCP'I(;XW>MT(>(/Z`"14LB%'1FQ:#EUSFRFB/?3U'Y);0^
MB$F<JT#MT4;W!FA[)\1"#,%DT+_!Y_7[,P<YUOE<+$X^.4DJR/),5B$\A:N!
M04&O6V*\(%C6"<"+/!<@N7][>X)Z)K,U&"HB1X9^.!^"_!SF!,NR25UQ7X/6
ME4A`^>4US\'BM)912CZ#P,H20<IM+!SBZ(X%D!8@7Z2.BFH`&V]1EH+$!\%.
MK-M&CPR(C$3JV`G9^Y,`U@6'4&7M&\L^4S"M,[MBX2\F,$#QM=PEDY#$PNO%
M&#8!\HE<-`Q!94S3XPQ*'Y2!!+?J*7^!@FF"\M<5B11Q))'S99"<*RS!`=OK
M2C!F\-T5R>D,6`7`;,?;LZ*\1'N$?`E("00UI3C4PP\OW$A7`!)0PD];473C
ME7NYI(E1=(8UDNO@V)A23+M%%;\2/:YS]VR5G0U?::;88<.PSX1`#Y/#+UCE
M'CA)?\R]V/^@Z0CM6%I]`C2I[V2)@R7K_*[7;F_-(DP7L\DN-)/P:KE$4L4F
MBEQ"&?Y(.B\[]J#-)O-++D1O:I3I'):D?-6"G4#%4`Y\$4WFDN_$>I</`O2X
M]1!R>^QM`!@5&!%IIWRL+X=VKSO@9?=Z[)`H+N"Y$_G!TGN^3Z!\]L]UI%^F
MK+ZP^@$2)78\\=VZ7"4H]6SK8^BVR,-%#N^2N]V:(&8B&K(2HEUL^-@'O$7`
M2)XK-+]93I+$@>%`[[9`JZ`0'T]+Y)>=-MAX0V`B&%Q!^L9+8"S=]H`B12;H
MS06U(HMCLNUXJG+$2)5I=AW%W]A-A<L0!0>LS^$;J)4#J<4MZW?TE:766_QK
MY24,J&E$S]M`18X?`\"5E'X;.;''_D\8%PW?=WX,I(/:P[0&GK:*<D+_!A-A
MG<#GX6$D-6J"5N\GL.R[<L<;$;AQ>E6(P`(A=';R<9TE+OP-I&)=@*ZV<*Q?
M``F7>(#J!LPQ)%B2@@(L;D+ZKG0"%W`>A8?&>>D+J<'WRA6A?P%Q=)K,HXCF
MD0\R2BY%!OI;8DR*F/])!-9E%*-D`PT==?D<DPT@V>27@L\7(";HWI(#->:^
MF%KOOPLW(Y_*E^D45$26E_E8M2O&QZK6R":'(X.Q,B3=29;`V2=HG`1D3B1S
MGP?07BBI)Z-"/0>['"R-EO5K=`VF.-`P[E7MT_(B1!J`$<\#.,!+K9F%T`!!
M<AW"H/@-3%>]I49P'AQK4-KQ%KS!DJK4;WR]'\%;ER*^`I1/3!4:T>6?'W^S
MM$M(/T^WO+_]=B[=RFML8Y,LHX0"ME$5DP'T90M\@W0]M;M]>9D'6*MDLB$)
M#9]DY>3%&S"/.=/+0=_N=-&?CF%WQ!K`F#76>;<[H&<AE@J:FKX\.+V5B)I;
MERDPNC"IPRQY&5./*6,223OA`-B3HW89!S0F[^GY'Y)/^1P$4!:0H6E&OS8R
MYJ#H'*C[;!G[@55CAFTD[;*.9ERU(J6[C"%Y`)GCH3BRHBMY80HOD?Z47HO@
M2OHB5,0+>C%B?6N[C,72B?.1Z*),S#@&*9J@CH6/%DP\[3E1-X`INDV4[A@(
MQ\N=TO)+:34R@RK?;\(007Z/*V];IT(85[AYY$1=A$6G2SZ92(%=^JG82Z/C
M(@8J5L'T\U=RWYN,,X8&.JI@3NGI);^9"GU+"WM4FS/N#>]UGYVJ?:+5$`3%
M,4CYS8T-#AIK%-C#8BX4W)4'%A#")()#%--Y+1H#PH2NOP2L<QU0'O(+=HXR
M-,*)-(V'L'^ZRX#_2Y#6$=$3&4=2<DF:'M+^J&UW>T/3V.T.AG9W.+(H[)-R
M=NB:A;P\(=X9.1,_\,U0632UD?]YQ/&P``L'\3H!WBF!T2=$NIY+9)S\F;R;
M-^?#@6F];A1DBQ#X(?JOR;:53^,E_EKZ71["N7!\TJ,EC?.O.7"4O[:<D=;9
M@LAR3>?^PZ4VXSDEW0**M7^X3Y0]W9D<-Q+G$@SODTDLG&\GSA0$Z!LGN'96
M2?7BJS?KDN2M>*,NFFSWH;;8T.:!.>5[/T_D*17Z?`#F>!C9GBP=#(']^47[
M!7V6J>'T6262MS%#OZ#`[YHDQ2G=]-=ZOOHNU8J>1M1Q@GII^6FT/-BU*]`#
M"P<$@"^Z+ZPPNHZ=Y<\O^-^#W=HA'\LAKWT-I8;U*+6Y1MR6(FC/M.8:9X3,
MLTW,N'Z1?WB[RO_^7U1^MA$EAX\[ZD/<"(C]7/LN`N(94?-7\@,_#QH]HK4W
MV%R)S61Y-\A\8&MOD+D.F;O/!)DKM"=]X+6U<JT-J"0-_6'_AWH@W(0L^^O)
M+N28>$:.B8IFN^%J<!MB-&KNW0S`_>$A.RW[T,[]Y;T=Z[@:/K(&Y0T`NI\"
ME`\"H>ZX8[<[XP;]CWC9#=4V5/N,T?]`E]U0[;%1K0XDZ&YW7WC0)+"3A:*Z
MTCU?"\6(6,PCGHX>28YRV<?*OF387(.4S;(;6FIHZ?DBY8$N^UAIJ5&K&\=_
M'51_\__,9,BSYRR<F4AT=@!G\L5B)BN;12'7@TD:!?S`EWVLC&[4IU3W!BF;
M93>TU-#2\T7*`UWVL=)2HX`_M%][8_C1H>GD[S)!Y3JQ+B/7FWD4K-FW$*[M
M=[(YA&^OJ&-[!KCUI@Z>/8Z[]J@S:G#\F>RDH=:&6H\=QX]G)PVU'C2U/K;I
ML6^(_B37`56]XP_6&KEC/M_M<:?_U+AS-R8)R[>\*)L$8@.7/#1D>)@8QNW!
M=_#\6-8L:NCIF>RDX0P-9V@X0\,9&LYPZY3CY\T6[L6`,^%X2-14L-[4!PQ.
MJMU^Y:>__)@E)S/'6;XYS\M/GH4>-M"#[6*'8Y&\\Q,WB)(L%E\!*F_QS/_Z
MG_]A6?B_OZCW+[-)@CW,PO3]%0ZB'Z5$:?CPNYC^_.*<__[7\-/[?_7:)W_+
MPA.L(_&"QI-8:"#D8Q*V,=V]GN<6XZW7(QBW%$#T\=]NH/Q8+#Z7M7'KO]`8
M4_Q<=2`[E1UDS+EI2#[C^ZXB<?,>;E-G]J&=?3=<#W^1W=>[E?T4\DYY@CN+
M73M8V)R[53DN=76'5WOV:-`U>N.9/?!@/">5W<EC<>5'&78<\Y,DDU5DHS#$
M/E;PO&XB7%4"EUNB+V/_BGIX@W3B8$D8`EO>XX+,C72-:K+Y7Q]IOC^RL#2A
M*-=_5OMD<&#1W0#[,(CO(G9][(@LG!28&G4)\D0@L/EOU835X)TZ?HQB)!.E
M^?*%4%<TUPG<+*`XTG(CR+<HGD\NW7F$C8&Y4^$)0(?:RB\B6),M%\==!OD4
M)\)ZV1F/[=/>V'KULMT:];"X.)_<:VX,=^T'V!DX;]`;P>@BEM6&;^B6MK%O
M>_[7U^U@0!LP8(#=7F:RUY,JH>R'RRR%<6(?)5CR1B(=0D)8)Q;N<?Q3?F[&
M][U>[R?J$N?BV($_Q>\[5`G8^/XJPLXR@9^N+(V.G9]@>Z>MTQ^,YX`C8)\=
MSUKY(O!@I#;\&OO)MY,I@LFGLO&`P%BDO3!2N]7I_[#.LJLXZ4W<=?US^==<
M9M?*W'7Q?,$=N9(/P%\N$;I?"-N2]Q*H6-O$]1=.D'`QUQME-CR4A3X_\8_+
M=R_^VL[7=>-D?WW8M77*:QNTVT^ZO/,,&Z[>^PH#_WM:>/9C@OS%%5^FGZ-4
M)!<<K_XUDBFBQ/3OX9QO,^_CK7@-MGNXXIL1`N0AH<0=5_Z[6,H:HO7/WQM*
M;#/9`Z^M]O"?9&T['O/V:]02`)G#1]+#N'WI!;49^1\4R8_!2G>>_[&7_Z_+
M%(0UPO0]*+KI"K72*"0K][N?_.N<E%R:ZA/I/.7M=DZ/9[-GWA4RCN0?F+[$
M3WSP0_@*UE*]^R,ZZ3/=^^7"\;V/X;FSQ!92U?ONCT^[Q[/UWP4V$A+>>R?&
M=D+)$YWU)9F63T[6O`RD[,YXV+]QTQM6;8@+>NJM`U_B2L#R(5/K'!N]W56X
M=KOC7GO0D2*B?J('6<T:^Q_WNJ/^8ZUE"_&Y.W#.I1]`'>.7Z3^EG^`L].01
MG\EF.D(]=$$FYUV!=]KOMD=RK;=?QB/MY6;@']1VME1A[[2/O_SX?1('_AO\
M?_CX_P%02P,$%`````@`BH$,/['_]8"W!P``%VH``!4`'`!L:7AT+3(P,3$P
M-C,P7V-A;"YX;6Q55`D``R2)14XDB45.=7@+``$$)0X```0Y`0``[5U?<]HX
M$'_O3+\#0Y\)D'0Z;2:Y#B7-#3-)R>3/S;UU%'L!36W))\DD?/N3C"&`)5O&
M@&W:)X+1KG;WMY)6*ZUS\?75]QI38!Q3<MGLGG2:#2`.=3$97S:?'J];GYM?
M_WK_[OV["P^37\^(0T-2$'[^RO%E<R)$<-YNO[R\G+R<G5`V;I]V.MWVO[<W
M#\X$?-3"A`M$'&@V9/MS'CV\H0X247<KY*_/S%LP.&LO^S*V4-]:BV8M]:C5
M/6V==4]>N=N<BVC!O[E01CW0J=/]\N5+._JU*:W0:%PPZL$]C!KJ\^E^L$;C
MX5<!)P[UV^K7]H-``GP@8CBZQD1:`2/OCG*L=.][B',\PJ"$5>S/Q2R`RR;'
M?N#!XMF$P>BRJ=A*#;O=SJ>SCM+O@R7G=A&1!](+?.AY`AB1<$VAH*!)?H7$
MZR,^N?;H"Q\0%S-P1$'QDOQB\1SD.:$7.>R-Y+76"TCIB/N&H1)R!QX1=2R[
M]JBSUIVG!@YEZUK%O47^/4+\.7+;D+?&"`5MI6T;/,$73R+]6YUN/%(^Q(]_
M]C@'P?LA8U*Z10<>>@8OZO:GOEV[!$D54"D"1C\OY5H!K\?6143,6;"1?R:0
M6Y\OXA9M'OI^Q*V%)9`+^A&C?IJ9%OU2C:B-D,N.::"8(J_9H,P%=MD\[:B9
M^`7P>"+DM%R*I6\I@=DM8K]`7(?$Y3W11XS-Y,KP#_)"2`$AB[(>^&3JKX?N
M8P6@NX)`32O<=ECKV]<#)H.N>G`^50"<OQDB@M^#`WB*GCW(AL=$40^`C/KJ
M(?I<"*+D(J^>_.RY4Q6&\B&Y!PY2S4F/N%<P!8\&:D'N4R(8<L0#L"F6[31@
M;,>GVA!M:1L]<-U.!0;7'8,`8??[:P"$@U1D*";`;.=!&^IJ(YK+#@8<]<''
M17LC%/[]XN/,P+@4ER\8NY?KQB;_M?+4/XZ:<(8;C)ZQ)P4!"X_0-"[%@1V'
MAC)$N$,S%1_(R4H^82&XN93)PZ5TYS=KEA@(>8RSC\VD(:)*CQ56A#.%4O8,
M:H!67I/L8^MH`.H&_Q=B5\Y7[A7RT1@6GO0D)SQV#V/,I7A*D'O5+>^-&413
MFPFWK?G5!<;M#5;=/>=5"(]T.!K)^)WQ(7L0U/DUH9Z4SR8[D$U<`VSSF"+/
MSO2W#C=6K?==#ALQ2_$C3>.2MH@CD$"[D3Q9N4Q=Z]*]W6QVS3XPJ6QU<\Y]
MZON46`&3:%HC5))J5C>7W'-=/!?K#F%W0/HHP`)Y*RJD!>79Q#6"S<84%8X!
MWF)2N:",X3L1P`*&.5R!7`VQD!N+T%<(R,@G9)B,-RE23Q`*,Z^1(^S"E#8Q
M1NM/D+$>V\FM5:Z0(Y.TC(&XLQQ-!8+M5$`VA\VA4A85BVWK!I.N99[XY+"3
M5?)B40F^,@Q`Y03(.#YP23LJ2+8MY10:B!3#4_E$U\<D3FI,(18J[30Z@[)T
MOS>"D3B9SK)!=2>G*P@8R"5:B?:#DH!1-W34E_1;'@::^D"6HG=UMU#ZQ'#V
M2$NGJP]H&?KO8\MD/+50=YWA%M@86)]R[9FNJ67U#6[4L;H)S4HLWS]`S.6X
MH3QMZ5YO5\94LG0!*WEUK4OW8JVQ-Z<,K9[578X'9`I<*(^>RRN7)KK0(`6?
M5+)Z`)6N>777Y(%*V4C)LU?AS99UP65#/YM5MK6O,^>='397_Y0Y%9UMK5/A
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ML&)XE.YA9TJ#>^RE]#DIXZXK0G;80XU]8N?&-N4Y#N,DA>N[BK`\/C<H7!MV
M6H5BURKG>N<'405SO3HF.QE@<M0K$_)'VG/DA,!@\^TRIF&435C5P9("R-I@
ML3"-3<JWI&@J*3UR)I@`F\FAKFY/!H:E,R>#&J.<UU0V&>0_AUT)).);^\4F
M0!V3<HKTJ`/@\FOIAU%N=!CY`__^"LS!_`T\;<E>%FU5!U,*A,G"ODP#'?!M
M`&O2(`_D2'DKBGJD,L[AH:=FB6O,?.-2EXM)C3'<QF0'/%;+D.Q:;G!EYUNB
MN*`^<OB61CK@T=NJ2`/.0Y72'(Y^4+'<="[=2KV1S09`&S;'A*25V0[XWKI[
M".*@R2R1^335@K;NX-D9:#_';+M[H6T<#[O*!:._YV67*3%.&E6-,;4R2J[7
MUI48MJ(H_WN+1,BPF`U'\RVM\LX'<-2S]`@]/Z\C`'X+`UH=Q96;'!B.HK!@
ML;J8"D^LR(X!Y%2S5/GL;-4]H^0M?@X%N/&+("P'LX;P&$#-,$VN,Z_?,*L3
M+7G$51\J%S:5DY\Z1P2&J;MYGI`5&-BR*>D:<SE7M<L:6ML`J[D";6VTZMZ/
M+NWDY@BAUQJMNN56I>6LCQ!ZK='RY)ETJ^O%\I\BR2__`U!+`P04````"`"*
M@0P_^()Q+C$0``"3\P``%0`<`&QI>'0M,C`Q,3`V,S!?9&5F+GAM;%54"0`#
M)(E%3B2)14YU>`L``00E#@``!#D!``#M75MSXR@6?I^J^0^IS'/:L=T],]W5
MO5.>7*92VXE=27HO3RI%P@[;,GA!<I+]]0N2[<@V($"205UYBF/#T?G.Q^5P
M.*#/?SS/DZ,E(!1B].6X_^[T^`B@",<0S;X<?[N_//G]^(^__?S3SS]]3B#Z
M_A!2<,1J(/KIF<(OQX]INOC4ZST]/;U[&K[#9-8;G)[V>_^Z_GH7/8)Y>`(1
M34,4@>,C5OX3S;_\BJ,PS1]7JO[\0)*U@&%O\RQI"?[?R;K8"?_JI#\X&?;?
M/=/XN%!10_[Q&@S[-4XW%<J%/_2*'S=%>5T1\O['CQ][^:_'S&!'1Y\)3L`M
MF![QO]]NK[;J)/`Y!>\B/._Q7WOG.,KF`*4C%%^@%*8O5VB*R3PW$WLP%_HI
M?5F`+\<4SA<)6'_W2,#TRS$7QDS0[Y_^.CSE!OA%*:]GK-Y=&J:`RQM/+R%B
M?,(PF6`*N;BS)*043B&(;135E&RN\AE&,4`4Q.P#Q0F,V7/B/\.$-\:[1P!2
M.@D)>^XC2&$4)C:ZFSZBEMVO6*><@U&2`H(8C4M0T]K[\FK8."H9@*Z?0?$4
M+P#)VQRM95\-\;5L>_?(>'K$2<R&P8O_9JR[L'XS9KR1,SQ?L)^8%LQ"A<EJ
MVMWL6;5@G87T\3+!3_0*Q9"`**VI^KZ\E7HAB=8:KCZ6E=P,IA"EO1C.>ZLR
MO3#1Z':2(7P]*O.1_T.N*)=63Q_VF1L?HY,83,,LT;"7MG;[LAO3%<]#J#%)
MV*A:B*ZI:2[D9`[F#X`TJ>:6W'HZ/C)U2)0]@),-^`8U%4FOIR_"Z:C1SK,2
MN-**-5&(\BGX*Y.U]13`!ALV*F_F>JZ.M6.3/XT]+\'1UD,2[B!B(L22XYB&
M]"$'D]&361@N>GS(ZH$DI>MO\D'LY+2_\@A_67T=;(8SA@Q<L8^;F2D)'T"2
M/SN0%PY.5S9RI/5]^/#*L4KCO&#0?]7VE=,1V=:;-:JUQ%7[,AJZIP3/-<RV
M?B2N4/@HH^SY>,$UY6X9)FRF_')\RA<F1:O]Q-R!E+7#BR2OR%H^F/$/K[\G
MF#D-7XY3DH$:=%$0O9OA92\&L&"*?=@EB'T5%.WZ%LP@34F(TIMP+J)(5C08
MM$62<.2UHTNAO(2P/F?L4,8_8]J3,&%^"7C^.WA16G^G;##LE/GWM9?8?W`8
M^Y]EA"]Q+B%E*YQ_@Y!<H/B<`9)0("L>O.\("PH`$B*&A^P(ES!A"PFFSPP3
M=3?8*AE\Z(CYQ;I++/_^,):_)R&/EMV]S!]P(K'Y5IG@UXY8>U=KB9T_''2H
MQ_,Y1G<ICK[G2VDZSE(>8N2*JL=]1<7@MXXPH@5%0M.OAZ%I[?'?,[$20LI%
M@M\[8OH=I25&_NTP1AXQ36*NS642RIK]5IG@8T?,O*NUQ,Z_'[8Q3P"!.%;[
M-L*R0?^T(X:7JB]AX.-A&2@\KD*Y2_:=:-VN+!_T6UL-M\2$$()TN>6"#NX`
MZY.Q*1WTN[+F50"0$5%:^'[N;4?2&H^N:>Z>O<79WN)L_L;9[.D:40I2.GK@
M\:C7W2T!7=L%.Q%QDZK>3KS-G@2^*Z@P/?_9>8QMWXAB8Z^45?0-%Q:^Q@B\
M7(?D.T@O,Q3347H6$O+"%GO_")-,-4Q5U'0>==/EI1J';[WB'"SX/$P+A*NH
MH8(I87GG83E=?F3:MQ.;MF?E+[YO06]!!."2SX/5O$AJ.`_AZ3(CU[^Y</5^
MT@C_)AC%2YX)1<?H%E#F.4>/([:H!$N0X`6?_,XPRI6_`V0)63D!"U9RG`?S
MJKBQ1=5.F-N^-TT(6(0POGA>\"RM=1J3[HBG4=MY;%"WE^EA:2=\7M=]KF9J
M&X?K0*(N)[M:MQ,5KVO]2K.[#R":&5P1,:P9&[<W]5<8/L"$V0U0UC?S?9/M
M#,SJ%:2NB&Y$&6U0^>;+C:((9XCG6+]PQX;IS[XA&8A+H#3&-GTI[J.61G1)
M.JD9WL96PA(?4>W[E'22.8?:`H*^ZR!$#?;,H3:W'I8P]Q4RI?.,_/-P'L[`
MND5]0^Q!ZR0Q_O1;.'MDT\>,`#`7]\5:\H*^ZR!&75[K(/=M4#[/P#T>3Z=L
MQ4+HF)2-H1$#J:P<]%U'1!H8@O5@MI--UH@/5<VD:#)Q'3%I@#DQ+-^6Y3P[
M"*;Y$2D&E,\/$,T`BL2SJ$:MH.\ZHM(`=Q7X?%N;6RU25(9Q'4II@$(U/-_6
M]Q,F"[!!HL!:M5,C*!WT78=:*@PNC86)D'BVIU9*H:RB9K=H,'`=D;'B103#
MMUVS41S#0I=)".,K=!8N8!HF)=552_G*RL'`?7#&@CD]8-XM!5[7J'<I6]9<
MH!20!8$4G#/+1S`=15$VSY)\X9,1-AOOUE!NE]85'@Q<1W.LVD(SP'U;7.R;
MPLC+"0:N8SM67(J!^+:<J'+<:@3-@T&'8S<F(*LW1%I/%36]K.0M9_0M9_1'
MS!G=7IZP-L\C<+POY$[Q!)#\1)7V2DTFH%,YIMJ0?%LO;"M>G(4;9>DC)O!_
MKT-C)8F[%9WGJ]J3)X#BV\)`I/`5I9DQ844EYTFL=<G:P/#-*R\M,"W&28W:
MSO-;3:C3P^.;][YW5%AK>%34<I[Y:LF9`(=O,?\];2M'14D-YQFPM3C:8/`M
MHF]X]8!.-><9KK68V@;BP2)7>;_EVXKV;47[(ZYH;\$2H$RYN;\NTJE5:4EI
MW]:=X^+B631;9?SKG$&5UNG4:E.%PK>%YE\`,643GN,:SYE9BSRZ)5BIKN"J
MHJ;S):>2!3%QU9`\VZ$_!PL"(IAG/MY@M"`XSJ+R?>CB4Y3B.LY7FA:,J<#X
M-B"*<Y.K.YJRGO.EI@5I58":&R.E&?7\90[@&I`9OU*<"H\824HZ7S<:&%P.
MP;<PVAXH$R?!^0+1H@^(0/@6%]OH6*P3OV*J1<MK:>?G(*V\MBW]?>LH5V@)
M:)ZB6ZC))CV\5EQ!CJJ:^].3)C15(?&M$UWQY".F<?4\OU.R6Z<D!<HW%SK6
M/5[5V+FJZF-%70@2V&/S+:I\`U*M.6BKG/O3C"8=:$]UWPZ(7X0$L3&6KC?R
M_@PIC+@+#Y,L5>[`5-1T?SK1A"<-,,U=QRH9^/X)>)<%\6@YN\DXM/&TM,U0
M[#M4TV,KROT!0^W!SQ)=]6VNATM%U'BOU]NFS=NFC5^;-I)Q:SU@\@3;.?<3
M\P;,8Q*RX4E>HQ/;--486K^#0!QLRS>H5SK)K:]3MQ,[,R9H#A!]K-;C%N2G
M4R8A$1X>L)+C?$>F4:9VD+5^4Y]8IUN^_T!!?E!Z0G`$V"0]GOZ%EX`@_GM^
MM:`9@5HBG>_5U.12%V1U-.>0^3)F[R5]<\O>W#*_W+*&Z2JZ`&_Z&.5W1CQ#
MK?8FJM>>.Z=X;ZF"W`UA%<1*L'B6)["CY?G6ZW!%$1M1^18]/<F+>A7\R.PN
M"=I(\/R8-`7G6Z]/;I.N[7=`M\W7!IAGO)62?J^W_"9UIG-1UKE;+NT<8FY$
M`-J^`G%]$72^=U'HNWJ7"YI)+:Y9T[DKK6E_?3B^)3Y)[N:H["K*>LX3GPR[
M3148WQ)#;T'*\(!XO=]1R9:X@O-T*4.:I"A\2P2QVQ+UX!(0VRU1^;4?_<[>
MR>(Z<<UL+2M0W[>IQN3,V?[YK"ZEJXFT]VT.R9M,<52QN&>I>$]C?A[X!CSE
MOZ@C!AKUNY6^I@W)M_E&HGC1#&N0N2/`AZPW78:,&!;@]&P5JP(^BMB(7[PS
MT[;#ED5T(W_.!I5OZ:?*UEB/U7T9/F3<&5!ET7]WT;8=^"B?]K]"$P*7K-E.
MDC#*VRYSD,?3\70*N)K*<RRF<KJ1DV<-K?749+52=BQU*.^N&DAS&<86(<-R
MO[8)');KN[^T7YL5$TB^91^K!O;\MW&N*KUX!B2"5)F/;"S+_>7^3;DK4GC-
MY2P?P&]IB'"%,/?O`FB`\0I\U5G.=2=!54.4)D7*?1@[<3Z\(D!WVK1'*`W$
MM<WFJI$U1F>E/'>O%JC-D3[E6E8XY.)#/)/DNLG>N::Y'+&3[,-K"BR<87NP
ML@[>7*:X3,_2--(TWP:B?7@704W"#='*&!^X27X]"^GC98*?Z!6*(0%1^I;@
M^I;@^D,FN/*6SM]_QO[P5?(R3'C&6M&'KU!$0,C?)%+\U;C4S$9<)TXWU03H
MV][Q#4@YA`G!2\B&R#]?OE$>O=K<"S**4K@LWF%13;JY,.<'J6QI%#<**P-X
MMB-FEV/C.G)N9WDIBUO(/"-H%/\G*RZ#H??X%K"9)8()V%+Z'C?7J=MXG//T
MTR:;2TL&\FVF*-\ZJ&@NY6+.TU7;HD;<$':@'R12T=3!<M>Q_L,P56V%[A]-
M=QW#/R"3FO;P+4-PUZ\L05\ER&M,R_I"G&=X'G84-C*,;PF'"N5'E()4QV'3
MEN$^B=2,*V.^]^%ZYLKOZ\Y\"$QAFI^O+]0W8GJ_NOO<4C."=$D6(VW;Y]K7
M([^T@0UJ`"XE<4Z]BNZS0^OPI(^Q=0=K7XMU"M`8R38?4([K#I`EC(3YW`U)
M=I\K6F?$;=`(OBUN]U%-"%B$D.$H7LNWNN)U??6)Q="L(]!]!FH[,[(N]@YY
MZN6W.]?RR02"W">]MNR823#[[XV/H@AG?(,@?.$3&G]I2A21#,0E1$;-0$>@
M^VQ;"RIUVX2N`0[OV>U=(KU2T?;"[>:>X#XUMP4WHHXQFCN`I-TZU+Z.>CBH
M*])]HFX+_!NA]^T-K?K[28ULG[M/[VUXO]4`MV\^HD3[XI4=#650*(2YRPP^
M:`I%A05:CRJPR6@5P,Y/0Q)PC1%XN0[)=Y!>9BB6#O.5%=TG]5J:7#"J:X'U
M+`:[KW,8/4($"+_GE#?HA<2I,Q/@/I6W$9K-0?L6ZM$W0R/CM/O;AQKEW0QX
M1^;JS8'0)N9JA;!@X#J\=Y"YNL("OC6*]57<E\Q:IH<L*^L&`]>A/$N2),.^
M#MZV0S5;2K`6/)Z6KN>\QVS)2+.$#T:7D,RE?IF)D&#@.@+7"(MVP-OWK=4:
M7>*,AX`LB5S5#@:N0V8'8["$N/77>I15X6>_^$;@>'J#TTWX;M.B0B0_*F<H
M)ABXCG^U0Z8F]`.\]F.Q<N_EFLAS%*OK!@-/PU<6_.GB]>V.K-P3+)9N,6][
MI4N>%/Z.HE8P=!V(:M33J4#J6P!Z=TY@3OYUF&8$IB_C:1&`X:WR#D3\._7B
MUEA6,/0TA-6`DZN+W[>WQTXVH]+FM@4^M<A.K.M4"X:>AK`L::Z`ZMMM4.5F
MF6^+P0?^[L[5?IMF?]ZO&`P]#5#5[[QBL+[=^J0/OY%@5#!T'81JE&\SX,U=
M_W3X4_=5;IFFF&#H.B+5;!#2%+MO269<\0IJ@Z'K\%/SE'%,OJV)[K+%HKB@
M(TS6-[]<H2DF\SSQ2&-/0%-",'0=C3*Z[T0?E&^Q_2N4`@)HRE\_H\S+?"T6
M#%T'ETSL+69L%X]G6^[%N;_[\)E'2RJ(V2H9#%T'CIK@9@^2;UOD:V`W&$7L
MX^OF+HH%?M4YI/SVHHSHW@M41W3PWG64R?22H+IH6X_V[I_D$=V5+(OWZM4.
MWKN.$#5"A2#^JX^_<A`67&SWN<>?^,#DLW_^#U!+`P04````"`"*@0P_,JQ7
M(^$I``#L0`(`%0`<`&QI>'0M,C`Q,3`V,S!?;&%B+GAM;%54"0`#)(E%3B2)
M14YU>`L``00E#@``!#D!``#M/6MSW+B1WZ_J_@/*EZK852-;MK.7>)/<U5B2
M]W2Q+9VD3>XJ=96B.)@9WG+(69(C6?GUAP8(/H8D'@0XP&CS86MEB4"_&T"C
MN_&'?_^VB=$#SO(H3?[XXNWKTQ<()V&ZB)+5'U_\>/?IY'<O_OW?_OF?_OF?
M_A!'R4_W08X1&9'DWW_+HS^^6!?%]OLW;QX?'U\_OG^=9JLW[TY/W[[Y[R^?
M;\,UW@0G49(701+B%XA\_WU.?_DY#8."@FL,_W:?Q7R"]V\J6(-?P+].^&<G
M\*N3M^].WK]]_2U?O&`H*LS_@A,#O^@CY^V'#Q_>T+^^(%Q`Z`]9&N,;O$3P
M_Q]O+JLQ=/Y=_F:7GZR"8/L&_OXF#NYQ_";!JZ#`@!7,\WWQM,5_?)%'FVV,
M^>_6&5[VHQMG&9NKG`5(_=T)H9:1^B]\\C=B]/99\*$UZ6?`TQY^'T`4;_^U
MB1^#8(3D-<ZB='&1'`#;/5`6T+XM@JPX%.(-8$:HWZ5%$$^/=`.,$;I?\0$X
M7`$QXRQQN/@`G*W!C$77$DN++H9M/E)7^9G,UX*$OQ4X6=2^$V83N'7F="MG
M#=.F86O"&-:>-&OC'D??`+^W;T__]?TIQ0Y^\[?S--QM<%+,$^(*BJAXNDR6
M:;:A:]?\/B^R("SX1!1].OW?U,>^J;"$T2T\,YRGNRS$^_,']QKSZS"ME/(F
M)J!@Z<?)R8^W+_Z-PT%!LD`,$FJ`0G_EP/[W#VR.%DGSK,W](`LY4N1'"5[E
M%V_"E.P?ML5)W%3$999N=-G-44EU^>B1G,A.[3ZM78==<3FE;%'.1R<0D3;O
M)>WU/D$JAM_<NRV#_)ZBQ'=PX!#>X+BH]G3419R<ON5;K_+7?R/+;8$!M;O@
M/N[PBZCHP(?CU$H,U<36JQG17^F<SDQ:3"*W7\^X*K%,*7,=Z"M9;O$E^3%7
MT=GZ8TL<[D"WI+LP+Z(3^Z/`'5H'E=@/-JLKLX#;NAJ=X_#U*GUXL\`14V;R
MP[X.DU_]C3G_&[R*8)5)BJ_!IL_K#GXZCK$RR";:6RYG]<0(9G:EO3)*N>YZ
MR&")WJKQ>5J]/2-FDP7Q)3G6?/L3?A(J[OZWIHP=@&U!=<N9$9T:D;G=*^\`
ML5WM]8C+:OHK9?94&GRVRS("^U.4AT'\/SC(+I+%.5D*!I1X\//Q')9A8*+*
MY=R(38Y@=G+06""8WZ4ZRVAN:K2G+)?HM0[GI_7.GZ(89V<$["K-Q+ZY_:6I
MS^B%:\$OTWD1G]B]4^ZEL^N2/6&NFCL6\W@J?;W+`KBDNWW:W*?Q@*:VOQG/
MQEY8)MI93HC8C"[5LI>TID(ZYZ%$"<6LG'@OFVXV:7);I.%/M^N`,.!J5\!]
M+R`DWMB*!AKOOQ2PLK'EI6`0A3-##!)J@'+O;%48T;,=/@;9*&Z4-44TE;7P
MV/4=F7;`+EJ?C.=R'R0K]S\PH4N-[B.LJ;N.^:=Z+]/'QJFT;DX@+@#JIS@8
M<L?M;\;SK1>6B>)5$R*8T:7F]9+65#WG/)0HGYB54_N\*I=&$"CH_];<BGMA
M6W&';&8OP@-"8OM<I#=<5G6:$F9/K<$L*L&0^$1^UW==)O[>G,>#.%C1YC+N
M4O*9SN^#1@\2W:?5WG%=5;L5F'\8#8>PF[I^UU_;XG,'ODW=IC%%SS2[0_"P
M7GO";4V='F:Z@VR'J^6G*`F2,"(6G>:1)(M/:[BEJWH%#.WD2*1+5$%"')0'
MN7QC.#*827$\`E/.MM"5V^&L;)[GN,@5[&GO0S-!]$,U.G;2&3TRA7X2]Y7>
M$Z[*#J*WMQ=WM^Z4]"S(UP+5I'\V8UT3@M%5-)G'M>8U:=G7-P>LDETA#W!L
M:K2VW?*>/M2^1Q^#&`KA4%"@>[R*D@0N;8A#9Q.X0[U14"5%'),3^"#*A[/C
M+VF"G[X$V4^X^+1+%OF\.`NR[(DP],]!O!-E8,M&FJFT(EXFCH&"0`P&HD!F
M(!@.!U%`KCV'(A_VG<K1"$?BBIB,-DQ&2X#ESE3.\1:VB3E;T\L\&X&!]']O
MQGDA#B;&0.6(KA)40D!_B8HU^AP\DEURMG%M!4*R]W7?2[Y+])RQGQQ`%B7[
M'X'],6'_LH?]A]/Y'R"S-[_!(8X>H-1"KO5#(\SX+\'#1//9U*B>V[6R2VC=
M5W=O&2Y1>0H!98-L-Z@VG2\>8)N57R4W.,>$_>MYLCC'#SA.MW#X/TL3>AZ[
MQ=E#1+[K4>=Q\QA4-X[%V>B$7L($O\^ATG+'!ES$`2,.V6EUZE@VM2I5GXM<
M93$"+EZRKF1-\2X:X@VY>'.!>+VA6%;9>K?&:)<$FS0KHK_C!=K"#X1\<M(J
MR)_('W;@[+=!M$!1@@*&*EJF6<4(,FJ069Q'9+(`UN@X)@=0A+]M<9*3<731
M!CC;(,^#%:9@HPWY?T9_G88A=:,A_4N`BBQ:K<@!D!PV")"DF%&`?-IP'60K
M,FNP"J#U"R(HP4$WIV`(\F1KC)[(+\FHG!-X7QXP\S4F&^9%4&"'Q;S7&09&
M7S#V$"6X(BAFJMMGE=%F:YP&?B9>M@2#2CA4QA028J!FJ`3F>N.AP8_]3<C1
M"4OB.KG,2M/.J=!2*K2P++`(*&@;P2;+I!7-5C/6"#OT_8?<0=C4+NM&[YEI
M*QFQ%PR5I>B#<D]@@]-8FPJVAS8LJ459D;P]&_+#=,0V<W"6*5F);>NP;!:N
MS>%S%-Q'<51$."=K+BUL6*?Q`F?YQ<^[J'A2N(%7GL),/W0Q-3&Z!BRZ-VA"
M^S5B\#RZT]=ES;[]'K$$)3[@\^7\X^7GR[O+BULT_WJ.;N^NSO[T'U>?SR]N
M;HD@_^O'R[O_<;@6A2$]BE\'3Q#\(TPAO\EV>-'@E,(64&,60Q>MCZ_1TE>"
M0R4\:HHE1-0`Z<\&4Y\_G:7TV(4I"\=QF6X;,@U*F?+SF)75>AKRA$NZML+.
M$-T%6(SZBZ.-#1R&POWJ$QC$@[6Q-'$C\J!^`Z#3N+XV6UH!_>.5G,1GW$C#
M]K%8@.XIE(7L;W<;'KT.>>K-`Z21Y,*X-OPEO8^C%9TW1U%"C]D+\GF6[E9K
M%J*G7U+>[?!^W!R]Y&'Y+<[(+`1N^!3&>(:B)8K39(6S5S.8-][1K@`-3M?0
M7L+D<'WPN(Z(F*+D(:47!.O@`2/"]2@,XO@)W6.<E'>=>/&*8L17@2)%#SA9
MI%FN?`U!_AP]4$1&1?<'_.?GB&Q%@6&+\V`3K#!?/WY,R#Z5]_D"9M]$JW61
MSU<9IJG40^YT]'P&-FI*@]G)B<-&)?!J,:3@41,^8@B@"@.GWM>4;2UG_%SE
M+CMOU>)?E.+G)KZCXL^:XL^8^`.1^+WC@,R5G[7\M]1]<X?Z5+M3\("Q$2-?
MHQ_A*I9X5>+K8DQ62+JRE"'8O?O@&@.Z6D0Y72=V6YJ(M2%NU^'MZ?D.WZ57
MRR593K+\*FO&#!1R#^6##1/BE+$SJCS<T?61PX%[]"8D;TZ_ZMSH)"L>EZ!D
M18M,7GD-Q,9YUBX)PF.LG``G\6FYP5N/D4P3U_(Q=*4>H?*,R5I7I9;.B78P
MU[@T%>!]R,+G$9=#DUTF3'L!U'OA,R^*++K?%?S$>AU0X?AS#Z1_\^.Y>*2%
MS$TI80KF>Z>I?DL,.WB*EZQTK.]KX^RP(?B&J7ML6M[WCLX\0Y=YOL.]A88'
MSM<;(KHG/\\OCLOS[TK&YXSQOSI]?7IZ^I:<!#-VNOP]"G;%.LUHFN\)>GLZ
M(W^'_\@A$WH3_IZ<YD!(Y&]?TZ2WJ./`),OR\@2:-G!9XH`(A1I=&2D?JY+=
MLAS6&[($];LRHBYH$\PAB@Y8EU\W!95YX<ZGAD7H`Y"-:O=;34>]<KY#Y';*
M^_WALJSLGS%;V>$.>ER:4EQWAD6_1^^_F[W[[L/L[6_>E=_2;\AO3W_[V]G;
MW_ZN^FV!_G.78/3^=(9`P<M[RQ!O[G&&WK^EOR5_(]]N,5R"X+BW$?LAN2IT
MZP(%MNC33=!7:;H@(F(2;VY.D*@5@X@<7_SX?+&@'8F"^#J(%I?)6;"-B+8T
M&"-*BY(/-DR@4<;.K#R10T'79<%6"6C6:D?M>BE0YT8GY>FX!"6M-ZSD!34F
M)T1>(8-G):O)*BD*;D]5_2;R@5/0*_"*ZM3ZXB(;*2I$CBM\D10XVV91CL_Q
M,@JC8AZ&N\TNIG>B.ZBRW!\AND`SG]RTXX0MZHPNX!I9)W125.,Q0R4FJ($*
M8KB@SD#73MH>/[O]1GY1JB*[`BQU(FCHQ(+I!-RXMZJIA_3"4P:TWYW_Q3/@
M3GB1:L@%EW<[6G<ZUB\+#GR'X]HO#S-`?F'CE/=*MZ]Y2Q#LFL:&P9NAKG#]
MZB?B"KMVBSMP&[@*=MS.-]"RHC2U=)/^H=.6RUE.11DL='3M'%7YH%O5Z)%X
ME-QHO">KJ;R33<(4G.P8L@P2_,_29$$;%9$?\C1F.;:E%[J%S-R<;0G6N("R
M!4&*B]%T!FG>AA28N`L3^$YS^PUYUDKM?YXBE[@@FY)WE9%#D(/$64":7GA<
MXXP^X:B<I#,X@<TL$AF65E-Y"#"63T[/IA0>/!S$GK9TO?#K\46<[7,THM/-
M":JNIM'+*$&+-(Z#+(>.ZNPZ^94OQL<>2YU7M^?*1M<9:%-B0UA9-;+RG=@:
MBE^&-<0#L4%Y*Q9=`^)9%X/2<6LQ[$Y>TUK*0?9%TL9F"BOQ([%)3KN*=7@D
MAI%6$0U*PPT9>NFC+94RZ+5A/2MQQ$Y49;2UK+HI]Z#M>W2O-Z`:'!%D/!Z'
MN+3R(OW==#:XHK'C%(VR)J4I]IIM8_)NHZE`O<!P_!2%EJ%XM+GLD"_=60Z-
ML"P&>WO*/FOP,%5>93OI+>_'J+^]7:0%`C12U=L:Y-,&DF%V5=<7Z)AQ<YAE
M?>K!R+Y!-X!X9]4]#)":MG_R&&/DJ5@JKDC1+NWHT;+I"SPLD*A<[-%+H"_Y
MS)=)F&YP]4*U0H>!H1%FEB3!P\2IL:E1_0JW/PT$)%3O>S)O62_Q7QH2.)SF
MW\#K1[O>QJR=3\P8O`_)1)GY7*XU=Y^F?55UR#II=]-A#AX"/>%^>`BYPYG%
M%>]+6KX,U'E'OL=.AL>825^*BXDE59/S-[)RCQ8&*>7[]N:U"*3;V[Q@N6B\
M(;G#IC(_X(10'$/_\L4F2LJ>CP^XI%]@!;*1AF^CJN%E8A$E"-9%O06$FXAK
MLU!D0N>UVF.1C.SUVH:`@K:`0K"A9N/H7_WF=/;=N]_1;W_UCOS\_C?0@)2>
M(4_N`VA72C9E@"%K:4HGH*U0H52F(":%$3G$%.L<X61!ON[V2.BV19BUP7YX
M/WOW6QVP>?1M#%!&X^P=@7?ZW5L->.PDAT#1T'RWVN4%^@"P3K^#BQ;02#+F
M%=2MM!%Y6=87$?B=NQ?'*B3<7L@MW'G0[1QO,QQ&5%I?TV2;I8M=6+;^'?*\
MPV.,'V`7XV)6Y5I//D.MZ5V[62G=W6I4CP4@K1VM8;@\C?:]@B#?=(C'F1Z^
M%'`R.\P.O!3BR79#B0'=D^\12&3\"R"YG<?]K%$B.4Z+%6R*]X`(:W/\!6<K
MG-&#38_Q#GUI]$[,$%S3:!.9%;%IT=F0]`_X8L\0F7M/\_C#6X5P%+!XPUAL
M;&`6,)9&J#S#5_Y"1+Y&2W*>J5Y\:#0%R#!]GH'\JSP,0`.A-$DPW6?0YWOH
M=V?D%!$D3[_.V7T.\2#AF@#!]6,J#I]MZ$1I=()UMB-$TP3G7.\%!LF41N)<
M\E>M6WLG_F9CA3?"6Z57NQ1K!_;';KH^I[F2!3:^MJ0C7?AVK+"\P7L),_=&
M/)R88I?:06/TA=6R]YS(="P<5;X/ER9VC7$<UD)S'-`2YY&DR^0!YP6LS`RO
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M&!Z3*6WL>T?C*%R:AC`\G&5=!!E42.6\^\#'((]"N$^/XETA+#26C333"46\
M3.R1@ZA;5\P0!<,N^AD@U\:HR(=]\SP:X2B:,&U3$985C/3J]*0AJP6#J]C7
MPC'%2@[!)KT&!^>_8-@"X,7\8?5U!R^972T;!8BL)E'N,49/97#",L#<Q*=P
ML&A.%!L>'6'`T=62]_EH5ZCZXFY,>=8Z2C\O44L\5"7QH)1XTVI;!=:#)LP^
M-?)3AV"$T'']<M@@.WK?D4,V9T+"K!]J"9I--3KO3!;KH$#@Y7=0:T!?'XM#
M6AM`_A@V"O?1?8=U%]>W,[3`!<XV44+^S>H5R`!:@A%M8`J"`$"&*O$F,DFC
M?F%4XI&L77?8:#F<\\+=/%W6]]+*K;HUIK+1LUD?<Y-E0P.L!_6%IISJ;\S]
M+`0L+5*T)6>?B)8'(WLZD%=U_#EQSQ5XFUZ(;]0!;EV\!9'1(6<C&&&@<G(\
M3%P'G?V$3H^:\SMU#G*26S[`9[X+=SV,^?<=YENX<+5)`J1%#Y(@+'+TA`*)
M6ST*&I3VC:M51L/W*-BDNZ2`S5I"["W(U[/R5962S`QO=DGI-:&T%&^V<?J$
MR^=8'G"R2+.JE)?M*:DFHY6T_#?#[-$[,JO@XP`*9^D#,*_1W3K*T29XXN#H
MMI*U&N5EM-`O=I=$A*(M6][HE!NXBOH[(X)\"=?_6106O*,Q'T1`S/.:$06`
MPS'K`A/!5`0YV/B2$8]KW-X])[A`,*RD!>:^?T)5!E*##K+YYI=D$=F69S@L
MT`87:[M[X_Z:):K!I8H-KT]*8XUJ5-1QFZ)D;\:Z72&^FN5N$PMTV+%7.71<
M<E)>(++)2OHFH6ML@6)UU*;KB8^4>;*8B/6AM90,?FJXD,S45Y%9N8[]WZY,
M284.#NER&87TU;+FSN$7MN#<,#E=!UGOVXGCYIG8P?7A?)A%:89*V(@"]WZ-
MZN.4]GIU#**UYN]GW'%MAP3L#<W3K@0M/NRM`!!>IJM`/>F@D^]R^!]K@[=K
MPPTT,\G)#P2#ZRP-,5[D5\L?4F)>"?S]ARP83I$VF=*Z6]&B9(K%@W4[@`6C
M1@1Q3.!6N,8%460\7$RTF*BPKCP771BYVH#G:R@#O8'C"D$\5(!6M4JLAE3"
M1WXHK4354D%)0\%V&T?$"X*W!3X1/X>C!_(+EHX*S+DF\P$O"(Y%V4^!=AY;
MDC$+FCEY!C>G<^(@\VB5T,6)K"EQ\`B7H%^H"-Z]ISW73NE(XJ390K3;D@]^
MW@5QM(SH,%ZK!NO,`APO=''[4'6,@S6H(H',0I`E*,!U+G7[9+7(B7\GL`'M
MX7D=MGBH+EVNEMTGHA5ZM*J--TLNT\+1Z.:DZB1-U+'O#74/KEI',64_&?`H
MI28-^8\7G@-[8SC!]4&:@".8?XM$>>SB<98D)<+)BEW-N"AJ&$0J!(H_YB3B
MP:`9^2P45;-1E\T!<]';M)^GFR`2=>SL_]XPM5F$@U&V^1Z[T5_9W,YM04AQ
M)Z_<1Y9+=%Z9\TX>A?J"(450H.7=;ZT]-]2&;9;`5C]6XUJA!PD4O.G4X:Q!
M4&6^>(!$2U;4QY3O4Y207Y&#UJ"T54<:'(O5\3+1A!)*635>VEX%QVEX0YT!
MK2B&EE0.YT/FBT4$I^$@O@ZBQ65R%FRC(HBE_D0\SLRW*.%DIET<``(()^2(
M7L)P[7642-_W0*JR.&0+Z2*`-')>\"15IX$!IBV*15B8*-`Y7D9A5*!Y6';?
MAT87=75\,W1+]LHKYUUTQ)SHMHV6"..`1U^-QRYMOZ@XR;.6?KU,J_QPI5>\
ME>S4RX<,T<M;\U(@*_@JO$-9X6RG@LDBVH*W)160/F20C&S`F54Q3WQ-T?\S
M7.U^Q8_T+^)@F<IXT_B,!HYFP3.XE6:0^,+$8,T0A39#!![[P'D[8RVN=,-I
M1R@V67BM5>57I&B9[EB%7UZ'J+VS-(:U@:GM3S")T`:PG,K8^'+OO;4-\$71
MW'P7G0V#\W^9FX<_[Z*<'@7'KG2M*:;SFGV83KS>-4%Z:H.#K-%9]#R7H)8E
M]KQ_D;7?_"BR(,F#WI?*G-LDH\7,*'OFF-"W'M(L^<IX!'8YS!RMY=%W*4YG
MFJ9+IZ@T.V=LN$RNL^@A*/!U'(3T;OHK+JZ65\LE!OX(G[_2GL>TG'@$SN8Q
M)VZ'EPDJP:(*+FQ0"T@DY;`]>%]K+*>Z->'/0+2ZMKDM);SEX(FGA;3Q=`D)
MADS$%LN:)Z):E@OZYRIO?W\#WZ4?;7<9]*ZAJ95!V0X-\Y>SJNZD_5RRWE!B
MD&'C?-1T:GL8_^.QHQGA5OR0QF0NPVJ;+7OTRIS%UX$N6GY["U':0'/K-R89
MI#5^HI20/APM)(;D`YDA[5.&MWDB?5Q1SA;Q66P2I\/3>EA=!JL91$M16H]S
MBF1NA9-4U9S</]$<@)`]TMELFL];Y:^S=+=:=\A'09:!>Z&.Y66.X[C3MX\X
M(ZCC>X@6NR"&JL,HR8NHV)7)+*Q&),WR5TZK0X:C1O1O5ZRL\N(;SL(H%W:'
MUI]KNHB7$/>)@Y?LDQ(XJJ![&B^1LTLGH'ET<I8E$I=S-NJ-M[W1+^<FR_9F
MEFQ6--F$P;#IK':@:1N:-[PX60N:WUT'3_37<W@K9<;M>589-&VFZG;K8LY4
MK9CH\>G#6.N>*@8J\F2#'>>&0Z$CIS,Y\9I1,/7*.V#F;B,69BQKAS*>I<0=
MMWJ<GD`'K;MZCC)0<.]-=\?IO6JYA%ASJ_+Y[%N9,@U37_P>DV=59IJ*:SUZ
MJ1LY5[O1XP-0J^=IA]YJZ+DOM^N*M?OM3G2EU7^>IF+H[R"C?#4_<F9+ES%F
M=-F[/A,%B%ASP1MA%REOKMK,&#IX'??<M43#^6;3]MD]+-U^;'@/T&[0X:YW
M0*"-R(EM/ZXS]00F.H*RR3QYM2\^;E<^@J5*OOQY:HHU;SY94L8!F#`V<Z/K
MGJ&%'C!J%U/?#_>O>>.8V3J-;&/HMD<&0X-`Z+>:5*L`][&/9(G(U]&6??OR
MXO;JVNW-:M4=[8PL:9_B]%'T\IG2,&O]V@8Q,HLC-/JS`01$0?C94F^0`X).
M>KX*1*=OGI)<#M@5B:!#'!+\#U)`R&8+$KJ8`[M,P@P35W".V?\5K&?4=(:]
ME0PH,&J_!(*$U87^T``]*S<IB$-'+SG\5Q[9H@G?.EV=GI_89:\*6I;^X2S^
M*RX`Y^LL?8@6>/'QZ<<<DDFO>$/T>74@4[#W$9.9B7T\]B:V#O4>5-`<+N0J
MO/R1/1S["E7040W>(TL?S[-].W]FXE:Q\25=JH&IO6\&?._.D.?5PPGY77J#
M01FB&!..$<^3;O#G-">_MV?JDX`S;7TV'0?,TJXKO"#V56%&Z\88;N@E8/<*
M_GR\CF5*_G?;MOU#_733QUM:F%5:"&48,4$.?EN]CL)?0??,R9W#BPEAQ(,=
M0\ZI]9F95/L@FCB#YGRN#;:/MGU#\X"5$L66<?10:`J?*6Y..O`T\>&L:/]`
MU'!!9?M+A0V`QB1F:J./K8E]]IW3+I/&TEO"]&C=U6?0OI$?N2QE&W=:>)CO
M+6=YC@MV7QA'P7T4NU[:!*R94US-;')OCLG$V(^K;8N,FA;)0!Z'0?:S1\,>
M_9>CQ!I?<J"OT*($"^(\\<GRR&J=YE%Q!1=<C!%:1M<SW+:<AC&<8/'[M$O@
MJ;P$E5#17R`%[W/PB#Y%V<8_:QMFCMS0O)>=Q+R8K-*$&!>3%4V7A*?8E@.R
M<D;0!T900K..!AOEZA%DD,'3I8N^OW=#:Y/AE;NA_!SY0(.<"F6L)K!["@G5
MH)SFS"@SHI41<SRRD=@UDT4FE(4[Y%42#".N9&E6K_Q$RU9[E#534S)B\QG=
MY+$DE4X"B2.RU5R73&96G17OWW"5#&46)70K=XNSARCL[3%L:V:K)C66K@G\
M8=4_A6R%!-F%#!_$$?+,:X[EI\2M/E\E46O+0K<H@C3#4BER@5)XS`,5_T[O
M#EB/)X$'A[->H,(RSJDI7/XDK%);$^RHB\O#\341:1`1=BUQEN'%Q3=("\6$
M@6./RTH3VCZ$Z5`Q0?2J!(]*N%0#*.0RFN7?H5J'8?)C]K.0N61EX#+&#`X+
M-K.DZ7!'$(!RET%A>T2MFF,;3:T7(?;/]1V`69R];Z+)@K0"K">-N#?@'D?8
M7<`HC=C[,<E6XIMJ$2^:(O8J"C\/0RA$S*^#)S@]$\]%?I/MB`NJ6:-EI$H3
MVA:H#A53G%E+\*B$3]URB4'3COTS7AW&R8WX6<A>=A3ELMXV9!V4LN;K\C2;
M#=N4"I-I!M8G554WR+]1CL9]CG[>10O8+YT'FV"%.6-H=]4;O"J[2J3)3;1:
M%_F<-T56C\J-AF`U\&)*YP0>KT8)E3A5"L'Z'C?10@PO5"'F6;3.E+^2J-TO
M1XDDKK.A-(M2:;@39?V6LZ;29$QI`I'2'`%/[$;UX/=UZXAXD*$VNRYT^28.
MZ(EWCL936K4*;4JL^-)7+5\JO^7P8`MIBW\27_F<U$#B#6^D@>E8+'8?:19N
M*9\EQ5/Z=_G=18-A#OL^J)<,"D()&I,<JL#1AM,?4<?J.DR@SZ#Q1:M>RE+B
MN;^J%'#9"`%,0YW01X^BS;FGN:3OBEBJI!=--HFV*F`_H0>JH/M9\#J>9XI.
MZ5C%K5E)'U5B-BPR'3@EED]'Y'<I?=XUPU_2!#]]";*?<$'3BX?.@O*!!EM]
M9:Q,#(P#07<I*L$@"@<Q0"RWW^G)39D/K?/9\8A&6K[*HY@\098&LS=42!LF
MI.60D-Q1I7*VH(MUNBO`U.'R/X4"6.+::08_[3Q'T%T'[,&/+L'='G7FN6!V
M>*"6$3%:LH?;LW39$83K*,'9$SF(0ANC[<"EA.8$9HN5'I96W&71<)<<&#WJ
M5N!<;S[TF+*_X3A2N<DRKAK^)%TNHQ#3SL6#\G)(D&)2U;$2="<ZR.E0Y>/Y
MS<JY[6`;>$?G--?^49]!XP]E7LI2-5*T;8ITQT7:=R:;,&YD2*M:W&@\I<Z]
M4/44KXTHDFBR2319`?L)O5/]P/4Q19$4>*;HL(Y5W)I1I,9;T#ZT*B-,"3%>
MY)\(;KK/P,K'&F[,57$S.DN50)AT/'V%69D3G0/4,8E(6JC2E!2V^<;R4$2V
M25T0XZOE&7VJG5)ZEYX1:+L8UF1H,#(8G=6:Q"0<.`9;*Z;SB9H.`8FNEH@!
M+2WI+D4U7*=]6,:SJ!W0/7II:EE9#D(E%A8RH3)#*U)(G^!"-6W8,BVUR@'@
M**'Q7QVJ;:8(2ACP*:7YG2-]#!\]G3KNX3>]5RD!^NQ-]GBBXT:\%)@5Q[$<
MEIMC\JQZBI+,J3P$O-L$]?E7RZ]I425=5WXR2(:?:=.=QI(*:F!LSWEPH.!`
M*-BJQ*+>EP!D;[R(!I<&W<GQ"E7+P41<MO0!R*)1"5$OU(&%FH<)Z1WE<0)T
MGV99^D@W(>P7-;4HWVTA)9;%E@+TF$5%@1,(*6[@K$180[@$[Z"E]W&THH!M
M^J@;O"VO:H99-.28E,8:**X.;B8NJ(8C<3M.O8X.-UJNYMC$)*TA*,%-[4=L
MTZ6=V;),LP,X#W=\4;NJ'BOO`S]NQZZY%[#HT)_S2/*6A&B4A3?+Q/B8N$L:
M'^?S,Z5L0'`=>%4@OO=9.9\EH?1('!=(!/V_R`AB_QN<K>`EU2Q(<KB[Z$K'
MT;5%0"OYOP3%CGBLIZLERY,#F[[%(?Q.G`RA/Y?%F+D.[I:C*I`GQ@'#5J4&
MC6K8K@UP-+.$-R''+F5I%UYX*&G;&Y#)A:+UBDIANL3>O5U'H=,!A7;^K,UU
MM=VAL2I^IFP]J=WGI43#["1`BC"RDJY*9,("N%5@QNDC]SKT#V6F>BP.63BE
MW@=OL^B!;)KA#?20O_F\Q#2K/1P2T,&I4DQ%'4^5F]T++9Z.[G>$IO)M(<6M
M2L]`>RO6,%;V<BT:,/AS5<X]@1(+1%L+CZ6BVB&:=8+GAS%ZI;%.8\-+&_OD
M"'<'^L3XF#LI\`0:DQPJ><Z&AQB1(^G:9^@S:'Q"I)>R')/!W9<%.6'>MB&%
M^GG;*O0=.*28+.!_4"WS0`Y+T`21%BON-WF1Q1A5I[$0ZM+$V#@*">='^D,#
MY`PQH*BGC9]KSS.&2;W1RN.6J4(\\WOZB'GUM$_=3=B&SYF*+JG74:#G<#[F
M=K?=QO28%<3`BD]Q^GB9+--L0R^*%,I`5&<PTT)-/$V<2A,4<RP`##6@>53?
MH<F7?3]RM,*3>(^6#!=1'L9IOLLPC66%O+0#$C0X#D[?YBTP0:VX#B)1V4;K
M,]->TEV()A;#YT,PH6N+Z".NV\';.2^E+?39M'8::H]#4=(FNQ_!@_;T3S?X
M+O@&R0<2TVE_:=R)O0^NF0'!E(C.Z8D1]=+8TPG?#\;*'Z0`_A8PM:46]6,Q
ME?6>'\3SL.=.6**_$ETA/];5T\FBYT1^7JVN"IM%XZG-SS(V*#,^LP(2,U2B
MT>AP`&?9WHKB&A>/-I^VV-EWNOV%:(DL"I<F)VR_:JO^>"`%N/M\(>T%#R?C
MXJFBNL>R=48;Y)?JX6=BGU5CK>:;K.QM!P:M-E"GJ<!Z'&DE`Q^CN%0;W35?
M`&6/*V`FM:5(:HZ)$VX*CILT6<+SGX-X1S.<%NIDH@#2?[,R&9BMH8W\1INE
M$1^#/,JOEM?0D;PD0K#-D0XQ,"D%3$S<'IT>\@F;`#S8:ZC2WG)P?HM`XLK&
M2,(%&3++/L=YF$6TNP/MVQ]$"6^X249!\T,R7Y!$?Z<3S&@6?QK#LRXP`G;"
M]Y03-">HP0GR[](3!#'*R2\Q2U.KPWP.7P0H>5N^%M:_91K^UFS?.@A[`K]P
MA[\5Z".AYB?GIY!!LO>/%5[Q6]4)U+,+F6ZPQ%TUK)`<<3[N\BC!>5XVVR=&
M*5OPU"<P\+W:6)HH?1,8]40<'*KA^;(V:C.FM5(>K^PD!F1!A.YIE"RQ;PYB
M_N!UJ-,9;?_U#%,J40?/Z3V`!ZO@2-[H.0&/!6C%#4CDZ`&9*G7#Y:ZZW@>C
M#,?L"9LBI?ON!,IL\*SQMLV6S)+/@#%\7UX\_3I'['&MI[*XEGQ)SNCDT!V@
M5<H2\8E.9DE9G`S']C2A!3OE@UYDBUY$&Y?[\'K;=$W.%*%:1U/!(+.=HAP;
M$U_5V"+RZ3W8G*C3OK]/]UP,LM23:)5$RRB$TGP]R1PPZZO&L<L3T7JO.8%A
MVI`6ED8I7S*9>;#0C^-*)^'K.`5G:G/3G)QOUT&&+[ZQ%RZK1Y+)HG_-:MBN
M>0F;[`2M/Y'!/FPTUD86!D`1AUJ_B$[W9"5@5$'V8/DR8U5K>_U\I"LS0YM"
M]H?J0YS"E0F0GL9'S'0(=;.[7FLJF@?+MR&WQCF4(Q"Q99=B\R0_+>%V3O1Z
M_+%Y,]Y?/Z.4#:@WWD!U=7&<I!;-K]R]47QI>9]C%9Q2`RTC^3DGT>I.9<HB
MUII,E6B#^AQ3E#H*<)W>7WBP<QG-';6BU2,1HQ7O81B&L&.1-["%P(OK("N>
M[NJL.94`N72HF>!4,3,QNQ(&HD!0$XH'B[,N(_8M[(CD(VWP.T),[FU(;UW3
MF64:R4VTM@FDY^GB-H)!JL9W--(<;Y+>K7'T6/PQR/%BGF5P,BX?(KZZAS34
M'])TD9,=PBW.'J)0Z6IXY(2&]RA&5!@'V$[N`31JPH:P`X..*'BZY>$(>+2`
MFG&N<VGV/(6O$GJSJ`.'L_[:'5TM:S:>I9LM)CZ+)N8TZ/GX5']3]J&</P;9
M0F4%MPW)3&4FHMNHFJY>&:"-;$.EFFBU]>O^J?4A[PU*D?-JTS`1O_?=SS^4
M3+$&\)"Z=L`(6KK91`5%%Z(:-!UOA9-0N_9>:Q[#$,P8G(VB:35`%H9I@O0K
M`F_$HTY,[3D(519;$\K6APV'$F>4(MUZ$QU`GG9CWLI6ZM$J/XY-HPS5?\D:
MF:I_88+=?8Y_WA%T+QXHLU3:'0X,,6V1)\;$Z#!?S8W8Y!XM@C*ZNPT+O66_
MM"6ANA3<68!2\O?@&+M"L)LRUF6_1VN,E'29'7@E`WU+\&(U$*R:X[9LTZWB
MDV_&7!N$`NT:.RP_!*&Y=PI%\C!,W(MQGE]\PUD8Y?AJ^9<`0B*4N*LMN]%=
MK3+Z8@__Z#J+NBQJII.-G-$P1\R,#M/T'8".^,P0<^((4/F5**`*A_I3BH7S
M#$`SYG5R`I^K!J@DZ@:5C#&7\1;@@%(\-I4B+96"?T9^D\!SOER;:,L;\^=Y
M#\,9V=-$5IG2Y$GY\V>"*/DW^1?Y`0*XY!__#U!+`P04````"`"*@0P_A1<W
M:H\4``"^1@$`%0`<`&QI>'0M,C`Q,3`V,S!?<')E+GAM;%54"0`#)(E%3B2)
M14YU>`L``00E#@``!#D!``#M7=USVS82?[^9_@\9]]FQ9:<?Z2374?R1\9QC
M:6SW>O?$@2E(QH4B58!4[/[U!Y"43$D$"("0L%3\U%0&EKO[6P"+Q6+QX?>G
M:?1FCBDC2?SQH/?V^.`-CL-D1.+)QX,_[B\/?SWX_9\__..'?WR(2/SU`3'\
MAO>(V6]/C'P\>$S3V6]'1]^^?7O[[?1M0B=')\?'O:/_?+F^"Q_Q%!V2F*4H
M#O'!&][^-Y;_>)V$*,T_5^G^]$"C!8'3H^6WI"W$_QTNFAV*GPY[)X>GO;=/
M;'10L*A!_V`AC/BA3IS>^_?OC_*_'G`MO'GS@281OL7C-^*_?]Q>K?2)R%.*
MWX;)]$C\]>@\";,ICM-^/+J(4Y(^7\7CA$YSV?F'!='?TN<9_GC`R'06X<5O
MCQ2//QX(8ERN7N_XY]-C(=6/2GI'QNS=I2C%@MY@?$EB#A)!T3!A1)`[BQ!C
M9$SPR(913<KF+)\E\0C'#(_X/U@2D1'_SN@3BH2%W3UBG+(AHOR[CS@E(8IL
M>#?]1"N]7_&1-L7]*,4TYC#.<4MM;])KH>.PH@"V^`9+QLD,T]SF6"O]:I!O
MI=N[1X[38Q*-^-QV\5?&APL?-P..&SU+IC/^)\X%UU"ALI9Z-_M6*['.$'N\
MC))O["H>$8K#M"7KF_3,V?N$&&&#\9!BQFE:SV]U9,R9&=`)BLG?>7>.PJ>,
MD1@S-FAEM<U$+4#-IE-$G[GUD$G,9\00\:D]#).,S^WQ9,C'1DBP%;>:E"U8
M%G:.G\)'%$\PFO!_"R-"\6A&R9R;U"Q"8?Z3%=?:Q,T9_Y+$^)GKY"M.QUD\
M8F-$Z!Q%F=7`EQ,S9^P61V("Y&M*^GQ/4<Q0:&VD4EHV$TX2?AW,\N[<WO]$
ME--+[8Q10LIF99I.29HO$YP07TB$-7-GU7*4J,C9C.8'AO_*.+6+.;95U3H-
M#3:J?NW[@I483X0=7*,'K.$"U=&**%TA)?SK]\*_[OV<,[KRA59,#C$E"7=G
M=\#MVJ<<L,V749KNBO'*QUJQ?I^D*-H^TY7/M&+W!N]`P\N/M-,L]_[P#C3[
M\AE;=AVI--WD<%6/LXHK=\W)KGP0\_F3[P66.TQ!U'H[G7^/?S%*PI6/1"+6
MD-"FF5?\$J@^T']@*44OWG8DQ,S)!]I]@^-2+[I\EKK(53]&["'7?\8.)PC-
MC@3_1SA*V>*77*+#XUX9!/FQ_#E8.OOWZ.$%X(H`]0V#W@NW51S[=)5S1,,%
M3?[/#1!7XRYEBZ-9OH<^#!])M,1_3).IN487O"0-LKS)&&<LR?T0$1E(*-^L
M?3PX%@$O+MX84UHN:`KV<]ZCBH5[0I*/)7S%_\ETT%PV#DZ\(2J'I0&^*O-P
M(&0X?#M)YD<C3`KT^#_60>,_!87AWN()$?8:IS=H6C<`94V#4SB`K0"Q"IJ"
M?05DN]+^&6>>HNB*+S5/_\+/2O6OM0W>=4S_F_Q+`.CM!H&SC`HA+PD+4?1?
MC"CWOL^Y0!(09,V#GSJ#@T($"10GNQP,ER3"](SS,TFH>BBLM`Q^[@P`]=Q+
M='^Z&]W?4R3.T^Z>IP]))-'Z2IO@E\[H>YUOB:;?[73*3Z;3),X#3WE0D0VR
M5!Q#"D;5\[^B8_!K9S#1$D8"U$^[`6KAW=]SLA)(JDV"]YU1_AK;$C7_O!LU
M]SDG(\'-981DIK_2)N@==T;3&XQ+=/W+;DUZ&6=4>#JU;8.>ORVWK95O""#!
MX-?=8E#X7P5SE_RWNHVRLGW0`[19UL2B5@@)'N]]X"'\87TTEJV#7G?VP0H1
MI%NQ%R@^'*U'3+<01]7,SNEFI/(U&O?]1>/L(>PSAE.FB.W7-^Q(7$[*O#OH
MYI@^)*NG4;M%4*0O*7`3?P80Q=M$H!ZIDMT]PB?/E?F2Y\I<BER9?GJ&*'WF
M6]!_5]-O:J!KZ`D@)JB+:K,DJBAMUQ`_QS/A3+!".V4\5(%S;7L``4===&7\
MJ\*]7</T<YZR=8M#3.;"56A&5=(#0&!3%U>Y!*I@\NZ0E20Q]$=SD:K.!O$M
M5R]7S6.?;\[Q'$?)3/@+(L]-"'Z'Z9R$N,YGM:(#(#S:A*RM7*J0=M=&\I#B
M&2*CBZ>92,)?9*GKSM4:O0%$:G5'N)XTJCBY(?KI>DZ<C]U.,\JK&@`0$-8%
M=(-Q5?"]B]@U@@8AA&R&EB)F_$OW8+HFZ(%$)"58Y)3G9V^KUX*:0PVZ)+H2
MH;:1:Y_V0^7%&S9$S\*-Y++S7VC&V7]1B,:<K$\%0KC<"&S)]&`F,8B8B<0G
M5WN:%7EDSK@V@:#G/]C5`GMS86',%!+<KPD7.+_@>HZF:((7MOQ'S)E<Y$H*
MSF_)Y)$OF8L[;S(SL*47]/P'R]I:11O9]RD4<Y[A^V0P'O.]*64#6E6D1JRM
ML7/0\Q]Y<[!XZ`GJ,)`#Q^]LMH*Z!=1_7,X!ZO6".0S?>$99XP)LW1F8O%?0
M\Q^U<X![@X0.(SC>IW^K+:5*J?[#=0X,0"V@PRB0=_R'"W9SD9O.4&M:!R?^
MXWD-<$FCM76R@-CWN9O>RX3M)F#7FP8G_N-^5JC6"0)C3^<H^C,:D4*.(2*C
MJ_@,S0CW(2IBJX(^C9V#$PA!0`O<]43;JXW;2RSC+N4;V(LXQ71&"</GF.]3
MB*C0DTVSO(3+>4:Y![/>0YE$T99X<.(_:FAE26Y$=[$5E-;9@.$H&CF(P8G_
M0**5.=2+LC][P"9ON<7)4G#2Z3"AB9C[<^*HRN;7VAHV=P\@[!BTV)3."3LI
M!K*3VQNF]4E?KW'H<GO]>HVCH]<X5D,#W/Y%Q%^,BWQ+.<0TO_^L'2>1$>C8
MM0]MH?8HA+(J<W'MO9^ECPDE?[_,L8T6L-X1P!42>^1KA-FG"$N=L%>,9<9P
M%YT`W"MI"_52D'T*GU0B0Q83O$9O`%=.3(#7DPC&507G%F`PL2MZ`;B,8HEX
MC23[=$EA0]+&^5S2`\"EE%8(+Z78IR-LP^I,.MT`7#IIA?.J*##.JR4YC8;Q
MAZ:ZN9;D/(:D6K+]'82HE`_2O,:C7N-1^QZ/NL5S'&?*I+Q%DX[%E"ILNP/*
M\PE*^8A//"DO@NK4@Y'VZ5BD2"7'/@6)/N.8"QJ)2T2C*8G+RP)S7(JM0+JA
M)X!PD1+#>MB;A=JCF/`YY@R')(?E)HEG-!EE^<-(RGP:21\`42(+O%7B[-,P
MK[\ZUCS(E?T`A(DL(&\2"49L6'IA4KQ(B[]@.A%/*++:F^^2E@!B/@9PR878
MG\M)&^HP<:P`A'8L1E^=&/N3@[:4KMC>7R=,"]*7UA"*BEBYR:LBP)A#W6!Z
M%<\QR^]0%3)R-R%92*T`5]4-0C$2$Y2;9-FGP[0KD27-I6WVC=9:=JWL2`W[
M+B;BNJ<VMU,SP%FQ@.:;\MV(1=E+Y^(4K3WP;@;P#4ZU5M^5=A#*@Y@,W@WF
M]Z>@UP6B,5]7V")90SQ^'HK-&HFR5'G6W=`30K$/$XPUQ(&0K2^9KO_$8IK!
MH_Y\<I--'S`=C"N'N<7I;C.TMJ0@5.O0GK(MY5,]*-*M(5],94M]:1PS2'H`
MN)`AY^P[..!>GOZ'E=-_MA"0)>-RV\#_^GK>_7K>#?B\6[*J+19BD=\R%?NF
M7*4B,BE;O.0].G+"W2P%B",QHPJ#>899*8X<.IV^'3G6-I$'QKE7"SQO<7ZG
M?8AH[:U?*SH`CK.=XKPF&XR`K1'FM[C$@?O(0YJ$F'L:@_'GA'\_%G_/GRDP
M@U^+)("#[I:6H"LFC+!N4[IMLZNIG6JK3PI,FJT1R]_!#J228IO[+*LU$LJ7
M#(0/P__$%4CFN-BPO6Y'MKT=\9]]T&([(LTZL/&*_.7?VL7&052\J8-$)S8N
MKW'3L_%NO!<U:5>\R'_.B`F2M0(X'(BS_$5@SA%-NPOI"4A_U`33$WFNI4T.
MT&SQ\K9'3`VN[VU>=(.9`R1'M$X`AQM*&*.T%:(`ZH>U0U1>&:QGLQV$,$3%
M/%1<(RZ*'Q;/P^=U`F[PM_PO:@]7HS_01"_UY*PC%(S0P%8MH1@$+4QAC0",
M_#!=?(WLHT92&$'D[4\5_9#[,$6Y/=O9HDH"1JK95HRD5E88<><=S"/M[&23
M!HR$-0.@+2:4=7DAGS-6RY)<Q4-*YGS5'48HS)?>&YP.QH,QYY"+J+RV8TH'
M:%+;AH=A+1R,\CU6J-MA##1US09119;:C@OT-+P)GN=(%]&(LHIN/*G.1S(D
M=?M#>$9*&U,3H6!4Y-F^FY?_;9"+R2Z>,`T)4Z8B&]."\."4JYVB5$"'Z<I0
MK:68$!V9BX(8A/>I'-A+@X0.4YRWL/BKAH`T7T[N^=F1@_%LE:Z[8"^CQ!3>
M0S:%TKJ=V4(C/9^O7;4&6-]>M/30E=UB_?*9RU6?OJ6]?[2C#./E+(O]A[VX
MTF`E:&.IK)VNK<6`-(SGL5J:BZ&\,GOI:'2[5%ZQU1-S:1*+),+^$]%*\:KK
MU\7+)Q(Y]J'NXIIHY\D4$565K]KVD.ZKR+"JAU@FCL/8E#]L*S63OV!Q>U2!
MZT9;2-=7S#"M$\5SCJ9%D%&*F&9/2-=2]/#3%\SAV:"_T2EYSK5QI"K[0;J"
M8C9JF\1RF%?B#_-;G/+U!8\6!1P:P:[O`*"\HB7*4GD<'N;Y@[=ZQ43Z#*>.
MXZSJ#Z"2@2Z?37[U?MTJ.D/L\3)*OK&K>$0HYDB_WAS:\LVA#NXEK\$4,G"T
MR>!6WX]'XC]B_,]1)%:!(GAR%8<4(_&J>/%?C2G0AARD[>=U<_4F2Q%!1*V=
M7383T@]I,B=\KOWT_`<322++DJ'],"7SXC7J9HLQ)P9@:VMK`_469:6"_;(G
MB\N+_C?(=KA);6!%MCV"MS_Z7U84F67WR2T.DS@D$5X1^#YQ-Z%LXW,`]N4N
MC6U+*MJGJP'5]R,4QE9M!F!;ORU@Z\UH37@04]8NRGOY3^C;#<[->G`XXE/Q
M'D27ZH/Y3]/;H15H:L1A9-_:'IQ5+EWQXBM**T/;>L5,-8E`N!J^V\7#3#?[
M="U5(7F?,9SJ.+G:-"!<5#:$VMA>-B4&X8ILRUJXVY4PDN8%KPK1C0QELSN$
M"\QF\.J:2+VL#JQC:X]A;,J0%^WCTS$F<\F9@%Y'"#>0VZ"L+Z4+KW2'`"]R
M)@:Q+#LQSG5RA^F<A+4%"QQ1AG#WN-5BX5`/,(QH6VO(D.(9(EP'A1CE4T&+
M,HH6JXH.00A7FK?DB^B*[V*#!->JEJJ\)NB!1+H16S-"$*Y1;]NCE8B]W[N@
M?A@FF3A&0\]B)1=/-8<AS;A`+]HPLB(=@A`N<%L8@JY%Z:H`Q(9)VV/:>`JM
M%,_VX3AW7X!PVWL;'E0;?8`N]+$IJMI%5,]%;4E"N/R]#?,Q4H##RQN>B_KJ
MG]DZ29"!<&/<<4Z$@>0NSQY`FDWQ6*^C_"H%,9]WS7>:8-6@`QCI#))UBZ^_
MY4E-7DR-XB])C)^_(/H5IY=9/)*N3HT=(5P3MP2L9BW2$A=$0-C-W+$I+^*Z
MCC$5;V2(H323.,)F!"!<#G=B).9BNP\,WG=EN7&RS$!X=<*IZ9B)OO=NRO*^
MIPLW14$,0NWUG;@I#3K8ITJ[BT?++KFF34NM-?:%\*"&)<22-4M'8LB1O14!
M^-@9C"N7_^^3,RY+%HDI])+0J=2A-2$2G/@/]SJQ`3O186]IU-)<)ID(-EJ:
M0=D[./$?G]T9_A6982P2&L"+$D[BK'XPODG299AY:<LHEM>\,B03G/B/M6['
M%#2%AW&:*$W?GI4[,KD4\O3MYK[!*=A8J07ZNA*[.(J!$NG(?>]BKSX25E]Y
M5$#A)2IZ!:?^XYY._<,&66$4<-_"Q@'E!]U?4)I1DCX/QD6T3XR'.QR*W]2A
M#&-:P2G8B*F#C86N!O:I8OQP.9LN"]6*!556<E.G6W`*-F)J:20-PKJH"0]E
MK:D.B/S4FCQDG*'R/%QS+MGL&)R"#86VGSCJQ758^+TSX4\G8<_@U'^XTZFM
MF(GNL$J\9[LQB1DW.;*:9()3_Y%/MZ%R4^EA['7=&5"#802G_L.<[@$74CE,
M)@3Q_+`6F/YCEML`4QJ5M-F!0GAX.)O-HCSK%46+8H)7\3BATP(MC0*2>A2"
M4_^12Y.*:09BP3B@<'7#(<4<G%04Q%7>6WAI%KSS'Y4T0:L>[W6)W!U!>G;=
MBD((]^A)!%@;0%UI&;SS'UIT@>N&4"X+P/AWRX5*;I(XY/]\R=Z)1S5;DG/"
MPBAA&=4MBMF&=/#.?WS1M$)F6WE!'UANWBRNJW<O.Y[2ZQV\\Q\O=`)DS7&5
MO@8@S"\2(Q#*B3!;9ML,QG\B*HH1,''MM\C$Z4\F-(]=+AH-*0FE)1Q:4-Q7
M2VFCY.J4X;F<_+*VN%D5^8UNL(K'U[$GVP+L4<WX3X@1-A@/*S3-2L5+)I0:
MN@IS:>H2^#'ZDJ/RWG']*BAM&WA^Y%*M3HEIUTFQU:3+G1CY@$Y03/XN=!"/
M/F6,^WV,E7?O^*SKQ.0;O](T`+0)&`\'6X[ON:8_<8I?K5E>4O`]'$R46[=X
M&TG:_2%SETVGB#X/QG=D$I,Q";F;\C(K#).(A.(PT$<%[@TN=.IH2SMY6EJ4
M:E4-.S,"'D>=ENIE'I:N<'LPT$1)8OP4/J)X@M&BU`2*1S-*YMS/G$4H+.I]
M."L=?5%^;5G8@L]GP^)KP\77FM8J8T*NUBSM#S>N7>:4?*]A-DJO6\NL)._^
M4,MO2T_SC+^QN"T]1H3.Q1/<3H96_:FB5FS5J+^G!:N)/9TU2YN&[X%F@(51
M3D>]J-T?6;<X$CF-0T33YWN*8L9U8[ZO<F.H,EXTO,2FKIZ&GHPML\%G0`6`
MUZ@!A63DF<G9_;%7O2S+9YQ%2-G+@X_+YS7Z@HD)+JM0#![$2ZN?DV0D.%P4
MIM4)'UL1]#1,7PR,[YIK'QJI"O'I^:5-F7W>_X;H2&<H._X2@.%N#;1D$G"O
MH>Y/%.(Z+2F>Q!">29)OJG'L*XZC8,<L(<&$CB_G68='+0_:B!"`@6V*CLR=
M-I6[^\/U+GM@^*^,T[N88U\+^AH/6FF?]5U\Q5G7V-$*K<KZ`!A/"O7*8JD*
M:78_2CX<"28?^$K+_^?_4$L#!!0````(`(J!##\`3`F#S`D``-=2```1`!P`
M;&EX="TR,#$Q,#8S,"YX<V155`D``R2)14XDB45.=7@+``$$)0X```0Y`0``
M[5Q?;^.X$7\_X+Z#X)>V#X[CS6UZ"9(]./YS:S2)4MO;O4-1'&AI9!,KD5Z2
M\B;]]!U2DBW)LB+9:=<N_!1)G!G.S(\<#LEQ;GYY#GQK"4)2SFX;[;/SA@7,
MX2YEL]O&I\F@^7/CEP\__O#C#S?2F4-`+$7$#-0C"4`NB`.WC;E2B^M6Z]NW
M;V<^?59PYO"@]>Z\W6Z>7S8OM#P?`F!JP$70`X^$OKIM?`V)3ST*;L-"!9C,
MB/EV<<;%#&6<MUN_/=R/3<<QX;7NHT*G$7$HFS-"%BMZC\BID1TWQ"SMYD4[
M81'@9<0_3X6?J'/9PM:$D''&PJ"8UE6BI5X6T$*B)E*!H$["Y\)"@$,4N%O[
MN6H1X0CN`RKLJ"8\+WS"B.+B98#OB2#-X:Y]D1;POA4UKDC]K7U=M'Z[I^Q+
MSF--HM1VKV&CH--0@4S8'!XR)5ZRRDAPSF9\V8H;"YSMA$+@<-O&%[<6,/JH
M<HE)NGE*)*Q]3HN[P(8"Z?#LS(OI=4L!`P-5`J9!$DD2:LJ6(%5Q!U%;41>O
MC[7L.&.$.K*X$]-4T,?SAEOCJ=B^NKIJF=:$5%*G6#8V%$C&D:-UE(5CRK04
M>G7VRC2)/6O(5IJIA=BB&K8468TTM&0P428580XT,`Y:U@UAC"NB,%Z:=_UE
ML:#,X_$K?M".ND[&X`@\R[CN6MMYVY`T6/AZ9)IO<Q-O=`QK:LW.+R_._\#X
M<(:J)23:R!+UC`^016*,-6K=KSM.1,3AI!Q:%,(7(!1%,%83J/5F5CG$KVL5
MLCBA?\A&N>#5-0I9**,';)-/IG5M0A;P_ZOF:#$3-,#2#Y]&PRTI@-&FQYU0
M9QP=YO:9HNIEB+-3!&8<-2R*`:648M5STO<:L0_G;:MI)=SI1Y1D1:*LE*R;
M5EY`7G8HP;79!_.<G\0Q=TQ2QID=4]7Y<A.LF#'^FB"P!S!CM,WD@K8WH`QC
M*B7^$Y=&\:Y/I(Q30@U11=I2L-XA0BLY^-RU'WO]QW&_IY_&]OVPUYG@RUWG
MOO/8[5OCC_W^9'S"+(-9ES,7&$K'!\E]ZNJU]H[X>D4<SP&4?"*8I:DY*(JJ
M1>#592I%\6(7%*U_9GKXUPG5;3-QB-N]`#J^`H%[#+J$C?FW25&*UT_5\!I/
M\,]#_Q&QL@>6_=0?=29#)#@A53S_G-14DHE[)??TVFFTD;FY5X&A%,?W^^%X
MFH%59^!XCHZ:<]\%(?M?0\PA,)NPT7&BRP-TQ!SAQ%D73<.-V5F/NQ3QRYJ(
M:\#'$[O[MX_V?:\_&O_)ZO_]TW#RN_7G7G\P[`[[C]W?_W+"?1ON72+G`Y]_
MDT/F4@'Z9">'[29%*7Y_W67&=COCC];@WOY\BKQ9I.Z(I-+VGE)V1@`5-93B
M\K/>*5#I^%R&`O#%2+"X9Z5EG-R?<;\M9H31?YO^,*+=A9(RD-+.+7>ODY5"
M<Y6')BW/(KBK2R1::Y$GI+(A+0P"(EYP*:(SAMLRA^#.VC&GOI3-GC`'<2C$
M<%6D+<.L?9['+!:J)U1*K+66:R6"3\AED=.Y@S[3)FP&9(;/>N7`4;\0=(GK
MR,(GCOD4@U>9O!2_]@9^6J[5CP5;G42RF7]/D6SK*1%^PC"#X0-G\(+#_PLH
M+V2N]`@52^*'<::XO;D4HW=YC(P<Z\$(L@9:DC5`4=8_M*P3)!E(1N#K31?N
M?]3+1!`FB9-:L;:VE@)RD0<D%F,9.59:T`F-7,;-G2_VPK@&,X3/1*"O5+(>
M;6DLQ>*GC0"FI5BQ&!.U$D$G+'*G&4%`E3F(0&]WN5F=@:WS@S*"4DS>YS%)
M23*(9&2=8,EE<%,)7T.TL;^$]=S(?RT%X'(S*TO8K8C__]CI-ZWT)3"^92^)
M;VBPX$)9K+!L9LMULQ55W-QSQP@J8=%OS82OJ3\UV^^:%^VS9^G&-VEU--`&
M1M43]31(^.IJ4%RY4K'OA$%W^KY2=Z5%0%MZ-3T6,K;`5S+YTER+JFYY2>E'
MF38%;/'S7EH4%>M442/-E[SLITA1]4\E3=*,J[>]=-DH^ZFBQXK)/.W5_V;!
M3A4%UES1XUXJY.MZJBB0\.B'_3K/5^Y4ZCUA,D]U^W^MV*A*>/*%R'#I&'6E
M`V/[<C\=*H;'5/]J_[[+:Q*KZI.6TE\+J:M>:15?E=&1\.B'O<;&9OU=%5?D
MN?:"I[C<M)X:G#V6:A)7\1I5R@MH.E.I!$EN,W2F^4<U\JA`R93C7>,W3-:'
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MDJ0[9E9']4=QO2Z;/4`P!5&0&Y411T9'OZZZ=GE`*'MKFZM;9VXFY5#*$-PA
MBZ\B5S>1CZ!LS_8\T',Q'^OKLQ[((K^/1RK;GXMF$>UW@[EL7/9"#=&3D55Q
M*&=9C@[6M/KF>G<=H[;E]-N'_J["CMIKT?>W<ELM:8<TK8SB\=H6+##?,;2Y
MW*",Z!@6P"'#T8/J]R#Z.T1=<(\T`@<PY$U]2-E:@?8HQOVF'7L<F+R%L"/U
MVAN<*;RET..<;KN<3>TEY1C<A)B;G>2$=QP<#@),_594OF6JMU+.J$![%//K
M27`'<!L]$#P8$Q]L3]>`<&96S@G7ATJAKVM`!E0$:?OK\1T%_.4F#7BH@T%U
M'ZP8CLUXG4UI8;;WR-4J%*Y`71>";7BA$N<QN&,$BWB";S<E<TQ1A?PH`L)F
M1E&T6TO?4U5D.`;8"WZE4G`064IU0`>.K_[,H\"V&CS'9.D$GM6=CV&YCJDI
MILP!FTJ^?^==8E+\O\I&T8K\F5$!Q#OP'A#4E;4O@GP7YD.#7O^^49?YXA\=
M8Y>8>."ZLZXB+;HYJ<QR2$#K+&K;>=C6\X_,V="N$HYBH=YB77SPM8^#*H@X
MI!.SXEWH".)B:&U6G*+:WJ]\"8+I=G.(].I-4T4I1S%@]/3W<8'K/X-PJ,0D
M/?G!A?[Q>_QSCAD&15UWEQ!A8'0@%TIV%7(47OH,^H0'W,YR]ACJVS7;LT.E
M2SCT_W>,IH9.`!T]4*@?*DC?<.S$_1TGTTTKJGC#Q_\`4$L!`AX#%`````@`
MBH$,/]0V7+LSA@``=AH&`!$`&````````0```*2!`````&QI>'0M,C`Q,3`V
M,S`N>&UL550%``,DB45.=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`BH$,
M/['_]8"W!P``%VH``!4`&````````0```*2!?H8``&QI>'0M,C`Q,3`V,S!?
M8V%L+GAM;%54!0`#)(E%3G5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`(J!
M##_X@G$N,1```)/S```5`!@```````$```"D@82.``!L:7AT+3(P,3$P-C,P
M7V1E9BYX;6Q55`4``R2)14YU>`L``00E#@``!#D!``!02P$"'@,4````"`"*
M@0P_,JQ7(^$I``#L0`(`%0`8```````!````I($$GP``;&EX="TR,#$Q,#8S
M,%]L86(N>&UL550%``,DB45.=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`
MBH$,/X47-VJ/%```OD8!`!4`&````````0```*2!-,D``&QI>'0M,C`Q,3`V
M,S!?<')E+GAM;%54!0`#)(E%3G5X"P`!!"4.```$.0$``%!+`0(>`Q0````(
M`(J!##\`3`F#S`D``-=2```1`!@```````$```"D@1+>``!L:7AT+3(P,3$P
M-C,P+GAS9%54!0`#)(E%3G5X"P`!!"4.```$.0$``%!+!08`````!@`&`!H"
(```IZ```````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0EAPAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
        <td class="nump">$ 0.0001<span></span></td>
        <td class="nump">$ 0.0001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="nump">10,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
        <td class="nump">$ 0.0001<span></span></td>
        <td class="nump">$ 0.0001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">100,000,000<span></span></td>
        <td class="nump">100,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">35,259,142<span></span></td>
        <td class="nump">35,077,178<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">35,259,142<span></span></td>
        <td class="nump">35,077,178<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 129<br> -Paragraph 4<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 02<br> -Paragraph 29<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 129<br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 02<br> -Paragraph 29<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 129<br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 02<br> -Paragraph 29<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0EYLAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
        <th class="th" colspan="1">71 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2010</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2010</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative costs, including $40,528 and $20,534 of stock-based compensation costs for the three months ended June 30, 2011 and 2010, respectively, $40,528 and $93,274 of stock-based compensation costs for the six months ended June 30, 2011 and 2010, respectively, and $2,293,051 of stock-based compensation costs for the period from August 9, 2005 (inception) to June 30, 2011 (cumulative)</a></td>
        <td class="nump">123,581<span></span></td>
        <td class="nump">76,892<span></span></td>
        <td class="nump">213,197<span></span></td>
        <td class="nump">265,470<span></span></td>
        <td class="nump">3,819,075<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationNonproduction', window );">Depreciation</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,909<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
        <td class="nump">224,208<span></span></td>
        <td class="nump">233,104<span></span></td>
        <td class="nump">485,654<span></span></td>
        <td class="nump">394,977<span></span></td>
        <td class="nump">2,708,501<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_ReverseMergerCosts', window );">Reverse merger costs</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">50,000<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total costs and expenses</a></td>
        <td class="nump">347,789<span></span></td>
        <td class="nump">309,996<span></span></td>
        <td class="nump">698,851<span></span></td>
        <td class="nump">660,447<span></span></td>
        <td class="nump">6,579,485<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num">(347,789)<span></span></td>
        <td class="num">(309,996)<span></span></td>
        <td class="num">(698,851)<span></span></td>
        <td class="num">(660,447)<span></span></td>
        <td class="num">(6,579,485)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNonoperating', window );">Interest income</a></td>
        <td class="nump">37<span></span></td>
        <td class="nump">333<span></span></td>
        <td class="nump">83<span></span></td>
        <td class="nump">548<span></span></td>
        <td class="nump">27,385<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(2,469)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_LiquidatedDamagesUnderRegistrationRightsAgreement', window );">Liquidated damages under registration rights agreement</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(74,000)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (347,752)<span></span></td>
        <td class="num">$ (309,663)<span></span></td>
        <td class="num">$ (698,768)<span></span></td>
        <td class="num">$ (659,899)<span></span></td>
        <td class="num">$ (6,628,569)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share - Basic and diluted (in dollars per share)</a></td>
        <td class="num">$ (0.01)<span></span></td>
        <td class="num">$ (0.01)<span></span></td>
        <td class="num">$ (0.02)<span></span></td>
        <td class="num">$ (0.02)<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_WeightedAvgNumberOfOutstandingSharesBasicAndDiluted', window );">Weighted average common shares outstanding - Basic and diluted (in shares)</a></td>
        <td class="nump">35,079,178<span></span></td>
        <td class="nump">35,077,178<span></span></td>
        <td class="nump">35,078,183<span></span></td>
        <td class="nump">34,389,333<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lixt_LiquidatedDamagesUnderRegistrationRightsAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Costs incurred during the reporting period towards liquidated damages under registration rights agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>lixt_LiquidatedDamagesUnderRegistrationRightsAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>lixt</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lixt_ReverseMergerCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash fee incurred during the reporting period in connection with the Company's Share Exchange Agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>lixt_ReverseMergerCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>lixt</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lixt_WeightedAvgNumberOfOutstandingSharesBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The average number of shares issued and outstanding that are used in calculating common stock basic and diluted EPS, determined based on the timing of issuance of shares in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>lixt_WeightedAvgNumberOfOutstandingSharesBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>lixt</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationNonproduction">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 5<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationNonproduction</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cost of borrowed funds accounted for as interest that was charged against earnings during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 34<br> -Paragraph 21<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 9<br> -Article 9<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher OTS<br> -Name Federal Regulation (FR)<br> -Number Title 12<br> -Chapter V<br> -Section 563c.102<br> -Paragraph 9<br> -Subsection II<br> -LegacyDoc This is a non-GAAP reference that was included in the 2009 taxonomy.  It will be removed from future versions of this taxonomy.<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNonoperating">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 7<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentIncomeNonoperating</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 38<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph A7<br> -Appendix A<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 130<br> -Paragraph 10, 15<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 38<br> -Subparagraph d<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Emerging Issues Task Force (EITF)<br> -Number 87-21<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 19<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28, 29, 30<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 141<br> -Paragraph 51<br> -Subparagraph g<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 2<br> -Paragraph 12, 13<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 86<br> -Paragraph 11, 12<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E5EAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document And Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Aug. 11, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">LIXTE BIOTECHNOLOGY HOLDINGS, INC.<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001335105<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
        <td class="text">lixt<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text"> <span></span></td>
        <td class="nump">35,259,142<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Jun. 30,
         2011<span></span></td>
        <td class="text"><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q2<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2011<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document as an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, and Other.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Trading symbol of an instrument as listed on an exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_TradingSymbol</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Money Market Funds Fair Value<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_CashAndCashEquivalentsDisclosureAbstract', window );"><strong>Cash and Cash Equivalents Disclosure [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash and Cash Equivalents Disclosure [Text Block]</a></td>
        <td class="text"><div><div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >5. Money Market Funds &#8212; Fair Value
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Money market funds at June 30, 2011 and December 31, 2010 consisted of an investment in the Class A Shares of Western Asset New York Municipal Money Market Fund with a market value of $1,301,089 and $1,601,006, respectively. The stated purpose of this money market fund is to provide income exempt from both regular federal income tax and New York State and New York City personal income tax from a portfolio of high quality short-term municipal obligations selected for liquidity and stability of principal.
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required.
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Level 1: quoted prices (unadjusted) in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives.
</font>
</div><div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;" ><div>&#160;
</div>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Level 2: inputs other than quoted prices included within Level 1 that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges.
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Level 3: unobservable inputs for the asset or liability are only used when there is little, if any, market activity for the asset or liability at the measurement date. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models.
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end.
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Money market funds are the only financial instrument that is measured and recorded at fair value on the Company&#8217;s balance sheet on a recurring basis. The following table presents money market funds at their level within the fair value hierarchy at June 30, 2011 and December&#160;31, 2010.
</font>
</div>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;" ><table cellspacing="0" cellpadding="0" width="100%"  style="font-family:times new roman;font-size:10pt;" ><tr><td valign="bottom"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" colspan="2" nowrap="nowrap"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Total
</font>
</div>
</td><td valign="top"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" colspan="2" nowrap="nowrap"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new
 roman;font-size:10pt;font-weight:bold;" >Level&#160;1
</font>
</div>
</td><td valign="top"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" colspan="2" nowrap="nowrap"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Level&#160;2
</font>
</div>
</td><td valign="top"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" colspan="2" nowrap="nowrap"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Level&#160;3
</font>
</div>
</td><td valign="top"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr><td valign="bottom"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" colspan="2" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" colspan="2" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" colspan="2" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" colspan="2" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom"  style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >June 30, 2011:
</font>
</div>
</td><td valign="top"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" colspan="2" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" colspan="2" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" colspan="2" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" colspan="2" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="52%"  style="text-align:left;padding-bottom:2px;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Money market funds
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 2px solid;text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</div>
</td><td valign="top" width="9%"  style="border-bottom:black 2px solid;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >1,301,089
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 2px solid;text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</div>
</td><td valign="top" width="9%"  style="border-bottom:black 2px solid;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >1,301,089
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 2px solid;text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</div>
</td><td valign="top" width="9%"  style="border-bottom:black 2px solid;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#8212;
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 2px solid;text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</div>
</td><td valign="top" width="9%"  style="border-bottom:black 2px solid;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#8212;
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="52%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="52%"  style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >December 31, 2010:
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="52%"  style="text-align:left;padding-bottom:4px;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Money market funds
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</div>
</td><td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >1,601,006
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</div>
</td><td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >1,601,006
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</div>
</td><td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#8212;
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</div>
</td><td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#8212;
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr>
</table>
</div>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lixt_CashAndCashEquivalentsDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>lixt_CashAndCashEquivalentsDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>lixt</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for cash and cash equivalent footnotes,  which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 7<br> -Footnote 1<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 8, 9, 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 6.H.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13728-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 6<br> -Section H<br> -Subsection 3<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Basis of Presentation<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_BasisOfPresentationAbstract', window );"><strong>Basis Of Presentation [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">Basis Of Accounting [Text Block]</a></td>
        <td class="text"><div><div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >1. Basis of Presentation
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The condensed consolidated financial statements of Lixte Biotechnology Holdings, Inc. and its wholly-owned subsidiary, Lixte Biotechnology, Inc. (the &#8220;Company&#8221;) at June 30, 2011, for the three months and six months ended June 30, 2011 and 2010, and for the period from August 9, 2005 (inception) to June 30, 2011 (cumulative), are unaudited. In the opinion of management, all adjustments (including normal recurring adjustments) have been made that are necessary to present fairly the financial position of the Company as of June 30, 2011, the results of its operations for the three months and six months ended June 30, 2011 and 2010, and for the period from August 9, 2005 (inception) to June 30, 2011 (cumulative), and its cash flows for the six months ended June 30, 2011 and 2010, and for the period from August 9, 2005 (inception) to June 30, 2011 (cumulative). Operating results for the interim periods presented are not necessarily indicative of the results to be expected for a full fiscal year. The condensed balance sheet at December 31, 2010 has been derived from the company's audited financial statements.
</font>
</div>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The statements and related notes have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been omitted pursuant to such rules and regulations. These financial statements should be read in conjunction with the financial statements and other information included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2010, as filed with the SEC.
</font>
</div>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lixt_BasisOfPresentationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description containing the entire organization, consolidation and basis of presentation of financial statements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>lixt_BasisOfPresentationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>lixt</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfAccounting</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock Options and Warrants<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Share-based Arrangements to Obtain Goods and Services [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Text Block]</a></td>
        <td class="text">
  <div>
  <div>
  <div>
  <div>
  <div>
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;">7. Stock Options and Warrants
  </font>
  </div>
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </div>
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">On June 30, 2006, effective with the closing of the Exchange, the Company granted to Dr.&#160;Philip Palmedo, an outside director of the Company, stock options to purchase an aggregate of 200,000 shares of common stock, exercisable for a period of five years at $0.333 per share, with one-third of the options (66,666 shares) vesting immediately upon joining the Board and one-third vesting annually on each of June 30, 2007 and 2008. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $62,000 ($0.31 per share), of which $20,666 was charged to operations on June 30, 2006, and the remaining $41,334 was charged to operations ratably from July 1, 2006 through June 30, 2008.
  </font>
  </div>
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </div>
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">On June 30, 2006, effective with the closing of the Exchange, the Company also granted to Dr.&#160;Palmedo additional stock options to purchase 190,000 shares of common stock exercisable for a period of five years at $0.333 per share for services rendered in developing the business plan for Lixte, all of which were fully vested upon issuance. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $58,900 ($0.31 per share), and was charged to operations at June 30, 2006.
  </font>
  </div>
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">On June 30, 2011, Dr. Palmedo exercised options to acquire 100,000 shares of common stock, which were part of the above described grants, on a cashless basis. Such cashless exercise resulted in Dr. Palmedo receiving a net of 66,020 shares. The remaining above described options to acquire 290,000 shares of common stock subsequently expired unexercised.
  </font>
  </div>
  <div style="text-indent:0pt;display:block;">
  <br/>
  </div>
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">On June 30, 2011, the Company granted to Dr.&#160;Palmedo stock options to purchase 200,000 shares of common stock exercisable for a period of five years from date of grant at $0.98 per share, which was the fair market value of the Company&#8217;s common stock on such date. The options vest ratably in equal quarterly installments of 25,000 each beginning July 1, 2011. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was initially determined to be $196,000 ($0.98 per share).
  </font>
  </div>
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  </div>
  <br/>
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">On June 30, 2006, effective with the closing of the Exchange, the Company granted to Dr. Stefan Madajewicz and Dr. Iwao Ojima, two members of its Scientific Advisory Committee, stock options to purchase an aggregate of 100,000 shares of common stock (50,000 each) exercisable for a period of five years at $0.333 per share, with one-half of the options vesting annually on each of June 30, 2007 and June 30, 2008. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was charged to operations ratably from July 1, 2006 through June 30, 2008.
  </font>
  </div>
  <div style="text-indent:0pt;display:block;">
  <br/>
  </div>
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">In August 2008, Dr. Madajewicz resigned from his position and waived his right to his vested stock option to purchase 50,000 shares of common stock.
  </font>
  </div>
  <div style="text-indent:0pt;display:block;">
  <br/>
  </div>
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">On June 30, 2011, Dr. Ojima exercised options to acquire 15,015 shares of common stock for a cash payment of $5,000. Dr. Ojima&#8217;s remaining options to acquire 34,985 shares of common stock subsequently expired unexercised.
  </font>
  </div>
  <div style="text-indent:0pt;display:block;">
  <br/>
  </div>
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">On June 30, 2011, the Company granted to Dr.&#160;Ojima stock options to purchase 50,000 shares of common stock exercisable for a period of five years from the date of grant at $0.98 per share, which was the fair market value of the Company&#8217;s common stock on such date. The options vest ratably in equal quarterly installments of 6,250 shares each beginning July 1, 2011. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was initially determined to be $49,000 ($0.98 per share).
  </font>
  </div>

  </div>
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </div>
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">On June 30, 2006, the fair value of the aforementioned stock options was initially calculated using the following Black-Scholes input variables: stock price - $0.333; exercise price - $0.333; expected life - 5 to 7 years; expected volatility - 150%; expected dividend yield - 0%; risk-free interest rate - 5%. On June 30, 2007, the Black-Scholes input variables utilized to determine the fair value of the aforementioned stock options were stock price - $0.333; exercise price - $0.333; expected life - 4 to 6 years; expected volatility - 150%; expected dividend yield - 0%; risk-free interest rate - 4.5%. On June 30, 2008, the fair value of the aforementioned stock options was calculated using the following Black-Scholes input variables: stock price - $0.30; exercise price - $0.333; expected life - 3 to 5 years; expected volatility - 154.5%; expected dividend yield - 0%; risk-free interest rate - 3.28%. On June 30, 2011, the fair value of the aforementioned stock options was calculated using the following Black-Scholes input variables: stock price - $0.98; exercise price - $0.98; expected life - 5 years; expected volatility - 308.8%; expected dividend yield - 0%; risk-free interest rate - 1.58%.
  </font>
  </div>
  <div style="text-indent:0pt;display:block;">
  <br/>
  </div>
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">On February 5, 2007, the Company entered into an agreement (the &#8220;Chem-Master Agreement&#8221;) with Chem-Master International, Inc. (&#8220;Chem-Master&#8221;), a company co-owned by Francis Johnson, a consultant to the Company, pursuant to which the Company granted a five-year option to purchase 100,000 shares of the Company&#8217;s common stock at an exercise price of $0.333 per share. The fair value of this option, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $31,000 ($0.31 per share) using the following Black-Scholes input variables: stock price on date of grant - $0.333; exercise price - $0.333; expected life - 5 years; expected volatility - 150%; expected dividend yield - 0%; risk-free interest rate - 4.5%. The $31,000 fair value was charged to operations as research and development costs on February 5, 2007 as the option was fully vested and non-forfeitable on the date of issuance. The Company has the right to terminate the Chem-Master Agreement at any time during its term upon sixty days prior written notice. On February 5, 2009, provided that the Chem-Master Agreement had not been terminated prior to such date, the Company agreed to grant Chem-Master a second five-year option to purchase an additional 100,000 shares of the Company&#8217;s common stock at an exercise price of $0.333 per share. As of September 30, 2008, the Company determined that it was likely that this option would be issued. Accordingly, the fair value of the option has been reflected as a charge to operations for the period from October 1, 2008 through February 5, 2009. The Company granted the second five-year option on February 5, 2009.&#160;
  </font>
  </div>
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </div>
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">On September 30, 2008, the fair value of the aforementioned stock option was initially calculated using the following Black-Scholes input variables: stock price - $0.50; exercise price - $0.333; expected life &#8211; 5.35 years; expected volatility &#8211; 275.7%; expected dividend yield - 0%; risk-free interest rate &#8211; 2.48%. On February 5, 2009, the fair value of the aforementioned stock option was calculated for the stock option revaluation purposes using the following Black-Scholes input variables: stock price - $0.60; exercise price - $0.333; expected life &#8211; 5 years; expected volatility &#8211; 414.1%; expected dividend yield - 0%; risk-free interest rate &#8211; 1.89%.
  </font>
  </div>
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </div>
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">On January 29, 2008, the Chem-Master Agreement was amended to extend its term to February 15, 2014. Pursuant to the amendment, the Company issued 100,000 shares of its restricted common stock, valued at $75,000, and granted an option to purchase 200,000 shares of common stock. The option is exercisable for a period of two years from the vesting date at $1.65 per share, with one-half (100,000 shares) vesting on August 1, 2009, and one-half (100,000 shares) vesting on February 1, 2011. The fair value of this option, as calculated pursuant to the Black-Scholes option-pricing model, was initially determined to be $96,000 ($0.48 per share) using the following Black-Scholes input variables: stock price on date of grant - $0.75; exercise price - $1.65; expected life - 5 years; expected volatility - 120.1%; expected dividend yield - 0%; risk-free interest rate - 3.09%.
  </font>
  </div>
  <div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;">
  <div>
  </div>
  </div>
  <div style="text-indent:0pt;display:block;">
  <br/>
  </div>
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">The fair value of the restricted common stock issued was charged to operations as research and development costs on January 29, 2008. On February 1, 2011, the fair value of the aforementioned stock options was determined to be $66,000 ($0.33 per share) calculated using the following Black-Scholes input variables: stock price - $0.35; exercise price - $1.65; expected life - 2 years; expected volatility &#8211; 325.6%; expected dividend yield - 0%; risk-free interest rate -2.07%, which resulted in a charge to operations of $982 during the six months ended June 30, 2011. On June 30, 2010, the fair value of the aforementioned stock options was determined to be $62,000 ($0.31 per share) calculated using the following Black-Scholes input variables: stock price - $0.35; exercise price - $1.65; expected life - 2.59 years; expected volatility &#8211; 233.2%; expected dividend yield - 0%; risk-free interest rate - 0.93%, which resulted in a credit to operations of $1,472 during the three months ended June 30, 2010 and a charge to operations of $5,786 during the six months ended June 30, 2010.
  </font>
  </div>
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </div>
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">On June 20, 2007, the Board of Directors of the Company approved the 2007 Stock Compensation Plan (the &#8220;2007 Plan&#8221;), which provides for the granting of awards, consisting of common stock options, stock appreciation rights, performance shares, or restricted shares of common stock, to employees and independent contractors, for up to 2,500,000 shares of the Company&#8217;s common stock, under terms and condition, as determined by the Company&#8217;s Board of Directors.
  </font>
  </div>
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </div>
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">On September 12, 2007, in conjunction with his appointment as a director of the Company, the Company granted to Dr. Stephen Carter stock options to purchase an aggregate of 200,000 shares of common stock under the 2007 Plan, exercisable for a period of five years from vesting date at $0.333 per share, with one-half (100,000 shares) vesting annually on each of September 12, 2008 and 2009. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $204,000 ($1.02 per share), and was charged to operations ratably from September 12, 2007 through September 12, 2009. Effective April 20, 2010, Dr. Carter resigned as a director for personal reasons. Consequently, pursuant to the stock option agreement, Dr. Carter had twelve months from April 20, 2010 to exercise his stock options to acquire 200,000 shares of the Company&#8217;s common stock. On April 20, 2011 Dr. Carter&#8217;s stock options expired unexercised.
  </font>
  </div>
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </div>
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">On September 12, 2007, the Company entered into a consulting agreement with Gil Schwartzberg, pursuant to which the Company granted to Mr. Schwartzberg stock options to purchase an aggregate of 1,000,000 shares of common stock, exercisable for a period of four years from the vesting date at $1.00 per share, with one-half of the options (500,000 shares) vesting immediately and one-half (500,000 shares) vesting on September 12, 2008. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was initially determined to be $945,000 ($0.945 per share), of which $465,000 was attributed to the fully-vested options and was thus charged to operations on September 12, 2007. The remaining unvested portion of the fair value of the options was charged to operations ratably from September 12, 2007 through September 12, 2008.
  </font>
  </div>
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </div>
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">On October 15, 2009, the Company amended the above described consulting agreement with Gil Schwartzberg to extend it for an additional four years and granted to Mr. Schwartzberg stock options to purchase an additional aggregate of 1,000,000 shares of common stock, exercisable for a period of four years from the vesting date at $1.00 per share, with one-half of the options (500,000 shares) vesting immediately and one-half (500,000 shares) vesting on October 15, 2010. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $750,000 ($0.75 per share) on October 15, 2009, of which $375,000 was attributed to the fully-vested options and was thus charged to operations on October 15, 2009. The remaining unvested portion of the fair value of the options was charged to operations ratably from October 15, 2009 through October 15, 2010. On June 30, 2010, the fair value of the aforementioned stock options was determined to be $170,000 ($0.34 per share) calculated using the following Black-Scholes input variables: stock price - $0.35; exercise price - $1.00; expected life - 4.29 years; expected volatility &#8211; 233.2%; expected dividend yield - 0%; risk-free interest rate - 0.93%, which resulted in a charge to operations of $8,068 during the three months ended June 30, 2010 and a charge to operations of $68,479 during the six months ended June 30, 2010.
  </font>
  </div>
  <div style="text-indent:0pt;display:block;">
  <br/>
  </div>
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">On September 12, 2007, the Company entered into a consulting agreement with Francis Johnson, a co-owner of Chem-Master International, Inc., and granted to Professor Johnson stock options to purchase an aggregate of 300,000 shares of common stock, exercisable for a period of four years from the vesting date at $0.333 per share, with one-third (100,000 shares) vesting annually on each of September 12, 2008, 2009 and 2010. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was initially determined to be $300,000 ($1.00 per share). The unvested portion of the fair value of the options was charged to operations ratably from September 12, 2007 through September 12, 2010. On June 30, 2010, the fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $102,000 ($0.34 per share) which resulted a credit to operations of $290 during the three months ended June 30, 2010 and a charge to operations of $12,340 during the six months ended June 30, 2010.
  </font>
  </div>
  <div style="text-indent:0pt;display:block;">
  <br/>
  </div>
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">On September 12, 2007, the fair value of the aforementioned stock options was initially calculated using the following Black-Scholes input variables: stock price - $1.05; exercise price - $0.333 to $1.00; expected life - 4 to 6 years; expected volatility - 150%; expected dividend yield - 0%; risk-free interest rate - 5%. On October 15, 2009, the fair value of the aforementioned stock options was initially calculated using the following Black-Scholes input variables: stock price - $0.75; exercise price - $1.00; expected life - 5 years; expected volatility &#8211; 259.1%; expected dividend yield - 0%; risk-free interest rate &#8211; 1.91%. On June 30, 2010, the fair value of the aforementioned stock options was calculated for the stock option revaluation purposes using the following Black-Scholes input variables: stock price - $0.35; exercise price - $0.333; expected life - 4.23; expected volatility &#8211; 233.2%; expected dividend yield - 0%; risk-free interest rate &#8211; 0.93%.
  </font>
  </div>
  <div style="text-indent:0pt;display:block;">
  <br/>
  </div>
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">As the Company&#8217;s common stock commenced trading on September 24, 2007, the Company was able to utilize such trading data to generate revised volatility factors as of the various subsequent measurement dates.
  </font>
  </div>
  <div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;">
  <div>
  </div>
  </div>
  <div style="text-indent:0pt;display:block;">
  <br/>
  </div>
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">On September 20, 2007, the Company entered into a one-year consulting agreement (the &#8220;Mirador Agreement&#8221;) with Mirador Consulting, Inc. (&#8220;Mirador&#8221;), pursuant to which Mirador was to provide the Company with various financial services. Pursuant to the Mirador Agreement, the Company agreed to pay Mirador $5,000 per month and also agreed to sell Mirador 250,000 shares of the Company&#8217;s restricted common stock for $250 ($0.001 per share). The fair value of this transaction was determined to be in excess of the purchase price by $262,250 ($1.049 per share), reflecting the difference between the $0.001 purchase price and the $1.05 price per share as quoted on the OTC Bulletin Board on the transaction date, and was charged to operations as stock-based compensation on September 20, 2007, being that the shares were fully vested and non-forfeitable on the date of issuance.
  </font>
  </div>
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </div>
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">On October 7, 2008, the Company appointed Dr. Mel Sorensen to its Board of Directors. Dr. Sorensen is a medical oncologist with extensive experience in cancer drug development, first at the National Cancer Institute, then at Bayer and GlaxoSmithKline, before becoming President and Chief Executive Officer of a new cancer therapeutics company, Ascenta Therapeutics, in 2004. Dr. Sorensen was paid an annual consulting fee of $40,000, payable in quarterly installments over a one year period commencing October 7, 2008, to assist the Company in identifying a strategic partner. Dr. Sorensen was also granted a stock option to purchase 200,000 shares of the Company&#8217;s common stock, exercisable at $0.50 per share for a period of five years from each tranche&#8217;s vesting date. The option vests as to 25,000 shares on January 1, 2009, and a further 25,000 shares on the first day of each subsequent calendar quarter until all of the shares are vested. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $100,000 ($0.50 per share), and was charged to operations ratably from October 7, 2008 through October 7, 2010. During the three and six months ended June 30, 2010, the Company recorded charges to operations of $12,466 and $24,795, respectively, with respect to these options.
  </font>
  </div>
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </div>
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">On October 7, 2008, the fair value of the aforementioned stock options was calculated using the following Black-Scholes input variables: stock price - $0.50; exercise price - $0.50; expected life - 5 years; expected volatility &#8211; 275.7%; expected dividend yield - 0%; risk-free interest rate &#8211; 2.48%.
  </font>
  </div>
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </div>
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">On July 27, 2009, the Company entered into an agreement with Pro-Active Capital Group, LLC (&#8220;Pro-Active&#8221;) to retain Pro-Active on a non-exclusive basis for a period of twelve months to provide consulting advice to the Company to assist the Company in obtaining research coverage, gaining web-site exposure and coverage on financial blogs and web-sites, enhancing the Company&#8217;s visibility to the institutional, retail brokerage and on-line trading communities, and organizing, or assisting in organizing, investor road-shows and presentations. In exchange for such consulting advice, at the initiation of the agreement, the Company agreed to issue to Pro-Active 150,000 shares of restricted common stock and three-year warrants to purchase an aggregate of 150,000 shares of common stock, exercisable 50,000 at $0.75 per share, 50,000 at $1.00 per share, and 50,000 at $1.25 per share. The fair value of the 150,000 shares issued was determined to be $100,500 ($0.67 per share), reflecting the price per share of the Company&#8217;s common stock, as quoted on the OTC Bulletin Board, on the transaction date. The fair value of the three-year warrants, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $97,500 ($0.65 per share) using the following Black-Scholes input variables: stock price on date of grant - $0.67; exercise price - $0.75 to $1.25; expected life - 3 years; expected volatility &#8211; 259.1%; expected dividend yield - 0%; risk-free interest rate - 1.91%. The $198,000 aggregate fair value of the shares and warrants issued was charged to operations as stock-based compensation on July 27, 2009, as the shares and warrants were fully vested and non-forfeitable on the date of issuance.
  </font>
  </div>
  <div style="text-indent:0pt;display:block;">
  <br/>
  </div>
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">
  </font>
  </div>
  <div>

  <div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">Effective May 2, 2011, the Company elected Dr. Robert B. Royds to its Board of Directors. Dr. Royds<font style="display:inline;font-weight:bold;">&#160;
  </font>is Chairman of the Board and Medical Director of Theradex Systems, Inc., a leading clinical research organization, with research bases in Europe, Australia and Japan. Dr. Royds is responsible for the scientific affairs of Theradex Systems, Inc. Dr. Royds was trained in internal medicine and pharmacology, and he has extensive experience in all stages of the clinical drug development process. Before founding Theradex Systems, Inc., Dr. Royds was Senior Research Physician at Hoffmann-La Roche, Inc., and Associate Director for Clinical Pharmacology International at Merck, Sharp, and Dohme Research Laboratories. Dr. Royds has been a consultant/advisor to the National Institute of Child Health and Development and the National Cancer Institute on issues of clinical trial design and international standardization of data sets of clinical trials of new investigational anti-cancer agents. Dr. Royds has served as the physician-monitor for the Clinical Trials Monitoring Service of the National Cancer Institute since 1979, and has been the Principal Investigator for this contract since 1982.
  </font>
  <br/>
  &#160;
  </div>
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">Effective May 1, 2011, Dr. Royds was granted stock options to purchase 200,000 shares of the Company&#8217;s common stock, exercisable for a period of five years from each tranche&#8217;s vesting date, at $0.98 per share, which was the fair market value of the Company&#8217;s common stock on such date. The options vested as to 25,000 shares on May 1, 2011, and a further 25,000 shares vest on the first day of each subsequent quarter until all of the shares are vested. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $196,000 ($0.98 per share), and is being charged to operations ratably from May 2, 2011 through February 1, 2013. During the three months and six months ended June 30, 2011, the Company recorded a charge to operations of $40,528 with respect to these options.
  </font>
  </div>
  </div>
  <div style="text-indent:0pt;display:block;">
  <br/>
  </div>
  <div>
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">On May 2, 2011, the fair value of the aforementioned stock options was calculated using the following Black-Scholes input variables: stock price - $0.98; exercise price - $0.98; expected life &#8211; 6.76 years; expected volatility &#8211; 308.8%; expected dividend yield - 0%; risk-free interest rate &#8211; 1.58%.<br/>
  <br/>
  </font>
  </div>
  </div>
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">
  </font>
  </div>
  <div>
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">Additional information with respect to common stock warrants and stock options issued is provided at Notes 4 and 8.<br/>
  <br/>
  </font>
  </div>
  </div>
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">
  </font>
  </div>
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">If and when the aforementioned stock options and warrants are exercised, the Company expects to satisfy such stock obligations through the issuance of authorized but unissued shares of common stock.
  </font>
  </div>
  <br/>
  <div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;">
  <div>
  </div>
  <div>
  </div>
  </div>
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">A summary of stock option and warrant activity, including warrants to purchase common stock that were issued in conjunction with the Company&#8217;s private placements, is presented in the tables below.<br/>
  <br/>
  </font>
  </div>
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">
  </font>
  </div>
  <div style="text-align:left;">
  <div>
  <table cellspacing="0" cellpadding="0" width="100%" style="font-family:times new roman;font-size:10pt;">
  <tr>
  <td valign="bottom" style="text-align:left;padding-bottom:2px;">
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;&#160;
  </font>
  </div>
  </td>
  <td valign="bottom" style="text-align:left;padding-bottom:2px;">
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;&#160;
  </font>
  </div>
  </td>
  <td valign="bottom" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;">
  <div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;">
  <font style="display:inline;">Number
  </font>
  </font>
  </div>
  <div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;">
  <font style="display:inline;">of
  </font>
  </font>
  </div>
  <div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;">
  <font style="display:inline;">Shares
  </font>
  </font>
  </div>
  </td>
  <td valign="bottom" style="text-align:left;padding-bottom:2px;">
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;&#160;
  </font>
  </div>
  </td>
  <td valign="bottom" style="text-align:left;padding-bottom:2px;">
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;&#160;
  </font>
  </div>
  </td>
  <td valign="bottom" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;">
  <div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;">
  <font style="display:inline;">Weighted
  </font>
  </font>
  </div>
  <div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;">
  <font style="display:inline;">Average
  </font>
  </font>
  </div>
  <div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;">
  <font style="display:inline;">Exercise
  </font>
  </font>
  </div>
  <div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;">
  <font style="display:inline;">Price
  </font>
  </font>
  </div>
  </td>
  <td valign="bottom" style="text-align:left;padding-bottom:2px;">
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;&#160;
  </font>
  </div>
  </td>
  <td valign="bottom" style="text-align:left;padding-bottom:2px;">
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;&#160;
  </font>
  </div>
  </td>
  <td valign="bottom" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;">
  <div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;">
  <font style="display:inline;">Weighted
  </font>
  </font>
  </div>
  <div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;">
  <font style="display:inline;">Average
  </font>
  </font>
  </div>
  <div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;">
  <font style="display:inline;">Remaining
  </font>
  </font>
  </div>
  <div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;">
  <font style="display:inline;">Contractual
  </font>
  </font>
  </div>
  <div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;">
  <font style="display:inline;">Life
  </font>
  </font>
  </div>
  <div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;">
  <font style="display:inline;">(in&#160;Years)
  </font>
  </font>
  </div>
  </td>
  <td valign="bottom" style="text-align:left;padding-bottom:2px;">
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;&#160;
  </font>
  </div>
  </td>
  </tr>
  <tr style="background-color:#ccffcc;">
  <td valign="bottom" width="64%" style="text-align:left;">
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">Options and warrants outstanding at December 31, 2009
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="9%" style="text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">7,997,426
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">$
  </font>
  </div>
  </td>
  <td valign="bottom" width="9%" style="text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">0.664
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="9%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  </tr>
  <tr style="background-color:#ffffff;">
  <td valign="bottom" width="64%" style="text-align:left;">
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">Granted
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="9%" style="text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">9,150,000
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="9%" style="text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">0.625
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="9%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  </tr>
  <tr style="background-color:#ccffcc;">
  <td valign="bottom" width="64%" style="text-align:left;">
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">Exercised
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="9%" style="text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#8212;
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="9%" style="text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#8212;
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="9%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  </tr>
  <tr style="background-color:#ffffff;">
  <td valign="bottom" width="64%" style="text-align:left;padding-bottom:2px;">
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">Cancelled
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">
  <font style="display:inline;">&#8212;
  </font>
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">
  <font style="display:inline;">&#8212;
  </font>
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="9%" style="text-align:left;padding-bottom:2px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  </tr>
  <tr style="background-color:#ccffcc;">
  <td valign="bottom" width="64%" style="text-align:left;">
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">Options and warrants outstanding at December 31, 2010
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="9%" style="text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">17,147,426
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">$
  </font>
  </div>
  </td>
  <td valign="bottom" width="9%" style="text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">0.643
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="9%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  </tr>
  <tr style="background-color:#ffffff;">
  <td valign="bottom" width="64%" style="text-align:left;">
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">Granted
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="9%" style="text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">450,000
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="9%" style="text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">0.980
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="9%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  </tr>
  <tr style="background-color:#ccffcc;">
  <td valign="bottom" width="64%" style="text-align:left;">
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">Exercised
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="9%" style="text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">(267,889
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">)&#160;
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="9%" style="text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">0.333
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="9%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  </tr>
  <tr style="background-color:#ffffff;">
  <td valign="bottom" width="64%" style="text-align:left;padding-bottom:2px;">
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">Cancelled
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">
  <font style="display:inline;">(524,985
  </font>
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;">
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">)&#160;
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">
  <font style="display:inline;">0.333
  </font>
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="9%" style="text-align:left;padding-bottom:2px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  </tr>
  <tr style="background-color:#ccffcc;">
  <td valign="bottom" width="64%" style="text-align:left;padding-bottom:4px;">
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">Options and warrants outstanding at June 30, 2011
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="9%" style="border-bottom:black 4px double;text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">
  <font style="display:inline;">16,804,552
  </font>
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;">
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">
  <font style="display:inline;">$
  </font>
  </font>
  </div>
  </td>
  <td valign="bottom" width="9%" style="border-bottom:black 4px double;text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">
  <font style="display:inline;">0.667
  </font>
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="9%" style="border-bottom:black 4px double;text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">
  <font style="display:inline;">1.78
  </font>
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  </tr>
  <tr style="background-color:#ffffff;">
  <td valign="bottom" width="64%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="9%" style="text-align:right;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="9%" style="text-align:right;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="9%" style="text-align:right;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  </tr>
  <tr style="background-color:#ccffcc;">
  <td valign="bottom" width="64%" style="text-align:left;padding-bottom:4px;">
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">Options and warrants exercisable at December 31, 2010
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="9%" style="border-bottom:black 4px double;text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">
  <font style="display:inline;">16,877,026
  </font>
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;">
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">
  <font style="display:inline;">$
  </font>
  </font>
  </div>
  </td>
  <td valign="bottom" width="9%" style="border-bottom:black 4px double;text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">
  <font style="display:inline;">0.639
  </font>
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="9%" style="text-align:left;padding-bottom:4px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  </tr>
  <tr style="background-color:#ffffff;">
  <td valign="bottom" width="64%" style="text-align:left;padding-bottom:4px;">
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">Options and warrants exercisable at June 30, 2011
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="9%" style="border-bottom:black 4px double;text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">16,209,152
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;">
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">$
  </font>
  </div>
  </td>
  <td valign="bottom" width="9%" style="border-bottom:black 4px double;text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">0.660
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="9%" style="border-bottom:black 4px double;text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">1.68
  </font>
  </div>
  </td>
  <td valign="top" width="1%" style="text-align:left;padding-bottom:4px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  </tr>
  </table>
  <br/>
  </div>
  </div>
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">
  </font>
  </div>
  <div>
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">Total deferred compensation expense for the outstanding value of unvested stock options was approximately $400,500 at June 30, 2011, which is being recognized subsequent to June 30, 2011 over a weighted-average period of forty-four months.<br/>
  <br/>
  </font>
  </div>
  </div>
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">
  </font>
  </div>
  <div>
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">Information regarding stock options and warrants outstanding and exercisable is summarized as follows at June 30, 2011:<br/>
  <br/>
  </font>
  </div>
  </div>
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">
  </font>
  </div>
  <div style="text-align:center;">
  <table cellspacing="0" cellpadding="0" width="80%" style="font-family:times new roman;font-size:10pt;">
  <tr>
  <td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="31%" nowrap="nowrap" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="32%" colspan="2" nowrap="nowrap">
  <div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;">Warrants
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="31%" colspan="2" nowrap="nowrap">
  <div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;">Warrants
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  </tr>
  <tr>
  <td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="31%" nowrap="nowrap" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="32%" colspan="2" nowrap="nowrap">
  <div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;">And
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="31%" colspan="2" nowrap="nowrap">
  <div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;">And
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  </tr>
  <tr>
  <td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="31%" nowrap="nowrap" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="32%" colspan="2" nowrap="nowrap">
  <div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;">Options
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="31%" colspan="2" nowrap="nowrap">
  <div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;">Options
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  </tr>
  <tr>
  <td valign="bottom" width="1%" nowrap="nowrap">
  <font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;">&#160;
  </font>
  </td>
  <td valign="bottom" width="31%" nowrap="nowrap">
  <div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;">Exercise
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" nowrap="nowrap">
  <font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="32%" colspan="2" nowrap="nowrap">
  <div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;">Outstanding
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="31%" colspan="2" nowrap="nowrap">
  <div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;">Exercisable
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  </tr>
  <tr>
  <td valign="bottom" width="1%" nowrap="nowrap" style="border-bottom:black 2px double;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;">&#160;
  </font>
  </td>
  <td valign="bottom" width="31%" nowrap="nowrap" style="border-bottom:black 2px double;">
  <div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;">
  <font style="display:inline;">Prices
  </font>
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" nowrap="nowrap" style="padding-bottom:2px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="32%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px double;">
  <div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;">
  <font style="display:inline;">(Shares)
  </font>
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="31%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px double;">
  <div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;">
  <font style="display:inline;">(Shares)
  </font>
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  </tr>
  <tr style="background-color:#ccffcc;">
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">$
  </font>
  </td>
  <td valign="bottom" width="31%" style="text-align:right;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">0.333
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:right;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="31%" style="text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">773,752
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:right;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="30%" style="text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">773,752
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  </tr>
  <tr style="background-color:#ffffff;">
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">$
  </font>
  </td>
  <td valign="bottom" width="31%" style="text-align:right;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">0.500
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:right;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:right;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="31%" style="text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">7,535,800
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:right;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="30%" style="text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">7,365,400
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  </tr>
  <tr style="background-color:#ccffcc;">
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">$
  </font>
  </td>
  <td valign="bottom" width="31%" style="text-align:right;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">0.650
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:right;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="31%" style="text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">120,000
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:right;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="30%" style="text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">120,000
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  </tr>
  <tr style="background-color:#ffffff;">
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">$
  </font>
  </td>
  <td valign="bottom" width="31%" style="text-align:right;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">0.750
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:right;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="31%" style="text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">5,625,000
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:right;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="30%" style="text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">5,625,000
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  </tr>
  <tr style="background-color:#ccffcc;">
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">$
  </font>
  </td>
  <td valign="bottom" width="31%" style="text-align:right;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">0.980
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="31%" style="text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">450,000
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="30%" style="text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">25,000
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  </tr>
  <tr style="background-color:#ffffff;">
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">$
  </font>
  </td>
  <td valign="bottom" width="31%" style="text-align:right;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">1.000
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:right;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="31%" style="text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">2,050,000
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:right;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="30%" style="text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">2,050,000
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  </tr>
  <tr style="background-color:#ccffcc;">
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">$
  </font>
  </td>
  <td valign="bottom" width="31%" style="text-align:right;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">1.250
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:right;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="31%" style="text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">50,000
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:right;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="30%" style="text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">50,000
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  </tr>
  <tr style="background-color:#ffffff;">
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">$
  </font>
  </td>
  <td valign="bottom" width="31%" style="text-align:right;padding-bottom:2px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">1.650
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:right;padding-bottom:2px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:right;padding-bottom:2px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="31%" style="border-bottom:black 2px solid;text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">
  <font style="display:inline;">200,000
  </font>
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:right;padding-bottom:2px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="30%" style="border-bottom:black 2px solid;text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">
  <font style="display:inline;">200,000
  </font>
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:2px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  </tr>
  <tr style="background-color:#ccffcc;">
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="31%" style="text-align:left;padding-bottom:4px;">&#160;
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:right;padding-bottom:4px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="31%" style="border-bottom:black 4px double;text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">16,804,552
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="text-align:right;padding-bottom:4px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  <td valign="bottom" width="30%" style="border-bottom:black 4px double;text-align:right;">
  <div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">16,209,152
  </font>
  </div>
  </td>
  <td valign="bottom" width="1%" style="text-align:left;padding-bottom:4px;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">&#160;
  </font>
  </td>
  </tr>
  </table>
  <br/>
  <br/>
  </div>
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">
  </font>
  </div>
  <div>
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">The intrinsic value of exercisable but unexercised in-the-money stock options and warrants at June 30, 2011 was approximately $5,369,360, based on a fair market value of $0.98 per share on June 30, 2011. The intrinsic value of exercisable but unexercised in-the-money stock options and warrants at December 31, 2010 was approximately $26,600, based on a fair market value of $0.35 per share on December 31, 2010.<br/>
  <br/>
  </font>
  </div>
  </div>

  </div>
  </div>
  <div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;">
  <font style="display:inline;font-family:times new roman;font-size:10pt;">Outstanding options and warrants to acquire 425,000 shares of the Company&#8217;s common stock had not vested at June 30, 2011. At June 30, 2011, warrants and options exercisable do not include warrants to acquire 170,400 shares of common stock that are contingent upon the exercise of warrants contained in units sold as part of the third private placement (see Note 4).
  </font>
  </div>
  <div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;">
  <br/>
  </div>
  </div>
  </div>
  </div>
  </div>
</div>
  <span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan.  Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 123R<br> -Paragraph 64, 65, A240<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
        <td class="text"><div><div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-weight:bold;" >8.
</font><font style="display:inline;font-weight:bold;" >Commitments and Contingencies
</font>
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >CRADA
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Effective March 22, 2006, the Company entered into a CRADA, as amended, with the NINDS of the NIH. The CRADA is for a term of 66 months from the effective date and can be unilaterally terminated by either party by providing written notice within sixty days. The CRADA provides for the collaboration between the parties in the identification and evaluation of agents that target the Nuclear Receptor CoRepressor (N-CoR) pathway for glioma cell differentiation. The CRADA also provides that NINDS and the Company will conduct research to determine if expression of N-CoR correlates with prognosis in glioma patients. Pursuant to the CRADA, the Company initially agreed to provide funds under the CRADA in the amount of $200,000 per year to fund two technical assistants for the technical, statistical and administrative support for the research activities, as well as to pay for supplies and travel expenses. The first $200,000 was due within 180 days of the effective date and was paid in full on July 6, 2006. The second $200,000 was paid in full on June 29, 2007. In June 2008, the CRADA was extended to September 30, 2009, with no additional funding required for the period between July 1, 2008 and September 30, 2008. For the period from October 1, 2008 through September 30, 2009, the Company agreed to provide additional funding under the CRADA of $200,000, to be paid in four quarterly installments of $50,000, each commencing on October 1, 2008. The first and second quarterly installments of $50,000 were paid on September 29, 2008 and March 5, 2009, respectively.&#160;During August&#160;2009, the Company entered into an amendment to the CRADA to extend its term from September 30, 2009 through September 30, 2011.&#160;Pursuant to such amendment, the Company has agreed to aggregate payments of $100,000 in two installments of $50,000, payable on October 1, 2010 and January 5, 2011, inclusive of any prior unpaid commitments. The October 1, 2010 installment was paid on September 29, 2010 and the January 5, 2011 installment was paid on December 27, 2010.
</font>
</div><div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;" ><div>&#160;
</div>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Effective as of September 19, 2008, the Company entered into an agreement with the NIH providing the Company with an exclusive license for all patents submitted jointly with the NIH under the CRADA. The agreement provided for an initial payment of $25,000 to NIH within 60 days of September 19, 2008, and for a minimum annual royalty of $30,000 on January 1 of each calendar year following the year in which the CRADA is terminated. The agreement also provides for the Company to pay specified royalties based on (i) net sales by the Company and its sub-licensees, (ii) the achievement of certain clinical benchmarks, and (iii) the granting of sublicenses. The Company paid the initial $25,000 obligation on November 10, 2008 and charged the amount to general and administrative costs during the year ended December 31, 2008. As of June 30, 2011, no additional amounts were due pursuant to this agreement.
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Research and Development Contracts
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >On February 5, 2007, the Company entered into a two-year agreement pursuant to which the Company engaged Chem-Master to synthesize a compound designated as LB-100, and any other compound synthesized by Chem-Master pursuant to the Company&#8217;s request, which have potential use in treating a disease, including, without limitation, cancers such as glioblastomas. Pursuant to the Chem-Master Agreement, the Company agreed to reimburse Chem-Master for the cost of materials, labor, and expenses for other items used in the synthesis process, and also agreed to grant Chem-Master a five-year option to purchase shares of the Company&#8217;s common stock. The Company has the right to terminate the Chem-Master Agreement at any time during its term upon sixty days prior written notice.
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >On January 29, 2008, the Chem-Master Agreement was amended to extend its term to February 15, 2014, and to expressly provide for the design and synthesis of a new series of compounds designated as LB-300. Pursuant to the Chem-Master Agreement, as amended, the Company reimbursed Chem-Master for the costs of materials, labor and expenses aggregating $1,500 and $20,000 during the three months ending June 30, 2011 and 2010, respectively. During the six months ending June 30, 2011 and 2010, reimbursements to Chem-Master amounted to $6,325 and $33,000, respectively.
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;On March 17, 2010, the Company engaged Theradex Systems, Inc. to assist the Company in bringing LB-100 through the FDA approval process at a total estimated cost of $105,064, of which $15,205 had been incurred through June 30, 2011. As of June 30, 2011, work was proceeding under this contract. Dr. Robert B. Royds, the founder, Chairman of the Board and Medical Director of Theradex Systems, Inc., was appointed to the Company&#8217;s Board of Directors on May 2, 2011.
</font>
</div>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >On March 17, 2011, the Company entered into an agreement with Ascentage Pharma Group to conduct a series of studies at a total estimated cost of $20,000, of which $15,000 had been paid through June 30, 2011. Ascentage Pharma Group is an offshoot of Ascenta Therapeutics, of which Dr. Mel Sorensen, a director of the Company, is the President and Chief Executive Officer and a director. Ascentage Pharma Group and Ascenta Therapeutics have a continuing business relationship and certain common shareholders. However, Dr. Sorensen does not have any direct business relationship with or ownership in Ascentage Pharma Group.
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >On January 7, 2011, the Company entered into a Master Laboratory Services Agreement with WIL Research Laboratories, LLC for a series of studies. As of June 30, 2011, work orders for studies having a total estimated cost of $108,240 were in process under this agreement. As of June 30, 2011, the Company had paid $54,120 towards these work orders.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;On January 18, 2011, the Company entered into an agreement with Ash Stevens for a series of studies with a total estimated cost of $90,000. As of June 30, 2011, the Company had paid $29,700 towards these studies.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Consulting Arrangements
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >On April 7, 2010, the Company entered into an agreement with Dr. Mel Sorensen providing for consultation and advice over the ensuing twelve month period regarding the preparation and strategy for obtaining FDA approval for the clinical trial of the lead compound of the LB-100 series. The agreement called for an annual fee of $25,000, payable in two installments of $12,500 on April 15, 2010 and October 15, 2010. On February 18, 2011, the Company&#8217;s Board of Directors approved a one-year extension of the agreement for an additional annual fee of $25,000, payable in two installments of $12,500 on April 15, 2011 and October 15, 2011. All installments have been paid as due.
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The following table sets forth the Company&#8217;s principal cash obligations and commitments for the next five fiscal years as of June 30, 2011 aggregating $470,236, of which $256,267 is included in current liabilities in the condensed consolidated balance sheet at June 30, 2011.&#160; Amounts included in the 2011 column represent amounts due at June 30, 2011 for the remainder of the 2011 fiscal year ending December 31, 2011.
</font>
</div><br />
<div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;" ><div><div style="text-align:left;width:100%;" ><font style="display:inline;font-family:times new roman;font-size:8pt;" >&#160;
</font>
</div>
</div><div style="page-break-after:always;width:100%;" ><div style="text-align:center;width:100%;" >&#160;
</div><div style="text-align:center;width:100%;" >
</div>
</div><div><div style="text-align:right;width:100%;" ><font style="display:inline;font-family:times new roman;font-size:8pt;" >&#160;
</font>
</div>
</div>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:left;" ><table cellspacing="0" cellpadding="0" width="100%"  style="font-family:times new roman;font-size:10pt;" ><tr><td valign="bottom"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" colspan="2" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" colspan="6" nowrap="nowrap"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Payments&#160;Due&#160;By&#160;Year
</font>
</div>
</td><td valign="top"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr><td valign="bottom"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" colspan="2" nowrap="nowrap"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Total
</font>
</div>
</td><td valign="top"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" colspan="2" nowrap="nowrap"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >2011
</font>
</div>
</td><td valign="top"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" colspan="2" nowrap="nowrap"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >2012
</font>
</div>
</td><td valign="top"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="64%"  style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Research and development contracts
</font>
</div>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</div>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >291,019
</font>
</div>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</div>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >291,019
</font>
</div>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</div>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#8212;
</font>
</div>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="64%"  style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Consulting agreement
</font>
</div>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >12,500
</font>
</div>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >12,500
</font>
</div>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#8212;
</font>
</div>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="64%"  style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Liquidated damages payable under registration rights agreement
</font>
</div>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >74,000
</font>
</div>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >74,000
</font>
</div>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#8212;
</font>
</div>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="64%"  style="text-align:left;padding-bottom:2px;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Due to stockholder
</font>
</div>
</td><td valign="bottom" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="border-bottom:black 2px solid;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >92,717
</font>
</div>
</td><td valign="bottom" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="border-bottom:black 2px solid;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >92,717
</font>
</div>
</td><td valign="bottom" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="border-bottom:black 2px solid;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#8212;
</font>
</div>
</td><td valign="bottom" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="64%"  style="text-align:left;padding-bottom:4px;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Total
</font>
</div>
</td><td valign="bottom" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</div>
</td><td valign="bottom" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >470,236
</font>
</div>
</td><td valign="bottom" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</div>
</td><td valign="bottom" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >470,236
</font>
</div>
</td><td valign="bottom" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</div>
</td><td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#8212;
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr>
</table>
</div>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name FASB Interpretation (FIN)<br> -Number 14<br> -Paragraph 3<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 5<br> -Paragraph 9, 10, 11, 12<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transactions<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions Disclosure [Text Block]</a></td>
        <td class="text">
  <div><div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >6. Related Party Transactions
  </font>
  </div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
  </font>
  </div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Prior to June 30, 2006, the Company&#8217;s founding stockholder and Chief Executive Officer, Dr. John Kovach, had periodically made advances to the Company to meet operating expenses. Such advances are non-interest-bearing and are due on demand. At June 30, 2011 and December 31, 2010, stockholder advances totaled $92,717.
  </font>
  </div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
  </font>
  </div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company&#8217;s office facilities have been provided without charge by Dr. Kovach. Such costs were not material to the financial statements and, accordingly, have not been reflected therein.
  </font>
  </div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
  </font>
  </div><div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><div style="text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >In view of the Company&#8217;s development stage status and limited resources, Dr. Kovach did not receive any compensation from the Company during 2010 or in prior years. However, on February 18, 2011, the Company&#8217;s Board of Directors approved a salary to Dr. Kovach of $5,000 per month beginning March 15, 2011.&#160;&#160;In connection therewith, Dr. Kovach reduced his academic commitment from 80% to 60% in order to devote more time to the Company&#8217;s activities. Accordingly, during the three months ended June 30, 2011, the six months ended June 30, 2011, and the period from August 9, 2005 (inception) through June 30, 2011 (cumulative), Dr. Kovach was paid a salary of $15,000, $17,500 and $17,500, respectively.
  </font>
  </div>

  </div>
  </div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
  </font>
  </div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Dr. Kovach is not involved in other business activities but could, in the future, become involved in other business opportunities that become available. Accordingly, he may face a conflict in selecting between the Company and his other business interests. The Company has not yet formulated a policy for the resolution of such potential conflicts.
  </font>
  </div>
  </div>
</div>
  <span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for related party transactions, including the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k))<br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 3A<br> -Section 04<br> -Paragraph b<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 57<br> -Paragraph 1-4<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 4<br> -Section 08<br> -Paragraph k<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0EHPBK">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIENCY) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Common Stock</div>
        </th>
        <th class="th">
          <div>Advance Under Equity Financing</div>
        </th>
        <th class="th">
          <div>Additional Paid-in Capital</div>
        </th>
        <th class="th">
          <div>Deficit Accumulated During the Development Stage</div>
        </th>
        <th class="th">
          <div>Total</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Aug. 09, 2005</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Aug. 09, 2005</a></td>
        <td class="nump">0<span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued to founding stockholder</a></td>
        <td class="nump">1,902<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(402)<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,500<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued to founding stockholder (in shares)</a></td>
        <td class="nump">19,021,786<span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(16,124)<span></span></td>
        <td class="num">(16,124)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2005</a></td>
        <td class="nump">1,902<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(402)<span></span></td>
        <td class="num">(16,124)<span></span></td>
        <td class="num">(14,624)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2005</a></td>
        <td class="nump">19,021,786<span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Shares issued in connection with reverse merger transaction</a></td>
        <td class="nump">401<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">62,099<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">62,500<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued in connection with reverse merger transaction (in shares)</a></td>
        <td class="nump">4,005,177<span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_SharesIssuedInPrivatePlacementNetOfOfferingCosts', window );">Shares issued in private placements, net of offering costs</a></td>
        <td class="nump">355<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">969,017<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">969,372<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_SharesIssuedInPrivatePlacement', window );">Shares issued in private placements, net of offering costs (in shares)</a></td>
        <td class="nump">3,555,220<span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_StockIssuedDuringPeriodValueShareBasedCompensationCosts', window );">Stock-based compensation costs</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">97,400<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">97,400<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(562,084)<span></span></td>
        <td class="num">(562,084)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2006</a></td>
        <td class="nump">2,658<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,128,114<span></span></td>
        <td class="num">(578,208)<span></span></td>
        <td class="nump">552,564<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2006</a></td>
        <td class="nump">26,582,183<span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_SharesIssuedInPrivatePlacementNetOfOfferingCosts', window );">Shares issued in private placements, net of offering costs</a></td>
        <td class="nump">100<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">531,220<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">531,320<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_SharesIssuedInPrivatePlacement', window );">Shares issued in private placements, net of offering costs (in shares)</a></td>
        <td class="nump">999,995<span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_StockIssuedDuringPeriodValueShareBasedCompensationCosts', window );">Stock-based compensation costs</a></td>
        <td class="nump">25<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">890,669<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">890,694<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_StockIssuedDuringPeriodSharesShareBasedCompensationCosts', window );">Stock-based compensation costs (in shares)</a></td>
        <td class="nump">250,000<span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts', window );">Stock-based research and development costs</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">50,836<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">50,836<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(1,648,488)<span></span></td>
        <td class="num">(1,648,488)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2007</a></td>
        <td class="nump">2,783<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">2,600,839<span></span></td>
        <td class="num">(2,226,696)<span></span></td>
        <td class="nump">376,926<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2007</a></td>
        <td class="nump">27,832,178<span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_StockIssuedDuringPeriodValueShareBasedCompensationCosts', window );">Stock-based compensation costs</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">357,987<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">357,987<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts', window );">Stock-based research and development costs</a></td>
        <td class="nump">10<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">213,051<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">213,061<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_SharesIssuedDuringPeriodSharesStockBasedResearchAndDevelopmentCosts', window );">Stock-based research and development costs (in shares)</a></td>
        <td class="nump">100,000<span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(1,271,522)<span></span></td>
        <td class="num">(1,271,522)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2008</a></td>
        <td class="nump">2,793<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">3,171,877<span></span></td>
        <td class="num">(3,498,218)<span></span></td>
        <td class="num">(323,548)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2008</a></td>
        <td class="nump">27,932,178<span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_SharesIssuedInPrivatePlacementNetOfOfferingCosts', window );">Shares issued in private placements, net of offering costs</a></td>
        <td class="nump">242<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,096,808<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,097,050<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_SharesIssuedInPrivatePlacement', window );">Shares issued in private placements, net of offering costs (in shares)</a></td>
        <td class="nump">2,420,000<span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_AdvancesUnderEquityFinancingDuringPeriod', window );">Advance under equity financing</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,200,000<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,200,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_StockIssuedDuringPeriodValueShareBasedCompensationCosts', window );">Stock-based compensation costs</a></td>
        <td class="nump">15<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">745,965<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">745,980<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_StockIssuedDuringPeriodSharesShareBasedCompensationCosts', window );">Stock-based compensation costs (in shares)</a></td>
        <td class="nump">150,000<span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts', window );">Stock-based research and development costs</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">132,933<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">132,933<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(1,551,333)<span></span></td>
        <td class="num">(1,551,333)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2009</a></td>
        <td class="nump">3,050<span></span></td>
        <td class="nump">1,200,000<span></span></td>
        <td class="nump">5,147,583<span></span></td>
        <td class="num">(5,049,551)<span></span></td>
        <td class="nump">1,301,082<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2009</a></td>
        <td class="nump">30,502,178<span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_SharesIssuedInPrivatePlacementNetOfOfferingCosts', window );">Shares issued in private placements, net of offering costs</a></td>
        <td class="nump">458<span></span></td>
        <td class="num">(1,200,000)<span></span></td>
        <td class="nump">2,287,042<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,087,500<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_SharesIssuedInPrivatePlacement', window );">Shares issued in private placements, net of offering costs (in shares)</a></td>
        <td class="nump">4,575,000<span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_StockIssuedDuringPeriodValueShareBasedCompensationCosts', window );">Stock-based compensation costs</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">160,712<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">160,712<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts', window );">Stock-based research and development costs</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">67,222<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">67,222<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(880,250)<span></span></td>
        <td class="num">(880,250)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2010</a></td>
        <td class="nump">3,508<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">7,662,559<span></span></td>
        <td class="num">(5,929,801)<span></span></td>
        <td class="nump">1,736,266<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2010</a></td>
        <td class="nump">35,077,178<span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
        <td class="nump">18<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">4,982<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">5,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
        <td class="nump">181,964<span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_StockIssuedDuringPeriodValueShareBasedCompensationCosts', window );">Stock-based compensation costs</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">40,528<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">40,528<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts', window );">Stock-based research and development costs</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">982<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">982<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(698,768)<span></span></td>
        <td class="num">(698,768)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2011</a></td>
        <td class="nump">$ 3,526<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 7,709,051<span></span></td>
        <td class="num">$ (6,628,569)<span></span></td>
        <td class="nump">$ 1,084,008<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2011</a></td>
        <td class="nump">35,259,142<span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lixt_AdvancesUnderEquityFinancingDuringPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Advance received by the company during the period through equity financing arrangement (selling common stock to individual or institutional investors).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>lixt_AdvancesUnderEquityFinancingDuringPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>lixt</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lixt_SharesIssuedDuringPeriodSharesStockBasedResearchAndDevelopmentCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of any share-based compensation plan other than an employee stock ownership plan (ESOP).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>lixt_SharesIssuedDuringPeriodSharesStockBasedResearchAndDevelopmentCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>lixt</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lixt_SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based remuneration to employees and vendors during the period related to research and development activities. This may include the value of stock or unit options and amortization of restricted stock or units.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>lixt_SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>lixt</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lixt_SharesIssuedInPrivatePlacement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued to private placements pursuant to a share exchange agreement net of offering costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>lixt_SharesIssuedInPrivatePlacement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>lixt</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lixt_SharesIssuedInPrivatePlacementNetOfOfferingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of shares issued to private placements pursuant to a share exchange agreement net of offering costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>lixt_SharesIssuedInPrivatePlacementNetOfOfferingCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>lixt</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lixt_StockIssuedDuringPeriodSharesShareBasedCompensationCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate number of shares issued in connection with noncash, equity-based remuneration to employees and vendors during the period related to general and administrative activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>lixt_StockIssuedDuringPeriodSharesShareBasedCompensationCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>lixt</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lixt_StockIssuedDuringPeriodValueShareBasedCompensationCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based remuneration to employees and vendors during the period for general and administrative activities. This may include the value of stock or unit options and amortization of restricted stock or units.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>lixt_StockIssuedDuringPeriodValueShareBasedCompensationCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>lixt</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 38<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph A7<br> -Appendix A<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 130<br> -Paragraph 10, 15<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 38<br> -Subparagraph d<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Emerging Issues Task Force (EITF)<br> -Number 87-21<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 19<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28, 29, 30<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued and outstanding as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph A3<br> -Appendix A<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period pursuant to acquisitions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 141<br> -Paragraph 53<br> -Subparagraph b<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 141<br> -Paragraph 51<br> -Subparagraph d<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesAcquisitions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued pursuant to acquisitions during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueAcquisitions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value stock issued during the period as a result of the exercise of stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Business Operations<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_OrganizationAndBusinessOperationsAbstract', window );"><strong>Organization and Business Operations [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_OrganizationAndBusinessOperationsTextBlock', window );">Organization and Business Operations [Text Block]</a></td>
        <td class="text"><div><div><div><div><div><div><div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >2.&#160; Organization and Business Operations
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Organization<br />
<br />

</font>
</div>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >
</font>
</div><div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >On June 30, 2006, Lixte Biotechnology, Inc., a privately-held Delaware corporation (&#8220;Lixte&#8221;) incorporated on August 9, 2005, completed a reverse merger transaction with SRKP 7, Inc. (&#8220;SRKP&#8221;), a non-trading public shell company, whereby Lixte became a wholly-owned subsidiary of SRKP. On December 7, 2006, SRKP amended its Certificate of Incorporation to change its name to Lixte Biotechnology Holdings, Inc. (&#8220;Holdings&#8221;). Unless the context indicates otherwise, Lixte and Holdings are hereinafter referred to as the &#8220;Company&#8221;.<br />
<br />

</font>
</div>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >
</font>
</div><div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >For financial reporting purposes, Lixte was considered the accounting acquirer in the merger and the merger was accounted for as a reverse merger. Accordingly, the historical financial statements presented herein are those of Lixte. The stockholders&#8217; equity section of SRKP has been retroactively restated for all periods presented to reflect the accounting effect of the reverse merger transaction. All costs associated with the reverse merger transaction were expensed as incurred.<br />
<br />

</font>
</div>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >
</font>
</div><div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company is considered a &#8220;development stage company&#8221; under current accounting standards, as it has not yet commenced any revenue-generating operations, does not have any cash flows from operations, and is dependent on debt and equity funding to finance its operations.<br />
<br />

</font>
</div>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >
</font>
</div><div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company&#8217;s common stock was listed for trading on the OTC Bulletin Board commencing September 24, 2007 under the symbol &#8220;LIXT&#8221;. It is presently traded on the OTC Market (also referred to as the &#8220;Pink Sheets&#8221;) under the symbol &#8220;LIXT.PK&#8221;.<br />
<br />

</font>
</div>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >
</font>
</div><div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Operating Plans<br />
<br />

</font>
</div>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >
</font>
</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company is developing new treatments for human cancers for which better therapies are urgently needed. The Company&#8217;s drug discovery process is based on discerning clues to potential new targets for cancer treatments reported in the increasingly large body of literature characterizing the molecular variants, which characterize human cancers. In the past decade, there has been an unprecedented expansion in knowledge of biochemical defects in the cancer cell. The Company selects drugs for which there are existing data suggesting that they may affect the altered pathways of the cancer cell and may be given safely to humans. The Company seeks to rapidly arrive at patentable structures through analysis of the literature rather than screening of thousands of structures for activity against a particular biochemical pathway.
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;&#160;
</font>
</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >This approach has led to the development of two classes of drugs, phosphatase inhibitors (PTase-i), designated by the Company as the LB-100 series of compounds, and histone deacetylase inhibitors (HDACi), designated by the Company as the LB-200 series of compounds. The LB-100 series consists of novel structures, which have the potential to be first in their class and the latter group contains compounds, which have the potential to be the most effective of this class. The Company has demonstrated that lead compounds of both series of drugs are active against a broad spectrum of human cancers in cell culture and against several types of human cancers in animal models. The research on new drug treatment was initiated in 2006 with the National Institute of Neurologic Disorders and Stroke (NINDS), National Institutes of Health (NIH) under a continuing Cooperative Research and Development Agreement (CRADA). The research at NINDS is led by Dr. Zhengping Zhuang, an internationally recognized investigator in the molecular pathology of cancer. The initial focus of the CRADA was on the most common and uniformly fatal brain tumor of adults, glioblastoma multiforme (GBM). The work at NIH has now extended to the most common brain tumor of children, medulloblastoma, and to the most common cancer of children, neuroblastoma. Because of the propensity of malignant melanoma to metastasize to the brain, recent studies have encompassed studying the effectiveness of drugs developed for the treatment of primary brain tumors to the treatment of melanoma.
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" >
</div><div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;" ><div>
</div><div>
</div>
</div><br />
<div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The second class of drugs (LB-200) under development by the Company is the histone deacetylase inhibitors. Many pharmaceutical companies are also developing drugs of this type, and at least two companies have an HDACi approved for clinical use, in both cases for the treatment of a type of lymphoma. Despite this significant competition, the Company has demonstrated that its HDACi have broad activity against many cancer types, have neuroprotective activity, and have anti-fungal activity. In addition, these compounds have low toxicity, making them attractive candidates for development. It appears that one type of molecule has diverse effects, affecting biochemical processes that are fundamental to the life of the cell, whether they are cancer cells, nerve cells, or even fungal cells. The neuroprotective activity of the Company&#8217;s HDACi has been demonstrated in the test tube in model systems that mimic injury to brain cells such as occurs in stroke and Alzheimer&#8217;s disease. Potentially, this type of protective activity may have application to a broad spectrum of other chronic neurodegenerative diseases, including Parkinson&#8217;s Disease and Amytrophic Lateral Sclerosis (ALS, or Lou Gehrig&#8217;s Disease).<br />
<br />

</font>
</div>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >
</font>
</div><div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company&#8217;s primary objective is to bring one lead compound of the LB-100 series to clinical trial. In late 2009 and early 2010, the Company raised sufficient financial resources to carry out the preclinical studies needed for an application to the FDA to carry out a Phase I clinical trial. The Company has engaged a leading pharmaceutical manufacturing company, a clinical research organization, and a drug development company specializing in pharmacologic and toxocologic characterization of new anticancer drugs to oversee and carry out the studies necessary to obtain FDA approval to commence a Phase I clinical trial.<br />
<br />

</font>
</div>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >
</font>
</div><div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >On September 17, 2010, the National Cancer Institute Experimental Therapeutics (NExT) Program Senior Advisory Committee (SAC) approved a collaboration by NCI with the Company for clinical evaluation of LB-100, one of the Company&#8217;s drug compounds. This collaboration is a milestone-based approach in which NCI will first confirm studies of the LB-100 compound in an animal model of glioblastoma multiforme, the most common brain tumor of adults, and conduct an initial exploratory toxicology study in an animal model. At milestone intervals, the SAC will re-evaluate project progress before considering assignment of additional support and resources to this project.<br />
<br />

</font>
</div>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >
</font>
</div><div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company believes that it has adequate funds on hand to support operations at current levels, including commencing, but not completing, a Phase I clinical trial of the Company&#8217;s LB-100 compound, and to continue to grow its patent portfolio and maintain its applications for international protection of lead compounds of both the LB-100 and LB-200 series, without having to raise additional funds, until early 2012.<br />
<br />

</font>
</div>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >
</font>
</div><div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Going Concern<br />
<br />

</font>
</div>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >
</font>
</div><div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company&#8217;s condensed consolidated financial statements have been presented on the basis that it is a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company is in the development stage and has not generated any revenues from operations to date, and does not expect to do so in the foreseeable future. The Company has experienced recurring operating losses and negative operating cash flows since inception, and has financed its working capital requirements through the recurring sale of its equity securities. As a result, the Company&#8217;s independent registered public accounting firm, in its report on the Company&#8217;s 2010 consolidated financial statements, has raised substantial doubt about the Company&#8217;s ability to continue as a going concern.<br />
<br />

</font>
</div>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >
</font>
</div><div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company&#8217;s ability to continue as a going concern is dependent upon its ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations. The Company&#8217;s condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.<br />
<br />

</font>
</div>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >
</font>
</div><div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >At June 30, 2011, the Company had not yet commenced any revenue-generating operations. All activity through June 30, 2011 has been related to the Company&#8217;s formation, capital raising efforts and research and development activities. As such, the Company has yet to generate any cash flows from operations, and is dependent on debt and equity funding from both related and unrelated parties to finance its operations. Prior to June 30, 2006, the Company&#8217;s cash requirements were funded by advances from the Company&#8217;s founder aggregating $92,717.<br />
<br />

</font>
</div>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >
</font>
</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Because the Company is currently engaged in research at an early stage, it will likely take a significant amount of time to develop any product or intellectual property capable of generating revenues. As such, the Company&#8217;s business is unlikely to generate any sustainable revenues in the next several years, and may never do so. Even if the Company is able to generate revenues in the future through licensing its technologies or through product sales, there can be no assurance that the Company will be able to generate a profit.
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" >
</div><div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;" ><div>
</div><div>
</div>
</div><br />
<div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company&#8217;s activities for the remainder of 2011 will consist of continuing drug discovery and development efforts. The Company&#8217;s primary objective is to&#160;gain FDA approval of&#160;the Company's LB-100 compound for entry into a&#160;Phase I clinical trial by the end of 2011. The Company was not able to expedite this process so as to obtain such approval by its June 30, 2011 target date.&#160;Although the Company has not identified any specific obstacles to the submission of the FDA application, the overall process of large animal testing and formal documentation of the long-term stability of the LB-100 compound has been slower than originally anticipated.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company raised $500,000 in November 2009, $1,787,500 in January 2010, and $500,000 in February 2010, all through the sale of its securities to fund its business activities. The Company also received $244,479 from the Internal Revenue Service under its Qualifying Therapeutic Discovery Grant program, consisting of $127,994 on November 9, 2010 and $116,485 on February&#160;1, 2011. As a result, the Company believes that its existing resources are adequate to fund operations until early 2012 at a level that will allow the continuation of the Company&#8217;s two drug development programs currently in process and commencement, but not completion, of a Phase I clinical trial of LB-100. <br />
<br />

</font>
</div>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >
</font>
</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The amount and timing of future cash requirements will depend on the pace of these programs, particularly the completion of the Phase I trial of LB-100. After completion of the Phase I trial, the next step will be to determine the anti-cancer activity against a particular type of human cancer in Phase II trials. To complete the Phase I trial and carry out Phase II trials, the Company anticipates that it will be necessary to raise additional funds beginning in early 2012 from a combination of debt or equity financings, and/or the sale, licensing or joint venturing of its intellectual properties. Market conditions present uncertainty as to the Company&#8217;s ability to secure additional funds, as well as its ability to reach profitability. There can be no assurances that the Company will be able to secure additional financing, or obtain favorable terms on such financing if it is available, or as to the Company&#8217;s ability to achieve positive earnings and cash flows from operations. Continued negative cash flows and lack of liquidity create significant uncertainty about the Company&#8217;s ability to fully implement its operating plan beyond early 2012, as a result of which the Company may have to reduce the scope of its planned operations. If cash resources are insufficient to satisfy the Company&#8217;s liquidity requirements, the Company would be required to scale back or discontinue its technology and product development programs, or obtain funds, if available, through strategic alliances that may require the Company to relinquish rights to certain of its technologies products, or to discontinue its operations entirely.
</font>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lixt_OrganizationAndBusinessOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>lixt_OrganizationAndBusinessOperationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>lixt</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lixt_OrganizationAndBusinessOperationsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure relating to the nature, operating plans,and the entity's ability to continue as a going concern for a reasonable period of time.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>lixt_OrganizationAndBusinessOperationsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>lixt</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
        <td class="text"><div><div><div><div><div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >3. Summary of Significant Accounting Policies
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Principles of Consolidation
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The accompanying condensed consolidated financial statements include the financial statements of Holdings and its wholly-owned subsidiary, Lixte. All intercompany balances and transactions have been eliminated in consolidation.
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Cash Concentrations
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company&#8217;s cash balances may periodically exceed federally insured limits. The Company has not experienced a loss in such accounts to date. The Company maintains its accounts with financial institutions with high credit ratings.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Research and Development
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Research and development costs are expensed as incurred. Research and development expenses consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company's treatments and product candidates.
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Amounts that become due, pursuant to contractual commitments, on research and development contracts with third parties are recorded as a liability, with the related amount of such contracts recorded as advances on research and development contract services on the Company&#8217;s balance sheet. Such advances on research and development contract services are expensed over their life on the straight-line basis, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different expensing schedule is more appropriate. The Company reviews the status of its research and development contracts on a quarterly basis.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The funds paid to NINDS of the NIH, pursuant to the CRADA effective March 22, 2006, as amended, represented an advance on research and development costs and therefore had future economic benefit. Accordingly, such costs have been charged to expense when they are actually expended by the provider, which is, effectively, as they perform the research activities that they were contractually committed to provide. Absent information that would indicate that a different expensing schedule was more appropriate (such as, for example, from the achievement of performance milestones or the completion of contract work), such advances have been expensed over the contractual service term on a straight-line basis, which, in management&#8217;s opinion, reflects a reasonable estimate of when the underlying research and development costs were being incurred.
</font>
</div><div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;" ><div>
</div>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Patent Costs
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company's research efforts and any related patent applications, all patent costs, including patent-related legal and filing fees, are expensed as incurred. Patent costs were $95,126 and $82,091 for the three months ended June 30, 2011 and 2010, respectively, $234,271 and $170,780 for the six months ended June 30, 2011 and 2010, respectively, and $1,005,605 for the period from August 9, 2005 (inception) to June 30, 2011 (cumulative). Patent costs are included in research and development costs in the Company's condensed consolidated statements of operations.
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Income Taxes
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities.
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company has elected to deduct research and development costs on a current basis for federal income tax purposes. Start-up and organization costs were deferred until January 1, 2008. Accordingly, the Company then began to amortize such costs over a 180-month period.
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made.
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >For federal income tax purposes, net operating losses can be carried forward for a period of 20 years until they are either utilized or until they expire.
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >On January 1, 2007, the Company adopted new accounting rules which address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. The new accounting rules also provide guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. The adoption of the new accounting rules did not have a material effect on the Company&#8217;s financial statements. As of June 30, 2011, no liability for unrecognized tax benefits was required to be recorded.
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company files income tax returns in the U.S. federal jurisdiction and is subject to income tax examinations by federal tax authorities for the year 2008 and thereafter. The Company&#8217;s policy is to record interest and penalties on uncertain tax provisions as income tax expense. As of June 30, 2011, the Company has no accrued interest or penalties related to uncertain tax positions.
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Government Grant Under Qualifying Therapeutic Discovery Project
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Under the Patient Protection and Affordable Care Act signed into law on March 23, 2010 (the &#8220;Act&#8221;), the Internal Revenue Service and the Department of Health and Human Services established the qualifying therapeutic discovery project to consider and award certifications for qualified investments by project sponsors. On July 20, 2010, the Company applied for a grant pursuant to the Act based upon qualified investments made in 2009 and 2010. On October 29, 2010, the Company was notified that qualified investments totaling $488,958 had been certified and that a grant in the amount of $244,479 had been awarded to the Company.
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new
 roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The proceeds of the grant were received by the Company in installments, consisting of $127,994 on November 9, 2010, and $116,485 on February 1, 2011, which was reflected as a receivable at December 31, 2010. For financial statement purposes, the grant of $244,479 was offset against research and development costs in the statement of operations for the year ended December 31, 2010.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Stock-Based Compensation
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company periodically issues stock options and warrants to officers, directors and consultants for services rendered. Options vest and expire according to terms established at the grant date.
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company accounts for share-based payments to officers and directors by measuring the cost of services received in exchange for equity awards based on the grant date fair value of the awards, with the cost recognized as compensation expense in the Company&#8217;s financial statements over the vesting period of the awards.
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company accounts for share-based payments to consultants by determining the value of the stock compensation based upon the measurement date at either (a) the date at which a performance commitment is reached or (b) at the date at which the necessary performance to earn the equity instruments is complete.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Options granted to Scientific Advisory Board committee members and outside consultants are revalued each reporting period to determine the amount to be recorded as an expense in the respective period. As the options vest, they are valued on each vesting date and an adjustment is recorded for the difference between the value already recorded and the then current value on the date of vesting.
</font>
</div><div><div style="text-indent:0pt;display:block;" ><br />
<div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Earnings Per Share<br />
<br />

</font>
</div>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >
</font>
</div><div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company&#8217;s computation of earnings per share (&#8220;EPS&#8221;) includes basic and diluted EPS. Basic EPS is measured as the income (loss) available to common shareholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., warrants and options) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.<br />
<br />

</font>
</div>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >
</font>
</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted loss per common share is the same for all periods presented because all warrants and stock options outstanding are anti-dilutive.<br />
<br />

</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >
</font>
</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >At June 30, 2011 and 2010, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.<br />
<br />

</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >
</font>
</div><div style="text-align:center;" ><table cellspacing="0" cellpadding="0" width="80%"  style="font-family:times new roman;font-size:10pt;" ><tr><td valign="bottom" width="76%"  style="text-align:left;padding-bottom:2px;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;&#160;&#160;
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="22%" colspan="6" nowrap="nowrap"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >June 30,
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr><td valign="bottom" width="76%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2" nowrap="nowrap"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >2011
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2" nowrap="nowrap"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >2010
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr><td valign="bottom" width="76%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="76%"  style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Warrants
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >13,454,552
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >13,607,426
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="76%"  style="text-align:left;padding-bottom:2px;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Stock options
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="border-bottom:black 2px solid;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >3,350,000
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="border-bottom:black 2px solid;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >3,540,000
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="76%"  style="text-align:left;padding-bottom:4px;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Total
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >16,804,552
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >17,147,426
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr>
</table><br />

</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >
</font>
</div><div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Fair Value of Financial Instruments<br />
<br />

</font>
</div>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >
</font>
</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The carrying amounts of cash, money market funds, advances on research and development contract services, prepaid expenses and other current assets, accounts payable and accrued expenses, research and development contract liabilities, liquidated damages payable under registration rights agreement and due to stockholder approximate their respective fair values due to the short-term nature of these items.<br />
<br />

</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >
</font>
</div><div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Use of Estimates<br />
<br />

</font>
</div>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >
</font>
</div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.<br />
<br />

</font>
</div><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Recent Accounting Pronouncements<br />
<br />

</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >
</font>
</div><div style="text-align:justify;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >In May&#160;2011, the Financial Accounting Standards Board (the &#8220;FASB&#8221;)&#160;issued Accounting Standards Update (the &#8220;ASU&#8221;)&#160;No.&#160;2011-4, which amends the Fair Value Measurements Topic of the Accounting Standards Codification (the &#8220;ASC&#8221;)&#160;to help achieve common fair value measurement and disclosure requirements in U.S. GAAP and IFRS.&#160;&#160;ASU No.&#160;2011-4 does not require additional fair value measurements and is not intended to establish valuation standards or affect valuation practices outside of financial reporting.&#160;&#160;The ASU is effective for interim and annual periods beginning after December&#160;15, 2011. The Company will adopt the ASU as required.&#160;&#160;The ASU will affect the Company&#8217;s fair value disclosures, but is not expected to have any impact on the Company&#8217;s financial position or results of operations.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:justify;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >In June&#160;2011, the FASB issued ASU No.&#160;2011-5, which amends the Comprehensive Income Topic of the ASC.&#160;&#160;The ASU eliminates the option to present the components of other comprehensive income as part of the statement of changes in shareholders&#8217; equity, and instead requires consecutive presentation of the statement of net income and other comprehensive income either in a continuous statement of comprehensive income or in two separate but consecutive statements.&#160;&#160;ASU No.&#160;2011-5 is effective for interim and annual periods beginning after December&#160;15, 2011.&#160;&#160;The Company will adopt the ASU as required.&#160;&#160;The ASU is not expected to have any impact on the Company&#8217;s financial position or results of operations.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:justify;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company&#8217;s financial statement presentation or disclosures.
</font>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 22<br> -Paragraph 8<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Share Exchange Agreement and Private Placement<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_ShareExchangeAgreementAndPrivatePlacementAbstract', window );"><strong>Share Exchange Agreement and Private Placement [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_ShareExchangeAgreementAndPrivatePlacementTextBlock', window );">Share Exchange Agreement and Private Placement [Text Block]</a></td>
        <td class="text">
  <div><div><div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >4. Share Exchange Agreement and Private Placement
  </font>
  </div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
  </font>
  </div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Share Exchange Agreement
  </font>
  </div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
  </font>
  </div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >On June 30, 2006, pursuant to a Share Exchange Agreement dated as of June 8, 2006 (the &#8220;Share Exchange Agreement&#8221;) by and among Holdings, Dr. John S. Kovach (&#8220;Seller&#8221;) and Lixte, Holdings issued 19,021,786 shares of its common stock in exchange for all of the issued and outstanding shares of Lixte (the &#8220;Exchange&#8221;). Previously, on October 3, 2005, Lixte had issued 1,500 shares of its no par value common stock to its founder for $1,500, which constituted all of the issued and outstanding shares of Lixte prior to the Exchange. As a result of the Exchange, Lixte became a wholly-owned subsidiary of Holdings.
  </font>
  </div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
  </font>
  </div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Pursuant to the Exchange, Holdings issued to the Seller 19,021,786 shares of its common stock. Holdings had a total of 25,000,832 shares of common stock issued and outstanding after giving effect to the Exchange and the 1,973,869 shares of common stock issued in the initial closing of the private placement.<br />
  <br />

  </font>
  </div>
  </div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >
  </font>
  </div><div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >As a result of the Exchange and the shares of common stock issued in the initial closing of the private placement, on June 30, 2006, the stockholders of the Company immediately prior to the Exchange owned 4,005,177 shares of common stock, equivalent to approximately 16% of the issued and outstanding shares of the Company&#8217;s common stock, and the former stockholder of Lixte acquired control of the Company.<br />
  <br />

  </font>
  </div>
  </div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >
  </font>
  </div><div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Share Exchange Agreement was determined through arms-length negotiations between Holdings, the Seller and Lixte. In connection with the Exchange, the Company paid WestPark Capital, Inc. an aggregate cash fee of $50,000.<br />
  <br />

  </font>
  </div>
  </div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >
  </font>
  </div><div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Private Placements<br />
  <br />

  </font>
  </div>
  </div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >
  </font>
  </div><div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >On June 30, 2006, concurrently with the closing of the Exchange, the Company sold an aggregate of 1,973,869 shares of its common stock to accredited investors in an initial closing of a private placement at a per share price of $0.333, resulting in aggregate gross proceeds to the Company of $657,299. The Company paid to WestPark Capital, Inc., as placement agent, a commission of 10% and a non-accountable fee of 4% of the gross proceeds of the private placement and issued five-year warrants to purchase common stock equal to (a) 10% of the number of shares sold in the private placement exercisable at $0.333 per share and (b) an additional 2% of the number of shares sold in the private placement also exercisable at $0.333 per share. A total of 236,864 warrants were issued. Net cash proceeds to the Company, after the deduction of all private placement offering costs and expenses, were $522,939.<br />
  <br />

  </font>
  </div>
  </div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >
  </font>
  </div><div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >On July 27, 2006, the Company sold an aggregate of 1,581,351 shares of its common stock to accredited investors in a second closing of the private placement at a per share price of $0.333 resulting in aggregate gross proceeds to the Company of $526,590. The Company paid to WestPark Capital, Inc., as placement agent, a commission of 10% and a non-accountable fee of 4% of the gross proceeds of the private placement and issued five-year warrants to purchase common stock equal to (a) 10% of the number of shares sold in the private placement exercisable at $0.333 per share and (b) an additional 2% of the number of shares sold in the private placement also exercisable at $0.333 per share. A total of 189,762 warrants were issued. Net cash proceeds to the Company were $446,433.&#160;<br />
  <br />

  </font>
  </div>
  </div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >
  </font>
  </div><div style="text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >In conjunction with the private placement of common stock, the Company issued a total of 426,626 five-year warrants to WestPark Capital, Inc. exercisable at the per share price of the common stock sold in the private placement ($0.333 per share). The warrants issued to WestPark Capital, Inc. do not contain any price anti-dilution provisions. However, such warrants contain cashless exercise provisions and demand registration rights, but the warrant holder has agreed to waive any claims to monetary damages or financial penalties for any failure by the Company to comply with such registration requirements. Based on the foregoing, the warrants were accounted for as equity and were not accounted for separately from the common stock and additional paid-in capital accounts. The warrants had no accounting impact on the Company&#8217;s consolidated financial statements.
  </font>
  </div><div style="text-indent:0pt;display:block;" ><br />

  </div><div style="text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >On June 30, 2011, WestPark Capital, Inc. exercised warrants to acquire a portion of the above described warrants, consisting of 152,874 shares of common stock, on a cashless basis. Such cashless exercise resulted in WestPark Capital, Inc. receiving a net of 100,929 shares.
  </font>
  </div><div style="text-indent:0pt;display:block;" ><br />

  </div><div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >On July 27, 2011, the Company agreed to extend warrants to acquire the remaining portion of the above described warrants, consisting of 273,752 shares of common stock, to July 27, 2012.&#160;&#160;In conjunction with the extension of the warrants, the cashless exercise feature was deleted.&#160;&#160;On July 27, 2011, the fair value of the warrant extension, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $199,839 ($0.73 per share), and will be charged to operations during the three months ending September 30, 2011.&#160;&#160;The fair value of the warrant extension was calculated using the following input variables: stock price - $0.79; exercise price - $0.333; expected life - 1 year; expected volatility &#8211; 308.8%; expected dividend yield - 0%; risk-free interest rate &#8211; 0.14%.<br />
  <br />

  </font>
  </div>
  </div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >
  </font>
  </div><div style="text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >As part of the Company&#8217;s private placement of its securities completed on July 27, 2006, the Company entered into a registration rights agreement with the purchasers, whereby the Company agreed to register the shares of common stock sold in the private placement, and to maintain the effectiveness of such registration statement, subject to certain conditions. The agreement required the Company to file a registration statement within 45 days of the closing of the private placement and to have the registration statement declared effective within 120 days of the closing of the private placement. On September 8, 2006, the Company filed a registration statement on Form SB-2 to register 3,555,220 shares of the common stock sold in the private placement. Since the registration statement was not declared effective by the Securities and Exchange Commission within 120 days of the closing of the private placement, the Company was required to pay each investor prorated liquidated damages equal to 1.0% of the amount raised per month, payable monthly in cash.
  </font>
  </div>

  </div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
  </font>
  </div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >On the date of the closing of the private placement, the Company believed it would meet the deadlines under the registration rights agreement with respect to filing a registration statement and having it declared effective by the Securities and Exchange Commission. As a result, the Company did not record any liabilities associated with the registration rights agreement at June 30, 2006. At December 31, 2006, the Company determined that the registration statement covering the shares sold in the private placement would not be declared effective within the requisite time frame and therefore accrued six months liquidated damages under the registration rights agreement aggregating approximately $74,000, which has been presented as a current liability for all periods presented. The Company&#8217;s registration statement on Form SB-2 was declared effective by the Securities and Exchange Commission on May 14, 2007. At March 31, 2011, the registration penalty to the investors had not been paid.
  </font>
  </div><div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;" ><div>
  </div>
  </div><div style="text-indent:0pt;display:block;" ><br />

  </div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >On December 12, 2007, the Company sold an aggregate of 999,995 shares of its common stock to accredited investors in a second private placement at a per share price of $0.65, resulting in aggregate gross proceeds to the Company of $650,000. The Company paid to WestPark Capital, Inc., as placement agent, a commission of 10% and a non-accountable fee of 4% of the gross proceeds of the private placement and issued five-year warrants to purchase common stock equal to (a) 10% of the number of shares sold in the private placement exercisable at $0.65 per share and (b) an additional 2% of the number of shares sold in the private placement also exercisable at $0.65 per share. Net cash proceeds to the Company were $531,320.
  </font>
  </div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
  </font>
  </div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >In conjunction with the second private placement of common stock, the Company issued a total of 120,000 five-year warrants to WestPark Capital, Inc. exercisable at the per share price of the common stock sold in the private placement ($0.65 per share). The warrants issued to WestPark Capital, Inc. do not contain any price anti-dilution provisions. However, such warrants contain cashless exercise provisions and demand registration rights, but the warrant holder has agreed to waive any claims to monetary damages or financial penalties for any failure by the Company to comply with such registration requirements. Based on the foregoing, the warrants were accounted for as equity and were not accounted for separately from the common stock and additional paid-in capital accounts. The warrants had no accounting impact on the Company&#8217;s consolidated financial statements.
  </font>
  </div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
  </font>
  </div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >As part of the Company&#8217;s second private placement of its securities completed on December 12, 2007, the Company entered into a registration rights agreement with the purchasers, whereby the Company agreed to register the shares of common stock sold in the second private placement at its sole cost and expense. The registration rights agreement terminates at such time as the common shares may be sold in market transactions without regard to any volume limitations. The registration rights agreement requires the Company to file a registration statement within 75 days of receipt of written demand from holders who represent at least 50% of the common shares issued pursuant to the second private placement, provided that no demand shall be made for less than 500,000 shares, and to use its best efforts to cause such registration statement to become and remain effective for the requisite period. The registration rights agreement also provides for unlimited piggyback registration rights. The registration rights agreement does not provide for any penalties in the event that the Company is unable to comply with its terms.
  </font>
  </div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
  </font>
  </div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >During the year ended December 31, 2009, the Company completed three closings of the third private placement of common stock units, consisting of a total of 1,420,000 shares of common stock and 1,420,000 warrants to acquire common stock, as follows:
  </font>
  </div><div style="text-indent:0pt;display:block;" ><br />

  </div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >On February 10, 2009, the Company sold an aggregate of 658,000 common stock units to accredited investors in a first closing of a third private placement at a per unit price of $0.50, resulting in aggregate gross proceeds to the Company of $329,000. Net cash proceeds to the Company were $269,790.
  </font>
  </div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
  </font>
  </div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >On March 2, 2009, the Company sold an aggregate of 262,000 common stock units to accredited investors in a second closing of the third private placement at a per unit price of $0.50, resulting in aggregate gross proceeds to the Company of $131,000. Net cash proceeds to the Company were $112,460.
  </font>
  </div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
  </font>
  </div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >On April 6, 2009, the Company sold an aggregate of 500,000 common stock units to accredited investors in a third closing of the third private placement at a per unit price of $0.50, resulting in aggregate gross proceeds to the Company of $250,000. Net cash proceeds to the Company were $214,800.
  </font>
  </div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
  </font>
  </div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Each unit sold in the third private placement consisted of one share of the Company&#8217;s common stock and a five-year warrant to purchase an additional share of the Company&#8217;s common stock on a cashless exercise basis at an exercise price of $0.50 per common share. The Company paid to WestPark Capital, Inc., as placement agent, a commission of 10% and a non-accountable fee of 4% of the gross proceeds of the third private placement and issued five-year warrants to purchase common stock equal to (a) 10% of the number of shares sold in the third private placement exercisable at $0.50 per share and 10% of the number of shares issuable upon exercise of warrants issued in the third private placement exercisable at $0.50 per share; and (b) an additional 2% of the number of shares sold in the third private placement also exercisable at $0.50 per share and 2% of the number of shares issuable upon exercise of the warrants issued in the third private placement exercisable at $0.50 per share.
  </font>
  </div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
  </font>
  </div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >In conjunction with the closings of the third private placement of common stock units during the year ended December 31, 2009, the Company issued a total of 340,800 five-year warrants to WestPark Capital, Inc., which are exercisable at the per unit price of the common stock units sold in the third private placement ($0.50 per unit). Included in the 340,800 warrants issued to WestPark Capital, Inc. are 170,400 warrants which are only exercisable with respect to common shares that are acquired by investors upon their exercise of the warrants acquired as part of the units sold in the third private placement. The warrants issued to WestPark Capital, Inc. do not contain any price anti-dilution provisions. However, such warrants contain cashless exercise provisions and demand registration rights, but the warrant holder has agreed to waive any claims to monetary damages or financial penalties for any failure by the Company to comply with such registration requirements. Based on the foregoing, the warrants were accounted for as equity and were not accounted for separately from the common stock and additional paid-in capital accounts. The warrants had no accounting impact on the Company&#8217;s consolidated financial statements.
  </font>
  </div><div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;" ><div>
  </div>
  </div><div style="text-indent:0pt;display:block;" ><br />

  </div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >At the request of the holders, the Company has agreed to include any shares sold in the third private placement and any shares issuable upon exercise of the related warrants to be included in any registration statement filed with the Securities and Exchange Commission permitting the resale of such shares, subject to customary cutbacks, at the Company&#8217;s sole cost and expense.
  </font>
  </div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
  </font>
  </div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Effective November 6, 2009, the Company sold 1,000,000 common stock units to an accredited investor in a fourth private placement at a per unit price of $0.50, resulting in proceeds to the Company of $500,000. There were no commissions paid with respect to the fourth private placement. The closing price of the Company&#8217;s common stock on November 6, 2009 was $0.50 per share.
  </font>
  </div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
  </font>
  </div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Each unit sold in the fourth private placement consisted of one share of the Company&#8217;s common stock, one three-year warrant to purchase an additional share of the Company&#8217;s common stock at an exercise price of $0.50 per share, and one three-year warrant to purchase an additional share of the Company&#8217;s common stock at an exercise price of $0.75 per share.&#160;The warrants do not have any reset provisions.
  </font>
  </div><div style="text-indent:0pt;display:block;" ><br />

  </div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >At the request of the holder, the Company has agreed to include the shares sold in the fourth private placement and any shares issuable upon exercise of the related warrants in any registration statement filed by the Company with the Securities and Exchange Commission permitting the resale of such securities, subject to customary cutbacks. The units sold were not registered under the Securities Act of 1933, as amended (the &#8220;Act&#8221;), in reliance upon the exemption from registration contained in Section 4(2) of the Act and Regulation D promulgated thereunder. Based on the foregoing, the warrants were accounted for as equity and were not accounted for separately from the common stock and additional paid-in capital accounts. The warrants had no accounting impact on the Company&#8217;s consolidated financial statements.
  </font>
  </div><div style="text-indent:0pt;display:block;" ><br />

  </div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Effective January 20, 2010, the Company raised $1,787,500 in a fifth private placement of units sold to certain of its existing stockholders or their designees, all of whom were accredited investors, consisting of an aggregate of 3,575,000 units at a purchase price of $0.50 per unit. Each unit consisted of one share of common stock, one three-year warrant to purchase a share of common stock at an exercise price of $0.50 per share, and one three-year warrant to purchase a share of common stock at an exercise price of $0.75 per share. The warrants do not have any reset provisions. The closing price of the Company&#8217;s common stock on January 20, 2010 was $0.49 per share. There were no commissions paid with respect to the private placement. Upon request by the holder, the Company has agreed to include the shares issued and those shares issuable upon exercise of the warrants in any registration statement filed by the Company with the Securities and Exchange Commission permitting the resale of such securities, subject to customary cutbacks. The units sold were not registered under the Act, in reliance upon the exemption from registration contained in Section 4(2) of the Act and Regulation D promulgated thereunder. The Company accounted for the issuance of the units as a capital transaction. As of December 31, 2009, $1,200,000 had been advanced to the Company under this private placement, with the balance of $587,500 being received by the Company in January 2010.
  </font>
  </div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
  </font>
  </div><div style="text-align:left;text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Effective February 22, 2010, the Company raised $500,000 through the sale to an accredited investor of 1,000,000 units at a purchase price of $0.50 per unit. Each unit consisted of one share of common stock, one three-year warrant to purchase a share of common stock at an exercise price of $0.50 per share, and one three year-year warrant to purchase a share of common stock at an exercise price of $0.75 per share. The warrants do not have any reset provisions. The closing price of the Company&#8217;s common stock on February 22, 2010 was $0.50 per share. There were no commissions paid with respect to the private placement. Upon request by the holder, the Company has agreed to include the shares issued and those shares issuable upon exercise of the warrants in any registration statement filed by the Company with the Securities and Exchange Commission permitting the resale of such securities, subject to customary cutbacks. The units sold were not registered under the Act, in reliance upon the exemption from registration contained in Section 4(2) of the Act and Regulation D promulgated thereunder. The Company accounted for the issuance of the units as a capital transaction.
  </font>
  </div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
  </font>
  </div>
  </div>
  </div>
</div>
  <span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lixt_ShareExchangeAgreementAndPrivatePlacementAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>lixt_ShareExchangeAgreementAndPrivatePlacementAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>lixt</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lixt_ShareExchangeAgreementAndPrivatePlacementTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure relating to the Share Exchange Agreement and Private Placement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>lixt_ShareExchangeAgreementAndPrivatePlacementTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>lixt</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0EWJAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Parenthetical] (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
        <th class="th" colspan="1">71 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2010</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2010</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_ShareBasedCompensationCost', window );">Stock-based compensation costs</a></td>
        <td class="nump">$ 40,528<span></span></td>
        <td class="nump">$ 20,534<span></span></td>
        <td class="nump">$ 93,274<span></span></td>
        <td class="nump">$ 2,293,051<span></span></td>
        <td class="nump">$ 2,293,051<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_ResearchAndDevelopmentStockBasedCost', window );">Research and development stock based costs</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(1,762)<span></span></td>
        <td class="nump">982<span></span></td>
        <td class="nump">18,127<span></span></td>
        <td class="nump">465,034<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_ResearchAndDevelopmentStockBasedCostRelatedParty', window );">Research and development stock based costs,related party</a></td>
        <td class="nump">6,250<span></span></td>
        <td class="nump">5,208<span></span></td>
        <td class="nump">12,500<span></span></td>
        <td class="nump">5,208<span></span></td>
        <td class="nump">30,208<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_ResearchAndDevelopmentRepresentingProceedsOfGovernmentGrant', window );">Research and development, representing the proceeds of a government grant</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 244,479<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lixt_ResearchAndDevelopmentRepresentingProceedsOfGovernmentGrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of grant applied for and received under the Patient Protection and Affordable Care Act signed into law on March 23, 2010 and is based upon qualified investments made in 2009 and 2010. The amount is recorded as an offset to the qualified investments made.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>lixt_ResearchAndDevelopmentRepresentingProceedsOfGovernmentGrant</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>lixt</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lixt_ResearchAndDevelopmentStockBasedCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based remuneration to employees and vendors, included in total research and development costs, related to research and development activities. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>lixt_ResearchAndDevelopmentStockBasedCost</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>lixt</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lixt_ResearchAndDevelopmentStockBasedCostRelatedParty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based remuneration to related party, included in the total amount of research and development stock based costs, related to research and development activities. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>lixt_ResearchAndDevelopmentStockBasedCostRelatedParty</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>lixt</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lixt_ShareBasedCompensationCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based remuneration to employees and vendors, included in total general and administrative costs, related to general and administrative activities. This may include the value of stock or unit options and amortization of restricted stock or units. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>lixt_ShareBasedCompensationCost</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>lixt</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0EDYBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">6 Months Ended</th>
        <th class="th" colspan="1">71 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2010</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (698,768)<span></span></td>
        <td class="num">$ (659,899)<span></span></td>
        <td class="num">$ (6,628,569)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,909<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_ShareBasedCompensationCost', window );">Stock-based compensation costs</a></td>
        <td class="nump">93,274<span></span></td>
        <td class="nump">2,293,051<span></span></td>
        <td class="nump">2,293,051<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_ResearchAndDevelopmentStockBasedCost', window );">Stock-based research and development costs</a></td>
        <td class="nump">982<span></span></td>
        <td class="nump">18,127<span></span></td>
        <td class="nump">465,034<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>(Increase) decrease in -</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDepositOtherAssets', window );">Funds on deposit with law firm</a></td>
        <td class="nump">50,000<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_IncreaseDecreaseInGrantReceivable', window );">Grant receivable</a></td>
        <td class="nump">116,485<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices', window );">Advances on research and development contract services</a></td>
        <td class="num">(53,256)<span></span></td>
        <td class="num">(8,310)<span></span></td>
        <td class="num">(63,356)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">12,251<span></span></td>
        <td class="nump">4,958<span></span></td>
        <td class="num">(22,395)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Increase (decrease) in -</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
        <td class="nump">52,454<span></span></td>
        <td class="num">(6,430)<span></span></td>
        <td class="nump">80,799<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_IncreaseDecreaseInLiquidatedDamagesPayableUnderRegistrationRightsAgreement', window );">Liquidated damages payable under registration rights agreement</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">74,000<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities', window );">Research and development contract liabilities</a></td>
        <td class="nump">89,550<span></span></td>
        <td class="nump">29,007<span></span></td>
        <td class="nump">89,550<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
        <td class="num">(389,774)<span></span></td>
        <td class="num">(529,273)<span></span></td>
        <td class="num">(3,709,977)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_PaymentsToAcquireMoneyMarketFunds', window );">Decrease (increase) in money market funds</a></td>
        <td class="nump">299,917<span></span></td>
        <td class="num">(2,050,150)<span></span></td>
        <td class="num">(1,301,089)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMachineryAndEquipment', window );">Purchase of office equipment</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(1,909)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
        <td class="nump">299,917<span></span></td>
        <td class="num">(2,050,150)<span></span></td>
        <td class="num">(1,302,998)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
        <td class="nump">5,000<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">5,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_ProceedsFromSaleOfCommonStockToConsultingFirm', window );">Proceeds from sale of common stock to consulting firm</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">250<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_ProceedsFromSaleOfCommonStockToFounder', window );">Proceeds from sale of common stock to founder</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,500<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_ProceedsFromIssuanceOfNotesPayableToConsultants', window );">Proceeds from issuance of notes payable to consultant</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">200,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_RepaymentsOfNotesPayableToConsultant', window );">Repayment of notes payable to consultant</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(200,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired in reverse merger transaction</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">62,500<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Gross proceeds from sale of securities</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,087,500<span></span></td>
        <td class="nump">5,331,389<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of private placement offering costs</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(446,147)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromContributedCapital', window );">Advances received from stockholder</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">92,717<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
        <td class="nump">5,000<span></span></td>
        <td class="nump">1,087,500<span></span></td>
        <td class="nump">5,047,209<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Cash: Net increase (decrease)</a></td>
        <td class="num">(84,857)<span></span></td>
        <td class="num">(1,491,923)<span></span></td>
        <td class="nump">34,234<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash: Balance at beginning of period</a></td>
        <td class="nump">119,091<span></span></td>
        <td class="nump">1,543,991<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash: Balance at end of period</a></td>
        <td class="nump">34,234<span></span></td>
        <td class="nump">52,068<span></span></td>
        <td class="nump">34,234<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">2,469<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash financing activities:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_DecreaseInAdvancesUnderEquityFinancing', window );">Decrease in advances under equity financing</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,200,000<span></span></td>
        <td class="nump">1,200,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_CashlessExerciseOfWarrantsAndOptionsAggregateExercisePrice', window );">Cashless Exercise of Warrants and Options Aggregate Exercise Price</a></td>
        <td class="nump">$ 84,207<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 84,207<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lixt_CashlessExerciseOfWarrantsAndOptionsAggregateExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate exercise price of warrants and options exercised on a cashless basis.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>lixt_CashlessExerciseOfWarrantsAndOptionsAggregateExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>lixt</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lixt_DecreaseInAdvancesUnderEquityFinancing">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of decrease in advances under equity financing as part of noncash transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>lixt_DecreaseInAdvancesUnderEquityFinancing</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>lixt</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lixt_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net change during the reporting period in advances on research and development services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>lixt_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>lixt</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lixt_IncreaseDecreaseInGrantReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase or decrease In grant receivable during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>lixt_IncreaseDecreaseInGrantReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>lixt</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lixt_IncreaseDecreaseInLiquidatedDamagesPayableUnderRegistrationRightsAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net change during the reporting period in the amount of liquidated damages payable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>lixt_IncreaseDecreaseInLiquidatedDamagesPayableUnderRegistrationRightsAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>lixt</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lixt_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net change during the reporting period in the amount of research and development contract liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>lixt_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>lixt</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lixt_PaymentsToAcquireMoneyMarketFunds">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the purchase of money market funds during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>lixt_PaymentsToAcquireMoneyMarketFunds</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>lixt</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lixt_ProceedsFromIssuanceOfNotesPayableToConsultants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from a borrowing from a consultant supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>lixt_ProceedsFromIssuanceOfNotesPayableToConsultants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>lixt</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lixt_ProceedsFromSaleOfCommonStockToConsultingFirm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from sale of common stock to consulting firm.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>lixt_ProceedsFromSaleOfCommonStockToConsultingFirm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>lixt</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lixt_ProceedsFromSaleOfCommonStockToFounder">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from sale of common stock to founder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>lixt_ProceedsFromSaleOfCommonStockToFounder</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>lixt</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lixt_RepaymentsOfNotesPayableToConsultant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for a borrowing from a consultant supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>lixt_RepaymentsOfNotesPayableToConsultant</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>lixt</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lixt_ResearchAndDevelopmentStockBasedCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based remuneration to employees and vendors, included in total research and development costs, related to research and development activities. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>lixt_ResearchAndDevelopmentStockBasedCost</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>lixt</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lixt_ShareBasedCompensationCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based remuneration to employees and vendors, included in total general and administrative costs, related to general and administrative activities. This may include the value of stock or unit options and amortization of restricted stock or units. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>lixt_ShareBasedCompensationCost</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>lixt</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrestricted cash available for day-to-day operating needs, for an entity that has cash equivalents, but does not aggregate cash equivalents with cash on the balance sheet.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 7<br> -Footnote 1<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Cash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 15, 16, 17<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAcquiredFromAcquisition</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in cash and cash equivalents. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 5<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Depreciation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 29<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 27<br> -Subparagraph f<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxesPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDepositOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDepositOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets,or  income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 29<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from financing activity for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from investing activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 38<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph A7<br> -Appendix A<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 130<br> -Paragraph 10, 15<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 38<br> -Subparagraph d<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Emerging Issues Task Force (EITF)<br> -Number 87-21<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 19<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28, 29, 30<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for cost incurred directly with the issuance of an equity security.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 18, 19, 20<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsOfStockIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMachineryAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for acquisition of machinery and equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 15<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 17<br> -Subparagraph c<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireMachineryAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributedCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received by a corporation from a shareholder during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 18<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 19<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromContributedCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 15<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 16<br> -Subparagraph b<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 16<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 123R<br> -Paragraph A240<br> -Subparagraph i<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 18<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 19<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
        <td class="text">
  <div><div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><div><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-weight:bold;" >9.
  </font><font style="display:inline;font-weight:bold;" >Subsequent Events
  </font>
  </font>
  </div>
  </div><div style="text-indent:0pt;display:block;" ><br />

  </div><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><div><div style="text-indent:36pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;background-color:#ffffff;" >On July 27, 2011, the Company agreed to extend warrants to acquire 273,752 shares of common stock that were previously issued in connection with the Company&#8217;s first private placement in 2006 to July 27, 2012.&#160;&#160;In conjunction with the extension of the warrants, the cashless exercise feature was deleted.&#160;&#160;On July 27, 2011, the fair value of the warrant extension, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $199,839 ($0.73 per share), and will be charged to operations during the three months ending September 30, 2011.&#160;&#160;The fair value of the warrant extension was calculated using the following input variables: stock price - $0.79; exercise price - $0.333; expected life - 1 year; expected volatility &#8211; 308.8%; expected dividend yield - 0%; risk-free interest rate &#8211; 0.14%.
  </font>
  </div>

  </div>
  </div>
  </div>
</div>
  <span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E53AE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
        <td class="nump">$ 34,234<span></span></td>
        <td class="nump">$ 119,091<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds</a></td>
        <td class="nump">1,301,089<span></span></td>
        <td class="nump">1,601,006<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Funds on deposit with law firm</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">50,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Grant receivable</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">116,485<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_AdvancesOnResearchAndDevelopmentContractServices', window );">Advances on research and development contract services</a></td>
        <td class="nump">63,356<span></span></td>
        <td class="nump">10,100<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">22,395<span></span></td>
        <td class="nump">34,646<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">1,421,074<span></span></td>
        <td class="nump">1,931,328<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">1,421,074<span></span></td>
        <td class="nump">1,931,328<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>LIABILITIES AND STOCKHOLDERS' EQUITY</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
        <td class="nump">80,799<span></span></td>
        <td class="nump">28,345<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_ResearchAndDevelopmentContractLiabilities', window );">Research and development contract liabilities</a></td>
        <td class="nump">89,550<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lixt_LiquidatedDamagesPayableUnderRegistrationRightsAgreement', window );">Liquidated damages payable under registration rights agreement</a></td>
        <td class="nump">74,000<span></span></td>
        <td class="nump">74,000<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToOfficersOrStockholdersCurrent', window );">Due to stockholder</a></td>
        <td class="nump">92,717<span></span></td>
        <td class="nump">92,717<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">337,066<span></span></td>
        <td class="nump">195,062<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; authorized - 10,000,000 shares; issued - None</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; authorized - 100,000,000 shares; issued and outstanding ; 35,259,142 shares and 35,077,178 shares at June 30, 2011 and December 31, 2010, respectively</a></td>
        <td class="nump">3,526<span></span></td>
        <td class="nump">3,508<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
        <td class="nump">77,090,561<span></span></td>
        <td class="nump">7,662,559<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage', window );">Deficit accumulated during the development stage</a></td>
        <td class="num">(6,628,569)<span></span></td>
        <td class="num">(5,929,801)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
        <td class="nump">1,084,008<span></span></td>
        <td class="nump">1,736,266<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
        <td class="nump">$ 1,421,074<span></span></td>
        <td class="nump">$ 1,931,328<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lixt_AdvancesOnResearchAndDevelopmentContractServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The unamortized portion of the amounts paid in advance for contracted research and development services that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year, as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>lixt_AdvancesOnResearchAndDevelopmentContractServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>lixt</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lixt_LiquidatedDamagesPayableUnderRegistrationRightsAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liability incurred for liquidated damages payable under registration rights agreement. Used to reflect the current portion of the liability that is due upon demand.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>lixt_LiquidatedDamagesPayableUnderRegistrationRightsAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>lixt</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lixt_ResearchAndDevelopmentContractLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for contracted research and development activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>lixt_ResearchAndDevelopmentContractLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>lixt</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 20<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 19<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapitalCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 7<br> -Section 03<br> -Paragraph 12<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Topic 210<br> -SubTopic 10<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br> -Section S99<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -Paragraph 1<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Concepts (CON)<br> -Number 6<br> -Paragraph 25<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 18<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Section 45<br> -SubTopic 10<br> -Topic 210<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Paragraph 1<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 9<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrestricted cash available for day-to-day operating needs, for an entity that has cash equivalents, but does not aggregate cash equivalents with cash on the balance sheet.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 7<br> -Footnote 1<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Cash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 17<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepositsAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cumulative net losses reported during the development stage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 7<br> -Paragraph 11<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 915<br> -SubTopic 210<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472335&amp;loc=d3e37729-110921<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToOfficersOrStockholdersCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 12<br> -Subparagraph a(1)<br> -Article 6<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 19<br> -Subparagraph a<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 4<br> -Section 08<br> -Paragraph k<br> -Subparagraph 1<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 57<br> -Paragraph 2<br> -Subparagraph d<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DueToOfficersOrStockholdersCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 8<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GrantsReceivableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 32<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.32)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 7<br> -Section 03<br> -Paragraph 25<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 21<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 8, 9<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MoneyMarketFundsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 129<br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 02<br> -Paragraph 29<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 8<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 43<br> -Section A<br> -Paragraph 4<br> -Chapter 3<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Section 45<br> -SubTopic 10<br> -Topic 210<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Paragraph 1<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph A3<br> -Appendix A<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.3.0.11</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ReportType />
  <ContextCount>82</ContextCount>
  <ElementCount>104</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>4</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>true</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>01 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lixte.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>02 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lixte.com/role/StatementOfFinancialPositionClassified</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>03 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical]</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lixte.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical]</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>04 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lixte.com/role/StatementOfIncomeAlternative</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>05 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Parenthetical]</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lixte.com/role/Condensedconsolidatedstatementsofoperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Parenthetical]</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>06 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIENCY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lixte.com/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIENCY)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>07 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lixte.com/role/StatementOfCashFlowsIndirect</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>08 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lixte.com/role/BasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>09 - Disclosure - Organization and Business Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lixte.com/role/OrganizationAndBusinessOperations</Role>
      <ShortName>Organization and Business Operations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lixte.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>11 - Disclosure - Share Exchange Agreement and Private Placement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lixte.com/role/Shareexchangeagreementandprivateplacement</Role>
      <ShortName>Share Exchange Agreement and Private Placement</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>12 - Disclosure - Money Market Funds Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lixte.com/role/Moneymarketfundsfairvalue</Role>
      <ShortName>Money Market Funds Fair Value</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>13 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lixte.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>14 - Disclosure - Stock Options and Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lixte.com/role/StockOptionsAndWarrants</Role>
      <ShortName>Stock Options and Warrants</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>15 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lixte.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>16 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lixte.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 02 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Jun. 30, 2010'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2009'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2008'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2007'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2006'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2005'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Aug. 09, 2005'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Aug. 08, 2005'</Log>
    <Log type="Info">Process Flow-Through: 03 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical]</Log>
    <Log type="Info">Process Flow-Through: 04 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</Log>
    <Log type="Info">	Process Flow-Through: Removing column '4 Months Ended
Dec. 31, 2005'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2010'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2009'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2008'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2007'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2006'</Log>
    <Log type="Info">Process Flow-Through: 05 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Parenthetical]</Log>
    <Log type="Info">Process Flow-Through: 07 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</Log>
  </Logs>
  <InputFiles>
    <File>lixt-20110630.xml</File>
    <File>lixt-20110630.xsd</File>
    <File>lixt-20110630_cal.xml</File>
    <File>lixt-20110630_def.xml</File>
    <File>lixt-20110630_lab.xml</File>
    <File>lixt-20110630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>30
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?06YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].1$5.4T5$7T-/
M3E-/3$E$051%1%]"04Q!3D-%/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0T].1$5.4T5$7T-/3E-/3$E$051%1%]"04Q!3D-%,3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-/3D1%3E-%
M1%]#3TY33TQ)1$%4141?4U1!5$5-13PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-/3D1%3E-%1%]#3TY33TQ)1$%4141?4U1!5$5-
M13$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#3TY$
M14Y3141?0T].4T],241!5$5$7U-4051%344R/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^0T].1$5.4T5$7T-/3E-/3$E$051%1%]3
M5$%414U%,SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970P-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/D)A<VES7V]F7U!R97-E;G1A=&EO;CPO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P."YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D]R9V%N:7IA=&EO;E]A;F1?0G5S:6YE<W-?3W!E
M<CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970P.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U;6UA
M<GE?;V9?4VEG;FEF:6-A;G1?06-C;W5N=#PO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,"YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/E-H87)E7T5X8VAA;F=E7T%G<F5E;65N=%]A
M;F1?4#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970Q,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DUO
M;F5Y7TUA<FME=%]&=6YD<U]&86ER7U9A;'5E/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$R+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^4F5L871E9%]087)T>5]4<F%N<V%C=&EO
M;G,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,3,N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C
M:U]/<'1I;VYS7V%N9%]787)R86YT<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-O;6UI=&UE;G1S7V%N9%]#;VYT:6YG96YC:65S
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#$U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W5B<V5Q
M=65N=%]%=F5N=',\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,38N:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`\+W@Z17AC96Q7;W)K<VAE971S/@T*("`\>#I3
M='EL97-H965T($A2968],T0B5V]R:W-H965T<R]R97!O<G0N8W-S(B\^#0H@
M(#QX.D%C=&EV95-H965T/C`\+W@Z06-T:79E4VAE970^#0H@(#QX.E!R;W1E
M8W13=')U8W1U<F4^1F%L<V4\+W@Z4')O=&5C=%-T<G5C='5R93X-"B`@/'@Z
M4')O=&5C=%=I;F1O=W,^1F%L<V4\+W@Z4')O=&5C=%=I;F1O=W,^#0H@/"]X
M.D5X8V5L5V]R:V)O;VL^#0H\+WAM;#X\(5ME;F1I9ETM+3X-"CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`\<#Y4:&ES('!A9V4@<VAO=6QD(&)E(&]P96YE9"!W
M:71H($UI8W)O<V]F="!%>&-E;"!84"!O<B!N97=E<BX\+W`^#0H@(#PO8F]D
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M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P135%044^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^1&]C=6UE;G0@06YD($5N=&ET>2!);F9O<FUA
M=&EO;CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R
M,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%U9RX@,3$L
M(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N
M=&ET>2!296=I<W1R86YT($YA;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/DQ)6%1%($))3U1%0TA.3TQ/1UD@2$],1$E.1U,L($E.0RX\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N
M=&ET>2!#96YT<F%L($EN9&5X($ME>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^,#`P,3,S-3$P-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0W5R<F5N="!&:7-C86P@665A<B!%;F0@
M1&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^+2TQ,BTS,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M16YT:71Y($9I;&5R($-A=&5G;W)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#Y3;6%L;&5R(%)E<&]R=&EN9R!#;VUP86YY/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4<F%D:6YG(%-Y
M;6)O;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^;&EX=#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT
M:71Y($-O;6UO;B!3=&]C:RP@4VAA<F5S($]U='-T86YD:6YG/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-2PR-3DL,30R/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!4
M>7!E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XQ,"U1/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;65N
M9&UE;G0@1FQA9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^9F%L
M<V4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D1O8W5M96YT(%!E<FEO9"!%;F0@1&%T93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^2G5N(#,P+`T*"0DR,#$Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!&:7-C
M86P@4&5R:6]D($9O8W5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#Y1,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1&]C=6UE;G0@1FES8V%L(%EE87(@1F]C=7,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/C(P,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7V1A8V(Y8S$X7S@Q-F1?-#1B,5\Y835A7SDT
M-&$Q839E.3@W-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]D86-B
M.6,Q.%\X,39D7S0T8C%?.6$U85\Y-#1A,6$V93DX-S<O5V]R:W-H965T<R]3
M:&5E=#`R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%-3-!13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T
M<F]N9SY#3TY$14Y3140@0T].4T],241!5$5$($)!3$%.0T4@4TA%1513("A5
M4T0@)FYB<W`[)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^2G5N+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$P/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%34T544SPO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#,T+#(S-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@,3$Y
M+#`Y,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^36]N97D@;6%R:V5T(&9U;F1S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#,P,2PP.#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#8P,2PP,#8\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9U;F1S(&]N(&1E<&]S
M:70@=VET:"!L87<@9FER;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1W)A;G0@<F5C96EV86)L93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$Q-BPT.#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%D=F%N8V5S(&]N(')E<V5A<F-H
M(&%N9"!D979E;&]P;65N="!C;VYT<F%C="!S97)V:6-E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-C,L,S4V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L,3`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E<&%I9"!E
M>'!E;G-E<R!A;F0@;W1H97(@8W5R<F5N="!A<W-E=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(R+#,Y-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,T+#8T-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-U<G)E
M;G0@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0R
M,2PP-S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#DS,2PS,C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!A<W-E=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L-#(Q+#`W-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.3,Q+#,R.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY,
M24%"24Q)5$E%4R!!3D0@4U1/0TM(3TQ$15)3)R!%455)5%D\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<&%Y
M86)L92!A;F0@86-C<G5E9"!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.#`L-SDY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C@L,S0U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E87)C:"!A;F0@9&5V96QO
M<&UE;G0@8V]N=')A8W0@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C@Y+#4U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQI<75I9&%T960@9&%M86=E<R!P87EA
M8FQE('5N9&5R(')E9VES=')A=&EO;B!R:6=H=',@86=R965M96YT/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$=64@
M=&\@<W1O8VMH;VQD97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/CDR+#<Q-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/CDR+#<Q-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-U<G)E;G0@;&EA8FEL:71I97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,S-RPP-C8\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.34L,#8R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/E-T;V-K:&]L9&5R<R<@97%U:71Y.CPO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL("9N
M8G-P.R0P+C`P,#$@<&%R('9A;'5E.R!A=71H;W)I>F5D("T@,3`L,#`P+#`P
M,"!S:&%R97,[(&ES<W5E9"`M($YO;F4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL("9N8G-P.R0P+C`P,#$@<&%R
M('9A;'5E.R!A=71H;W)I>F5D("T@,3`P+#`P,"PP,#`@<VAA<F5S.R!I<W-U
M960@86YD(&]U='-T86YD:6YG(#L@,S4L,C4Y+#$T,B!S:&%R97,@86YD(#,U
M+#`W-RPQ-S@@<VAA<F5S(&%T($IU;F4@,S`L(#(P,3$@86YD($1E8V5M8F5R
M(#,Q+"`R,#$P+"!R97-P96-T:79E;'D\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,L-3(V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,RPU,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%D9&ET:6]N86P@<&%I9"UI;B!C87!I
M=&%L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-RPP.3`L-38Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-RPV-C(L-34Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1&5F:6-I="!A8V-U;75L871E9"!D=7)I;F<@=&AE(&1E
M=F5L;W!M96YT('-T86=E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@V+#8R."PU-CDI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH-2PY,CDL.#`Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L('-T;V-K:&]L9&5R<R<@
M97%U:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`X-"PP
M,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+#<S-BPR-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y4;W1A;"!L:6%B:6QI=&EE<R!A;F0@<W1O8VMH;VQD
M97)S)R!E<75I='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B9N
M8G-P.R0@,2PT,C$L,#<T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`Q+#DS,2PS,C@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V1A8V(Y8S$X7S@Q-F1?-#1B
M,5\Y835A7SDT-&$Q839E.3@W-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B]D86-B.6,Q.%\X,39D7S0T8C%?.6$U85\Y-#1A,6$V93DX-S<O5V]R
M:W-H965T<R]3:&5E=#`S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%05!!0SX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#$^/'-T<F]N9SY#3TY$14Y3140@0T].4T],241!5$5$($)!3$%.0T4@
M4TA%1513(%M087)E;G1H971I8V%L72`H55-$("9N8G-P.R0I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P
M,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E
M9F5R<F5D('-T;V-K+"!P87(@=F%L=64@*&EN(&1O;&QA<G,@<&5R('-H87)E
M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`P+C`P
M,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XF;F)S<#LD(#`N,#`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!S:&%R97,@875T
M:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L,#`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@<VAA<F5S(&ES<W5E
M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S
M=&]C:RP@<&%R('9A;'5E("AI;B!D;VQL87)S('!E<B!S:&%R92D\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@,"XP,#`Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[
M)"`P+C`P,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<VAA<F5S(&%U=&AO<FEZ960\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"PP,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`P+#`P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;6UO;B!S=&]C:RP@<VAA<F5S(&ES<W5E9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,S4L,C4Y+#$T,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,U+#`W-RPQ-S@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M;6UO;B!S=&]C:RP@<VAA<F5S(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS-2PR-3DL,30R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S4L,#<W+#$W.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9&%C8CEC,3A?.#$V
M9%\T-&(Q7SEA-6%?.30T83%A-F4Y.#<W#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+V1A8V(Y8S$X7S@Q-F1?-#1B,5\Y835A7SDT-&$Q839E.3@W
M-R]7;W)K<VAE971S+U-H965T,#0N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$593$%'/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/D-/3D1%3E-%1"!#3TY33TQ)1$%4140@4U1!
M5$5-14Y44R!/1B!/4$52051)3TY3("A54T0@)FYB<W`[)"D\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^
M,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,CXV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C<Q($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y*=6XN(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DIU;BX@,S`L(#(P,3`\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^2G5N+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y*=6XN(#,P+"`R,#$P/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DIU;BX@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y2979E;G5E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)FYB<W`[)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[
M)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)FYB<W`[)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O<W1S(&%N9"!E>'!E;G-E<SH\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V5N97)A
M;"!A;F0@861M:6YI<W1R871I=F4@8V]S=',L(&EN8VQU9&EN9R`F;F)S<#LD
M-#`L-3(X(&%N9"`F;F)S<#LD,C`L-3,T(&]F('-T;V-K+6)A<V5D(&-O;7!E
M;G-A=&EO;B!C;W-T<R!F;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!*=6YE
M(#,P+"`R,#$Q(&%N9"`R,#$P+"!R97-P96-T:79E;'DL("9N8G-P.R0T,"PU
M,C@@86YD("9N8G-P.R0Y,RPR-S0@;V8@<W1O8VLM8F%S960@8V]M<&5N<V%T
M:6]N(&-O<W1S(&9O<B!T:&4@<VEX(&UO;G1H<R!E;F1E9"!*=6YE(#,P+"`R
M,#$Q(&%N9"`R,#$P+"!R97-P96-T:79E;'DL(&%N9"`F;F)S<#LD,BPR.3,L
M,#4Q(&]F('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!C;W-T<R!F;W(@=&AE
M('!E<FEO9"!F<F]M($%U9W5S="`Y+"`R,#`U("AI;F-E<'1I;VXI('1O($IU
M;F4@,S`L(#(P,3$@*&-U;75L871I=F4I/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,C,L-3@Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-S8L.#DR/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$S+#$Y-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V-2PT-S`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#@Q.2PP
M-S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D1E<')E8VEA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L.3`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y297-E87)C:"!A;F0@9&5V96QO<&UE;G0@8V]S=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(R-"PR,#@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,S,L,3`T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-#@U+#8U-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,Y-"PY-S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR+#<P."PU,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2979E<G-E(&UE<F=E<B!C;W-T
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1O=&%L(&-O<W1S(&%N9"!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S0W+#<X.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,P.2PY.38\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV.3@L.#4Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C8P+#0T-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L-3<Y
M+#0X-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3&]S<R!F<F]M(&]P97)A=&EO;G,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#,T-RPW.#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,S`Y+#DY-BD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V.3@L.#4Q*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8V,"PT-#<I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M-BPU-SDL-#@U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^26YT97)E<W0@:6YC;VUE/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,S,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C@S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-30X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C<L,S@U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!E>'!E
M;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,BPT-CDI
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y,:7%U:61A=&5D(&1A;6%G97,@=6YD97(@<F5G:7-T<F%T:6]N(')I9VAT
M<R!A9W)E96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@W-"PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^)FYB<W`[)"`H,S0W+#<U,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B9N8G-P.R0@*#,P.2PV-C,I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XF;F)S<#LD
M("@V.3@L-S8X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^)FYB<W`[)"`H-C4Y+#@Y.2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B9N8G-P.R0@*#8L-C(X+#4V.2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y.970@;&]S<R!P97(@8V]M;6]N('-H87)E("T@0F%S:6,@86YD(&1I;'5T
M960@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XF;F)S<#LD("@P+C`Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^)FYB<W`[)"`H,"XP,2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B9N8G-P.R0@
M*#`N,#(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XF;F)S<#LD("@P+C`R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D(&%V97)A9V4@8V]M;6]N
M('-H87)E<R!O=71S=&%N9&EN9R`M($)A<VEC(&%N9"!D:6QU=&5D("AI;B!S
M:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-2PP-SDL
M,3<X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,S4L,#<W+#$W.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,U+#`W."PQ.#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-"PS.#DL,S,S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]D86-B.6,Q.%\X,39D7S0T
M8C%?.6$U85\Y-#1A,6$V93DX-S<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z
M+R\O0SHO9&%C8CEC,3A?.#$V9%\T-&(Q7SEA-6%?.30T83%A-F4Y.#<W+U=O
M<FMS:&5E=',O4VAE970P-2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D
M:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M
M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15=*044^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^0T].1$5.4T5$($-/3E-/3$E$051%1"!35$%414U%
M3E13($]&($]015)!5$E/3E,@6U!A<F5N=&AE=&EC86Q=("A54T0@)FYB<W`[
M)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXV($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C<Q($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3`\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$P/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3$\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E
M;G-A=&EO;B!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)FYB<W`[)"`T,"PU,C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XF;F)S<#LD(#(P+#4S-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@.3,L,C<T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB
M<W`[)"`R+#(Y,RPP-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XF;F)S<#LD(#(L,CDS+#`U,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S96%R8V@@86YD
M(&1E=F5L;W!M96YT('-T;V-K(&)A<V5D(&-O<W1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,2PW-C(I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3@R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@L,3(W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#8U+#`S-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S
M96%R8V@@86YD(&1E=F5L;W!M96YT('-T;V-K(&)A<V5D(&-O<W1S+')E;&%T
M960@<&%R='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L,C4P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-2PR,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,BPU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU+#(P.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,P+#(P.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S96%R8V@@86YD(&1E=F5L;W!M
M96YT+"!R97!R97-E;G1I;F<@=&AE('!R;V-E961S(&]F(&$@9V]V97)N;65N
M="!G<F%N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[
M)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)FYB<W`[)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)FYB<W`[)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`R-#0L-#<Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
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M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14A0
M0DL^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0T].1$5.4T5$($-/3E-/3$E$
M051%1"!35$%414U%3E0@3T8@4U1/0TM(3TQ$15)3)R!%455)5%D@*$1%1DE#
M245.0UDI("A54T0@)FYB<W`[)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^0V]M;6]N(%-T;V-K/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D%D=F%N8V4@56YD97(@17%U:71Y($9I;F%N
M8VEN9SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!9&1I=&EO
M;F%L(%!A:60M:6X@0V%P:71A;#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$969I8VET($%C8W5M=6QA=&5D($1U<FEN9R!T:&4@1&5V96QO
M<&UE;G0@4W1A9V4\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M5&]T86P\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A
M;&%N8V4@870@075G+B`P.2P@,C`P-3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)FYB<W`[)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)FYB<W`[)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y"86QA;F-E("AI;B!S:&%R97,I(&%T($%U9RX@,#DL(#(P
M,#4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!I
M<W-U960@=&\@9F]U;F1I;F<@<W1O8VMH;VQD97(\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L.3`R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#0P,BD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!I<W-U
M960@=&\@9F]U;F1I;F<@<W1O8VMH;VQD97(@*&EN('-H87)E<RD\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Y+#`R,2PW.#8\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,38L,3(T*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$V
M+#$R-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D)A;&%N8V4@870@1&5C+B`S,2P@,C`P-3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PY,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#`R*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$V+#$R-"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-"PV,C0I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"
M86QA;F-E("AI;B!S:&%R97,I(&%T($1E8RX@,S$L(#(P,#4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$Y+#`R,2PW.#8\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!I<W-U
M960@:6X@8V]N;F5C=&EO;B!W:71H(')E=F5R<V4@;65R9V5R('1R86YS86-T
M:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,#$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C(L,#DY
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C8R+#4P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4VAA<F5S(&ES<W5E9"!I;B!C;VYN96-T:6]N('=I=&@@<F5V
M97)S92!M97)G97(@=')A;G-A8W1I;VX@*&EN('-H87)E<RD\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,#`U+#$W-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S(&ES<W5E
M9"!I;B!P<FEV871E('!L86-E;65N=',L(&YE="!O9B!O9F9E<FEN9R!C;W-T
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S4U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDV.2PP,3<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.38Y+#,W,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4VAA<F5S(&ES<W5E9"!I;B!P<FEV871E('!L86-E;65N=',L
M(&YE="!O9B!O9F9E<FEN9R!C;W-T<R`H:6X@<VAA<F5S*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,RPU-34L,C(P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:RUB87-E9"!C
M;VUP96YS871I;VX@8V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^.3<L-#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/CDW+#0P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@U-C(L,#@T*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4V,BPP.#0I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E
M(&%T($1E8RX@,S$L(#(P,#8\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(L-C4X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L,3(X+#$Q-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#4W."PR,#@I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-34R+#4V-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92`H
M:6X@<VAA<F5S*2!A="!$96,N(#,Q+"`R,#`V/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR-BPU.#(L,3@S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@:7-S=65D(&EN('!R
M:79A=&4@<&QA8V5M96YT<RP@;F5T(&]F(&]F9F5R:6YG(&-O<W1S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3,Q+#(R,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,S$L,S(P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3:&%R97,@:7-S=65D(&EN('!R:79A=&4@<&QA8V5M96YT<RP@;F5T(&]F
M(&]F9F5R:6YG(&-O<W1S("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XY.3DL.3DU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:RUB87-E9"!C;VUP96YS871I
M;VX@8V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@Y
M,"PV-CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^.#DP+#8Y-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(&-O<W1S
M("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3=&]C:RUB87-E9"!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@
M8V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`L.#,V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4P+#@S-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@Q+#8T."PT.#@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,2PV-#@L-#@X*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92!A="!$96,N
M(#,Q+"`R,#`W/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#<X
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR+#8P,"PX,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@R+#(R-BPV.38I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,S<V+#DR-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92`H:6X@<VAA
M<F5S*2!A="!$96,N(#,Q+"`R,#`W/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR-RPX,S(L,3<X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:RUB87-E9"!C;VUP96YS871I;VX@
M8V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S4W+#DX
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS-3<L.3@W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3=&]C:RUB87-E9"!R97-E87)C:"!A;F0@9&5V96QO<&UE
M;G0@8V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q
M,RPP-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C$S+#`V,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4W1O8VLM8F%S960@<F5S96%R8V@@86YD(&1E=F5L
M;W!M96YT(&-O<W1S("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#$L,C<Q+#4R,BD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#(W,2PU,C(I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA
M;F-E(&%T($1E8RX@,S$L(#(P,#@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(L-SDS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,L,3<Q+#@W-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#,L-#DX+#(Q."D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S,C,L-30X*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L
M86YC92`H:6X@<VAA<F5S*2!A="!$96,N(#,Q+"`R,#`X/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR-RPY,S(L,3<X/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@:7-S=65D
M(&EN('!R:79A=&4@<&QA8V5M96YT<RP@;F5T(&]F(&]F9F5R:6YG(&-O<W1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-#(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP.38L.#`X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L,#DW+#`U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4VAA<F5S(&ES<W5E9"!I;B!P<FEV871E('!L86-E;65N
M=',L(&YE="!O9B!O9F9E<FEN9R!C;W-T<R`H:6X@<VAA<F5S*3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPT,C`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9'9A;F-E('5N
M9&5R(&5Q=6ET>2!F:6YA;F-I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#(P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L,C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VLM8F%S960@8V]M
M<&5N<V%T:6]N(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XW-#4L.38U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C<T-2PY.#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO
M;B!C;W-T<R`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,34P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4W1O8VLM8F%S960@<F5S96%R8V@@86YD(&1E=F5L
M;W!M96YT(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$S,BPY,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3,R+#DS,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@Q+#4U,2PS,S,I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PU-3$L,S,S*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC
M92!A="!$96,N(#,Q+"`R,#`Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS+#`U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L,C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4L,30W+#4X,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4L,#0Y+#4U,2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,P,2PP
M.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D)A;&%N8V4@*&EN('-H87)E<RD@870@1&5C+B`S,2P@,C`P.3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`L-3`R+#$W.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S
M(&ES<W5E9"!I;B!P<FEV871E('!L86-E;65N=',L(&YE="!O9B!O9F9E<FEN
M9R!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#4X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PR
M,#`L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(L,C@W+#`T,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#`X-RPU,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!I<W-U960@:6X@
M<')I=F%T92!P;&%C96UE;G1S+"!N970@;V8@;V9F97)I;F<@8V]S=',@*&EN
M('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-3<U
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(&-O<W1S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V,"PW,3(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38P+#<Q,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O
M8VLM8F%S960@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&-O<W1S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8W+#(R,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-RPR,C(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.#@P
M+#(U,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@X.#`L,C4P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0F%L86YC92!A="!$96,N(#,Q+"`R,#$P/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#4P.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#8V,BPU-3D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U+#DR
M.2PX,#$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PW,S8L,C8V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E("AI;B!S:&%R97,I(&%T($1E8RX@
M,S$L(#(P,3`\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,U+#`W
M-RPQ-S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5X97)C:7-E(&]F('-T;V-K(&]P=&EO;G,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0L.3@R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!O
M9B!S=&]C:R!O<'1I;VYS("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ.#$L.38T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:RUB87-E9"!C;VUP96YS871I
M;VX@8V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`L
M-3(X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0P+#4R.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4W1O8VLM8F%S960@<F5S96%R8V@@86YD(&1E=F5L;W!M
M96YT(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDX
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XY.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH-CDX+#<V."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@V.3@L-S8X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92!A="!*=6XN(#,P+"`R
M,#$Q/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#,L
M-3(V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)FYB<W`[)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)FYB<W`[)"`W+#<P.2PP-3$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B9N8G-P.R0@*#8L-C(X+#4V
M.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XF;F)S<#LD(#$L,#@T+#`P.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92`H:6X@<VAA<F5S*2!A="!*
M=6XN(#,P+"`R,#$Q/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M-2PR-3DL,30R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
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M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14190D<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0T].1$5.4T5$
M($-/3E-/3$E$051%1"!35$%414U%3E13($]&($-!4T@@1DQ/5U,@*%531"`F
M;F)S<#LD*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,CXV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C<Q($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y*=6XN(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DIU;BX@,S`L(#(P,3`\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#87-H(&9L;W=S(&9R;VT@;W!E
M<F%T:6YG(&%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B9N8G-P.R0@*#8Y."PW-C@I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XF;F)S<#LD("@V-3DL.#DY*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)FYB
M<W`[)"`H-BPV,C@L-38Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!9&IU<W1M96YT<R!T;R!R96-O
M;F-I;&4@;F5T(&QO<W,@=&\@;F5T(&-A<V@@=7-E9"!I;B!O<&5R871I;F<@
M86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1&5P<F5C:6%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L.3`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y3=&]C:RUB87-E9"!C;VUP96YS871I;VX@8V]S
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDS+#(W-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,CDS
M+#`U,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(L,CDS+#`U,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4W1O8VLM8F%S960@<F5S96%R8V@@86YD(&1E=F5L
M;W!M96YT(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY
M.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ."PQ,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT-C4L,#,T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/BA);F-R96%S92D@9&5C<F5A<V4@
M:6X@+3PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y&=6YD<R!O;B!D97!O<VET('=I=&@@;&%W(&9I<FT\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F%N="!R96-E:79A8FQE
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,38L-#@U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%D
M=F%N8V5S(&]N(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!C;VYT<F%C="!S
M97)V:6-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-3,L,C4V
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#@L,S$P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#8S+#,U-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@97AP96YS97,@86YD(&]T:&5R(&-U
M<G)E;G0@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,BPR-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT+#DU.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#(R+#,Y-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^26YC<F5A<V4@*&1E8W)E87-E
M*2!I;B`M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D%C8V]U;G1S('!A>6%B;&4@86YD(&%C8W)U960@97AP96YS97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4R+#0U-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8L-#,P*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@P+#<Y
M.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3&EQ=6ED871E9"!D86UA9V5S('!A>6%B;&4@=6YD97(@<F5G:7-T<F%T
M:6]N(')I9VAT<R!A9W)E96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-S0L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&-O
M;G1R86-T(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XX.2PU-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR.2PP,#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XX.2PU-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@8V%S:"!U<V5D(&EN(&]P
M97)A=&EN9R!A8W1I=FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@S.#DL-S<T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#4R.2PR-S,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,RPW,#DL.3<W*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#87-H
M(&9L;W=S(&9R;VT@:6YV97-T:6YG(&%C=&EV:71I97,Z/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E8W)E87-E("AI;F-R
M96%S92D@:6X@;6]N97D@;6%R:V5T(&9U;F1S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR.3DL.3$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,BPP-3`L,34P*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L,S`Q+#`X.2D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M=7)C:&%S92!O9B!O9F9I8V4@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#$L.3`Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H('!R;W9I9&5D(&)Y
M("AU<V5D(&EN*2!I;G9E<W1I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,CDY+#DQ-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L,#4P+#$U,"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#,P,BPY.3@I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D-A<V@@9FQO=W,@9G)O;2!F:6YA;F-I;F<@86-T:79I=&EE
M<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')O8V5E9',@9G)O;2!E>&5R8VES92!O9B!S=&]C:R!O<'1I;VYS/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E
M9',@9G)O;2!S86QE(&]F(&-O;6UO;B!S=&]C:R!T;R!C;VYS=6QT:6YG(&9I
M<FT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C
M965D<R!F<F]M('-A;&4@;V8@8V]M;6]N('-T;V-K('1O(&9O=6YD97(\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S
M(&9R;VT@:7-S=6%N8V4@;V8@;F]T97,@<&%Y86)L92!T;R!C;VYS=6QT86YT
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E
M<&%Y;65N="!O9B!N;W1E<R!P87EA8FQE('1O(&-O;G-U;'1A;G0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C`P+#`P,"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86-Q
M=6ER960@:6X@<F5V97)S92!M97)G97(@=')A;G-A8W1I;VX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C(L-3`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F]S<R!P<F]C965D
M<R!F<F]M('-A;&4@;V8@<V5C=7)I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L,#@W+#4P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,S,Q+#,X.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&%Y;65N="!O9B!P
M<FEV871E('!L86-E;65N="!O9F9E<FEN9R!C;W-T<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@T-#8L,30W*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%D=F%N8V5S(')E8V5I
M=F5D(&9R;VT@<W1O8VMH;VQD97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^.3(L-S$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@<')O=FED960@8GD@9FEN86YC
M:6YG(&%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PP.#<L-3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-2PP-#<L,C`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H.B!.970@:6YC<F5A<V4@
M*&1E8W)E87-E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.#0L
M.#4W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#$L-#DQ+#DR,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS-"PR,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@Z($)A;&%N8V4@870@8F5G:6YN
M:6YG(&]F('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3$Y+#`Y,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L-30S+#DY,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V%S:#H@0F%L86YC92!A="!E;F0@;V8@<&5R
M:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-"PR,S0\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,BPP
M-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS-"PR,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^4W5P<&QE;65N=&%L(&1I<V-L;W-U<F5S(&]F
M(&-A<V@@9FQO=R!I;F9O<FUA=&EO;CH\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(L-#8Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YC;VUE('1A>&5S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3F]N+6-A
M<V@@9FEN86YC:6YG(&%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$96-R96%S92!I;B!A9'9A;F-E<R!U
M;F1E<B!E<75I='D@9FEN86YC:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PR,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PR,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H;&5S<R!%>&5R8VES
M92!O9B!787)R86YT<R!A;F0@3W!T:6]N<R!!9V=R96=A=&4@17AE<F-I<V4@
M4')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@
M.#0L,C`W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)FYB<W`[)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`X-"PR,#<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V1A8V(Y8S$X7S@Q-F1?-#1B,5\Y
M835A7SDT-&$Q839E.3@W-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B]D86-B.6,Q.%\X,39D7S0T8C%?.6$U85\Y-#1A,6$V93DX-S<O5V]R:W-H
M965T<R]3:&5E=#`X+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,D@^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^0F%S:7,@;V8@4')E<V5N=&%T:6]N/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3$\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0F%S:7,@3V8@4')E
M<V5N=&%T:6]N(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0F%S:7,@3V8@06-C;W5N=&EN9R!;5&5X="!"
M;&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^/&1I
M=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C!P
M=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z
M,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.F)O;&0[)R`^,2X@0F%S:7,@;V8@4')E<V5N=&%T:6]N(`T*/"]F;VYT/@T*
M/"]D:78^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L
M;V-K.R`^/&)R("\^#0H-"CPO9&EV/CQD:78^/&1I=B!S='EL93TS1'1E>'0M
M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HS-G!T.V1I<W!L87DZ8FQO8VL[;6%R
M9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^5&AE(&-O;F1E;G-E9"!C;VYS;VQI9&%T960@
M9FEN86YC:6%L('-T871E;65N=',@;V8@3&EX=&4@0FEO=&5C:&YO;&]G>2!(
M;VQD:6YG<RP@26YC+B!A;F0@:71S('=H;VQL>2UO=VYE9"!S=6)S:61I87)Y
M+"!,:7AT92!":6]T96-H;F]L;V=Y+"!);F,N("AT:&4@)B,X,C(P.T-O;7!A
M;GDF(S@R,C$[*2!A="!*=6YE(#,P+"`R,#$Q+"!F;W(@=&AE('1H<F5E(&UO
M;G1H<R!A;F0@<VEX(&UO;G1H<R!E;F1E9"!*=6YE(#,P+"`R,#$Q(&%N9"`R
M,#$P+"!A;F0@9F]R('1H92!P97)I;V0@9G)O;2!!=6=U<W0@.2P@,C`P-2`H
M:6YC97!T:6]N*2!T;R!*=6YE(#,P+"`R,#$Q("AC=6UU;&%T:79E*2P@87)E
M('5N875D:71E9"X@26X@=&AE(&]P:6YI;VX@;V8@;6%N86=E;65N="P@86QL
M(&%D:G5S=&UE;G1S("AI;F-L=61I;F<@;F]R;6%L(')E8W5R<FEN9R!A9&IU
M<W1M96YT<RD@:&%V92!B965N(&UA9&4@=&AA="!A<F4@;F5C97-S87)Y('1O
M('!R97-E;G0@9F%I<FQY('1H92!F:6YA;F-I86P@<&]S:71I;VX@;V8@=&AE
M($-O;7!A;GD@87,@;V8@2G5N92`S,"P@,C`Q,2P@=&AE(')E<W5L=',@;V8@
M:71S(&]P97)A=&EO;G,@9F]R('1H92!T:')E92!M;VYT:',@86YD('-I>"!M
M;VYT:',@96YD960@2G5N92`S,"P@,C`Q,2!A;F0@,C`Q,"P@86YD(&9O<B!T
M:&4@<&5R:6]D(&9R;VT@075G=7-T(#DL(#(P,#4@*&EN8V5P=&EO;BD@=&\@
M2G5N92`S,"P@,C`Q,2`H8W5M=6QA=&EV92DL(&%N9"!I=',@8V%S:"!F;&]W
M<R!F;W(@=&AE('-I>"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q,2!A;F0@
M,C`Q,"P@86YD(&9O<B!T:&4@<&5R:6]D(&9R;VT@075G=7-T(#DL(#(P,#4@
M*&EN8V5P=&EO;BD@=&\@2G5N92`S,"P@,C`Q,2`H8W5M=6QA=&EV92DN($]P
M97)A=&EN9R!R97-U;'1S(&9O<B!T:&4@:6YT97)I;2!P97)I;V1S('!R97-E
M;G1E9"!A<F4@;F]T(&YE8V5S<V%R:6QY(&EN9&EC871I=F4@;V8@=&AE(')E
M<W5L=',@=&\@8F4@97AP96-T960@9F]R(&$@9G5L;"!F:7-C86P@>65A<BX@
M5&AE(&-O;F1E;G-E9"!B86QA;F-E('-H965T(&%T($1E8V5M8F5R(#,Q+"`R
M,#$P(&AA<R!B965N(&1E<FEV960@9G)O;2!T:&4@8V]M<&%N>2=S(&%U9&ET
M960@9FEN86YC:6%L('-T871E;65N=',N(`T*/"]F;VYT/@T*/"]D:78^#0H\
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M:7IE.C$P<'0[)R`^5&AE('-T871E;65N=',@86YD(')E;&%T960@;F]T97,@
M:&%V92!B965N('!R97!A<F5D('!U<G-U86YT('1O('1H92!R=6QE<R!A;F0@
M<F5G=6QA=&EO;G,@;V8@=&AE(%-E8W5R:71I97,@86YD($5X8VAA;F=E($-O
M;6UI<W-I;VX@*'1H92`F(S@R,C`[4T5#)B,X,C(Q.RDN($%C8V]R9&EN9VQY
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M;F1E9"!$96-E;6)E<B`S,2P@,C`Q,"P@87,@9FEL960@=VET:"!T:&4@4T5#
M+B`-"CPO9F]N=#X-"CPO9&EV/@T*/"]D:78^#0H\+V1I=CX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V1A8V(Y8S$X7S@Q-F1?
M-#1B,5\Y835A7SDT-&$Q839E.3@W-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B]D86-B.6,Q.%\X,39D7S0T8C%?.6$U85\Y-#1A,6$V93DX-S<O
M5V]R:W-H965T<R]3:&5E=#`Y+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,D@^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^3W)G86YI>F%T:6]N(&%N9"!"=7-I;F5S<R!/<&5R
M871I;VYS/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@
M,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^3W)G86YI>F%T:6]N(&%N9"!"=7-I;F5S<R!/<&5R871I;VYS
M(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3W)G86YI>F%T:6]N(&%N9"!"=7-I;F5S<R!/<&5R871I;VYS
M(%M497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/&1I=CX\9&EV/CQD:78^/&1I=CX\9&EV/CQD:78^/&1I=CX\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L
M;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^,BXF
M(S$V,#L@3W)G86YI>F%T:6]N(&%N9"!"=7-I;F5S<R!/<&5R871I;VYS(`T*
M/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD
M:7-P;&%Y.F)L;V-K.R`^/&)R("\^#0H-"CPO9&EV/CQD:78^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB
M;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<W1Y;&4Z:71A;&EC.V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IB;VQD.R<@/D]R9V%N:7IA=&EO;CQB<B`O/@T*/&)R("\^#0H-
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M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^3VX@2G5N92`S,"P@,C`P-BP@
M3&EX=&4@0FEO=&5C:&YO;&]G>2P@26YC+BP@82!P<FEV871E;'DM:&5L9"!$
M96QA=V%R92!C;W)P;W)A=&EO;B`H)B,X,C(P.TQI>'1E)B,X,C(Q.RD@:6YC
M;W)P;W)A=&5D(&]N($%U9W5S="`Y+"`R,#`U+"!C;VUP;&5T960@82!R979E
M<G-E(&UE<F=E<B!T<F%N<V%C=&EO;B!W:71H(%-22U`@-RP@26YC+B`H)B,X
M,C(P.U-22U`F(S@R,C$[*2P@82!N;VXM=')A9&EN9R!P=6)L:6,@<VAE;&P@
M8V]M<&%N>2P@=VAE<F5B>2!,:7AT92!B96-A;64@82!W:&]L;'DM;W=N960@
M<W5B<VED:6%R>2!O9B!34DM0+B!/;B!$96-E;6)E<B`W+"`R,#`V+"!34DM0
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M.T-O;7!A;GDF(S@R,C$[+CQB<B`O/@T*/&)R("\^#0H-"CPO9F]N=#X-"CPO
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M="US:7IE.C$P<'0[)R`^1F]R(&9I;F%N8VEA;"!R97!O<G1I;F<@<'5R<&]S
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M:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/@T*/"]F
M;VYT/@T*/"]D:78^/&1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.W1E>'0M:6YD96YT.C,V<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP
M<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG(#Y4:&4@0V]M<&%N>2!I<R!C;VYS:61E<F5D(&$@)B,X,C(P.V1E
M=F5L;W!M96YT('-T86=E(&-O;7!A;GDF(S@R,C$[('5N9&5R(&-U<G)E;G0@
M86-C;W5N=&EN9R!S=&%N9&%R9',L(&%S(&ET(&AA<R!N;W0@>65T(&-O;6UE
M;F-E9"!A;GD@<F5V96YU92UG96YE<F%T:6YG(&]P97)A=&EO;G,L(&1O97,@
M;F]T(&AA=F4@86YY(&-A<V@@9FQO=W,@9G)O;2!O<&5R871I;VYS+"!A;F0@
M:7,@9&5P96YD96YT(&]N(&1E8G0@86YD(&5Q=6ET>2!F=6YD:6YG('1O(&9I
M;F%N8V4@:71S(&]P97)A=&EO;G,N/&)R("\^#0H\8G(@+SX-"@T*/"]F;VYT
M/@T*/"]D:78^#0H\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P
M=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
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M97(@=&AE('-Y;6)O;"`F(S@R,C`[3$E85"8C.#(R,3LN($ET(&ES('!R97-E
M;G1L>2!T<F%D960@;VX@=&AE($]40R!-87)K970@*&%L<V\@<F5F97)R960@
M=&\@87,@=&AE("8C.#(R,#M0:6YK(%-H965T<R8C.#(R,3LI('5N9&5R('1H
M92!S>6UB;VP@)B,X,C(P.TQ)6%0N4$LF(S@R,C$[+CQB<B`O/@T*/&)R("\^
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M;VYT+7=E:6=H=#IB;VQD.R<@/D]P97)A=&EN9R!0;&%N<SQB<B`O/@T*/&)R
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M.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O
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M;"!P871H=V%Y+B`-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R
M9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[)B,Q-C`[(`T*/"]F;VYT/@T*/"]D
M:78^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HS
M-G!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H
M=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^5&AI<R!A
M<'!R;V%C:"!H87,@;&5D('1O('1H92!D979E;&]P;65N="!O9B!T=V\@8VQA
M<W-E<R!O9B!D<G5G<RP@<&AO<W!H871A<V4@:6YH:6)I=&]R<R`H4%1A<V4M
M:2DL(&1E<VEG;F%T960@8GD@=&AE($-O;7!A;GD@87,@=&AE($Q"+3$P,"!S
M97)I97,@;V8@8V]M<&]U;F1S+"!A;F0@:&ES=&]N92!D96%C971Y;&%S92!I
M;FAI8FET;W)S("A(1$%#:2DL(&1E<VEG;F%T960@8GD@=&AE($-O;7!A;GD@
M87,@=&AE($Q"+3(P,"!S97)I97,@;V8@8V]M<&]U;F1S+B!4:&4@3$(M,3`P
M('-E<FEE<R!C;VYS:7-T<R!O9B!N;W9E;"!S=')U8W1U<F5S+"!W:&EC:"!H
M879E('1H92!P;W1E;G1I86P@=&\@8F4@9FER<W0@:6X@=&AE:7(@8VQA<W,@
M86YD('1H92!L871T97(@9W)O=7`@8V]N=&%I;G,@8V]M<&]U;F1S+"!W:&EC
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M.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^#0H\
M+V1I=CX\9&EV('-T>6QE/3-$=&5X="UI;F1E;G0Z,'!T.VUA<F=I;BUL969T
M.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&1I=CX-"CPO9&EV/CQD:78^#0H\
M+V1I=CX-"CPO9&EV/CQB<B`O/@T*/&1I=CX\9&EV('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.W1E>'0M:6YD96YT.C,V<'0[9&ES<&QA>3IB;&]C:SMM87)G
M:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG(#Y4:&4@<V5C;VYD(&-L87-S(&]F(&1R=6=S("A,
M0BTR,#`I('5N9&5R(&1E=F5L;W!M96YT(&)Y('1H92!#;VUP86YY(&ES('1H
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M<B`O/@T*#0H\+V9O;G0^#0H\+V1I=CX-"CPO9&EV/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[
M;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^#0H\+V9O;G0^#0H\+V1I=CX\9&EV/CQD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,S9P=#MD
M:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/E1H92!#;VUP86YY
M)B,X,C$W.W,@<')I;6%R>2!O8FIE8W1I=F4@:7,@=&\@8G)I;F<@;VYE(&QE
M860@8V]M<&]U;F0@;V8@=&AE($Q"+3$P,"!S97)I97,@=&\@8VQI;FEC86P@
M=')I86PN($EN(&QA=&4@,C`P.2!A;F0@96%R;'D@,C`Q,"P@=&AE($-O;7!A
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M<B`O/@T*#0H\+V9O;G0^#0H\+V1I=CX-"CPO9&EV/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[
M;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^#0H\+V9O;G0^#0H\+V1I=CX\9&EV/CQD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,S9P=#MD
M:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/D]N(%-E<'1E;6)E
M<B`Q-RP@,C`Q,"P@=&AE($YA=&EO;F%L($-A;F-E<B!);G-T:71U=&4@17AP
M97)I;65N=&%L(%1H97)A<&5U=&EC<R`H3D5X5"D@4')O9W)A;2!396YI;W(@
M061V:7-O<GD@0V]M;6ET=&5E("A304,I(&%P<')O=F5D(&$@8V]L;&%B;W)A
M=&EO;B!B>2!.0TD@=VET:"!T:&4@0V]M<&%N>2!F;W(@8VQI;FEC86P@979A
M;'5A=&EO;B!O9B!,0BTQ,#`L(&]N92!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS
M(&1R=6<@8V]M<&]U;F1S+B!4:&ES(&-O;&QA8F]R871I;VX@:7,@82!M:6QE
M<W1O;F4M8F%S960@87!P<F]A8V@@:6X@=VAI8V@@3D-)('=I;&P@9FER<W0@
M8V]N9FER;2!S='5D:65S(&]F('1H92!,0BTQ,#`@8V]M<&]U;F0@:6X@86X@
M86YI;6%L(&UO9&5L(&]F(&=L:6]B;&%S=&]M82!M=6QT:69O<FUE+"!T:&4@
M;6]S="!C;VUM;VX@8G)A:6X@='5M;W(@;V8@861U;'1S+"!A;F0@8V]N9'5C
M="!A;B!I;FET:6%L(&5X<&QO<F%T;W)Y('1O>&EC;VQO9WD@<W1U9'D@:6X@
M86X@86YI;6%L(&UO9&5L+B!!="!M:6QE<W1O;F4@:6YT97)V86QS+"!T:&4@
M4T%#('=I;&P@<F4M979A;'5A=&4@<')O:F5C="!P<F]G<F5S<R!B969O<F4@
M8V]N<VED97)I;F<@87-S:6=N;65N="!O9B!A9&1I=&EO;F%L('-U<'!O<G0@
M86YD(')E<V]U<F-E<R!T;R!T:&ES('!R;VIE8W0N/&)R("\^#0H\8G(@+SX-
M"@T*/"]F;VYT/@T*/"]D:78^#0H\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I
M;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G
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M:6YI8V%L('1R:6%L(&]F('1H92!#;VUP86YY)B,X,C$W.W,@3$(M,3`P(&-O
M;7!O=6YD+"!A;F0@=&\@8V]N=&EN=64@=&\@9W)O=R!I=',@<&%T96YT('!O
M<G1F;VQI;R!A;F0@;6%I;G1A:6X@:71S(&%P<&QI8V%T:6]N<R!F;W(@:6YT
M97)N871I;VYA;"!P<F]T96-T:6]N(&]F(&QE860@8V]M<&]U;F1S(&]F(&)O
M=&@@=&AE($Q"+3$P,"!A;F0@3$(M,C`P('-E<FEE<RP@=VET:&]U="!H879I
M;F<@=&\@<F%I<V4@861D:71I;VYA;"!F=6YD<RP@=6YT:6P@96%R;'D@,C`Q
M,BX\8G(@+SX-"CQB<B`O/@T*#0H\+V9O;G0^#0H\+V1I=CX-"CPO9&EV/CQD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I
M<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^#0H\+V9O;G0^#0H\
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M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
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M,C`Q,"!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',L(&AA<R!R
M86ES960@<W5B<W1A;G1I86P@9&]U8G0@86)O=70@=&AE($-O;7!A;GDF(S@R
M,3<[<R!A8FEL:71Y('1O(&-O;G1I;G5E(&%S(&$@9V]I;F<@8V]N8V5R;BX\
M8G(@+SX-"CQB<B`O/@T*#0H\+V9O;G0^#0H\+V1I=CX-"CPO9&EV/CQD:78@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L
M87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^#0H\+V9O;G0^#0H\+V1I
M=CX\9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E
M;G0Z,S9P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM
M<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
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M969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/@T*/"]F;VYT/@T*/"]D:78^/&1I=CX\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C,V<'0[9&ES<&QA>3IB
M;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#Y!="!*=6YE(#,P+"`R,#$Q+"!T
M:&4@0V]M<&%N>2!H860@;F]T('EE="!C;VUM96YC960@86YY(')E=F5N=64M
M9V5N97)A=&EN9R!O<&5R871I;VYS+B!!;&P@86-T:79I='D@=&AR;W5G:"!*
M=6YE(#,P+"`R,#$Q(&AA<R!B965N(')E;&%T960@=&\@=&AE($-O;7!A;GDF
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M:6]R('1O($IU;F4@,S`L(#(P,#8L('1H92!#;VUP86YY)B,X,C$W.W,@8V%S
M:"!R97%U:7)E;65N=',@=V5R92!F=6YD960@8GD@861V86YC97,@9G)O;2!T
M:&4@0V]M<&%N>28C.#(Q-SMS(&9O=6YD97(@86=G<F5G871I;F<@)FYB<W`[
M)#DR+#<Q-RX\8G(@+SX-"CQB<B`O/@T*#0H\+V9O;G0^#0H\+V1I=CX-"CPO
M9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z
M,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H
M=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^#0H\+V9O
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M=#MM87)G:6XM<FEG:'0Z,'!T.R`^#0H\+V1I=CX\9&EV('-T>6QE/3-$=&5X
M="UI;F1E;G0Z,'!T.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T
M.R`^/&1I=CX-"CPO9&EV/CQD:78^#0H\+V1I=CX-"CPO9&EV/CQB<B`O/@T*
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HS-G!T
M.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP
M<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^5&AE($-O;7!A
M;GDF(S@R,3<[<R!A8W1I=FET:65S(&9O<B!T:&4@<F5M86EN9&5R(&]F(#(P
M,3$@=VEL;"!C;VYS:7-T(&]F(&-O;G1I;G5I;F<@9')U9R!D:7-C;W9E<GD@
M86YD(&1E=F5L;W!M96YT(&5F9F]R=',N(%1H92!#;VUP86YY)B,X,C$W.W,@
M<')I;6%R>2!O8FIE8W1I=F4@:7,@=&\F(S$V,#MG86EN($9$02!A<'!R;W9A
M;"!O9B8C,38P.W1H92!#;VUP86YY)W,@3$(M,3`P(&-O;7!O=6YD(&9O<B!E
M;G1R>2!I;G1O(&$F(S$V,#M0:&%S92!)(&-L:6YI8V%L('1R:6%L(&)Y('1H
M92!E;F0@;V8@,C`Q,2X@5&AE($-O;7!A;GD@=V%S(&YO="!A8FQE('1O(&5X
M<&5D:71E('1H:7,@<')O8V5S<R!S;R!A<R!T;R!O8G1A:6X@<W5C:"!A<'!R
M;W9A;"!B>2!I=',@2G5N92`S,"P@,C`Q,2!T87)G970@9&%T92XF(S$V,#M!
M;'1H;W5G:"!T:&4@0V]M<&%N>2!H87,@;F]T(&ED96YT:69I960@86YY('-P
M96-I9FEC(&]B<W1A8VQE<R!T;R!T:&4@<W5B;6ES<VEO;B!O9B!T:&4@1D1!
M(&%P<&QI8V%T:6]N+"!T:&4@;W9E<F%L;"!P<F]C97-S(&]F(&QA<F=E(&%N
M:6UA;"!T97-T:6YG(&%N9"!F;W)M86P@9&]C=6UE;G1A=&EO;B!O9B!T:&4@
M;&]N9RUT97)M('-T86)I;&ET>2!O9B!T:&4@3$(M,3`P(&-O;7!O=6YD(&AA
M<R!B965N('-L;W=E<B!T:&%N(&]R:6=I;F%L;'D@86YT:6-I<&%T960N(`T*
M/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD
M:7-P;&%Y.F)L;V-K.R`^/&)R("\^#0H-"CPO9&EV/CQD:78^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HS-G!T.V1I<W!L87DZ
M8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^5&AE($-O;7!A;GD@<F%I<V5D
M("9N8G-P.R0U,#`L,#`P(&EN($YO=F5M8F5R(#(P,#DL("9N8G-P.R0Q+#<X
M-RPU,#`@:6X@2F%N=6%R>2`R,#$P+"!A;F0@)FYB<W`[)#4P,"PP,#`@:6X@
M1F5B<G5A<GD@,C`Q,"P@86QL('1H<F]U9V@@=&AE('-A;&4@;V8@:71S('-E
M8W5R:71I97,@=&\@9G5N9"!I=',@8G5S:6YE<W,@86-T:79I=&EE<RX@5&AE
M($-O;7!A;GD@86QS;R!R96-E:79E9"`F;F)S<#LD,C0T+#0W.2!F<F]M('1H
M92!);G1E<FYA;"!2979E;G5E(%-E<G9I8V4@=6YD97(@:71S(%%U86QI9GEI
M;F<@5&AE<F%P975T:6,@1&ES8V]V97)Y($=R86YT('!R;V=R86TL(&-O;G-I
M<W1I;F<@;V8@)FYB<W`[)#$R-RPY.30@;VX@3F]V96UB97(@.2P@,C`Q,"!A
M;F0@)FYB<W`[)#$Q-BPT.#4@;VX@1F5B<G5A<GDF(S$V,#LQ+"`R,#$Q+B!!
M<R!A(')E<W5L="P@=&AE($-O;7!A;GD@8F5L:65V97,@=&AA="!I=',@97AI
M<W1I;F<@<F5S;W5R8V5S(&%R92!A9&5Q=6%T92!T;R!F=6YD(&]P97)A=&EO
M;G,@=6YT:6P@96%R;'D@,C`Q,B!A="!A(&QE=F5L('1H870@=VEL;"!A;&QO
M=R!T:&4@8V]N=&EN=6%T:6]N(&]F('1H92!#;VUP86YY)B,X,C$W.W,@='=O
M(&1R=6<@9&5V96QO<&UE;G0@<')O9W)A;7,@8W5R<F5N=&QY(&EN('!R;V-E
M<W,@86YD(&-O;6UE;F-E;65N="P@8G5T(&YO="!C;VUP;&5T:6]N+"!O9B!A
M(%!H87-E($D@8VQI;FEC86P@=')I86P@;V8@3$(M,3`P+B`\8G(@+SX-"CQB
M<B`O/@T*#0H\+V9O;G0^#0H\+V1I=CX-"CPO9&EV/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[
M;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^#0H\+V9O;G0^#0H\+V1I=CX\9&EV('-T
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M=&AE(&-O;7!L971I;VX@;V8@=&AE(%!H87-E($D@=')I86P@;V8@3$(M,3`P
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M<&5R871I;F<@<&QA;B!B97EO;F0@96%R;'D@,C`Q,BP@87,@82!R97-U;'0@
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M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9&%C
M8CEC,3A?.#$V9%\T-&(Q7SEA-6%?.30T83%A-F4Y.#<W#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V1A8V(Y8S$X7S@Q-F1?-#1B,5\Y835A7SDT
M-&$Q839E.3@W-R]7;W)K<VAE971S+U-H965T,3`N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4R
M2#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=6UM87)Y(&]F(%-I9VYI9FEC
M86YT($%C8V]U;G1I;F<@4&]L:6-I97,\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!8V-O=6YT:6YG(%!O;&EC:65S
M(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R!;5&5X
M="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^
M/&1I=CX\9&EV/CQD:78^/&1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL
M969T.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T
M.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^,RX@4W5M;6%R>2!O9B!3:6=N
M:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S(`T*/"]F;VYT/@T*/"]D:78^
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M87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93II
M=&%L:6,[9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^4')I;F-I
M<&QE<R!O9B!#;VYS;VQI9&%T:6]N(`T*/"]F;VYT/@T*/"]D:78^/&1I=B!S
M='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HP<'0[9&ES<&QA
M>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^
M#0H\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD
M96YT.C,V<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN
M+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#Y4
M:&4@86-C;VUP86YY:6YG(&-O;F1E;G-E9"!C;VYS;VQI9&%T960@9FEN86YC
M:6%L('-T871E;65N=',@:6YC;'5D92!T:&4@9FEN86YC:6%L('-T871E;65N
M=',@;V8@2&]L9&EN9W,@86YD(&ET<R!W:&]L;'DM;W=N960@<W5B<VED:6%R
M>2P@3&EX=&4N($%L;"!I;G1E<F-O;7!A;GD@8F%L86YC97,@86YD('1R86YS
M86-T:6]N<R!H879E(&)E96X@96QI;6EN871E9"!I;B!C;VYS;VQI9&%T:6]N
M+B`-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE
M9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z
M,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS
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M:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P
M.R`-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE
M9G0[=&5X="UI;F1E;G0Z,S9P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T
M.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
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M:"!H:6=H(&-R961I="!R871I;F=S+B`-"CPO9F]N=#X-"CPO9&EV/CQD:78@
M<W1Y;&4],T1T97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SL@/CQB<B`O
M/@T*#0H\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M
M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G
M:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93II=&%L
M:6,[9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^4F5S96%R8V@@
M86YD($1E=F5L;W!M96YT(`T*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS
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M(`T*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F
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M=6%R=&5R;'D@8F%S:7,N(`T*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS
M1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.R`^/&)R("\^#0H-"CPO
M9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z
M,S9P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG
M:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/E1H92!F
M=6YD<R!P86ED('1O($Y)3D13(&]F('1H92!.24@L('!U<G-U86YT('1O('1H
M92!#4D%$02!E9F9E8W1I=F4@36%R8V@@,C(L(#(P,#8L(&%S(&%M96YD960L
M(')E<')E<V5N=&5D(&%N(&%D=F%N8V4@;VX@<F5S96%R8V@@86YD(&1E=F5L
M;W!M96YT(&-O<W1S(&%N9"!T:&5R969O<F4@:&%D(&9U='5R92!E8V]N;VUI
M8R!B96YE9FET+B!!8V-O<F1I;F=L>2P@<W5C:"!C;W-T<R!H879E(&)E96X@
M8VAA<F=E9"!T;R!E>'!E;G-E('=H96X@=&AE>2!A<F4@86-T=6%L;'D@97AP
M96YD960@8GD@=&AE('!R;W9I9&5R+"!W:&EC:"!I<RP@969F96-T:79E;'DL
M(&%S('1H97D@<&5R9F]R;2!T:&4@<F5S96%R8V@@86-T:79I=&EE<R!T:&%T
M('1H97D@=V5R92!C;VYT<F%C='5A;&QY(&-O;6UI='1E9"!T;R!P<F]V:61E
M+B!!8G-E;G0@:6YF;W)M871I;VX@=&AA="!W;W5L9"!I;F1I8V%T92!T:&%T
M(&$@9&EF9F5R96YT(&5X<&5N<VEN9R!S8VAE9'5L92!W87,@;6]R92!A<'!R
M;W!R:6%T92`H<W5C:"!A<RP@9F]R(&5X86UP;&4L(&9R;VT@=&AE(&%C:&EE
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M=F5L;W!M96YT(&-O<W1S('=E<F4@8F5I;F<@:6YC=7)R960N(`T*/"]F;VYT
M/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MM87)G:6XM
M;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQD:78^#0H\+V1I=CX-"CPO
M9&EV/CQD:78@<W1Y;&4],T1T97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C
M:SL@/CQB<B`O/@T*#0H\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL
M969T.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T
M.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9F]N="US
M='EL93II=&%L:6,[9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^
M4&%T96YT($-O<W1S(`T*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS1'1E
M>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.R`^/&)R("\^#0H-"CPO9&EV
M/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,S9P
M=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z
M,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
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M2G5N92`S,"P@,C`Q,2!A;F0@,C`Q,"P@<F5S<&5C=&EV96QY+"`F;F)S<#LD
M,C,T+#(W,2!A;F0@)FYB<W`[)#$W,"PW.#`@9F]R('1H92!S:7@@;6]N=&AS
M(&5N9&5D($IU;F4@,S`L(#(P,3$@86YD(#(P,3`L(')E<W!E8W1I=F5L>2P@
M86YD("9N8G-P.R0Q+#`P-2PV,#4@9F]R('1H92!P97)I;V0@9G)O;2!!=6=U
M<W0@.2P@,C`P-2`H:6YC97!T:6]N*2!T;R!*=6YE(#,P+"`R,#$Q("AC=6UU
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M=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y;&4],T1T
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M;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N
M=#X-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI
M;F1E;G0Z,S9P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G
M:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
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M;&ET:65S+B`-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN
M+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]D:78^/&1I=B!S
M='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HS-G!T.V1I<W!L
M87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^5&AE($-O;7!A;GD@:&%S
M(&5L96-T960@=&\@9&5D=6-T(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!C
M;W-T<R!O;B!A(&-U<G)E;G0@8F%S:7,@9F]R(&9E9&5R86P@:6YC;VUE('1A
M>"!P=7)P;W-E<RX@4W1A<G0M=7`@86YD(&]R9V%N:7IA=&EO;B!C;W-T<R!W
M97)E(&1E9F5R<F5D('5N=&EL($IA;G5A<GD@,2P@,C`P."X@06-C;W)D:6YG
M;'DL('1H92!#;VUP86YY('1H96X@8F5G86X@=&\@86UO<G1I>F4@<W5C:"!C
M;W-T<R!O=F5R(&$@,3@P+6UO;G1H('!E<FEO9"X@#0H\+V9O;G0^#0H\+V1I
M=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C!P
M=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z
M,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-
M"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M=&5X="UI;F1E;G0Z,S9P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P
M=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
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M<FUI;F%T:6]N('=A<R!M861E+B`-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ
M8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*
M/"]D:78^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N
M=#HS-G!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR
M:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^1F]R
M(&9E9&5R86P@:6YC;VUE('1A>"!P=7)P;W-E<RP@;F5T(&]P97)A=&EN9R!L
M;W-S97,@8V%N(&)E(&-A<G)I960@9F]R=V%R9"!F;W(@82!P97)I;V0@;V8@
M,C`@>65A<G,@=6YT:6P@=&AE>2!A<F4@96ET:&5R('5T:6QI>F5D(&]R('5N
M=&EL('1H97D@97AP:7)E+B`-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO
M8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]D
M:78^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HS
M-G!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H
M=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^3VX@2F%N
M=6%R>2`Q+"`R,#`W+"!T:&4@0V]M<&%N>2!A9&]P=&5D(&YE=R!A8V-O=6YT
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M;F-I86P@<W1A=&5M96YT<RX@07,@;V8@2G5N92`S,"P@,C`Q,2P@;F\@;&EA
M8FEL:71Y(&9O<B!U;G)E8V]G;FEZ960@=&%X(&)E;F5F:71S('=A<R!R97%U
M:7)E9"!T;R!B92!R96-O<F1E9"X@#0H\+V9O;G0^#0H\+V1I=CX\9&EV('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y
M.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-
M"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E
M;G0Z,S9P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM
M<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/E1H
M92!#;VUP86YY(&9I;&5S(&EN8V]M92!T87@@<F5T=7)N<R!I;B!T:&4@52Y3
M+B!F961E<F%L(&IU<FES9&EC=&EO;B!A;F0@:7,@<W5B:F5C="!T;R!I;F-O
M;64@=&%X(&5X86UI;F%T:6]N<R!B>2!F961E<F%L('1A>"!A=71H;W)I=&EE
M<R!F;W(@=&AE('EE87(@,C`P."!A;F0@=&AE<F5A9G1E<BX@5&AE($-O;7!A
M;GDF(S@R,3<[<R!P;VQI8WD@:7,@=&\@<F5C;W)D(&EN=&5R97-T(&%N9"!P
M96YA;'1I97,@;VX@=6YC97)T86EN('1A>"!P<F]V:7-I;VYS(&%S(&EN8V]M
M92!T87@@97AP96YS92X@07,@;V8@2G5N92`S,"P@,C`Q,2P@=&AE($-O;7!A
M;GD@:&%S(&YO(&%C8W)U960@:6YT97)E<W0@;W(@<&5N86QT:65S(')E;&%T
M960@=&\@=6YC97)T86EN('1A>"!P;W-I=&EO;G,N(`T*/"]F;VYT/@T*/"]D
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M=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL
M93II=&%L:6,[9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^1V]V
M97)N;65N="!'<F%N="!5;F1E<B!1=6%L:69Y:6YG(%1H97)A<&5U=&EC($1I
M<V-O=F5R>2!0<F]J96-T(`T*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS
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M('-I9VYE9"!I;G1O(&QA=R!O;B!-87)C:"`R,RP@,C`Q,"`H=&AE("8C.#(R
M,#M!8W0F(S@R,C$[*2P@=&AE($EN=&5R;F%L(%)E=F5N=64@4V5R=FEC92!A
M;F0@=&AE($1E<&%R=&UE;G0@;V8@2&5A;'1H(&%N9"!(=6UA;B!397)V:6-E
M<R!E<W1A8FQI<VAE9"!T:&4@<75A;&EF>6EN9R!T:&5R87!E=71I8R!D:7-C
M;W9E<GD@<')O:F5C="!T;R!C;VYS:61E<B!A;F0@87=A<F0@8V5R=&EF:6-A
M=&EO;G,@9F]R('%U86QI9FEE9"!I;G9E<W1M96YT<R!B>2!P<F]J96-T('-P
M;VYS;W)S+B!/;B!*=6QY(#(P+"`R,#$P+"!T:&4@0V]M<&%N>2!A<'!L:65D
M(&9O<B!A(&=R86YT('!U<G-U86YT('1O('1H92!!8W0@8F%S960@=7!O;B!Q
M=6%L:69I960@:6YV97-T;65N=',@;6%D92!I;B`R,#`Y(&%N9"`R,#$P+B!/
M;B!/8W1O8F5R(#(Y+"`R,#$P+"!T:&4@0V]M<&%N>2!W87,@;F]T:69I960@
M=&AA="!Q=6%L:69I960@:6YV97-T;65N=',@=&]T86QI;F<@)FYB<W`[)#0X
M."PY-3@@:&%D(&)E96X@8V5R=&EF:65D(&%N9"!T:&%T(&$@9W)A;G0@:6X@
M=&AE(&%M;W5N="!O9B`F;F)S<#LD,C0T+#0W.2!H860@8F5E;B!A=V%R9&5D
M('1O('1H92!#;VUP86YY+B`-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y;&4]
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M,C<L.3DT(&]N($YO=F5M8F5R(#DL(#(P,3`L(&%N9"`F;F)S<#LD,3$V+#0X
M-2!O;B!&96)R=6%R>2`Q+"`R,#$Q+"!W:&EC:"!W87,@<F5F;&5C=&5D(&%S
M(&$@<F5C96EV86)L92!A="!$96-E;6)E<B`S,2P@,C`Q,"X@1F]R(&9I;F%N
M8VEA;"!S=&%T96UE;G0@<'5R<&]S97,L('1H92!G<F%N="!O9B`F;F)S<#LD
M,C0T+#0W.2!W87,@;V9F<V5T(&%G86EN<W0@<F5S96%R8V@@86YD(&1E=F5L
M;W!M96YT(&-O<W1S(&EN('1H92!S=&%T96UE;G0@;V8@;W!E<F%T:6]N<R!F
M;W(@=&AE('EE87(@96YD960@1&5C96UB97(@,S$L(#(P,3`N(`T*/"]F;VYT
M/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y
M.F)L;V-K.R`^/&)R("\^#0H-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L
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M,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-
M"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M=&5X="UI;F1E;G0Z,S9P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P
M=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
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M960@870@=&AE(&=R86YT(&1A=&4N(`T*/"]F;VYT/@T*/"]D:78^/&1I=B!S
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M:&4@87=A<F1S+B`-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R
M9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]D:78^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HS-G!T.V1I
M<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^5&AE($-O;7!A;GD@
M86-C;W5N=',@9F]R('-H87)E+6)A<V5D('!A>6UE;G1S('1O(&-O;G-U;'1A
M;G1S(&)Y(&1E=&5R;6EN:6YG('1H92!V86QU92!O9B!T:&4@<W1O8VL@8V]M
M<&5N<V%T:6]N(&)A<V5D('5P;VX@=&AE(&UE87-U<F5M96YT(&1A=&4@870@
M96ET:&5R("AA*2!T:&4@9&%T92!A="!W:&EC:"!A('!E<F9O<FUA;F-E(&-O
M;6UI=&UE;G0@:7,@<F5A8VAE9"!O<B`H8BD@870@=&AE(&1A=&4@870@=VAI
M8V@@=&AE(&YE8V5S<V%R>2!P97)F;W)M86YC92!T;R!E87)N('1H92!E<75I
M='D@:6YS=')U;65N=',@:7,@8V]M<&QE=&4N(`T*/"]F;VYT/@T*/"]D:78^
M/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.R`^
M/&)R("\^#0H-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M=&5X="UI;F1E;G0Z,S9P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P
M=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
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M96X@8W5R<F5N="!V86QU92!O;B!T:&4@9&%T92!O9B!V97-T:6YG+B`-"CPO
M9F]N=#X-"CPO9&EV/CQD:78^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P
M=#MD:7-P;&%Y.F)L;V-K.R`^/&)R("\^#0H\9&EV/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[
M;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL
M93TS1"=F;VYT+7-T>6QE.FET86QI8SMD:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z8F]L9#LG(#Y%87)N:6YG<R!097(@4VAA<F4\8G(@+SX-"CQB<B`O/@T*
M#0H\+V9O;G0^#0H\+V1I=CX-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN
M+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)R`^#0H\+V9O;G0^#0H\+V1I=CX\9&EV/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,S9P=#MD:7-P;&%Y
M.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/E1H92!#;VUP86YY)B,X,C$W
M.W,@8V]M<'5T871I;VX@;V8@96%R;FEN9W,@<&5R('-H87)E("@F(S@R,C`[
M15!3)B,X,C(Q.RD@:6YC;'5D97,@8F%S:6,@86YD(&1I;'5T960@15!3+B!"
M87-I8R!%4%,@:7,@;65A<W5R960@87,@=&AE(&EN8V]M92`H;&]S<RD@879A
M:6QA8FQE('1O(&-O;6UO;B!S:&%R96AO;&1E<G,@9&EV:61E9"!B>2!T:&4@
M=V5I9VAT960@879E<F%G92!C;VUM;VX@<VAA<F5S(&]U='-T86YD:6YG(&9O
M<B!T:&4@<&5R:6]D+B!$:6QU=&5D($504R!I<R!S:6UI;&%R('1O(&)A<VEC
M($504R!B=70@<')E<V5N=',@=&AE(&1I;'5T:79E(&5F9F5C="!O;B!A('!E
M<B!S:&%R92!B87-I<R!O9B!P;W1E;G1I86P@8V]M;6]N('-H87)E<R`H92YG
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M<B`O/@T*#0H\+V9O;G0^#0H\+V1I=CX-"CPO9&EV/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[
M;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^#0H\+V9O;G0^#0H\+V1I=CX\9&EV('-T
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M92!A;G1I+61I;'5T:79E+CQB<B`O/@T*/&)R("\^#0H-"CPO9F]N=#X-"CPO
M9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z
M,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H
M=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^#0H\+V9O
M;G0^#0H\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M
M:6YD96YT.C,V<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R
M9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M(#Y!="!*=6YE(#,P+"`R,#$Q(&%N9"`R,#$P+"!T:&4@0V]M<&%N>2!E>&-L
M=61E9"!T:&4@;W5T<W1A;F1I;F<@<V5C=7)I=&EE<R!S=6UM87)I>F5D(&)E
M;&]W+"!W:&EC:"!E;G1I=&QE('1H92!H;VQD97)S('1H97)E;V8@=&\@86-Q
M=6ER92!S:&%R97,@;V8@8V]M;6]N('-T;V-K+"!F<F]M(&ET<R!C86QC=6QA
M=&EO;B!O9B!E87)N:6YG<R!P97(@<VAA<F4L(&%S('1H96ER(&5F9F5C="!W
M;W5L9"!H879E(&)E96X@86YT:2UD:6QU=&EV92X\8G(@+SX-"CQB<B`O/@T*
M#0H\+V9O;G0^#0H\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P
M=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/@T*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ8V5N=&5R.R`^/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`@=VED=&@],T0X,"4@('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#X\='(^/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#<V)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ
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M:6YL:6YE.R`^2G5N92`S,"P-"CPO9F]N=#X-"CPO9F]N=#X-"CPO9&EV/@T*
M/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C)P>#L@/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/@T*
M/"]T<CX\='(^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<V)2`@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-
M"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E
M>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O;3HR<'@[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R(&YO
M=W)A<#TS1&YO=W)A<"`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`R
M<'@@<V]L:60[)R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.W1E
M>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM
M87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.F)O;&0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN
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M9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$P)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@
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M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X-"CPO='(^/'1R/CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0W-B4@('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO
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M;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"`@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT
M/@T*/"]T9#X-"CPO='(^/'1R('-T>6QE/3-$8F%C:V=R;W5N9"UC;VQO<CHC
M8V-F9F-C.R`^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<V)2`@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9&EV('-T>6QE/3-$=&5X="UA;&EG
M;CIL969T.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL
M969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES
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M,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q
M)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$.24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H
M=#L@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M:6YD96YT
M.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG
M:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/C$S+#0U
M-"PU-3(-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO
M=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M
M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF
M(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@('-T>6QE/3-$=&5X="UA;&EG;CIR
M:6=H=#L@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M:6YD
M96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM
M<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/C$S
M+#8P-RPT,C8-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-
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M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^4W1O8VL@;W!T:6]N<PT*
M/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ
M,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-
M"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.F)L86-K(#)P>"!S;VQI9#MT97AT+6%L
M:6=N.FQE9G0[)R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#DE("!S='EL93TS1"=B;W)D97(M8F]T=&]M.F)L86-K(#)P>"!S;VQI9#MT
M97AT+6%L:6=N.G)I9VAT.R<@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I
M9VAT.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T
M.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[(#XS+#,U
M,"PP,#`-"CPO9F]N=#X-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.W!A9&1I;F<M8F]T=&]M.C)P>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN
M9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#$E("!S='EL93TS1"=B;W)D97(M8F]T=&]M.F)L86-K(#)P>"!S;VQI
M9#MT97AT+6%L:6=N.FQE9G0[)R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#DE("!S='EL93TS1"=B;W)D97(M8F]T=&]M.F)L86-K(#)P
M>"!S;VQI9#MT97AT+6%L:6=N.G)I9VAT.R<@/CQD:78@<W1Y;&4],T1T97AT
M+6%L:6=N.G)I9VAT.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA
M<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI
M;F4[(#XS+#4T,"PP,#`-"CPO9F]N=#X-"CPO9F]N=#X-"CPO9&EV/@T*/"]T
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M<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4]
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M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ8FQA8VL@-'!X(&1O=6)L93MT97AT+6%L:6=N.FQE9G0[)R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO
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M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C1P
M>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\
M+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`T<'@@9&]U8FQE.W1E>'0M86QI
M9VXZ;&5F=#LG(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M.24@('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@-'!X(&1O=6)L93MT
M97AT+6%L:6=N.G)I9VAT.R<@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I
M9VAT.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T
M.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
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M="US:7IE.C$P<'0[)R`^#0H\+V9O;G0^#0H\+V1I=CX\9&EV/CQD:78@<W1Y
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M<G5M96YT<SQB<B`O/@T*/&)R("\^#0H-"CPO9F]N=#X-"CPO9&EV/@T*/"]D
M:78^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HP
M<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT
M.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#X-"CPO9F]N
M=#X-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI
M;F1E;G0Z,S9P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G
M:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
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M<RX\8G(@+SX-"CQB<B`O/@T*#0H\+V9O;G0^#0H\+V1I=CX\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L
M;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/@T*/"]F;VYT/@T*/"]D:78^/&1I
M=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C!P
M=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z
M,'!T.R`^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93II=&%L:6,[9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^57-E(&]F($5S=&EM871E<SQB
M<B`O/@T*/&)R("\^#0H-"CPO9F]N=#X-"CPO9&EV/@T*/"]D:78^/&1I=B!S
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M,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
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M=6QD(&1I9F9E<B!F<F]M('1H;W-E(&5S=&EM871E<RX\8G(@+SX-"CQB<B`O
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M8F]L9#LG(#Y296-E;G0@06-C;W5N=&EN9R!0<F]N;W5N8V5M96YT<SQB<B`O
M/@T*/&)R("\^#0H-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R
M9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^#0H\+V9O;G0^#0H\+V1I=CX\9&EV('-T>6QE
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M(%-T86YD87)D<R!5<&1A=&4@*'1H92`F(S@R,C`[05-5)B,X,C(Q.RDF(S$V
M,#M.;RXF(S$V,#LR,#$Q+30L('=H:6-H(&%M96YD<R!T:&4@1F%I<B!686QU
M92!-96%S=7)E;65N=',@5&]P:6,@;V8@=&AE($%C8V]U;G1I;F<@4W1A;F1A
M<F1S($-O9&EF:6-A=&EO;B`H=&AE("8C.#(R,#M!4T,F(S@R,C$[*28C,38P
M.W1O(&AE;'`@86-H:65V92!C;VUM;VX@9F%I<B!V86QU92!M96%S=7)E;65N
M="!A;F0@9&ES8VQO<W5R92!R97%U:7)E;65N=',@:6X@52Y3+B!'04%0(&%N
M9"!)1E)3+B8C,38P.R8C,38P.T%352!.;RXF(S$V,#LR,#$Q+30@9&]E<R!N
M;W0@<F5Q=6ER92!A9&1I=&EO;F%L(&9A:7(@=F%L=64@;65A<W5R96UE;G1S
M(&%N9"!I<R!N;W0@:6YT96YD960@=&\@97-T86)L:7-H('9A;'5A=&EO;B!S
M=&%N9&%R9',@;W(@869F96-T('9A;'5A=&EO;B!P<F%C=&EC97,@;W5T<VED
M92!O9B!F:6YA;F-I86P@<F5P;W)T:6YG+B8C,38P.R8C,38P.U1H92!!4U4@
M:7,@969F96-T:79E(&9O<B!I;G1E<FEM(&%N9"!A;FYU86P@<&5R:6]D<R!B
M96=I;FYI;F<@869T97(@1&5C96UB97(F(S$V,#LQ-2P@,C`Q,2X@5&AE($-O
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M86X[9F]N="US:7IE.C$P<'0[)R`^26X@2G5N928C,38P.S(P,3$L('1H92!&
M05-"(&ES<W5E9"!!4U4@3F\N)B,Q-C`[,C`Q,2TU+"!W:&EC:"!A;65N9',@
M=&AE($-O;7!R96AE;G-I=F4@26YC;VUE(%1O<&EC(&]F('1H92!!4T,N)B,Q
M-C`[)B,Q-C`[5&AE($%352!E;&EM:6YA=&5S('1H92!O<'1I;VX@=&\@<')E
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M96=I;FYI;F<@869T97(@1&5C96UB97(F(S$V,#LQ-2P@,C`Q,2XF(S$V,#LF
M(S$V,#M4:&4@0V]M<&%N>2!W:6QL(&%D;W!T('1H92!!4U4@87,@<F5Q=6ER
M960N)B,Q-C`[)B,Q-C`[5&AE($%352!I<R!N;W0@97AP96-T960@=&\@:&%V
M92!A;GD@:6UP86-T(&]N('1H92!#;VUP86YY)B,X,C$W.W,@9FEN86YC:6%L
M('!O<VET:6]N(&]R(')E<W5L=',@;V8@;W!E<F%T:6]N<RX-"CPO9F]N=#X-
M"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB
M;&]C:SL@/CQB<B`O/@T*#0H\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG
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M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M9&%C8CEC,3A?.#$V9%\T-&(Q7SEA-6%?.30T83%A-F4Y.#<W#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V1A8V(Y8S$X7S@Q-F1?-#1B,5\Y835A
M7SDT-&$Q839E.3@W-R]7;W)K<VAE971S+U-H965T,3$N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$4R2#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3:&%R92!%>&-H86YG92!!
M9W)E96UE;G0@86YD(%!R:79A=&4@4&QA8V5M96YT/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3$\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4@17AC:&%N
M9V4@06=R965M96YT(&%N9"!0<FEV871E(%!L86-E;65N="!;06)S=')A8W1=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H
M87)E($5X8VAA;F=E($%G<F5E;65N="!A;F0@4')I=F%T92!0;&%C96UE;G0@
M6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X-
M"B`@/&1I=CX\9&EV/CQD:78^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#MT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP
M<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IB;VQD.R<@/C0N(%-H87)E($5X8VAA;F=E($%G
M<F5E;65N="!A;F0@4')I=F%T92!0;&%C96UE;G0-"B`@/"]F;VYT/@T*("`\
M+V1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT
M.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG
M:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P
M.PT*("`\+V9O;G0^#0H@(#PO9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE
M9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=F;VYT
M+7-T>6QE.FET86QI8SMD:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z8F]L9#LG
M(#Y3:&%R92!%>&-H86YG92!!9W)E96UE;G0-"B`@/"]F;VYT/@T*("`\+V1I
M=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C!P
M=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z
M,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*
M("`\+V9O;G0^#0H@(#PO9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE
M9G0[=&5X="UI;F1E;G0Z,S9P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T
M.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/D]N($IU;F4@,S`L(#(P,#8L('!U<G-U86YT('1O(&$@4VAA
M<F4@17AC:&%N9V4@06=R965M96YT(&1A=&5D(&%S(&]F($IU;F4@."P@,C`P
M-B`H=&AE("8C.#(R,#M3:&%R92!%>&-H86YG92!!9W)E96UE;G0F(S@R,C$[
M*2!B>2!A;F0@86UO;F<@2&]L9&EN9W,L($1R+B!*;VAN(%,N($MO=F%C:"`H
M)B,X,C(P.U-E;&QE<B8C.#(R,3LI(&%N9"!,:7AT92P@2&]L9&EN9W,@:7-S
M=65D(#$Y+#`R,2PW.#8@<VAA<F5S(&]F(&ET<R!C;VUM;VX@<W1O8VL@:6X@
M97AC:&%N9V4@9F]R(&%L;"!O9B!T:&4@:7-S=65D(&%N9"!O=71S=&%N9&EN
M9R!S:&%R97,@;V8@3&EX=&4@*'1H92`F(S@R,C`[17AC:&%N9V4F(S@R,C$[
M*2X@4')E=FEO=7-L>2P@;VX@3V-T;V)E<B`S+"`R,#`U+"!,:7AT92!H860@
M:7-S=65D(#$L-3`P('-H87)E<R!O9B!I=',@;F\@<&%R('9A;'5E(&-O;6UO
M;B!S=&]C:R!T;R!I=',@9F]U;F1E<B!F;W(@)FYB<W`[)#$L-3`P+"!W:&EC
M:"!C;VYS=&ET=71E9"!A;&P@;V8@=&AE(&ES<W5E9"!A;F0@;W5T<W1A;F1I
M;F<@<VAA<F5S(&]F($QI>'1E('!R:6]R('1O('1H92!%>&-H86YG92X@07,@
M82!R97-U;'0@;V8@=&AE($5X8VAA;F=E+"!,:7AT92!B96-A;64@82!W:&]L
M;'DM;W=N960@<W5B<VED:6%R>2!O9B!(;VQD:6YG<RX-"B`@/"]F;VYT/@T*
M("`\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD
M96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM
M<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.PT*("`\+V9O;G0^#0H@(#PO9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[=&5X="UI;F1E;G0Z,S9P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I
M;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&1I=CX\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C,V<'0[9&ES<&QA>3IB
M;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#Y0=7)S=6%N="!T;R!T:&4@17AC
M:&%N9V4L($AO;&1I;F=S(&ES<W5E9"!T;R!T:&4@4V5L;&5R(#$Y+#`R,2PW
M.#8@<VAA<F5S(&]F(&ET<R!C;VUM;VX@<W1O8VLN($AO;&1I;F=S(&AA9"!A
M('1O=&%L(&]F(#(U+#`P,"PX,S(@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!I
M<W-U960@86YD(&]U='-T86YD:6YG(&%F=&5R(&=I=FEN9R!E9F9E8W0@=&\@
M=&AE($5X8VAA;F=E(&%N9"!T:&4@,2PY-S,L.#8Y('-H87)E<R!O9B!C;VUM
M;VX@<W1O8VL@:7-S=65D(&EN('1H92!I;FET:6%L(&-L;W-I;F<@;V8@=&AE
M('!R:79A=&4@<&QA8V5M96YT+CQB<B`O/@T*("`\8G(@+SX-"B`@#0H@(#PO
M9F]N=#X-"B`@/"]D:78^#0H@(#PO9&EV/CQD:78@<W1Y;&4],T1T97AT+6EN
M9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN
M+7)I9VAT.C!P=#MT97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)R`^#0H@(#PO9F]N=#X-"B`@/"]D:78^/&1I=CX\9&EV
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M('!L86-E;65N="P@;VX@2G5N92`S,"P@,C`P-BP@=&AE('-T;V-K:&]L9&5R
M<R!O9B!T:&4@0V]M<&%N>2!I;6UE9&EA=&5L>2!P<FEO<B!T;R!T:&4@17AC
M:&%N9V4@;W=N960@-"PP,#4L,3<W('-H87)E<R!O9B!C;VUM;VX@<W1O8VLL
M(&5Q=6EV86QE;G0@=&\@87!P<F]X:6UA=&5L>2`Q-B4@;V8@=&AE(&ES<W5E
M9"!A;F0@;W5T<W1A;F1I;F<@<VAA<F5S(&]F('1H92!#;VUP86YY)B,X,C$W
M.W,@8V]M;6]N('-T;V-K+"!A;F0@=&AE(&9O<FUE<B!S=&]C:VAO;&1E<B!O
M9B!,:7AT92!A8W%U:7)E9"!C;VYT<F]L(&]F('1H92!#;VUP86YY+CQB<B`O
M/@T*("`\8G(@+SX-"B`@#0H@(#PO9F]N=#X-"B`@/"]D:78^#0H@(#PO9&EV
M/CQD:78@<W1Y;&4],T1T97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM
M87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#MT97AT+6%L:6=N.FQE
M9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^#0H@(#PO9F]N
M=#X-"B`@/"]D:78^/&1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.W1E>'0M:6YD96YT.C,V<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP
M<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG(#Y4:&4@4VAA<F4@17AC:&%N9V4@06=R965M96YT('=A<R!D971E
M<FUI;F5D('1H<F]U9V@@87)M<RUL96YG=&@@;F5G;W1I871I;VYS(&)E='=E
M96X@2&]L9&EN9W,L('1H92!396QL97(@86YD($QI>'1E+B!);B!C;VYN96-T
M:6]N('=I=&@@=&AE($5X8VAA;F=E+"!T:&4@0V]M<&%N>2!P86ED(%=E<W10
M87)K($-A<&ET86PL($EN8RX@86X@86=G<F5G871E(&-A<V@@9F5E(&]F("9N
M8G-P.R0U,"PP,#`N/&)R("\^#0H@(#QB<B`O/@T*("`-"B`@/"]F;VYT/@T*
M("`\+V1I=CX-"B`@/"]D:78^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P
M=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z
M,'!T.W1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG(#X-"B`@/"]F;VYT/@T*("`\+V1I=CX\9&EV/CQD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO
M8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S
M='EL93TS1"=F;VYT+7-T>6QE.FET86QI8SMD:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z8F]L9#LG(#Y0<FEV871E(%!L86-E;65N=',\8G(@+SX-"B`@/&)R
M("\^#0H@(`T*("`\+V9O;G0^#0H@(#PO9&EV/@T*("`\+V1I=CX\9&EV('-T
M>6QE/3-$=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE
M9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[=&5X="UA;&EG;CIL969T.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/@T*("`\+V9O;G0^#0H@(#PO
M9&EV/CQD:78^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN
M9&5N=#HS-G!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I
M;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M3VX@2G5N92`S,"P@,C`P-BP@8V]N8W5R<F5N=&QY('=I=&@@=&AE(&-L;W-I
M;F<@;V8@=&AE($5X8VAA;F=E+"!T:&4@0V]M<&%N>2!S;VQD(&%N(&%G9W)E
M9V%T92!O9B`Q+#DW,RPX-CD@<VAA<F5S(&]F(&ET<R!C;VUM;VX@<W1O8VL@
M=&\@86-C<F5D:71E9"!I;G9E<W1O<G,@:6X@86X@:6YI=&EA;"!C;&]S:6YG
M(&]F(&$@<')I=F%T92!P;&%C96UE;G0@870@82!P97(@<VAA<F4@<')I8V4@
M;V8@)FYB<W`[)#`N,S,S+"!R97-U;'1I;F<@:6X@86=G<F5G871E(&=R;W-S
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M("AA*2`Q,"4@;V8@=&AE(&YU;6)E<B!O9B!S:&%R97,@<V]L9"!I;B!T:&4@
M<')I=F%T92!P;&%C96UE;G0@97AE<F-I<V%B;&4@870@)FYB<W`[)#`N,S,S
M('!E<B!S:&%R92!A;F0@*&(I(&%N(&%D9&ET:6]N86P@,B4@;V8@=&AE(&YU
M;6)E<B!O9B!S:&%R97,@<V]L9"!I;B!T:&4@<')I=F%T92!P;&%C96UE;G0@
M86QS;R!E>&5R8VES86)L92!A="`F;F)S<#LD,"XS,S,@<&5R('-H87)E+B!!
M('1O=&%L(&]F(#(S-BPX-C0@=V%R<F%N=',@=V5R92!I<W-U960N($YE="!C
M87-H('!R;V-E961S('1O('1H92!#;VUP86YY+"!A9G1E<B!T:&4@9&5D=6-T
M:6]N(&]F(&%L;"!P<FEV871E('!L86-E;65N="!O9F9E<FEN9R!C;W-T<R!A
M;F0@97AP96YS97,L('=E<F4@)FYB<W`[)#4R,BPY,SDN/&)R("\^#0H@(#QB
M<B`O/@T*("`-"B`@/"]F;VYT/@T*("`\+V1I=CX-"B`@/"]D:78^/&1I=B!S
M='EL93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL
M969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.W1E>'0M86QI9VXZ;&5F=#L@/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#X-"B`@/"]F;VYT/@T*("`\
M+V1I=CX\9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI
M;F1E;G0Z,S9P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G
M:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
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M9B`F;F)S<#LD,"XS,S,@<F5S=6QT:6YG(&EN(&%G9W)E9V%T92!G<F]S<R!P
M<F]C965D<R!T;R!T:&4@0V]M<&%N>2!O9B`F;F)S<#LD-3(V+#4Y,"X@5&AE
M($-O;7!A;GD@<&%I9"!T;R!797-T4&%R:R!#87!I=&%L+"!);F,N+"!A<R!P
M;&%C96UE;G0@86=E;G0L(&$@8V]M;6ES<VEO;B!O9B`Q,"4@86YD(&$@;F]N
M+6%C8V]U;G1A8FQE(&9E92!O9B`T)2!O9B!T:&4@9W)O<W,@<')O8V5E9',@
M;V8@=&AE('!R:79A=&4@<&QA8V5M96YT(&%N9"!I<W-U960@9FEV92UY96%R
M('=A<G)A;G1S('1O('!U<F-H87-E(&-O;6UO;B!S=&]C:R!E<75A;"!T;R`H
M82D@,3`E(&]F('1H92!N=6UB97(@;V8@<VAA<F5S('-O;&0@:6X@=&AE('!R
M:79A=&4@<&QA8V5M96YT(&5X97)C:7-A8FQE(&%T("9N8G-P.R0P+C,S,R!P
M97(@<VAA<F4@86YD("AB*2!A;B!A9&1I=&EO;F%L(#(E(&]F('1H92!N=6UB
M97(@;V8@<VAA<F5S('-O;&0@:6X@=&AE('!R:79A=&4@<&QA8V5M96YT(&%L
M<V\@97AE<F-I<V%B;&4@870@)FYB<W`[)#`N,S,S('!E<B!S:&%R92X@02!T
M;W1A;"!O9B`Q.#DL-S8R('=A<G)A;G1S('=E<F4@:7-S=65D+B!.970@8V%S
M:"!P<F]C965D<R!T;R!T:&4@0V]M<&%N>2!W97)E("9N8G-P.R0T-#8L-#,S
M+B8C,38P.SQB<B`O/@T*("`\8G(@+SX-"B`@#0H@(#PO9F]N=#X-"B`@/"]D
M:78^#0H@(#PO9&EV/CQD:78@<W1Y;&4],T1T97AT+6EN9&5N=#HP<'0[9&ES
M<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#MT
M97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)R`^#0H@(#PO9F]N=#X-"B`@/"]D:78^/&1I=B!S='EL93TS1'1E>'0M:6YD
M96YT.C,V<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN
M+7)I9VAT.C!P=#MT97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)R`^26X@8V]N:G5N8W1I;VX@=VET:"!T:&4@<')I=F%T
M92!P;&%C96UE;G0@;V8@8V]M;6]N('-T;V-K+"!T:&4@0V]M<&%N>2!I<W-U
M960@82!T;W1A;"!O9B`T,C8L-C(V(&9I=F4M>65A<B!W87)R86YT<R!T;R!7
M97-T4&%R:R!#87!I=&%L+"!);F,N(&5X97)C:7-A8FQE(&%T('1H92!P97(@
M<VAA<F4@<')I8V4@;V8@=&AE(&-O;6UO;B!S=&]C:R!S;VQD(&EN('1H92!P
M<FEV871E('!L86-E;65N="`H)FYB<W`[)#`N,S,S('!E<B!S:&%R92DN(%1H
M92!W87)R86YT<R!I<W-U960@=&\@5V5S=%!A<FL@0V%P:71A;"P@26YC+B!D
M;R!N;W0@8V]N=&%I;B!A;GD@<')I8V4@86YT:2UD:6QU=&EO;B!P<F]V:7-I
M;VYS+B!(;W=E=F5R+"!S=6-H('=A<G)A;G1S(&-O;G1A:6X@8V%S:&QE<W,@
M97AE<F-I<V4@<')O=FES:6]N<R!A;F0@9&5M86YD(')E9VES=')A=&EO;B!R
M:6=H=',L(&)U="!T:&4@=V%R<F%N="!H;VQD97(@:&%S(&%G<F5E9"!T;R!W
M86EV92!A;GD@8VQA:6US('1O(&UO;F5T87)Y(&1A;6%G97,@;W(@9FEN86YC
M:6%L('!E;F%L=&EE<R!F;W(@86YY(&9A:6QU<F4@8GD@=&AE($-O;7!A;GD@
M=&\@8V]M<&QY('=I=&@@<W5C:"!R96=I<W1R871I;VX@<F5Q=6ER96UE;G1S
M+B!"87-E9"!O;B!T:&4@9F]R96=O:6YG+"!T:&4@=V%R<F%N=',@=V5R92!A
M8V-O=6YT960@9F]R(&%S(&5Q=6ET>2!A;F0@=V5R92!N;W0@86-C;W5N=&5D
M(&9O<B!S97!A<F%T96QY(&9R;VT@=&AE(&-O;6UO;B!S=&]C:R!A;F0@861D
M:71I;VYA;"!P86ED+6EN(&-A<&ET86P@86-C;W5N=',N(%1H92!W87)R86YT
M<R!H860@;F\@86-C;W5N=&EN9R!I;7!A8W0@;VX@=&AE($-O;7!A;GDF(S@R
M,3<[<R!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',N#0H@(#PO
M9F]N=#X-"B`@/"]D:78^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD
M:7-P;&%Y.F)L;V-K.R`^/&)R("\^#0H@(`T*("`\+V1I=CX\9&EV('-T>6QE
M/3-$=&5X="UI;F1E;G0Z,S9P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T
M.C!P=#MM87)G:6XM<FEG:'0Z,'!T.W1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#Y/;B!*=6YE(#,P+"`R,#$Q+"!7
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M=FEN9R!A(&YE="!O9B`Q,#`L.3(Y('-H87)E<RX-"B`@/"]F;VYT/@T*("`\
M+V1I=CX\9&EV('-T>6QE/3-$=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO
M8VL[(#X\8G(@+SX-"B`@#0H@(#PO9&EV/CQD:78^/&1I=B!S='EL93TS1'1E
M>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HS-G!T.V1I<W!L87DZ8FQO8VL[
M;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^3VX@2G5L>2`R-RP@,C`Q,2P@=&AE($-O
M;7!A;GD@86=R965D('1O(&5X=&5N9"!W87)R86YT<R!T;R!A8W%U:7)E('1H
M92!R96UA:6YI;F<@<&]R=&EO;B!O9B!T:&4@86)O=F4@9&5S8W)I8F5D('=A
M<G)A;G1S+"!C;VYS:7-T:6YG(&]F(#(W,RPW-3(@<VAA<F5S(&]F(&-O;6UO
M;B!S=&]C:RP@=&\@2G5L>2`R-RP@,C`Q,BXF(S$V,#LF(S$V,#M);B!C;VYJ
M=6YC=&EO;B!W:71H('1H92!E>'1E;G-I;VX@;V8@=&AE('=A<G)A;G1S+"!T
M:&4@8V%S:&QE<W,@97AE<F-I<V4@9F5A='5R92!W87,@9&5L971E9"XF(S$V
M,#LF(S$V,#M/;B!*=6QY(#(W+"`R,#$Q+"!T:&4@9F%I<B!V86QU92!O9B!T
M:&4@=V%R<F%N="!E>'1E;G-I;VXL(&%S(&-A;&-U;&%T960@<'5R<W5A;G0@
M=&\@=&AE($)L86-K+5-C:&]L97,@;W!T:6]N+7!R:6-I;F<@;6]D96PL('=A
M<R!D971E<FUI;F5D('1O(&)E("9N8G-P.R0Q.3DL.#,Y("@F;F)S<#LD,"XW
M,R!P97(@<VAA<F4I+"!A;F0@=VEL;"!B92!C:&%R9V5D('1O(&]P97)A=&EO
M;G,@9'5R:6YG('1H92!T:')E92!M;VYT:',@96YD:6YG(%-E<'1E;6)E<B`S
M,"P@,C`Q,2XF(S$V,#LF(S$V,#M4:&4@9F%I<B!V86QU92!O9B!T:&4@=V%R
M<F%N="!E>'1E;G-I;VX@=V%S(&-A;&-U;&%T960@=7-I;F<@=&AE(&9O;&QO
M=VEN9R!I;G!U="!V87)I86)L97,Z('-T;V-K('!R:6-E("T@)FYB<W`[)#`N
M-SD[(&5X97)C:7-E('!R:6-E("T@)FYB<W`[)#`N,S,S.R!E>'!E8W1E9"!L
M:69E("T@,2!Y96%R.R!E>'!E8W1E9"!V;VQA=&EL:71Y("8C.#(Q,3L@,S`X
M+C@E.R!E>'!E8W1E9"!D:79I9&5N9"!Y:65L9"`M(#`E.R!R:7-K+69R964@
M:6YT97)E<W0@<F%T92`F(S@R,3$[(#`N,30E+CQB<B`O/@T*("`\8G(@+SX-
M"B`@#0H@(#PO9F]N=#X-"B`@/"]D:78^#0H@(#PO9&EV/CQD:78@<W1Y;&4]
M,T1T97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP
M<'0[;6%R9VEN+7)I9VAT.C!P=#MT97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^#0H@(#PO9F]N=#X-"B`@/"]D:78^
M/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C,V<'0[9&ES<&QA>3IB;&]C:SMM
M87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#MT97AT+6%L:6=N.FQE
M9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^07,@<&%R="!O
M9B!T:&4@0V]M<&%N>28C.#(Q-SMS('!R:79A=&4@<&QA8V5M96YT(&]F(&ET
M<R!S96-U<FET:65S(&-O;7!L971E9"!O;B!*=6QY(#(W+"`R,#`V+"!T:&4@
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M<&QA8V5M96YT+B!/;B!397!T96UB97(@."P@,C`P-BP@=&AE($-O;7!A;GD@
M9FEL960@82!R96=I<W1R871I;VX@<W1A=&5M96YT(&]N($9O<FT@4T(M,B!T
M;R!R96=I<W1E<B`S+#4U-2PR,C`@<VAA<F5S(&]F('1H92!C;VUM;VX@<W1O
M8VL@<V]L9"!I;B!T:&4@<')I=F%T92!P;&%C96UE;G0N(%-I;F-E('1H92!R
M96=I<W1R871I;VX@<W1A=&5M96YT('=A<R!N;W0@9&5C;&%R960@969F96-T
M:79E(&)Y('1H92!396-U<FET:65S(&%N9"!%>&-H86YG92!#;VUM:7-S:6]N
M('=I=&AI;B`Q,C`@9&%Y<R!O9B!T:&4@8VQO<VEN9R!O9B!T:&4@<')I=F%T
M92!P;&%C96UE;G0L('1H92!#;VUP86YY('=A<R!R97%U:7)E9"!T;R!P87D@
M96%C:"!I;G9E<W1O<B!P<F]R871E9"!L:7%U:61A=&5D(&1A;6%G97,@97%U
M86P@=&\@,2XP)2!O9B!T:&4@86UO=6YT(')A:7-E9"!P97(@;6]N=&@L('!A
M>6%B;&4@;6]N=&AL>2!I;B!C87-H+@T*("`\+V9O;G0^#0H@(#PO9&EV/@T*
M("`-"B`@/"]D:78^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT
M+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R
M9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M(#XF(S$V,#L-"B`@/"]F;VYT/@T*("`\+V1I=CX\9&EV('-T>6QE/3-$=&5X
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M92!R96=I<W1R871I;VX@<FEG:'1S(&%G<F5E;65N="!A="!*=6YE(#,P+"`R
M,#`V+B!!="!$96-E;6)E<B`S,2P@,C`P-BP@=&AE($-O;7!A;GD@9&5T97)M
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M(')I9VAT<R!A9W)E96UE;G0@86=G<F5G871I;F<@87!P<F]X:6UA=&5L>2`F
M;F)S<#LD-S0L,#`P+"!W:&EC:"!H87,@8F5E;B!P<F5S96YT960@87,@82!C
M=7)R96YT(&QI86)I;&ET>2!F;W(@86QL('!E<FEO9',@<')E<V5N=&5D+B!4
M:&4@0V]M<&%N>28C.#(Q-SMS(')E9VES=')A=&EO;B!S=&%T96UE;G0@;VX@
M1F]R;2!30BTR('=A<R!D96-L87)E9"!E9F9E8W1I=F4@8GD@=&AE(%-E8W5R
M:71I97,@86YD($5X8VAA;F=E($-O;6UI<W-I;VX@;VX@36%Y(#$T+"`R,#`W
M+B!!="!-87)C:"`S,2P@,C`Q,2P@=&AE(')E9VES=')A=&EO;B!P96YA;'1Y
M('1O('1H92!I;G9E<W1O<G,@:&%D(&YO="!B965N('!A:60N#0H@(#PO9F]N
M=#X-"B`@/"]D:78^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MM87)G
M:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQD:78^#0H@(#PO9&EV
M/@T*("`\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UI;F1E;G0Z,'!T.V1I<W!L
M87DZ8FQO8VL[(#X\8G(@+SX-"B`@#0H@(#PO9&EV/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,S9P=#MD:7-P;&%Y.F)L;V-K
M.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/D]N($1E8V5M8F5R(#$R+"`R,#`W+"!T
M:&4@0V]M<&%N>2!S;VQD(&%N(&%G9W)E9V%T92!O9B`Y.3DL.3DU('-H87)E
M<R!O9B!I=',@8V]M;6]N('-T;V-K('1O(&%C8W)E9&ET960@:6YV97-T;W)S
M(&EN(&$@<V5C;VYD('!R:79A=&4@<&QA8V5M96YT(&%T(&$@<&5R('-H87)E
M('!R:6-E(&]F("9N8G-P.R0P+C8U+"!R97-U;'1I;F<@:6X@86=G<F5G871E
M(&=R;W-S('!R;V-E961S('1O('1H92!#;VUP86YY(&]F("9N8G-P.R0V-3`L
M,#`P+B!4:&4@0V]M<&%N>2!P86ED('1O(%=E<W1087)K($-A<&ET86PL($EN
M8RXL(&%S('!L86-E;65N="!A9V5N="P@82!C;VUM:7-S:6]N(&]F(#$P)2!A
M;F0@82!N;VXM86-C;W5N=&%B;&4@9F5E(&]F(#0E(&]F('1H92!G<F]S<R!P
M<F]C965D<R!O9B!T:&4@<')I=F%T92!P;&%C96UE;G0@86YD(&ES<W5E9"!F
M:79E+7EE87(@=V%R<F%N=',@=&\@<'5R8VAA<V4@8V]M;6]N('-T;V-K(&5Q
M=6%L('1O("AA*2`Q,"4@;V8@=&AE(&YU;6)E<B!O9B!S:&%R97,@<V]L9"!I
M;B!T:&4@<')I=F%T92!P;&%C96UE;G0@97AE<F-I<V%B;&4@870@)FYB<W`[
M)#`N-C4@<&5R('-H87)E(&%N9"`H8BD@86X@861D:71I;VYA;"`R)2!O9B!T
M:&4@;G5M8F5R(&]F('-H87)E<R!S;VQD(&EN('1H92!P<FEV871E('!L86-E
M;65N="!A;'-O(&5X97)C:7-A8FQE(&%T("9N8G-P.R0P+C8U('!E<B!S:&%R
M92X@3F5T(&-A<V@@<')O8V5E9',@=&\@=&AE($-O;7!A;GD@=V5R92`F;F)S
M<#LD-3,Q+#,R,"X-"B`@/"]F;VYT/@T*("`\+V1I=CX\9&EV('-T>6QE/3-$
M=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K
M.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO
M9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z
M,S9P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG
M:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/DEN(&-O
M;FIU;F-T:6]N('=I=&@@=&AE('-E8V]N9"!P<FEV871E('!L86-E;65N="!O
M9B!C;VUM;VX@<W1O8VLL('1H92!#;VUP86YY(&ES<W5E9"!A('1O=&%L(&]F
M(#$R,"PP,#`@9FEV92UY96%R('=A<G)A;G1S('1O(%=E<W1087)K($-A<&ET
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M=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S+@T*("`\+V9O;G0^#0H@(#PO9&EV
M/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T
M.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP
M<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H@
M(#PO9F]N=#X-"B`@/"]D:78^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#MT97AT+6EN9&5N=#HS-G!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z
M,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^07,@<&%R="!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS('-E8V]N
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M(')E<')E<V5N="!A="!L96%S="`U,"4@;V8@=&AE(&-O;6UO;B!S:&%R97,@
M:7-S=65D('!U<G-U86YT('1O('1H92!S96-O;F0@<')I=F%T92!P;&%C96UE
M;G0L('!R;W9I9&5D('1H870@;F\@9&5M86YD('-H86QL(&)E(&UA9&4@9F]R
M(&QE<W,@=&AA;B`U,#`L,#`P('-H87)E<RP@86YD('1O('5S92!I=',@8F5S
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M('=I=&@@:71S('1E<FUS+@T*("`\+V9O;G0^#0H@(#PO9&EV/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ
M8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H@(#PO9F]N=#X-
M"B`@/"]D:78^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN
M9&5N=#HS-G!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I
M;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M1'5R:6YG('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#`Y+"!T:&4@
M0V]M<&%N>2!C;VUP;&5T960@=&AR964@8VQO<VEN9W,@;V8@=&AE('1H:7)D
M('!R:79A=&4@<&QA8V5M96YT(&]F(&-O;6UO;B!S=&]C:R!U;FET<RP@8V]N
M<VES=&EN9R!O9B!A('1O=&%L(&]F(#$L-#(P+#`P,"!S:&%R97,@;V8@8V]M
M;6]N('-T;V-K(&%N9"`Q+#0R,"PP,#`@=V%R<F%N=',@=&\@86-Q=6ER92!C
M;VUM;VX@<W1O8VLL(&%S(&9O;&QO=W,Z#0H@(#PO9F]N=#X-"B`@/"]D:78^
M/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.R`^
M/&)R("\^#0H@(`T*("`\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL
M969T.W1E>'0M:6YD96YT.C,V<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F
M=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG(#Y/;B!&96)R=6%R>2`Q,"P@,C`P.2P@=&AE($-O;7!A;GD@
M<V]L9"!A;B!A9V=R96=A=&4@;V8@-C4X+#`P,"!C;VUM;VX@<W1O8VL@=6YI
M=',@=&\@86-C<F5D:71E9"!I;G9E<W1O<G,@:6X@82!F:7)S="!C;&]S:6YG
M(&]F(&$@=&AI<F0@<')I=F%T92!P;&%C96UE;G0@870@82!P97(@=6YI="!P
M<FEC92!O9B`F;F)S<#LD,"XU,"P@<F5S=6QT:6YG(&EN(&%G9W)E9V%T92!G
M<F]S<R!P<F]C965D<R!T;R!T:&4@0V]M<&%N>2!O9B`F;F)S<#LD,S(Y+#`P
M,"X@3F5T(&-A<V@@<')O8V5E9',@=&\@=&AE($-O;7!A;GD@=V5R92`F;F)S
M<#LD,C8Y+#<Y,"X-"B`@/"]F;VYT/@T*("`\+V1I=CX\9&EV('-T>6QE/3-$
M=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K
M.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO
M9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z
M,S9P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG
M:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/D]N($UA
M<F-H(#(L(#(P,#DL('1H92!#;VUP86YY('-O;&0@86X@86=G<F5G871E(&]F
M(#(V,BPP,#`@8V]M;6]N('-T;V-K('5N:71S('1O(&%C8W)E9&ET960@:6YV
M97-T;W)S(&EN(&$@<V5C;VYD(&-L;W-I;F<@;V8@=&AE('1H:7)D('!R:79A
M=&4@<&QA8V5M96YT(&%T(&$@<&5R('5N:70@<')I8V4@;V8@)FYB<W`[)#`N
M-3`L(')E<W5L=&EN9R!I;B!A9V=R96=A=&4@9W)O<W,@<')O8V5E9',@=&\@
M=&AE($-O;7!A;GD@;V8@)FYB<W`[)#$S,2PP,#`N($YE="!C87-H('!R;V-E
M961S('1O('1H92!#;VUP86YY('=E<F4@)FYB<W`[)#$Q,BPT-C`N#0H@(#PO
M9F]N=#X-"B`@/"]D:78^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT
M97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[
M;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL
M:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG(#XF(S$V,#L-"B`@/"]F;VYT/@T*("`\+V1I=CX\9&EV('-T>6QE/3-$
M=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C,V<'0[9&ES<&QA>3IB;&]C
M:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#Y/;B!!<')I;"`V+"`R,#`Y+"!T:&4@
M0V]M<&%N>2!S;VQD(&%N(&%G9W)E9V%T92!O9B`U,#`L,#`P(&-O;6UO;B!S
M=&]C:R!U;FET<R!T;R!A8V-R961I=&5D(&EN=F5S=&]R<R!I;B!A('1H:7)D
M(&-L;W-I;F<@;V8@=&AE('1H:7)D('!R:79A=&4@<&QA8V5M96YT(&%T(&$@
M<&5R('5N:70@<')I8V4@;V8@)FYB<W`[)#`N-3`L(')E<W5L=&EN9R!I;B!A
M9V=R96=A=&4@9W)O<W,@<')O8V5E9',@=&\@=&AE($-O;7!A;GD@;V8@)FYB
M<W`[)#(U,"PP,#`N($YE="!C87-H('!R;V-E961S('1O('1H92!#;VUP86YY
M('=E<F4@)FYB<W`[)#(Q-"PX,#`N#0H@(#PO9F]N=#X-"B`@/"]D:78^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HP<'0[9&ES
M<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-"B`@/"]F
M;VYT/@T*("`\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E
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M8F%S:7,@870@86X@97AE<F-I<V4@<')I8V4@;V8@)FYB<W`[)#`N-3`@<&5R
M(&-O;6UO;B!S:&%R92X@5&AE($-O;7!A;GD@<&%I9"!T;R!797-T4&%R:R!#
M87!I=&%L+"!);F,N+"!A<R!P;&%C96UE;G0@86=E;G0L(&$@8V]M;6ES<VEO
M;B!O9B`Q,"4@86YD(&$@;F]N+6%C8V]U;G1A8FQE(&9E92!O9B`T)2!O9B!T
M:&4@9W)O<W,@<')O8V5E9',@;V8@=&AE('1H:7)D('!R:79A=&4@<&QA8V5M
M96YT(&%N9"!I<W-U960@9FEV92UY96%R('=A<G)A;G1S('1O('!U<F-H87-E
M(&-O;6UO;B!S=&]C:R!E<75A;"!T;R`H82D@,3`E(&]F('1H92!N=6UB97(@
M;V8@<VAA<F5S('-O;&0@:6X@=&AE('1H:7)D('!R:79A=&4@<&QA8V5M96YT
M(&5X97)C:7-A8FQE(&%T("9N8G-P.R0P+C4P('!E<B!S:&%R92!A;F0@,3`E
M(&]F('1H92!N=6UB97(@;V8@<VAA<F5S(&ES<W5A8FQE('5P;VX@97AE<F-I
M<V4@;V8@=V%R<F%N=',@:7-S=65D(&EN('1H92!T:&ER9"!P<FEV871E('!L
M86-E;65N="!E>&5R8VES86)L92!A="`F;F)S<#LD,"XU,"!P97(@<VAA<F4[
M(&%N9"`H8BD@86X@861D:71I;VYA;"`R)2!O9B!T:&4@;G5M8F5R(&]F('-H
M87)E<R!S;VQD(&EN('1H92!T:&ER9"!P<FEV871E('!L86-E;65N="!A;'-O
M(&5X97)C:7-A8FQE(&%T("9N8G-P.R0P+C4P('!E<B!S:&%R92!A;F0@,B4@
M;V8@=&AE(&YU;6)E<B!O9B!S:&%R97,@:7-S=6%B;&4@=7!O;B!E>&5R8VES
M92!O9B!T:&4@=V%R<F%N=',@:7-S=65D(&EN('1H92!T:&ER9"!P<FEV871E
M('!L86-E;65N="!E>&5R8VES86)L92!A="`F;F)S<#LD,"XU,"!P97(@<VAA
M<F4N#0H@(#PO9F]N=#X-"B`@/"]D:78^/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ;&5F=#MT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM
M;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#XF(S$V,#L-"B`@/"]F;VYT/@T*("`\+V1I=CX\9&EV
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M;F1E9"!$96-E;6)E<B`S,2P@,C`P.2P@=&AE($-O;7!A;GD@:7-S=65D(&$@
M=&]T86P@;V8@,S0P+#@P,"!F:79E+7EE87(@=V%R<F%N=',@=&\@5V5S=%!A
M<FL@0V%P:71A;"P@26YC+BP@=VAI8V@@87)E(&5X97)C:7-A8FQE(&%T('1H
M92!P97(@=6YI="!P<FEC92!O9B!T:&4@8V]M;6]N('-T;V-K('5N:71S('-O
M;&0@:6X@=&AE('1H:7)D('!R:79A=&4@<&QA8V5M96YT("@F;F)S<#LD,"XU
M,"!P97(@=6YI="DN($EN8VQU9&5D(&EN('1H92`S-#`L.#`P('=A<G)A;G1S
M(&ES<W5E9"!T;R!797-T4&%R:R!#87!I=&%L+"!);F,N(&%R92`Q-S`L-#`P
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M;F-I86P@<W1A=&5M96YT<RX-"B`@/"]F;VYT/@T*("`\+V1I=CX\9&EV('-T
M>6QE/3-$=&5X="UI;F1E;G0Z,'!T.VUA<F=I;BUL969T.C!P=#MM87)G:6XM
M<FEG:'0Z,'!T.R`^/&1I=CX-"B`@/"]D:78^#0H@(#PO9&EV/CQD:78@<W1Y
M;&4],T1T97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SL@/CQB<B`O/@T*
M("`-"B`@/"]D:78^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT
M+6EN9&5N=#HS-G!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA
M<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)R`^070@=&AE(')E<75E<W0@;V8@=&AE(&AO;&1E<G,L('1H92!#;VUP86YY
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M-SMS('-O;&4@8V]S="!A;F0@97AP96YS92X-"B`@/"]F;VYT/@T*("`\+V1I
M=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C!P
M=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z
M,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*
M("`\+V9O;G0^#0H@(#PO9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE
M9G0[=&5X="UI;F1E;G0Z,S9P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T
M.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/D5F9F5C=&EV92!.;W9E;6)E<B`V+"`R,#`Y+"!T:&4@0V]M
M<&%N>2!S;VQD(#$L,#`P+#`P,"!C;VUM;VX@<W1O8VL@=6YI=',@=&\@86X@
M86-C<F5D:71E9"!I;G9E<W1O<B!I;B!A(&9O=7)T:"!P<FEV871E('!L86-E
M;65N="!A="!A('!E<B!U;FET('!R:6-E(&]F("9N8G-P.R0P+C4P+"!R97-U
M;'1I;F<@:6X@<')O8V5E9',@=&\@=&AE($-O;7!A;GD@;V8@)FYB<W`[)#4P
M,"PP,#`N(%1H97)E('=E<F4@;F\@8V]M;6ES<VEO;G,@<&%I9"!W:71H(')E
M<W!E8W0@=&\@=&AE(&9O=7)T:"!P<FEV871E('!L86-E;65N="X@5&AE(&-L
M;W-I;F<@<')I8V4@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!C;VUM;VX@<W1O
M8VL@;VX@3F]V96UB97(@-BP@,C`P.2!W87,@)FYB<W`[)#`N-3`@<&5R('-H
M87)E+@T*("`\+V9O;G0^#0H@(#PO9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN
M+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]D:78^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HS-G!T.V1I
M<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^16%C:"!U;FET('-O
M;&0@:6X@=&AE(&9O=7)T:"!P<FEV871E('!L86-E;65N="!C;VYS:7-T960@
M;V8@;VYE('-H87)E(&]F('1H92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T
M;V-K+"!O;F4@=&AR964M>65A<B!W87)R86YT('1O('!U<F-H87-E(&%N(&%D
M9&ET:6]N86P@<VAA<F4@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!C;VUM;VX@
M<W1O8VL@870@86X@97AE<F-I<V4@<')I8V4@;V8@)FYB<W`[)#`N-3`@<&5R
M('-H87)E+"!A;F0@;VYE('1H<F5E+7EE87(@=V%R<F%N="!T;R!P=7)C:&%S
M92!A;B!A9&1I=&EO;F%L('-H87)E(&]F('1H92!#;VUP86YY)B,X,C$W.W,@
M8V]M;6]N('-T;V-K(&%T(&%N(&5X97)C:7-E('!R:6-E(&]F("9N8G-P.R0P
M+C<U('!E<B!S:&%R92XF(S$V,#M4:&4@=V%R<F%N=',@9&\@;F]T(&AA=F4@
M86YY(')E<V5T('!R;W9I<VEO;G,N#0H@(#PO9F]N=#X-"B`@/"]D:78^/&1I
M=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.R`^/&)R
M("\^#0H@(`T*("`\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T
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M($%C="!O9B`Q.3,S+"!A<R!A;65N9&5D("AT:&4@)B,X,C(P.T%C="8C.#(R
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M8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S+@T*("`\+V9O;G0^
M#0H@(#PO9&EV/CQD:78@<W1Y;&4],T1T97AT+6EN9&5N=#HP<'0[9&ES<&QA
M>3IB;&]C:SL@/CQB<B`O/@T*("`-"B`@/"]D:78^/&1I=B!S='EL93TS1'1E
M>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HS-G!T.V1I<W!L87DZ8FQO8VL[
M;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^169F96-T:79E($IA;G5A<GD@,C`L(#(P
M,3`L('1H92!#;VUP86YY(')A:7-E9"`F;F)S<#LD,2PW.#<L-3`P(&EN(&$@
M9FEF=&@@<')I=F%T92!P;&%C96UE;G0@;V8@=6YI=',@<V]L9"!T;R!C97)T
M86EN(&]F(&ET<R!E>&ES=&EN9R!S=&]C:VAO;&1E<G,@;W(@=&AE:7(@9&5S
M:6=N965S+"!A;&P@;V8@=VAO;2!W97)E(&%C8W)E9&ET960@:6YV97-T;W)S
M+"!C;VYS:7-T:6YG(&]F(&%N(&%G9W)E9V%T92!O9B`S+#4W-2PP,#`@=6YI
M=',@870@82!P=7)C:&%S92!P<FEC92!O9B`F;F)S<#LD,"XU,"!P97(@=6YI
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M86X@97AE<F-I<V4@<')I8V4@;V8@)FYB<W`[)#`N-S4@<&5R('-H87)E+B!4
M:&4@=V%R<F%N=',@9&\@;F]T(&AA=F4@86YY(')E<V5T('!R;W9I<VEO;G,N
M(%1H92!C;&]S:6YG('!R:6-E(&]F('1H92!#;VUP86YY)B,X,C$W.W,@8V]M
M;6]N('-T;V-K(&]N($IA;G5A<GD@,C`L(#(P,3`@=V%S("9N8G-P.R0P+C0Y
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M:6X@4V5C=&EO;B`T*#(I(&]F('1H92!!8W0@86YD(%)E9W5L871I;VX@1"!P
M<F]M=6QG871E9"!T:&5R975N9&5R+B!4:&4@0V]M<&%N>2!A8V-O=6YT960@
M9F]R('1H92!I<W-U86YC92!O9B!T:&4@=6YI=',@87,@82!C87!I=&%L('1R
M86YS86-T:6]N+B!!<R!O9B!$96-E;6)E<B`S,2P@,C`P.2P@)FYB<W`[)#$L
M,C`P+#`P,"!H860@8F5E;B!A9'9A;F-E9"!T;R!T:&4@0V]M<&%N>2!U;F1E
M<B!T:&ES('!R:79A=&4@<&QA8V5M96YT+"!W:71H('1H92!B86QA;F-E(&]F
M("9N8G-P.R0U.#<L-3`P(&)E:6YG(')E8V5I=F5D(&)Y('1H92!#;VUP86YY
M(&EN($IA;G5A<GD@,C`Q,"X-"B`@/"]F;VYT/@T*("`\+V1I=CX\9&EV('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y
M.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*("`\+V9O;G0^
M#0H@(#PO9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI
M;F1E;G0Z,S9P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G
M:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/D5F9F5C=&EV92!&96)R=6%R>2`R,BP@,C`Q,"P@=&AE($-O;7!A;GD@<F%I
M<V5D("9N8G-P.R0U,#`L,#`P('1H<F]U9V@@=&AE('-A;&4@=&\@86X@86-C
M<F5D:71E9"!I;G9E<W1O<B!O9B`Q+#`P,"PP,#`@=6YI=',@870@82!P=7)C
M:&%S92!P<FEC92!O9B`F;F)S<#LD,"XU,"!P97(@=6YI="X@16%C:"!U;FET
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M8VES92!P<FEC92!O9B`F;F)S<#LD,"XW-2!P97(@<VAA<F4N(%1H92!W87)R
M86YT<R!D;R!N;W0@:&%V92!A;GD@<F5S970@<')O=FES:6]N<RX@5&AE(&-L
M;W-I;F<@<')I8V4@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!C;VUM;VX@<W1O
M8VL@;VX@1F5B<G5A<GD@,C(L(#(P,3`@=V%S("9N8G-P.R0P+C4P('!E<B!S
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M=&EO;B`T*#(I(&]F('1H92!!8W0@86YD(%)E9W5L871I;VX@1"!P<F]M=6QG
M871E9"!T:&5R975N9&5R+B!4:&4@0V]M<&%N>2!A8V-O=6YT960@9F]R('1H
M92!I<W-U86YC92!O9B!T:&4@=6YI=',@87,@82!C87!I=&%L('1R86YS86-T
M:6]N+@T*("`\+V9O;G0^#0H@(#PO9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN
M+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]D:78^#0H@
M(#PO9&EV/@T*("`\+V1I=CX-"CPO9&EV/@T*("`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
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M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,D@^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^36]N97D@36%R:V5T($9U;F1S($9A:7(@5F%L=64\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,3QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#87-H
M(&%N9"!#87-H($5Q=6EV86QE;G1S($1I<V-L;W-U<F4@6T%B<W1R86-T73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H
M(&%N9"!#87-H($5Q=6EV86QE;G1S($1I<V-L;W-U<F4@6U1E>'0@0FQO8VM=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/CQD:78^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HP<'0[9&ES
M<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD
M.R<@/C4N($UO;F5Y($UA<FME="!&=6YD<R`F(S@R,3([($9A:7(@5F%L=64@
M#0H\+V9O;G0^#0H\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P
M=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,S9P=#MD:7-P;&%Y.F)L;V-K
M.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/DUO;F5Y(&UA<FME="!F=6YD<R!A="!*
M=6YE(#,P+"`R,#$Q(&%N9"!$96-E;6)E<B`S,2P@,C`Q,"!C;VYS:7-T960@
M;V8@86X@:6YV97-T;65N="!I;B!T:&4@0VQA<W,@02!3:&%R97,@;V8@5V5S
M=&5R;B!!<W-E="!.97<@66]R:R!-=6YI8VEP86P@36]N97D@36%R:V5T($9U
M;F0@=VET:"!A(&UA<FME="!V86QU92!O9B`F;F)S<#LD,2PS,#$L,#@Y(&%N
M9"`F;F)S<#LD,2PV,#$L,#`V+"!R97-P96-T:79E;'DN(%1H92!S=&%T960@
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M.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,S9P=#MD:7-P;&%Y.F)L
M;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@
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M;65N=',L(&ES(&%L<V\@<F5Q=6ER960N(`T*/"]F;VYT/@T*/"]D:78^/&1I
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M(#Y,979E;"`Q.B!Q=6]T960@<')I8V5S("AU;F%D:G5S=&5D*2!I;B!A8W1I
M=F4@;6%R:V5T<R!F;W(@86X@:61E;G1I8V%L(&%S<V5T(&]R(&QI86)I;&ET
M>2!T:&%T('1H92!#;VUP86YY(&AA<R!T:&4@86)I;&ET>2!T;R!A8V-E<W,@
M87,@;V8@=&AE(&UE87-U<F5M96YT(&1A=&4N($9I;F%N8VEA;"!A<W-E=',@
M86YD(&QI86)I;&ET:65S('5T:6QI>FEN9R!,979E;"`Q(&EN<'5T<R!I;F-L
M=61E(&%C=&EV92UE>&-H86YG92!T<F%D960@<V5C=7)I=&EE<R!A;F0@97AC
M:&%N9V4M8F%S960@9&5R:79A=&EV97,N(`T*/"]F;VYT/@T*/"]D:78^/&1I
M=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MM87)G:6XM;&5F=#HP<'0[;6%R
M9VEN+7)I9VAT.C!P=#L@/CQD:78^)B,Q-C`[(`T*/"]D:78^#0H\+V1I=CX\
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M<'0[)R`^3&5V96P@,CH@:6YP=71S(&]T:&5R('1H86X@<75O=&5D('!R:6-E
M<R!I;F-L=61E9"!W:71H:6X@3&5V96P@,2!T:&%T(&%R92!D:7)E8W1L>2!O
M8G-E<G9A8FQE(&9O<B!T:&4@87-S970@;W(@;&EA8FEL:71Y(&]R(&EN9&ER
M96-T;'D@;V)S97)V86)L92!T:')O=6=H(&-O<G)O8F]R871I;VX@=VET:"!O
M8G-E<G9A8FQE(&UA<FME="!D871A+B!&:6YA;F-I86P@87-S971S(&%N9"!L
M:6%B:6QI=&EE<R!U=&EL:7II;F<@3&5V96P@,B!I;G!U=',@:6YC;'5D92!F
M:7AE9"!I;F-O;64@<V5C=7)I=&EE<RP@;F]N+65X8VAA;F=E(&)A<V5D(&1E
M<FEV871I=F5S+"!M=71U86P@9G5N9',L(&%N9"!F86ER+79A;'5E(&AE9&=E
M<RX@#0H\+V9O;G0^#0H\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL
M969T.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T
M.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,S9P=#MD:7-P;&%Y.F)L
M;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@
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M('5T:6QI>FEN9R!,979E;"`S(&EN<'5T<R!I;F-L=61E(&EN9G)E<75E;G1L
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M<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.R`-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[=&5X="UI;F1E;G0Z,S9P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL
M969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES
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M;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO9&EV/CQD:78^
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HS-G!T
M.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP
M<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^36]N97D@;6%R
M:V5T(&9U;F1S(&%R92!T:&4@;VYL>2!F:6YA;F-I86P@:6YS=')U;65N="!T
M:&%T(&ES(&UE87-U<F5D(&%N9"!R96-O<F1E9"!A="!F86ER('9A;'5E(&]N
M('1H92!#;VUP86YY)B,X,C$W.W,@8F%L86YC92!S:&5E="!O;B!A(')E8W5R
M<FEN9R!B87-I<RX@5&AE(&9O;&QO=VEN9R!T86)L92!P<F5S96YT<R!M;VYE
M>2!M87)K970@9G5N9',@870@=&AE:7(@;&5V96P@=VET:&EN('1H92!F86ER
M('9A;'5E(&AI97)A<F-H>2!A="!*=6YE(#,P+"`R,#$Q(&%N9"!$96-E;6)E
M<B8C,38P.S,Q+"`R,#$P+B`-"CPO9F]N=#X-"CPO9&EV/@T*/"]D:78^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HP<'0[9&ES
M<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O
M;G0^#0H\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/'1A
M8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q
M,#`E("!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)R`^/'1R/CQT9"!V86QI9VX],T1B;W1T;VT@('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C)P>#L@/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\
M+W1D/CQT9"!V86QI9VX],T1T;W`@('-T>6QE/3-$=&5X="UA;&EG;CIL969T
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M;"`-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P("!S
M='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O;3HR<'@[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT
M/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P("!S='EL93TS1'1E>'0M86QI9VXZ
M;&5F=#MP861D:6YG+6)O='1O;3HR<'@[(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"`@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L:60[)R`^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ8V5N=&5R.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y
M.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W#0H@<F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z8F]L9#LG
M(#Y,979E;"8C,38P.S$@#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^/'1D('9A
M;&EG;CTS1'1O<"`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB
M;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"`@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO
M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!N;W=R87`],T1N
M;W=R87`@('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@,G!X('-O;&ED
M.R<@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMT97AT+6EN9&5N
M=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I
M9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IB;VQD.R<@/DQE=F5L)B,Q-C`[,B`-"CPO9F]N=#X-"CPO9&EV/@T*
M/"]T9#X\=&0@=F%L:6=N/3-$=&]P("!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#MP861D:6YG+6)O='1O;3HR<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$
M=&]P("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O;3HR
M<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*
M/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R
M(&YO=W)A<#TS1&YO=W)A<"`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C
M:R`R<'@@<V]L:60[)R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R
M.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P
M=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^3&5V96PF(S$V,#LS(`T*/"]F;VYT
M/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C)P>#L@/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/@T*
M/"]T<CX\='(^/'1D('9A;&EG;CTS1&)O='1O;2`@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P("!S='EL93TS
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M(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O
M<"`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"`@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$
M=&]P("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V
M86QI9VX],T1T;W`@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO
M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!N;W=R87`],T1N
M;W=R87`@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D
M('9A;&EG;CTS1'1O<"`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*
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M#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@('-T>6QE/3-$=&5X="UA;&EG;CIL
M969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-
M"CPO9F]N=#X-"CPO=&0^#0H\+W1R/CQT<B!S='EL93TS1&)A8VMG<F]U;F0M
M8V]L;W(Z(V-C9F9C8SL@/CQT9"!V86QI9VX],T1B;W1T;VT@('-T>6QE/3-$
M=&5X="UA;&EG;CIL969T.R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#MT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP
M<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IB;VQD.R<@/DIU;F4@,S`L(#(P,3$Z(`T*/"]F
M;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@('-T>6QE/3-$
M=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"`@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P
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M;W`@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A
M;&EG;CTS1'1O<"`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T
M9#X\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO
M=W)A<"`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@
M=F%L:6=N/3-$=&]P("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\
M+W1D/CQT9"!V86QI9VX],T1T;W`@('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO
M9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!N
M;W=R87`],T1N;W=R87`@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-
M"CPO=&0^/'1D('9A;&EG;CTS1'1O<"`@<W1Y;&4],T1T97AT+6%L:6=N.FQE
M9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*
M/"]F;VYT/@T*/"]T9#X-"CPO='(^/'1R('-T>6QE/3-$8F%C:V=R;W5N9"UC
M;VQO<CHC9F9F9F9F.R`^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4R
M)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X
M.R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HP
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M<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#$E("!S='EL93TS1"=B;W)D97(M8F]T=&]M.F)L86-K(#)P
M>"!S;VQI9#MT97AT+6%L:6=N.FQE9G0[)R`^/&1I=B!S='EL93TS1'1E>'0M
M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G
M:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG(#XF;F)S<#LD(`T*/"]F;VYT/@T*/"]D:78^#0H\
M+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Y)2`@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L:60[=&5X="UA;&EG;CIR:6=H=#LG
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M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MP861D:6YG+6)O='1O;3HR
M<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*
M/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@,G!X('-O;&ED.W1E>'0M86QI
M9VXZ;&5F=#LG(#X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M
M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G
M:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
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M.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/C$L,S`Q+#`X.2`-"CPO9F]N=#X-"CPO
M9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C)P>#L@/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\
M+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT
M+6%L:6=N.G)I9VAT.W!A9&1I;F<M8F]T=&]M.C)P>#L@/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3IB;&%C:R`R<'@@<V]L:60[=&5X="UA;&EG;CIL969T.R<@/CQD:78@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L
M87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)FYB<W`[)"`-"CPO9F]N
M=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@,G!X('-O;&ED.W1E>'0M
M86QI9VXZ<FEG:'0[)R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[
M=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T
M.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)R`^)B,X,C$R.R`-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.W!A9&1I;F<M8F]T=&]M.C)P>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W!A9&1I
M;F<M8F]T=&]M.C)P>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED
M=&@],T0Q)2`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L
M:60[=&5X="UA;&EG;CIL969T.R<@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE
M9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^)FYB<W`[)"`-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ8FQA8VL@,G!X('-O;&ED.W1E>'0M86QI9VXZ<FEG:'0[)R`^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[=&5X="UI;F1E;G0Z,'!T.V1I
M<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,X,C$R.R`-"CPO
M9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C)P
M>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\
M+V9O;G0^#0H\+W1D/@T*/"]T<CX\='(@<W1Y;&4],T1B86-K9W)O=6YD+6-O
M;&]R.B-C8V9F8V,[(#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-3(E
M("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO
M9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL
M93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0Y)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-
M"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E
M>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED
M=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^
M/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI
M9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V
M,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Y
M)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\
M+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y
M;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS
M1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^
M#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Y)2`@<W1Y;&4],T1T
M97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D
M/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L
M:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V
M86QI9VX],T1T;W`@=VED=&@],T0Y)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I
M9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-
M"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S
M='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/@T*/"]T<CX\='(@
M<W1Y;&4],T1B86-K9W)O=6YD+6-O;&]R.B-F9F9F9F8[(#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-3(E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#L@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z
M,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H
M=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z8F]L9#LG(#Y$96-E;6)E<B`S,2P@,C`Q,#H@#0H\+V9O;G0^#0H\+V1I
M=CX-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS
M1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO
M=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#DE("!S='EL93TS1'1E>'0M
M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ
M<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[
M(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@
M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#DE("!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F
M;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*
M/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#DE("!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG
M;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P
M.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E
M("!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO
M9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#DE("!S='EL
M93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-
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M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^36]N97D@;6%R:V5T(&9U
M;F1S(`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@
M=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB
M;W1T;VTZ-'!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS
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M.C$P<'0[)R`^)FYB<W`[)"`-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ8FQA8VL@-'!X(&1O=6)L93MT97AT+6%L:6=N.G)I9VAT.R<@/CQD:78@
M<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M:6YD96YT.C!P=#MD:7-P
M;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/C$L-C`Q+#`P-B`-"CPO
M9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C1P
M>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\
M+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ-'!X.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-
M"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.F)L86-K(#1P>"!D;W5B;&4[=&5X="UA;&EG;CIL969T
M.R<@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z
M,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H
M=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)FYB<W`[
M)"`-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$.24@('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@-'!X(&1O
M=6)L93MT97AT+6%L:6=N.G)I9VAT.R<@/CQD:78@<W1Y;&4],T1T97AT+6%L
M:6=N.G)I9VAT.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I
M;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/C$L-C`Q+#`P-B`-"CPO9F]N=#X-"CPO9&EV/@T*
M/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C1P>#L@/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[<&%D9&EN9RUB;W1T;VTZ-'!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG
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M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)FYB<W`[)"`-"CPO9F]N=#X-"CPO
M9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@-'!X(&1O=6)L93MT97AT+6%L:6=N
M.G)I9VAT.R<@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M
M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G
M:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
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M)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M8F]T
M=&]M.C1P>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V
M,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q
M)2`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`T<'@@9&]U8FQE.W1E
M>'0M86QI9VXZ;&5F=#LG(#X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P
M=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
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M(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S@R,3([(`T*/"]F;VYT
M/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ-'!X.R`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N
M=#X-"CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV/@T*/"]D:78^#0H\
M+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
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M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%,D@^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4F5L871E9"!087)T>2!4
M<F%N<V%C=&EO;G,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M2G5N+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY296QA=&5D(%!A<G1Y(%1R86YS86-T:6]N<R!;06)S
M=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E)E;&%T960@4&%R='D@5')A;G-A8W1I;VYS($1I<V-L;W-U<F4@6U1E
M>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X-"B`@
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M<PT*("`\+V9O;G0^#0H@(#PO9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE
M9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]D:78^/&1I=B!S
M='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HS-G!T.V1I<W!L
M87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^4')I;W(@=&\@2G5N92`S
M,"P@,C`P-BP@=&AE($-O;7!A;GDF(S@R,3<[<R!F;W5N9&EN9R!S=&]C:VAO
M;&1E<B!A;F0@0VAI968@17AE8W5T:79E($]F9FEC97(L($1R+B!*;VAN($MO
M=F%C:"P@:&%D('!E<FEO9&EC86QL>2!M861E(&%D=F%N8V5S('1O('1H92!#
M;VUP86YY('1O(&UE970@;W!E<F%T:6YG(&5X<&5N<V5S+B!3=6-H(&%D=F%N
M8V5S(&%R92!N;VXM:6YT97)E<W0M8F5A<FEN9R!A;F0@87)E(&1U92!O;B!D
M96UA;F0N($%T($IU;F4@,S`L(#(P,3$@86YD($1E8V5M8F5R(#,Q+"`R,#$P
M+"!S=&]C:VAO;&1E<B!A9'9A;F-E<R!T;W1A;&5D("9N8G-P.R0Y,BPW,3<N
M#0H@(#PO9F]N=#X-"B`@/"]D:78^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ
M;&5F=#MT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F
M=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG(#XF(S$V,#L-"B`@/"]F;VYT/@T*("`\+V1I=CX\9&EV('-T
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M("`\+V9O;G0^#0H@(#PO9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE
M9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z
M,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]D:78^/&1I=CX\9&EV
M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C,V<'0[9&ES
M<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@
M/CQD:78@<W1Y;&4],T1T97AT+6EN9&5N=#HS-G!T.V1I<W!L87DZ8FQO8VL[
M;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[=&5X="UA;&EG;CIL
M969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/DEN('9I97<@
M;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!D979E;&]P;65N="!S=&%G92!S=&%T
M=7,@86YD(&QI;6ET960@<F5S;W5R8V5S+"!$<BX@2V]V86-H(&1I9"!N;W0@
M<F5C96EV92!A;GD@8V]M<&5N<V%T:6]N(&9R;VT@=&AE($-O;7!A;GD@9'5R
M:6YG(#(P,3`@;W(@:6X@<')I;W(@>65A<G,N($AO=V5V97(L(&]N($9E8G)U
M87)Y(#$X+"`R,#$Q+"!T:&4@0V]M<&%N>28C.#(Q-SMS($)O87)D(&]F($1I
M<F5C=&]R<R!A<'!R;W9E9"!A('-A;&%R>2!T;R!$<BX@2V]V86-H(&]F("9N
M8G-P.R0U+#`P,"!P97(@;6]N=&@@8F5G:6YN:6YG($UA<F-H(#$U+"`R,#$Q
M+B8C,38P.R8C,38P.TEN(&-O;FYE8W1I;VX@=&AE<F5W:71H+"!$<BX@2V]V
M86-H(')E9'5C960@:&ES(&%C861E;6EC(&-O;6UI=&UE;G0@9G)O;2`X,"4@
M=&\@-C`E(&EN(&]R9&5R('1O(&1E=F]T92!M;W)E('1I;64@=&\@=&AE($-O
M;7!A;GDF(S@R,3<[<R!A8W1I=FET:65S+B!!8V-O<F1I;F=L>2P@9'5R:6YG
M('1H92!T:')E92!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q,2P@=&AE('-I
M>"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q,2P@86YD('1H92!P97)I;V0@
M9G)O;2!!=6=U<W0@.2P@,C`P-2`H:6YC97!T:6]N*2!T:')O=6=H($IU;F4@
M,S`L(#(P,3$@*&-U;75L871I=F4I+"!$<BX@2V]V86-H('=A<R!P86ED(&$@
M<V%L87)Y(&]F("9N8G-P.R0Q-2PP,#`L("9N8G-P.R0Q-RPU,#`@86YD("9N
M8G-P.R0Q-RPU,#`L(')E<W!E8W1I=F5L>2X-"B`@/"]F;VYT/@T*("`\+V1I
M=CX-"B`@#0H@(#PO9&EV/@T*("`\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I
M;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO9&EV/CQD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,S9P=#MD
M:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
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M('!O=&5N=&EA;"!C;VYF;&EC=',N#0H@(#PO9F]N=#X-"B`@/"]D:78^#0H@
M(#PO9&EV/@T*/"]D:78^#0H@(#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?9&%C8CEC,3A?.#$V9%\T-&(Q7SEA-6%?.30T83%A
M-F4Y.#<W#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V1A8V(Y8S$X
M7S@Q-F1?-#1B,5\Y835A7SDT-&$Q839E.3@W-R]7;W)K<VAE971S+U-H965T
M,30N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$4R2#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3
M=&]C:R!/<'1I;VYS(&%N9"!787)R86YT<SQB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($%R<F%N
M9V5M96YT<R!T;R!/8G1A:6X@1V]O9',@86YD(%-E<G9I8V5S(%M!8G-T<F%C
M=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1&ES8VQO<W5R92!O9B!3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG
M96UE;G1S(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0@6U1E>'0@0FQO
M8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X-"B`@/&1I=CX-
M"B`@/&1I=CX-"B`@/&1I=CX-"B`@/&1I=CX-"B`@/&1I=CX-"B`@/&1I=B!S
M='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HP<'0[9&ES<&QA
M>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L^#0H@
M(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD
M.R<^-RX@4W1O8VL@3W!T:6]N<R!A;F0@5V%R<F%N=',-"B`@/"]F;VYT/@T*
M("`\+V1I=CX-"B`@/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT
M+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R
M9VEN+7)I9VAT.C!P=#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL
M:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO9&EV/@T*("`\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C,V<'0[9&ES<&QA>3IB
M;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L^#0H@(#QF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/D]N($IU;F4@,S`L(#(P,#8L
M(&5F9F5C=&EV92!W:71H('1H92!C;&]S:6YG(&]F('1H92!%>&-H86YG92P@
M=&AE($-O;7!A;GD@9W)A;G1E9"!T;R!$<BXF(S$V,#M0:&EL:7`@4&%L;65D
M;RP@86X@;W5T<VED92!D:7)E8W1O<B!O9B!T:&4@0V]M<&%N>2P@<W1O8VL@
M;W!T:6]N<R!T;R!P=7)C:&%S92!A;B!A9V=R96=A=&4@;V8@,C`P+#`P,"!S
M:&%R97,@;V8@8V]M;6]N('-T;V-K+"!E>&5R8VES86)L92!F;W(@82!P97)I
M;V0@;V8@9FEV92!Y96%R<R!A="`F;F)S<#LD,"XS,S,@<&5R('-H87)E+"!W
M:71H(&]N92UT:&ER9"!O9B!T:&4@;W!T:6]N<R`H-C8L-C8V('-H87)E<RD@
M=F5S=&EN9R!I;6UE9&EA=&5L>2!U<&]N(&IO:6YI;F<@=&AE($)O87)D(&%N
M9"!O;F4M=&AI<F0@=F5S=&EN9R!A;FYU86QL>2!O;B!E86-H(&]F($IU;F4@
M,S`L(#(P,#<@86YD(#(P,#@N(%1H92!F86ER('9A;'5E(&]F('1H97-E(&]P
M=&EO;G,L(&%S(&-A;&-U;&%T960@<'5R<W5A;G0@=&\@=&AE($)L86-K+5-C
M:&]L97,@;W!T:6]N+7!R:6-I;F<@;6]D96PL('=A<R!D971E<FUI;F5D('1O
M(&)E("9N8G-P.R0V,BPP,#`@*"9N8G-P.R0P+C,Q('!E<B!S:&%R92DL(&]F
M('=H:6-H("9N8G-P.R0R,"PV-C8@=V%S(&-H87)G960@=&\@;W!E<F%T:6]N
M<R!O;B!*=6YE(#,P+"`R,#`V+"!A;F0@=&AE(')E;6%I;FEN9R`F;F)S<#LD
M-#$L,S,T('=A<R!C:&%R9V5D('1O(&]P97)A=&EO;G,@<F%T86)L>2!F<F]M
M($IU;'D@,2P@,C`P-B!T:')O=6=H($IU;F4@,S`L(#(P,#@N#0H@(#PO9F]N
M=#X-"B`@/"]D:78^#0H@(#QD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T
M.VUA<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+V1I=CX-"B`@/&1I=B!S
M='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HS-G!T.V1I<W!L
M87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[/@T*
M("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SY/;B!*=6YE(#,P+"`R
M,#`V+"!E9F9E8W1I=F4@=VET:"!T:&4@8VQO<VEN9R!O9B!T:&4@17AC:&%N
M9V4L('1H92!#;VUP86YY(&%L<V\@9W)A;G1E9"!T;R!$<BXF(S$V,#M086QM
M961O(&%D9&ET:6]N86P@<W1O8VL@;W!T:6]N<R!T;R!P=7)C:&%S92`Q.3`L
M,#`P('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@97AE<F-I<V%B;&4@9F]R(&$@
M<&5R:6]D(&]F(&9I=F4@>65A<G,@870@)FYB<W`[)#`N,S,S('!E<B!S:&%R
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M9"!T;R!B92`F;F)S<#LD-3@L.3`P("@F;F)S<#LD,"XS,2!P97(@<VAA<F4I
M+"!A;F0@=V%S(&-H87)G960@=&\@;W!E<F%T:6]N<R!A="!*=6YE(#,P+"`R
M,#`V+@T*("`\+V9O;G0^#0H@(#PO9&EV/@T*("`\9&EV('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C,V<'0[9&ES<&QA>3IB;&]C:SMM
M87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L^#0H@(#QD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,S9P=#MD:7-P;&%Y
M.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.SX-"B`@
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^3VX@2G5N92`S,"P@,C`Q
M,2P@1'(N(%!A;&UE9&\@97AE<F-I<V5D(&]P=&EO;G,@=&\@86-Q=6ER92`Q
M,#`L,#`P('-H87)E<R!O9B!C;VUM;VX@<W1O8VLL('=H:6-H('=E<F4@<&%R
M="!O9B!T:&4@86)O=F4@9&5S8W)I8F5D(&=R86YT<RP@;VX@82!C87-H;&5S
M<R!B87-I<RX@4W5C:"!C87-H;&5S<R!E>&5R8VES92!R97-U;'1E9"!I;B!$
M<BX@4&%L;65D;R!R96-E:79I;F<@82!N970@;V8@-C8L,#(P('-H87)E<RX@
M5&AE(')E;6%I;FEN9R!A8F]V92!D97-C<FEB960@;W!T:6]N<R!T;R!A8W%U
M:7)E(#(Y,"PP,#`@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!S=6)S97%U96YT
M;'D@97AP:7)E9"!U;F5X97)C:7-E9"X-"B`@/"]F;VYT/@T*("`\+V1I=CX-
M"B`@/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K
M.SX-"B`@/&)R+SX-"B`@/"]D:78^#0H@(#QD:78@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[=&5X="UI;F1E;G0Z,S9P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I
M;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.SX-"B`@/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<^3VX@2G5N92`S,"P@,C`Q,2P@=&AE($-O;7!A
M;GD@9W)A;G1E9"!T;R!$<BXF(S$V,#M086QM961O('-T;V-K(&]P=&EO;G,@
M=&\@<'5R8VAA<V4@,C`P+#`P,"!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&5X
M97)C:7-A8FQE(&9O<B!A('!E<FEO9"!O9B!F:79E('EE87)S(&9R;VT@9&%T
M92!O9B!G<F%N="!A="`F;F)S<#LD,"XY."!P97(@<VAA<F4L('=H:6-H('=A
M<R!T:&4@9F%I<B!M87)K970@=F%L=64@;V8@=&AE($-O;7!A;GDF(S@R,3<[
M<R!C;VUM;VX@<W1O8VL@;VX@<W5C:"!D871E+B!4:&4@;W!T:6]N<R!V97-T
M(')A=&%B;'D@:6X@97%U86P@<75A<G1E<FQY(&EN<W1A;&QM96YT<R!O9B`R
M-2PP,#`@96%C:"!B96=I;FYI;F<@2G5L>2`Q+"`R,#$Q+B!4:&4@9F%I<B!V
M86QU92!O9B!T:&5S92!O<'1I;VYS+"!A<R!C86QC=6QA=&5D('!U<G-U86YT
M('1O('1H92!";&%C:RU38VAO;&5S(&]P=&EO;BUP<FEC:6YG(&UO9&5L+"!W
M87,@:6YI=&EA;&QY(&1E=&5R;6EN960@=&\@8F4@)FYB<W`[)#$Y-BPP,#`@
M*"9N8G-P.R0P+CDX('!E<B!S:&%R92DN#0H@(#PO9F]N=#X-"B`@/"]D:78^
M#0H@(#QD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z
M,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H
M=#HP<'0[/@T*("`\+V1I=CX-"B`@/&)R+SX-"B`@/&1I=B!S='EL93TS1'1E
M>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HS-G!T.V1I<W!L87DZ8FQO8VL[
M;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)SY/;B!*=6YE(#,P+"`R,#`V+"!E9F9E
M8W1I=F4@=VET:"!T:&4@8VQO<VEN9R!O9B!T:&4@17AC:&%N9V4L('1H92!#
M;VUP86YY(&=R86YT960@=&\@1'(N(%-T969A;B!-861A:F5W:6-Z(&%N9"!$
M<BX@27=A;R!/:FEM82P@='=O(&UE;6)E<G,@;V8@:71S(%-C:65N=&EF:6,@
M061V:7-O<GD@0V]M;6ET=&5E+"!S=&]C:R!O<'1I;VYS('1O('!U<F-H87-E
M(&%N(&%G9W)E9V%T92!O9B`Q,#`L,#`P('-H87)E<R!O9B!C;VUM;VX@<W1O
M8VL@*#4P+#`P,"!E86-H*2!E>&5R8VES86)L92!F;W(@82!P97)I;V0@;V8@
M9FEV92!Y96%R<R!A="`F;F)S<#LD,"XS,S,@<&5R('-H87)E+"!W:71H(&]N
M92UH86QF(&]F('1H92!O<'1I;VYS('9E<W1I;F<@86YN=6%L;'D@;VX@96%C
M:"!O9B!*=6YE(#,P+"`R,#`W(&%N9"!*=6YE(#,P+"`R,#`X+B!4:&4@9F%I
M<B!V86QU92!O9B!T:&5S92!O<'1I;VYS+"!A<R!C86QC=6QA=&5D('!U<G-U
M86YT('1O('1H92!";&%C:RU38VAO;&5S(&]P=&EO;BUP<FEC:6YG(&UO9&5L
M+"!W87,@8VAA<F=E9"!T;R!O<&5R871I;VYS(')A=&%B;'D@9G)O;2!*=6QY
M(#$L(#(P,#8@=&AR;W5G:"!*=6YE(#,P+"`R,#`X+@T*("`\+V9O;G0^#0H@
M(#PO9&EV/@T*("`\9&EV('-T>6QE/3-$=&5X="UI;F1E;G0Z,'!T.V1I<W!L
M87DZ8FQO8VL[/@T*("`\8G(O/@T*("`\+V1I=CX-"B`@/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HS-G!T.V1I<W!L87DZ8FQO
M8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SY);B!!=6=U<W0@,C`P."P@1'(N
M($UA9&%J97=I8WH@<F5S:6=N960@9G)O;2!H:7,@<&]S:71I;VX@86YD('=A
M:79E9"!H:7,@<FEG:'0@=&\@:&ES('9E<W1E9"!S=&]C:R!O<'1I;VX@=&\@
M<'5R8VAA<V4@-3`L,#`P('-H87)E<R!O9B!C;VUM;VX@<W1O8VLN#0H@(#PO
M9F]N=#X-"B`@/"]D:78^#0H@(#QD:78@<W1Y;&4],T1T97AT+6EN9&5N=#HP
M<'0[9&ES<&QA>3IB;&]C:SL^#0H@(#QB<B\^#0H@(#PO9&EV/@T*("`\9&EV
M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C,V<'0[9&ES
M<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L^
M#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/D]N($IU;F4@,S`L
M(#(P,3$L($1R+B!/:FEM82!E>&5R8VES960@;W!T:6]N<R!T;R!A8W%U:7)E
M(#$U+#`Q-2!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&9O<B!A(&-A<V@@<&%Y
M;65N="!O9B`F;F)S<#LD-2PP,#`N($1R+B!/:FEM828C.#(Q-SMS(')E;6%I
M;FEN9R!O<'1I;VYS('1O(&%C<75I<F4@,S0L.3@U('-H87)E<R!O9B!C;VUM
M;VX@<W1O8VL@<W5B<V5Q=65N=&QY(&5X<&ER960@=6YE>&5R8VES960N#0H@
M(#PO9F]N=#X-"B`@/"]D:78^#0H@(#QD:78@<W1Y;&4],T1T97AT+6EN9&5N
M=#HP<'0[9&ES<&QA>3IB;&]C:SL^#0H@(#QB<B\^#0H@(#PO9&EV/@T*("`\
M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C,V<'0[
M9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P
M=#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/D]N($IU;F4@
M,S`L(#(P,3$L('1H92!#;VUP86YY(&=R86YT960@=&\@1'(N)B,Q-C`[3VII
M;6$@<W1O8VL@;W!T:6]N<R!T;R!P=7)C:&%S92`U,"PP,#`@<VAA<F5S(&]F
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M:6YE9"!T;R!B92`F;F)S<#LD-#DL,#`P("@F;F)S<#LD,"XY."!P97(@<VAA
M<F4I+@T*("`\+V9O;G0^#0H@(#PO9&EV/@T*("`-"B`@/"]D:78^#0H@(#QD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I
M<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[
M/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@
M/"]F;VYT/@T*("`\+V1I=CX-"B`@/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ
M;&5F=#MT97AT+6EN9&5N=#HS-G!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE
M9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)SY/;B!*=6YE(#,P+"`R,#`V+"!T:&4@9F%I<B!V86QU
M92!O9B!T:&4@869O<F5M96YT:6]N960@<W1O8VL@;W!T:6]N<R!W87,@:6YI
M=&EA;&QY(&-A;&-U;&%T960@=7-I;F<@=&AE(&9O;&QO=VEN9R!";&%C:RU3
M8VAO;&5S(&EN<'5T('9A<FEA8FQE<SH@<W1O8VL@<')I8V4@+2`F;F)S<#LD
M,"XS,S,[(&5X97)C:7-E('!R:6-E("T@)FYB<W`[)#`N,S,S.R!E>'!E8W1E
M9"!L:69E("T@-2!T;R`W('EE87)S.R!E>'!E8W1E9"!V;VQA=&EL:71Y("T@
M,34P)3L@97AP96-T960@9&EV:61E;F0@>6EE;&0@+2`P)3L@<FES:RUF<F5E
M(&EN=&5R97-T(')A=&4@+2`U)2X@3VX@2G5N92`S,"P@,C`P-RP@=&AE($)L
M86-K+5-C:&]L97,@:6YP=70@=F%R:6%B;&5S('5T:6QI>F5D('1O(&1E=&5R
M;6EN92!T:&4@9F%I<B!V86QU92!O9B!T:&4@869O<F5M96YT:6]N960@<W1O
M8VL@;W!T:6]N<R!W97)E('-T;V-K('!R:6-E("T@)FYB<W`[)#`N,S,S.R!E
M>&5R8VES92!P<FEC92`M("9N8G-P.R0P+C,S,SL@97AP96-T960@;&EF92`M
M(#0@=&\@-B!Y96%R<SL@97AP96-T960@=F]L871I;&ET>2`M(#$U,"4[(&5X
M<&5C=&5D(&1I=FED96YD('EI96QD("T@,"4[(')I<VLM9G)E92!I;G1E<F5S
M="!R871E("T@-"XU)2X@3VX@2G5N92`S,"P@,C`P."P@=&AE(&9A:7(@=F%L
M=64@;V8@=&AE(&%F;W)E;65N=&EO;F5D('-T;V-K(&]P=&EO;G,@=V%S(&-A
M;&-U;&%T960@=7-I;F<@=&AE(&9O;&QO=VEN9R!";&%C:RU38VAO;&5S(&EN
M<'5T('9A<FEA8FQE<SH@<W1O8VL@<')I8V4@+2`F;F)S<#LD,"XS,#L@97AE
M<F-I<V4@<')I8V4@+2`F;F)S<#LD,"XS,S,[(&5X<&5C=&5D(&QI9F4@+2`S
M('1O(#4@>65A<G,[(&5X<&5C=&5D('9O;&%T:6QI='D@+2`Q-30N-24[(&5X
M<&5C=&5D(&1I=FED96YD('EI96QD("T@,"4[(')I<VLM9G)E92!I;G1E<F5S
M="!R871E("T@,RXR."4N($]N($IU;F4@,S`L(#(P,3$L('1H92!F86ER('9A
M;'5E(&]F('1H92!A9F]R96UE;G1I;VYE9"!S=&]C:R!O<'1I;VYS('=A<R!C
M86QC=6QA=&5D('5S:6YG('1H92!F;VQL;W=I;F<@0FQA8VLM4V-H;VQE<R!I
M;G!U="!V87)I86)L97,Z('-T;V-K('!R:6-E("T@)FYB<W`[)#`N.3@[(&5X
M97)C:7-E('!R:6-E("T@)FYB<W`[)#`N.3@[(&5X<&5C=&5D(&QI9F4@+2`U
M('EE87)S.R!E>'!E8W1E9"!V;VQA=&EL:71Y("T@,S`X+C@E.R!E>'!E8W1E
M9"!D:79I9&5N9"!Y:65L9"`M(#`E.R!R:7-K+69R964@:6YT97)E<W0@<F%T
M92`M(#$N-3@E+@T*("`\+V9O;G0^#0H@(#PO9&EV/@T*("`\9&EV('-T>6QE
M/3-$=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[/@T*("`\8G(O/@T*
M("`\+V1I=CX-"B`@/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT
M+6EN9&5N=#HS-G!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA
M<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)SY/;B!&96)R=6%R>2`U+"`R,#`W+"!T:&4@0V]M<&%N>2!E;G1E<F5D
M(&EN=&\@86X@86=R965M96YT("AT:&4@)B,X,C(P.T-H96TM36%S=&5R($%G
M<F5E;65N="8C.#(R,3LI('=I=&@@0VAE;2U-87-T97(@26YT97)N871I;VYA
M;"P@26YC+B`H)B,X,C(P.T-H96TM36%S=&5R)B,X,C(Q.RDL(&$@8V]M<&%N
M>2!C;RUO=VYE9"!B>2!&<F%N8VES($IO:&YS;VXL(&$@8V]N<W5L=&%N="!T
M;R!T:&4@0V]M<&%N>2P@<'5R<W5A;G0@=&\@=VAI8V@@=&AE($-O;7!A;GD@
M9W)A;G1E9"!A(&9I=F4M>65A<B!O<'1I;VX@=&\@<'5R8VAA<V4@,3`P+#`P
M,"!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!C;VUM;VX@<W1O8VL@
M870@86X@97AE<F-I<V4@<')I8V4@;V8@)FYB<W`[)#`N,S,S('!E<B!S:&%R
M92X@5&AE(&9A:7(@=F%L=64@;V8@=&AI<R!O<'1I;VXL(&%S(&-A;&-U;&%T
M960@<'5R<W5A;G0@=&\@=&AE($)L86-K+5-C:&]L97,@;W!T:6]N+7!R:6-I
M;F<@;6]D96PL('=A<R!D971E<FUI;F5D('1O(&)E("9N8G-P.R0S,2PP,#`@
M*"9N8G-P.R0P+C,Q('!E<B!S:&%R92D@=7-I;F<@=&AE(&9O;&QO=VEN9R!"
M;&%C:RU38VAO;&5S(&EN<'5T('9A<FEA8FQE<SH@<W1O8VL@<')I8V4@;VX@
M9&%T92!O9B!G<F%N="`M("9N8G-P.R0P+C,S,SL@97AE<F-I<V4@<')I8V4@
M+2`F;F)S<#LD,"XS,S,[(&5X<&5C=&5D(&QI9F4@+2`U('EE87)S.R!E>'!E
M8W1E9"!V;VQA=&EL:71Y("T@,34P)3L@97AP96-T960@9&EV:61E;F0@>6EE
M;&0@+2`P)3L@<FES:RUF<F5E(&EN=&5R97-T(')A=&4@+2`T+C4E+B!4:&4@
M)FYB<W`[)#,Q+#`P,"!F86ER('9A;'5E('=A<R!C:&%R9V5D('1O(&]P97)A
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M1F5B<G5A<GD@-2P@,C`P.2P@<')O=FED960@=&AA="!T:&4@0VAE;2U-87-T
M97(@06=R965M96YT(&AA9"!N;W0@8F5E;B!T97)M:6YA=&5D('!R:6]R('1O
M('-U8V@@9&%T92P@=&AE($-O;7!A;GD@86=R965D('1O(&=R86YT($-H96TM
M36%S=&5R(&$@<V5C;VYD(&9I=F4M>65A<B!O<'1I;VX@=&\@<'5R8VAA<V4@
M86X@861D:71I;VYA;"`Q,#`L,#`P('-H87)E<R!O9B!T:&4@0V]M<&%N>28C
M.#(Q-SMS(&-O;6UO;B!S=&]C:R!A="!A;B!E>&5R8VES92!P<FEC92!O9B`F
M;F)S<#LD,"XS,S,@<&5R('-H87)E+B!!<R!O9B!397!T96UB97(@,S`L(#(P
M,#@L('1H92!#;VUP86YY(&1E=&5R;6EN960@=&AA="!I="!W87,@;&EK96QY
M('1H870@=&AI<R!O<'1I;VX@=V]U;&0@8F4@:7-S=65D+B!!8V-O<F1I;F=L
M>2P@=&AE(&9A:7(@=F%L=64@;V8@=&AE(&]P=&EO;B!H87,@8F5E;B!R969L
M96-T960@87,@82!C:&%R9V4@=&\@;W!E<F%T:6]N<R!F;W(@=&AE('!E<FEO
M9"!F<F]M($]C=&]B97(@,2P@,C`P."!T:')O=6=H($9E8G)U87)Y(#4L(#(P
M,#DN(%1H92!#;VUP86YY(&=R86YT960@=&AE('-E8V]N9"!F:79E+7EE87(@
M;W!T:6]N(&]N($9E8G)U87)Y(#4L(#(P,#DN)B,Q-C`[#0H@(#PO9F]N=#X-
M"B`@/"]D:78^#0H@(#QD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X
M="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA
M<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+V1I=CX-"B`@/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HS-G!T.V1I<W!L87DZ
M8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[/@T*("`\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SY/;B!397!T96UB97(@,S`L
M(#(P,#@L('1H92!F86ER('9A;'5E(&]F('1H92!A9F]R96UE;G1I;VYE9"!S
M=&]C:R!O<'1I;VX@=V%S(&EN:71I86QL>2!C86QC=6QA=&5D('5S:6YG('1H
M92!F;VQL;W=I;F<@0FQA8VLM4V-H;VQE<R!I;G!U="!V87)I86)L97,Z('-T
M;V-K('!R:6-E("T@)FYB<W`[)#`N-3`[(&5X97)C:7-E('!R:6-E("T@)FYB
M<W`[)#`N,S,S.R!E>'!E8W1E9"!L:69E("8C.#(Q,3L@-2XS-2!Y96%R<SL@
M97AP96-T960@=F]L871I;&ET>2`F(S@R,3$[(#(W-2XW)3L@97AP96-T960@
M9&EV:61E;F0@>6EE;&0@+2`P)3L@<FES:RUF<F5E(&EN=&5R97-T(')A=&4@
M)B,X,C$Q.R`R+C0X)2X@3VX@1F5B<G5A<GD@-2P@,C`P.2P@=&AE(&9A:7(@
M=F%L=64@;V8@=&AE(&%F;W)E;65N=&EO;F5D('-T;V-K(&]P=&EO;B!W87,@
M8V%L8W5L871E9"!F;W(@=&AE('-T;V-K(&]P=&EO;B!R979A;'5A=&EO;B!P
M=7)P;W-E<R!U<VEN9R!T:&4@9F]L;&]W:6YG($)L86-K+5-C:&]L97,@:6YP
M=70@=F%R:6%B;&5S.B!S=&]C:R!P<FEC92`M("9N8G-P.R0P+C8P.R!E>&5R
M8VES92!P<FEC92`M("9N8G-P.R0P+C,S,SL@97AP96-T960@;&EF92`F(S@R
M,3$[(#4@>65A<G,[(&5X<&5C=&5D('9O;&%T:6QI='D@)B,X,C$Q.R`T,30N
M,24[(&5X<&5C=&5D(&1I=FED96YD('EI96QD("T@,"4[(')I<VLM9G)E92!I
M;G1E<F5S="!R871E("8C.#(Q,3L@,2XX.24N#0H@(#PO9F]N=#X-"B`@/"]D
M:78^#0H@(#QD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E
M;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR
M:6=H=#HP<'0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF
M(S$V,#L-"B`@/"]F;VYT/@T*("`\+V1I=CX-"B`@/&1I=B!S='EL93TS1'1E
M>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HS-G!T.V1I<W!L87DZ8FQO8VL[
M;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)SY/;B!*86YU87)Y(#(Y+"`R,#`X+"!T
M:&4@0VAE;2U-87-T97(@06=R965M96YT('=A<R!A;65N9&5D('1O(&5X=&5N
M9"!I=',@=&5R;2!T;R!&96)R=6%R>2`Q-2P@,C`Q-"X@4'5R<W5A;G0@=&\@
M=&AE(&%M96YD;65N="P@=&AE($-O;7!A;GD@:7-S=65D(#$P,"PP,#`@<VAA
M<F5S(&]F(&ET<R!R97-T<FEC=&5D(&-O;6UO;B!S=&]C:RP@=F%L=65D(&%T
M("9N8G-P.R0W-2PP,#`L(&%N9"!G<F%N=&5D(&%N(&]P=&EO;B!T;R!P=7)C
M:&%S92`R,#`L,#`P('-H87)E<R!O9B!C;VUM;VX@<W1O8VLN(%1H92!O<'1I
M;VX@:7,@97AE<F-I<V%B;&4@9F]R(&$@<&5R:6]D(&]F('1W;R!Y96%R<R!F
M<F]M('1H92!V97-T:6YG(&1A=&4@870@)FYB<W`[)#$N-C4@<&5R('-H87)E
M+"!W:71H(&]N92UH86QF("@Q,#`L,#`P('-H87)E<RD@=F5S=&EN9R!O;B!!
M=6=U<W0@,2P@,C`P.2P@86YD(&]N92UH86QF("@Q,#`L,#`P('-H87)E<RD@
M=F5S=&EN9R!O;B!&96)R=6%R>2`Q+"`R,#$Q+B!4:&4@9F%I<B!V86QU92!O
M9B!T:&ES(&]P=&EO;BP@87,@8V%L8W5L871E9"!P=7)S=6%N="!T;R!T:&4@
M0FQA8VLM4V-H;VQE<R!O<'1I;VXM<')I8VEN9R!M;V1E;"P@=V%S(&EN:71I
M86QL>2!D971E<FUI;F5D('1O(&)E("9N8G-P.R0Y-BPP,#`@*"9N8G-P.R0P
M+C0X('!E<B!S:&%R92D@=7-I;F<@=&AE(&9O;&QO=VEN9R!";&%C:RU38VAO
M;&5S(&EN<'5T('9A<FEA8FQE<SH@<W1O8VL@<')I8V4@;VX@9&%T92!O9B!G
M<F%N="`M("9N8G-P.R0P+C<U.R!E>&5R8VES92!P<FEC92`M("9N8G-P.R0Q
M+C8U.R!E>'!E8W1E9"!L:69E("T@-2!Y96%R<SL@97AP96-T960@=F]L871I
M;&ET>2`M(#$R,"XQ)3L@97AP96-T960@9&EV:61E;F0@>6EE;&0@+2`P)3L@
M<FES:RUF<F5E(&EN=&5R97-T(')A=&4@+2`S+C`Y)2X-"B`@/"]F;VYT/@T*
M("`\+V1I=CX-"B`@/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MM87)G
M:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L^#0H@(#QD:78^#0H@(#PO
M9&EV/@T*("`\+V1I=CX-"B`@/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P
M=#MD:7-P;&%Y.F)L;V-K.SX-"B`@/&)R+SX-"B`@/"]D:78^#0H@(#QD:78@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,S9P=#MD:7-P
M;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.SX-
M"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^5&AE(&9A:7(@=F%L
M=64@;V8@=&AE(')E<W1R:6-T960@8V]M;6]N('-T;V-K(&ES<W5E9"!W87,@
M8VAA<F=E9"!T;R!O<&5R871I;VYS(&%S(')E<V5A<F-H(&%N9"!D979E;&]P
M;65N="!C;W-T<R!O;B!*86YU87)Y(#(Y+"`R,#`X+B!/;B!&96)R=6%R>2`Q
M+"`R,#$Q+"!T:&4@9F%I<B!V86QU92!O9B!T:&4@869O<F5M96YT:6]N960@
M<W1O8VL@;W!T:6]N<R!W87,@9&5T97)M:6YE9"!T;R!B92`F;F)S<#LD-C8L
M,#`P("@F;F)S<#LD,"XS,R!P97(@<VAA<F4I(&-A;&-U;&%T960@=7-I;F<@
M=&AE(&9O;&QO=VEN9R!";&%C:RU38VAO;&5S(&EN<'5T('9A<FEA8FQE<SH@
M<W1O8VL@<')I8V4@+2`F;F)S<#LD,"XS-3L@97AE<F-I<V4@<')I8V4@+2`F
M;F)S<#LD,2XV-3L@97AP96-T960@;&EF92`M(#(@>65A<G,[(&5X<&5C=&5D
M('9O;&%T:6QI='D@)B,X,C$Q.R`S,C4N-B4[(&5X<&5C=&5D(&1I=FED96YD
M('EI96QD("T@,"4[(')I<VLM9G)E92!I;G1E<F5S="!R871E("TR+C`W)2P@
M=VAI8V@@<F5S=6QT960@:6X@82!C:&%R9V4@=&\@;W!E<F%T:6]N<R!O9B`F
M;F)S<#LD.3@R(&1U<FEN9R!T:&4@<VEX(&UO;G1H<R!E;F1E9"!*=6YE(#,P
M+"`R,#$Q+B!/;B!*=6YE(#,P+"`R,#$P+"!T:&4@9F%I<B!V86QU92!O9B!T
M:&4@869O<F5M96YT:6]N960@<W1O8VL@;W!T:6]N<R!W87,@9&5T97)M:6YE
M9"!T;R!B92`F;F)S<#LD-C(L,#`P("@F;F)S<#LD,"XS,2!P97(@<VAA<F4I
M(&-A;&-U;&%T960@=7-I;F<@=&AE(&9O;&QO=VEN9R!";&%C:RU38VAO;&5S
M(&EN<'5T('9A<FEA8FQE<SH@<W1O8VL@<')I8V4@+2`F;F)S<#LD,"XS-3L@
M97AE<F-I<V4@<')I8V4@+2`F;F)S<#LD,2XV-3L@97AP96-T960@;&EF92`M
M(#(N-3D@>65A<G,[(&5X<&5C=&5D('9O;&%T:6QI='D@)B,X,C$Q.R`R,S,N
M,B4[(&5X<&5C=&5D(&1I=FED96YD('EI96QD("T@,"4[(')I<VLM9G)E92!I
M;G1E<F5S="!R871E("T@,"XY,R4L('=H:6-H(')E<W5L=&5D(&EN(&$@8W)E
M9&ET('1O(&]P97)A=&EO;G,@;V8@)FYB<W`[)#$L-#<R(&1U<FEN9R!T:&4@
M=&AR964@;6]N=&AS(&5N9&5D($IU;F4@,S`L(#(P,3`@86YD(&$@8VAA<F=E
M('1O(&]P97)A=&EO;G,@;V8@)FYB<W`[)#4L-S@V(&1U<FEN9R!T:&4@<VEX
M(&UO;G1H<R!E;F1E9"!*=6YE(#,P+"`R,#$P+@T*("`\+V9O;G0^#0H@(#PO
M9&EV/@T*("`\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD
M96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM
M<FEG:'0Z,'!T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^
M)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]D:78^#0H@(#QD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,S9P=#MD:7-P;&%Y.F)L;V-K
M.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.SX-"B`@/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^3VX@2G5N92`R,"P@,C`P-RP@=&AE
M($)O87)D(&]F($1I<F5C=&]R<R!O9B!T:&4@0V]M<&%N>2!A<'!R;W9E9"!T
M:&4@,C`P-R!3=&]C:R!#;VUP96YS871I;VX@4&QA;B`H=&AE("8C.#(R,#LR
M,#`W(%!L86XF(S@R,C$[*2P@=VAI8V@@<')O=FED97,@9F]R('1H92!G<F%N
M=&EN9R!O9B!A=V%R9',L(&-O;G-I<W1I;F<@;V8@8V]M;6]N('-T;V-K(&]P
M=&EO;G,L('-T;V-K(&%P<')E8VEA=&EO;B!R:6=H=',L('!E<F9O<FUA;F-E
M('-H87)E<RP@;W(@<F5S=')I8W1E9"!S:&%R97,@;V8@8V]M;6]N('-T;V-K
M+"!T;R!E;7!L;WEE97,@86YD(&EN9&5P96YD96YT(&-O;G1R86-T;W)S+"!F
M;W(@=7`@=&\@,BPU,#`L,#`P('-H87)E<R!O9B!T:&4@0V]M<&%N>28C.#(Q
M-SMS(&-O;6UO;B!S=&]C:RP@=6YD97(@=&5R;7,@86YD(&-O;F1I=&EO;BP@
M87,@9&5T97)M:6YE9"!B>2!T:&4@0V]M<&%N>28C.#(Q-SMS($)O87)D(&]F
M($1I<F5C=&]R<RX-"B`@/"]F;VYT/@T*("`\+V1I=CX-"B`@/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB
M;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L^#0H@(#QF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P.PT*("`\+V9O;G0^
M#0H@(#PO9&EV/@T*("`\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E
M>'0M:6YD96YT.C,V<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[
M;6%R9VEN+7)I9VAT.C!P=#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG/D]N(%-E<'1E;6)E<B`Q,BP@,C`P-RP@:6X@8V]N:G5N8W1I;VX@
M=VET:"!H:7,@87!P;VEN=&UE;G0@87,@82!D:7)E8W1O<B!O9B!T:&4@0V]M
M<&%N>2P@=&AE($-O;7!A;GD@9W)A;G1E9"!T;R!$<BX@4W1E<&AE;B!#87)T
M97(@<W1O8VL@;W!T:6]N<R!T;R!P=7)C:&%S92!A;B!A9V=R96=A=&4@;V8@
M,C`P+#`P,"!S:&%R97,@;V8@8V]M;6]N('-T;V-K('5N9&5R('1H92`R,#`W
M(%!L86XL(&5X97)C:7-A8FQE(&9O<B!A('!E<FEO9"!O9B!F:79E('EE87)S
M(&9R;VT@=F5S=&EN9R!D871E(&%T("9N8G-P.R0P+C,S,R!P97(@<VAA<F4L
M('=I=&@@;VYE+6AA;&8@*#$P,"PP,#`@<VAA<F5S*2!V97-T:6YG(&%N;G5A
M;&QY(&]N(&5A8V@@;V8@4V5P=&5M8F5R(#$R+"`R,#`X(&%N9"`R,#`Y+B!4
M:&4@9F%I<B!V86QU92!O9B!T:&5S92!O<'1I;VYS+"!A<R!C86QC=6QA=&5D
M('!U<G-U86YT('1O('1H92!";&%C:RU38VAO;&5S(&]P=&EO;BUP<FEC:6YG
M(&UO9&5L+"!W87,@9&5T97)M:6YE9"!T;R!B92`F;F)S<#LD,C`T+#`P,"`H
M)FYB<W`[)#$N,#(@<&5R('-H87)E*2P@86YD('=A<R!C:&%R9V5D('1O(&]P
M97)A=&EO;G,@<F%T86)L>2!F<F]M(%-E<'1E;6)E<B`Q,BP@,C`P-R!T:')O
M=6=H(%-E<'1E;6)E<B`Q,BP@,C`P.2X@169F96-T:79E($%P<FEL(#(P+"`R
M,#$P+"!$<BX@0V%R=&5R(')E<VEG;F5D(&%S(&$@9&ER96-T;W(@9F]R('!E
M<G-O;F%L(')E87-O;G,N($-O;G-E<75E;G1L>2P@<'5R<W5A;G0@=&\@=&AE
M('-T;V-K(&]P=&EO;B!A9W)E96UE;G0L($1R+B!#87)T97(@:&%D('1W96QV
M92!M;VYT:',@9G)O;2!!<')I;"`R,"P@,C`Q,"!T;R!E>&5R8VES92!H:7,@
M<W1O8VL@;W!T:6]N<R!T;R!A8W%U:7)E(#(P,"PP,#`@<VAA<F5S(&]F('1H
M92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K+B!/;B!!<')I;"`R,"P@
M,C`Q,2!$<BX@0V%R=&5R)B,X,C$W.W,@<W1O8VL@;W!T:6]N<R!E>'!I<F5D
M('5N97AE<F-I<V5D+@T*("`\+V9O;G0^#0H@(#PO9&EV/@T*("`\9&EV('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y
M.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.SX-"B`@
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N
M=#X-"B`@/"]D:78^#0H@(#QD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M=&5X="UI;F1E;G0Z,S9P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P
M=#MM87)G:6XM<FEG:'0Z,'!T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<^3VX@4V5P=&5M8F5R(#$R+"`R,#`W+"!T:&4@0V]M<&%N>2!E
M;G1E<F5D(&EN=&\@82!C;VYS=6QT:6YG(&%G<F5E;65N="!W:71H($=I;"!3
M8VAW87)T>F)E<F<L('!U<G-U86YT('1O('=H:6-H('1H92!#;VUP86YY(&=R
M86YT960@=&\@37(N(%-C:'=A<G1Z8F5R9R!S=&]C:R!O<'1I;VYS('1O('!U
M<F-H87-E(&%N(&%G9W)E9V%T92!O9B`Q+#`P,"PP,#`@<VAA<F5S(&]F(&-O
M;6UO;B!S=&]C:RP@97AE<F-I<V%B;&4@9F]R(&$@<&5R:6]D(&]F(&9O=7(@
M>65A<G,@9G)O;2!T:&4@=F5S=&EN9R!D871E(&%T("9N8G-P.R0Q+C`P('!E
M<B!S:&%R92P@=VET:"!O;F4M:&%L9B!O9B!T:&4@;W!T:6]N<R`H-3`P+#`P
M,"!S:&%R97,I('9E<W1I;F<@:6UM961I871E;'D@86YD(&]N92UH86QF("@U
M,#`L,#`P('-H87)E<RD@=F5S=&EN9R!O;B!397!T96UB97(@,3(L(#(P,#@N
M(%1H92!F86ER('9A;'5E(&]F('1H97-E(&]P=&EO;G,L(&%S(&-A;&-U;&%T
M960@<'5R<W5A;G0@=&\@=&AE($)L86-K+5-C:&]L97,@;W!T:6]N+7!R:6-I
M;F<@;6]D96PL('=A<R!I;FET:6%L;'D@9&5T97)M:6YE9"!T;R!B92`F;F)S
M<#LD.30U+#`P,"`H)FYB<W`[)#`N.30U('!E<B!S:&%R92DL(&]F('=H:6-H
M("9N8G-P.R0T-C4L,#`P('=A<R!A='1R:6)U=&5D('1O('1H92!F=6QL>2UV
M97-T960@;W!T:6]N<R!A;F0@=V%S('1H=7,@8VAA<F=E9"!T;R!O<&5R871I
M;VYS(&]N(%-E<'1E;6)E<B`Q,BP@,C`P-RX@5&AE(')E;6%I;FEN9R!U;G9E
M<W1E9"!P;W)T:6]N(&]F('1H92!F86ER('9A;'5E(&]F('1H92!O<'1I;VYS
M('=A<R!C:&%R9V5D('1O(&]P97)A=&EO;G,@<F%T86)L>2!F<F]M(%-E<'1E
M;6)E<B`Q,BP@,C`P-R!T:')O=6=H(%-E<'1E;6)E<B`Q,BP@,C`P."X-"B`@
M/"]F;VYT/@T*("`\+V1I=CX-"B`@/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ
M;&5F=#MT97AT+6EN9&5N=#HS-G!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE
M9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+V1I=CX-"B`@
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HS-G!T
M.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP
M<'0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SY/;B!/8W1O
M8F5R(#$U+"`R,#`Y+"!T:&4@0V]M<&%N>2!A;65N9&5D('1H92!A8F]V92!D
M97-C<FEB960@8V]N<W5L=&EN9R!A9W)E96UE;G0@=VET:"!':6P@4V-H=V%R
M='IB97)G('1O(&5X=&5N9"!I="!F;W(@86X@861D:71I;VYA;"!F;W5R('EE
M87)S(&%N9"!G<F%N=&5D('1O($UR+B!38VAW87)T>F)E<F<@<W1O8VL@;W!T
M:6]N<R!T;R!P=7)C:&%S92!A;B!A9&1I=&EO;F%L(&%G9W)E9V%T92!O9B`Q
M+#`P,"PP,#`@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:RP@97AE<F-I<V%B;&4@
M9F]R(&$@<&5R:6]D(&]F(&9O=7(@>65A<G,@9G)O;2!T:&4@=F5S=&EN9R!D
M871E(&%T("9N8G-P.R0Q+C`P('!E<B!S:&%R92P@=VET:"!O;F4M:&%L9B!O
M9B!T:&4@;W!T:6]N<R`H-3`P+#`P,"!S:&%R97,I('9E<W1I;F<@:6UM961I
M871E;'D@86YD(&]N92UH86QF("@U,#`L,#`P('-H87)E<RD@=F5S=&EN9R!O
M;B!/8W1O8F5R(#$U+"`R,#$P+B!4:&4@9F%I<B!V86QU92!O9B!T:&5S92!O
M<'1I;VYS+"!A<R!C86QC=6QA=&5D('!U<G-U86YT('1O('1H92!";&%C:RU3
M8VAO;&5S(&]P=&EO;BUP<FEC:6YG(&UO9&5L+"!W87,@9&5T97)M:6YE9"!T
M;R!B92`F;F)S<#LD-S4P+#`P,"`H)FYB<W`[)#`N-S4@<&5R('-H87)E*2!O
M;B!/8W1O8F5R(#$U+"`R,#`Y+"!O9B!W:&EC:"`F;F)S<#LD,S<U+#`P,"!W
M87,@871T<FEB=71E9"!T;R!T:&4@9G5L;'DM=F5S=&5D(&]P=&EO;G,@86YD
M('=A<R!T:'5S(&-H87)G960@=&\@;W!E<F%T:6]N<R!O;B!/8W1O8F5R(#$U
M+"`R,#`Y+B!4:&4@<F5M86EN:6YG('5N=F5S=&5D('!O<G1I;VX@;V8@=&AE
M(&9A:7(@=F%L=64@;V8@=&AE(&]P=&EO;G,@=V%S(&-H87)G960@=&\@;W!E
M<F%T:6]N<R!R871A8FQY(&9R;VT@3V-T;V)E<B`Q-2P@,C`P.2!T:')O=6=H
M($]C=&]B97(@,34L(#(P,3`N($]N($IU;F4@,S`L(#(P,3`L('1H92!F86ER
M('9A;'5E(&]F('1H92!A9F]R96UE;G1I;VYE9"!S=&]C:R!O<'1I;VYS('=A
M<R!D971E<FUI;F5D('1O(&)E("9N8G-P.R0Q-S`L,#`P("@F;F)S<#LD,"XS
M-"!P97(@<VAA<F4I(&-A;&-U;&%T960@=7-I;F<@=&AE(&9O;&QO=VEN9R!"
M;&%C:RU38VAO;&5S(&EN<'5T('9A<FEA8FQE<SH@<W1O8VL@<')I8V4@+2`F
M;F)S<#LD,"XS-3L@97AE<F-I<V4@<')I8V4@+2`F;F)S<#LD,2XP,#L@97AP
M96-T960@;&EF92`M(#0N,CD@>65A<G,[(&5X<&5C=&5D('9O;&%T:6QI='D@
M)B,X,C$Q.R`R,S,N,B4[(&5X<&5C=&5D(&1I=FED96YD('EI96QD("T@,"4[
M(')I<VLM9G)E92!I;G1E<F5S="!R871E("T@,"XY,R4L('=H:6-H(')E<W5L
M=&5D(&EN(&$@8VAA<F=E('1O(&]P97)A=&EO;G,@;V8@)FYB<W`[)#@L,#8X
M(&1U<FEN9R!T:&4@=&AR964@;6]N=&AS(&5N9&5D($IU;F4@,S`L(#(P,3`@
M86YD(&$@8VAA<F=E('1O(&]P97)A=&EO;G,@;V8@)FYB<W`[)#8X+#0W.2!D
M=7)I;F<@=&AE('-I>"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q,"X-"B`@
M/"]F;VYT/@T*("`\+V1I=CX-"B`@/&1I=B!S='EL93TS1'1E>'0M:6YD96YT
M.C!P=#MD:7-P;&%Y.F)L;V-K.SX-"B`@/&)R+SX-"B`@/"]D:78^#0H@(#QD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,S9P=#MD
M:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T
M.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^3VX@4V5P=&5M
M8F5R(#$R+"`R,#`W+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!C;VYS
M=6QT:6YG(&%G<F5E;65N="!W:71H($9R86YC:7,@2F]H;G-O;BP@82!C;RUO
M=VYE<B!O9B!#:&5M+4UA<W1E<B!);G1E<FYA=&EO;F%L+"!);F,N+"!A;F0@
M9W)A;G1E9"!T;R!0<F]F97-S;W(@2F]H;G-O;B!S=&]C:R!O<'1I;VYS('1O
M('!U<F-H87-E(&%N(&%G9W)E9V%T92!O9B`S,#`L,#`P('-H87)E<R!O9B!C
M;VUM;VX@<W1O8VLL(&5X97)C:7-A8FQE(&9O<B!A('!E<FEO9"!O9B!F;W5R
M('EE87)S(&9R;VT@=&AE('9E<W1I;F<@9&%T92!A="`F;F)S<#LD,"XS,S,@
M<&5R('-H87)E+"!W:71H(&]N92UT:&ER9"`H,3`P+#`P,"!S:&%R97,I('9E
M<W1I;F<@86YN=6%L;'D@;VX@96%C:"!O9B!397!T96UB97(@,3(L(#(P,#@L
M(#(P,#D@86YD(#(P,3`N(%1H92!F86ER('9A;'5E(&]F('1H97-E(&]P=&EO
M;G,L(&%S(&-A;&-U;&%T960@<'5R<W5A;G0@=&\@=&AE($)L86-K+5-C:&]L
M97,@;W!T:6]N+7!R:6-I;F<@;6]D96PL('=A<R!I;FET:6%L;'D@9&5T97)M
M:6YE9"!T;R!B92`F;F)S<#LD,S`P+#`P,"`H)FYB<W`[)#$N,#`@<&5R('-H
M87)E*2X@5&AE('5N=F5S=&5D('!O<G1I;VX@;V8@=&AE(&9A:7(@=F%L=64@
M;V8@=&AE(&]P=&EO;G,@=V%S(&-H87)G960@=&\@;W!E<F%T:6]N<R!R871A
M8FQY(&9R;VT@4V5P=&5M8F5R(#$R+"`R,#`W('1H<F]U9V@@4V5P=&5M8F5R
M(#$R+"`R,#$P+B!/;B!*=6YE(#,P+"`R,#$P+"!T:&4@9F%I<B!V86QU92!O
M9B!T:&5S92!O<'1I;VYS+"!A<R!C86QC=6QA=&5D('!U<G-U86YT('1O('1H
M92!";&%C:RU38VAO;&5S(&]P=&EO;BUP<FEC:6YG(&UO9&5L+"!W87,@9&5T
M97)M:6YE9"!T;R!B92`F;F)S<#LD,3`R+#`P,"`H)FYB<W`[)#`N,S0@<&5R
M('-H87)E*2!W:&EC:"!R97-U;'1E9"!A(&-R961I="!T;R!O<&5R871I;VYS
M(&]F("9N8G-P.R0R.3`@9'5R:6YG('1H92!T:')E92!M;VYT:',@96YD960@
M2G5N92`S,"P@,C`Q,"!A;F0@82!C:&%R9V4@=&\@;W!E<F%T:6]N<R!O9B`F
M;F)S<#LD,3(L,S0P(&1U<FEN9R!T:&4@<VEX(&UO;G1H<R!E;F1E9"!*=6YE
M(#,P+"`R,#$P+@T*("`\+V9O;G0^#0H@(#PO9&EV/@T*("`\9&EV('-T>6QE
M/3-$=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[/@T*("`\8G(O/@T*
M("`\+V1I=CX-"B`@/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT
M+6EN9&5N=#HS-G!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA
M<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)SY/;B!397!T96UB97(@,3(L(#(P,#<L('1H92!F86ER('9A;'5E(&]F
M('1H92!A9F]R96UE;G1I;VYE9"!S=&]C:R!O<'1I;VYS('=A<R!I;FET:6%L
M;'D@8V%L8W5L871E9"!U<VEN9R!T:&4@9F]L;&]W:6YG($)L86-K+5-C:&]L
M97,@:6YP=70@=F%R:6%B;&5S.B!S=&]C:R!P<FEC92`M("9N8G-P.R0Q+C`U
M.R!E>&5R8VES92!P<FEC92`M("9N8G-P.R0P+C,S,R!T;R`F;F)S<#LD,2XP
M,#L@97AP96-T960@;&EF92`M(#0@=&\@-B!Y96%R<SL@97AP96-T960@=F]L
M871I;&ET>2`M(#$U,"4[(&5X<&5C=&5D(&1I=FED96YD('EI96QD("T@,"4[
M(')I<VLM9G)E92!I;G1E<F5S="!R871E("T@-24N($]N($]C=&]B97(@,34L
M(#(P,#DL('1H92!F86ER('9A;'5E(&]F('1H92!A9F]R96UE;G1I;VYE9"!S
M=&]C:R!O<'1I;VYS('=A<R!I;FET:6%L;'D@8V%L8W5L871E9"!U<VEN9R!T
M:&4@9F]L;&]W:6YG($)L86-K+5-C:&]L97,@:6YP=70@=F%R:6%B;&5S.B!S
M=&]C:R!P<FEC92`M("9N8G-P.R0P+C<U.R!E>&5R8VES92!P<FEC92`M("9N
M8G-P.R0Q+C`P.R!E>'!E8W1E9"!L:69E("T@-2!Y96%R<SL@97AP96-T960@
M=F]L871I;&ET>2`F(S@R,3$[(#(U.2XQ)3L@97AP96-T960@9&EV:61E;F0@
M>6EE;&0@+2`P)3L@<FES:RUF<F5E(&EN=&5R97-T(')A=&4@)B,X,C$Q.R`Q
M+CDQ)2X@3VX@2G5N92`S,"P@,C`Q,"P@=&AE(&9A:7(@=F%L=64@;V8@=&AE
M(&%F;W)E;65N=&EO;F5D('-T;V-K(&]P=&EO;G,@=V%S(&-A;&-U;&%T960@
M9F]R('1H92!S=&]C:R!O<'1I;VX@<F5V86QU871I;VX@<'5R<&]S97,@=7-I
M;F<@=&AE(&9O;&QO=VEN9R!";&%C:RU38VAO;&5S(&EN<'5T('9A<FEA8FQE
M<SH@<W1O8VL@<')I8V4@+2`F;F)S<#LD,"XS-3L@97AE<F-I<V4@<')I8V4@
M+2`F;F)S<#LD,"XS,S,[(&5X<&5C=&5D(&QI9F4@+2`T+C(S.R!E>'!E8W1E
M9"!V;VQA=&EL:71Y("8C.#(Q,3L@,C,S+C(E.R!E>'!E8W1E9"!D:79I9&5N
M9"!Y:65L9"`M(#`E.R!R:7-K+69R964@:6YT97)E<W0@<F%T92`F(S@R,3$[
M(#`N.3,E+@T*("`\+V9O;G0^#0H@(#PO9&EV/@T*("`\9&EV('-T>6QE/3-$
M=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[/@T*("`\8G(O/@T*("`\
M+V1I=CX-"B`@/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN
M9&5N=#HS-G!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I
M;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)SY!<R!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!C;VUM96YC
M960@=')A9&EN9R!O;B!397!T96UB97(@,C0L(#(P,#<L('1H92!#;VUP86YY
M('=A<R!A8FQE('1O('5T:6QI>F4@<W5C:"!T<F%D:6YG(&1A=&$@=&\@9V5N
M97)A=&4@<F5V:7-E9"!V;VQA=&EL:71Y(&9A8W1O<G,@87,@;V8@=&AE('9A
M<FEO=7,@<W5B<V5Q=65N="!M96%S=7)E;65N="!D871E<RX-"B`@/"]F;VYT
M/@T*("`\+V1I=CX-"B`@/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MM
M87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L^#0H@(#QD:78^#0H@
M(#PO9&EV/@T*("`\+V1I=CX-"B`@/&1I=B!S='EL93TS1'1E>'0M:6YD96YT
M.C!P=#MD:7-P;&%Y.F)L;V-K.SX-"B`@/&)R+SX-"B`@/"]D:78^#0H@(#QD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,S9P=#MD
M:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T
M.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^3VX@4V5P=&5M
M8F5R(#(P+"`R,#`W+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!O;F4M
M>65A<B!C;VYS=6QT:6YG(&%G<F5E;65N="`H=&AE("8C.#(R,#M-:7)A9&]R
M($%G<F5E;65N="8C.#(R,3LI('=I=&@@36ER861O<B!#;VYS=6QT:6YG+"!)
M;F,N("@F(S@R,C`[36ER861O<B8C.#(R,3LI+"!P=7)S=6%N="!T;R!W:&EC
M:"!-:7)A9&]R('=A<R!T;R!P<F]V:61E('1H92!#;VUP86YY('=I=&@@=F%R
M:6]U<R!F:6YA;F-I86P@<V5R=FEC97,N(%!U<G-U86YT('1O('1H92!-:7)A
M9&]R($%G<F5E;65N="P@=&AE($-O;7!A;GD@86=R965D('1O('!A>2!-:7)A
M9&]R("9N8G-P.R0U+#`P,"!P97(@;6]N=&@@86YD(&%L<V\@86=R965D('1O
M('-E;&P@36ER861O<B`R-3`L,#`P('-H87)E<R!O9B!T:&4@0V]M<&%N>28C
M.#(Q-SMS(')E<W1R:6-T960@8V]M;6]N('-T;V-K(&9O<B`F;F)S<#LD,C4P
M("@F;F)S<#LD,"XP,#$@<&5R('-H87)E*2X@5&AE(&9A:7(@=F%L=64@;V8@
M=&AI<R!T<F%N<V%C=&EO;B!W87,@9&5T97)M:6YE9"!T;R!B92!I;B!E>&-E
M<W,@;V8@=&AE('!U<F-H87-E('!R:6-E(&)Y("9N8G-P.R0R-C(L,C4P("@F
M;F)S<#LD,2XP-#D@<&5R('-H87)E*2P@<F5F;&5C=&EN9R!T:&4@9&EF9F5R
M96YC92!B971W965N('1H92`F;F)S<#LD,"XP,#$@<'5R8VAA<V4@<')I8V4@
M86YD('1H92`F;F)S<#LD,2XP-2!P<FEC92!P97(@<VAA<F4@87,@<75O=&5D
M(&]N('1H92!/5$,@0G5L;&5T:6X@0F]A<F0@;VX@=&AE('1R86YS86-T:6]N
M(&1A=&4L(&%N9"!W87,@8VAA<F=E9"!T;R!O<&5R871I;VYS(&%S('-T;V-K
M+6)A<V5D(&-O;7!E;G-A=&EO;B!O;B!397!T96UB97(@,C`L(#(P,#<L(&)E
M:6YG('1H870@=&AE('-H87)E<R!W97)E(&9U;&QY('9E<W1E9"!A;F0@;F]N
M+69O<F9E:71A8FQE(&]N('1H92!D871E(&]F(&ES<W5A;F-E+@T*("`\+V9O
M;G0^#0H@(#PO9&EV/@T*("`\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P
M=#MM87)G:6XM<FEG:'0Z,'!T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]D:78^#0H@(#QD:78@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,S9P=#MD:7-P
M;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.SX-
M"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^3VX@3V-T;V)E<B`W
M+"`R,#`X+"!T:&4@0V]M<&%N>2!A<'!O:6YT960@1'(N($UE;"!3;W)E;G-E
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M<&5U=&EC<R!C;VUP86YY+"!!<V-E;G1A(%1H97)A<&5U=&EC<RP@:6X@,C`P
M-"X@1'(N(%-O<F5N<V5N('=A<R!P86ED(&%N(&%N;G5A;"!C;VYS=6QT:6YG
M(&9E92!O9B`F;F)S<#LD-#`L,#`P+"!P87EA8FQE(&EN('%U87)T97)L>2!I
M;G-T86QL;65N=',@;W9E<B!A(&]N92!Y96%R('!E<FEO9"!C;VUM96YC:6YG
M($]C=&]B97(@-RP@,C`P."P@=&\@87-S:7-T('1H92!#;VUP86YY(&EN(&ED
M96YT:69Y:6YG(&$@<W1R871E9VEC('!A<G1N97(N($1R+B!3;W)E;G-E;B!W
M87,@86QS;R!G<F%N=&5D(&$@<W1O8VL@;W!T:6]N('1O('!U<F-H87-E(#(P
M,"PP,#`@<VAA<F5S(&]F('1H92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T
M;V-K+"!E>&5R8VES86)L92!A="`F;F)S<#LD,"XU,"!P97(@<VAA<F4@9F]R
M(&$@<&5R:6]D(&]F(&9I=F4@>65A<G,@9G)O;2!E86-H('1R86YC:&4F(S@R
M,3<[<R!V97-T:6YG(&1A=&4N(%1H92!O<'1I;VX@=F5S=',@87,@=&\@,C4L
M,#`P('-H87)E<R!O;B!*86YU87)Y(#$L(#(P,#DL(&%N9"!A(&9U<G1H97(@
M,C4L,#`P('-H87)E<R!O;B!T:&4@9FER<W0@9&%Y(&]F(&5A8V@@<W5B<V5Q
M=65N="!C86QE;F1A<B!Q=6%R=&5R('5N=&EL(&%L;"!O9B!T:&4@<VAA<F5S
M(&%R92!V97-T960N(%1H92!F86ER('9A;'5E(&]F('1H97-E(&]P=&EO;G,L
M(&%S(&-A;&-U;&%T960@<'5R<W5A;G0@=&\@=&AE($)L86-K+5-C:&]L97,@
M;W!T:6]N+7!R:6-I;F<@;6]D96PL('=A<R!D971E<FUI;F5D('1O(&)E("9N
M8G-P.R0Q,#`L,#`P("@F;F)S<#LD,"XU,"!P97(@<VAA<F4I+"!A;F0@=V%S
M(&-H87)G960@=&\@;W!E<F%T:6]N<R!R871A8FQY(&9R;VT@3V-T;V)E<B`W
M+"`R,#`X('1H<F]U9V@@3V-T;V)E<B`W+"`R,#$P+B!$=7)I;F<@=&AE('1H
M<F5E(&%N9"!S:7@@;6]N=&AS(&5N9&5D($IU;F4@,S`L(#(P,3`L('1H92!#
M;VUP86YY(')E8V]R9&5D(&-H87)G97,@=&\@;W!E<F%T:6]N<R!O9B`F;F)S
M<#LD,3(L-#8V(&%N9"`F;F)S<#LD,C0L-SDU+"!R97-P96-T:79E;'DL('=I
M=&@@<F5S<&5C="!T;R!T:&5S92!O<'1I;VYS+@T*("`\+V9O;G0^#0H@(#PO
M9&EV/@T*("`\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD
M96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM
M<FEG:'0Z,'!T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^
M)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]D:78^#0H@(#QD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,S9P=#MD:7-P;&%Y.F)L;V-K
M.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.SX-"B`@/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^3VX@3V-T;V)E<B`W+"`R,#`X+"!T
M:&4@9F%I<B!V86QU92!O9B!T:&4@869O<F5M96YT:6]N960@<W1O8VL@;W!T
M:6]N<R!W87,@8V%L8W5L871E9"!U<VEN9R!T:&4@9F]L;&]W:6YG($)L86-K
M+5-C:&]L97,@:6YP=70@=F%R:6%B;&5S.B!S=&]C:R!P<FEC92`M("9N8G-P
M.R0P+C4P.R!E>&5R8VES92!P<FEC92`M("9N8G-P.R0P+C4P.R!E>'!E8W1E
M9"!L:69E("T@-2!Y96%R<SL@97AP96-T960@=F]L871I;&ET>2`F(S@R,3$[
M(#(W-2XW)3L@97AP96-T960@9&EV:61E;F0@>6EE;&0@+2`P)3L@<FES:RUF
M<F5E(&EN=&5R97-T(')A=&4@)B,X,C$Q.R`R+C0X)2X-"B`@/"]F;VYT/@T*
M("`\+V1I=CX-"B`@/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT
M+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R
M9VEN+7)I9VAT.C!P=#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL
M:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO9&EV/@T*("`\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C,V<'0[9&ES<&QA>3IB
M;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L^#0H@(#QF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/D]N($IU;'D@,C<L(#(P,#DL
M('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A;B!A9W)E96UE;G0@=VET:"!0
M<F\M06-T:79E($-A<&ET86P@1W)O=7`L($Q,0R`H)B,X,C(P.U!R;RU!8W1I
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M>2!A9W)E960@=&\@:7-S=64@=&\@4')O+4%C=&EV92`Q-3`L,#`P('-H87)E
M<R!O9B!R97-T<FEC=&5D(&-O;6UO;B!S=&]C:R!A;F0@=&AR964M>65A<B!W
M87)R86YT<R!T;R!P=7)C:&%S92!A;B!A9V=R96=A=&4@;V8@,34P+#`P,"!S
M:&%R97,@;V8@8V]M;6]N('-T;V-K+"!E>&5R8VES86)L92`U,"PP,#`@870@
M)FYB<W`[)#`N-S4@<&5R('-H87)E+"`U,"PP,#`@870@)FYB<W`[)#$N,#`@
M<&5R('-H87)E+"!A;F0@-3`L,#`P(&%T("9N8G-P.R0Q+C(U('!E<B!S:&%R
M92X@5&AE(&9A:7(@=F%L=64@;V8@=&AE(#$U,"PP,#`@<VAA<F5S(&ES<W5E
M9"!W87,@9&5T97)M:6YE9"!T;R!B92`F;F)S<#LD,3`P+#4P,"`H)FYB<W`[
M)#`N-C<@<&5R('-H87)E*2P@<F5F;&5C=&EN9R!T:&4@<')I8V4@<&5R('-H
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M9"!T;R!B92`F;F)S<#LD.3<L-3`P("@F;F)S<#LD,"XV-2!P97(@<VAA<F4I
M('5S:6YG('1H92!F;VQL;W=I;F<@0FQA8VLM4V-H;VQE<R!I;G!U="!V87)I
M86)L97,Z('-T;V-K('!R:6-E(&]N(&1A=&4@;V8@9W)A;G0@+2`F;F)S<#LD
M,"XV-SL@97AE<F-I<V4@<')I8V4@+2`F;F)S<#LD,"XW-2!T;R`F;F)S<#LD
M,2XR-3L@97AP96-T960@;&EF92`M(#,@>65A<G,[(&5X<&5C=&5D('9O;&%T
M:6QI='D@)B,X,C$Q.R`R-3DN,24[(&5X<&5C=&5D(&1I=FED96YD('EI96QD
M("T@,"4[(')I<VLM9G)E92!I;G1E<F5S="!R871E("T@,2XY,24N(%1H92`F
M;F)S<#LD,3DX+#`P,"!A9V=R96=A=&4@9F%I<B!V86QU92!O9B!T:&4@<VAA
M<F5S(&%N9"!W87)R86YT<R!I<W-U960@=V%S(&-H87)G960@=&\@;W!E<F%T
M:6]N<R!A<R!S=&]C:RUB87-E9"!C;VUP96YS871I;VX@;VX@2G5L>2`R-RP@
M,C`P.2P@87,@=&AE('-H87)E<R!A;F0@=V%R<F%N=',@=V5R92!F=6QL>2!V
M97-T960@86YD(&YO;BUF;W)F96ET86)L92!O;B!T:&4@9&%T92!O9B!I<W-U
M86YC92X-"B`@/"]F;VYT/@T*("`\+V1I=CX-"B`@/&1I=B!S='EL93TS1'1E
M>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.SX-"B`@/&)R+SX-"B`@/"]D
M:78^#0H@(#QD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E
M;G0Z,S9P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM
M<FEG:'0Z,'!T.SX-"B`@/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT
M97AT+6EN9&5N=#HS-G!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T
M.VUA<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)SX-"B`@/"]F;VYT/@T*("`\+V1I=CX-"B`@/&1I=CX-"B`@#0H@
M(#QD:78@<W1Y;&4],T1T97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM
M87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L^#0H@(#QD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,S9P=#MD:7-P;&%Y
M.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.SX-"B`@
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^169F96-T:79E($UA>2`R
M+"`R,#$Q+"!T:&4@0V]M<&%N>2!E;&5C=&5D($1R+B!2;V)E<G0@0BX@4F]Y
M9',@=&\@:71S($)O87)D(&]F($1I<F5C=&]R<RX@1'(N(%)O>61S/&9O;G0@
M<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93MF;VYT+7=E:6=H=#IB;VQD.SXF(S$V
M,#L-"B`@/"]F;VYT/FES($-H86ER;6%N(&]F('1H92!";V%R9"!A;F0@365D
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M:RP@4VAA<G`L(&%N9"!$;VAM92!297-E87)C:"!,86)O<F%T;W)I97,N($1R
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M<B!T:&ES(&-O;G1R86-T('-I;F-E(#$Y.#(N#0H@(#PO9F]N=#X-"B`@/&)R
M+SX-"B`@)B,Q-C`[#0H@(#PO9&EV/@T*("`\9&EV('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.W1E>'0M:6YD96YT.C,V<'0[9&ES<&QA>3IB;&]C:SMM87)G
M:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L^#0H@(#QF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG/D5F9F5C=&EV92!-87D@,2P@,C`Q,2P@1'(N
M(%)O>61S('=A<R!G<F%N=&5D('-T;V-K(&]P=&EO;G,@=&\@<'5R8VAA<V4@
M,C`P+#`P,"!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!C;VUM;VX@
M<W1O8VLL(&5X97)C:7-A8FQE(&9O<B!A('!E<FEO9"!O9B!F:79E('EE87)S
M(&9R;VT@96%C:"!T<F%N8VAE)B,X,C$W.W,@=F5S=&EN9R!D871E+"!A="`F
M;F)S<#LD,"XY."!P97(@<VAA<F4L('=H:6-H('=A<R!T:&4@9F%I<B!M87)K
M970@=F%L=64@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!C;VUM;VX@<W1O8VL@
M;VX@<W5C:"!D871E+B!4:&4@;W!T:6]N<R!V97-T960@87,@=&\@,C4L,#`P
M('-H87)E<R!O;B!-87D@,2P@,C`Q,2P@86YD(&$@9G5R=&AE<B`R-2PP,#`@
M<VAA<F5S('9E<W0@;VX@=&AE(&9I<G-T(&1A>2!O9B!E86-H('-U8G-E<75E
M;G0@<75A<G1E<B!U;G1I;"!A;&P@;V8@=&AE('-H87)E<R!A<F4@=F5S=&5D
M+B!4:&4@9F%I<B!V86QU92!O9B!T:&5S92!O<'1I;VYS+"!A<R!C86QC=6QA
M=&5D('!U<G-U86YT('1O('1H92!";&%C:RU38VAO;&5S(&]P=&EO;BUP<FEC
M:6YG(&UO9&5L+"!W87,@9&5T97)M:6YE9"!T;R!B92`F;F)S<#LD,3DV+#`P
M,"`H)FYB<W`[)#`N.3@@<&5R('-H87)E*2P@86YD(&ES(&)E:6YG(&-H87)G
M960@=&\@;W!E<F%T:6]N<R!R871A8FQY(&9R;VT@36%Y(#(L(#(P,3$@=&AR
M;W5G:"!&96)R=6%R>2`Q+"`R,#$S+B!$=7)I;F<@=&AE('1H<F5E(&UO;G1H
M<R!A;F0@<VEX(&UO;G1H<R!E;F1E9"!*=6YE(#,P+"`R,#$Q+"!T:&4@0V]M
M<&%N>2!R96-O<F1E9"!A(&-H87)G92!T;R!O<&5R871I;VYS(&]F("9N8G-P
M.R0T,"PU,C@@=VET:"!R97-P96-T('1O('1H97-E(&]P=&EO;G,N#0H@(#PO
M9F]N=#X-"B`@/"]D:78^#0H@(#PO9&EV/@T*("`\9&EV('-T>6QE/3-$=&5X
M="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[/@T*("`\8G(O/@T*("`\+V1I
M=CX-"B`@/&1I=CX-"B`@/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT
M97AT+6EN9&5N=#HS-G!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T
M.VUA<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)SY/;B!-87D@,BP@,C`Q,2P@=&AE(&9A:7(@=F%L=64@;V8@=&AE
M(&%F;W)E;65N=&EO;F5D('-T;V-K(&]P=&EO;G,@=V%S(&-A;&-U;&%T960@
M=7-I;F<@=&AE(&9O;&QO=VEN9R!";&%C:RU38VAO;&5S(&EN<'5T('9A<FEA
M8FQE<SH@<W1O8VL@<')I8V4@+2`F;F)S<#LD,"XY.#L@97AE<F-I<V4@<')I
M8V4@+2`F;F)S<#LD,"XY.#L@97AP96-T960@;&EF92`F(S@R,3$[(#8N-S8@
M>65A<G,[(&5X<&5C=&5D('9O;&%T:6QI='D@)B,X,C$Q.R`S,#@N."4[(&5X
M<&5C=&5D(&1I=FED96YD('EI96QD("T@,"4[(')I<VLM9G)E92!I;G1E<F5S
M="!R871E("8C.#(Q,3L@,2XU."4N/&)R+SX-"B`@/&)R+SX-"B`@/"]F;VYT
M/@T*("`\+V1I=CX-"B`@/"]D:78^#0H@(#QD:78@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN
M+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)SX-"B`@/"]F;VYT/@T*("`\+V1I=CX-"B`@/&1I
M=CX-"B`@/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N
M=#HS-G!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR
M:6=H=#HP<'0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SY!
M9&1I=&EO;F%L(&EN9F]R;6%T:6]N('=I=&@@<F5S<&5C="!T;R!C;VUM;VX@
M<W1O8VL@=V%R<F%N=',@86YD('-T;V-K(&]P=&EO;G,@:7-S=65D(&ES('!R
M;W9I9&5D(&%T($YO=&5S(#0@86YD(#@N/&)R+SX-"B`@/&)R+SX-"B`@/"]F
M;VYT/@T*("`\+V1I=CX-"B`@/"]D:78^#0H@(#QD:78@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R
M9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)SX-"B`@/"]F;VYT/@T*("`\+V1I=CX-"B`@
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HS-G!T
M.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP
M<'0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SY)9B!A;F0@
M=VAE;B!T:&4@869O<F5M96YT:6]N960@<W1O8VL@;W!T:6]N<R!A;F0@=V%R
M<F%N=',@87)E(&5X97)C:7-E9"P@=&AE($-O;7!A;GD@97AP96-T<R!T;R!S
M871I<V9Y('-U8V@@<W1O8VL@;V)L:6=A=&EO;G,@=&AR;W5G:"!T:&4@:7-S
M=6%N8V4@;V8@875T:&]R:7IE9"!B=70@=6YI<W-U960@<VAA<F5S(&]F(&-O
M;6UO;B!S=&]C:RX-"B`@/"]F;VYT/@T*("`\+V1I=CX-"B`@/&)R+SX-"B`@
M/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MM87)G:6XM;&5F=#HP<'0[
M;6%R9VEN+7)I9VAT.C!P=#L^#0H@(#QD:78^#0H@(#PO9&EV/@T*("`\9&EV
M/@T*("`\+V1I=CX-"B`@/"]D:78^#0H@(#QD:78@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[=&5X="UI;F1E;G0Z,S9P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I
M;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.SX-"B`@/&9O;G0@<W1Y;&4]
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M#0H@(#QB<B\^#0H@(#PO9F]N=#X-"B`@/"]D:78^#0H@(#QD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,S9P=#MD:7-P;&%Y.F)L
M;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.SX-"B`@/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^#0H@(#PO9F]N=#X-"B`@/"]D
M:78^#0H@(#QD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[/@T*("`\9&EV
M/@T*("`\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W
M:61T:#TS1#$P,"4@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<^#0H@(#QT<CX-"B`@/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O
M;3HR<'@[/@T*("`\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M
M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G
M:6XM<FEG:'0Z,'!T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<^)B,Q-C`[)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]D:78^#0H@(#PO=&0^
M#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1T97AT+6%L:6=N.FQE
M9G0[<&%D9&EN9RUB;W1T;VTZ,G!X.SX-"B`@/&1I=B!S='EL93TS1'1E>'0M
M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G
M:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L^#0H@(#QF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P.R8C,38P.PT*("`\+V9O;G0^#0H@
M(#PO9&EV/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0R(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.F)L86-K(#)P>"!S;VQI9#LG/@T*("`\9&EV('-T>6QE/3-$=&5X="UA;&EG
M;CIC96YT97([=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN
M+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z8F]L9#LG/@T*("`\9F]N="!S
M='EL93TS1&1I<W!L87DZ:6YL:6YE.SY.=6UB97(-"B`@/"]F;VYT/@T*("`\
M+V9O;G0^#0H@(#PO9&EV/@T*("`\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC
M96YT97([=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE
M9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[9F]N="UW96EG:'0Z8F]L9#LG/@T*("`\9F]N="!S='EL
M93TS1&1I<W!L87DZ:6YL:6YE.SYO9@T*("`\+V9O;G0^#0H@(#PO9F]N=#X-
M"B`@/"]D:78^#0H@(#QD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMT
M97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[
M;6%R9VEN+7)I9VAT.C!P=#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IB;VQD.R<^#0H@(#QF;VYT('-T>6QE/3-$9&ES
M<&QA>3II;FQI;F4[/E-H87)E<PT*("`\+V9O;G0^#0H@(#PO9F]N=#X-"B`@
M/"]D:78^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X.SX-"B`@/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HP<'0[9&ES
M<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L^
M#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P.R8C,38P
M.PT*("`\+V9O;G0^#0H@(#PO9&EV/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M8F]T
M=&]M.C)P>#L^#0H@(#QD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X
M="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA
M<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)SXF(S$V,#LF(S$V,#L-"B`@/"]F;VYT/@T*("`\+V1I=CX-"B`@/"]T
M9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!N;W=R87`]
M,T1N;W=R87`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L
M:60[)SX-"B`@/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.W1E>'0M
M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G
M:6XM<FEG:'0Z,'!T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.F)O;&0[)SX-"B`@/&9O;G0@<W1Y;&4],T1D:7-P;&%Y
M.FEN;&EN93L^5V5I9VAT960-"B`@/"]F;VYT/@T*("`\+V9O;G0^#0H@(#PO
M9&EV/@T*("`\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([=&5X="UI
M;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I
M;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z8F]L9#LG/@T*("`\9F]N="!S='EL93TS1&1I<W!L87DZ
M:6YL:6YE.SY!=F5R86=E#0H@(#PO9F]N=#X-"B`@/"]F;VYT/@T*("`\+V1I
M=CX-"B`@/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.W1E>'0M:6YD
M96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM
M<FEG:'0Z,'!T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.F)O;&0[)SX-"B`@/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN
M;&EN93L^17AE<F-I<V4-"B`@/"]F;VYT/@T*("`\+V9O;G0^#0H@(#PO9&EV
M/@T*("`\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([=&5X="UI;F1E
M;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR
M:6=H=#HP<'0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z8F]L9#LG/@T*("`\9F]N="!S='EL93TS1&1I<W!L87DZ:6YL
M:6YE.SY0<FEC90T*("`\+V9O;G0^#0H@(#PO9F]N=#X-"B`@/"]D:78^#0H@
M(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X.SX-"B`@/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C
M:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L^#0H@(#QF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P.R8C,38P.PT*("`\+V9O
M;G0^#0H@(#PO9&EV/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C)P>#L^
M#0H@(#QD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z
M,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H
M=#HP<'0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V
M,#LF(S$V,#L-"B`@/"]F;VYT/@T*("`\+V1I=CX-"B`@/"]T9#X-"B`@/'1D
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L:60[)SX-"B`@
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.W1E>'0M:6YD96YT.C!P
M=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z
M,'!T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.F)O;&0[)SX-"B`@/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L^
M5V5I9VAT960-"B`@/"]F;VYT/@T*("`\+V9O;G0^#0H@(#PO9&EV/@T*("`\
M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([=&5X="UI;F1E;G0Z,'!T
M.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP
M<'0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z8F]L9#LG/@T*("`\9F]N="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.SY!
M=F5R86=E#0H@(#PO9F]N=#X-"B`@/"]F;VYT/@T*("`\+V1I=CX-"B`@/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.W1E>'0M:6YD96YT.C!P=#MD
M:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T
M.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.F)O;&0[)SX-"B`@/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L^4F5M
M86EN:6YG#0H@(#PO9F]N=#X-"B`@/"]F;VYT/@T*("`\+V1I=CX-"B`@/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.W1E>'0M:6YD96YT.C!P=#MD
M:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T
M.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.F)O;&0[)SX-"B`@/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L^0V]N
M=')A8W1U86P-"B`@/"]F;VYT/@T*("`\+V9O;G0^#0H@(#PO9&EV/@T*("`\
M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([=&5X="UI;F1E;G0Z,'!T
M.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP
M<'0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z8F]L9#LG/@T*("`\9F]N="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.SY,
M:69E#0H@(#PO9F]N=#X-"B`@/"]F;VYT/@T*("`\+V1I=CX-"B`@/&1I=B!S
M='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.W1E>'0M:6YD96YT.C!P=#MD:7-P
M;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.SX-
M"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O
M;&0[)SX-"B`@/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L^*&EN)B,Q
M-C`[665A<G,I#0H@(#PO9F]N=#X-"B`@/"]F;VYT/@T*("`\+V1I=CX-"B`@
M/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'1E>'0M86QI
M9VXZ;&5F=#MP861D:6YG+6)O='1O;3HR<'@[/@T*("`\9&EV('-T>6QE/3-$
M=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K
M.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.SX-"B`@/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[)B,Q-C`[#0H@(#PO9F]N
M=#X-"B`@/"]D:78^#0H@(#PO=&0^#0H@(#PO='(^#0H@(#QT<B!S='EL93TS
M1&)A8VMG<F]U;F0M8V]L;W(Z(V-C9F9C8SL^#0H@(#QT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0V-"4@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[/@T*
M("`\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C!P
M=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z
M,'!T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^3W!T:6]N
M<R!A;F0@=V%R<F%N=',@;W5T<W1A;F1I;F<@870@1&5C96UB97(@,S$L(#(P
M,#D-"B`@/"]F;VYT/@T*("`\+V1I=CX-"B`@/"]T9#X-"B`@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@
M(#PO9F]N=#X-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.SX-"B`@/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]T
M9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$
M=&5X="UA;&EG;CIR:6=H=#L^#0H@(#QD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.G)I9VAT.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL
M969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.SX-"B`@/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<^-RPY.3<L-#(V#0H@(#PO9F]N=#X-"B`@/"]D:78^
M#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S
M='EL93TS1'1E>'0M86QI9VXZ;&5F=#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO=&0^#0H@(#QT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1'1E>'0M86QI
M9VXZ;&5F=#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B8C
M,38P.PT*("`\+V9O;G0^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L^#0H@(#QD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I
M<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[
M/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#LD#0H@
M(#PO9F]N=#X-"B`@/"]D:78^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[/@T*
M("`\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MT97AT+6EN9&5N=#HP
M<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT
M.C!P=#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/C`N-C8T
M#0H@(#PO9F]N=#X-"B`@/"]D:78^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L^
M#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P.PT*("`\
M+V9O;G0^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L^#0H@(#QF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO=&0^
M#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1'1E
M>'0M86QI9VXZ;&5F=#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL
M:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L^
M#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P.PT*("`\
M+V9O;G0^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L^#0H@(#QF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO=&0^
M#0H@(#PO='(^#0H@(#QT<B!S='EL93TS1&)A8VMG<F]U;F0M8V]L;W(Z(V9F
M9F9F9CL^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V-"4@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[/@T*("`\9&EV('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I
M;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.SX-"B`@/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<^1W)A;G1E9`T*("`\+V9O;G0^#0H@(#PO9&EV
M/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[/@T*("`\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF
M(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$.24@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.SX-"B`@
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[=&5X="UI;F1E;G0Z,'!T
M.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP
M<'0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXY+#$U,"PP
M,#`-"B`@/"]F;VYT/@T*("`\+V1I=CX-"B`@/"]T9#X-"B`@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@
M(#PO9F]N=#X-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.SX-"B`@/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]T
M9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$
M=&5X="UA;&EG;CIL969T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<^)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H
M=#L^#0H@(#QD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M:6YD
M96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM
M<FEG:'0Z,'!T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^
M,"XV,C4-"B`@/"]F;VYT/@T*("`\+V1I=CX-"B`@/"]T9#X-"B`@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL
M969T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[
M#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.SX-"B`@/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N=#X-"B`@
M/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$=&5X="UA;&EG;CIL
M969T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[
M#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.SX-"B`@/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N=#X-"B`@
M/"]T9#X-"B`@/"]T<CX-"B`@/'1R('-T>6QE/3-$8F%C:V=R;W5N9"UC;VQO
M<CHC8V-F9F-C.SX-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8T
M)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L^#0H@(#QD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[
M;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)SY%>&5R8VES960-"B`@/"]F;VYT/@T*
M("`\+V1I=CX-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.SX-"B`@/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]T
M9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$
M=&5X="UA;&EG;CIL969T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<^)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H
M=#L^#0H@(#QD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M:6YD
M96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM
M<FEG:'0Z,'!T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^
M)B,X,C$R.PT*("`\+V9O;G0^#0H@(#PO9&EV/@T*("`\+W1D/@T*("`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V
M,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[/@T*("`\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*
M("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T1T97AT+6%L:6=N
M.G)I9VAT.SX-"B`@/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[=&5X
M="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA
M<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)SXF(S@R,3([#0H@(#PO9F]N=#X-"B`@/"]D:78^#0H@(#PO=&0^#0H@
M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1'1E>'0M
M86QI9VXZ;&5F=#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L^#0H@
M(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P.PT*("`\+V9O
M;G0^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L^#0H@(#QF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO=&0^#0H@
M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1'1E>'0M
M86QI9VXZ;&5F=#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L^#0H@
M(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P.PT*("`\+V9O
M;G0^#0H@(#PO=&0^#0H@(#PO='(^#0H@(#QT<B!S='EL93TS1&)A8VMG<F]U
M;F0M8V]L;W(Z(V9F9F9F9CL^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0V-"4@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T
M;VTZ,G!X.SX-"B`@/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT
M+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R
M9VEN+7)I9VAT.C!P=#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL
M:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG/D-A;F-E;&QE9`T*("`\+V9O;G0^#0H@(#PO9&EV/@T*("`\+W1D/@T*
M("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X.SX-"B`@/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]T
M9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ8FQA8VL@,G!X('-O;&ED.W1E>'0M86QI9VXZ;&5F
M=#LG/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-
M"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$.24@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L
M:60[=&5X="UA;&EG;CIR:6=H=#LG/@T*("`\9&EV('-T>6QE/3-$=&5X="UA
M;&EG;CIR:6=H=#MT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G
M:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L^#0H@(#QF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG/@T*("`\9F]N="!S='EL93TS1&1I<W!L87DZ
M:6YL:6YE.SXF(S@R,3([#0H@(#PO9F]N=#X-"B`@/"]F;VYT/@T*("`\+V1I
M=CX-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C)P>#L^
M#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P.PT*("`\
M+V9O;G0^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O;3HR
M<'@[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-
M"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L
M:60[=&5X="UA;&EG;CIL969T.R<^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO=&0^#0H@(#QT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.F)L86-K(#)P>"!S;VQI9#MT97AT+6%L:6=N.G)I9VAT.R<^#0H@(#QD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M:6YD96YT.C!P=#MD
M:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T
M.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^#0H@(#QF;VYT
M('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[/B8C.#(Q,CL-"B`@/"]F;VYT/@T*
M("`\+V9O;G0^#0H@(#PO9&EV/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D
M9&EN9RUB;W1T;VTZ,G!X.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<^)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.W!A9&1I;F<M8F]T=&]M.C)P>#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO=&0^#0H@(#QT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1'1E>'0M86QI9VXZ
M;&5F=#MP861D:6YG+6)O='1O;3HR<'@[/@T*("`\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X.SX-"B`@/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]T9#X-
M"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C)P>#L^#0H@(#QF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO
M=&0^#0H@(#PO='(^#0H@(#QT<B!S='EL93TS1&)A8VMG<F]U;F0M8V]L;W(Z
M(V-C9F9C8SL^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V-"4@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[/@T*("`\9&EV('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA
M<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.SX-"B`@/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<^3W!T:6]N<R!A;F0@=V%R<F%N=',@;W5T
M<W1A;F1I;F<@870@1&5C96UB97(@,S$L(#(P,3`-"B`@/"]F;VYT/@T*("`\
M+V1I=CX-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.SX-"B`@/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]T9#X-
M"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<^)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L^
M#0H@(#QD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M:6YD96YT
M.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG
M:'0Z,'!T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^,3<L
M,30W+#0R-@T*("`\+V9O;G0^#0H@(#PO9&EV/@T*("`\+W1D/@T*("`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V
M,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[/@T*("`\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*
M("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[/@T*("`\9&EV('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I
M;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.SX-"B`@/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[)`T*("`\+V9O;G0^#0H@(#PO9&EV
M/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@
M<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.SX-"B`@/&1I=B!S='EL93TS1'1E
M>'0M86QI9VXZ<FEG:'0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[
M;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)SXP+C8T,PT*("`\+V9O;G0^#0H@(#PO
M9&EV/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[/@T*("`\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*
M("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[/@T*
M("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F
M;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M.24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[/@T*("`\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*
M("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\+W1R/@T*("`\='(@
M<W1Y;&4],T1B86-K9W)O=6YD+6-O;&]R.B-F9F9F9F8[/@T*("`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-C0E('-T>6QE/3-$=&5X="UA;&EG;CIL
M969T.SX-"B`@/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN
M9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN
M+7)I9VAT.C!P=#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M/D=R86YT960-"B`@/"]F;VYT/@T*("`\+V1I=CX-"B`@/"]T9#X-"B`@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG
M;CIL969T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q
M-C`[#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.SX-"B`@/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N=#X-
M"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T
M>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L^#0H@(#QD:78@<W1Y;&4],T1T97AT
M+6%L:6=N.G)I9VAT.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA
M<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.SX-"B`@/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<^-#4P+#`P,`T*("`\+V9O;G0^#0H@(#PO
M9&EV/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[/@T*("`\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*
M("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[/@T*
M("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F
M;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M.24@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.SX-"B`@/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ<FEG:'0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO
M8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXP+CDX,`T*("`\+V9O;G0^#0H@
M(#PO9&EV/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[/@T*("`\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D
M/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@
M/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$.24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[/@T*("`\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D
M/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\+W1R/@T*("`\
M='(@<W1Y;&4],T1B86-K9W)O=6YD+6-O;&]R.B-C8V9F8V,[/@T*("`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C0E('-T>6QE/3-$=&5X="UA;&EG
M;CIL969T.SX-"B`@/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT
M+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R
M9VEN+7)I9VAT.C!P=#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL
M:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG/D5X97)C:7-E9`T*("`\+V9O;G0^#0H@(#PO9&EV/@T*("`\+W1D/@T*
M("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[/@T*
M("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F
M;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M.24@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.SX-"B`@/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ<FEG:'0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO
M8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXH,C8W+#@X.0T*("`\+V9O;G0^
M#0H@(#PO9&EV/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[/@T*("`\9&EV('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y
M.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.SX-"B`@
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^*28C,38P.PT*("`\+V9O
M;G0^#0H@(#PO9&EV/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[/@T*("`\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*
M("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T1T97AT+6%L:6=N
M.G)I9VAT.SX-"B`@/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[=&5X
M="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA
M<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)SXP+C,S,PT*("`\+V9O;G0^#0H@(#PO9&EV/@T*("`\+W1D/@T*("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF
M(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[/@T*("`\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT
M/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[/@T*("`\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF
M(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[/@T*("`\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT
M/@T*("`\+W1D/@T*("`\+W1R/@T*("`\='(@<W1Y;&4],T1B86-K9W)O=6YD
M+6-O;&]R.B-F9F9F9F8[/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-C0E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M
M.C)P>#L^#0H@(#QD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI
M;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I
M;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)SY#86YC96QL960-"B`@/"]F;VYT/@T*("`\+V1I=CX-"B`@/"]T9#X-"B`@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C)P>#L^#0H@(#QF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO=&0^
M#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.F)L86-K(#)P>"!S;VQI9#MT97AT+6%L:6=N.FQE9G0[
M)SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@
M(#PO9F]N=#X-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#DE('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@,G!X('-O;&ED
M.W1E>'0M86QI9VXZ<FEG:'0[)SX-"B`@/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ<FEG:'0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN
M+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)SX-"B`@/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN
M;&EN93L^*#4R-"PY.#4-"B`@/"]F;VYT/@T*("`\+V9O;G0^#0H@(#PO9&EV
M/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X.SX-
M"B`@/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HP
M<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT
M.C!P=#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/BDF(S$V
M,#L-"B`@/"]F;VYT/@T*("`\+V1I=CX-"B`@/"]T9#X-"B`@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.W!A9&1I;F<M8F]T=&]M.C)P>#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO=&0^#0H@(#QT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.F)L86-K(#)P>"!S;VQI9#MT97AT+6%L:6=N.FQE9G0[)SX-"B`@/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N=#X-
M"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@,G!X('-O;&ED.W1E>'0M86QI
M9VXZ<FEG:'0[)SX-"B`@/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[
M=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T
M.VUA<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)SX-"B`@/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L^,"XS
M,S,-"B`@/"]F;VYT/@T*("`\+V9O;G0^#0H@(#PO9&EV/@T*("`\+W1D/@T*
M("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X.SX-"B`@/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]T
M9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$
M=&5X="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C)P>#L^#0H@(#QF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P.PT*("`\+V9O;G0^#0H@
M(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL
M93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O;3HR<'@[/@T*("`\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT
M/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X.SX-
M"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@(#PO
M9F]N=#X-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C)P
M>#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P.PT*
M("`\+V9O;G0^#0H@(#PO=&0^#0H@(#PO='(^#0H@(#QT<B!S='EL93TS1&)A
M8VMG<F]U;F0M8V]L;W(Z(V-C9F9C8SL^#0H@(#QT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0V-"4@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN
M9RUB;W1T;VTZ-'!X.SX-"B`@/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#MT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP
M<'0[;6%R9VEN+7)I9VAT.C!P=#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG/D]P=&EO;G,@86YD('=A<G)A;G1S(&]U='-T86YD:6YG(&%T
M($IU;F4@,S`L(#(P,3$-"B`@/"]F;VYT/@T*("`\+V1I=CX-"B`@/"]T9#X-
M"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C1P>#L^#0H@(#QF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO
M=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.F)L86-K(#1P>"!D;W5B;&4[=&5X="UA;&EG;CIL
M969T.R<^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P
M.PT*("`\+V9O;G0^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Y)2!S='EL93TS1"=B;W)D97(M8F]T=&]M.F)L86-K(#1P>"!D
M;W5B;&4[=&5X="UA;&EG;CIR:6=H=#LG/@T*("`\9&EV('-T>6QE/3-$=&5X
M="UA;&EG;CIR:6=H=#MT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM
M87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L^#0H@(#QF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/@T*("`\9F]N="!S='EL93TS1&1I<W!L
M87DZ:6YL:6YE.SXQ-BPX,#0L-34R#0H@(#PO9F]N=#X-"B`@/"]F;VYT/@T*
M("`\+V1I=CX-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M
M.C1P>#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P
M.PT*("`\+V9O;G0^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O
M='1O;3HT<'@[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF
M(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`T
M<'@@9&]U8FQE.W1E>'0M86QI9VXZ;&5F=#LG/@T*("`\9&EV('-T>6QE/3-$
M=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K
M.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.SX-"B`@/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^#0H@(#QF;VYT('-T>6QE/3-$9&ES
M<&QA>3II;FQI;F4[/B9N8G-P.R0-"B`@/"]F;VYT/@T*("`\+V9O;G0^#0H@
M(#PO9&EV/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$.24@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`T<'@@9&]U8FQE
M.W1E>'0M86QI9VXZ<FEG:'0[)SX-"B`@/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ<FEG:'0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN
M+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)SX-"B`@/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN
M;&EN93L^,"XV-C<-"B`@/"]F;VYT/@T*("`\+V9O;G0^#0H@(#PO9&EV/@T*
M("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ-'!X.SX-"B`@
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N
M=#X-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C1P>#L^
M#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P.PT*("`\
M+V9O;G0^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!S='EL93TS1"=B;W)D97(M8F]T=&]M.F)L86-K(#1P>"!D;W5B;&4[
M=&5X="UA;&EG;CIL969T.R<^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO=&0^#0H@(#QT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.F)L86-K(#1P>"!D;W5B;&4[=&5X="UA;&EG;CIR:6=H=#LG/@T*("`\9&EV
M('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MT97AT+6EN9&5N=#HP<'0[9&ES
M<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L^
M#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/@T*("`\9F]N="!S
M='EL93TS1&1I<W!L87DZ:6YL:6YE.SXQ+C<X#0H@(#PO9F]N=#X-"B`@/"]F
M;VYT/@T*("`\+V1I=CX-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M
M8F]T=&]M.C1P>#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO=&0^#0H@(#PO='(^#0H@(#QT<B!S
M='EL93TS1&)A8VMG<F]U;F0M8V]L;W(Z(V9F9F9F9CL^#0H@(#QT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0V-"4@<W1Y;&4],T1T97AT+6%L:6=N.FQE
M9G0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-
M"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[/@T*("`\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\
M+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T1T97AT+6%L:6=N.G)I
M9VAT.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[
M#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.SX-"B`@/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N=#X-"B`@
M/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL
M969T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[
M#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#DE('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L^#0H@(#QF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P.PT*("`\+V9O;G0^#0H@
M(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL
M93TS1'1E>'0M86QI9VXZ;&5F=#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO=&0^#0H@(#QT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1'1E>'0M86QI9VXZ
M;&5F=#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P
M.PT*("`\+V9O;G0^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L^#0H@(#QF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P.PT*("`\+V9O;G0^#0H@
M(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL
M93TS1'1E>'0M86QI9VXZ<FEG:'0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V
M,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\+W1R/@T*("`\='(@<W1Y;&4]
M,T1B86-K9W)O=6YD+6-O;&]R.B-C8V9F8V,[/@T*("`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-C0E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W!A
M9&1I;F<M8F]T=&]M.C1P>#L^#0H@(#QD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE
M9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)SY/<'1I;VYS(&%N9"!W87)R86YT<R!E>&5R8VES86)L
M92!A="!$96-E;6)E<B`S,2P@,C`Q,`T*("`\+V9O;G0^#0H@(#PO9&EV/@T*
M("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ-'!X.SX-"B`@
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N
M=#X-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@-'!X(&1O=6)L93MT97AT
M+6%L:6=N.FQE9G0[)SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<^)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA
M8VL@-'!X(&1O=6)L93MT97AT+6%L:6=N.G)I9VAT.R<^#0H@(#QD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y
M.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.SX-"B`@
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^#0H@(#QF;VYT('-T>6QE
M/3-$9&ES<&QA>3II;FQI;F4[/C$V+#@W-RPP,C8-"B`@/"]F;VYT/@T*("`\
M+V9O;G0^#0H@(#PO9&EV/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN
M9RUB;W1T;VTZ-'!X.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<^)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W!A
M9&1I;F<M8F]T=&]M.C1P>#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO=&0^#0H@(#QT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.F)L86-K(#1P>"!D;W5B;&4[=&5X="UA;&EG;CIL969T.R<^#0H@(#QD:78@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L
M87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[/@T*
M("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SX-"B`@/&9O;G0@<W1Y
M;&4],T1D:7-P;&%Y.FEN;&EN93L^)FYB<W`[)`T*("`\+V9O;G0^#0H@(#PO
M9F]N=#X-"B`@/"]D:78^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Y)2!S='EL93TS1"=B;W)D97(M8F]T=&]M.F)L86-K(#1P
M>"!D;W5B;&4[=&5X="UA;&EG;CIR:6=H=#LG/@T*("`\9&EV('-T>6QE/3-$
M=&5X="UA;&EG;CIR:6=H=#MT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C
M:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L^#0H@(#QF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/@T*("`\9F]N="!S='EL93TS1&1I
M<W!L87DZ:6YL:6YE.SXP+C8S.0T*("`\+V9O;G0^#0H@(#PO9F]N=#X-"B`@
M/"]D:78^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O;3HT
M<'@[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-
M"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T
M;VTZ-'!X.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q
M-C`[#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.SX-"B`@/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N=#X-
M"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C1P>#L^#0H@
M(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P.PT*("`\+V9O
M;G0^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O;3HT<'@[
M/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@
M/"]F;VYT/@T*("`\+W1D/@T*("`\+W1R/@T*("`\='(@<W1Y;&4],T1B86-K
M9W)O=6YD+6-O;&]R.B-F9F9F9F8[/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-C0E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M
M8F]T=&]M.C1P>#L^#0H@(#QD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T
M.VUA<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)SY/<'1I;VYS(&%N9"!W87)R86YT<R!E>&5R8VES86)L92!A="!*
M=6YE(#,P+"`R,#$Q#0H@(#PO9F]N=#X-"B`@/"]D:78^#0H@(#PO=&0^#0H@
M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1'1E>'0M
M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O;3HT<'@[/@T*("`\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D
M/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3IB;&%C:R`T<'@@9&]U8FQE.W1E>'0M86QI9VXZ;&5F
M=#LG/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-
M"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$.24@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`T<'@@9&]U
M8FQE.W1E>'0M86QI9VXZ<FEG:'0[)SX-"B`@/&1I=B!S='EL93TS1'1E>'0M
M86QI9VXZ<FEG:'0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R
M9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)SXQ-BPR,#DL,34R#0H@(#PO9F]N=#X-"B`@
M/"]D:78^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O;3HT
M<'@[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-
M"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T
M;VTZ-'!X.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q
M-C`[#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@-'!X
M(&1O=6)L93MT97AT+6%L:6=N.FQE9G0[)SX-"B`@/&1I=B!S='EL93TS1'1E
M>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM
M87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L^#0H@(#QF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.R0-"B`@/"]F;VYT/@T*("`\
M+V1I=CX-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#DE('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@-'!X(&1O=6)L93MT
M97AT+6%L:6=N.G)I9VAT.R<^#0H@(#QD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.G)I9VAT.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL
M969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.SX-"B`@/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<^,"XV-C`-"B`@/"]F;VYT/@T*("`\+V1I=CX-"B`@
M/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C1P>#L^#0H@(#QF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P.PT*("`\+V9O;G0^
M#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S
M='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O;3HT<'@[/@T*
M("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F
M;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`T<'@@9&]U8FQE.W1E
M>'0M86QI9VXZ;&5F=#LG/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB
M;&%C:R`T<'@@9&]U8FQE.W1E>'0M86QI9VXZ<FEG:'0[)SX-"B`@/&1I=B!S
M='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L
M87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[/@T*
M("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXQ+C8X#0H@(#PO9F]N
M=#X-"B`@/"]D:78^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1T;W`@=VED
M=&@],T0Q)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O
M;3HT<'@[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V
M,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\+W1R/@T*("`\+W1A8FQE/@T*
M("`\8G(O/@T*("`\+V1I=CX-"B`@/"]D:78^#0H@(#QD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[
M;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)SX-"B`@/"]F;VYT/@T*("`\+V1I=CX-
M"B`@/&1I=CX-"B`@/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT
M+6EN9&5N=#HS-G!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA
M<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)SY4;W1A;"!D969E<G)E9"!C;VUP96YS871I;VX@97AP96YS92!F;W(@
M=&AE(&]U='-T86YD:6YG('9A;'5E(&]F('5N=F5S=&5D('-T;V-K(&]P=&EO
M;G,@=V%S(&%P<')O>&EM871E;'D@)FYB<W`[)#0P,"PU,#`@870@2G5N92`S
M,"P@,C`Q,2P@=VAI8V@@:7,@8F5I;F<@<F5C;V=N:7IE9"!S=6)S97%U96YT
M('1O($IU;F4@,S`L(#(P,3$@;W9E<B!A('=E:6=H=&5D+6%V97)A9V4@<&5R
M:6]D(&]F(&9O<G1Y+69O=7(@;6]N=&AS+CQB<B\^#0H@(#QB<B\^#0H@(#PO
M9F]N=#X-"B`@/"]D:78^#0H@(#PO9&EV/@T*("`\9&EV('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA
M<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.SX-"B`@/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<^#0H@(#PO9F]N=#X-"B`@/"]D:78^#0H@
M(#QD:78^#0H@(#QD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI
M;F1E;G0Z,S9P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G
M:6XM<FEG:'0Z,'!T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<^26YF;W)M871I;VX@<F5G87)D:6YG('-T;V-K(&]P=&EO;G,@86YD('=A
M<G)A;G1S(&]U='-T86YD:6YG(&%N9"!E>&5R8VES86)L92!I<R!S=6UM87)I
M>F5D(&%S(&9O;&QO=W,@870@2G5N92`S,"P@,C`Q,3H\8G(O/@T*("`\8G(O
M/@T*("`\+V9O;G0^#0H@(#PO9&EV/@T*("`\+V1I=CX-"B`@/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB
M;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L^#0H@(#QF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/@T*("`\+V9O;G0^#0H@(#PO
M9&EV/@T*("`\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([/@T*("`\
M=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS
M1#@P)2!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)SX-"B`@/'1R/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$=&5X="UA;&EG
M;CIL969T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q
M-C`[#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#,Q)2!N;W=R87`],T1N;W=R87`@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF
M(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^
M)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.SX-"B`@
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N
M=#X-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,R
M)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^#0H@(#QD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.F-E;G1E<CMT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB
M;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L^#0H@(#QF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD.R<^
M5V%R<F%N=',-"B`@/"]F;VYT/@T*("`\+V1I=CX-"B`@/"]T9#X-"B`@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG
M;CIL969T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q
M-C`[#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.SX-"B`@/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N=#X-
M"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,Q)2!C
M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^#0H@(#QD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.F-E;G1E<CMT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C
M:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L^#0H@(#QF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD.R<^5V%R
M<F%N=',-"B`@/"]F;VYT/@T*("`\+V1I=CX-"B`@/"]T9#X-"B`@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL
M969T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[
M#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@/"]T<CX-"B`@/'1R/@T*("`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,Q)2!N;W=R87`],T1N;W=R87`@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[/@T*("`\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P
M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.SX-"B`@/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^
M)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#,R)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^
M#0H@(#QD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMT97AT+6EN9&5N
M=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I
M9VAT.C!P=#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IB;VQD.R<^06YD#0H@(#PO9F]N=#X-"B`@/"]D:78^#0H@(#PO
M=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS
M1'1E>'0M86QI9VXZ;&5F=#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO=&0^#0H@(#QT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P.PT*
M("`\+V9O;G0^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0S,24@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/@T*("`\9&EV
M('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([=&5X="UI;F1E;G0Z,'!T.V1I
M<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[
M/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M8F]L9#LG/D%N9`T*("`\+V9O;G0^#0H@(#PO9&EV/@T*("`\+W1D/@T*("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF
M(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\+W1R/@T*("`\='(^#0H@
M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R
M87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[/@T*("`\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*
M("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,S$E(&YO=W)A<#TS1&YO
M=W)A<"!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L^#0H@(#QF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO=&0^
M#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N
M;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[/@T*("`\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D
M/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,S(E(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO
M=W)A<#X-"B`@/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.W1E>'0M
M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G
M:6XM<FEG:'0Z,'!T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.F)O;&0[)SY/<'1I;VYS#0H@(#PO9F]N=#X-"B`@/"]D
M:78^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L^#0H@(#QF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO=&0^#0H@
M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1'1E>'0M
M86QI9VXZ;&5F=#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0S,24@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P
M/@T*("`\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([=&5X="UI;F1E
M;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR
M:6=H=#HP<'0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z8F]L9#LG/D]P=&EO;G,-"B`@/"]F;VYT/@T*("`\+V1I=CX-
M"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@/"]T
M<CX-"B`@/'1R/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M;F]W<F%P/3-$;F]W<F%P/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[9F]N="UW96EG:'0Z8F]L9#LG/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO
M=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S,24@;F]W<F%P
M/3-$;F]W<F%P/@T*("`\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([
M=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T
M.VUA<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[9F]N="UW96EG:'0Z8F]L9#LG/D5X97)C:7-E#0H@(#PO9F]N=#X-
M"B`@/"]D:78^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!N;W=R87`],T1N;W=R87`^#0H@(#QF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD.R<^)B,Q-C`[#0H@(#PO9F]N
M=#X-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.SX-"B`@/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,R)2!C;VQS<&%N/3-$,B!N
M;W=R87`],T1N;W=R87`^#0H@(#QD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E
M;G1E<CMT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F
M=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD.R<^3W5T<W1A;F1I;F<-"B`@
M/"]F;VYT/@T*("`\+V1I=CX-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.SX-"B`@
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N
M=#X-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.SX-"B`@/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,Q)2!C;VQS<&%N/3-$,B!N
M;W=R87`],T1N;W=R87`^#0H@(#QD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E
M;G1E<CMT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F
M=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD.R<^17AE<F-I<V%B;&4-"B`@
M/"]F;VYT/@T*("`\+V1I=CX-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.SX-"B`@
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N
M=#X-"B`@/"]T9#X-"B`@/"]T<CX-"B`@/'1R/@T*("`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ8FQA8VL@,G!X(&1O=6)L93LG/@T*("`\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z8F]L9#LG/B8C,38P.PT*
M("`\+V9O;G0^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0S,24@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ8FQA8VL@,G!X(&1O=6)L93LG/@T*("`\9&EV('-T>6QE/3-$=&5X="UA
M;&EG;CIC96YT97([=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R
M9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z8F]L9#LG/@T*("`\9F]N
M="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.SY0<FEC97,-"B`@/"]F;VYT/@T*
M("`\+V9O;G0^#0H@(#PO9&EV/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$<&%D
M9&EN9RUB;W1T;VTZ,G!X.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.F)O;&0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\
M+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X.SX-"B`@/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N=#X-
M"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,R)2!C
M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3IB;&%C:R`R<'@@9&]U8FQE.R<^#0H@(#QD:78@<W1Y;&4],T1T97AT
M+6%L:6=N.F-E;G1E<CMT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM
M87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L^#0H@(#QF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD.R<^#0H@(#QF
M;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[/BA3:&%R97,I#0H@(#PO9F]N
M=#X-"B`@/"]F;VYT/@T*("`\+V1I=CX-"B`@/"]T9#X-"B`@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.W!A9&1I;F<M8F]T=&]M.C)P>#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO=&0^#0H@(#QT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1'1E>'0M86QI9VXZ
M;&5F=#MP861D:6YG+6)O='1O;3HR<'@[/@T*("`\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,S$E(&-O;'-P86X],T0R(&YO
M=W)A<#TS1&YO=W)A<"!S='EL93TS1"=B;W)D97(M8F]T=&]M.F)L86-K(#)P
M>"!D;W5B;&4[)SX-"B`@/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R
M.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P
M=#MM87)G:6XM<FEG:'0Z,'!T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)SX-"B`@/&9O;G0@<W1Y;&4],T1D
M:7-P;&%Y.FEN;&EN93L^*%-H87)E<RD-"B`@/"]F;VYT/@T*("`\+V9O;G0^
M#0H@(#PO9&EV/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T
M;VTZ,G!X.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q
M-C`[#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@/"]T<CX-"B`@/'1R('-T>6QE
M/3-$8F%C:V=R;W5N9"UC;VQO<CHC8V-F9F-C.SX-"B`@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.SX-
M"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[)`T*("`\
M+V9O;G0^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0S,24@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.SX-"B`@/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<^,"XS,S,-"B`@/"]F;VYT/@T*("`\+W1D
M/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT
M.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@
M(#PO9F]N=#X-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.SX-"B`@/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]T
M9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,Q)2!S='EL93TS
M1'1E>'0M86QI9VXZ<FEG:'0[/@T*("`\9&EV('-T>6QE/3-$=&5X="UA;&EG
M;CIR:6=H=#MT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM
M;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L^#0H@(#QF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG/C<W,RPW-3(-"B`@/"]F;VYT/@T*("`\+V1I=CX-
M"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG
M;CIR:6=H=#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B8C
M,38P.PT*("`\+V9O;G0^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L^#0H@(#QF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P.PT*("`\+V9O;G0^
M#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S,"4@
M<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.SX-"B`@/&1I=B!S='EL93TS1'1E
M>'0M86QI9VXZ<FEG:'0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[
M;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)SXW-S,L-S4R#0H@(#PO9F]N=#X-"B`@
M/"]D:78^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L^#0H@(#QF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO=&0^
M#0H@(#PO='(^#0H@(#QT<B!S='EL93TS1&)A8VMG<F]U;F0M8V]L;W(Z(V9F
M9F9F9CL^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL
M93TS1'1E>'0M86QI9VXZ;&5F=#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG/B9N8G-P.R0-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,S$E('-T>6QE/3-$=&5X="UA;&EG
M;CIR:6=H=#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/C`N
M-3`P#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L^#0H@(#QF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P.PT*("`\+V9O;G0^
M#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S
M='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[/@T*("`\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF
M(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,S$E('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L^#0H@
M(#QD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M:6YD96YT.C!P
M=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z
M,'!T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^-RPU,S4L
M.#`P#0H@(#PO9F]N=#X-"B`@/"]D:78^#0H@(#PO=&0^#0H@(#QT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P.PT*
M("`\+V9O;G0^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[/@T*("`\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\
M+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,S`E('-T>6QE/3-$=&5X="UA;&EG;CIR
M:6=H=#L^#0H@(#QD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M
M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G
M:6XM<FEG:'0Z,'!T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<^-RPS-C4L-#`P#0H@(#PO9F]N=#X-"B`@/"]D:78^#0H@(#PO=&0^#0H@
M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1'1E>'0M
M86QI9VXZ;&5F=#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO=&0^#0H@(#PO='(^#0H@(#QT<B!S
M='EL93TS1&)A8VMG<F]U;F0M8V]L;W(Z(V-C9F9C8SL^#0H@(#QT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.R0-
M"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,S$E('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L^#0H@(#QF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/C`N-C4P#0H@(#PO9F]N=#X-"B`@
M/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIR
M:6=H=#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P
M.PT*("`\+V9O;G0^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L^#0H@(#QF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P.PT*("`\+V9O;G0^#0H@
M(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S,24@<W1Y
M;&4],T1T97AT+6%L:6=N.G)I9VAT.SX-"B`@/&1I=B!S='EL93TS1'1E>'0M
M86QI9VXZ<FEG:'0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R
M9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)SXQ,C`L,#`P#0H@(#PO9F]N=#X-"B`@/"]D
M:78^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L^#0H@(#QF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO=&0^#0H@
M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1'1E>'0M
M86QI9VXZ<FEG:'0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[/@T*
M("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F
M;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,S`E('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L^#0H@(#QD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L
M;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.SX-"B`@/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^,3(P+#`P,`T*("`\+V9O;G0^
M#0H@(#PO9&EV/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[/@T*("`\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\
M+W1D/@T*("`\+W1R/@T*("`\='(@<W1Y;&4],T1B86-K9W)O=6YD+6-O;&]R
M.B-F9F9F9F8[/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[/@T*("`\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)SXF;F)S<#LD#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,Q)2!S='EL93TS1'1E>'0M
M86QI9VXZ<FEG:'0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)SXP+C<U,`T*("`\+V9O;G0^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L^#0H@
M(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P.PT*("`\+V9O
M;G0^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[/@T*("`\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*
M("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,S$E('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L^
M#0H@(#QD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M:6YD96YT
M.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG
M:'0Z,'!T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^-2PV
M,C4L,#`P#0H@(#PO9F]N=#X-"B`@/"]D:78^#0H@(#PO=&0^#0H@(#QT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1'1E>'0M86QI9VXZ
M;&5F=#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P
M.PT*("`\+V9O;G0^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[/@T*("`\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*
M("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,S`E('-T>6QE/3-$=&5X="UA;&EG
M;CIR:6=H=#L^#0H@(#QD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W1E
M>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM
M87)G:6XM<FEG:'0Z,'!T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<^-2PV,C4L,#`P#0H@(#PO9F]N=#X-"B`@/"]D:78^#0H@(#PO=&0^
M#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1'1E
M>'0M86QI9VXZ;&5F=#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL
M:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO=&0^#0H@(#PO='(^#0H@(#QT
M<B!S='EL93TS1&)A8VMG<F]U;F0M8V]L;W(Z(V-C9F9C8SL^#0H@(#QT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1'1E>'0M86QI9VXZ
M;&5F=#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P
M.R0-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,S$E('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L^#0H@(#QF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/C`N.3@P#0H@(#PO9F]N=#X-
M"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*
M("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H@(#QF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO
M=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S,24@<W1Y;&4]
M,T1T97AT+6%L:6=N.G)I9VAT.SX-"B`@/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ<FEG:'0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN
M+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)SXT-3`L,#`P#0H@(#PO9F]N=#X-"B`@/"]D:78^
M#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@(#PO
M9F]N=#X-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-
M"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B8C
M,38P.PT*("`\+V9O;G0^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0S,"4@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.SX-"B`@
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[=&5X="UI;F1E;G0Z,'!T
M.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP
M<'0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXR-2PP,#`-
M"B`@/"]F;VYT/@T*("`\+V1I=CX-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\+W1R/@T*
M("`\='(@<W1Y;&4],T1B86-K9W)O=6YD+6-O;&]R.B-F9F9F9F8[/@T*("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF
M;F)S<#LD#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#,Q)2!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[/@T*
M("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXQ+C`P,`T*("`\+V9O
M;G0^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L^#0H@(#QF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO=&0^#0H@
M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1'1E>'0M
M86QI9VXZ<FEG:'0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[/@T*
M("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F
M;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,S$E('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L^#0H@(#QD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L
M;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.SX-"B`@/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^,BPP-3`L,#`P#0H@(#PO9F]N
M=#X-"B`@/"]D:78^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L^#0H@(#QF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P.PT*("`\+V9O;G0^#0H@
M(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL
M93TS1'1E>'0M86QI9VXZ<FEG:'0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V
M,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,S`E('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L^#0H@(#QD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M:6YD96YT.C!P=#MD
M:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T
M.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^,BPP-3`L,#`P
M#0H@(#PO9F]N=#X-"B`@/"]D:78^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L^
M#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P.PT*("`\
M+V9O;G0^#0H@(#PO=&0^#0H@(#PO='(^#0H@(#QT<B!S='EL93TS1&)A8VMG
M<F]U;F0M8V]L;W(Z(V-C9F9C8SL^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L^#0H@(#QF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.R0-"B`@/"]F;VYT/@T*
M("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,S$E('-T
M>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG/C$N,C4P#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG
M;CIL969T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q
M-C`[#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L^#0H@(#QF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P.PT*("`\+V9O;G0^
M#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S
M='EL93TS1'1E>'0M86QI9VXZ;&5F=#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO=&0^#0H@(#QT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S,24@<W1Y;&4],T1T97AT+6%L
M:6=N.G)I9VAT.SX-"B`@/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[
M=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T
M.VUA<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)SXU,"PP,#`-"B`@/"]F;VYT/@T*("`\+V1I=CX-"B`@/"]T9#X-
M"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<^)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L^
M#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P.PT*("`\
M+V9O;G0^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L^#0H@(#QF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO=&0^
M#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S,"4@<W1Y;&4],T1T
M97AT+6%L:6=N.G)I9VAT.SX-"B`@/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ
M<FEG:'0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE
M9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)SXU,"PP,#`-"B`@/"]F;VYT/@T*("`\+V1I=CX-"B`@
M/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@/"]T<CX-
M"B`@/'1R('-T>6QE/3-$8F%C:V=R;W5N9"UC;VQO<CHC9F9F9F9F.SX-"B`@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C)P>#L^#0H@(#QF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.R0-"B`@/"]F;VYT/@T*("`\+W1D
M/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,S$E('-T>6QE/3-$
M=&5X="UA;&EG;CIR:6=H=#MP861D:6YG+6)O='1O;3HR<'@[/@T*("`\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXQ+C8U,`T*("`\+V9O;G0^#0H@
M(#PO=&0^#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL
M93TS1'1E>'0M86QI9VXZ<FEG:'0[<&%D9&EN9RUB;W1T;VTZ,G!X.SX-"B`@
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N
M=#X-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MP861D:6YG+6)O='1O;3HR<'@[
M/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@
M/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L:60[
M=&5X="UA;&EG;CIL969T.R<^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO=&0^#0H@(#QT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0S,24@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3IB;&%C:R`R<'@@<V]L:60[=&5X="UA;&EG;CIR:6=H=#LG/@T*("`\9&EV
M('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MT97AT+6EN9&5N=#HP<'0[9&ES
M<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L^
M#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/@T*("`\9F]N="!S
M='EL93TS1&1I<W!L87DZ:6YL:6YE.SXR,#`L,#`P#0H@(#PO9F]N=#X-"B`@
M/"]F;VYT/@T*("`\+V1I=CX-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I
M;F<M8F]T=&]M.C)P>#L^#0H@(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL
M:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG/B8C,38P.PT*("`\+V9O;G0^#0H@(#PO=&0^#0H@(#QT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[
M<&%D9&EN9RUB;W1T;VTZ,G!X.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ8FQA8VL@,G!X('-O;&ED.W1E>'0M86QI9VXZ;&5F=#LG/@T*("`\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*
M("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,S`E('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@,G!X('-O;&ED.W1E>'0M86QI
M9VXZ<FEG:'0[)SX-"B`@/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[
M=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T
M.VUA<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)SX-"B`@/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L^,C`P
M+#`P,`T*("`\+V9O;G0^#0H@(#PO9F]N=#X-"B`@/"]D:78^#0H@(#PO=&0^
M#0H@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1'1E
M>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O;3HR<'@[/@T*("`\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\
M+W1D/@T*("`\+W1R/@T*("`\='(@<W1Y;&4],T1B86-K9W)O=6YD+6-O;&]R
M.B-C8V9F8V,[/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ-'!X.SX-
M"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@(#PO
M9F]N=#X-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#,Q)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O;3HT
M<'@[/B8C,38P.PT*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T
M;VTZ-'!X.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q
M-C`[#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MP861D:6YG
M+6)O='1O;3HT<'@[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C
M:R`T<'@@9&]U8FQE.W1E>'0M86QI9VXZ;&5F=#LG/@T*("`\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D
M/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,S$E('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ8FQA8VL@-'!X(&1O=6)L93MT97AT+6%L:6=N.G)I
M9VAT.R<^#0H@(#QD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M
M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G
M:6XM<FEG:'0Z,'!T.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<^,38L.#`T+#4U,@T*("`\+V9O;G0^#0H@(#PO9&EV/@T*("`\+W1D/@T*
M("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ-'!X.SX-"B`@/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]T
M9#X-"B`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$
M=&5X="UA;&EG;CIR:6=H=#MP861D:6YG+6)O='1O;3HT<'@[/@T*("`\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF(S$V,#L-"B`@/"]F;VYT/@T*
M("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`T<'@@9&]U8FQE.W1E>'0M86QI
M9VXZ;&5F=#LG/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SXF
M(S$V,#L-"B`@/"]F;VYT/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,S`E('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@
M-'!X(&1O=6)L93MT97AT+6%L:6=N.G)I9VAT.R<^#0H@(#QD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L
M;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.SX-"B`@/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^,38L,C`Y+#$U,@T*("`\+V9O
M;G0^#0H@(#PO9&EV/@T*("`\+W1D/@T*("`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB
M;W1T;VTZ-'!X.SX-"B`@/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^
M)B,Q-C`[#0H@(#PO9F]N=#X-"B`@/"]T9#X-"B`@/"]T<CX-"B`@/"]T86)L
M93X-"B`@/&)R+SX-"B`@/&)R+SX-"B`@/"]D:78^#0H@(#QD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO
M8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)SX-"B`@/"]F;VYT/@T*("`\+V1I
M=CX-"B`@/&1I=CX-"B`@/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT
M97AT+6EN9&5N=#HS-G!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T
M.VUA<F=I;BUR:6=H=#HP<'0[/@T*("`\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)SY4:&4@:6YT<FEN<VEC('9A;'5E(&]F(&5X97)C:7-A8FQE(&)U
M="!U;F5X97)C:7-E9"!I;BUT:&4M;6]N97D@<W1O8VL@;W!T:6]N<R!A;F0@
M=V%R<F%N=',@870@2G5N92`S,"P@,C`Q,2!W87,@87!P<F]X:6UA=&5L>2`F
M;F)S<#LD-2PS-CDL,S8P+"!B87-E9"!O;B!A(&9A:7(@;6%R:V5T('9A;'5E
M(&]F("9N8G-P.R0P+CDX('!E<B!S:&%R92!O;B!*=6YE(#,P+"`R,#$Q+B!4
M:&4@:6YT<FEN<VEC('9A;'5E(&]F(&5X97)C:7-A8FQE(&)U="!U;F5X97)C
M:7-E9"!I;BUT:&4M;6]N97D@<W1O8VL@;W!T:6]N<R!A;F0@=V%R<F%N=',@
M870@1&5C96UB97(@,S$L(#(P,3`@=V%S(&%P<')O>&EM871E;'D@)FYB<W`[
M)#(V+#8P,"P@8F%S960@;VX@82!F86ER(&UA<FME="!V86QU92!O9B`F;F)S
M<#LD,"XS-2!P97(@<VAA<F4@;VX@1&5C96UB97(@,S$L(#(P,3`N/&)R+SX-
M"B`@/&)R+SX-"B`@/"]F;VYT/@T*("`\+V1I=CX-"B`@/"]D:78^#0H@(`T*
M("`\+V1I=CX-"B`@/"]D:78^#0H@(#QD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[=&5X="UI;F1E;G0Z,S9P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL
M969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.SX-"B`@/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<^3W5T<W1A;F1I;F<@;W!T:6]N<R!A;F0@=V%R<F%N
M=',@=&\@86-Q=6ER92`T,C4L,#`P('-H87)E<R!O9B!T:&4@0V]M<&%N>28C
M.#(Q-SMS(&-O;6UO;B!S=&]C:R!H860@;F]T('9E<W1E9"!A="!*=6YE(#,P
M+"`R,#$Q+B!!="!*=6YE(#,P+"`R,#$Q+"!W87)R86YT<R!A;F0@;W!T:6]N
M<R!E>&5R8VES86)L92!D;R!N;W0@:6YC;'5D92!W87)R86YT<R!T;R!A8W%U
M:7)E(#$W,"PT,#`@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!T:&%T(&%R92!C
M;VYT:6YG96YT('5P;VX@=&AE(&5X97)C:7-E(&]F('=A<G)A;G1S(&-O;G1A
M:6YE9"!I;B!U;FET<R!S;VQD(&%S('!A<G0@;V8@=&AE('1H:7)D('!R:79A
M=&4@<&QA8V5M96YT("AS964@3F]T92`T*2X-"B`@/"]F;VYT/@T*("`\+V1I
M=CX-"B`@/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N
M=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I
M9VAT.C!P=#L^#0H@(#QB<B\^#0H@(#PO9&EV/@T*("`\+V1I=CX-"B`@/"]D
M:78^#0H@(#PO9&EV/@T*("`\+V1I=CX-"CPO9&EV/@T*("`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
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M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,D@^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q
M,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY#;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<R!$:7-C;&]S=7)E(%M!
M8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,@1&ES8VQO<W5R
M92!;5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQD:78^/&1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M
M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G
M:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[9F]N="UW96EG:'0Z8F]L
M9#L@/C@N(`T*/"]F;VYT/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[
M9F]N="UW96EG:'0Z8F]L9#L@/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC
M:65S(`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS1'1E
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M.R`^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93II=&%L:6,[9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^0U)!1$$@#0H\+V9O;G0^#0H\+V1I
M=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C!P
M=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z
M,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-
M"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M=&5X="UI;F1E;G0Z,S9P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P
M=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/D5F9F5C=&EV92!-87)C:"`R,BP@,C`P-BP@=&AE($-O;7!A;GD@
M96YT97)E9"!I;G1O(&$@0U)!1$$L(&%S(&%M96YD960L('=I=&@@=&AE($Y)
M3D13(&]F('1H92!.24@N(%1H92!#4D%$02!I<R!F;W(@82!T97)M(&]F(#8V
M(&UO;G1H<R!F<F]M('1H92!E9F9E8W1I=F4@9&%T92!A;F0@8V%N(&)E('5N
M:6QA=&5R86QL>2!T97)M:6YA=&5D(&)Y(&5I=&AE<B!P87)T>2!B>2!P<F]V
M:61I;F<@=W)I='1E;B!N;W1I8V4@=VET:&EN('-I>'1Y(&1A>7,N(%1H92!#
M4D%$02!P<F]V:61E<R!F;W(@=&AE(&-O;&QA8F]R871I;VX@8F5T=V5E;B!T
M:&4@<&%R=&EE<R!I;B!T:&4@:61E;G1I9FEC871I;VX@86YD(&5V86QU871I
M;VX@;V8@86=E;G1S('1H870@=&%R9V5T('1H92!.=6-L96%R(%)E8V5P=&]R
M($-O4F5P<F5S<V]R("A.+4-O4BD@<&%T:'=A>2!F;W(@9VQI;VUA(&-E;&P@
M9&EF9F5R96YT:6%T:6]N+B!4:&4@0U)!1$$@86QS;R!P<F]V:61E<R!T:&%T
M($Y)3D13(&%N9"!T:&4@0V]M<&%N>2!W:6QL(&-O;F1U8W0@<F5S96%R8V@@
M=&\@9&5T97)M:6YE(&EF(&5X<')E<W-I;VX@;V8@3BU#;U(@8V]R<F5L871E
M<R!W:71H('!R;V=N;W-I<R!I;B!G;&EO;6$@<&%T:65N=',N(%!U<G-U86YT
M('1O('1H92!#4D%$02P@=&AE($-O;7!A;GD@:6YI=&EA;&QY(&%G<F5E9"!T
M;R!P<F]V:61E(&9U;F1S('5N9&5R('1H92!#4D%$02!I;B!T:&4@86UO=6YT
M(&]F("9N8G-P.R0R,#`L,#`P('!E<B!Y96%R('1O(&9U;F0@='=O('1E8VAN
M:6-A;"!A<W-I<W1A;G1S(&9O<B!T:&4@=&5C:&YI8V%L+"!S=&%T:7-T:6-A
M;"!A;F0@861M:6YI<W1R871I=F4@<W5P<&]R="!F;W(@=&AE(')E<V5A<F-H
M(&%C=&EV:71I97,L(&%S('=E;&P@87,@=&\@<&%Y(&9O<B!S=7!P;&EE<R!A
M;F0@=')A=F5L(&5X<&5N<V5S+B!4:&4@9FER<W0@)FYB<W`[)#(P,"PP,#`@
M=V%S(&1U92!W:71H:6X@,3@P(&1A>7,@;V8@=&AE(&5F9F5C=&EV92!D871E
M(&%N9"!W87,@<&%I9"!I;B!F=6QL(&]N($IU;'D@-BP@,C`P-BX@5&AE('-E
M8V]N9"`F;F)S<#LD,C`P+#`P,"!W87,@<&%I9"!I;B!F=6QL(&]N($IU;F4@
M,CDL(#(P,#<N($EN($IU;F4@,C`P."P@=&AE($-2041!('=A<R!E>'1E;F1E
M9"!T;R!397!T96UB97(@,S`L(#(P,#DL('=I=&@@;F\@861D:71I;VYA;"!F
M=6YD:6YG(')E<75I<F5D(&9O<B!T:&4@<&5R:6]D(&)E='=E96X@2G5L>2`Q
M+"`R,#`X(&%N9"!397!T96UB97(@,S`L(#(P,#@N($9O<B!T:&4@<&5R:6]D
M(&9R;VT@3V-T;V)E<B`Q+"`R,#`X('1H<F]U9V@@4V5P=&5M8F5R(#,P+"`R
M,#`Y+"!T:&4@0V]M<&%N>2!A9W)E960@=&\@<')O=FED92!A9&1I=&EO;F%L
M(&9U;F1I;F<@=6YD97(@=&AE($-2041!(&]F("9N8G-P.R0R,#`L,#`P+"!T
M;R!B92!P86ED(&EN(&9O=7(@<75A<G1E<FQY(&EN<W1A;&QM96YT<R!O9B`F
M;F)S<#LD-3`L,#`P+"!E86-H(&-O;6UE;F-I;F<@;VX@3V-T;V)E<B`Q+"`R
M,#`X+B!4:&4@9FER<W0@86YD('-E8V]N9"!Q=6%R=&5R;'D@:6YS=&%L;&UE
M;G1S(&]F("9N8G-P.R0U,"PP,#`@=V5R92!P86ED(&]N(%-E<'1E;6)E<B`R
M.2P@,C`P."!A;F0@36%R8V@@-2P@,C`P.2P@<F5S<&5C=&EV96QY+B8C,38P
M.T1U<FEN9R!!=6=U<W0F(S$V,#LR,#`Y+"!T:&4@0V]M<&%N>2!E;G1E<F5D
M(&EN=&\@86X@86UE;F1M96YT('1O('1H92!#4D%$02!T;R!E>'1E;F0@:71S
M('1E<FT@9G)O;2!397!T96UB97(@,S`L(#(P,#D@=&AR;W5G:"!397!T96UB
M97(@,S`L(#(P,3$N)B,Q-C`[4'5R<W5A;G0@=&\@<W5C:"!A;65N9&UE;G0L
M('1H92!#;VUP86YY(&AA<R!A9W)E960@=&\@86=G<F5G871E('!A>6UE;G1S
M(&]F("9N8G-P.R0Q,#`L,#`P(&EN('1W;R!I;G-T86QL;65N=',@;V8@)FYB
M<W`[)#4P+#`P,"P@<&%Y86)L92!O;B!/8W1O8F5R(#$L(#(P,3`@86YD($IA
M;G5A<GD@-2P@,C`Q,2P@:6YC;'5S:79E(&]F(&%N>2!P<FEO<B!U;G!A:60@
M8V]M;6ET;65N=',N(%1H92!/8W1O8F5R(#$L(#(P,3`@:6YS=&%L;&UE;G0@
M=V%S('!A:60@;VX@4V5P=&5M8F5R(#(Y+"`R,#$P(&%N9"!T:&4@2F%N=6%R
M>2`U+"`R,#$Q(&EN<W1A;&QM96YT('=A<R!P86ED(&]N($1E8V5M8F5R(#(W
M+"`R,#$P+B`-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6EN
M9&5N=#HP<'0[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\
M9&EV/B8C,38P.R`-"CPO9&EV/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M
M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.R`^/&)R("\^#0H-"CPO9&EV/CQD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,S9P=#MD
M:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
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M('!A>6UE;G0@;V8@)FYB<W`[)#(U+#`P,"!T;R!.24@@=VET:&EN(#8P(&1A
M>7,@;V8@4V5P=&5M8F5R(#$Y+"`R,#`X+"!A;F0@9F]R(&$@;6EN:6UU;2!A
M;FYU86P@<F]Y86QT>2!O9B`F;F)S<#LD,S`L,#`P(&]N($IA;G5A<GD@,2!O
M9B!E86-H(&-A;&5N9&%R('EE87(@9F]L;&]W:6YG('1H92!Y96%R(&EN('=H
M:6-H('1H92!#4D%$02!I<R!T97)M:6YA=&5D+B!4:&4@86=R965M96YT(&%L
M<V\@<')O=FED97,@9F]R('1H92!#;VUP86YY('1O('!A>2!S<&5C:69I960@
M<F]Y86QT:65S(&)A<V5D(&]N("AI*2!N970@<V%L97,@8GD@=&AE($-O;7!A
M;GD@86YD(&ET<R!S=6(M;&EC96YS965S+"`H:6DI('1H92!A8VAI979E;65N
M="!O9B!C97)T86EN(&-L:6YI8V%L(&)E;F-H;6%R:W,L(&%N9"`H:6EI*2!T
M:&4@9W)A;G1I;F<@;V8@<W5B;&EC96YS97,N(%1H92!#;VUP86YY('!A:60@
M=&AE(&EN:71I86P@)FYB<W`[)#(U+#`P,"!O8FQI9V%T:6]N(&]N($YO=F5M
M8F5R(#$P+"`R,#`X(&%N9"!C:&%R9V5D('1H92!A;6]U;G0@=&\@9V5N97)A
M;"!A;F0@861M:6YI<W1R871I=F4@8V]S=',@9'5R:6YG('1H92!Y96%R(&5N
M9&5D($1E8V5M8F5R(#,Q+"`R,#`X+B!!<R!O9B!*=6YE(#,P+"`R,#$Q+"!N
M;R!A9&1I=&EO;F%L(&%M;W5N=',@=V5R92!D=64@<'5R<W5A;G0@=&\@=&AI
M<R!A9W)E96UE;G0N(`T*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS1'1E
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M.R`^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93II=&%L:6,[9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^4F5S96%R8V@@86YD($1E=F5L;W!M
M96YT($-O;G1R86-T<R`-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[
M;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]D:78^
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HS-G!T
M.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP
M<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^3VX@1F5B<G5A
M<GD@-2P@,C`P-RP@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@='=O+7EE
M87(@86=R965M96YT('!U<G-U86YT('1O('=H:6-H('1H92!#;VUP86YY(&5N
M9V%G960@0VAE;2U-87-T97(@=&\@<WEN=&AE<VEZ92!A(&-O;7!O=6YD(&1E
M<VEG;F%T960@87,@3$(M,3`P+"!A;F0@86YY(&]T:&5R(&-O;7!O=6YD('-Y
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M96X@;F]T:6-E+B`-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R
M9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]D:78^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HS-G!T.V1I
M<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^3VX@2F%N=6%R>2`R
M.2P@,C`P."P@=&AE($-H96TM36%S=&5R($%G<F5E;65N="!W87,@86UE;F1E
M9"!T;R!E>'1E;F0@:71S('1E<FT@=&\@1F5B<G5A<GD@,34L(#(P,30L(&%N
M9"!T;R!E>'!R97-S;'D@<')O=FED92!F;W(@=&AE(&1E<VEG;B!A;F0@<WEN
M=&AE<VES(&]F(&$@;F5W('-E<FEE<R!O9B!C;VUP;W5N9',@9&5S:6=N871E
M9"!A<R!,0BTS,#`N(%!U<G-U86YT('1O('1H92!#:&5M+4UA<W1E<B!!9W)E
M96UE;G0L(&%S(&%M96YD960L('1H92!#;VUP86YY(')E:6UB=7)S960@0VAE
M;2U-87-T97(@9F]R('1H92!C;W-T<R!O9B!M871E<FEA;',L(&QA8F]R(&%N
M9"!E>'!E;G-E<R!A9V=R96=A=&EN9R`F;F)S<#LD,2PU,#`@86YD("9N8G-P
M.R0R,"PP,#`@9'5R:6YG('1H92!T:')E92!M;VYT:',@96YD:6YG($IU;F4@
M,S`L(#(P,3$@86YD(#(P,3`L(')E<W!E8W1I=F5L>2X@1'5R:6YG('1H92!S
M:7@@;6]N=&AS(&5N9&EN9R!*=6YE(#,P+"`R,#$Q(&%N9"`R,#$P+"!R96EM
M8G5R<V5M96YT<R!T;R!#:&5M+4UA<W1E<B!A;6]U;G1E9"!T;R`F;F)S<#LD
M-BPS,C4@86YD("9N8G-P.R0S,RPP,#`L(')E<W!E8W1I=F5L>2X@#0H\+V9O
M;G0^#0H\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M
M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G
M:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/B8C,38P.R`-"CPO9F]N=#X-"CPO9&EV/CQD:78^/&1I=B!S='EL93TS1'1E
M>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HS-G!T.V1I<W!L87DZ8FQO8VL[
M;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[3VX@36%R8V@@,3<L(#(P,3`L
M('1H92!#;VUP86YY(&5N9V%G960@5&AE<F%D97@@4WES=&5M<RP@26YC+B!T
M;R!A<W-I<W0@=&AE($-O;7!A;GD@:6X@8G)I;F=I;F<@3$(M,3`P('1H<F]U
M9V@@=&AE($9$02!A<'!R;W9A;"!P<F]C97-S(&%T(&$@=&]T86P@97-T:6UA
M=&5D(&-O<W0@;V8@)FYB<W`[)#$P-2PP-C0L(&]F('=H:6-H("9N8G-P.R0Q
M-2PR,#4@:&%D(&)E96X@:6YC=7)R960@=&AR;W5G:"!*=6YE(#,P+"`R,#$Q
M+B!!<R!O9B!*=6YE(#,P+"`R,#$Q+"!W;W)K('=A<R!P<F]C965D:6YG('5N
M9&5R('1H:7,@8V]N=')A8W0N($1R+B!2;V)E<G0@0BX@4F]Y9',L('1H92!F
M;W5N9&5R+"!#:&%I<FUA;B!O9B!T:&4@0F]A<F0@86YD($UE9&EC86P@1&ER
M96-T;W(@;V8@5&AE<F%D97@@4WES=&5M<RP@26YC+BP@=V%S(&%P<&]I;G1E
M9"!T;R!T:&4@0V]M<&%N>28C.#(Q-SMS($)O87)D(&]F($1I<F5C=&]R<R!O
M;B!-87D@,BP@,C`Q,2X-"CPO9F]N=#X-"CPO9&EV/@T*/"]D:78^/&1I=B!S
M='EL93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.R`^/&)R("\^
M#0H-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI
M;F1E;G0Z,S9P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G
M:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/D]N($UA<F-H(#$W+"`R,#$Q+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@
M86X@86=R965M96YT('=I=&@@07-C96YT86=E(%!H87)M82!'<F]U<"!T;R!C
M;VYD=6-T(&$@<V5R:65S(&]F('-T=61I97,@870@82!T;W1A;"!E<W1I;6%T
M960@8V]S="!O9B`F;F)S<#LD,C`L,#`P+"!O9B!W:&EC:"`F;F)S<#LD,34L
M,#`P(&AA9"!B965N('!A:60@=&AR;W5G:"!*=6YE(#,P+"`R,#$Q+B!!<V-E
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M=7`N(`T*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ
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M92`S,"P@,C`Q,2P@=V]R:R!O<F1E<G,@9F]R('-T=61I97,@:&%V:6YG(&$@
M=&]T86P@97-T:6UA=&5D(&-O<W0@;V8@)FYB<W`[)#$P."PR-#`@=V5R92!I
M;B!P<F]C97-S('5N9&5R('1H:7,@86=R965M96YT+B!!<R!O9B!*=6YE(#,P
M+"`R,#$Q+"!T:&4@0V]M<&%N>2!H860@<&%I9"`F;F)S<#LD-30L,3(P('1O
M=V%R9',@=&AE<V4@=V]R:R!O<F1E<G,N(`T*/"]F;VYT/@T*/"]D:78^/&1I
M=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.R`^/&)R
M("\^#0H-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X
M="UI;F1E;G0Z,S9P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM
M87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<@/B8C,38P.T]N($IA;G5A<GD@,3@L(#(P,3$L('1H92!#;VUP86YY(&5N
M=&5R960@:6YT;R!A;B!A9W)E96UE;G0@=VET:"!!<V@@4W1E=F5N<R!F;W(@
M82!S97)I97,@;V8@<W1U9&EE<R!W:71H(&$@=&]T86P@97-T:6UA=&5D(&-O
M<W0@;V8@)FYB<W`[)#DP+#`P,"X@07,@;V8@2G5N92`S,"P@,C`Q,2P@=&AE
M($-O;7!A;GD@:&%D('!A:60@)FYB<W`[)#(Y+#<P,"!T;W=A<F1S('1H97-E
M('-T=61I97,N(`T*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M
M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.R`^/&)R("\^#0H-"CPO9&EV/CQD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I
M<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[
M(#X\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.FET86QI8SMD:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[9F]N="UW96EG:'0Z8F]L9#LG(#Y#;VYS=6QT:6YG($%R<F%N9V5M96YT
M<R`-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE
M9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z
M,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HS-G!T.V1I<W!L87DZ8FQO
M8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^3VX@07!R:6P@-RP@,C`Q,"P@=&AE
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M:&4@;&5A9"!C;VUP;W5N9"!O9B!T:&4@3$(M,3`P('-E<FEE<RX@5&AE(&%G
M<F5E;65N="!C86QL960@9F]R(&%N(&%N;G5A;"!F964@;V8@)FYB<W`[)#(U
M+#`P,"P@<&%Y86)L92!I;B!T=V\@:6YS=&%L;&UE;G1S(&]F("9N8G-P.R0Q
M,BPU,#`@;VX@07!R:6P@,34L(#(P,3`@86YD($]C=&]B97(@,34L(#(P,3`N
M($]N($9E8G)U87)Y(#$X+"`R,#$Q+"!T:&4@0V]M<&%N>28C.#(Q-SMS($)O
M87)D(&]F($1I<F5C=&]R<R!A<'!R;W9E9"!A(&]N92UY96%R(&5X=&5N<VEO
M;B!O9B!T:&4@86=R965M96YT(&9O<B!A;B!A9&1I=&EO;F%L(&%N;G5A;"!F
M964@;V8@)FYB<W`[)#(U+#`P,"P@<&%Y86)L92!I;B!T=V\@:6YS=&%L;&UE
M;G1S(&]F("9N8G-P.R0Q,BPU,#`@;VX@07!R:6P@,34L(#(P,3$@86YD($]C
M=&]B97(@,34L(#(P,3$N($%L;"!I;G-T86QL;65N=',@:&%V92!B965N('!A
M:60@87,@9'5E+B`-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R
M9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]D:78^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HS-G!T.V1I
M<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^5&AE(&9O;&QO=VEN
M9R!T86)L92!S971S(&9O<G1H('1H92!#;VUP86YY)B,X,C$W.W,@<')I;F-I
M<&%L(&-A<V@@;V)L:6=A=&EO;G,@86YD(&-O;6UI=&UE;G1S(&9O<B!T:&4@
M;F5X="!F:79E(&9I<V-A;"!Y96%R<R!A<R!O9B!*=6YE(#,P+"`R,#$Q(&%G
M9W)E9V%T:6YG("9N8G-P.R0T-S`L,C,V+"!O9B!W:&EC:"`F;F)S<#LD,C4V
M+#(V-R!I<R!I;F-L=61E9"!I;B!C=7)R96YT(&QI86)I;&ET:65S(&EN('1H
M92!C;VYD96YS960@8V]N<V]L:61A=&5D(&)A;&%N8V4@<VAE970@870@2G5N
M92`S,"P@,C`Q,2XF(S$V,#L@06UO=6YT<R!I;F-L=61E9"!I;B!T:&4@,C`Q
M,2!C;VQU;6X@<F5P<F5S96YT(&%M;W5N=',@9'5E(&%T($IU;F4@,S`L(#(P
M,3$@9F]R('1H92!R96UA:6YD97(@;V8@=&AE(#(P,3$@9FES8V%L('EE87(@
M96YD:6YG($1E8V5M8F5R(#,Q+"`R,#$Q+B`-"CPO9F]N=#X-"CPO9&EV/CQB
M<B`O/@T*/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MM87)G:6XM;&5F
M=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQD:78^/&1I=B!S='EL93TS1'1E
M>'0M86QI9VXZ;&5F=#MW:61T:#HQ,#`E.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HX<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]D:78^#0H\+V1I=CX\
M9&EV('-T>6QE/3-$<&%G92UB<F5A:RUA9G1E<CIA;'=A>7,[=VED=&@Z,3`P
M)3L@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMW:61T:#HQ,#`E
M.R`^)B,Q-C`[(`T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N
M=&5R.W=I9'1H.C$P,"4[(#X-"CPO9&EV/@T*/"]D:78^/&1I=CX\9&EV('-T
M>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MW:61T:#HQ,#`E.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HX<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]D:78^
M#0H\+V1I=CX-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6EN9&5N=#HP<'0[
M9&ES<&QA>3IB;&]C:SL@/CQB<B`O/@T*#0H\+V1I=CX\9&EV('-T>6QE/3-$
M=&5X="UA;&EG;CIL969T.R`^/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E("!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/'1R/CQT9"!V
M86QI9VX],T1B;W1T;VT@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I
M;F<M8F]T=&]M.C)P>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C)P>#L@/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^
M#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@;F]W<F%P
M/3-$;F]W<F%P("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O
M='1O;3HR<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P("!S='EL93TS
M1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O;3HR<'@[(#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T
M9#X\=&0@=F%L:6=N/3-$=&]P("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP
M861D:6YG+6)O='1O;3HR<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0V(&YO=W)A<#TS1&YO=W)A<"`@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L:60[)R`^/&1I=B!S='EL93TS1'1E
M>'0M86QI9VXZ8V5N=&5R.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K
M.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^4&%Y;65N
M=',F(S$V,#M$=64F(S$V,#M">28C,38P.UEE87(@#0H\+V9O;G0^#0H\+V1I
M=CX-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"`@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^#0H\+W1R/CQT
M<CX\=&0@=F%L:6=N/3-$8F]T=&]M("!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#MP861D:6YG+6)O='1O;3HR<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$
M=&]P("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O;3HR
M<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*
M/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R
M(&YO=W)A<#TS1&YO=W)A<"`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C
M:R`R<'@@<V]L:60[)R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R
M.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P
M=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^5&]T86P@#0H\+V9O;G0^#0H\+V1I
M=CX-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"`@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG
M;CTS1'1O<"`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T
M;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P
M.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,B!N;W=R87`],T1N;W=R87`@('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
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M+V1I=CX-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"`@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A
M;&EG;CTS1'1O<"`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB
M;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,B!N;W=R87`],T1N;W=R87`@('-T>6QE/3-$)V)O<F1E<BUB;W1T
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M#0H\+V1I=CX-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"`@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^#0H\
M+W1R/CQT<B!S='EL93TS1&)A8VMG<F]U;F0M8V]L;W(Z(V-C9F9C8SL@/CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V-"4@('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT
M+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R
M9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M(#Y297-E87)C:"!A;F0@9&5V96QO<&UE;G0@8V]N=')A8W1S(`T*/"]F;VYT
M/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL
M969T.R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N
M=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I
M9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF;F)S
M<#LD(`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Y)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[=&5X="UI;F1E;G0Z,'!T.V1I
M<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^,CDQ+#`Q.2`-"CPO
M9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI
M9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V
M,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9&EV('-T>6QE/3-$
M=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K
M.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y
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M+7-I>F4Z,3!P=#LG(#XR.3$L,#$Y(`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M
M86QI9VXZ;&5F=#L@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X
M="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA
M<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)R`^)FYB<W`[)"`-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$.24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H
M=#L@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M:6YD96YT
M.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG
M:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
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M.C$P<'0[)R`^0V]N<W5L=&EN9R!A9W)E96UE;G0@#0H\+V9O;G0^#0H\+V1I
M=CX-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E("!S='EL
M93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT
M/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@('-T>6QE
M/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.G)I9VAT.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL
M969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/C$R+#4P,"`-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$.24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L
M;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/C$R+#4P,"`-"CPO9F]N=#X-"CPO
M9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O
M;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$.24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@
M/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M:6YD96YT.C!P
M=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z
M,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
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M<'0[)R`^3&EQ=6ED871E9"!D86UA9V5S('!A>6%B;&4@=6YD97(@<F5G:7-T
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M=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T
M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@('-T>6QE/3-$=&5X
M="UA;&EG;CIR:6=H=#L@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT
M.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P
M=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/C<T+#`P,"`-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL
M969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-
M"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE
M9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*
M/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@
M('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQD:78@<W1Y;&4],T1T97AT
M+6%L:6=N.G)I9VAT.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA
M<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/C<T+#`P,"`-"CPO9F]N=#X-"CPO9&EV/@T*
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@('-T>6QE/3-$
M=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$.24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQD:78@
M<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M:6YD96YT.C!P=#MD:7-P
M;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^
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M<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/D1U92!T;R!S=&]C:VAO;&1E<B`-"CPO9F]N
M=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C)P
M>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\
M+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L:60[=&5X="UA
M;&EG;CIL969T.R<@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF
M(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Y)2`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L
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M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG
M;CIL969T.W!A9&1I;F<M8F]T=&]M.C)P>#L@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3IB;&%C:R`R<'@@<V]L:60[=&5X="UA;&EG;CIL969T.R<@/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2`@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L:60[=&5X="UA;&EG;CIR:6=H=#LG
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M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M
M.C)P>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@
M#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L:60[=&5X
M="UA;&EG;CIL969T.R<@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Y)2`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@
M<V]L:60[=&5X="UA;&EG;CIR:6=H=#LG(#X\9&EV('-T>6QE/3-$=&5X="UA
M;&EG;CIR:6=H=#MT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G
M:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG(#XF(S@R,3([(`T*/"]F;VYT/@T*/"]D:78^#0H\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^
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M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^5&]T86P@#0H\+V9O;G0^#0H\+V1I
M=CX-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E("!S='EL
M93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O;3HT<'@[(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ8FQA8VL@-'!X(&1O=6)L93MT97AT+6%L:6=N.FQE
M9G0[)R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N
M=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I
M9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF;F)S
M<#LD(`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Y)2`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`T
M<'@@9&]U8FQE.W1E>'0M86QI9VXZ<FEG:'0[)R`^/&1I=B!S='EL93TS1'1E
M>'0M86QI9VXZ<FEG:'0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[
M;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^-#<P+#(S-B`-"CPO9F]N=#X-"CPO9&EV
M/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C1P>#L@/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ-'!X.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E("!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.F)L86-K(#1P>"!D;W5B;&4[=&5X="UA;&EG;CIL969T.R<@
M/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T
M.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP
M<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)FYB<W`[)"`-
M"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$.24@('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@-'!X(&1O
M=6)L93MT97AT+6%L:6=N.G)I9VAT.R<@/CQD:78@<W1Y;&4],T1T97AT+6%L
M:6=N.G)I9VAT.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I
M;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G
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M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C1P>#L@/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3IB;&%C:R`T<'@@9&]U8FQE.W1E>'0M86QI9VXZ;&5F=#LG(#X\9&EV
M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C!P=#MD:7-P
M;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^
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M,3!P=#LG(#XF(S@R,3([(`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V
M86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE
M9G0[<&%D9&EN9RUB;W1T;VTZ-'!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^#0H\+W1R/@T*/"]T
M86)L93X-"CPO9&EV/@T*/"]D:78^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
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M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,D@^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^4W5B<V5Q=65N="!%=F5N=',\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=6)S97%U96YT($5V96YT
M<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-U8G-E<75E;G0@179E;G1S(%M497AT($)L;V-K73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^#0H@(#QD:78^/&1I=CX\9&EV
M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C!P=#MD:7-P
M;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^
M/&1I=CX\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/&9O;G0@<W1Y
M;&4],T1D:7-P;&%Y.FEN;&EN93MF;VYT+7=E:6=H=#IB;VQD.R`^.2X-"B`@
M/"]F;VYT/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[9F]N="UW96EG
M:'0Z8F]L9#L@/E-U8G-E<75E;G0@179E;G1S#0H@(#PO9F]N=#X-"B`@/"]F
M;VYT/@T*("`\+V1I=CX-"B`@/"]D:78^/&1I=B!S='EL93TS1'1E>'0M:6YD
M96YT.C!P=#MD:7-P;&%Y.F)L;V-K.R`^/&)R("\^#0H@(`T*("`\+V1I=CX\
M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([=&5X="UI;F1E;G0Z,'!T
M.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP
M<'0[(#X\9&EV/CQD:78@<W1Y;&4],T1T97AT+6EN9&5N=#HS-G!T.V1I<W!L
M87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[=&5X
M="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V)A
M8VMG<F]U;F0M8V]L;W(Z(V9F9F9F9CLG(#Y/;B!*=6QY(#(W+"`R,#$Q+"!T
M:&4@0V]M<&%N>2!A9W)E960@=&\@97AT96YD('=A<G)A;G1S('1O(&%C<75I
M<F4@,C<S+#<U,B!S:&%R97,@;V8@8V]M;6]N('-T;V-K('1H870@=V5R92!P
M<F5V:6]U<VQY(&ES<W5E9"!I;B!C;VYN96-T:6]N('=I=&@@=&AE($-O;7!A
M;GDF(S@R,3<[<R!F:7)S="!P<FEV871E('!L86-E;65N="!I;B`R,#`V('1O
M($IU;'D@,C<L(#(P,3(N)B,Q-C`[)B,Q-C`[26X@8V]N:G5N8W1I;VX@=VET
M:"!T:&4@97AT96YS:6]N(&]F('1H92!W87)R86YT<RP@=&AE(&-A<VAL97-S
M(&5X97)C:7-E(&9E871U<F4@=V%S(&1E;&5T960N)B,Q-C`[)B,Q-C`[3VX@
M2G5L>2`R-RP@,C`Q,2P@=&AE(&9A:7(@=F%L=64@;V8@=&AE('=A<G)A;G0@
M97AT96YS:6]N+"!A<R!C86QC=6QA=&5D('!U<G-U86YT('1O('1H92!";&%C
M:RU38VAO;&5S(&]P=&EO;BUP<FEC:6YG(&UO9&5L+"!W87,@9&5T97)M:6YE
M9"!T;R!B92`F;F)S<#LD,3DY+#@S.2`H)FYB<W`[)#`N-S,@<&5R('-H87)E
M*2P@86YD('=I;&P@8F4@8VAA<F=E9"!T;R!O<&5R871I;VYS(&1U<FEN9R!T
M:&4@=&AR964@;6]N=&AS(&5N9&EN9R!397!T96UB97(@,S`L(#(P,3$N)B,Q
M-C`[)B,Q-C`[5&AE(&9A:7(@=F%L=64@;V8@=&AE('=A<G)A;G0@97AT96YS
M:6]N('=A<R!C86QC=6QA=&5D('5S:6YG('1H92!F;VQL;W=I;F<@:6YP=70@
M=F%R:6%B;&5S.B!S=&]C:R!P<FEC92`M("9N8G-P.R0P+C<Y.R!E>&5R8VES
M92!P<FEC92`M("9N8G-P.R0P+C,S,SL@97AP96-T960@;&EF92`M(#$@>65A
M<CL@97AP96-T960@=F]L871I;&ET>2`F(S@R,3$[(#,P."XX)3L@97AP96-T
M960@9&EV:61E;F0@>6EE;&0@+2`P)3L@<FES:RUF<F5E(&EN=&5R97-T(')A
M=&4@)B,X,C$Q.R`P+C$T)2X-"B`@/"]F;VYT/@T*("`\+V1I=CX-"B`@#0H@
M(#PO9&EV/@T*("`\+V1I=CX-"B`@/"]D:78^#0H\+V1I=CX-"B`@/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
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M.D9I;&4@2%)E9CTS1")3:&5E=#`Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970P,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#,N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`T+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970P-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,#8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`W
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P."YH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,#DN:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#$P+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q
M,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3(N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$S+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970Q-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,34N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$V+FAT;6PB+SX-
M"CPO>&UL/@T*+2TM+2TM/5].97AT4&%R=%]D86-B.6,Q.%\X,39D7S0T8C%?
5.6$U85\Y-#1A,6$V93DX-S<M+0T*
`
end

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
